PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	[Anonymous]				[Anonymous]			BMA hopes for at least 10% pay rise	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1999	318	7177					199	199						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888938				2022-12-28	WOS:000078175100080
J	Welte, T; Leitenberg, D; Dittel, BN; al-Ramadi, BK; Xie, B; Chin, YE; Janeway, CA; Bothwell, ALM; Bottomly, K; Fu, XY				Welte, T; Leitenberg, D; Dittel, BN; al-Ramadi, BK; Xie, B; Chin, YE; Janeway, CA; Bothwell, ALM; Bottomly, K; Fu, XY			STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; ANTIGEN RECEPTORS; ACTIVATION; LYMPHOCYTES; EXPRESSION; INDUCTION	The role of STAT (signal transducer and activator of transcription) proteins in T cell receptor (TCR) signaling was analyzed. STAT5 became immediately and transiently phosphorylated on tyrosine 694 in response to TCR stimulation. Expression of the protein tyrosine kinase Lck, a key signaling protein in the TCR complex, activated DNA binding of transfected STAT5A and STAT5B to specific STAT inducible elements. The role of Lck in STAT5 activation was confirmed in a Lck-deficient T cell Line in which the activation of STAT5 by TCR stimulation was abolished. Expression of Lck induced specific interaction of STAT5 with the subunits of the TCR, indicating that STAT5 may be directly involved in TCR signaling. Stimulation of T cell clones and primary T cell lines also induced the association of STAT5 with the TCR complex. Inhibition of STAT5 function by expression of a dominant negative mutant STAT5 reduced antigen-stimulated proliferation of T cells. Thus, TCR stimulation appears to directly activate STAT5, which may participate in the regulation of gene transcription and T cell proliferation during immunological responses.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06520 USA.			Leitenberg, David/0000-0002-0622-9522	NIAID NIH HHS [AI34522] Funding Source: Medline; NIGMS NIH HHS [GM46367, GM55590] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055590, R01GM046367] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRamadi BK, 1996, J IMMUNOL, V157, P4751; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leitenberg D, 1998, J IMMUNOL, V161, P1194; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; PERLMUTTER RM, 1995, CANCER SURV, V22, P85; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELTE T, UNPUB; YOKOYAMA WM, 1989, IMMUNOL REV, V109, P153, DOI 10.1111/j.1600-065X.1989.tb00024.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	26	115	123	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					222	225		10.1126/science.283.5399.222	http://dx.doi.org/10.1126/science.283.5399.222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880255				2022-12-28	WOS:000077976700040
J	O'Leary, DH; Polak, JF; Kronmal, RA; Manolio, TA; Burke, GL; Wolfson, SK				O'Leary, DH; Polak, JF; Kronmal, RA; Manolio, TA; Burke, GL; Wolfson, SK		Cardiovascular Hlth Study Collaborative Res Grp	Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR HEALTH; WALL THICKNESS; ATHEROSCLEROSIS RISK; SERUM-CHOLESTEROL; BLOOD-PRESSURE; PREVALENCE; ROTTERDAM; DETERMINANTS; ASSOCIATION	Background The combined thickness of the intima and media of the carotid artery is associated with the prevalence of cardiovascular disease. We studied the associations between the thickness of the carotid-artery intima and media and the incidence of new myocardial infarction or stroke in persons without clinical cardiovascular disease. Methods Noninvasive measurements of the intima and media of the common and internal carotid artery were made with high-resolution ultrasonography in 5858 subjects 65 years of age or older. Cardiovascular events (new myocardial infarction or stroke) served as outcome variables in subjects without clinical cardiovascular disease (4476 subjects) over a median follow-up period of 6.2 years. Results The incidence of cardiovascular events correlated with measurements of carotid-artery intima-media thickness. The relative risk of myocardial infarction or stroke increased with intima-media thickness (P<0.001). The relative risk of myocardial infarction or stroke (adjusted for age and sex) for the quintile with the highest thickness as compared with the lowest quintile was 3.87 (95 percent confidence interval, 2.72 to 5.51). The association between cardiovascular events and intima-media thickness remained significant after adjustment for traditional risk factors, showing increasing risks for each quintile of combined intima-media thickness, from the second quintile (relative risk, 1.54; 95 percent confidence interval, 1.04 to 2.28), to the third (relative risk, 1.84; 95 percent confidence interval, 1.26 to 2.67), fourth (relative risk, 2.01; 95 percent confidence interval, 1.38 to 2.91), and fifth (relative risk, 3.15; 95 percent confidence interval, 2.19 to 4.52). The results of separate analyses of myocardial infarction and stroke paralleled those for the combined end point. Conclusions Increases in the thickness of the intima and media of the carotid artery, as measured noninvasively by ultrasonography, are directly associated with an increased risk of myocardial infarction and stroke in order adults without a history of cardiovascular disease. (N Engl J Med 1999;340:14-22.) (C) 1999, Massachusetts Medical Society.	Tufts Univ New England Med Ctr, Dept Radiol, Boston, MA USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA	Tufts Medical Center; Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	O'Leary, DH (corresponding author), CHS Coordinating Ctr, Century Sq,1501 4th Ave,Suite 2025, Seattle, WA 98101 USA.	daniel.oleary@es.nemc.org			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080, N01HC085081, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC85079, N01-HC85081, N01-HC85080] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan PL, 1997, STROKE, V28, P348, DOI 10.1161/01.STR.28.2.348; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; HARRIS M, 1979, DIABETES, V28, P1039; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KULLER L, 1994, AM J EPIDEMIOL, V139, P1164, DOI 10.1093/oxfordjournals.aje.a116963; Mannami T, 1997, STROKE, V28, P518, DOI 10.1161/01.STR.28.3.518; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; NEWMAN AB, 1993, JAMA-J AM MED ASSOC, V270, P487, DOI 10.1001/jama.270.4.487; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OLeary DH, 1996, STROKE, V27, P224, DOI 10.1161/01.STR.27.2.224; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; Price T R, 1993, Ann Epidemiol, V3, P504; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RUTAN GH, 1992, HYPERTENSION, V19, P508, DOI 10.1161/01.HYP.19.6.508; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; *SPSS, 1998, SPSS WIND REL 8 0; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Wilson PWF, 1997, NEW ENGL J MED, V337, P516, DOI 10.1056/NEJM199708213370802; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	39	3745	3869	3	113	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					14	22		10.1056/NEJM199901073400103	http://dx.doi.org/10.1056/NEJM199901073400103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878640	Bronze			2022-12-28	WOS:000077943700003
J	Zametkin, AJ; Ernst, M				Zametkin, AJ; Ernst, M			Problems in the management of attention-deficit-hyperactivity disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEARNING-DISABILITIES; STIMULANT MEDICATION; CHILDREN; METHYLPHENIDATE; ASSOCIATION; ADHD		NIMH, NIH, Bethesda, MD 20892 USA; NIDA, Brain Imaging Ctr, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Zametkin, AJ (corresponding author), NIMH, NIH, Rm 3N238,Bldg 10,10 Ctr Dr, Bethesda, MD 20892 USA.							ABIKOFF H, 1991, J LEARN DISABIL, V24, P205, DOI 10.1177/002221949102400404; ADELMAN HS, 1977, J SPEC EDUC, V11, P377, DOI 10.1177/002246697701100402; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P78; Arnold LE, 1997, ARCH GEN PSYCHIAT, V54, P865; BARKLEY, 1995, SEX DIFFERNCES ADHD, V3, P1; BARKLEY RA, 1977, J CHILD PSYCHOL PSYC, V18, P137, DOI 10.1111/j.1469-7610.1977.tb00425.x; Barkley RA, 1997, J AM ACAD CHILD PSY, V36, P1204, DOI 10.1097/00004583-199709000-00012; BARKLEY RA, 1990, ATTENTION DEFICIT HY, V252, P278; BIEDERMAN J, 1992, ARCH GEN PSYCHIAT, V49, P728; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; CARLSON CL, 1993, SCHOOL PSYCHOL REV, V22, P184; CONNERS CK, 1994, CHILD ADOL PSYCH CL, V3, P361; COOK EH, 1995, AM J HUM GENET, V56, P993; ERNST M, 1996, NEUROIMAGING WINDOW, P95; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; Greenhill LL, 1995, CHILD ADOL PSYCH CL, V4, P123; HAUSER P, 1993, NEW ENGL J MED, V328, P997, DOI 10.1056/NEJM199304083281403; HECHTMAN L, 1985, PSYCHOPHARMACOL BULL, V21, P178; HINSHAW SP, 1991, J CLIN CHILD PSYCHOL, V20, P301, DOI 10.1207/s15374424jccp2003_9; INGERSOL BD, 1993, ATTENTION DEFICIT DI; Kolata Gina, 1996, N Y Times Web, pC8; Lahey BB, 1998, J AM ACAD CHILD PSY, V37, P695, DOI 10.1097/00004583-199807000-00008; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; LONEY J, 1998, NIH CONS DEV C DIAGN; RAPPORT MD, 1994, J AM ACAD CHILD PSY, V33, P882, DOI 10.1097/00004583-199407000-00015; Safer DJ, 1996, PEDIATRICS, V98, P1084; Satterfield JH, 1997, J AM ACAD CHILD PSY, V36, P1726, DOI 10.1097/00004583-199712000-00021; Shaywitz SE, 1998, NEW ENGL J MED, V338, P307, DOI 10.1056/NEJM199801293380507; Silberg J, 1996, J CHILD PSYCHOL PSYC, V37, P803, DOI 10.1111/j.1469-7610.1996.tb01476.x; SILVER LB, 1986, AM J DIS CHILD, V140, P1045, DOI 10.1001/archpedi.1986.02140240091033; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; SWANSON JM, 1993, EXCEPT CHILDREN, V60, P154, DOI 10.1177/001440299306000209; Szatmari P, 1992, CHILD ADOLESC PSYCHI, P361; WALKUP JT, 1994, NEWSLETTER J AM ACAD, V25, P248; WHALEN CK, 1976, PSYCHOL BULL, V83, P1113, DOI 10.1037/0033-2909.83.6.1113; WILENS TE, 1995, J NERV MENT DIS, V183, P48, DOI 10.1097/00005053-199501000-00010; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013; 1997, J AM ACAD CHILD ADOL, V36, pS85	38	117	124	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					40	46		10.1056/NEJM199901073400107	http://dx.doi.org/10.1056/NEJM199901073400107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155JQ	9878644				2022-12-28	WOS:000077943700007
J	Greenhalgh, T; Hurwitz, B				Greenhalgh, T; Hurwitz, B			Narrative based medicine - Why study narrative?	BRITISH MEDICAL JOURNAL			English	Article							EXPERTISE		Royal Free & UCL, Sch Med, Dept Primary Care & Populat Sci, London N19 5NF, England; St Marys Hosp, Imperial Coll Sch Med, Dept Primary Care, London W2 1PG, England	University of London; University College London; UCL Medical School; Imperial College London	Greenhalgh, T (corresponding author), Royal Free & UCL, Sch Med, Dept Primary Care & Populat Sci, London N19 5NF, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ANDERSON C, 1990, LIT SCI; ASHER R, 1972, TALKING SENSE, P3; Balint M., 1957, DOCTOR; Berger J., 1967, FORTUNATE MAN STORY; BRODY H, 1994, LIT MED, V13, P91; Custers EJFM, 1996, MEM COGNITION, V24, P384, DOI 10.3758/BF03213301; Epstein, 1995, ALTERED CONDITIONS D; HOLMES J, 1998, NARRATIVE BASED MED, P176; Hunter K, 1996, THEOR MED, V17, P225, DOI 10.1007/BF00489447; Hunter KM, 1996, J MED PHILOS, V21, P303; HUNTER KM, 1991, DOCTORS STORIES NARR, P12; Kleinman A., 1988, ILLNESS NARRATIVES; Launer J, 1997, BRIT J GEN PRACT, V47, P453; MILNE AA, 1974, HOUSE POOH CORNER; PREVEN DW, 1986, J MED EDUC, V61, P842; RATZAN RM, 1992, LIT MED, V11, P94, DOI 10.1353/lm.2011.0263; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; WIDDERSHOVEN G, 1993, NARRATIVE STUDY LIVE	18	374	388	0	29	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					48	50						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	156QG	9872892				2022-12-28	WOS:000078013100033
J	Kennerdell, JR; Carthew, RW				Kennerdell, JR; Carthew, RW			Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway	CELL			English	Article							SEGMENT-POLARITY GENE; CELL FATE DETERMINATION; DROSOPHILA-MELANOGASTER; TISSUE POLARITY; LARVAL CUTICLE; ZYGOTIC LOCI; PATTERN; EXPRESSION; EPIDERMIS; ARMADILLO	We investigated the potential of double-stranded RNA to interfere with the function of genes in Drosophila. Injection of dsRNA into embryos resulted in potent and specific interference of several genes that were tested. In contrast, single-stranded RNA weakly interfered with gene activity. The method was used to determine the reception mechanism of the morphogen Wingless. Interference of the frizzled and Drosophila frizzled 2 genes together produced defects in embryonic patterning that mimic loss of wingless function. Interference of either gene alone had no effect on patterning. Epistasis analysis indicates that frizzled and Drosophila frizzled 2 act downstream of wingless and upstream of zeste-white3 in the Wingless pathway. Our results demonstrate that dsRNA interference can be used to analyze many aspects of gene function.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carthew, RW (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	carthew@pop.pitt.edu			NATIONAL EYE INSTITUTE [R01EY010111] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY10111] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER PN, 1990, GENETICS, V126, P401; ARIAS AM, 1988, DEVELOPMENT, V103, P157; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Hays R, 1997, DEVELOPMENT, V124, P3727; Heberlein U, 1998, DEVELOPMENT, V125, P567; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Heldens JGM, 1997, J VIROL METHODS, V68, P57, DOI 10.1016/S0166-0934(97)00109-2; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Reifegerste R, 1997, MECH DEVELOP, V68, P69, DOI 10.1016/S0925-4773(97)00127-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WILDER EL, 1995, DEVELOPMENT, V121, P477; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang J, 1998, DEVELOPMENT, V125, P3075; ZHENG L, 1995, DEVELOPMENT, V121, P3045	48	867	1018	1	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1017	1026		10.1016/S0092-8674(00)81725-0	http://dx.doi.org/10.1016/S0092-8674(00)81725-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875855	Bronze			2022-12-28	WOS:000077759100016
J	Raman, CS; Li, HY; Martasek, P; Kral, V; Masters, BSS; Poulos, TL				Raman, CS; Li, HY; Martasek, P; Kral, V; Masters, BSS; Poulos, TL			Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pterin function involving a novel metal center	CELL			English	Article							ESCHERICHIA-COLI; OXYGENASE DOMAIN; DIFFRACTION DATA; L-ARGININE; TETRAHYDROBIOPTERIN; ZINC; REDUCTASE; SITE; INHIBITION; PROTEIN	Nitric oxide, a key signaling molecule, is produced by a family of enzymes collectively called nitric oxide synthases (NOS). Here, we report the crystal structure of the heme domain of endothelial NOS in tetrahydrobiopterin (H4B)-free and -bound forms at 1.95 Angstrom and 1.9 Angstrom resolution, respectively. In both structures a zinc ion is tetrahedrally coordinated to pairs of symmetry-related cysteine residues at the dimer interface. The phylogenetically conserved Cys-(X)(4)-Cys motif and its strategic location establish a structural role for the metal center in maintaining the integrity of the H4B-binding site. The unexpected recognition of the substrate, L-arginine, at the H4B site indicates that this site is poised to stabilize a positively charged pterin ring and suggests a model involving a cationic pterin radical in the catalytic cycle.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague 6, Czech Republic	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine; University of Chemistry & Technology, Prague	Poulos, TL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	masters@uthscsa.edu; poulos@uci.edu	Kral, Vladimir/I-9518-2017; Martasek, Pavel/G-6622-2017	Kral, Vladimir/0000-0001-5034-4184; Raman, C. S./0000-0002-1036-3193; Martasek, Pavel/0000-0001-6165-4444	NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM32688, GM57353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Alderton WK, 1998, BIOCHEM J, V332, P195, DOI 10.1042/bj3320195; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barber HJ, 1932, J CHEM SOC, P1365, DOI 10.1039/jr9320001365; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Birdsall DL, 1996, J MOL BIOL, V255, P522, DOI 10.1006/jmbi.1996.0043; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Cronk JD, 1996, PROTEIN SCI, V5, P1963, DOI 10.1002/pro.5560051002; Crow JP, 1997, J NEUROCHEM, V69, P1936; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Goodwill KE, 1998, BIOCHEMISTRY-US, V37, P13437, DOI 10.1021/bi981462g; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; Hemmens B, 1998, METH MOL B, V100, P1; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kaufman S., 1997, TETRAHYDROBIOPTERIN; KAW S, 1992, P NATL ACAD SCI USA, V89, P6886, DOI 10.1073/pnas.89.15.6886; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Luykx DMAM, 1998, BIOCHEMISTRY-US, V37, P11366, DOI 10.1021/bi972972y; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MATTHEWS RG, 1982, FED PROC, V41, P2600; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Werner-Felmayer G, 1996, METHODS NITRIC OXIDE, P271; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	79	559	576	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					939	950		10.1016/S0092-8674(00)81718-3	http://dx.doi.org/10.1016/S0092-8674(00)81718-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875848	Bronze			2022-12-28	WOS:000077759100009
J	Jones, AM				Jones, AM			Botany: Auxin transport: Down and out and up again	SCIENCE			English	Editorial Material							ARABIDOPSIS-THALIANA; POLAR TRANSPORT; ACID		Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu						BELL CJ, 1990, MOL GEN GENET, V220, P289, DOI 10.1007/BF00260496; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; DARWIN C, 1980, POWER MOVEMENT PLANT; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Fujita H, 1997, PLANT J, V12, P583, DOI 10.1046/j.1365-313X.1997.00583.x; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; GOLDSMITH MHM, 1977, ANNU REV PLANT PHYS, V28, P439, DOI 10.1146/annurev.pp.28.060177.002255; JONES AM, 1990, PLANT PHYSIOL, V93, P1154, DOI 10.1104/pp.93.3.1154; Lomax Terri L., 1995, P509; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Meinhardt H., 1984, Positional controls in plant development, P1; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; RAVEN JA, 1975, NEW PHYTOL, V74, P163, DOI 10.1111/j.1469-8137.1975.tb02602.x; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; WENT F. W., 1928, REC TRAV BOT NEERL, V25, P1; WOLPERT L, 1989, MOL BASIS POSITION S, P3	21	67	74	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2201	2202		10.1126/science.282.5397.2201	http://dx.doi.org/10.1126/science.282.5397.2201			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890827				2022-12-28	WOS:000077645800028
J	Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN				Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN			Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding	ANNALS OF INTERNAL MEDICINE			English	Article						Clostridium difficile; diarrhea; enteral feeding; hospitalization; Clostridium infections	CRITICALLY ILL PATIENTS; MICROBIAL-CONTAMINATION; ENTERAL FEEDS; COLONIZATION; INFECTION; SYSTEMS; HYPOALBUMINEMIA; ENVIRONMENT; DELIVERY; SEVERITY	Background: Clostridium difficile is the most common infectious cause of nosocomial diarrhea, but its role in diarrhea associated with tube feeding has not been rigorously investigated. Objective: To determine the incidence of C. difficile acquisition and C. difficile-associated diarrhea in tube-fed and non-tube-fed patients. Design: Prospective cohort study. Setting: A university-affiliated Veterans Affairs Medical Center. Patients: 76 consecutive hospitalized, tube-fed patients and 76 hospitalized, non-tube-fed patients. The two cohorts were matched for age, unit location, duration of hospitalization before surveillance, and severity of illness. Measurements: Incidence of C. difficile acquisition, incidence of C, difficile-associated diarrhea, and C. difficile restriction endonuclease analysis typing results. Results: More tube-fed patients than non-tube-fed patients acquired C. difficile (15 of 76 patients [20%] compared with 6 of 76 patients [8%]; P = 0.03) and developed C. difficile-associated diarrhea (7 of 76 patients [9%] compared with 1 of 76 patients [1%]; P = 0.03). The mean proportion (+/-SD) of surveillance days with diarrhea was greater for tube-fed patients after the development of C. difficile-associated diarrhea than for tube-fed patients without this diarrhea (0.68 +/- 0.4 compared with 0.22 +/- 0.2 [95% CI for the mean difference, 0.08 to 0.84]). Postpyloric tube feeding (odds ratio, 3.14 [CI, 1.008 to 9.77]) and duration of surveillance (odds ratio, 1.08 [CI, 1.0009 to 1.16]) were risk factors for the acquisition of C. difficile. Nineteen restriction endonuclease analysis types of C. difficile were identified from 20 patients. Conclusions: Hospitalized, tube-fed patients, especially those receiving postpyloric tube feeding, are at greater risk for the acquisition of C. difficile and the development of C. difficile-associated diarrhea than are hospitalized, non-tube-fed patients. Clinicians should test for C. difficile in tube-fed patients with diarrhea.	Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Vet Affairs Chicago Healthcare Syst, Chicago, IL 60611 USA; Vet Affairs Med Ctr, Res Serv 151, Minneapolis, MN 55417 USA; Northwestern Univ, Sch Med, Chicago, IL USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Northwestern University	Bliss, DZ (corresponding author), Univ Minnesota, Sch Nursing, 6-101 Weaver Densford Hall,308 Dr Johnson & Gerdi, Minneapolis, MN 55455 USA.	bliss@tc.umn.edu		Johnson, Stuart/0000-0001-9548-229X	NINR NIH HHS [1F32-NR06746] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ANDERSON KR, 1984, JPEN-PARENTER ENTER, V8, P673, DOI 10.1177/0148607184008006673; ANDERTON A, 1993, CLIN NUTR, V12, P16; ANDERTON A, 1990, CLIN NUTR, V9, P157, DOI 10.1016/0261-5614(90)90048-W; ANDERTON A, 1988, J HOSP INFECT, V11, P364, DOI 10.1016/0195-6701(88)90090-4; BETTIN K, 1994, INFECT CONT HOSP EP, V15, P697; BLISS DZ, 1992, AM J CLIN NUTR, V55, P753, DOI 10.1093/ajcn/55.3.753; BRINSON RR, 1987, CRIT CARE MED, V15, P506, DOI 10.1097/00003246-198705000-00011; BRINSON RR, 1988, CRIT CARE MED, V16, P130, DOI 10.1097/00003246-198802000-00007; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1989, J CLIN MICROBIOL, V27, P2386, DOI 10.1128/JCM.27.10.2386-2387.1989; CLABOTS CR, 1993, 33 INT C ANTI AG CHE; CROCKER KS, 1986, AM J INFECT CONTROL, V14, P250, DOI 10.1016/0196-6553(86)90037-4; DONIUS MA, 1993, JPEN-PARENTER ENTER, V17, P461, DOI 10.1177/0148607193017005461; EDES TE, 1990, AM J MED, V88, P91, DOI 10.1016/0002-9343(90)90454-L; FREEDLAND CP, 1989, JPEN-PARENTER ENTER, V13, P18, DOI 10.1177/014860718901300118; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; GOTTSCHLICH MM, 1988, JPEN-PARENTER ENTER, V12, P338, DOI 10.1177/0148607188012004338; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; Holdeman L.V., 1975, ANAEROBE LAB MANUAL; HORN SD, 1986, MED CARE, V24, P159, DOI 10.1097/00005650-198602000-00007; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY TWJ, 1983, CRIT CARE MED, V11, P7, DOI 10.1097/00003246-198301000-00003; Keohane P P, 1983, Clin Nutr, V1, P259, DOI 10.1016/0261-5614(83)90003-1; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; KOTILAINEN HR, 1983, P ROSS LABORATORIES, P16; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; MALAMOULADAS H, 1983, J CLIN PATHOL, V36, P88, DOI 10.1136/jcp.36.1.88; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; METCALF AM, 1986, CLIN GASTROENTEROL, V15, P705; MICKSCHL DB, 1990, HEART LUNG, V19, P362; PETERSON LR, 1986, AM J CLIN PATHOL, V86, P208, DOI 10.1093/ajcp/86.2.208; ROLFE RD, 1983, INFECT IMMUN, V42, P480, DOI 10.1128/IAI.42.2.480-486.1983; ROLFE RD, 1984, INFECT IMMUN, V45, P185, DOI 10.1128/IAI.45.1.185-191.1984; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SCHROEDER P, 1983, JPEN-PARENTER ENTER, V7, P364, DOI 10.1177/0148607183007004364; SIEGEL DL, 1990, JAMA-J AM MED ASSOC, V263, P979, DOI 10.1001/jama.263.7.979; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; WAGNER DR, 1994, JPEN-PARENTER ENTER, V18, P453, DOI 10.1177/0148607194018005453; WILSON KH, 1985, J INFECT DIS, V151, P355, DOI 10.1093/infdis/151.2.355; YANNELLI B, 1988, AM J INFECT CONTROL, V16, P246, DOI 10.1016/S0196-6553(88)80003-8; ZIMMARO DM, 1989, JPEN-PARENTER ENTER, V13, P117, DOI 10.1177/0148607189013002117	47	206	210	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1012	+		10.7326/0003-4819-129-12-199812150-00004	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867755				2022-12-28	WOS:000077471900003
J	Herrick, AL				Herrick, AL			Advances in treatment of systemic sclerosis	LANCET			English	Editorial Material							SCLERODERMA		Univ Manchester, Hope Hosp, Ctr Rheumat Dis, Salford M6 8HD, Lancs, England	University of Manchester	Herrick, AL (corresponding author), Univ Manchester, Hope Hosp, Ctr Rheumat Dis, Salford M6 8HD, Lancs, England.			Herrick, Ariane/0000-0003-4941-7926				Akesson Anita, 1998, Current Opinion in Rheumatology, V10, P579; Black C, 1998, BRIT MED J, V317, P294; Casale R, 1997, ARCH PHYS MED REHAB, V78, P767, DOI 10.1016/S0003-9993(97)90087-3; Clements P. J., 1997, Arthritis and Rheumatism, V40, pS173; Grassegger A, 1998, BRIT J DERMATOL, V139, P639; Menon N, 1998, ARTHRITIS RHEUM-US, V41, P466; Pope J, 1998, ARTHRITIS RHEUM, V41, pS102; Pope JE, 1996, RHEUM DIS CLIN N AM, V22, P893, DOI 10.1016/S0889-857X(05)70307-0; Seibold JR, 1998, J RHEUMATOL, V25, P302; Silman Alan, 1997, Arthritis and Rheumatism, V40, pS123; SJOGREN RW, 1994, ARTHRITIS RHEUM-US, V37, P1265, DOI 10.1002/art.1780370902; STEEN VD, 1990, ANN INTERN MED, V113, P352, DOI 10.7326/0003-4819-113-5-352; Tyndall A, 1997, LANCET, V349, P254, DOI 10.1016/S0140-6736(05)64864-7; WHITE B, 1995, ARTHRITIS RHEUM, V38, P351, DOI 10.1002/art.1780380309; Wigley FM, 1998, ARTHRITIS RHEUM-US, V41, P670, DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I	15	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1874	1875		10.1016/S0140-6736(05)60391-1	http://dx.doi.org/10.1016/S0140-6736(05)60391-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863781				2022-12-28	WOS:000077544600004
J	John, S; Workman, JL				John, S; Workman, JL			Molecular biology - Just the facts of chromatin transcription	SCIENCE			English	Editorial Material							RNA-POLYMERASE-II; REMODELING FACTOR; COMPLEX; CONTAINS; YEAST; ISWI		Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	John, S (corresponding author), Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA.	jlw10@psu.edu						Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Roberts SM, 1997, GENETICS, V147, P451; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	18	9	9	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1836	+		10.1126/science.282.5395.1836	http://dx.doi.org/10.1126/science.282.5395.1836			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9874634				2022-12-28	WOS:000077338100032
J	Samuels, MA				Samuels, MA			Update in neurology	ANNALS OF INTERNAL MEDICINE			English	Article							STROKE		Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Samuels, MA (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.							Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; Goldfarb S, 1998, ANN INTERN MED, V128, P49, DOI 10.7326/0003-4819-128-1-199801010-00008; Salzman EW, 1996, NEW ENGL J MED, V334, P114, DOI 10.1056/NEJM199601113340210; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; SOTANIEMI KA, 1983, ARCH NEUROL-CHICAGO, V40, P75, DOI 10.1001/archneur.1983.04050020037006; Turner GA, 1996, ANAESTH INTENS CARE, V24, P665, DOI 10.1177/0310057X9602400605; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1998, MED LETT DRUGS THER, V40, P45	11	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					878	885		10.7326/0003-4819-129-11_Part_1-199812010-00007	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867730				2022-12-28	WOS:000077239200006
J	Walheim, S; Schaffer, E; Mlynek, J; Steiner, U				Walheim, S; Schaffer, E; Mlynek, J; Steiner, U			Nanophase-separated polymer films as high-performance antireflection coatings	SCIENCE			English	Article								Optical surfaces coated with a thin layer to improve Light transmission are ubiquitous in everyday optical applications as well as in industrial and scientific instruments. Discovered first in 1817 by Fraunhofer, the coating of Lenses became standard practice in the 1930s. In spite of intensive research, broadband antireflection coatings are still limited by the Lack of materials with Low refractive indices. A method based on the phase separation of a macromolecular Liquid to generate nanoporous polymer films is demonstrated that creates surfaces with high optical transmission.	Univ Konstanz, Fak Phys, D-78457 Constance, Germany	University of Konstanz	Steiner, U (corresponding author), Univ Konstanz, Fak Phys, D-78457 Constance, Germany.		Schäffer, Erik/A-4664-2010; Steiner, Ullrich/K-4777-2013	Schäffer, Erik/0000-0001-7876-085X; Steiner, Ullrich/0000-0001-5936-339X				Boltau M, 1998, NATURE, V391, P877, DOI 10.1038/36075; HEINE C, 1995, APPL OPTICS, V34, P2476, DOI 10.1364/AO.34.002476; MACLEOD HA, 1986, THIN FILM OPTICAL FI; MINOT MJ, 1976, J OPT SOC AM, V66, P515, DOI 10.1364/JOSA.66.000515; Templin M, 1997, SCIENCE, V278, P1795, DOI 10.1126/science.278.5344.1795; Uhlmann DR, 1997, J NON-CRYST SOLIDS, V218, P113, DOI 10.1016/S0022-3093(97)00162-2; Walheim S, 1997, MACROMOLECULES, V30, P4995, DOI 10.1021/ma9619288; WILSON SJ, 1982, OPT ACTA, V29, P993, DOI 10.1080/713820946; 1998, Patent No. 19829172	9	606	668	8	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					520	522		10.1126/science.283.5401.520	http://dx.doi.org/10.1126/science.283.5401.520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915695				2022-12-28	WOS:000078203300031
J	Elwyn, G; Gwyn, R				Elwyn, G; Gwyn, R			Stories we hear and stories we tell: analysing talk in clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DECISION-MAKING; PATIENT		Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Cardiff, Ctr Language & Commun Res, Cardiff CF1 3XB, S Glam, Wales	Cardiff University; Cardiff University	Elwyn, G (corresponding author), Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales.	ElwynG@cf.ac.uk	Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; 				Brody H., 1987, STORIES SICKNESS; Brown P., 1978, POLITENESS SOME UNIV; Byrne P.S., 1976, DOCTORS TALKING PATI; Calman KC, 1997, BMJ-BRIT MED J, V315, P939; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; COUPLAND J, 1994, DISCOURSE SOC, V5, P89, DOI 10.1177/0957926594005001005; DAVIDOFF F, 1996, WHO SEEN BLOOD SUGAR; DREW P, 1992, ANAL TALK WORK; Edwards D., 1992, DISCURSIVE PSYCHOL, V8; Geertz Clifford, 1973, INTERPRETATION CULTU; Hillman J., 1983, HEALING FICTION; KINNERSLEY P, 1997, THESIS U BRISTOL BRI; Kleinman A., 1988, ILLNESS NARRATIVES; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Levenstein JH, 1984, S AFRICA FAMILY PRAC, V5, P276; Margalith I, 1997, SOC SCI MED, V45, P419, DOI 10.1016/S0277-9536(96)00357-7; Mishler EG, 1984, DISCOURSE MED DIALEC; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Parson T., 1951, SOCIAL SYSTEM; Pendleton D., 1984, CONSULTATION APPROAC; Potter J, 1987, DISCOURSE SOCIAL PSY; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; REDELMEIER DA, 1995, LANCET, V345, P1131, DOI 10.1016/S0140-6736(95)90975-3; Silverman D., 1987, COMMUNICATION MED PR; Silverman D, 1997, DISCOURSES COUNSELLI; Stewart M, 1995, PATIENT CTR MED TRAN; STEWART MA, 1997, IMPACT PATIENT CTR C; Tuckett D., 1985, M EXPERTS APPROACH S; Wodak R, 1996, DISORDERS DISCOURSE	30	51	51	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1999	318	7177					186	188		10.1136/bmj.318.7177.186	http://dx.doi.org/10.1136/bmj.318.7177.186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888921	Green Published			2022-12-28	WOS:000078175100042
J	Shain, RN; Piper, JM; Newton, ER; Perdue, ST; Ramos, R; Champion, JD; Guerra, FA				Shain, RN; Piper, JM; Newton, ER; Perdue, ST; Ramos, R; Champion, JD; Guerra, FA			A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-REDUCTION INTERVENTION; HIV-AIDS-PREVENTION; CONDOM USE; AFRICAN-AMERICAN; LATINA WOMEN; ADOLESCENTS; INFECTION; GENDER; BLACK; TRANSMISSION	Background African-American and Hispanic women are disproportionately affected by sexually transmitted diseases, including the acquired immunodeficiency syndrome (AIDS). In the effort to reduce infection rates, it is important to create and evaluate behavioral interventions that are specific to the target populations. Methods We enrolled women with nonviral sexually transmitted diseases in a randomized trial of a sex- and culture-specific behavioral intervention. The intervention consisted of three small-group sessions of three to four hours each designed to help women recognize personal susceptibility, commit to changing their behavior, and acquire necessary skills. The control group received standard counseling about sexually transmitted diseases. The design of the intervention was based on the AIDS Risk Reduction Model and ethnographic data on the study populations. Participants in both groups underwent screening, counseling, and an interview before randomization and at the 6- and 12-month follow-up visits. The principal outcome variable was subsequent chlamydial or gonorrheal infection, which was evaluated on an intention-to-treat basis by logistic-regression analysis. Results A total of 424 Mexican-American and 193 African-American women were enrolled; 313 were assigned to the intervention group and 304 to the control group. The rate of participation in the intervention was 90 percent. The rates of retention in the sample were 82 and 89 percent at the 6- and 12-month visits, respectively. Rates of subsequent infection were significantly lower in the intervention group than in the control group during the first 6 months (11.3 vs. 17.2 percent, P=0.05), during the second 6 months (9.1 vs. 17.7 percent, P=0.008), and over the entire 12-month study period (16.8 vs. 26.9 percent, P=0.004). Conclusions A risk-reduction intervention consisting of three small-group sessions significantly decreased the rates of chlamydial and gonorrheal infection among Mexican-American and African-American women at high risk for sexually transmitted disease. (N Engl J Med 1999;340:93-100.) (C) 1999, Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78284 USA; E Carolina Univ, Dept Obstet & Gynecol, Greenville, NC USA; Mujeres Project, Res & Evaluat, San Antonio, TX USA; San Antonio Metropolitan Hlth Dist, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of North Carolina; East Carolina University	Shain, RN (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NIAID NIH HHS [U01 AI31498] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARO H, 1995, AM PSYCHOL, V50, P437, DOI 10.1037/0003-066X.50.6.437; ARAL SO, 1993, ANNU REV PUBL HEALTH, V14, P451; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; ARAL SO, 1995, AIDS PREVENT MENT H, P13; Auerbach J, 1994, AIDS BEHAV INTEGRATE; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; Boyer CB, 1997, AIDS, V11, P359, DOI 10.1097/00002030-199703110-00014; CATANIA JA, 1989, PRIM PREV P, V13, P242; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; *CDCP, 1994, HIV AIDS SURVEILLANC, V6; *CDCP, 1996, HIV AIDS SURVEILLANC, V8; Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; COHEN DA, 1992, PUBLIC HEALTH REP, V107, P727; Deren S, 1996, AIDS EDUC PREV, V8, P335; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; DONOVAN P, 1993, TESTING POSITIVE SEX; ENG TR, 1997, HIDDEN EPIDEMIC CONF; Fishbein M.A., 1975, PHILOS RHETORIC; FULLILOVE MT, 1990, J SEX RES, V27, P47, DOI 10.1080/00224499009551541; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HARLAP S, 1991, PREVENTING PREGNANCY; HOBFOLL SE, 1994, HEALTH PSYCHOL, V13, P397, DOI 10.1037/0278-6133.13.5.397; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; Kalichman SC, 1996, ANN BEHAV MED, V18, P6, DOI 10.1007/BF02903934; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; KELLY JA, 1995, J CONSULT CLIN PSYCH, V63, P907, DOI 10.1037/0022-006X.63.6.907; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KLINE A, 1992, SOC SCI MED, V34, P447, DOI 10.1016/0277-9536(92)90305-A; MAYS VM, 1988, AM PSYCHOL, V43, P949, DOI 10.1037/0003-066X.43.11.949; Miller J.B., 1997, HEALING CONNECTION W; *MMWR, 1997, MMWR-MORBID MORTAL W, V46, P165; MORRISON DM, 1994, J YOUTH ADOLESCENCE, V23, P271, DOI 10.1007/BF01537449; NEWMAN LF, 1991, RES ISSUES HUMAN BEH, P258; Nyamathi A, 1990, NAACOGS Clin Issu Perinat Womens Health Nurs, V1, P86; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; OLeary A, 1996, AIDS EDUC PREV, V8, P516; OLEARY A, 1995, AIDS PREVENT MENT H, P1; Orr DP, 1996, J PEDIATR-US, V128, P288, DOI 10.1016/S0022-3476(96)70413-4; RAMOS R, 1995, SOCIOL QUART, V36, P483, DOI 10.1111/j.1533-8525.1995.tb00449.x; Rogers EM., 1983, DIFFUSION INNOVATION; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SCHILLING RF, 1991, PUBLIC HEALTH REP, V106, P297; SOBO EJ, 1995, HUM ORGAN, V54, P115, DOI 10.17730/humo.54.2.g568548023132n37; StLawrence JS, 1997, J CONSULT CLIN PSYCH, V65, P504, DOI 10.1037/0022-006X.65.3.504; STLAWRENCE JS, 1995, J CONSULT CLIN PSYCH, V63, P221, DOI 10.1037/0022-006X.63.2.221; StLouis ME, 1997, AM J PUBLIC HEALTH, V87, P10, DOI 10.2105/AJPH.87.1.10; Surrey Janet L., 1991, WOMENS GROWTH CONNEC, P171; VALDISERRI RO, 1989, AIDS, V3, P21, DOI 10.1097/00002030-198903010-00005; WASSERHEIT JN, 1992, REPROD BIOL, P7; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WEEKS MR, 1995, AIDS EDUC PREV, V7, P251; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003; 1997, HIV AIDS PREV    JUL, P1	56	218	219	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					93	100		10.1056/NEJM199901143400203	http://dx.doi.org/10.1056/NEJM199901143400203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	156RQ	9887160	Bronze			2022-12-28	WOS:000078016200003
J	Clark, AG; Begun, DJ; Prout, T				Clark, AG; Begun, DJ; Prout, T			Female x male interactions in Drosophila sperm competition	SCIENCE			English	Article							ACCESSORY-GLAND PRODUCTS; MULTIPLE INSEMINATION; POPULATION-GENETICS; MELANOGASTER; DISPLACEMENT; PROTEIN; PSEUDOOBSCURA; POLYMORPHISM; ASSOCIATION; DIVERGENCE	In several organisms, the success of a male's sperm in multiply inseminated females depends on the male's genotype. In Drosophila, the female also plays a role in determining which sperm are successful. Pairwise tests among six isogenic lines of Drosophila melanogaster were performed to determine whether there is a genotype-specific interaction in the success of sperm. The success of a particular male's sperm was found to depend on the genotype of the female with which he mates, providing evidence for an interaction with profound evolutionary consequences.	Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Davis	Clark, AG (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.	c92@psu.edu		Clark, Andrew/0000-0001-7159-8511				Aguade M, 1998, GENETICS, V150, P1079; AGUADE M, 1992, GENETICS, V132, P755; Bertram MJ, 1996, INSECT BIOCHEM MOLEC, V26, P971, DOI 10.1016/S0965-1748(96)00064-1; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Chen PS, 1996, EXPERIENTIA, V52, P503, DOI 10.1007/BF01969718; CHEN PS, 1984, ANNU REV ENTOMOL, V29, P233, DOI 10.1146/annurev.en.29.010184.001313; Civetta A, 1995, J MOL EVOL, V41, P1085, DOI 10.1007/BF00173190; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; Clark AG, 1998, GENETICS, V149, P1487; CLARK AG, 1995, GENETICS, V139, P189; COBBS G, 1977, AM NAT, V111, P641, DOI 10.1086/283197; Gilchrist AS, 1997, P ROY SOC B-BIOL SCI, V264, P1271, DOI 10.1098/rspb.1997.0175; GRIFFITHS RC, 1982, THEOR APPL GENET, V62, P89, DOI 10.1007/BF00276292; Gromko M.H., 1984, P371; Harshman LG, 1998, EVOLUTION, V52, P1334, DOI [10.2307/2411303, 10.1111/j.1558-5646.1998.tb02015.x]; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; Hughes KA, 1997, GENETICS, V145, P139; LEVINE L, 1980, AM NAT, V116, P493, DOI 10.1086/283644; Noreen E. W., 1989, COMPUTER INTENSIVE M; Pitnick S, 1997, EVOLUTION, V51, P833, DOI [10.2307/2411158, 10.1111/j.1558-5646.1997.tb03665.x]; Price CSC, 1997, NATURE, V388, P663, DOI 10.1038/41753; Prout T, 1996, GENETICS, V144, P401; PROUT T, 1977, GENETICS, V85, P95; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Wolfner MF, 1997, INSECT BIOCHEM MOLEC, V27, P179, DOI 10.1016/S0965-1748(96)00084-7	28	278	280	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					217	220		10.1126/science.283.5399.217	http://dx.doi.org/10.1126/science.283.5399.217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880253				2022-12-28	WOS:000077976700038
J	Merkel, R; Nassoy, P; Leung, A; Ritchie, K; Evans, E				Merkel, R; Nassoy, P; Leung, A; Ritchie, K; Evans, E			Energy landscapes of receptor-ligand bonds explored with dynamic force spectroscopy	NATURE			English	Article							AVIDIN-BIOTIN COMPLEX; MOLECULAR ADHESION; STREPTAVIDIN; BINDING; ORIGINS	Atomic force microscopy (AFM)(1,2) has been used to measure the strength of bonds between biological receptor molecules and their ligands(3-6). But for weak noncovalent bonds, a dynamic spectrum of bond strengths is predicted as the loading rate is altered, with the measured strength being governed by the prominent barriers traversed in the energy landscape along the force-driven bond-dissociation pathway(7). In other words, the pioneering early AFM measurements represent only a single point in a continuous spectrum of bond strengths, because theory predicts that these will depend on the rate at which the load is applied. Here we report the strength spectra for the bonds between streptavidin (or avidin) and biotin(8)-the prototype of receptor-ligand interactions used in earlier AFM studies(3-5), and which have been modelled by molecular dynamics(9,10). We have probed bond formation over six orders of magnitude in loading rate, and find that the bond survival time diminished from about 1 min to 0.001 s with increasing loading rate over this range. The bond strength, meanwhile, increased from about 5 pN to 170 pN. Thus, although they are among the strongest noncovalent linkages in biology (affinity of 10(13) to 10(15) M-1)(8,11), these bonds in fact appear strong or weak depending on how fast they are loaded. We are also able to relate the activation barriers derived from our strength spectra to the shape of the energy landscape derived from simulations of the biotin-avidin complex.	Univ British Columbia, Dept Phys, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 1Z1, Canada; Tech Univ Munich, Dept Phys, D-85748 Garching, Germany; Inst Curie, F-75231 Paris, France; Boston Univ, Boston, MA 02215 USA	University of British Columbia; University of British Columbia; Technical University of Munich; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Boston University	Evans, E (corresponding author), Univ British Columbia, Dept Phys, 6224 Agr Rd, Vancouver, BC V6T 1Z1, Canada.	evans@physics.ubc.ca	Merkel, Rudolf/G-3647-2013; Nassoy, Pierre/AAC-2606-2019	Merkel, Rudolf/0000-0003-3178-3282; 				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brunk DK, 1996, BIOPHYS J, V71, P2902, DOI 10.1016/S0006-3495(96)79487-0; CHILKOTI A, 1995, J AM CHEM SOC, V117, P10622, DOI 10.1021/ja00148a003; Chu V, 1998, PROTEIN SCI, V7, P848; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; EVANS E, 1995, BIOPHYS J, V68, P2580, DOI 10.1016/S0006-3495(95)80441-8; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LEE UG, 1994, LANGMUIR, V8, P354; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873	23	1408	1436	8	379	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					50	53		10.1038/16219	http://dx.doi.org/10.1038/16219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892352				2022-12-28	WOS:000077959400043
J	Hanberger, H; Garcia-Rodriguez, JA; Gobernado, M; Goossens, H; Nilsson, LE; Struelens, MJ				Hanberger, H; Garcia-Rodriguez, JA; Gobernado, M; Goossens, H; Nilsson, LE; Struelens, MJ		French Portuguese ICU Study Grps	Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECTRUM BETA-LACTAMASES; ANTIMICROBIAL RESISTANCE; BACTEREMIA; FEATURES; CEPHALOSPORINS; EPIDEMIOLOGY; KLEBSIELLA; EMERGENCE; HOSPITALS; INFECTION	Context Surveillance of antibiotic resistance is especially important in intensive care units (ICUs) because the infection rates are much higher there than in other hospital wards and most epidemics with multiresistant bacteria originate in ICUs, Objective To evaluate the incidence of decreased antibiotic susceptibility among aerobic gram-negative bacilli isolated from patients in ICUs. Design Consecutive specimens collected on clinical indications from ICU patients were cultured and tested. Minimum inhibitory concentrations for amikacin, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, piperacillin, and piperacillin-tazobactam were determined using E test. Setting Eighteen hospitals in Belgium, 40 in France, 20 in Portugal, 30 in Spain, and 10 in Sweden. Subjects A total of 9166 gram-negative strains were initially isolated from 7308 patients between June 1994 and June 1995. Main Outcome Measures The incidence of decreased susceptibility, defined as the sum of resistant and intermediate categories with use of the minimum inhibitory concentration break points recommended by the National Committee for Clinical Laboratory Standards. Results The most frequently isolated organisms were Enterobacteriaceae (59%) followed by Pseudomonas aeruginosa (24%). The main sources were respiratory tract (42%), urine (26%), blood (14%), abdomen (11%), and skin and soft tissue (7%), Decreased antibiotic susceptibility across all species and drugs was highest in Portuguese ICUs followed by French, Spanish, Belgian, and Swedish ICUs. The highest incidence of resistance was seen in all countries among P aeruginosa (up to 37% resistant to ciprofloxacin in Portuguese ICUs and 46% resistant to gentamicin in French ICUs), Enterobacter species, Acinetobacter species, and Stenotrophomonas maltophilia, and in Portugal and France among Klebsiella species. Conclusion The high incidence of reduced antibiotic susceptibility among gramnegative bacteria in these ICUs suggests that more effective strategies are needed to control the selection and spread of resistant organisms.	Linkoping Univ Hosp, Dept Infect Dis, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Clin Microbiol, S-58185 Linkoping, Sweden; Univ Hosp, Dept Microbiol, Salamanca, Spain; Hosp La Fe, Dept Microbiol, E-46009 Valencia, Spain; Univ Hosp, Dept Microbiol, Antwerp, Belgium; Univ Brussels, Erasme Hosp, Dept Microbiol, Brussels, Belgium	Linkoping University; Linkoping University; Hospital Universitari i Politecnic La Fe; Universite Libre de Bruxelles	Hanberger, H (corresponding author), Linkoping Univ Hosp, Dept Infect Dis, S-58185 Linkoping, Sweden.	hakan.hanberger@inf.liu.se		Struelens, Marc/0000-0001-5150-4944				[Anonymous], 1997, M7A4 NCCLS; Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; BROWN DFJ, 1991, J ANTIMICROB CHEMOTH, V27, P185, DOI 10.1093/jac/27.2.185; BUIRMA RJA, 1991, SCAND J INFECT DIS, P35; BURWEN DR, 1994, J INFECT DIS, V170, P1622, DOI 10.1093/infdis/170.6.1622; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Cisneros JM, 1996, CLIN INFECT DIS, V22, P1026, DOI 10.1093/clinids/22.6.1026; DavinRegli A, 1996, J CLIN MICROBIOL, V34, P1474, DOI 10.1128/JCM.34.6.1474-1480.1996; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; Glupczynski Y, 1998, ACTA CLIN BELG, V53, P28; Goetz A, 1997, CURR OPIN INFECT DIS, V10, P319, DOI 10.1097/00001432-199708000-00013; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; Hanberger Hkan, 1997, Clin Microbiol Infect, V3, P208, DOI 10.1111/j.1469-0691.1997.tb00599.x; Itokazu GS, 1996, CLIN INFECT DIS, V23, P779, DOI 10.1093/clinids/23.4.779; JACOBSON KL, 1995, CLIN INFECT DIS, V21, P1107, DOI 10.1093/clinids/21.5.1107; Jarlier V, 1996, INTENS CARE MED, V22, P1057, DOI 10.1007/s001340050213; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; Livermore DM, 1996, J ANTIMICROB CHEMOTH, V38, P409, DOI 10.1093/jac/38.3.409; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; Riley TV, 1996, PATHOLOGY, V28, P359, DOI 10.1080/00313029600169354; SHAH PM, 1991, SCAND J INFECT DIS, P22; TILLEY PAG, 1994, CLIN INFECT DIS, V18, P896, DOI 10.1093/clinids/18.6.896; VERBIST L, 1991, SCAND J INFECT DIS, P45; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	25	231	247	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					67	71		10.1001/jama.281.1.67	http://dx.doi.org/10.1001/jama.281.1.67			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892453	Bronze			2022-12-28	WOS:000077829300037
J	Starzl, TE; Zinkernagel, RM				Starzl, TE; Zinkernagel, RM			Antigen localization and migration in immunity and tolerance	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WHOLE-ORGAN TRANSPLANTATION; LIVER ALLOGRAFT-REJECTION; T-CELL TOLERANCE; GRAFT ACCEPTANCE; DENDRITIC CELLS; BONE-MARROW; CHIMERISM; INDUCTION; VIRUS; LEUKOCYTES		Univ Pittsburgh, Med Ctr, Inst Transplantat, Pittsburgh, PA USA; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Zurich	Starzl, TE (corresponding author), Falk Clin 5C, 3601 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40329] Funding Source: Medline; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; AUST J. BRADLEY, 1965, ANN SURG, V162, P738, DOI 10.1097/00000658-196510000-00015; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bishop GA, 1997, TRANSPLANTATION, V64, P1377, DOI 10.1097/00007890-199711270-00001; BURNET FM, 1961, NEW ENGL J MED, V264, P24, DOI 10.1056/NEJM196101052640107; COHN M, 1994, ANNU REV IMMUNOL, V12, P1; Collette Y, 1997, IMMUNOL TODAY, V18, P393, DOI 10.1016/S0167-5699(97)01104-3; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; Demetris AJ, 1997, AM J PATHOL, V150, P563; DEMETRIS AJ, 1991, AM J PATHOL, V138, P609; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Ehl S, 1998, NAT MED, V4, P1015, DOI 10.1038/2001; ELKINS WL, 1968, SCIENCE, V159, P1250, DOI 10.1126/science.159.3820.1250; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; HART DNJ, 1980, TRANSPLANTATION, V30, P73, DOI 10.1097/00007890-198007000-00016; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KASHIWAGI N, 1969, Surgical Forum (Chicago), V20, P374; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; LAWRENCE HS, 1959, PHYSIOL REV, V39, P811, DOI 10.1152/physrev.1959.39.4.811; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; LU L, 1995, J EXP MED, V182, P379, DOI 10.1084/jem.182.2.379; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MILLER JF, 1961, LANCET, V2, P748; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MOSKOPHIDIS D, 1993, NATURE, V364, P262, DOI 10.1038/364262a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Murase N, 1996, TRANSPLANTATION, V61, P1, DOI 10.1097/00007890-199601150-00001; MURASE N, 1990, TRANSPLANTATION, V50, P739, DOI 10.1097/00007890-199011000-00002; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; NEMLANDER A, 1982, J EXP MED, V156, P1087, DOI 10.1084/jem.156.4.1087; NOSSAL GJ, 1971, ANTIGENS LYMPHOID CE; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PICUS J, 1985, J EXP MED, V162, P2035, DOI 10.1084/jem.162.6.2035; PRZEPIORKA D, 1991, AM J CLIN PATHOL, V95, P201, DOI 10.1093/ajcp/95.2.201; Qian SG, 1997, J IMMUNOL, V158, P4654; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SIMONSEN M, 1960, ANN NY ACAD SCI, V87, P382, DOI 10.1111/j.1749-6632.1960.tb23207.x; Starzl TE, 1996, IMMUNOL TODAY, V17, P588; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1969, EXPERIENCE HEPATIC T, P229; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STEINMULLER D, 1967, SCIENCE, V158, P127, DOI 10.1126/science.158.3797.127; Sterzl J, 1967, Adv Immunol, V6, P337, DOI 10.1016/S0065-2776(08)60525-8; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Terakura M, 1998, TRANSPLANTATION, V66, P350, DOI 10.1097/00007890-199808150-00012; Traub E, 1936, J EXP MED, V63, P847, DOI 10.1084/jem.63.6.847; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	71	199	207	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1905	1913		10.1056/NEJM199812243392607	http://dx.doi.org/10.1056/NEJM199812243392607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862947	Green Accepted			2022-12-28	WOS:000077696600007
J	Braun, V				Braun, V			Protein structure - Pumping iron through cell membranes	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; OUTER-MEMBRANE; TONB PROTEIN; TRANSPORT; FHUA; BINDING; RECEPTOR; TRANSDUCTION; CHANNEL		Univ Tubingen, Dept Mikrobiol Membranphysiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Braun, V (corresponding author), Univ Tubingen, Dept Mikrobiol Membranphysiol, D-72076 Tubingen, Germany.							Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Bos C, 1998, J BACTERIOL, V180, P605; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KILLMANN H, 1995, J BACTERIOL, V177, P694, DOI 10.1128/jb.177.3.694-698.1995; KOSTER W, 1990, J BIOL CHEM, V265, P21407; Locher KP, 1997, EUR J BIOCHEM, V247, P770, DOI 10.1111/j.1432-1033.1997.t01-1-00770.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907	15	27	28	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2202	2203		10.1126/science.282.5397.2202	http://dx.doi.org/10.1126/science.282.5397.2202			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890828				2022-12-28	WOS:000077645800029
J	Aronin, SI; Peduzzi, P; Quagliarello, VJ				Aronin, SI; Peduzzi, P; Quagliarello, VJ			Community-acquired bacterial meningitis: Risk stratification for adverse clinical outcome and effect of antibiotic timing	ANNALS OF INTERNAL MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS MENINGITIS; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; RAT; PREDICTION; PROGNOSIS; MANAGEMENT; MORBIDITY; EMERGENCY; CHILDREN	Background: Community-acquired bacterial meningitis causes substantial morbidity and mortality in adults. Objective: To create and test a prognostic model for persons with community-acquired bacterial meningitis and to determine whether antibiotic timing influences clinical outcome. Design: Retrospective cohort study; patients were divided into derivation and validation samples. Setting: Four hospitals in Connecticut. Patients: 269 persons who, between 1970 and 1995, had community-acquired bacterial meningitis microbiologically proven by a lumbar puncture done within 24 hours of presentation in the emergency department. Measurements: Baseline clinical and laboratory features and times of arrival in the emergency department, performance of lumbar puncture, and administration of antibiotics. The target end point was the development of an adverse clinical outcome (death or neurologic deficit at discharge). Results: For the total group, the hospital mortality rate was 27%. Fifty-six of 269 patients (21%) developed a neurologic deficit, and in 9% the neurologic deficit persisted at discharge. Three baseline clinical features (hypotension, altered mental status, and seizures) were independently associated with adverse clinical outcome and were used to create a prognostic model from the derivation sample. The prediction accuracy of the model was determined by using the concordance index (c-index). For both the derivation sample (c-index, 0.73 [95% CI, 0.65 to 0.81]) and the validation sample (c-index, 0.81 [CI, 0.71 to 0.92]), the model predicted adverse clinical outcome significantly better than chance. For the total group, the model stratified patients into three prognostic stages: low risk for adverse clinical outcome (9%; stage I), intermediate risk (33%; stage II), and high risk (56%; stage III) (P = 0.001). Adverse clinical outcome was more common for patients in whom the prognostic stage advanced from low risk (P = 0.008) or intermediate risk (P = 0.003) at arrival in the emergency department to high risk before administration of antibiotics. Conclusions: In persons with community-acquired bacterial meningitis, three baseline clinical features of disease severity predicted adverse clinical outcome and stratified patients into three stages of prognostic severity. Delay in therapy after arrival in the emergency department was associated with adverse clinical outcome when the patient's condition advanced to the highest stage of prognostic severity before the initial antibiotic dose was given.	Yale Univ, Sch Med, New Haven, CT 06510 USA; Waterbury Hosp & Hlth Ctr, Waterbury, CT 06721 USA; Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program, West Haven, CT 06516 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Quagliarello, VJ (corresponding author), Yale Univ, Sch Med, 800 LCI, New Haven, CT 06510 USA.							BAIRD DR, 1976, LANCET, V2, P1344; BEHRMAN RE, 1989, ARCH INTERN MED, V149, P1596; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BRYAN CS, 1986, ANN EMERG MED, V15, P544, DOI 10.1016/S0196-0644(86)80990-8; CARPENTER R R, 1962, Am J Med, V33, P262, DOI 10.1016/0002-9343(62)90024-4; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; FEINSTEIN AR, 1996, MULTIVRIABLE ANAL IN; FEINSTEIN AR, 1989, PUBLICATION PHS, P189; FINE MJ, 1990, AM J MED, V88, pN1; FINLAND M, 1977, J INFECT DIS, V136, P400, DOI 10.1093/infdis/136.3.400; FONG IW, 1984, Q J MED, V53, P289; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HERSON VC, 1977, PEDIATRICS, V59, P35; HODGES GR, 1975, AM J MED SCI, V270, P427, DOI 10.1097/00000441-197511000-00003; ISPAHANI P, 1983, J HYG-CAMBRIDGE, V91, P189, DOI 10.1017/S0022172400060198; JENSEN AG, 1993, ARCH INTERN MED, V153, P1902, DOI 10.1001/archinte.153.16.1902; KALLIO MJT, 1994, JAMA-J AM MED ASSOC, V272, P787, DOI 10.1001/jama.272.10.787; KILPI T, 1993, PEDIATR INFECT DIS J, V12, P184, DOI 10.1097/00006454-199303000-00002; LEBEL MH, 1989, PEDIATRICS, V83, P161; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; Magnussen C R, 1980, N Y State J Med, V80, P901; MEADOW WL, 1993, AM J DIS CHILD, V147, P40, DOI 10.1001/archpedi.1993.02160250042014; OLSSON RA, 1961, ANN INTERN MED, V55, P545, DOI 10.7326/0003-4819-55-4-545; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; QUAGLIARELLO VJ, 1991, J EXP MED, V174, P657, DOI 10.1084/jem.174.3.657; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RASMUSSEN HH, 1992, AGE AGEING, V21, P216, DOI 10.1093/ageing/21.3.216; ROMER FK, 1977, DAN MED BULL, V24, P35; SCHELD WM, 1994, HARRISONS PRINCIPLES, P2296; SCHLESINGER LS, 1987, MEDICINE, V66, P148, DOI 10.1097/00005792-198703000-00006; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TALAN DA, 1993, ANN EMERG MED, V22, P1733, DOI 10.1016/S0196-0644(05)81314-9; TUNKEL AR, 1995, MANDELL DOUGLAS BENN, P831; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WIEBE RA, 1972, SOUTH MED J, V65, P257, DOI 10.1097/00007611-197203000-00001	48	308	318	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					862	869		10.7326/0003-4819-129-11_Part_1-199812010-00004	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867727				2022-12-28	WOS:000077239200003
J	Selker, HP; Beshansky, JR; Griffith, JL; Aufderheide, TP; Ballin, DS; Bernard, SA; Crespo, SG; Feldman, JA; Fish, SS; Gibler, WB; Kiez, DA; McNutt, RA				Selker, HP; Beshansky, JR; Griffith, JL; Aufderheide, TP; Ballin, DS; Bernard, SA; Crespo, SG; Feldman, JA; Fish, SS; Gibler, WB; Kiez, DA; McNutt, RA			Use of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia - A multicenter, controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; ACUTE MYOCARDIAL-INFARCTION; EMERGENCY; ADMISSION	Background: Approximately 6 million U.S. patients present to emergency departments annually with symptoms suggesting acute cardiac ischemia. Triage decisions for these patients are important but remain difficult. Objective: To test whether computerized prediction of the probability of acute ischemia, used with electrocardiography, improves the accuracy of triage decisions. Design: Controlled clinical trial. Setting: 10 hospital emergency departments in the midwestern, southeastern, and northeastern United States. Patients: 10 689 patients with chest pain or other symptoms suggestive of acute cardiac ischemia. Intervention: The probability of acute ischemia predicted by the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI), either automatically printed or not printed on patients' electrocardiograms. Measurements: Emergency department triage to a coronary care unit (CCU), telemetry unit, ward, or home. Other measurements were the bed capacity of the CCU relative to that of the telemetry unit; training or supervision status of the triaging physician; and patient diagnoses and outcomes based on clinical, electrocardiographic, and creatine kinase data. Results: Fbr patients without cardiac ischemia, in hospitals with high-capacity CCUs and relatively few-capacity cardiac telemetry units, use of ACI-TIPI was associated with a reduction in CCU admissions from 15% to 12%, a change of -16% (95% CI, -30% to 0%), and an increase in emergency department discharges to home from 49% to 52%, a change of 6% (CI, 0% to 14%; overall P = 0.09). Across all hospitals, for patients evaluated by unsupervised residents, use of ACI-TIPI was associated with a reduction in CCU admissions from 14% to 10%, a change of -32% (CI, -55% to 3%); a reduction in telemetry unit admissions from 39% to 31%, a change of -20% (CI, -34% to -2%); and an increase in discharges to home from 45% to 56%, a change of 25% (CI, 8% to 45%; overall P = 0.008). Among patients with stable angina, in hospitals with high-capacity CCUs, use of ACI-TIP[ was associated with a reduction in CCU admissions from 26% to 13%, a change of -50% (CI, -70% to -17%), and an increase in discharges to home from 20% to 22%, a change of 10% (CI, -29% to 71%; overall P = 0.02). At hospitals with high-capacity telemetry units, use of ACI-TIPI was associated with a reduction in telemetry unit admissions from 68% to 59%, a change of -14% (CI, -27% to 1%), and an increase in emergency department discharges to home from 10% to 21%, a change of 100% (CI, 22% to 230%; overall P = 0.02). Among patients with acute myocardial infarction or unstable angina, use of ACI-TIPI did not change appropriate admission (96%) to the CCU or telemetry unit at hospitals with high-capacity CCUs or telemetry units. Conclusions: Use of ACI-TIPI was associated with reduced hospitalization among emergency department patients without acute cardiac ischemia. This result varied as expected according to the CCU and cardiac telemtry unit capacities and physician supervision at individual hospitals. Appropriate admission for unstable angina or acute infarction was not affected. If ACI-TIPI is used widely in the United States, its potential incremental impact may be more than 200 000 fewer unnecessary hospitalizations and more than 100 000 fewer unnecessary CCU admissions.	Tufts Univ New England Med Ctr, Div Clin Care Res, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr, Boston, MA 02111 USA; Boston City Hosp, Boston, MA 02118 USA; Boston Univ, Med Ctr, Boston, MA USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Newton Wellesley Hosp, Wellesley, MA USA; Baystate Med Ctr, Springfield, MA 01199 USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ N Carolina Hosp, Chapel Hill, NC USA; Rhode Isl Hosp, Providence, RI 02903 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Tufts Medical Center; Tufts Medical Center; Tufts University; Boston Medical Center; Boston University; Medical College of Wisconsin; Newton Wellesley Hospital; Baystate Medical Center; University System of Ohio; University of Cincinnati; University North Carolina Hospital; Lifespan Health Rhode Island; Rhode Island Hospital; Virginia Commonwealth University	Selker, HP (corresponding author), Tufts Univ New England Med Ctr, Div Clin Care Res, 63,750 Washington St, Boston, MA 02111 USA.		woolard, robert h/A-7860-2011; Sayre, Michael R/E-8383-2017	Sayre, Michael R/0000-0003-0322-3181; Feldman, James/0000-0003-3962-0189; Fish, Susan/0000-0001-6309-0558	AHRQ HHS [R01 HS07360] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Aufderheide TP, 1996, ANN EMERG MED, V27, P193, DOI 10.1016/S0196-0644(96)70322-0; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CAIRNS CB, 1992, J ELECTROCARDIOL, V24, P46; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cochrane A.L., 1971, EFFECTIVENESS EFFICI; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; JAYES RL, 1992, J CLIN EPIDEMIOL, V45, P621, DOI 10.1016/0895-4356(92)90134-9; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SELKER HP, 1989, AM J MED, V87, P491	21	268	274	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					845	855		10.7326/0003-4819-129-11_Part_1-199812010-00002	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867725				2022-12-28	WOS:000077239200001
J	Cembrowicz, S				Cembrowicz, S			Tales of crack - Some quotes from patients and their doctors	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					163	163		10.1136/bmj.318.7177.163	http://dx.doi.org/10.1136/bmj.318.7177.163			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888911	Green Published			2022-12-28	WOS:000078175100028
J	White, C				White, C			Some "cot deaths" are child abuse	BRITISH MEDICAL JOURNAL			English	News Item																		Meadow R, 1999, ARCH DIS CHILD, V80, P7, DOI 10.1136/adc.80.1.7	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					147	147		10.1136/bmj.318.7177.147	http://dx.doi.org/10.1136/bmj.318.7177.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888898	Green Published			2022-12-28	WOS:000078175100016
J	Porrill, J; Frisby, JP; Adams, WJ; Buckley, D				Porrill, J; Frisby, JP; Adams, WJ; Buckley, D			Robust and optimal use of information in stereo vision	NATURE			English	Article							VERTICAL DISPARITY; DEPTH-PERCEPTION; HOUGH TRANSFORM; MODEL	Differences between the left and right eye's views of the world carry information about three-dimensional scene structure and about the position of the eyes in the head The contemporary Bayesian approach to perception(1,2) implies that human performance in using this source of eye-position information can be analysed most usefully by comparison with the performance of a statistically optimal observer. Here we argue that the comparison observer should also be statistically robust, and we find that this requirement leads to qualitatively new behaviours. For example, when presented with a class of stereoscopic stimuli containing inconsistent information about eccentricity of gaze, estimates of this gaze parameter recorded from one robust ideal observer bifurcate at a critical value of stimulus inconsistency. We report an experiment in which human observers also show this phenomenon and we use the experimentally determined critical value to estimate the vertical acuity of the visual system. The Bayesian analysis also provides a highly reliable and biologically plausible algorithm that can recover eye positions even before the classic stereo-correspondence problem is solved, that is, before deciding which features in the left and right images are to be matched.	Univ Sheffield, Dept Psychol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Dept Ophthalmol & Orthopt, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield; University of Sheffield	Frisby, JP (corresponding author), Univ Sheffield, Dept Psychol, Sheffield S10 2TN, S Yorkshire, England.		Porrill, John/F-3223-2010	Buckley, David/0000-0001-9140-8543				Adams W, 1996, PERCEPTION, V25, P165, DOI 10.1068/p250165; ADELSON EH, 1980, PERCEPTION S, V27, P18; BALLARD DH, 1986, BEHAV BRAIN SCI, V9, P67, DOI 10.1017/S0140525X00021555; BALLARD DH, 1981, PATTERN RECOGN, V13, P111, DOI 10.1016/0031-3203(81)90009-1; BARLOW HB, 1980, PHILOS T ROY SOC B, V290, P71, DOI 10.1098/rstb.1980.0083; DRASDO N, 1977, NATURE, V266, P554, DOI 10.1038/266554a0; FRISBY JP, 1984, NATURE, V307, P592, DOI 10.1038/307592a0; GARDING J, 1995, VISION RES, V35, P703, DOI 10.1016/0042-6989(94)00162-F; Kaneko H, 1997, VISION RES, V37, P2871, DOI 10.1016/S0042-6989(97)00099-0; KAY S. M., 1993, FUNDAMENTALS SIGNAL; Knill DC, 1996, PERCEPTION BAYESIAN; KOENDERINK JJ, 1976, BIOL CYBERN, V21, P29, DOI 10.1007/BF00326670; Marr D., 1982, VISION; MAYHEW J, 1982, PERCEPTION, V11, P387, DOI 10.1068/p110387; MAYHEW JEW, 1982, NATURE, V297, P376, DOI 10.1038/297376a0; OGLE KN, 1962, EYE, V4, P209; Peek S. A., 1984, Image and Vision Computing, V2, P180, DOI 10.1016/0262-8856(84)90021-0; PETROV AP, 1980, VISION RES, V20, P409, DOI 10.1016/0042-6989(80)90031-0; Porrill J, 1997, PERCEPTION, V26, P39; PORRILL J, 1985, FRONTIERS VISUAL SCI, P90; ROGERS BJ, 1996, INVEST OPHTH VIS SCI, V37, P684; STENTON SP, 1984, NATURE, V309, P622, DOI 10.1038/309622a0; STEPHENS RS, 1991, IMAGE VISION COMPUT, V9, P66, DOI 10.1016/0262-8856(91)90051-P; STEPHENSON SB, 1997, VISION RES, V37, P2717; VANDEGRIND WA, 1995, PERCEPTION, V24, P215, DOI 10.1068/p240215	25	29	29	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					63	66		10.1038/16244	http://dx.doi.org/10.1038/16244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155RD	9892353				2022-12-28	WOS:000077959400047
J	Wang, HB; Bedford, FK; Brandon, NJ; Moss, SJ; Olsen, RW				Wang, HB; Bedford, FK; Brandon, NJ; Moss, SJ; Olsen, RW			GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton	NATURE			English	Article							GLYCINE RECEPTOR; A RECEPTOR; TUBULIN; PHOSPHORYLATION; BINDING; KINASE; SITES; GEPHYRIN; SUBUNIT; BRAIN	Type-A receptors for the neurotransmitter GABA (gamma-aminobutyric acid) are ligand-gated chloride channels that mediate inhibitory neurotransmission. Each subunit of the pentameric receptor protein has ligand-binding sites in the amino-terminal extracellular domain and four membrane-spanning regions, one of which forms a wall of the ion channel(1). Each subunit also has a large intracellular loop that may be a target for protein kinases and be required for subcellular targeting and membrane clustering of the receptor, perhaps by anchoring the receptor to the cytoskeleton(2-4) Neurotransmitter receptors need to be positioned in high density in the cell membrane at sites postsynaptic to nerve terminals releasing that neurotransmitter, Other members of the superfamily of ligand-gated ion-channel receptors associate in postsynaptic-membrane clusters by binding to the proteins rapsyn or gephyrin(5-7). Here we identify a new cellular protein, GABA(A)-receptor-associated protein (GABARAP), which can interact with the gamma 2 subunit of GABA(A) receptors, GABARAP binds to GABA(A) receptors both in vitro and in vivo, and co-localizes with the punctate staining of GABA(A) receptors on cultured cortical neurons, Sequence analysis shows similarity between GABARAP and light chain-3 of microtubule-associated proteins 1A and 1B. Moreover, the N terminus of GABARAP is highly positively charged and features a putative tubulin-binding motif. The interactions among GABA(A) receptors, GABARAP and tubulin suggest a mechanism for the targeting and clustering of GABA(A) receptors.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; UCL, MRC, Lab Mol & Cell Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of London; University College London; University of London; University College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Olsen, RW (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	rolsen@mednet.ucla.edu		Brandon, Nicholas/0000-0002-3917-0096				CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GAO B, 1994, EUR J NEUROSCI, V6, P837, DOI 10.1111/j.1460-9568.1994.tb00994.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; HILL JA, 1992, MOL NEUROBIOL, V6, P1, DOI 10.1007/BF02935564; ITEM C, 1994, J NEUROCHEM, V63, P1119; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MANN SS, 1994, J BIOL CHEM, V269, P11492; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Nishimura RN, 1996, MOL BRAIN RES, V36, P227, DOI 10.1016/0169-328X(95)00261-P; NUSSER Z, 1995, J NEUROSCI, V15, P2948; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SANCHEZ C, 1994, ARCH BIOCHEM BIOPHYS, V310, P428, DOI 10.1006/abbi.1994.1188; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	21	471	488	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					69	72		10.1038/16264	http://dx.doi.org/10.1038/16264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892355				2022-12-28	WOS:000077959400049
J	Lot, F; Seguier, JC; Fegueux, S; Astagneau, P; Simon, P; Aggoune, M; van Amerongen, P; Ruch, M; Cheron, M; Brucker, G; Desenclos, JC; Drucker, J				Lot, F; Seguier, JC; Fegueux, S; Astagneau, P; Simon, P; Aggoune, M; van Amerongen, P; Ruch, M; Cheron, M; Brucker, G; Desenclos, JC; Drucker, J			Probable transmission of HIV from an orthopedic surgeon to a patient in France	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; SURGICAL-PROCEDURES; INFECTED SURGEON; HEPATITIS-B; TYPE-1	Background: Transmission of HIV from infected health care workers to patients has been documented in only one cluster involving 6 patients of a dentist in Florida. in October 1995, the French Ministry of Health offered HIV testing to patients who had been operated on by an orthopedic surgeon in whom AIDS was recently diagnosed. Objective: To determine whether the surgeon transmitted HIV to patients during operations. Design: Epidemiologic investigation. Setting: The practice of an orthopedic surgeon in a French public hospital. Participants: 1 surgeon and 983 of his former patients. Measurements: 3004 patients who had undergone invasive procedures were contacted by mail for counseling and HIV testing. One HIV-positive patient was interviewed, and DNA sequence analysis was performed to compare the genetic relation of the patient's and the surgeon's viruses. Infection-control precautions and the surgeon's practices were assessed. Results: Of 983 patients in whom serologic status was ascertained, 982 were HIV negative and 1 was HIV positive. The HIV-positive patient, a woman born in 1925, tested negative for HIV before placement of a total hip prosthesis with bone graft (a prolonged operation) performed by the surgeon in 1992. She had no identified risk for HIV exposure. Molecular analysis indicated that the viral sequences obtained from the surgeon and the HIV-infected woman were closely related. Infection-control precautions were in accordance with recommendations, but blood contact between the surgeon and his patients occurred commonly during surgical procedures. Conclusions: An HIV-infected surgeon may have transmitted HIV to one of his patients during surgery.	Reseau Natl Sante Publ, F-94415 St Maurice, France; Hop St Germaine en Laye, F-78105 St Germain En Laye, France; Inst Biomed Cordeliers, Ctr Interreg Coordinat Lutte Contre Infect Nosoco, F-75006 Paris, France; Direct Dept Affaires Sanit & Sociales Yvelines, F-78007 Versailles, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Lot, F (corresponding author), Reseau Natl Sante Publ, 14 Rue Val Dosne, F-94415 St Maurice, France.	Lot@b3e.jussieu.fr	Astagneau, Pascal/AAF-3473-2020					BELL DM, 1995, SURG CLIN N AM, V75, P1189; BELL DM, 1992, INFECT AGENT DIS, V1, P263; Blanchard A, 1998, J VIROL, V72, P4537, DOI 10.1128/JVI.72.5.4537-4540.1998; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Folin AC, 1997, INFECT CONT HOSP EP, V18, P244; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; Heptonstall J, 1997, NEW ENGL J MED, V336, P178, DOI 10.1056/NEJM199701163360304; Hochuli V, 1995, Commun Dis Rep CDR Rev, V5, pR7; JONSTON BL, 1994, C PREV TRANSM BLOODB, pA52; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; Porter KR, 1997, J ACQ IMMUN DEF SYND, V14, P1, DOI 10.1097/00042560-199701010-00001; ROBERT LM, 1995, ANN INTERN MED, V122, P653, DOI 10.7326/0003-4819-122-9-199505010-00002; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; Simon F, 1996, AIDS RES HUM RETROV, V12, P1427, DOI 10.1089/aid.1996.12.1427; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807	19	66	68	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					1	6		10.7326/0003-4819-130-1-199901050-00002	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890844				2022-12-28	WOS:000077744500001
J	Matsumoto, A; Momomura, S; Sugiura, S; Fujita, H; Aoyagi, T; Sata, M; Omata, M; Hirata, Y				Matsumoto, A; Momomura, S; Sugiura, S; Fujita, H; Aoyagi, T; Sata, M; Omata, M; Hirata, Y			Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; HYPERTENSION; EXERCISE	Background: Conventional vasodilators increase ventilation-perfusion mismatch and do not improve gas exchange even though they reduce pulmonary hypertension. However, the effects of nitric oxide inhalation on ventilatory and gas exchange values in patients with congestive heart failure are not known. Objective: To investigate the effect of nitric oxide inhalation on gas exchange in patients with congestive heart failure. Design: Randomized, controlled trial. Setting: University hospital. Patients: 16 patients with congestive heart failure (New York Heart Association class II or III). Interventions: Patients inhaled nitric oxide gas at graded concentrations (n = 8) or were given intravenous isosorbide dinitrate, 2.5 mg (n = 8). Measurements: Hemodynamic and ventilatory variables and blood gases were measured 5 minutes after inhalation of different doses of nitric oxide and 10 minutes after administration of isosorbide dinitrate. Results: Nitric oxide inhalation reduced the mean pulmonary arterial pressure in a dose-dependent manner without altering the mean arterial pressure or cardiac output. At a dose of 40 parts per million, nitric oxide inhalation increased PaO2 (change from baseline, 12.0 mm Hg [95% CI, 2.3 to 21.7 mm Hg]; P = 0.014) and decreased the alveolar-arterial difference in partial pressure of oxygen (change, -8.6 mm Hg [CI, -16.8 to -0.4 mm Hg]; P = 0.038) and the ventilatory equivalent for carbon dioxide output (change, -6.7 [CI, -10.3 to -3.1]; P < 0.001). Although isosorbide dinitrate similarly decreased pulmonary arterial pressure, it did not alter gas exchange or ventilatory variables. Conclusions: Because nitric oxide inhalation improved gas exchange, it may be used as a supportive therapy when other conventional vasodilators worsen gas exchange.	Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Matsumoto, A (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	amatsu-tky@umin.u-tokyo.ac.jp	FUJITA, HIDEO/AHC-6839-2022	Fujita, Hideo/0000-0002-4901-3502				ARMITAGE P, 1994, STAT METHODS MED RES, P207; BENCOWITZ HZ, 1984, J AM COLL CARDIOL, V4, P918, DOI 10.1016/S0735-1097(84)80051-0; Casaburi R., 1994, PRINCIPLES EXERCISE, P454; CHOONG CYP, 1986, J AM COLL CARDIOL, V8, P1461, DOI 10.1016/S0735-1097(86)80324-2; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GIRARD C, 1992, ANESTHESIOLOGY, V77, P880, DOI 10.1097/00000542-199211000-00007; GROSSMAN W, 1996, CARDIAC CATHETERIZAT, P109; Harrison TR, 1930, J CLIN INVEST, V8, P291, DOI 10.1172/JCI100265; LOH E, 1994, CIRCULATION, V90, P2780, DOI 10.1161/01.CIR.90.6.2780; MATSUMOTO A, 1995, AM HEART J, V129, P139, DOI 10.1016/0002-8703(95)90054-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOOKHERJEE S, 1978, CIRCULATION, V57, P106, DOI 10.1161/01.CIR.57.1.106; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1993, CIRCULATION, V87, P447, DOI 10.1161/01.CIR.87.2.447; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SEMIGRAN MJ, 1994, J AM COLL CARDIOL, V24, P982, DOI 10.1016/0735-1097(94)90859-1	16	10	11	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					40	44		10.7326/0003-4819-130-1-199901050-00008	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890849				2022-12-28	WOS:000077744500007
J	Choudhury, P				Choudhury, P			Nilima Choudhury, nee Kundu - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					61	61						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872907				2022-12-28	WOS:000078013100068
J	Garman, SC; Kinet, JP; Jardetzky, TS				Garman, SC; Kinet, JP; Jardetzky, TS			Crystal structure of the human high-affinity IgE receptor	CELL			English	Article							FC-EPSILON-RI; IMMUNOGLOBULIN-E-RECEPTOR; STRUCTURE-BASED DESIGN; BINDING-SITE; ALPHA-CHAIN; GAMMA-RII; BETA-SUBUNIT; DOMAIN; ANAPHYLAXIS; ATOPY	Allergic responses result from the activation of mast cells by the human high-affinity IgE receptor. IgE-mediated allergic reactions may develop to a variety of environmental compounds, but the initiation of a response requires the binding of IgE to its high-affinity receptor. We have solved the X-ray crystal structure of the antibody-binding domains of the human IgE receptor at 2.4 Angstrom resolution. The structure reveals a highly bent arrangement of immunoglobulin domains that form an extended convex surface of interaction with IgE. A prominent loop that confers specificity for IgE molecules extends from the receptor surface near an unusual arrangement of four exposed tryptophans. The crystal structure of the IgE receptor provides a foundation for the development of new therapeutic approaches to allergy treatment.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Harvard Univ, Sch Med, Lab Mol Allergy & Immunol, Boston, MA 02215 USA	Northwestern University; Harvard University; Harvard Medical School	Jardetzky, TS (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	jardetz@tochtli.biochem.nwu.edu			NIAID NIH HHS [AI-38972] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038972, R37AI038972] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASU M, 1993, J BIOL CHEM, V268, P13118; BLANK U, 1991, J BIOL CHEM, V266, P2639; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; HEMMING SA, 1995, J MOL BIOL, V246, P308, DOI 10.1006/jmbi.1994.0086; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HULETT MD, 1995, J BIOL CHEM, V270, P21188, DOI 10.1074/jbc.270.36.21188; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; JEFFERIS R, 1990, MOL IMMUNOL, V27, P1237, DOI 10.1016/0161-5890(90)90027-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; Kim H S, 1998, Curr Opin Pulm Med, V4, P46, DOI 10.1097/00063198-199801000-00009; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACROIX EL, 1993, MOL IMMUNOL, V30, P321, DOI 10.1016/0161-5890(93)90060-O; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LUND J, 1991, J IMMUNOL, V147, P2657; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; Mao XQ, 1998, CLIN GENET, V53, P54, DOI 10.1034/j.1399-0004.1998.531530111.x; Maurer D, 1998, J IMMUNOL, V161, P2731; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; McDonnell JM, 1997, BIOCHEM SOC T, V25, P387, DOI 10.1042/bst0250387; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1994, CURR BIOL, V4, P644, DOI 10.1016/S0960-9822(00)00143-3; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRESTA L, 1994, J BIOL CHEM, V269, P26368; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SCARSELLI E, 1993, FEBS LETT, V329, P223, DOI 10.1016/0014-5793(93)80226-K; Sechi S, 1996, J BIOL CHEM, V271, P19256, DOI 10.1074/jbc.271.32.19256; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0	60	142	151	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					951	961		10.1016/S0092-8674(00)81719-5	http://dx.doi.org/10.1016/S0092-8674(00)81719-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875849	Bronze			2022-12-28	WOS:000077759100010
J	Wetterhall, SF; Cogswell, ME; Kowdley, KV				Wetterhall, SF; Cogswell, ME; Kowdley, KV			Public health surveillance for hereditary hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			UNITED-STATES; GENETIC HEMOCHROMATOSIS; DISEASE SURVEILLANCE; DISCRIMINATION; CERTIFICATES; INFORMATION; PREVALENCE; HEPATITIS; SURVIVAL; DEATH	The recent realization that hemochromatosis is a common condition has created opportunities to develop unified public health surveillance for this disorder and its complications and to design programs to prevent unnecessary illness and death resulting from this disorder. Public health surveillance for hemochromatosis can be used to measure the magnitude of the problem (for example, to establish the number of persons with evidence of early iron overload); identify research needs; reveal the natural history of the disease; detect changes in health care practices, such as use of screening tests; and evaluate interventions, such as phlebotomy. Existing surveillance has been limited to periodic measurement of morbidity and mortality done by using hospital discharge records, health examination surveys, vital statistics, and data from small research registries. The improvement of surveillance will entail the ongoing collection of information from population-based surveys, such as the Behavioral Risk Factor Surveillance System; the collection of data on provider practices (for example, through the National Ambulatory Medical Care Survey); and the establishment of population-based registries. Creating population-based registries requires consensus on case definitions; strategies to encourage case ascertainment and reporting; policies and procedures for protecting privacy and ensuring confidentiality; and partnerships among providers, researchers, and public health officials. Longitudinal data from population-based registries will provide insight into determinants of disease expression, such as pattern or degree of iron overload. This information is critical for developing evidence-based recommendations for population screening, monitoring changes in medical practices, and assessing the effect of preventive measures.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle	Wetterhall, SF (corresponding author), Ctr Dis Control & Prevent, Mailstop D-24,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	sfw1@cdc.gov	Kowdley, Kris/AAF-5202-2019					ADAMS PC, 1991, AM J MED, V90, P445; Alper J S, 1994, J Public Health Policy, V15, P345, DOI 10.2307/3342910; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ANDRESEN EM, 1993, AM J PUBLIC HEALTH, V83, P1021, DOI 10.2105/AJPH.83.7.1021; AUSTIN D, 1983, REV CANC RES, V2, P119; BRADBEAR RA, 1985, J NATL CANCER I, V75, P81; Bradley L A, 1996, J Med Screen, V3, P178; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; CLAYTON C, 1993, MED J AUSTRALIA, V159, P614, DOI 10.5694/j.1326-5377.1993.tb138051.x; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; DAVIS JP, 1982, J INFECT DIS, V145, P449, DOI 10.1093/infdis/145.4.449; EARLEY CL, 1995, AM J HUM GENET, V57, P727; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Ezzati T M, 1992, Vital Health Stat 2, P1; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GABLE CB, 1992, J AM DIET ASSOC, V92, P208; GRAVES EJ, 1996, NATL HOSP DISCHARGE; Haddow J E, 1994, J Med Screen, V1, P16; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; *INF POL COMM NAT, 1997, OPT PROM PRIV NAT IN; KONOWITZ PM, 1984, PUBLIC HEALTH REP, V99, P31; Kowdley K V, 1995, Liver Transpl Surg, V1, P237, DOI 10.1002/lt.500010408; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; LOOKER AC, 1995, NUTR REV, V53, P246, DOI 10.1111/j.1753-4887.1995.tb05481.x; MAST WE, 1976, JAMA-J AM MED ASSOC, V236, P859, DOI 10.1001/jama.236.7.859; May D S, 1991, MMWR CDC Surveill Summ, V40, P7; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Meek J I, 1996, J Public Health Manag Pract, V2, P61; MILLER M, 1994, JAMA-J AM MED ASSOC, V272, P231, DOI 10.1001/jama.272.3.231; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Osterholm M T, 1996, J Public Health Manag Pract, V2, P11; PHILLIPS JA, 1995, AM J HUM GENET, V57, P1499; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; POWELL LW, 1994, IRON METABOLISM HLTH, P272; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Schulman Jane, 1993, Morbidity and Mortality Weekly Report, V42, P1; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; SKIKNE BS, 1987, AM J CLIN NUTR, V46, P840, DOI 10.1093/ajcn/46.5.840; Strass E, 1996, AM J HUM GENET, V59, P471; STROUP NE, 1994, PRINCIPLES PRACTICE, P31; Teutsch SM, 1994, PRINCIPLES PRACTICE, P18; THACKER SB, 1994, AM J EPIDEMIOL, V140, P383, DOI 10.1093/oxfordjournals.aje.a117261; THACKER SB, 1986, AM J PREV MED, V2, P345; THACKER SB, 1995, STAT MED, V14, P629, DOI 10.1002/sim.4780140520; VOGT RL, 1983, AM J PUBLIC HEALTH, V73, P795, DOI 10.2105/AJPH.73.7.795; WATKINS M, 1991, AM J PUBLIC HEALTH, V81, P637, DOI 10.2105/AJPH.81.5.637; WETTERHALL SF, 1992, DIABETES CARE, V15, P960, DOI 10.2337/diacare.15.8.960; Wetterhall SF, 1997, PUBLIC HLTH CONSEQUE, P37; Wharton M, 1990, MMWR Recomm Rep, V39, P1; WHARTON M, 1994, PRINCIPLES PRACTICE, P218; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; WOODWELL DA, 1997, NATL AMBULATORY MED; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005; 1994, MMWR MORB MORTAL WKL, V43, P826; 1996, MMWR MORB MORTAL WKL, V45, P991	58	6	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					980	986		10.7326/0003-4819-129-11_Part_2-199812011-00009	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867751				2022-12-28	WOS:000077239200031
J	Dodd, J; Jessell, TM; Placzek, M				Dodd, J; Jessell, TM; Placzek, M			Neuroscience - The when and where of floor plate induction	SCIENCE			English	Editorial Material							CHICK-EMBRYO; NO TAIL; ZEBRAFISH; SPECIFICATION; NOTOCHORD; MESODERM; EPIBLAST; MUTATION		Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Univ Sheffield, Krebs Inst, Dev Genet Programme, Sheffield S10 2TN, S Yorkshire, England	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute; University of Sheffield	Dodd, J (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA.	tmjl@columbia.edu	Placzek, Marysia/E-6172-2010	Placzek, Marysia/0000-0002-4106-9229				ALTABA AR, 1995, DEV BIOL, V170, P299; BEACHY PA, 1995, CURR BIOL, V5, P944; Catala M, 1996, DEVELOPMENT, V122, P2599; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DALE L, 1987, DEVELOPMENT, V100, P279; Ding Q, 1998, DEVELOPMENT, V125, P2533; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIAMARTINEZ V, 1993, J EXP ZOOL, V267, P431, DOI 10.1002/jez.1402670409; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; JESSELL TM, 1989, CIBA F SYMP, V144, P255; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; Leonardo ED, 1997, COLD SPRING HARB SYM, V62, P467; Matise MP, 1998, DEVELOPMENT, V125, P2759; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1995, CURR OPIN GENET DEV, V5, P499, DOI 10.1016/0959-437X(95)90055-L; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Schauerte HE, 1998, DEVELOPMENT, V125, P2983; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1997, CURR OPIN NEUROBIOL, V7, P119, DOI 10.1016/S0959-4388(97)80129-8; SCHOENWOLF GC, 1990, J EXP ZOOL, V255, P323, DOI 10.1002/jez.1402550309; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; Strahle U, 1997, Genes Funct, V1, P131; Teillet MA, 1998, P NATL ACAD SCI USA, V95, P11733, DOI 10.1073/pnas.95.20.11733; Vogel G, 1998, SCIENCE, V280, P1838, DOI 10.1126/science.280.5371.1838; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	33	59	60	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1654	1657		10.1126/science.282.5394.1654	http://dx.doi.org/10.1126/science.282.5394.1654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9867664				2022-12-28	WOS:000077246600031
J	Nei, M; Zhang, JZ				Nei, M; Zhang, JZ			Evolution - Molecular origin of species	SCIENCE			English	Editorial Material							SELECTION; BINDIN		Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Nei, M (corresponding author), Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA.							Cameron RA, 1996, DEV BIOL, V180, P348, DOI 10.1006/dbio.1996.0307; Dobzhansky T., 1937; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; NEI M, 1983, GENETICS, V103, P557; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995	8	23	23	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1428	1429		10.1126/science.282.5393.1428	http://dx.doi.org/10.1126/science.282.5393.1428			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867649				2022-12-28	WOS:000077110800028
J	Hurwitz, B				Hurwitz, B			Commentary: Bevan's covenant continues intact	BRITISH MEDICAL JOURNAL			English	Editorial Material									Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	Imperial College London	Hurwitz, B (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.							*DEP HLTH, 1998, 1 CLASS SERV; *GEN PRACT COMM, 1998, PRIM CAR GROUPS; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; *NAT HLTH SERV EX, 1998, PRESCR INC SCHEM; *NAT HLTH SERV EX, 1998, DEV PRIM CAR GROUPS; Prayle D, 1998, J MED ETHICS, V24, P93, DOI 10.1136/jme.24.2.93; TOWSE A, 1997, GUIDELINES EVALUATIO	7	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1365	1365						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9882107				2022-12-28	WOS:000077081600025
J	Fan, SS; Chapline, MG; Franklin, NR; Tombler, TW; Cassell, AM; Dai, HJ				Fan, SS; Chapline, MG; Franklin, NR; Tombler, TW; Cassell, AM; Dai, HJ			Self-oriented regular arrays of carbon nanotubes and their field emission properties	SCIENCE			English	Article							POROUS SILICON; FILAMENTS	The synthesis of massive arrays of monodispersed cart;on nanotubes that are self-oriented on patterned porous silicon and plain silicon substrates is reported. The approach involves chemical vapor deposition, catalytic particle size control by substrate design, nanotube positioning by patterning, and nanotube self-assembly for orientation. The mechanisms of nanotube growth and self-orientation are elucidated. The well-ordered nanotubes can be used as electron field emission arrays. Scaling up of the synthesis process should be entirely compatible with the existing semiconductor processes, and should allow the development of nanotube devices integrated into silicon technology.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Dai, HJ (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Han, Jinhua/F-9464-2010; Dai, Hongjie/ABC-4574-2021; Funde, Adinath M./D-8169-2012					AMELINCKX S, 1994, SCIENCE, V265, P635, DOI 10.1126/science.265.5172.635; BAKER RTK, 1989, CARBON, V27, P315, DOI 10.1016/0008-6223(89)90062-6; Bonard JM, 1998, APPL PHYS LETT, V73, P918, DOI 10.1063/1.122037; CANHAM LT, 1990, APPL PHYS LETT, V57, P1046, DOI 10.1063/1.103561; Che GL, 1998, NATURE, V393, P346, DOI 10.1038/30694; Collins PG, 1996, APPL PHYS LETT, V69, P1969, DOI 10.1063/1.117638; Collins RT, 1997, PHYS TODAY, V50, P24, DOI 10.1063/1.881650; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; Dai HJ, 1998, APPL PHYS LETT, V73, P1508, DOI 10.1063/1.122188; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; Kong J, 1998, CHEM PHYS LETT, V292, P567, DOI 10.1016/S0009-2614(98)00745-3; Kyotani T, 1996, CHEM MATER, V8, P2109, DOI 10.1021/cm960063+; Li WZ, 1996, SCIENCE, V274, P1701, DOI 10.1126/science.274.5293.1701; Normile D, 1998, SCIENCE, V281, P632, DOI 10.1126/science.281.5377.632; Pan ZW, 1998, NATURE, V394, P631, DOI 10.1038/29206; Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105; Saito Y, 1998, ULTRAMICROSCOPY, V73, P1, DOI 10.1016/S0304-3991(97)00128-9; Service RF, 1998, SCIENCE, V281, P940, DOI 10.1126/science.281.5379.940; SMITH RL, 1992, J APPL PHYS, V71, pR1, DOI 10.1063/1.350839; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Terrones M, 1997, NATURE, V388, P52, DOI 10.1038/40369; Terrones M, 1998, CHEM PHYS LETT, V285, P299, DOI 10.1016/S0009-2614(98)00093-1; TIBBETTS GG, 1984, J CRYST GROWTH, V66, P632, DOI 10.1016/0022-0248(84)90163-5; Vial J., 1994, POROUS SILICON SCI T; Wang QH, 1997, APPL PHYS LETT, V70, P3308, DOI 10.1063/1.119146; Wang QH, 1998, APPL PHYS LETT, V72, P2912, DOI 10.1063/1.121493; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735	28	2999	3317	16	1061	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					512	514		10.1126/science.283.5401.512	http://dx.doi.org/10.1126/science.283.5401.512			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915692				2022-12-28	WOS:000078203300028
J	Roesler, FL; Moos, HW; Oliversen, RJ; Woodward, RC; Retherford, KD; Scherb, F; McGrath, MA; Smyth, WH; Feldman, PD; Strobel, DF				Roesler, FL; Moos, HW; Oliversen, RJ; Woodward, RC; Retherford, KD; Scherb, F; McGrath, MA; Smyth, WH; Feldman, PD; Strobel, DF			Far-ultraviolet imaging spectroscopy of Io's atmosphere with HST/STIS	SCIENCE			English	Article							PLASMA TORUS; GALILEO MAGNETOMETER; GLOBAL DISTRIBUTION; EMISSION; TELESCOPE; STABILITY; MODEL; SO2	Well-resolved far-ultraviolet spectroscopic images of O I, S I, and previously undetected H I Lyman-alpha emission from lo were obtained with the Hubble space telescope imaging spectrograph (STIS), Detected O I and S I lines (1250 to 1500 angstroms) have bright equatorial spots (up to 2.5 kilorayleighs) that shift position with jovian magnetic field orientation; limb glow that is brighter on the hemisphere facing the jovian magnetic equator; and faint diffuse emission extending to similar to 20 lo radii. All O I and S I features brightened by similar to 50 percent in the last two images, concurrently with a ground-based observation of increased iogenic [O I] 6300-angstrom emission. The H I Lyman-alpha emission, consisting of a small, similar to 2-kilorayleigh patch near each pole, has a different morphology and time variation.	Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; NASA, Astron & Solar Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Space Telescope Science Institute; Atmospheric & Environmental Research; Johns Hopkins University	Woodward, RC (corresponding author), Univ Wisconsin, Dept Phys, 1150 Univ Ave, Madison, WI 53706 USA.		Strobel, Darrell5/AAO-6643-2021	Strobel, Darrell5/0000-0002-0944-8675; Retherford, Kurt/0000-0001-9470-150X; Woodward, Carey/0000-0002-5441-7579				Bagenal F, 1997, GEOPHYS RES LETT, V24, P2119, DOI 10.1029/97GL01254; BALLESTER GE, 1987, ASTROPHYS J, V319, pL33, DOI 10.1086/184950; BALLESTER GE, 1997, MAGNETOSPHERES O MAR; BALLESTER GE, 1997, B AM ASTRON SOC, V29, P980; Carlson RW, 1997, GEOPHYS RES LETT, V24, P2479, DOI 10.1029/97GL02609; CHUST T, 1997, ANN GEOPHYS 3 S3, V15, pC824; CLARKE JT, 1994, J GEOPHYS RES-PLANET, V99, P8387, DOI 10.1029/93JE02547; DURRANCE ST, 1995, ASTROPHYS J, V447, P408, DOI 10.1086/175884; Fox GK, 1997, ASTRON J, V113, P1158, DOI 10.1086/118335; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; FRANK LA, 1998, EOS, V79, pS201; GEISSLER PE, 1998, B AM ASTRON SOC, V30, P1116; JUDGE DL, 1974, SCIENCE, V183, P317, DOI 10.1126/science.183.4122.317; Kimble RA, 1998, ASTROPHYS J, V492, pL83, DOI 10.1086/311102; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1996, SCIENCE, V274, P396, DOI 10.1126/science.274.5286.396; LELLOUCH E, 1992, ICARUS, V98, P271, DOI 10.1016/0019-1035(92)90095-O; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; MANATT SL, 1993, J QUANT SPECTROSC RA, V50, P267, DOI 10.1016/0022-4073(93)90077-U; McEwen AS, 1997, GEOPHYS RES LETT, V24, P2443, DOI 10.1029/97GL01956; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; MCEWEN AS, 1988, ICARUS, V75, P450, DOI 10.1016/0019-1035(88)90157-1; NASH DB, 1989, SCIENCE, V244, P454, DOI 10.1126/science.244.4903.454; OLIVERSEN RJ, 1997, B AM ASTRON SOC, V29, P1315; SALAMA F, 1994, ICARUS, V107, P413, DOI 10.1006/icar.1994.1033; SANDEL BR, 1982, J GEOPHYS RES-SPACE, V87, P212, DOI 10.1029/JA087iA01p00212; SAUR J, UNPUB; SCHERB F, 1993, J GEOPHYS RES-PLANET, V98, P18729, DOI 10.1029/93JE00539; SCHERB F, 1996, B AM ASTRON SOC, V28, P1155; SMITH TE, 1995, B AM ASTRON SOC, V27, P1157; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; TRAUGER JT, 1997, B AM ASTRON SOC, V29, P1002; VOIT M, 1997, HST DATA HDB; Williams DJ, 1996, SCIENCE, V274, P401, DOI 10.1126/science.274.5286.401; WOLFGLADROW DA, 1987, J GEOPHYS RES, V92, P9949, DOI 10.1029/JA092iA09p09949; Wong MC, 1996, J GEOPHYS RES-PLANET, V101, P23243, DOI 10.1029/96JE02510; Woodgate BE, 1998, PUBL ASTRON SOC PAC, V110, P1183, DOI 10.1086/316243; WOODWARD RC, 1994, B AM ASTRON SOC, V26, P1139; WU FM, 1995, J GEOPHYS RES-SPACE, V100, P3481, DOI 10.1029/94JA02557	39	91	91	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					353	357		10.1126/science.283.5400.353	http://dx.doi.org/10.1126/science.283.5400.353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888844				2022-12-28	WOS:000078067000038
J	Carrasquillo, O; Himmelstein, DU; Woolhandler, S; Bor, DH				Carrasquillo, O; Himmelstein, DU; Woolhandler, S; Bor, DH			A reappraisal of private employers' role in providing health insurance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background in 1996, according to official figures, 61 percent of Americans received health insurance through employers. However, this estimate includes persons who relied primarily on government insurance such as Medicare, workers whose employers arranged their insurance but contributed nothing toward the premiums, and government employees whose private coverage was paid for by taxpayers. Methods To estimate the number of persons whose principal health insurance was paid for in whole or in part by employers in the private sector and the number receiving government-funded insurance, we analyzed data from the March 1997 Current Population Survey. Approximately 130,000 persons representative of the noninstitutionalized U.S. population were sampled. We considered people to be covered principally by health insurance paid for by private-sector employers if they had no public insurance coverage and were covered by insurance from a nongovernmental employer who paid all or part of their premiums. Those who were covered by Medicaid, Medicare, insurance resulting from former or current military service, or the Indian Health Service were considered to be receiving government insurance. Results In 1996, 43.1 percent of the population (90 percent confidence interval, 42.7 to 43.5 percent) depended principally on health insurance paid for by private-sector employers, 34.2 percent (90 percent confidence interval, 33.8 to 34.6 percent) had publicly funded insurance, 7.1 percent (90 percent confidence interval, 6.8 to 7.6 percent) purchased their own coverage, and 15.6 percent (90 percent confidence interval, 15.3 to 15.9 percent) were uninsured. In only six states was more than half the population covered principally by health insurance paid for by private-sector employers. Conclusions Current definitions of health insurance overemphasize the role of private employers and underestimate the extent to which government pays for health insurance. (N Engl J Med 1999;340:109-14.) (C) 1999, Massachusetts Medical Society.	Columbia Presbyterian Med Ctr, Div Gen Med, New York, NY 10032 USA; Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA USA	Columbia University; NewYork-Presbyterian Hospital; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Harvard Medical School	Carrasquillo, O (corresponding author), Columbia Presbyterian Med Ctr, Div Gen Med, PH 9 E,Rm 105,622 W 168th St, New York, NY 10032 USA.				BHP HRSA HHS [2D28 PE50018-04] Funding Source: Medline	BHP HRSA HHS		ACS G, 1995, INQUIRY-J HEALTH CAR, V32, P102; Bennefield R.L., 1996, JOINT STAT M AM STAT; BENNEFIELD RL, 1997, CURRENT POPULATI P60; BENNEFIELD RL, 1996, CURRENT POPULATI P60, V195; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1084, DOI 10.1056/NEJM199804093381525; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1003, DOI 10.1056/NEJM199804023381422; *CENS BUR, 1997, ANN DEM SURV S; Chulis G S, 1993, Health Care Financ Rev, V14, P163; Cooper PF, 1997, HEALTH AFFAIR, V16, P142, DOI 10.1377/hlthaff.16.6.142; Cowan CA, 1996, HEALTH CARE FINANC R, V17, P157; Fronstin P, 1996, INQUIRY-J HEALTH CAR, V33, P317; *GEN ACC OFF, 1997, EMPL BAS HLTH INS CO; *GEN ACC OFF, 1997, PRIV HLTH INS CONT E; Gornick ME, 1996, HEALTH CARE FINANC R, V18, P179; *HCFA, 1995, HCFA PUBL; *HLTH INS ASS AM, 1997, SOURC BOOK HLTH INS; LONG SH, 1995, INQUIRY-J HEALTH CAR, V32, P111; MOORE T, 1997, SOURCE ACCURACY DATA; Pear Robert, 1998, N Y Times Web, pA10; Reinhardt UE, 1997, JAMA-J AM MED ASSOC, V278, P1446, DOI 10.1001/jama.278.17.1446; SWARTZ K, 1986, J ECON SOC MEAS, V14, P233, DOI 10.3233/JEM-1986-14306; SWARTZ K, 1990, J HEALTH POLIT POLIC, V15, P779, DOI 10.1215/03616878-15-4-779; VISTENES JP, 1997, HLTH INS STAT CIV NO	23	19	19	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					109	114		10.1056/NEJM199901143400206	http://dx.doi.org/10.1056/NEJM199901143400206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	156RQ	9887163	Bronze			2022-12-28	WOS:000078016200006
J	McCall, M; Salama, P				McCall, M; Salama, P			Selection, training, and support of relief workers: an occupational health issue	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA		Red Deer Reg Hosp, Red Deer, AB T4N 6R2, Canada; Concern Worldwide, Dublin 2, Ireland		Salama, P (corresponding author), Concern Worldwide, Camden St, Dublin 2, Ireland.	peter.salama@concern.ic						Allden K, 1996, AM J PUBLIC HEALTH, V86, P1561, DOI 10.2105/AJPH.86.11.1561; American Psychiatric Association A., 1980, DIAGN STAT MAN MENT, V3; Anderson Mary, 1996, DO NO HARM SUPPORTIN; Armstrong K., 1991, J TRAUM STRESS, V4, P581; Dabelstein N, 1996, DISASTERS, V20, P287, DOI 10.1111/j.1467-7717.1996.tb01044.x; *DIS REL, 1994, COD COND INT RED CRO; EITINGER L, 1969, J PSYCHOSOM RES, V13, P183, DOI 10.1016/0022-3999(69)90061-0; Figley C.R., 1995, COMPASSION FATIGUE C, DOI 10.1192/bjp.bp.114.150078; Fullerton C. S., 1997, POSTTRAUMATIC STRESS; FULLERTON CS, 1992, AM J ORTHOPSYCHIAT, V62, P371, DOI 10.1037/h0079363; HARTMANN K, 1981, MIL MED, V146, P323; Herman Judith, 2001, TRAUMA RECOVERY; Ignatieff Michael, 1997, NEW YORKER      0324, P54; KINSTON W, 1974, J PSYCHOSOM RES, V18, P437, DOI 10.1016/0022-3999(74)90035-X; Lane P. S., 1993, OMEGA, V28, P301; LAUTTZE S, 1996, 1 USAID U OXF REF ST; LEANING JL, 1994, MED GLOBAL SURVIVAL, V1, P3; Milgram N. A., 1986, STRESS COPING TIME W; MINEAR L, 1995, MERCY FIREWAR GLOBAL; Mitchell J T, 1983, JEMS, V8, P36; RAPHAEL B, 1986, WHEN DISASTER STRIKE; ROBINSON RC, 1993, J TRAUMA STRESS, V6, P367, DOI 10.1007/BF00974135; Slim H, 1997, DISASTERS, V21, P244, DOI 10.1111/1467-7717.00059; SMITH B, 1996, INT RESPONSES TRAUMA; SOLOMAN Z, 1986, STRESS COPING TIME W; TOOLE MJ, 1997, WORLD CRISIS	26	41	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					113	116		10.1136/bmj.318.7176.113	http://dx.doi.org/10.1136/bmj.318.7176.113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157XT	9880288	Green Published			2022-12-28	WOS:000078087500031
J	Darouiche, RO; Raad, II; Heard, SO; Thornby, JI; Wenker, OC; Gabrielli, A; Berg, J; Khardori, N; Hanna, H; Hachem, R; Harris, RL; Mayhall, G				Darouiche, RO; Raad, II; Heard, SO; Thornby, JI; Wenker, OC; Gabrielli, A; Berg, J; Khardori, N; Hanna, H; Hachem, R; Harris, RL; Mayhall, G		Catheter Study Grp	A comparison of two antimicrobial-impregnated central venous catheters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 28-OCT 02, 1997	TORONTO, CANADA				BLOOD-STREAM INFECTION; PREVENTION; TRIAL; COLONIZATION; MINOCYCLINE; RIFAMPIN; SEPSIS	Background The use of central venous catheters impregnated with either minocycline and rifampin or chlorhexidine and silver sulfadiazine reduces the rates of catheter colonization and catheter-related bloodstream infection as compared with the use of unimpregnated catheters. We compared the rates of catheter colonization and catheter-related bloodstream infection associated with these two kinds of antiinfective catheters. Methods We conducted a prospective, randomized clinical trial in 12 university-affiliate hospitals. High-risk adult patients in whom central venous catheters were expected to remain in place for three or more days were randomly assigned to undergo insertion of polyurethane, triple-lumen catheters impregnated with either minocycline and rifampin ton both the luminal and external surfaces) or chlorhexidine and silver sulfadiazine ton only the external surface). After their removal, the tips and subcutaneous segments of the catheters were cultured by both the roll-plate and the sonication methods. Peripheral-blood cultures were obtained if clinically indicated. Results Of 865 catheters inserted, 738 (85 percent) produced culture results that could be evaluated. The clinical characteristics of the patients and the risk factors for infection were similar in the two groups. Catheters impregnated with minocycline and rifampin were 1/3 as likely to be colonized as catheters impregnated with chlorhexidine and silver sulfadiazine (28 of 356 catheters [7.9 percent] vs. 87 of 382 [22.8 percent], P<0.001), and catheter-related bloodstream infection was 1/12 as likely in catheters impregnated with minocycline and rifampin (1 of 356 [0.3 percent], vs. 13 of 382 [3.4 percent] for those impregnated with chlorhexidine and silver sulfadiazine; P<0.002). Conclusions The use of central venous catheters impregnated with minocycline and rifampin is associated with a lower rate of infection than the use of catheters impregnated with chlorhexidine and silver sulfadiazine. (N Engl J Med 1999;340:1-8.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Subspecialties, Houston, TX USA; Univ Massachusetts, Med Ctr, Dept Anesthesiol, Worcester, MA USA; Univ Florida, Coll Med, Dept Surg, Gainesville, FL USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; So Illinois Univ, Sch Med, Dept Med, Springfield, IL 62708 USA; Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Massachusetts System; University of Massachusetts Worcester; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Southern Illinois University System; Southern Illinois University; University of Texas System; University of Texas Medical Branch Galveston	Darouiche, RO (corresponding author), Vet Affairs Med Ctr, Infect Dis Sect, Rm 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA.							Clarridge JE, 1996, J CLIN MICROBIOL, V34, P1995, DOI 10.1128/JCM.34.8.1995-2000.1996; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; National Committee for Clinical Laboratory Standards (NCCLS), 1997, METH DIL ANT SUSC TE, V17; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; PEARSON ML, 1996, AM J INFECT CONTROL, V24, P277; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418; RAAD I, 1995, ANTIMICROB AGENTS CH, V39, P2397, DOI 10.1128/AAC.39.11.2397; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad II, 1998, CRIT CARE MED, V26, P219, DOI 10.1097/00003246-199802000-00015; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; SALZMAN MB, 1993, J INFECT DIS, V167, P487, DOI 10.1093/infdis/167.2.487; *SAS I, 1991, SAS US GUID STAT VER; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348	19	545	573	0	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					1	8		10.1056/NEJM199901073400101	http://dx.doi.org/10.1056/NEJM199901073400101			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878638				2022-12-28	WOS:000077943700001
J	Luther, K				Luther, K			Lester's getting a bottle	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Tulane Univ, Med Ctr, New Orleans, LA 70112 USA	Tulane University	Luther, K (corresponding author), Tulane Univ, Med Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					73	74		10.7326/0003-4819-130-1-199901050-00016	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890858				2022-12-28	WOS:000077744500015
J	Kelsen, DP; Ginsberg, R; Pajak, TF; Sheahan, DG; Gunderson, L; Mortimer, J; Estes, N; Haller, DG; Ajani, J; Kocha, W; Minsky, BD; Roth, JA				Kelsen, DP; Ginsberg, R; Pajak, TF; Sheahan, DG; Gunderson, L; Mortimer, J; Estes, N; Haller, DG; Ajani, J; Kocha, W; Minsky, BD; Roth, JA			Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	33rd Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 17-21, 1997	DENVER, CO	Amer Soc Clin Oncol			SQUAMOUS-CELL CARCINOMA; CLINICAL-TRIALS; THERAPY; ADENOCARCINOMA; CHEMORADIOTHERAPY; RADIOTHERAPY	Background We performed a multi-institutional randomized trial comparing preoperative chemotherapy followed by surgery with surgery alone for patients with local and operable esophageal cancer. Methods Preoperative chemotherapy for patients randomly assigned to the chemotherapy group included three cycles of cisplatin and fluorouracil. Surgery was performed two to four weeks after the completion of the third cycle; patients also received two additional cycles of chemotherapy after the operation. Patients randomly assigned to the immediate-surgery group underwent the same surgical procedure. The main end point was overall survival. Results Of the 440 eligible patients with adequate data, 213 were assigned to receive preoperative chemotherapy and 227 to undergo immediate surgery. After a median possible study time of 55.4 months, there were no significant differences between the two groups in median survival: 14.9 months for the patients who received preoperative chemotherapy and 16.1 months for those who underwent immediate surgery (P=0.53). At one year, the survival rate was 59 percent for those who received chemotherapy and 60 percent for those who had surgery alone; at two years, survival was 35 percent and 37 percent, respectively. The toxic effects of chemotherapy were tolerable, and the addition of chemotherapy did not appear to increase the morbidity or mortality associated with surgery. There were no differences in survival between patients with squamous-cell carcinoma and those with adenocarcinoma. Weight loss was a significant predictor of poor outcome (P=0.03). With the addition of chemotherapy, there was no change in the rate of recurrence at locoregional or distant sites. Conclusions Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus. (N Engl J Med 1998;339:1979-84.) (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Radiat Therapy Oncol Grp, Stat Off, Philadelphia, PA USA; Univ Pittsburgh, Pittsburgh, PA USA; Mayo Clin, Rochester, MN USA; Washington Univ, St Louis, MO USA; Univ Kansas, Lawrence, KS 66045 USA; Univ Penn, Philadelphia, PA 19104 USA; MD Anderson Canc Ctr, Houston, TX USA; Univ Western Ontario, London, ON, Canada	Memorial Sloan Kettering Cancer Center; Radiation Therapy Oncology Group (RTOG); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Washington University (WUSTL); University of Kansas; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; Western University (University of Western Ontario)	Kelsen, DP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.			Mortimer, Joanne/0000-0002-2935-1934	NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115, U10CA037422] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJANI JA, 1994, J NATL CANCER I, V86, P1086, DOI 10.1093/jnci/86.14.1086; AlSarraf, 1997, J CLIN ONCOL, V15, P866; AlSarraf M, 1997, J CLIN ONCOL, V15, P277, DOI 10.1200/JCO.1997.15.1.277; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Bosset JF, 1997, NEW ENGL J MED, V337, P161, DOI 10.1056/NEJM199707173370304; COX DR, 1972, J R STAT SOC B, V34, P187; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; ILSON DH, 1994, SEMIN ONCOL, V21, P493; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEN DP, 1995, CHEST, V107, pS224, DOI 10.1378/chest.107.6_Supplement.224S; KOK TC, 1997, P AN M AM SOC CLIN, V16, pA277; LEPRISE E, 1994, CANCER, V73, P1779; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Sposto R, 1997, STAT MED, V16, P695, DOI 10.1002/(SICI)1097-0258(19970330)16:6<695::AID-SIM436>3.0.CO;2-C; URBA S, 1997, P AN M AM SOC CLIN, V16, pA277; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	22	1018	1051	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1979	1984		10.1056/NEJM199812313392704	http://dx.doi.org/10.1056/NEJM199812313392704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	152XX	9869669	Bronze			2022-12-28	WOS:000077803800004
J	Blendon, RJ; Young, JT; McCormick, MC; Kropf, M; Blair, J				Blendon, RJ; Young, JT; McCormick, MC; Kropf, M; Blair, J			Americans' views on children's health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PUBLIC-OPINION; POLICY		Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA; Harvard Univ, John F Kennedy Sch Govt, Boston, MA USA; Univ Maryland, Survey Res Ctr, College Pk, MD USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; University System of Maryland; University of Maryland College Park	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.			McCormmick, Marie/0000-0002-3938-1707				*AE CAS FDN, 1998, 1997 KIDS COUNT NAT, P15; *AE CAS FDN, 1996, KIDS COUNT DAT BOOK; BELLAMY C, 1997, STATE WORLDS CHILDRE; Bennefield R. L, 1998, CURRENT POPULATION R; Blendon RJ, 1998, JAMA-J AM MED ASSOC, V279, P827, DOI 10.1001/jama.279.11.827; *CHILDR DEF FUND, 1998, UN CHILDR WORK FAM N; *COAL AM CHILDR, 1997, GREAT EXP AM VOT VIE; Davis J. A., 1996, GEN SOCIAL SURVEYS 1; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; Key V O, 1966, POLITICS PARTIES PRE; KLERMAN L, 1997, HLTH CARE CHILDREN W; LAMISONWHITE L, 1996, CURRENT POPULATION R; LAMISONWHITE L, 1998, CURRENT POPULATIONS; Monroe AD, 1998, PUBLIC OPIN QUART, V62, P6, DOI 10.1086/297828; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; NEWACHECK PW, 1997, HLTH CARE CHILDREN W, P53; *NW NAT LIF INS CO, 1990, AM SPEAK OUT HLTH CA; PAGE BI, 1983, AM POLIT SCI REV, V77, P175, DOI 10.2307/1956018; *ROP CTR PUBL OP R, 1974, GALL POLL STORRS CON; *ROP CTR PUBL OP R, 1995, HARV KAIS FAM FDN HA; *ROP CTR PUBL OP R, 1996, KAIS FAM FDN HARV U; *ROP CTR PUBL OP R, 1986, L HARR ASS INC POLL; *ROP CTR PUBL OP R, 1937, GALL POLL; *ROP CTR PUBL OP R, 1997, L HARR ASS INC POLL; *ROP CTR PUBL OP R, 1995, KAIS FAM FDN HARV U; *ROP CTR PUBL OP R, 1994, AM TALK ISS CTR STUD; Rosenbaum S, 1998, HEALTH AFFAIR, V17, P75, DOI 10.1377/hlthaff.17.1.75; Sandel M, 1998, NOT SAFE HOME AM HOU; Shapiro Robert Y., 1989, POLITICAL BEHAV ANN, P149; *U MAR HARV SCH PU, 1997, ATT CHILDR HLTH CAR; ULLMAN F, 1998, 4 URB I; Verba S., 1995, VOICE EQUALITY CIVIC; WRIGHT GC, 1987, AM J POLIT SCI, V31, P980, DOI 10.2307/2111232; 1998, WALL STREET J    JUN	34	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2122	2127		10.1001/jama.280.24.2122	http://dx.doi.org/10.1001/jama.280.24.2122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875885				2022-12-28	WOS:000077606100041
J	Jones, KA; Borowsky, B; Tamm, JA; Craig, DA; Durkin, MM; Dai, M; Yao, WJ; Johnson, M; Gunwaldsen, C; Huang, LY; Tang, C; Shen, QR; Salon, JA; Morse, K; Laz, T; Smith, KE; Nagarathnam, D; Noble, SA; Branchek, TA; Gerald, C				Jones, KA; Borowsky, B; Tamm, JA; Craig, DA; Durkin, MM; Dai, M; Yao, WJ; Johnson, M; Gunwaldsen, C; Huang, LY; Tang, C; Shen, QR; Salon, JA; Morse, K; Laz, T; Smith, KE; Nagarathnam, D; Noble, SA; Branchek, TA; Gerald, C			GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2	NATURE			English	Article							MUSCARINIC RECEPTORS; EXPRESSION CLONING; K+-CHANNEL; RAT-BRAIN; DIMERIZATION; ANTAGONISTS; NEURONS; AGONISTS; PROTEINS; CELLS	The principal inhibitory neurotransmitter GABA (gamma-aminobutyric acid) exerts its effects through two ligand-gated channels, GABA(A) and GABA(C) receptors, and a third receptor, GABA(B) (ref. 1), which acts through G proteins to regulate potassium and calcium channels. Cells heterologously expressing the cloned DNA. encoding the GABA(B)R1 protein exhibit high-affinity antagonist-binding sites(2), but they produce little of the functional activity expected from studies of endogenous GABAB receptors in the brain. Here we describe a new member of the GABA(B) polypeptide family, GABA(B)R2, that shows sequence homology to GABA(B)R1. Neither GABA(B)R1 nor GABA(B)R2, when expressed individually, activates GIRK-type potassium channels; however, the combination of GABA(B)R1 and GABA(B)R2 confers robust stimulation of channel activity. Both genes are co-expressed in individual neurons, and both proteins co-localize in transfected cells. Moreover, immunoprecipitation experiments indicate that the two polypeptides associate with each other, probably as heterodimers. Several G-protein-coupled receptors (GPCRs) exist as high-molecutar-weight species, consistent with the formation of dimers by these receptors(3-7), but the relevance of these species for the functioning of GPCRs has not been established We have now shown that co-expression of two GPCR structures, GABA(B)R1 and GABA(B)R2, belonging to the same subfamily is essential for signal transduction by GABAB receptors.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Jones, KA (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.	kjones@synapticcorp.com	Shen, Qirong/AAB-6531-2020					ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Bon C, 1996, BRIT J PHARMACOL, V118, P961, DOI 10.1111/j.1476-5381.1996.tb15493.x; BOWERY NG, 1987, NEUROSCIENCE, V20, P365, DOI 10.1016/0306-4522(87)90098-4; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BRUGGER F, 1993, EUR J PHARMACOL, V235, P153, DOI 10.1016/0014-2999(93)90836-7; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; Graham J., 1984, CENTRIFUGATION PRACT, P161; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Kaupmann K., 1997, Society for Neuroscience Abstracts, V23, P954; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; QUICK MW, 1994, METH NEUROSCI, V19, P261; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SALON JA, 1995, METH NEUROSCI, V25, P201; SEABROOK GR, 1990, BRIT J PHARMACOL, V101, P949, DOI 10.1111/j.1476-5381.1990.tb14186.x; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	30	865	908	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					674	679		10.1038/25348	http://dx.doi.org/10.1038/25348			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872315				2022-12-28	WOS:000077694200053
J	Hopper, AK				Hopper, AK			Molecular biology - Nuclear functions charge ahead	SCIENCE			English	Editorial Material							TRANSFER-RNA; YEAST; CELLS		Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Hopper, AK (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.							[Anonymous], UNPUB; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; MAQUAT LE, 1995, RNA, V1, P453; Martinis Susan A., 1995, P349; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Sanders J, 1996, J CELL SCI, V109, P1113; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Sharma K, 1996, MOL CELL BIOL, V16, P294; Wolfe CL, 1996, J BIOL CHEM, V271, P4679	15	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2003	2004		10.1126/science.282.5396.2003	http://dx.doi.org/10.1126/science.282.5396.2003			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9874653				2022-12-28	WOS:000077467100032
J	Berger, A				Berger, A			Science commentary: What is fetal nuchal translucency?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	12	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					85	85						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880279				2022-12-28	WOS:000078087500022
J	Miller, GH; Magee, JW; Johnson, BJ; Fogel, ML; Spooner, NA; McCulloch, MT; Ayliffe, LK				Miller, GH; Magee, JW; Johnson, BJ; Fogel, ML; Spooner, NA; McCulloch, MT; Ayliffe, LK			Pleistocene extinction of Genyornis newtoni: Human impact on Australian megafauna	SCIENCE			English	Article							PROTEIN DIAGENESIS; NORTHERN AUSTRALIA; HUMAN OCCUPATION; TERRITORY; EGGSHELLS	More than 85 percent of Australian terrestrial genera with a body mass exceeding 44 kilograms became extinct in the Late Pleistocene. Although most were marsupials, the list includes the Large, flightless mihirung Genyornis newtoni. More than 700 dates on Genyornis eggshells from three different climate regions document the continuous presence of Genyornis from more than 100,000 years ago until their sudden disappearance 50,000 years ago, about the same time that humans arrived in Australia. Simultaneous extinction of Genyornis at all sites during an interval of modest climate change implies that human impact, not climate, was responsible.	Univ Colorado, Inst Arctic & Alpine Res, Ctr Geochron Res, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Australian National University; Carnegie Institution for Science; Australian National University	Miller, GH (corresponding author), Univ Colorado, Inst Arctic & Alpine Res, Ctr Geochron Res, Boulder, CO 80309 USA.		Fogel, Marilyn L/M-2395-2015; McCulloch, Malcolm T/C-3651-2009; Ayliffe, Linda/C-3627-2009	Fogel, Marilyn L/0000-0002-1176-3818; McCulloch, Malcolm T/0000-0003-1538-1558; Ayliffe, Linda/0000-0001-7662-5494				BAYNES A, 1995, TAPH S DEP ANTHR ARC, P12; Bowler J.M., 1998, ARCHAEOL OCEAN, V33, P120, DOI DOI 10.1002/J.1834-4453.1998.TB00414.X; BROOKS AS, 1990, SCIENCE, V248, P60, DOI 10.1126/science.248.4951.60; Field JH, 1998, ALCHERINGA, V22, P177, DOI 10.1080/03115519808619199; FLANNERY T F, 1990, Archaeology in Oceania, V25, P45; Flannery T. F., 1994, FUTURE EATERS; Fullagar RLK, 1996, ANTIQUITY, V70, P751, DOI 10.1017/S0003598X00084040; HORTON D R, 1980, Archaeology and Physical Anthropology in Oceania, V15, P86; Johnson B., 1995, THESIS U COLORADO; Johnson BJ, 1998, GEOCHIM COSMOCHIM AC, V62, P2451, DOI 10.1016/S0016-7037(98)00175-6; JONES R, 1969, Australian Natural History, V16, P224; JONES R, 1973, NATURE, V246, P278, DOI 10.1038/246278a0; Kershaw A.P., 1993, PROC OCEAN DRILL SCI, V133, P107, DOI DOI 10.2973/0DP.PR0C.SR.133.221.1993; KERSHAW AP, 1986, NATURE, V322, P47, DOI 10.1038/322047a0; Kohen James L., 1995, ABORIGINAL ENV IMPAC; MAGEE JM, 1997, THESIS AUSTR NATL U; MAGEE JW, 1995, PALAEOGEOGR PALAEOCL, V113, P3, DOI 10.1016/0031-0182(95)00060-Y; MCMAHON JP, 1995, CTR RESOURCE ENV STU; Meltzer D.J., 1985, P145; MERRILEES D, 1968, Journal of the Royal Society of Western Australia, V51, P1; Miller GH, 1997, NATURE, V385, P241, DOI 10.1038/385241a0; MILLER GH, 1992, PHILOS T ROY SOC B, V337, P149, DOI 10.1098/rstb.1992.0092; MURRAY P, IN PRESS REC S AUSTR; Owen R., 1877, RES FOSSIL REMAINS E; Roberts R, 1998, NATURE, V393, P358, DOI 10.1038/30718; ROBERTS RG, 1994, QUATERNARY SCI REV, V13, P575, DOI 10.1016/0277-3791(94)90080-9; ROBERTS RG, 1990, NATURE, V345, P153, DOI 10.1038/345153a0; Singh G., 1981, FIRE AUSTR BIOTA, P23; Smith M. A., 1994, Records of the South Australian Museum (Adelaide), V27, P228; Spooner NA, 1998, ANTIQUITY, V72, P173, DOI 10.1017/S0003598X00086361; STAFFORD TWJ, 1991, J ARCHAEOL SCI, V189, P35; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TATE R, 1879, T P PHILOS SOC S AUS, V2, P13; Trotter M.M., 1984, P708; VICKERSRICH P, 1987, ANTIPODEAN ARK CREAT, P48; WILLIAMS DLG, 1992, VERTEBRATE PALEONTOL, P871	36	246	255	29	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					205	208		10.1126/science.283.5399.205	http://dx.doi.org/10.1126/science.283.5399.205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880249				2022-12-28	WOS:000077976700034
J	Kupferminc, MJ; Eldor, A; Steinman, N; Many, A; Bar-Am, A; Jaffa, A; Fait, G; Lessing, JB				Kupferminc, MJ; Eldor, A; Steinman, N; Many, A; Bar-Am, A; Jaffa, A; Fait, G; Lessing, JB			Increased frequency of genetic thrombophilia in women with complications of pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; PLACENTAL PATHOLOGICAL FEATURES; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; VENOUS THROMBOSIS; FETAL LOSS; COMMON MUTATION; PREECLAMPSIA; RESISTANCE	Background Obstetrical complications such as severe preeclampsia, abruptio placentae, fetal growth retardation, and stillbirth are associated with intervillous or spiral-artery thrombosis and inadequate placental perfusion. Whether these complications are associated with an increased frequency of thrombophilic mutations is not known. Methods We studied 110 women who had one of the above-mentioned obstetrical complications and 110 women who had one or more normal pregnancies. The women were tested several days after delivery for the mutation of adenine to guanine at nucleotide 506 in the factor V gene (factor V Leiden), the mutation of cytosine to thymine at nucleotide 677 in the gene encoding methylenetetrahydrofolate reductase, and the mutation of guanine to adenine at nucleotide 20210 in the prothrombin gene. Two to three months after delivery the women were tested for deficiency of protein C, protein S, or antithrombin III and for the presence of anticardiolipin antibodies. Results The mutation at nucleotide 506 in the factor V gene was detected in 22 of the women with obstetrical complications and in 7 of the women with normal pregnancies (20 percent and 6 percent, respectively; P=0.003). Twenty-four women with complications, as compared with nine women without complications, were homozygous for the C677T mutation in the gene encoding methylenetetrahydrofotate reductase (22 percent and 8 percent, respectively; P=0.005). The G20210A mutation in the prothrombin gene was found in 11 women with complications as compared with 3 women without complications (10 percent and 3 percent, respectively; P=0.03). Overall, 57 women with obstetrical complications had a thrombophilic mutation, as compared with 19 women with normal pregnancies (52 percent and 17 percent, respectively; P<0.001). Deficiency of protein S, protein C, or antithrombin ill or anticardiolipin antibodies were detected in an additional 14 women with complications, as compared with 1 woman with a normal pregnancy (13 percent and 1 percent, respectively; P<0.001). Conclusions Women with serious obstetrical complications have an increased incidence of mutations predisposing them to thrombosis and other inherited and acquired forms of thrombophilia. (N Engl J Med 1999;340:9-13.) (C) 1999, Massachusetts Medical Society.	Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Lis Matern Hosp,Dept Obstet & Gynecol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Kupferminc, MJ (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Lis Matern Hosp,Dept Obstet & Gynecol, 6 Weizman St, IL-64239 Tel Aviv, Israel.							*AM COLL OBST GYN, 1996, TECHN B AM COLL OBST, V219; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1996, BLOOD, V88, P877; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; CREASY RK, 1994, MATERNAL FETAL MED P, P609; DAHLBACK B, 1994, HAEMOSTASIS, V24, P139; DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6; deVries JIP, 1997, BRIT J OBSTET GYNAEC, V104, P1248; DizonTownson DS, 1996, AM J OBSTET GYNECOL, V175, P902, DOI 10.1016/S0002-9378(96)80022-6; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P1052; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; KANG SS, 1991, AM J HUM GENET, V48, P536; KHONG TY, 1987, AM J OBSTET GYNECOL, V157, P360, DOI 10.1016/S0002-9378(87)80172-2; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Lindoff C, 1997, AM J OBSTET GYNECOL, V176, P457, DOI 10.1016/S0002-9378(97)70515-5; Lindqvist PG, 1998, THROMB HAEMOSTASIS, V79, P69; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1049, DOI 10.1016/0002-9378(95)91325-4; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1097, DOI 10.1016/0002-9378(95)91333-5; Seligsohn U, 1997, THROMB HAEMOSTASIS, V78, P297; SHANKLIN DR, 1989, AM J OBSTET GYNECOL, V161, P735, DOI 10.1016/0002-9378(89)90392-X; Sohda S, 1997, J MED GENET, V34, P525, DOI 10.1136/jmg.34.6.525; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	33	841	880	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					9	13		10.1056/NEJM199901073400102	http://dx.doi.org/10.1056/NEJM199901073400102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878639				2022-12-28	WOS:000077943700002
J	Osborn, EHS; Papadakis, MA; Gerberding, JL				Osborn, EHS; Papadakis, MA; Gerberding, JL			Occupational exposures to body fluids among medical students - A seven-year longitudinal study	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE WORKERS; UNIVERSAL PRECAUTIONS; NEEDLESTICK INJURIES; BLOOD; EPIDEMIOLOGY; MANAGEMENT; ABUSE; RISK; HIV	Background: Medical students may be at high risk for occupational exposures to blood. Objective: To measure the frequency of medical students' exposure to infectious body substances, to identify factors that affect the probability of such exposure, and to suggest targets for the prevention of such exposure. Design: Review of all exposures reported by medical students at the University of California, San Francisco, School of Medicine. Setting: Teaching hospitals affiliated with the University of California, San Francisco. Participants: Third- and fourth-year medical students from the classes of 1990 through 1996 at the University of California, San Francisco, School of Medicine. Interventions: A needlestick hotline service was instituted at teaching hospitals affiliated with the University of California, San Francisco, and a required course was created to train students in universal precautions and clinical skills before the beginning of the third-year clerkship. Measurements: Reports of exposures made to the needlestick hotline service, including type of exposure, training site, clerkship, and time of year. Results: 119 of 1022 medical students sustained 129 exposures. Of these exposures, 82% occurred on four services: obstetrics-gynecology, surgery, medicine, and emergency medicine. The probability of exposure was not related to graduation year, clerkship location, previous clerkship experience, or training site. Surveys of two graduating classes at the beginning and end of the study showed that the percentage of exposures reported increased from 45% to 65% over the 7-year study period. Thus, the reported injury rates represent minimum estimates of actual occurrences. Human immunodeficiency virus infection and hepatitis were not reported, although follow-up was limited. Conclusions: Instruction in universal precautions and clinical procedures is not sufficient to prevent exposures to blood during medical training. Medical schools must assume greater responsibility for ensuring that students are proficient in the safe conduct of clinical procedures and must develop systems that protect students so that they can report and learn from their mistakes.	Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30329 USA	Palo Alto Medical Foundation Research Institute; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Osborn, EHS (corresponding author), Palo Alto Med Fdn, 300 Home Ave, Palo Alto, CA 94301 USA.							Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Christakis DA, 1997, JAMA-J AM MED ASSOC, V278, P739, DOI 10.1001/jama.278.9.739; Diekema DJ, 1996, ACAD MED, V71, P1090, DOI 10.1097/00001888-199610000-00016; Diekema DJ, 1996, J GEN INTERN MED, V11, P109, DOI 10.1007/BF02599587; EVANS SE, 1996, 34 ANN M INF DIS SOC; GERBERDING JL, 1995, SURG CLIN N AM, V75, P1091; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Hanrahan A, 1997, J ADV NURS, V25, P144, DOI 10.1046/j.1365-2648.1997.1997025144.x; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEWIS FR, 1995, SURG CLIN N AM, V75, P1105; *LIAIS COMM MED ED, 1995, FUNCT STRUCT MED SCH, P75; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MANSOUR AM, 1990, AM J INFECT CONTROL, V18, P208, DOI 10.1016/0196-6553(90)90186-V; Orenstein R, 1995, AM J INFECT CONTROL, V23, P344, DOI 10.1016/0196-6553(95)90264-3; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; SHEEHAN KH, 1990, JAMA-J AM MED ASSOC, V263, P533, DOI 10.1001/jama.263.4.533; SILVER HK, 1990, JAMA-J AM MED ASSOC, V263, P527, DOI 10.1001/jama.263.4.527; STOTKA JL, 1991, INFECT CONT HOSP EP, V12, P583; Tereskerz PM, 1996, NEW ENGL J MED, V335, P1150, DOI 10.1056/NEJM199610103351512; VERGILIO JA, 1993, ARCH SURG-CHICAGO, V128, P36; 1991, MMWR MORB MORTAL WKL, V40, P1; 1997, MMWR MORB MORTAL WKL, V46, P21	24	90	99	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					45	51		10.7326/0003-4819-130-1-199901050-00009	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890850				2022-12-28	WOS:000077744500008
J	Mughal, MZ; Salama, H; Greenaway, T; Laing, I; Mawer, EB				Mughal, MZ; Salama, H; Greenaway, T; Laing, I; Mawer, EB			Lesson of the week - Florid rickets associated with prolonged breast feeding without vitamin D supplementation	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Cent Manchester Healthcare Trust, Manchester M13 0JH, Lancs, England; Alexandra Practice, Manchester M16 8NG, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Mughal, MZ (corresponding author), St Marys Hosp, Cent Manchester Healthcare Trust, Manchester M13 0JH, Lancs, England.		MUGHAL, Zulf/AAA-1230-2021					BROOKE OG, 1981, BRIT J OBSTET GYNAEC, V88, P18, DOI 10.1111/j.1471-0528.1981.tb00931.x; CLEMENS TL, 1982, LANCET, V1, P74; Department of Health, 1991, DIET REF VAL FOOD EN; DUNNIGAN MG, 1985, BMJ-BRIT MED J, V291, P239, DOI 10.1136/bmj.291.6490.239; ELDRISSY ATH, 1984, CALCIFIED TISSUES IN, V36, P266; SPECKER BL, 1985, AM J DIS CHILD, V139, P1134, DOI 10.1001/archpedi.1985.02140130072032	6	66	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					39	40						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872885	Green Published			2022-12-28	WOS:000078013100028
J	Barton, GM; Rudensky, AY				Barton, GM; Rudensky, AY			Requirement for diverse, low-abundance peptides in positive selection of T cells	SCIENCE			English	Article							SELF-PEPTIDES; MICE; RECEPTOR; LIGAND; THYMOCYTES; REPERTOIRE; DEFICIENT; THYMUS	Whether a single major histocompatibility complex (MHC)-bound peptide can drive the positive selection of large numbers of T cells has been-a controversial. issue. A diverse population of self peptides was shown to be essential for the in vivo development of CD4 T cells. Mice in which all but 5 percent of MHC class II molecules were bound by a single peptide had wild-type numbers of CD4 T cells. However, when the diversity within this 5 percent was lost, CD4 T cell development was impaired. Blocking the major peptide-MHC complex in thymus organ culture had no effect on T cell development; indicating that positive selection occurred on the diverse peptides present at low levels, This requirement for peptide diversity indicates that the interaction between self peptides and T cell receptors during positive selection is highly specific.	Univ Washington, Howard Hughes Med Inst, Sch Med, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rudensky, AY (corresponding author), Univ Washington, Howard Hughes Med Inst, Sch Med, Box 357370, Seattle, WA 98195 USA.			Barton, Gregory/0000-0002-3793-0100				Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BARTON G, UNPUB; Barton GM, 1998, INT IMMUNOL, V10, P1159, DOI 10.1093/intimm/10.8.1159; Benoist C, 1997, CURR OPIN IMMUNOL, V9, P245, DOI 10.1016/S0952-7915(97)80143-4; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; DENZIN L, COMMUNICATION; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FOWLKES BJ, 1995, CURR OPIN IMMUNOL, V7, P188, DOI 10.1016/0952-7915(95)80003-4; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; Hogquist KA, 1997, IMMUNITY, V6, P389, DOI 10.1016/S1074-7613(00)80282-4; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hu QH, 1997, IMMUNITY, V7, P221, DOI 10.1016/S1074-7613(00)80525-7; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kovats S, 1998, J EXP MED, V187, P245, DOI 10.1084/jem.187.2.245; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; Tourne S, 1997, P NATL ACAD SCI USA, V94, P9255, DOI 10.1073/pnas.94.17.9255; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; WONG P, UNPUB; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	32	93	92	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					67	70		10.1126/science.283.5398.67	http://dx.doi.org/10.1126/science.283.5398.67			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872742				2022-12-28	WOS:000077976600050
J	Iyer, VR; Eisen, MB; Ross, DT; Schuler, G; Moore, T; Lee, JCF; Trent, JM; Staudt, LM; Hudson, J; Boguski, MS; Lashkari, D; Shalon, D; Botstein, D; Brown, PO				Iyer, VR; Eisen, MB; Ross, DT; Schuler, G; Moore, T; Lee, JCF; Trent, JM; Staudt, LM; Hudson, J; Boguski, MS; Lashkari, D; Shalon, D; Botstein, D; Brown, PO			The transcriptional program in the response of human fibroblasts to serum	SCIENCE			English	Article							GENE-EXPRESSION PATTERNS; SYNCHRONIZATION; MICROARRAY	The temporal program of gene expression during a model physiological response of human cells, the response of fibroblasts to serum, was explored with a complementary DNA microarray representing about 8600 different human genes. Genes could be clustered into groups on the basis of their temporal patterns of expression in this program. Many features of the transcriptional program appeared to be related to the physiology of wound repair, suggesting that fibroblasts play a larger and richer role in this complex multicellular response than had previously been appreciated.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Res Genet Inc, Huntsville, AL 35801 USA; Incyte Pharmaceut, Fremont, CA 94555 USA; Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, Div Clin Sci, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Incyte; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.		Staudt, Louis/AAC-5324-2019	Eisen, Michael/0000-0002-7528-738X; Shalon, Tidhar Dari/0000-0003-2646-6215	NCI NIH HHS [CA 77097] Funding Source: Medline; NHGRI NIH HHS [T32 HG00450, HG00450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450, R01HG000450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KREK W, 1995, METHOD ENZYMOL, V254, P114; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEPPALUOTO J, 1992, ANN MED, V24, P153, DOI 10.3109/07853899209147813; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41	15	1590	1671	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					83	87		10.1126/science.283.5398.83	http://dx.doi.org/10.1126/science.283.5398.83			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872747				2022-12-28	WOS:000077976600055
J	Xoconostle-Cazares, B; Yu, X; Ruiz-Medrano, R; Wang, HL; Monzer, J; Yoo, BC; McFarland, KC; Franceschi, VR; Lucas, WJ				Xoconostle-Cazares, B; Yu, X; Ruiz-Medrano, R; Wang, HL; Monzer, J; Yoo, BC; McFarland, KC; Franceschi, VR; Lucas, WJ			Plant paralog to viral movement protein that potentiates transport of mRNA into the phloem	SCIENCE			English	Article							CELL-TO-CELL; TOBACCO PLANTS; PLASMODESMATA; TRAFFICKING; RNA; PATTERNS	CmPP16 from Cucurbita maxima was cloned and the protein was shown to possess properties similar to those of viral movement proteins. CmPP16 messenger RNA (mRNA) is present in phloem tissue, whereas protein appears confined to sieve elements (SE). Microinjection and grafting studies revealed that CmPP16 moves from cell to cell, mediates the transport of sense and antisense RNA, and moves together with its mRNA into the SE of scion tissue. CmPP16 possesses the characteristics that are likely required to mediate RNA delivery into the long-distance translocation stream. Thus, RNA may move within the phloem as a component of a plant information superhighway.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Washington State Univ, Ctr Electron Microscopy, Pullman, WA 99164 USA	University of California System; University of California Davis; Washington State University	Lucas, WJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA.							Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Esau K., 1969, ENCY PLANT ANATOMY, V5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISHER J, 1992, NEW THEAT Q, V8, P100; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Itaya A, 1997, PLANT J, V12, P1223, DOI 10.1046/j.1365-313X.1997.12051223.x; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kopka J, 1998, PLANT MOL BIOL, V36, P627, DOI 10.1023/A:1005915020760; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOMMEL SA, 1988, NUCLEIC ACIDS RES, V16, P8587, DOI 10.1093/nar/16.17.8587; Lough TJ, 1998, MOL PLANT MICROBE IN, V11, P801, DOI 10.1094/MPMI.1998.11.8.801; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; Sambrook J., 1989, MOL CLONING; TIEDEMANN R, 1994, J PLANT PHYSIOL, V143, P189, DOI 10.1016/S0176-1617(11)81685-8; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Wang HL, 1998, VIROLOGY, V245, P75, DOI 10.1006/viro.1998.9154	30	363	398	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					94	98		10.1126/science.283.5398.94	http://dx.doi.org/10.1126/science.283.5398.94			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872750				2022-12-28	WOS:000077976600058
J	Takechi, H; Eilers, J; Konnerth, A				Takechi, H; Eilers, J; Konnerth, A			A new class of synaptic response involving calcium release in dendritic spines	NATURE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; CENTRAL-NERVOUS-SYSTEM; INOSITOL TRISPHOSPHATE; NEURONS; MGLUR1; RAT; PLASTICITY; CURRENTS	In the classical view, transmission of signals across synapses in the mammalian brain involves changes in the membrane potential of the postsynaptic cell. The use of high-resolution cellular imaging has revealed excitatory synapses at which postsynaptic, transient alterations in calcium ion concentration are tightly associated with electrical responses (reviewed in ref. 1). Here, by investigating the synapse between parallel glutamatergic fibres and Purkinje cells in the mouse cerebellum, we identify a class of postsynaptic responses that consist of transient increases in dendritic Ca2+ concentration but not changes in somatic membrane potential. Our results indicate that these synaptic Ca2+ transients are mediated by activation of metabotropic glutamate-responsive mGluR1-type receptors(2-4) and require inositol-1,4,5-trisphosphate-mediated Ca2+ release(5,6) from to postsynaptic microdomains, which range, depending on the frequency of stimulation, from individual spines to small spinodendritic compartments. Thus, the synaptic Ca2+-release signal may be one of the critical cues that determine the input specificity of longterm depression, a well-established form of activity-dependent plasticity at these synapses(7-9).	Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany	Saarland University	Konnerth, A (corresponding author), Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany.		Eilers, Jens/E-6251-2012	Eilers, Jens/0000-0003-0497-5625				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BATCHELOR AM, 1993, NEUROPHARMACOLOGY, V32, P11, DOI 10.1016/0028-3908(93)90124-L; Batchelor AM, 1997, NATURE, V385, P74, DOI 10.1038/385074a0; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Eilers J, 1997, CURR OPIN NEUROBIOL, V7, P385, DOI 10.1016/S0959-4388(97)80067-0; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; EILERS J, 1997, PFLUGERS ARCH S, V433, P549; FRENGUELLI BG, 1993, NEUROPHARMACOLOGY, V32, P1229, DOI 10.1016/0028-3908(93)90017-W; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Ito M., 1984, CEREBELLUM NEURONAL; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; Khodakhah K, 1997, BIOPHYS J, V73, P3349, DOI 10.1016/S0006-3495(97)78359-0; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; Korkotian E, 1998, EUR J NEUROSCI, V10, P2076, DOI 10.1046/j.1460-9568.1998.00219.x; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; TAKEI K, 1992, J NEUROSCI, V12, P489	30	333	337	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 31	1998	396	6713					757	760		10.1038/25547	http://dx.doi.org/10.1038/25547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874373				2022-12-28	WOS:000077742800034
J	Krautwurst, D; Yau, KW; Reed, RR				Krautwurst, D; Yau, KW; Reed, RR			Identification of ligands for olfactory receptors by functional expression of a receptor library	CELL			English	Article							CYCLOPHILIN HOMOLOG NINAA; ODORANT RECEPTORS; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; PROTEIN; CHANNEL; CELLS; RHODOPSINS; EPITHELIUM; NEURONS	The recognition of odorants by olfactory receptors represents the first stage in odor discrimination. Here, we report the generation of an expression library containing a large and diverse repertoire of mouse olfactory receptor sequences in the transmembrane Il-VII region. From this library, 80 chimeric receptors were tested against 26 odorants after transfection into HEK-293 cells. Three receptors were identified to respond to micromolecular concentrations of carvene, (-) citronellal, and limonene, respectively. We also found that the mouse 17 receptor, unlike the rat 17 receptor, prefers heptanal instead of octanal, as a result of a single valine-to-isoleucine substitution. This finding represents the beginning of a molecular understanding of odorant recognition. The identification, on a large scale, of cognate receptor-odorant interactions should provide insight into olfactory coding mechanisms.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Reed, RR (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Reed, Russell/HGU-0528-2022; Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARGRAVE PA, 1986, EXP EYE RES, V42, P363, DOI 10.1016/0014-4835(86)90030-8; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; Qasba P, 1998, J NEUROSCI, V18, P227; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SCHILD D, 1995, J NEUROPHYSIOL, V73, P862, DOI 10.1152/jn.1995.73.2.862; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	40	473	518	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					917	926		10.1016/S0092-8674(00)81716-X	http://dx.doi.org/10.1016/S0092-8674(00)81716-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875846	hybrid			2022-12-28	WOS:000077759100007
J	Wenzel, SE				Wenzel, SE			Antileukotriene drugs in the management of asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RECEPTOR ANTAGONIST; INDUCED BRONCHOCONSTRICTION; INFLAMMATION; INHIBITION; POTENT; MK-571; TRIAL		Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	wenzels@njc.org						Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; *NIH, 1997, 2 NIH; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P347, DOI 10.1016/S1081-1206(10)63195-X; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; Virchow J. C., 1997, European Respiratory Journal Supplement, V10, p437S; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wenzel S, 1997, AM J RESP CRIT CARE, V155, pA203; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	22	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2068	2069		10.1001/jama.280.24.2068	http://dx.doi.org/10.1001/jama.280.24.2068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875862				2022-12-28	WOS:000077606100013
J	Huxford, T; Huang, DB; Malek, S; Ghosh, G				Huxford, T; Huang, DB; Malek, S; Ghosh, G			The crystal structure of the I kappa B alpha/NF-kappa B complex reveals mechanisms of NF-kappa B inactivation	CELL			English	Article							DNA-BINDING; CYTOPLASMIC RETENTION; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; REL PROTEIN; INHIBITOR; ACTIVATION; ANKYRIN; P50; PHOSPHORYLATION	I kappa B alpha regulates the transcription factor NF-kappa B through the formation of stable I kappa B alpha/NF-kappa B complexes. Prior to induction, I kappa B alpha retains NF-kappa B in the cytoplasm until the NF-kappa B activation signal is received. After activation, NF-kappa B is removed from gene promoters through association with nuclear I kappa B alpha, restoring the preinduction state. The 2.3 Angstrom crystal structure of I kappa B alpha in complex with the NF-kappa B p50/p65 heterodimer reveals mechanisms of these inhibitory activities. The presence of I kappa B alpha allows large en bloc movement of the NF-kappa B p65 subunit amino-terminal domain. This conformational change induces allosteric inhibition of NF-kappa B DNA binding. Amino acid residues immediately preceding the nuclear localization signals of both NF-kappa B p50 and p65 subunits are tethered to the I kappa B alpha aminoterminal ankyrin repeats, impeding NF-kappa B from nuclear import machinery recognition.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu		Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09523] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; ERNST MK, 1995, MOL CELL BIOL, V15, P872; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Govind S, 1996, MOL CELL BIOL, V16, P1103; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	61	487	510	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					759	770		10.1016/S0092-8674(00)81699-2	http://dx.doi.org/10.1016/S0092-8674(00)81699-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865694	Bronze			2022-12-28	WOS:000077498800006
J	Tsukazaki, T; Chiang, TA; Davison, AF; Attisano, L; Wrana, JL				Tsukazaki, T; Chiang, TA; Davison, AF; Attisano, L; Wrana, JL			SARA, a FYVE domain protein that recruits Smad2 to the TGF beta receptor	CELL			English	Article							SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; PHOSPHORYLATION; KINASE; SER(465); SCAFFOLD; MEDIATOR; GENES	Smads transmit signals from transmembrane ser/thr kinase receptors to the nucleus. We now identify SARA (for Smad anchor for receptor activation), a FYVE domain protein that interacts directly with Smad2 and Smad3. SARA functions to recruit Smad2 to the TGF beta receptor by controlling the subcellular localization of Smad2 and by interacting with the TGF beta receptor complex. Phosphorylation of Smad2 induces dissociation from SARA with concomitant formation of Smad2/Smad4 complexes and nuclear translocation. Furthermore, mutations in SARA that cause mislocalization of Smad2 inhibit TGF beta-dependent transcriptional responses, indicating that the regulation of Smad localization is important for TGF beta signaling. These results thus define SARA as a component of the TGF beta pathway that brings the Smad substrate to the receptor.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Wrana, JL (corresponding author), Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jwrana@sickkids.on.ca	Wrana, Jeffrey/F-8857-2013					Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	38	740	795	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					779	791		10.1016/S0092-8674(00)81701-8	http://dx.doi.org/10.1016/S0092-8674(00)81701-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865696	Bronze			2022-12-28	WOS:000077498800008
J	Perry, A; Tarrier, N; Morriss, R; McCarthy, E; Limb, K				Perry, A; Tarrier, N; Morriss, R; McCarthy, E; Limb, K			Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment	BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE FOLLOW-UP; PRODROMAL SYMPTOMS; PSYCHOSIS	Objective To determine the efficacy of teaching patients with bipolar disorder (manic-depressive psychosis) to identify early symptoms of relapse and seek prompt treatment from health services. Design Single blind randomised controlled trial with matching on four baseline variables using a minimisation algorithm. Setting Mental health services in four NHS trusts (one teaching, three non-teaching). Subjects 69 patients with bipolar disorder who had had a relapse in the previous 12 months. Interventions Seven to 12 individual treatment sessions from a research psychologist plus routine care or routine care alone. Main outcome measures Time to first manic or depressive relapse, number of manic or depressive relapses, and social functioning examined by standardised interviews every six months for 18 months. Results 25th centile time to first manic relapse in experimental group was 65 weeks compared with 17 weeks in the control group. Event curves of time to first manic relapse significantly differed between experimental and control groups (log rank 7.04, df = 1, P = 0.008), with significant reductions in the number of manic relapses over 18 months (median difference 30% (95% confidence interval 8% to 52%), P = 0.013). The experimental treatment had no effect on time to first relapse or number of relapses with depression but it significantly improved overall social functioning (mean difference 2.0 (0.7 to 3.2), P = 0.003) and employment (mean difference 0.7 (0.1 to 1.3), P = 0.030) by 18 months. Conclusion Teaching patients to recognise early symptoms of manic relapse and seek early treatment is associated with important clinical improvements in time to first manic relapse, social functioning, and employment.	Univ Manchester, Dept Community Psychiat, Manchester M13 9PL, Lancs, England; Univ Manchester, Withington Hosp, Dept Clin Psychol, Manchester M20 8LR, Lancs, England; Royal Preston Hosp, Guild NHS Trust, Preston PR2 9HT, Lancs, England	University of Manchester; University of Manchester; Royal Preston Hospital	Morriss, R (corresponding author), Univ Manchester, Dept Community Psychiat, Manchester M13 9PL, Lancs, England.			Morriss, Richard/0000-0003-2910-4121				ALTMAN ES, 1992, PSYCHIAT RES, V41, P1, DOI 10.1016/0165-1781(92)90012-R; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; CORYELL W, 1989, PSYCHOL MED, V19, P129, DOI 10.1017/S0033291700011090; GATER RA, 1989, PSYCHOL MED, V19, P719, DOI 10.1017/S0033291700024314; GITLIN MJ, 1995, AM J PSYCHIAT, V152, P1635; HARROW M, 1990, ARCH GEN PSYCHIAT, V47, P665; Hlastala S A, 1997, Depress Anxiety, V5, P73, DOI 10.1002/(SICI)1520-6394(1997)5:2<73::AID-DA3>3.3.CO;2-U; HURRY J, 1983, SOC PSYCHIATR, V18, P113, DOI 10.1007/BF00583561; Keck PE, 1998, AM J PSYCHIAT, V155, P646, DOI 10.1176/ajp.155.5.646; KELLER MB, 1993, J NERV MENT DIS, V181, P238, DOI 10.1097/00005053-199304000-00005; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P371; Kessing LV, 1998, BRIT J PSYCHIAT, V172, P29, DOI 10.1192/bjp.172.1.29; Lam D, 1997, PSYCHOL MED, V27, P1091, DOI 10.1017/S0033291797005540; Maj M, 1998, AM J PSYCHIAT, V155, P30, DOI 10.1176/ajp.155.1.30; MIKLOWITZ DJ, 1988, ARCH GEN PSYCHIAT, V45, P225; MOLNAR G, 1988, AM J PSYCHIAT, V145, P1575; PERRY A, 1995, BEHAV COGN PSYCHOTH, V23, P399; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SMITH JA, 1992, SOC PSYCH PSYCH EPID, V27, P245, DOI 10.1007/BF00788937; Spitzer RL, 1990, STRUCTURED CLIN INTE; Tarrier N, 1998, BRIT MED J, V317, P303, DOI 10.1136/bmj.317.7154.303; TOHEN M, 1990, ARCH GEN PSYCHIAT, V47, P1106; *WHO, 1994, AN THER CHEM ATC CLA; YOUNG MA, 1985, PSYCHIAT RES, V16, P309, DOI 10.1016/0165-1781(85)90122-2	24	376	386	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					149	153		10.1136/bmj.318.7177.149	http://dx.doi.org/10.1136/bmj.318.7177.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159LR	9888904	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000078175100022
J	Jenekhe, SA; Chen, XL				Jenekhe, SA; Chen, XL			Self-assembly of ordered microporous materials from rod-coil block copolymers	SCIENCE			English	Article							ORGANIZED HONEYCOMB MORPHOLOGY; MESOPOROUS MOLECULAR-SIEVES; DIBLOCK COPOLYMERS; MULTIPLE MORPHOLOGIES; COLLOIDAL CRYSTALS; POLYMERIC MICELLES; BINARY-MIXTURES; POLYQUINOLINES; TRANSITIONS; POLYANTHRAZOLINES	Rod-coil diblock copolymers in a selective solvent for the coil-like polymer serf-organize into hollow spherical micelles having diameters of a few micrometers. Long-range, close-packed self-ordering of the micelles produced highly iridescent periodic microporous materials. Solution-cast micellar films consisted of multilayers of hexagonally ordered arrays of spherical holes whose diameter, periodicity, and watt thickness depended on copolymer molecular weight and composition. Addition of fullerenes into the copolymer solutions also regulated the microstructure and optical properties of the microporous films. These results demonstrate the potential of hierarchical self-assembly of macromolecular components for engineering complex two- and three-dimensional periodic and functional mesostructures.	Univ Rochester, Dept Chem Engn & Chem, Rochester, NY 14627 USA	University of Rochester	Jenekhe, SA (corresponding author), Univ Rochester, Dept Chem Engn & Chem, 601 Elmwood Ave, Rochester, NY 14627 USA.	jenekhe@che.rochester.edu	Jenekhe, Samson/AAC-4212-2022					Agrawal AK, 1996, CHEM MATER, V8, P579, DOI 10.1021/cm9504753; AGRAWAL AK, 1992, J PHYS CHEM-US, V96, P2837, DOI 10.1021/j100186a011; AGRAWAL AK, 1993, MACROMOLECULES, V26, P895, DOI 10.1021/ma00057a003; BARTLETT P, 1992, PHYS REV LETT, V68, P3801, DOI 10.1103/PhysRevLett.68.3801; Bitzer T., 1997, HONEYCOMB TECHNOLOGY, P230; BUSCALL R, 1985, POLYM COLLOIDS; CARTER FL, 1987, MOL ELECT, V2; Chen HJ, 1996, J AM CHEM SOC, V118, P2584, DOI 10.1021/ja9523911; CHEN XQ, UNPUB; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; Czlikkely V, 1970, CHEM PHYS LETT, V6, P11, DOI 10.1016/0009-2614(70)80062-8; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EVANS DF, 1994, COLLOIDAL DOMAIN WHE; Fendler J. H., 1982, MEMBRANE MIMETIC CHE; Forster S, 1998, ADV MATER, V10, P195, DOI 10.1002/(SICI)1521-4095(199802)10:3<195::AID-ADMA195>3.0.CO;2-V; Francois B, 1995, ADV MATER, V7, P1041, DOI 10.1002/adma.19950071217; HACHISU S, 1980, NATURE, V283, P188, DOI 10.1038/283188a0; HALPERIN A, 1992, ADV POLYM SCI, V100, P31; HALPERIN A, 1990, MACROMOLECULES, V23, P2724, DOI 10.1021/ma00212a023; HOCHSTRASSER RM, 1964, PHOTOCHEM PHOTOBIOL, V3, P317, DOI 10.1111/j.1751-1097.1964.tb08155.x; HOLYST R, 1992, J CHEM PHYS, V96, P721, DOI 10.1063/1.462457; Hunter RJ, 1987, FDN COLLOID SCI, V1; Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; JENEKHE SA, 1994, SCIENCE, V265, P765, DOI 10.1126/science.265.5173.765; Jenekhe SA, 1997, CHEM MATER, V9, P409, DOI 10.1021/cm960474q; Jenekhe SA, 1998, SCIENCE, V279, P1903, DOI 10.1126/science.279.5358.1903; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; KASHA M, 1963, RADIAT RES, V20, P55, DOI 10.2307/3571331; KOSE A, 1974, J COLLOID INTERF SCI, V46, P460, DOI 10.1016/0021-9797(74)90056-3; Kramer E, 1998, LANGMUIR, V14, P2027, DOI 10.1021/la9712505; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MARTORELL J, 1990, PHYS REV LETT, V65, P1877, DOI 10.1103/PhysRevLett.65.1877; MCCONNELL GA, 1993, PHYS REV LETT, V71, P2102, DOI 10.1103/PhysRevLett.71.2102; McConnell GA, 1997, MACROMOLECULES, V30, P435, DOI 10.1021/ma961241n; McConnell GA, 1996, PHYS REV E, V54, P5447, DOI 10.1103/PhysRevE.54.5447; MCCONNELL GA, 1995, MACROMOLECULES, V28, P6754, DOI 10.1021/ma00124a009; Miguez H, 1997, APPL PHYS LETT, V71, P1148, DOI 10.1063/1.119849; Muller M, 1996, MACROMOLECULES, V29, P8900, DOI 10.1021/ma960782+; OSAHENI JA, 1995, J AM CHEM SOC, V117, P7389, DOI 10.1021/ja00133a012; PIERANSKI P, 1983, CONTEMP PHYS, V24, P25, DOI 10.1080/00107518308227471; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; RAPHAEL E, 1991, PHYSICA A, V177, P294, DOI 10.1016/0378-4371(91)90166-A; RAPHAEL E, 1992, MAKROMOL CHEM-M SYMP, V62, P1, DOI 10.1002/masy.19920620104; Sayari A, 1996, CHEM MATER, V8, P1840, DOI 10.1021/cm950585+; SEMENOV AN, 1991, MOL CRYST LIQ CRYST, V209, P191, DOI 10.1080/00268949108036194; SEMENOV AN, 1986, ZH EKSP TEOR FIZ, V63, P70; TUZAR Z, 1993, SURF COLLOID SCI, V15, P1; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Webber SE, 1998, J PHYS CHEM B, V102, P2618, DOI 10.1021/jp980386o; WEBBER SE, 1996, SOLVENTS SELF ORG PO; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959; WIDAWSKI G, 1994, NATURE, V369, P387, DOI 10.1038/369387a0; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; WILLIAMS DRM, 1993, PHYS REV LETT, V71, P1557, DOI 10.1103/PhysRevLett.71.1557; WILLIAMS DRM, 1992, MACROMOLECULES, V25, P3561, DOI 10.1021/ma00039a040; YABLONOVITCH E, 1993, J OPT SOC AM B, V10, P283, DOI 10.1364/JOSAB.10.000283; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	60	898	946	3	382	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					372	375		10.1126/science.283.5400.372	http://dx.doi.org/10.1126/science.283.5400.372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888850				2022-12-28	WOS:000078067000044
J	Usen, S; Weber, M; Mulholland, K; Jaffar, S; Oparaugo, A; Omosigho, C; Adegbola, R; Greenwood, B				Usen, S; Weber, M; Mulholland, K; Jaffar, S; Oparaugo, A; Omosigho, C; Adegbola, R; Greenwood, B			Clinical predictors of hypoxaemia in Gambian children with acute lower respiratory tract infection: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAPUA-NEW-GUINEA; DEVELOPING-COUNTRIES; SYNCYTIAL VIRUS; PNEUMONIA; HYPOXEMIA; SIGNS; BRONCHIOLITIS; CHILDHOOD; PROTEIN; HYPOXIA	Objectives To determine clinical correlates and outcome of hypoxaemia in children admitted to hospital with an acute lower respiratory tract infection. Design Prospective cohort study Setting Paediatric wards of the Royal Victoria Hospital and the hospital of the Medical Research Council's hospital in Banjul, the Gambia. Subjects 1072 of 42 848 children, aged 2 to 33 months, who were enrolled in a randomised trial of a Haemophilus influenzae type b vaccine in the western region or the Gambia, and who were admitted with a acute lower respiratory tract infection to two of three hospitals. Main outcome measures Prevalence of hypoxaemia, defined as an arterial oxygen saturation < 90% recorded by pulse oximetry, and the relation between hypoxaemia and aetiological agents. Results 1072 children aged 2-33 months were enrolled. Sixty three (5.9%) had an arterial oxygen saturation < 90%. A logistic regression model showed that cyanosis, a rapid respiratory rate, grunting, head nodding, an absence of a history of fever, and no spontaneous movement during examination were the best independent predictors of hypoxaemia. The presence of an inability to cry, head nodding, or a respiratory rate greater than or equal to 90 breaths/min formed the best predictors of hypoxaemia (sensitivity 70%, specificity 79%). Hypoxaemic children were five times more likely to die than non-hypoxaemic children. The presence of malaria parasitaemia had no effect on the prevalence of hypoxaemia or on its association with respiratory rate. Conclusion In children with an acute lower respiratory tract infection, simple physical signs that require minimal expertise to recognise can be used to determine oxygen therapy and to aid in screening for referral. The association between hypoxaemia and death highlights die need for early recognition of the condition and the potential benefit of treatment.	MRC Labs, Fajara, Gambia; WHO, Global Programme Vaccine & Immunisat, CH-1211 Geneva 27, Switzerland; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	MRC Laboratory Molecular Biology; World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Usen, S (corresponding author), MRC Labs, POB 273, Fajara, Gambia.	susen@mrc.enda.sn		Jaffar, Shabbar/0000-0002-9615-1588				CANE PA, 1995, J VIROL, V69, P2918, DOI 10.1128/JVI.69.5.2918-2925.1995; CHERIAN T, 1988, LANCET, V2, P125; DENNY FW, 1986, AM J TROP MED HYG, V35, P1; DYKE T, 1994, BRIT MED J, V308, P119, DOI 10.1136/bmj.308.6921.119; DYKE T, 1995, J TROP PEDIATRICS, V41, P196, DOI 10.1093/tropej/41.4.196; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; HALL CB, 1979, AM J DIS CHILD, V133, P798, DOI 10.1001/archpedi.1979.02130080038006; LEVENE S, 1988, LANCET, V1, P415; LOWESKI J, 1986, WORLD HLTH STAT Q, V5, P247; LOZANO JM, 1994, ARCH DIS CHILD, V71, P323, DOI 10.1136/adc.71.4.323; MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; ODEMPSEY TJD, 1993, BRIT MED J, V306, P1342, DOI 10.1136/bmj.306.6888.1342; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; REYNOLDS EO, 1963, BMJ-BRIT MED J, P1192, DOI 10.1136/bmj.1.5339.1192; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; SEATON A, 1989, CROFTON DOUGLAS RESP; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SIMPSON H, 1967, LANCET, V1, P7; SPITERI MA, 1988, LANCET, V1, P873; SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295; Stadie WC, 1919, J EXP MED, V30, P215, DOI 10.1084/jem.30.3.215; WANG EEL, 1992, AM REV RESPIR DIS, V145, P106, DOI 10.1164/ajrccm/145.1.106; Weber MW, 1997, ARCH DIS CHILD, V76, P310, DOI 10.1136/adc.76.4.310; WHO, 1990, AC RESP INF CHILDR C	26	67	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1999	318	7176					86	91		10.1136/bmj.318.7176.86	http://dx.doi.org/10.1136/bmj.318.7176.86			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880280	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000078087500023
J	Woodman, R				Woodman, R			Community care does not increase homicide risk in UK	BRITISH MEDICAL JOURNAL			English	News Item																		Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					77	77		10.1136/bmj.318.7176.77	http://dx.doi.org/10.1136/bmj.318.7176.77			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880268	Green Published			2022-12-28	WOS:000078087500013
J	Hughes, JR; Goldstein, MG; Hurt, RD; Shiffman, S				Hughes, JR; Goldstein, MG; Hurt, RD; Shiffman, S			Recent advances in the pharmacotherapy of smoking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICOTINE NASAL SPRAY; DOUBLE-BLIND TRIAL; REPLACEMENT THERAPY; RANDOMIZED TRIAL; ABUSE LIABILITY; CESSATION; PLACEBO; GUM; INHALER; BUPROPION	Since the 1996 publication of guidelines on smoking cessation from the Agency for Health Care Policy and Research and the American Psychiatric Association, several new treatments have become available, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride, In addition, nicotine gum and patch have become available over-the-counter. This article reviews the published literature and US Food and Drug Administration and pharmaceutical company reports on these therapies. Based on this review, clinical logic, and experience, we conclude that pharmacotherapy should be made available to all smokers. all currently available therapies appear to be equally efficacious, approximately doubling the quit rate compared with placebo, Concomitant behavioral or supportive therapy increases quit rates and should be encouraged but not required. Combining patch with gum or patch with bupropion may increase the quit rate compared with any single treatment. Because patient characteristics predictive of success with a particular therapy are not yet known, the best treatment choice for an individual patient should be guided by the patient's past experience and preference and the product's adverse effect profile.	Univ Vermont, Dept Psychiat, Human Behav Pharmacol Lab, Burlington, VT 05401 USA; Brown Univ, Dept Psychiat, Providence, RI 02912 USA; Mayo Clin, Nicotine Dependence Ctr, Rochester, MI USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	University of Vermont; Brown University; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughes, JR (corresponding author), Univ Vermont, Dept Psychiat, Human Behav Pharmacol Lab, 38 Fletcher Pl, Burlington, VT 05401 USA.	john.hughes@uvm.edu	Hughes, John/H-9687-2013; Shiffman, Saul/K-7337-2012	Hughes, John/0000-0002-0092-9309; 	NIDA NIH HHS [DA-00109] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abrams D. B., 1993, TOB CONTROL, V2, ps17; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395; Baillie A J, 1994, Drug Alcohol Rev, V13, P157, DOI 10.1080/09595239400185231; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; BENOWITZ NL, 1991, JAMA-J AM MED ASSOC, V266, P3174, DOI 10.1001/jama.266.22.3174; BERGSTROM M, 1995, CLIN PHARMACOL THER, V57, P309, DOI 10.1016/0009-9236(95)90156-6; Blondal T, 1997, EUR RESPIR J, V10, P1585, DOI 10.1183/09031936.97.10071585; Burns D, 1997, Tob Control, V6, P1; BURTON SL, 1997, MMWR-MORBID MORTAL W, V46, P867; Fagerstrom K O, 1996, Tob Control, V5, P52, DOI 10.1136/tc.5.1.52; FAGERSTROM KO, 1993, PSYCHOPHARMACOLOGY, V111, P271, DOI 10.1007/BF02244941; FAGERSTROM KO, 1994, HEALTH VALUES, V18, P15; *FDA, 1996, M NONPR DRUG ADV COM; *FDA, 1995, M NONPR DRUG ADV COM; FERRY LH, 1994, J ADDICT DIS, V13, P249; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; FIORE MC, 1995, AM J PUBLIC HEALTH, V85, P161, DOI 10.2105/AJPH.85.2.161; FOULDS J, 1994, PRESCRIBER, V19, P21; Gourlay SG, 1997, CLIN PHARMACOL THER, V62, P453, DOI 10.1016/S0009-9236(97)90124-7; GOURLAY SG, 1995, BRIT MED J, V311, P363, DOI 10.1136/bmj.311.7001.363; HATSUKAMI D, 1993, PSYCHOPHARMACOLOGY, V111, P449, DOI 10.1007/BF02253535; HAYFORD KE, IN PRESS BR J PSYCHI; Hays JT, 1997, J ADDICT DIS, V16, P136; Heishman SJ, 1998, ADDICTION, V93, P907, DOI 10.1046/j.1360-0443.1998.93690712.x; HJALMARSON A, 1994, ARCH INTERN MED, V154, P2567, DOI 10.1001/archinte.154.22.2567; Hughes J R, 1995, NIDA Res Monogr, V150, P92; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; Hughes JR, 1998, NICOTINE SAFETY AND TOXICITY, P147; HUGHES JR, 1989, BIOMED PHARMACOTHER, V43, P11, DOI 10.1016/0753-3322(89)90185-6; HUGHES JR, 1993, DRUG SAFETY, V8, P49, DOI 10.2165/00002018-199308010-00006; HUGHES JR, 1996, AM J PSYCHIAT S, V153, pS1; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Jimenez-Ruiz C, 1998, EUR RESPIR J, V11, P473, DOI 10.1183/09031936.98.11020473; KILLEN JD, 1990, J CONSULT CLIN PSYCH, V58, P85, DOI 10.1037/0022-006X.58.1.85; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; Leischow SJ, 1996, AM J HEALTH BEHAV, V20, P364; LEISCHOW SJ, 1997, J ADDICT DIS, V16, P140; Lichtenstein E, 1996, HEALTH EDUC RES, V11, P243, DOI 10.1093/her/11.2.243; MIKKELSEN EJ, 1995, EUR RESPIR J, V8, P1125; MILLER LG, 1990, CLIN PHARMACY, V9, P125; Murray RP, 1996, CHEST, V109, P438, DOI 10.1378/chest.109.2.438; Puska P., 1995, TOB CONTROL, V4, P231, DOI [DOI 10.1136/TC.4.3.231, 10.1136/tc.4.3.231]; SCHNEIDER NG, 1983, ADDICT BEHAV, V8, P253, DOI 10.1016/0306-4603(83)90020-5; SCHNEIDER NG, 1995, ADDICTION, V90, P1671, DOI 10.1046/j.1360-0443.1995.901216719.x; Schneider NG, 1996, CLIN PHARMACOKINET, V31, P65, DOI 10.2165/00003088-199631010-00005; Schneider NG, 1996, ADDICTION, V91, P1293; Schuh KJ, 1997, PSYCHOPHARMACOLOGY, V130, P352, DOI 10.1007/s002130050250; SCHWARTZ JL, 1992, MED CLIN N AM, V76, P451, DOI 10.1016/S0025-7125(16)30362-5; Shiffman S, 1997, Tob Control, V6, P306; Sonderskov J, 1997, AM J EPIDEMIOL, V145, P309; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268; TONNESEN P, 1993, ADDICTION, V88, P533, DOI 10.1111/j.1360-0443.1993.tb02060.x	55	263	266	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					72	76		10.1001/jama.281.1.72	http://dx.doi.org/10.1001/jama.281.1.72			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153JE	9892454				2022-12-28	WOS:000077829300038
J	Fitzgerald, FT				Fitzgerald, FT			Curiosity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Fitzgerald, FT (corresponding author), Univ Calif Davis, Med Ctr, Dept Internal Med, Box 179002, Sacramento, CA 95817 USA.								0	47	48	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					70	72		10.7326/0003-4819-130-1-199901050-00015	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890857				2022-12-28	WOS:000077744500014
J	Abraham, J; Sheppard, J; Reed, T				Abraham, J; Sheppard, J; Reed, T			Rethinking transparency and accountability in medicines regulation in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Univ Sussex, Dept Sociol, Brighton BN1 9QN, E Sussex, England; Comsumers Assoc, London NW1 4DF, England	University of Sussex	Abraham, J (corresponding author), Univ Sussex, Dept Sociol, Brighton BN1 9QN, E Sussex, England.							*ABPI, 1984, ABPI NEWS, V198, P3; Abraham J, 1996, SCI POLITICS PHARM I; DELAMOTHE T, 1989, BRIT MED J, V299, P476; GRIFFIN J, 1984, ABPI NEWS, V198, P1; *HOM SECR, 1993, CM2290, P49; *MED CONTR AG, 1997, ANN REP 1996; 1993, BMJ, V303, P84; 1993, SCRIP, P2; 1993, SCRIP, P4; 1993, SCRIP, V1788, P5	10	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					46	47						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872891				2022-12-28	WOS:000078013100032
J	Ward, J				Ward, J			Observing patients - The knock on the door	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					40	40						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872887				2022-12-28	WOS:000078013100029
J	Callister, TQ; Raggi, P; Cooil, B; Lippolis, NJ; Russo, DJ				Callister, TQ; Raggi, P; Cooil, B; Lippolis, NJ; Russo, DJ			Effect of HMG-Coa reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association Meeting	NOV 09-13, 1997	ORLANDO, FLORIDA	Amer Heart Assoc			ELEVATED SERUM-CHOLESTEROL; HEART-DISEASE; RISK-FACTORS; DENSITY-LIPOPROTEIN; HELICOBACTER-PYLORI; ATHEROSCLEROSIS; CALCIFICATION; PROGRESSION; REGRESSION; REPRODUCIBILITY	Background Angiographic studies of the regression of coronary artery disease are invasive and costly, and they permit only limited assessment of changes in the extent of atherosclerotic disease. Electron-beam computed tomography (CT) is noninvasive and inexpensive. The entire coronary-artery tree can be studied during a single imaging session, and the volume of coronary calcification as quantified with this technique correlates closely with the total burden of atherosclerotic plaque. Methods We conducted a retrospective study of 149 patients (61 percent men and 39 percent women; age range, 32 to 75 years) with no history of coronary artery disease who were referred by their primary care physicians for screening electron-beam CT. All patients underwent base-line scanning and follow-up assessment after a minimum of 12 months (range, 12 to 15), and a volumetric calcium score was calculated as an estimate of the total burden of plaque. Treatment with 3-hydroxy3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors was begun at the discretion of the referring physician. Serial measurements of low-density lipoprotein (LDL) cholesterol were obtained, and the change in the calcium-volume score was correlated with average LDL cholesterol levels. Results One hundred five patients (70 percent) received treatment with HMG-CoA reductase inhibitors, and 44 patients (30 percent) did not. At followup, a net reduction in the calcium-volume score was observed only in the 65 treated patients whose final LDL cholesterol levels were less than 120 mg per deciliter (3.10 mmol per liter) (mean [+/-SD] change in the score, -7+/-23 percent; P=0.01). Untreated patients had an average LDL cholesterol level of at least 120 mg per deciliter and at the time of follow-up had a significant net increase in mean calcium-volume score (mean change, +52+/-36 percent; P<0.001). The 40 treated patients who had average LDL cholesterol levels of at least 120 mg per deciliter had a measurable increase in mean calcium-volume score (mean change, +25+/-22 percent, P<0.001), although it was smaller than the increase in the untreated patients. Conclusions The extent to which the volume of atherosclerotic plaque decreased, stabilized, or increased was directly related to treatment with HMG-CoA reductase inhibitors and the resulting serum LDL cholesterol levels. These changes can be determined noninvasively by electron-beam CT and quantified with use of a calcium-volume score. (N Engl J Med 1998;339:1972-8.) (C) 1998, Massachusetts Medical Society.	Electron Beam Tomog Res Fdn, Nashville, TN USA; Vanderbilt Univ, Nashville, TN USA	Vanderbilt University	Raggi, P (corresponding author), EBT Res Fdn, 64 Valleybrook Dr, Hendersonville, TN 37075 USA.		Cooil, Bruce/X-8664-2019; Cooil, Bruce/B-1004-2009	Cooil, Bruce/0000-0002-1276-269X				AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; BROWN BG, 1995, ANN NY ACAD SCI, V748, P407; Callister TQ, 1998, RADIOLOGY, V208, P807, DOI 10.1148/radiology.208.3.9722864; CLARKSON TB, 1994, JAMA-J AM MED ASSOC, V271, P289, DOI 10.1001/jama.271.4.289; Cobbaert C, 1997, J AM COLL CARDIOL, V30, P1491, DOI 10.1016/S0735-1097(97)00353-7; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; DEVRIES S, 1995, AM J CARDIOL, V75, P973, DOI 10.1016/S0002-9149(99)80706-1; FROHLICH JJ, 1995, CAN J CARDIOL, V11, pC18; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; HATANAKA K, 1995, PATHOL INT, V45, P635, DOI 10.1111/j.1440-1827.1995.tb03515.x; Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9; Hernigou A, 1996, EUR RADIOL, V6, P210; Holvoet P, 1997, CURR OPIN LIPIDOL, V8, P320, DOI 10.1097/00041433-199710000-00012; JANOWITZ WR, 1993, AM J CARDIOL, V72, P247, DOI 10.1016/0002-9149(93)90668-3; JANOWITZ WR, 1991, AM J CARDIOL, V68, P1, DOI 10.1016/0002-9149(91)90700-U; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KAJINAMI K, 1993, CORONARY ARTERY DIS, V4, P1103, DOI 10.1097/00019501-199312000-00011; LARSEN RJ, 1997, STAT APPL PROBLEM SO, P633; Levenson J, 1997, ARTERIOSCL THROM VAS, V17, P45, DOI 10.1161/01.ATV.17.1.45; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; *MAAS INV, 1994, LANCET, V344, P762; MAUTNER GC, 1994, RADIOLOGY, V192, P619, DOI 10.1148/radiology.192.3.8058924; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; OLIVER MF, 1994, LANCET, V344, P633; PACKARD CJ, 1997, CIRCULATION S1, V96, P107; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PATEL P, 1995, BRIT MED J, V311, P985; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; RAYA SP, 1990, IEEE T MED IMAGING, V9, P32, DOI 10.1109/42.52980; RAYA SP, 1990, COMPUT MED IMAG GRAP, V14, P353, DOI 10.1016/0895-6111(90)90109-O; RAYA SP, 1990, IEEE T MED IMAGING, V9, P327, DOI 10.1109/42.57771; RUMBERGER JA, 1995, CIRCULATION, V92, P2157, DOI 10.1161/01.CIR.92.8.2157; RUMBERGER JA, 1994, CIRCULATION, V90, P300; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735-1097(97)00443-9; SANGIORGI G, 1995, J AM COLL CARDIOL, V25, pA386; Schmermund A, 1998, J AM COLL CARDIOL, V31, P1267, DOI 10.1016/S0735-1097(98)00082-5; SIMONS DB, 1992, J AM COLL CARDIOL, V20, P1118, DOI 10.1016/0735-1097(92)90367-V; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; SUPERKO HR, 1995, CURR OPIN CARDIOL, V10, P347, DOI 10.1097/00001573-199507000-00002; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056; TANENBAUM SR, 1989, AM J CARDIOL, V63, P870, DOI 10.1016/0002-9149(89)90060-X; Wang SJ, 1996, AM HEART J, V132, P550, DOI 10.1016/S0002-8703(96)90237-9; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1995, CAN J CARDIOL, V11, pG110; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	52	564	577	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1972	1978		10.1056/NEJM199812313392703	http://dx.doi.org/10.1056/NEJM199812313392703			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869668				2022-12-28	WOS:000077803800003
J	Douek, DC; McFarland, RD; Keiser, PH; Gage, EA; Massey, JM; Haynes, BF; Polis, MA; Haase, AT; Feinberg, MB; Sullivan, JL; Jamieson, BD; Zack, JA; Picker, LJ; Koup, RA				Douek, DC; McFarland, RD; Keiser, PH; Gage, EA; Massey, JM; Haynes, BF; Polis, MA; Haase, AT; Feinberg, MB; Sullivan, JL; Jamieson, BD; Zack, JA; Picker, LJ; Koup, RA			Changes in thymic function with age and during the treatment of HIV infection	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELLS; V(D)J RECOMBINATION; LYMPHOCYTES; CD4+; THYMOPOIESIS; REGENERATION; PRODUCTS; THERAPY; VIRGIN	The thymus represents the major site of the production and generation of T cells expressing alpha beta-type T-cell antigen receptors(1). Age-related involution(2) may affect the ability of the thymus to reconstitute T cells expressing CD4 cell-surface antigens that are lost during HIV infection(3); this effect has been seen after chemotherapy and bone-marrow transplantation(4,5). Adult HIV-infected patients treated with highly active antiretroviral therapy (HAART) show a progressive increase in their number of naive CD4-positive T cells(6,7). These cells could arise through expansion of existing naive T cells in the periphery(8) or through thymic production of new naive T cells(9,10). Here we quantify thymic output by measuring the excisional DNA products of TCR-gene rearrangement. We find that, although thymic function declines with age, substantial output is maintained into late adulthood. HIV infection leads to a decrease in thymic function that can be measured in the peripheral blood and lymphoid tissues. In adults treated with HAART, there is a rapid and sustained increase in thymic output in most subjects. These results indicate that the adult thymus fan contribute to immune reconstitution following HAART.	Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; NIAID, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Univ Massachusetts, Med Ctr, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Mol Med, Worcester, MA 01605 USA; Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; UCLA Inst, Los Angeles, CA 90095 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; Emory University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Koup, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Polis, Michael/0000-0002-9151-2268				ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; COSSARIZZA A, 1992, J IMMUNOL RES-ITALY, V4, P118; Dybul M, 1998, J CLIN INVEST, V101, P2299, DOI 10.1172/JCI3929; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HAYNES B, UNPUB J CLIN INVEST; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; Livak F, 1996, MOL CELL BIOL, V16, P609; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PICKER L, 1995, FUNDAMENTAL IMMUNOLO, P145; PICKER LJ, 1993, J IMMUNOL, V150, P1105; SCHNITTMAN SM, 1990, T ASSOC AM PHYSICIAN, V103, P96; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; Steinmann G G, 1986, Curr Top Pathol, V75, P43; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; WithersWard ES, 1997, NAT MED, V3, P1102, DOI 10.1038/nm1097-1102; Wykrzykowska JJ, 1998, J EXP MED, V187, P1767, DOI 10.1084/jem.187.11.1767; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	30	1453	1544	2	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					690	695		10.1038/25374	http://dx.doi.org/10.1038/25374			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872319				2022-12-28	WOS:000077694200057
J	Kaupmann, K; Malitschek, B; Schuler, V; Heid, J; Froest, W; Beck, P; Mosbacher, J; Bischoff, S; Kulik, A; Shigemoto, R; Karschin, A; Bettler, B				Kaupmann, K; Malitschek, B; Schuler, V; Heid, J; Froest, W; Beck, P; Mosbacher, J; Bischoff, S; Kulik, A; Shigemoto, R; Karschin, A; Bettler, B			GABA(B)-receptor subtypes assemble into functional heteromeric complexes	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; RECTIFYING K+ CHANNELS; GABA(B) RECEPTORS; BINDING; NEURONS	B-type receptors for the neurotransmitter GABA (gamma-aminobutyric acid) inhibit neuronal activity through G-protein-coupled second-messenger systems, which regulate the release of neurotransmitters and the activity of ion channels and adenylyl cyclase(1). Physiological and biochemical studies show that there are differences in drug efficiencies at different GABA(B) receptors, so it is expected that GABA(B)-receptor (GABA(B)R) subtypes exist(2). Two GABA(B)-receptor splice variants have been cloned(3) (GABA(B)R1a and GABA(B)R1b), but native GABA(B) receptors and recombinant receptors showed unexplained differences in agonist-binding potencies. Moreover, the activation of presumed effector ion channels in heterologous cells expressing the recombinant receptors proved difficult(3-4). Here we describe a new GABA(B) receptor subtype, GABA(B)R2, which does not bind available GABA(B) antagonists with measurable potency. GABA(B)R1a, GABA(B)R1b and GABA(B)R2 alone do not activate Kir3-type potassium channels efficiently, but co-expression of these receptors yields a robust coupling to activation of Kir3 channels. We provide evidence for the assembly of heteromeric GABA(B) receptors in vivo and show that GABA(B)R2 and GABA(B)R1a/b proteins immunoprecipitate and localize together at dendritic spines. The heteromeric receptor complexes exhibit a significant increase in agonist- and partial-agonist-binding potencies as compared with individual receptors and probably represent the predominant native GABA(B) receptor. Heteromeric assembly among G-protein-coupled receptors has not, to our knowledge, been described before.	Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland; Kyoto Univ, Fac Med, Dept Morphol Brain Sci, Kyoto 606, Japan; Max Planck Inst Biophys Chem, D-37030 Gottingen, Germany	Novartis; Kyoto University; Max Planck Society	Bettler, B (corresponding author), Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland.		bettler, bernhard/AAO-8018-2020; Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444; Bettler, Bernhard/0000-0003-0842-8207; Kaupmann, Klemens/0000-0001-8903-2508				Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Bischoff S, 1997, J COMP NEUROL, V379, P541, DOI 10.1002/(SICI)1096-9861(19970324)379:4<541::AID-CNE6>3.0.CO;2-2; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; HILL DR, 1984, J NEUROCHEM, V42, P652, DOI 10.1111/j.1471-4159.1984.tb02732.x; INOUE M, 1985, BRIT J PHARMACOL, V84, P843, DOI 10.1111/j.1476-5381.1985.tb17378.x; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KAUPMANN K, IN PRESS P NATL ACAD; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Morris SJ, 1998, J NEUROCHEM, V71, P1329; Mosbacher J, 1998, FEBS LETT, V436, P104, DOI 10.1016/S0014-5793(98)01066-7; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Slesinger PA, 1997, P NATL ACAD SCI USA, V94, P12210, DOI 10.1073/pnas.94.22.12210; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Uezono Y, 1998, NEUROREPORT, V9, P583, DOI 10.1097/00001756-199803090-00004; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	25	944	996	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					683	687		10.1038/25360	http://dx.doi.org/10.1038/25360			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872317				2022-12-28	WOS:000077694200055
J	Brodsky, RA; Petri, M; Smith, BD; Seifter, EJ; Spivak, JL; Styler, M; Dang, CV; Brodsky, I; Jones, RJ				Brodsky, RA; Petri, M; Smith, BD; Seifter, EJ; Spivak, JL; Styler, M; Dang, CV; Brodsky, I; Jones, RJ			Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; APLASTIC-ANEMIA; RHEUMATOID-ARTHRITIS; HEMATOPOIETIC STEM; PROGENITOR CELLS; REMISSION; MICE	Background: Immunoablative high-dose cyclophosphamide without stem-cell rescue induces durable, complete remission in most patients with aplastic anemia. Objective: To determine the efficacy of high-dose cyclophosphamide in various refractory, severe autoimmune diseases. Design: Prospective phase II study. Setting: Johns Hopkins University (Baltimore, Maryland) and Hahnemann University (Philadelphia, Pennsylvania). Patients: Eight patients with refractory, severe autoimmune disease. Intervention: Immunoablative high-dose cyclophosphamide (50 mg/kg of body weight per day) for 4 consecutive days. Measurements: Clinical and laboratory variables of autoimmune disease. Results: Seven patients improved markedly: Five achieved complete remission and two achieved partial remission. Four patients have remained in continuous complete remission for 3 to 21 months, and two patients in partial remission continue to improve after 14 and 19 months of follow-up. High-dose cyclophosphamide was well tolerated; median times to a neutrophil count of 0.5 x 10(9) cells/L and platelet transfusion independence were 17 and 16 days, respectively. Conclusions: Immunoablative high-dose cyclophosphamide without stem-cell rescue can induce complete remission in patients with refractory, severe autoimmune disease. Reemergence of marrow function is similar to that seen after autologous transplantation and does not carry the risk for reinfusion of autoaggressive lymphocytes with the autograft.	Johns Hopkins Univ, Sch Med, Dept Internal Med, Div Rheumatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Hematol, Baltimore, MD 21205 USA; Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA	Johns Hopkins University; Johns Hopkins University; Drexel University	Brodsky, RA (corresponding author), Johns Hopkins Oncol Ctr, Room 2-127,600 N Wolfe St, Baltimore, MD 21287 USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA70970, CA15396] Funding Source: Medline; NIAMS NIH HHS [AR43727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA015396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043727, R55AR043727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8; Euler HH, 1996, BLOOD, V88, P3621, DOI 10.1182/blood.V88.9.3621.bloodjournal8893621; GORDON MY, 1985, LEUKEMIA RES, V9, P1017, DOI 10.1016/0145-2126(85)90072-4; Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003; JACOBS P, 1986, BONE MARROW TRANSPL, V1, P237; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; KARUSSIS DM, 1995, CLIN EXP IMMUNOL, V100, P111; LEVITE M, 1995, CELL IMMUNOL, V162, P138, DOI 10.1006/cimm.1995.1061; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; MARMONT AM, 1995, BONE MARROW TRANSPL, V16, P497; PETRI M, 1992, J RHEUMATOL, V19, P53; REINER A, 1995, BLOOD, V85, P351; SANDERS JE, 1988, J CLIN ONCOL, V6, P813, DOI 10.1200/JCO.1988.6.5.813; SANTOS GW, 1965, B JOHNS HOPKINS HOSP, V116, P327; Snowden JA, 1997, BRIT J HAEMATOL, V99, P9, DOI 10.1046/j.1365-2141.1997.3273144.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; Tyndall A, 1996, ANN RHEUM DIS, V55, P149, DOI 10.1136/ard.55.3.149; Young NS, 1997, ANN INTERN MED, V126, P166, DOI 10.7326/0003-4819-126-2-199701150-00014; Zhang QW, 1997, TRANSPLANTATION, V63, P1667, DOI 10.1097/00007890-199706150-00022	20	173	187	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1031	1035		10.7326/0003-4819-129-12-199812150-00007	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867758				2022-12-28	WOS:000077471900006
J	Ginsberg, JS; Wells, PS; Kearon, C; Anderson, D; Crowther, M; Weitz, JI; Bormanis, J; Brill-Edwards, P; Turpie, AG; MacKinnon, B; Gent, M; Hirsh, J				Ginsberg, JS; Wells, PS; Kearon, C; Anderson, D; Crowther, M; Weitz, JI; Bormanis, J; Brill-Edwards, P; Turpie, AG; MacKinnon, B; Gent, M; Hirsh, J			Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						sensitivity and specificity; pulmonary embolism; D-dimer assay; ventilation-perfusion ratio; ultrasonography	FIBRIN DEGRADATION PRODUCTS; DEEP-VEIN THROMBOSIS; PERFUSION LUNG-SCAN; SIMPLIRED-D-DIMER; VENOUS THROMBOSIS; PLASMA; AID	Background: Patients with suspected pulmonary embolism often have nondiagnostic lung scans and may present in circumstances where lung scanning is unavailable. Levels of D-dimer, a fibrin-specific product, are increased in patients with a cute thrombosis; this may simplify the diagnosis of pulmonary embolism. Objective: To determine the sensitivity and specificity of a whole-blood D-dimer assay in patients with suspected pulmonary embolism and in subgroups of patients with low pretest probability of pulmonary embolism or nondiagnostic lung scans. Design: Prospective cohort. Setting: Four tertiary care hospitals. Patients: 1177 consecutive patients with suspected pulmonary embolism. Measurements: All patients underwent an assessment of pretest probability by use of a standardized clinical model, a D-dimer assay, ventilation-perfusion lung scanning, and bilateral compression ultrasonography. Patients in whom pulmonary embolism was not initially diagnosed were followed for 3 months. Accordingly, patients were categorized as positive or negative for pulmonary embolism. Results: Of the 1177 patients, 197 (17%) were classified as positive for pulmonary embolism. Overall, the D-dimer assay showed a sensitivity of 84.8% and a specificity of 68.4%. In 703 patients (3.4%) with a low pretest probability of pulmonary embolism, the likelihood ratio associated with a negative D-dimer test result was 0.27, resulting in a posterior probability of 1.0% (95% CI, 0.3% to 2.2%). In 698 patients with nondiagnostic lung scans (previous probability, 7.4%), the likelihood ratio associated with a negative D-dimer test result was 0.36, resulting in a posterior probability of 2.8% (CI, 1.4% to 4.8%). Conclusions: A normal D-dimer test result is useful in excluding pulmonary embolism in patients with a low pretest probability of pulmonary embolism or a nondiagnostic lung scan.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; Dalhousie Univ, Halifax, NS, Canada; Univ Ottawa, Ottawa, ON, Canada	McMaster University; Dalhousie University; University of Ottawa	Ginsberg, JS (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,Room 3W15, Hamilton, ON L8N 3Z5, Canada.		Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				BELL WR, 1977, AM J MED, V62, P355, DOI 10.1016/0002-9343(77)90832-4; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BOUNAMEAUX H, 1989, AM J CLIN PATHOL, V91, P82, DOI 10.1093/ajcp/91.1.82; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1993, THROMB HAEMOSTASIS, V69, P832; DEMERS C, 1992, THROMB HAEMOSTASIS, V67, P408; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GINSBERG JS, 1993, CHEST, V104, P1679, DOI 10.1378/chest.104.6.1679; GOLDHABER SZ, 1988, AM HEART J, V116, P505, DOI 10.1016/0002-8703(88)90625-4; HEATON DC, 1987, J LAB CLIN MED, V110, P588; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; PETZER H, 1988, THROMB HAEMOSTASIS, V59, P101; ROWBOTHAM BJ, 1987, THROMB HAEMOSTASIS, V57, P59; SHAUKAT N, 1993, THROMB HAEMOSTASIS, V69, P839; Turkstra F, 1998, THROMB HAEMOSTASIS, V79, P91; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; WELLS PS, 1993, BLOOD, V82, P407	25	187	198	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1006	+		10.7326/0003-4819-129-12-199812150-00003	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867754				2022-12-28	WOS:000077471900002
J	Rao, KS; Pilli, RD; Rao, AS; Chalam, PS				Rao, KS; Pilli, RD; Rao, AS; Chalam, PS			Sexual lifestyle of long distance lorry drivers in India: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Child Fdn India, AIDS Prevent Div, Visakhapatnam 530008, Andhra Pradesh, India		Rao, KS (corresponding author), Surya Clin Bldg,Kancharapalem Main Rd, Visakhapatnam 530008, Andhra Pradesh, India.							BLOOM DE, 1993, EC IMPLICATIONS AIDS, P80; FLEISS JL, 1981, STATISTICAL METHODS, P138; HUDDART J, 1993, HIV WORK PLACE DEALI; SINGH YN, 1992, HIV INFECT LONG DIST	4	38	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					162	163		10.1136/bmj.318.7177.162	http://dx.doi.org/10.1136/bmj.318.7177.162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888910	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078175100027
J	Mauersberger, K; Erbacher, B; Krankowsky, D; Gunther, J; Nickel, R				Mauersberger, K; Erbacher, B; Krankowsky, D; Gunther, J; Nickel, R			Ozone isotope enrichment: Isotopomer-specific rate coefficients	SCIENCE			English	Article							LYING ELECTRONIC STATES; HEAVY OZONE; ABSORPTION-SPECTROSCOPY; TROPOSPHERIC OZONE; MECHANISM; SYMMETRY; FRACTIONATION; EXPLANATION; ENHANCEMENT; ATMOSPHERE	Six rate coefficients of relative ozone formation contradict the role of molecular symmetry in the process that results in the enrichment of heavy ozone isotopomers. The results show that collisions between Light atoms, such as O-16, and heavy molecules, such as O-34(2) O-36(2), have a rate coefficient advantage of about 25 and 50 percent, respectively. over collisions involving heavy atoms and Light molecules, These results suggest that the observed isotope effect for each isotopomer may be caused by the preponderance of a single reaction channel and not through molecular symmetry selection.	Max Planck Inst Kernphys, Div Atmospher Phys, D-69029 Heidelberg, Germany	Max Planck Society	Mauersberger, K (corresponding author), Max Planck Inst Kernphys, Div Atmospher Phys, POB 103 980, D-69029 Heidelberg, Germany.							ANDERSON SM, 1995, J GEOPHYS RES-ATMOS, V100, P3033, DOI 10.1029/94JD03003; Anderson SM, 1997, J CHEM PHYS, V107, P5385, DOI 10.1063/1.474247; ANDERSON SM, 1989, CHEM PHYS LETT, V156, P175, DOI 10.1016/S0009-2614(89)87115-5; ANDERSON SM, 1992, ACS SYM SER, V502, P155; ARNOLD DW, 1994, J CHEM PHYS, V101, P912, DOI 10.1063/1.467745; BATES DR, 1988, GEOPHYS RES LETT, V15, P13, DOI 10.1029/GL015i001p00013; Gellene GI, 1996, SCIENCE, V274, P1344, DOI 10.1126/science.274.5291.1344; GRIFFITH KS, 1992, J CHEM PHYS, V96, P4403, DOI 10.1063/1.462831; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; Irion FW, 1996, GEOPHYS RES LETT, V23, P2377, DOI 10.1029/96GL01695; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; KAYE JA, 1983, J GEOPHYS RES-OCEANS, V88, P8447, DOI 10.1029/JC088iC13p08447; Krankowsky D, 1996, SCIENCE, V274, P1324, DOI 10.1126/science.274.5291.1324; KRANKOWSKY D, 1995, GEOPHYS RES LETT, V22, P1713, DOI 10.1029/95GL01436; LARSEN NW, 1991, INT J CHEM KINET, V23, P331, DOI 10.1002/kin.550230405; MAUERSBERGER K, 1993, GEOPHYS RES LETT, V20, P1031, DOI 10.1029/93GL01080; MAUERSBERGER K, 1977, REV SCI INSTRUM, V48, P1169, DOI 10.1063/1.1135210; MORGAN WL, 1992, PLANET SPACE SCI, V40, P1573, DOI 10.1016/0032-0633(92)90053-Q; MORTON J, 1990, J GEOPHYS RES-ATMOS, V95, P901, DOI 10.1029/JD095iD01p00901; SEHESTED J, 1995, J GEOPHYS RES-ATMOS, V100, P20979, DOI 10.1029/95JD02345; Sehested J, 1998, J GEOPHYS RES-ATMOS, V103, P3545, DOI 10.1029/97JD03124; THIEMENS MH, 1988, GEOPHYS RES LETT, V15, P639, DOI 10.1029/GL015i007p00639; THIEMENS MH, 1990, GEOPHYS RES LETT, V17, P717, DOI 10.1029/GL017i006p00717; VALENTINI JJ, 1987, J CHEM PHYS, V86, P6757, DOI 10.1063/1.452375; Yung YL, 1997, J GEOPHYS RES-ATMOS, V102, P10857, DOI 10.1029/97JD00528	25	191	193	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					370	372		10.1126/science.283.5400.370	http://dx.doi.org/10.1126/science.283.5400.370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888849				2022-12-28	WOS:000078067000043
J	Giladi, M; Avidor, B				Giladi, M; Avidor, B			Cat scratch disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Tel Aviv Med Ctr, IL-64239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Giladi, M (corresponding author), Tel Aviv Med Ctr, IL-64239 Tel Aviv, Israel.		Giladi, Michael/AAQ-6176-2020; Giladi, Michael/GVU-6295-2022						0	4	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					108	108		10.1056/NEJM199901143400205	http://dx.doi.org/10.1056/NEJM199901143400205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887162				2022-12-28	WOS:000078016200005
J	Soldan, K; Ramsay, M; Collins, M				Soldan, K; Ramsay, M; Collins, M			Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England	Public Health England	Soldan, K (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640; Soldan, Kate/0000-0002-0361-3174				BZUKA H, 1992, VOX SANG, V63, P107; Jongerius JM, 1998, TRANSFUSION, V38, P56, DOI 10.1046/j.1537-2995.1998.38198141499.x; SALISBURY D, 1996, IMMUNISATOIN INFECT; Williamson LM, 1996, BRIT MED J, V313, P1221, DOI 10.1136/bmj.313.7067.1221	4	27	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					95	95		10.1136/bmj.318.7176.95	http://dx.doi.org/10.1136/bmj.318.7176.95			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880282	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078087500026
J	Kerr, JM				Kerr, JM			Vergil	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					9	9		10.1001/jama.281.1.9	http://dx.doi.org/10.1001/jama.281.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892429				2022-12-28	WOS:000077829300001
J	Wright, SM; Kern, DE; Kolodner, K; Howard, DM; Brancati, FL				Wright, SM; Kern, DE; Kolodner, K; Howard, DM; Brancati, FL			Attributes of excellent attending-physician role models	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-STUDENTS; INTERNAL-MEDICINE; UNITED-STATES; RECENT TRENDS; RESIDENTS; CHOICES; ATTITUDES; EDUCATION; SCHOOL; FEMALE	Background Although effective role models are important in medical education, little is known about the characteristics of physicians who serve as excellent clinical role models. We therefore conducted a case-control study to identify attributes that distinguish such physicians from their colleagues. Methods We asked members of the internal-medicine house staff at four teaching hospitals to name physicians whom they considered to be excellent role models. A total of 165 physicians named by one or more house-staff members were classified as excellent role models (these served as the case physicians in our study). A questionnaire was sent to them as well as to 246 physicians who had residency-level teaching responsibilities but who were not named (controls). Of these 411 physicians, 341 (83 percent) completed questionnaires while unaware of their case-control status. Results Of the 341 attending physicians who responded, 144 (42 percent) had been identified as excellent role models. Having greater assigned teaching responsibilities was strongly associated with being identified as an excellent role model. In the multivariate analysis, five attributes were independently associated with being named as an excellent role model: spending more than 25 percent of one's time teaching (odds ratio, 5.12; 95 percent confidence interval, 1.81 to 14.47), spending 25 or more hours per week teaching and conducting rounds when serving as an attending physician (odds ratio, 2.48; 95 percent confidence interval, 1.15 to 5.37), stressing the importance of the doctor-patient relationship in one's teaching (odds ratio, 2.58; 95 percent confidence interval, 1.03 to 6.43), teaching the psychosocial aspects of medicine (odds ratio, 2.31; 95 percent confidence interval, 1.23 to 4.35), and having served as a chief resident (odds ratio, 2.07; 95 percent confidence interval, 1.07 to 3.98). Conclusions These data suggest that many of the attributes associated with being an excellent role model are related to skills that can be acquired and to modifiable behavior. (N Engl J Med 1998;339:1986-93.) (C) 1998, Massachusetts Medical Society.	Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Wright, SM (corresponding author), Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, B2N,4940 Eastern Ave, Baltimore, MD 21224 USA.							*AM BOARD INT MED, 1992, GUID EV RES INT MED, P4; Ambrozy DM, 1997, ACAD MED, V72, P1119, DOI 10.1097/00001888-199712000-00028; BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; BARONDESS JA, 1985, ANN INTERN MED, V103, P454, DOI 10.7326/0003-4819-103-3-454; Beasley BW, 1997, JAMA-J AM MED ASSOC, V278, P723, DOI 10.1001/jama.278.9.723; Branch WT, 1997, J GEN INTERN MED, V12, pS1, DOI 10.1046/j.1525-1497.12.s2.16.x; FICKLIN FL, 1988, J MED EDUC, V63, P392; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUNT DK, 1995, AM J MED SCI, V310, P19, DOI 10.1097/00000441-199507000-00007; LEVINSON W, 1991, WESTERN J MED, V154, P423; LIEU TA, 1989, ACAD MED, V64, P622, DOI 10.1097/00001888-198910000-00015; LINZER M, 1994, J GEN INTERN MED, V9, pS14, DOI 10.1007/BF02598114; LUBLIN JR, 1992, MED EDUC, V26, P116, DOI 10.1111/j.1365-2923.1992.tb00136.x; MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; Mufson MA, 1997, AM J MED, V103, P253; Mutha S, 1997, ACAD MED, V72, P635, DOI 10.1097/00001888-199707000-00017; NEUMAYER L, 1993, ARCH SURG-CHICAGO, V128, P669; QUILL TE, 1987, ARCH INTERN MED, V147, P971, DOI 10.1001/archinte.147.5.971; Rakatansky H, 1994, R I Med, V77, P339; REULER JB, 1994, WESTERN J MED, V160, P335; ROESKE NA, 1977, J MED EDUC, V52, P459; RUBECK RF, 1995, ACAD MED, V70, P318, DOI 10.1097/00001888-199504000-00016; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P285; SHUVAL JT, 1980, SOC SCI MED-MED SOC, V14, P5, DOI 10.1016/0160-7979(80)90003-X; SIEGLER M, 1987, J MED EDUC, V62, P935; VANCE RP, 1991, ARCH PATHOL LAB MED, V115, P1097; Wright S, 1997, J GEN INTERN MED, V12, P53, DOI 10.1007/s11606-006-0007-1; Wright S, 1996, ACAD MED, V71, P290, DOI 10.1097/00001888-199603000-00024; 1958, WEBSTERS NEW WORLD D	29	327	332	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1986	1993		10.1056/NEJM199812313392706	http://dx.doi.org/10.1056/NEJM199812313392706			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869671				2022-12-28	WOS:000077803800006
J	Young, ID				Young, ID			Achondroplasia: a case of neglect?	LANCET			English	Editorial Material							CERVICOMEDULLARY-JUNCTION COMPRESSION; INFANTS		City Hosp, Dept Clin Genet, Nottingham NG5 1PB, England	University of Nottingham	Young, ID (corresponding author), City Hosp, Dept Clin Genet, Nottingham NG5 1PB, England.							HECHT JT, 1987, AM J HUM GENET, V41, P454; Hunter AGW, 1998, J MED GENET, V35, P705, DOI 10.1136/jmg.35.9.705; Hunter AGW, 1998, AM J MED GENET, V78, P1, DOI 10.1002/(SICI)1096-8628(19980616)78:1<1::AID-AJMG1>3.0.CO;2-V; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; PAULI RM, 1995, AM J HUM GENET, V56, P732; RIMOIN DL, 1995, AM J HUM GENET, V56, P824; SEASHORE MR, 1995, PEDIATRICS, V95, P443; Tasker RC, 1998, ARCH DIS CHILD, V79, P99, DOI 10.1136/adc.79.2.99; Wilkin DJ, 1998, AM J HUM GENET, V63, P711, DOI 10.1086/302000	9	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1950	1951		10.1016/S0140-6736(98)00093-2	http://dx.doi.org/10.1016/S0140-6736(98)00093-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872238				2022-12-28	WOS:000077663000002
J	Amitai, M				Amitai, M			Hidden models in biopolymers	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; PROFILE ANALYSIS; MARKOV-MODELS; PREDICTION		Compugen Ltd, IL-69512 Tel Aviv, Israel		Amitai, M (corresponding author), Compugen Ltd, Pinchas Rozen 72, IL-69512 Tel Aviv, Israel.	mor@compugen.co.il						BIRNEY E, 1997, P 5 INT C INT SYST M, P56; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Durbin R., 1998, BIOL SEQUENCE ANAL P; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; EDDY SR, 1995, P 3 INT C INT SYST M, P114; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; Goldman N, 1996, J MOL BIOL, V263, P196, DOI 10.1006/jmbi.1996.0569; Gribskov M, 1996, METHOD ENZYMOL, V266, P198; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Murzin AG, 1997, PROTEINS, P105; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schuster-Bockler Benjamin, 2007, Curr Protoc Bioinformatics, VAppendix 3, p3A, DOI 10.1002/0471250953.bia03as18; Sjolander K, 1996, COMPUT APPL BIOSCI, V12, P327; Slonim D, 1997, J COMPUT BIOL, V4, P487, DOI 10.1089/cmb.1997.4.487; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	21	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1436	1437						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867651				2022-12-28	WOS:000077110800032
J	Ramanathan, K; Michael, TH; Jiang, GJ; Hiel, H; Fuchs, PA				Ramanathan, K; Michael, TH; Jiang, GJ; Hiel, H; Fuchs, PA			A molecular mechanism for electrical tuning of cochlear hair cells	SCIENCE			English	Article							ACTIVATED POTASSIUM CHANNELS; BETA-SUBUNIT; HUMAN BRAIN; EXPRESSION; CONDUCTANCES; ISOFORMS; CLONING; CHICK; HSLO	Cochlear frequency selectivity in Lower vertebrates arises in part from electrical tuning intrinsic to the sensory hair cells. The resonant frequency is determined largely by the gating kinetics of calcium-activated potassium (BK) channels encoded by the slo gene. Alternative splicing of slo from chick cochlea generated kinetically distinct BK channels. Combination with accessory beta subunits slowed the gating kinetics of alpha splice variants but preserved relative differences between them. In situ hybridization showed that the beta subunit is preferentially expressed by low-frequency (apical) hair cells in the avian cochlea, Interaction of beta with alpha splice variants could provide the kinetic range needed for electrical tuning of cochlear hair cells.	Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Fuchs, PA (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.	pfuchs@bme.jhu.edu			NIDCD NIH HHS [DC00276] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; ART JJ, 1995, J GEN PHYSIOL, V105, P49, DOI 10.1085/jgp.105.1.49; BERS DM, 1994, METHOD CELL BIOL, V40, P3; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1988, J COMP PHYSIOL A, V164, P151, DOI 10.1007/BF00603947; Hiel H, 1996, BRAIN RES, V738, P347, DOI 10.1016/S0006-8993(96)01046-3; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P237, DOI 10.1113/jphysiol.1988.sp017119; Jiang GJ, 1997, P ROY SOC B-BIOL SCI, V264, P731, DOI 10.1098/rspb.1997.0104; Jones EMC, 1998, P ROY SOC B-BIOL SCI, V265, P685, DOI 10.1098/rspb.1998.0348; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Michael T, 1997, BIOPHYS J, V72, pTHP20; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	22	152	158	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					215	217		10.1126/science.283.5399.215	http://dx.doi.org/10.1126/science.283.5399.215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880252				2022-12-28	WOS:000077976700037
J	Hanley, JG; Koulen, P; Bedford, F; Gordon-Weeks, PR; Moss, SJ				Hanley, JG; Koulen, P; Bedford, F; Gordon-Weeks, PR; Moss, SJ			The protein MAP-1B links GABA(c) receptors to the cytoskeleton at retinal synapses	NATURE			English	Article							A RECEPTORS; XENOPUS OOCYTES; EXPRESSION; SUBUNITS; GEPHYRIN; LOCALIZATION; CLONING; DOMAIN; RHO-1; GENE	The ionotropic type-A and type-C receptors for the neurotransmitter gamma-aminobutyric acid (GABA(A) and GABA(C) receptors) are the principal sites of fast synaptic inhibition in the central nervous system(1-3), but it is not known how these receptors are localized at GABA-dependent synapses. GABA(C) receptors, which are composed of rho-subunits(3-6), are expressed almost exclusively in the retina of adult vertebrates, where they are enriched on bipolar cell axon terminals(7-9). Here we show that the microtubule-associated protein 1B (MAP-1B) specifically interacts with the GABA(C) pi subunit but not with GABA(A) receptor subunits. Furthermore, GABA(C) receptors and MAP-1B co-localize at postsynaptic sites on bipolar cell axon terminals. Co-expression of MAP-1B and the pi subunit in COS cells results in a dramatic redistribution of the rho 1 subunit. Our observations suggest a novel mechanism for localizing ionotropic GABA receptors to synaptic sites. This mechanism, which is specific for GABA(C) but not GABA(A) receptors, may allow these receptor subtypes, which have distinct physiological and pharmacological properties, to be differentially localized at inhibitory synapses.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Max Planck Inst Hirnforsch, Neuroanat Abt, D-60528 Frankfurt, Germany; Kings Coll London, Dev Biol Res Ctr, Div Biomed Sci, London WC2R 5LL, England	University of London; University College London; University of London; University College London; Max Planck Society; University of London; King's College London	Moss, SJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	steve.moss@UCL.ac.uk	Gordon-Weeks, Phillip R./C-5328-2009	Gordon-Weeks, Phillip R./0000-0002-4738-4246; Hanley, Jonathan/0000-0003-1704-4707	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRECHT BE, 1995, NEUROSCI LETT, V189, P155, DOI 10.1016/0304-3940(95)11479-G; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJII T, 1993, J BIOCHEM-TOKYO, V114, P827, DOI 10.1093/oxfordjournals.jbchem.a124263; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; HAMMARBACK JA, 1997, BRAIN MICROTUBULE AS, P1; Johnstone M, 1997, J ANAT, V191, P229, DOI 10.1046/j.1469-7580.1997.19120229.x; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIEN LL, 1994, GENOMICS, V22, P273, DOI 10.1006/geno.1994.1384; Lukasiewicz PD, 1996, MOL NEUROBIOL, V12, P181, DOI 10.1007/BF02755587; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA M, 1987, P NATL ACAD SCI USA, V84, P3501, DOI 10.1073/pnas.84.10.3501; ULLOA L, 1997, BRAIN MICROTUBLE ASS, P17; WANG TL, 1994, J NEUROSCI, V14, P6524; Wyszynski M, 1998, J NEUROSCI, V18, P1383	25	110	111	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					66	69		10.1038/16258	http://dx.doi.org/10.1038/16258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892354				2022-12-28	WOS:000077959400048
J	Pelliccia, A; Culasso, F; DiPaolo, FM; Maron, BJ				Pelliccia, A; Culasso, F; DiPaolo, FM; Maron, BJ			Physiologic left ventricular cavity dilatation in elite athletes	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; NON-INVASIVE EVALUATION; ECHOCARDIOGRAPHIC MEASUREMENTS; HYPERTROPHIC CARDIOMYOPATHY; PROGNOSTIC IMPLICATIONS; CARDIAC-HYPERTROPHY; DIASTOLIC FUNCTION; DYNAMIC EXERCISE; DISTANCE RUNNERS; UPPER LIMIT	Background: Absolute left ventricular cavity dimension may be substantially increased in some highly trained athletes. This raises questions about the differential diagnosis between athlete's heart and dilated cardiomyopathy as well as possible disqualification from competitive sports. Objective: To evaluate the morphologic characteristics and physiologic limits of left ventricular cavity enlargement associated with intensive, long-term athletic conditioning. Design: Evaluation of left ventricular cavity dimension in a large sample of highly trained athletes. Setting: institute of Sports Science, Rome, Italy. Participants: 1309 elite Italian athletes (957 men and 352 women), 13 to 59 years of age (mean, 24 years), participating in 38 different sports. Measurements: Echocardiographic assessment of left ventricular cavity dimension and multivariate statistical analysis of the determinants. Results: Left ventricular end-diastolic cavity dimensions varied widely (38 to 66 mm [mean, 48 mm] in women and 43 to 70 mm [mean, 55 mm] in men) and was within generally accepted normal limits for most participants (less than or equal to 54 mm in 725 athletes [55%]). According to an arbitrary clinical cut-point of 60 mm, the left ventricular cavity was substantially enlarged in 185 participants (14%). These athletes had global left ventricular systolic function within normal limits and no regional wall-motion abnormalities; participants remained free of cardiac symptoms and impaired performance over 1 to 12 years (mean, 4.7 years). The major determinants of cavity dimension were greater body surface area and participation in certain endurance sports (cycling, cross-country skiing, and canoeing). Conclusions: In a sample of highly trained athletes, left ventricular cavity dimension varied widely but was strikingly increased to a degree compatible with primary dilated cardiomyopathy in almost 15% of participants. In the absence of systolic dysfunction, this cavity dilatation is most likely an extreme physiologic adaptation to intensive athletic conditioning. The long-term consequences and significance of this marked left Ventricular remodeling of the athlete's heart is not known.	Italian Natl Olymp Comm, Inst Sport Sci, Dept Med, I-00197 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med, I-00298 Rome, Italy; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Sapienza University Rome; Minneapolis Heart Institute Foundation	Pelliccia, A (corresponding author), Italian Natl Olymp Comm, Inst Sport Sci, Dept Med, Via Campi Sportivi 46, I-00197 Rome, Italy.	ISS-Fisiologia@coni.it						ADAMS TD, 1981, CIRCULATION, V64, P958, DOI 10.1161/01.CIR.64.5.958; ARMITAGE P, 1994, STAT METHODS MED RES, P277; BLAIR NL, 1980, AUST NZ J MED, V10, P540, DOI 10.1111/j.1445-5994.1980.tb04973.x; DEMARIA AN, 1978, CIRCULATION, V57, P237, DOI 10.1161/01.CIR.57.2.237; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; DEVEREUX RB, 1986, AM J CARDIOL, V57, P1388, DOI 10.1016/0002-9149(86)90224-9; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DIXON WJ, 1992, BMDP STAT SOFTWARE M, P145; EKBLOM B, 1968, J APPL PHYSIOL, V25, P619, DOI 10.1152/jappl.1968.25.5.619; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FORD LE, 1976, CIRC RES, V39, P297, DOI 10.1161/01.RES.39.3.297; GANAU A, 1992, J AM COLL CARDIOL, V19, P1550, DOI 10.1016/0735-1097(92)90617-V; GAVAZZI A, 1993, AM HEART J, V125, P410; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; HINDERLITER AL, 1992, AM J CARDIOL, V69, P1196, DOI 10.1016/0002-9149(92)90935-R; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; IKAHEIMO MJ, 1979, AM J CARDIOL, V44, P24, DOI 10.1016/0002-9149(79)90246-7; KEREN A, 1990, CIRCULATION, V81, P506, DOI 10.1161/01.CIR.81.2.506; KEUL J, 1981, CIRC RES, V48, P162; KNUTSEN KM, 1989, J INTERN MED, V225, P111, DOI 10.1111/j.1365-2796.1989.tb00049.x; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1039, DOI 10.1016/0735-1097(95)00275-0; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; LONGHURST JC, 1980, J APPL PHYSIOL, V48, P154, DOI 10.1152/jappl.1980.48.1.154; LONGHURST JC, 1981, CIRC RES, V48, P171; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; NISHIMURA T, 1980, CIRCULATION, V61, P832, DOI 10.1161/01.CIR.61.4.832; PARKER BM, 1978, CHEST, V73, P376, DOI 10.1378/chest.73.3.376; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; Pelliccia A, 1996, JAMA-J AM MED ASSOC, V276, P211, DOI 10.1001/jama.276.3.211; PELLICCIA A, 1993, AM J CARDIOL, V72, P1048, DOI 10.1016/0002-9149(93)90861-6; REDFIELD MM, 1994, AM J CARDIOL, V74, P737, DOI 10.1016/0002-9149(94)90323-9; REGUERO JJR, 1995, EUR J APPL PHYSIOL, V70, P375, DOI 10.1007/BF00618486; ROST R, 1983, INT J SPORTS MED, V4, P147, DOI 10.1055/s-2008-1026028; ROY A, 1988, J APPL PHYSIOL, V64, P2552, DOI 10.1152/jappl.1988.64.6.2552; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1994, AM J CARDIOL, V74, P802, DOI 10.1016/0002-9149(94)90439-1; SPIRITO P, 1988, BRIT HEART J, V59, P672; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; VALDEZ RS, 1979, CIRCULATION, V60, P921, DOI 10.1161/01.CIR.60.4.921; VOOGD PJ, 1984, EUR HEART J, V5, P762, DOI 10.1093/oxfordjournals.eurheartj.a061739	48	384	393	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					23	31		10.7326/0003-4819-130-1-199901050-00005	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890846				2022-12-28	WOS:000077744500004
J	Ganser, BK; Li, S; Klishko, VY; Finch, JT; Sundquist, WI				Ganser, BK; Li, S; Klishko, VY; Finch, JT; Sundquist, WI			Assembly and analysis of conical models for the HIV-1 core	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; IN-VITRO; VIRION MORPHOGENESIS; CAPSID PROTEINS; TYPE-1; GAG; INFECTIVITY; RETROVIRUS; PARTICLES	The genome of the human immunodeficiency virus (HIV) is packaged within an unusual conical core particle located-at the center of the infectious virion. The core is composed of a complex of the NC (nucleocapsid) protein and genomic RNA, surrounded by a shell of the CA (capsid) protein. A method was developed for assembling cones in vitro using pure recombinant HIV-1 CA-NC fusion proteins and RNA templates. These synthetic cores are capped at both ends and appear similar in size and morphology to authentic viral cores. It is proposed that both viral and synthetic cores are organized on conical hexagonal Lattices, which by Euler's theorem requires quantization of their cane angles. Electron microscopic analyses revealed that the cone angles of synthetic cores were indeed quantized into the five allowed angles. The viral core and most synthetic cones exhibited cone angles of approximately 19 degrees (the narrowest of the allowed angles). These observations suggest that the core of HIV is organized on the principles of a fullerene cone, in analogy to structures recently observed for elemental carbon.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; MRC, Mol Biol Lab, Struct Studies Div, Cambridge CB2 2QH, England	Utah System of Higher Education; University of Utah; MRC Laboratory Molecular Biology	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.			Li, Sam/0000-0002-0210-8192				Accola MA, 1998, J VIROL, V72, P2072, DOI 10.1128/JVI.72.3.2072-2078.1998; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Barklis E, 1998, J BIOL CHEM, V273, P7177, DOI 10.1074/jbc.273.13.7177; Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; Campbell S, 1997, J VIROL, V71, P4425, DOI 10.1128/JVI.71.6.4425-4435.1997; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; CROWTHER RA, 1976, P 3 J INN S, P15; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; FINCH JW, UNPUB; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; GE MH, 1994, CHEM PHYS LETT, V220, P192, DOI 10.1016/0009-2614(94)00167-7; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; HOGLUND S, 1992, AIDS RES HUM RETROV, V8, P1, DOI 10.1089/aid.1992.8.1; KELLENBERGER E, 1982, ULTRAMICROSCOPY, V9, P139, DOI 10.1016/0304-3991(82)90236-4; KLISHKO VY, UNPUB; Kong LB, 1998, J VIROL, V72, P4403, DOI 10.1128/JVI.72.5.4403-4407.1998; KRAUSSLICH HG, 1996, CURRENT TOPICS MICRO, V214; Krishnan A, 1997, NATURE, V388, P451, DOI 10.1038/41284; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; SEYMOUR J, 1987, J MICROSC-OXFORD, V148, P195, DOI 10.1111/j.1365-2818.1987.tb02866.x; Swanstrom R., 1997, P263; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; Vogt V. M., 1997, P27; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; VONSCHWEDLER U, UNPUB; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299	36	498	510	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					80	83		10.1126/science.283.5398.80	http://dx.doi.org/10.1126/science.283.5398.80			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872746				2022-12-28	WOS:000077976600054
J	Okimura, JT; Norton, SA				Okimura, JT; Norton, SA			Jealousy and mutilation: nose-biting as retribution for adultery	LANCET			English	Article									RW Bliss Hlth Ctr, Dermatol Clin, Ft Huachuca, AZ 85613 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	University of Hawaii System	Norton, SA (corresponding author), RW Bliss Hlth Ctr, Dermatol Clin, Ft Huachuca, AZ 85613 USA.							AKHTAR M, 1977, JPMA             FEB, P272; BHANGANADA K, 1983, AM J SURG, V146, P376, DOI 10.1016/0002-9610(83)90420-8; BOOK HE, 1971, COMPR PSYCHIAT, V12, P450, DOI 10.1016/0010-440X(71)90084-8; BOYD JP, 1950, PAPERS J JEFFERSON, V2, P497; BREWIS A, 1996, LIVES LINE WOMEN ECO, P48; ELLIS H, 1923, STUDIES PSYCHOL SEX, V4, P67; GOODWIN G, 1942, SOCIAL ORG W APACHE, P341; LEWIS DE, 1990, PACIFIC STUDIES, V13, P115; LUDNSGAARDE HP, 1974, J POLYNESIAN SOC, V83, P192; MACKENZIE JN, 1898, J HOPKINS HOSP B, V82, P10; MACKENZIE JN, 1884, AM J MED SCI, V87, P360; MAZZOLA R F, 1987, Handchirurgie Mikrochirurgie Plastische Chirurgie, V19, P4; OLLAPALLIL JJ, 1995, TROP DOCT, V25, P85, DOI 10.1177/004947559502500213; OPLER ME, 1941, EC SOCIAL RELIG I CH, P410; PHELAN N, 1958, ATOLL HOLIDAY, P145; STEVENSON RL, 1900, S SEAS, P268; SUMNER WG, 1927, SCI SCO, P984; TWAIN M, 1981, ADVENTURES T SAWYER, P176; WEIDEGER P, 1985, HIST MISTRESS NEW IN, P154; ZUCKER A, 1988, OTOLARYNG HEAD NECK, V98, P319, DOI 10.1177/019459988809800409	20	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2010	2011		10.1016/S0140-6736(98)10267-2	http://dx.doi.org/10.1016/S0140-6736(98)10267-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872265				2022-12-28	WOS:000077663000046
J	Matsui, H; Grubb, BR; Tarran, R; Randell, SH; Gatzy, JT; Davis, CW; Boucher, RC				Matsui, H; Grubb, BR; Tarran, R; Randell, SH; Gatzy, JT; Davis, CW; Boucher, RC			Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease	CELL			English	Article							PSEUDOMONAS-AERUGINOSA; ELECTROLYTE TRANSPORT; MUCOCILIARY CLEARANCE; RESPIRATORY MUCOSA; FLUID TRANSPORT; SURFACE FLUID; EPITHELIA; LUNG; MUCUS; BACTERIA	The pathogenesis of cystic fibrosis (CF) airways infection is unknown. Two hypotheses, "hypotonic [low salt]/defensin" and "isotonic volume transport/mucus clearance," attempt to link defects in cystic fibrosis transmembrane conductance regulator-mediated ion transport to CF airways disease. We tested these hypotheses with planar and cylindrical culture models and found no evidence that the liquids lining airway surfaces were hypotonic or that salt concentrations differed between CF and normal cultures. In contrast, CF airway epithelia exhibited abnormally high rates of airway surface liquid absorption, which depleted the periciliary liquid layer and abolished mucus transport. The failure to clear thickened mucus from airway surfaces likely initiates CF airways infection. These data indicate that therapy for CF lung disease should not be directed at modulation of ionic composition, but rather at restoring volume (salt and water) on airway surfaces.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Boucher, RC (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	rboucher@med.unc.edu			NHLBI NIH HHS [HL42384, P01 HL34322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL042384] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker E, 1998, J CLIN INVEST, V102, P10, DOI 10.1172/JCI1795; BALLARD ST, 1991, J APPL PHYSIOL, V70, P1665, DOI 10.1152/jappl.1991.70.4.1665; BLAKE J, 1975, J BIOMECH, V8, P179, DOI 10.1016/0021-9290(75)90023-8; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVOIS CW, 1998, PEDIATR PULM, V17, P247; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Grubb BR, 1997, AM J PHYSIOL-CELL PH, V273, pC21, DOI 10.1152/ajpcell.1997.273.1.C21; Hull J, 1998, AM J RESP CRIT CARE, V157, P10, DOI 10.1164/ajrccm.157.1.9703045; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JOHNSON JG, 1998, PED PULMONOL S, V17, P241; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KEREM E, 1997, PEDIATR PULM, V14, P78; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; KOHLER D, 1986, EUR J RESPIR DIS, V69, P319; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; LAM J, 1980, INFECT IMMUN, V28, P546; LEVISON H, 1983, EUR J RESPIR DIS, V64, P102; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; NOONE PG, 1996, AM J RESP CRIT CARE, V153, pA530; Novotny JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1764, DOI 10.1152/ajpcell.1996.270.6.C1764; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PLOTKOWSKI MC, 1992, MEM I OSWALDO CRUZ, V87, P61, DOI 10.1590/S0074-02761992000900008; PUCHELLE E, 1995, RESPIRATION, V62, P2; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; Rogers D. F., 1997, AIRWAY MUCUS BASIC M, P1; SATIR P, 1990, ANNU REV PHYSIOL, V52, P137, DOI 10.1146/annurev.ph.52.030190.001033; SCHERER PW, 1981, CHEST, V80, P830, DOI 10.1378/chest.80.6.830; Sims DE, 1997, AM J PHYSIOL-LUNG C, V273, pL1036; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; STUTTS MJ, 1998, PEDIATR PULM, V17, P217; TSANG KWT, 1994, EUR RESPIR J, V7, P1746, DOI 10.1183/09031936.94.07101746; Ulrich M, 1998, AM J RESP CELL MOL, V19, P83, DOI 10.1165/ajrcmb.19.1.3137; VISHWANATH S, 1984, INFECT IMMUN, V45, P197, DOI 10.1128/IAI.45.1.197-202.1984; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZAHM JM, 1989, BIORHEOLOGY, V26, P747; ZUELZER WW, 1949, PEDIATRICS, V4, P53	48	869	893	0	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1005	1015		10.1016/S0092-8674(00)81724-9	http://dx.doi.org/10.1016/S0092-8674(00)81724-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875854	Bronze, Green Published			2022-12-28	WOS:000077759100015
J	Racoosin, JA; Whitney, CG; Conover, CS; Diaz, PS				Racoosin, JA; Whitney, CG; Conover, CS; Diaz, PS			Serogroup Y meningococcal disease in Chicago, 1991-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS	Context.-In 1994, surveillance by the Chicago Department of Public Health detected a growing trend in the proportion of invasive meningococcal infections caused by serogroup Y. Objective.-To examine the emergence of serogroup Y meningococcal disease and compare its clinical characteristics with those of other meningococcal serogroups. Design.-Population-based retrospective review of surveillance records; medical record review and cohort analysis of serogroup Y vs non-serogroup Y case patients. Setting.-Chicago, Ill. Participants.-City residents with Neisseria meningitidis isolated from a normally sterile site from January 1, 1991, through December 31, 1997; cohort analysis included those identified through March 31, 1996. Main Outcome Measures.-Serogroup-specific incidence, demographics, and clinical outcomes. Results.-We identified 214 case patients; 53 (25%) had serogroup Y. The attack rate of serogroup Y meningococcal disease increased from 0.04 cases per 100 000 in 1991 to a peak of 0.82 cases per 100 000 in 1995 and subsequently decreased to 0.26 cases per 100 000 and 0.34 cases per 100 000 in 1996 and 1997, respectively. Compared with patients infected by other serogroups, patients with serogroup Y were older (median age, 16 years vs 1 year; P=.001) and more likely to have a chronic underlying illness (prevalence ratio, 2.3; 95% confidence interval, 1.2-4.4). Outcome did not differ significantly between the 2 groups. Multilocus enzyme electrophoresis typing of isolates from 19 case patients identified 5 different types. We found no clustering among the enzyme types by age, race/ethnicity, community area, or time. Conclusions.-Serogroup Y emerged as the most frequent cause of meningococcal disease in Chicago in 1995 and accounted for a substantial proportion of cases in 1996 and 1997. Current data suggest that the magnitude of serogroup Y meningococcal disease is sufficient for vaccine developers to incorporate serogroup Y into new vaccines.	Chicago Dept Publ Hlth, Chicago, IL 60612 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Illinois, Sch Publ Hlth, Chicago, IL USA	Chicago Department of Public Health; Centers for Disease Control & Prevention - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Diaz, PS (corresponding author), Chicago Dept Publ Hlth, 2160 W Ogden Ave, Chicago, IL 60612 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1976, J INFECT DIS, V134, P201, DOI 10.1093/infdis/134.2.201; BIBB WF, 1989, INT J FOOD MICROBIOL, V8, P233, DOI 10.1016/0168-1605(89)90018-4; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1010; Dean A.G., 1994, EPI INFO VERSION 6 W; GALAID EI, 1980, JAMA-J AM MED ASSOC, V244, P2167, DOI 10.1001/jama.244.19.2167; HEDRICH AW, 1952, PUBLIC HEALTH REP, V67, P411, DOI 10.2307/4588096; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; KOPPES GM, 1977, AM J MED, V62, P661, DOI 10.1016/0002-9343(77)90867-1; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SMILACK JD, 1974, ANN INTERN MED, V81, P740, DOI 10.7326/0003-4819-81-6-740; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; STEPHENS DS, 1995, ANN INTERN MED, V123, P937, DOI 10.7326/0003-4819-123-12-199512150-00007	15	52	55	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2094	2098		10.1001/jama.280.24.2094	http://dx.doi.org/10.1001/jama.280.24.2094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875877	Bronze			2022-12-28	WOS:000077606100033
J	Winberg, ML; Noordermeer, JN; Tamagnone, L; Comoglio, PM; Spriggs, MK; Tessier-Lavigne, M; Goodman, CS				Winberg, ML; Noordermeer, JN; Tamagnone, L; Comoglio, PM; Spriggs, MK; Tessier-Lavigne, M; Goodman, CS			Plexin A is a neuronal semaphorin receptor that controls axon guidance	CELL			English	Article							GROWTH CONE GUIDANCE; FASCICLIN-II; SYNAPSE FORMATION; GENETIC-ANALYSIS; EXPRESSION; NEUROPILIN; FAMILY; DROSOPHILA; SURFACE; TRANSMEMBRANE	The Semaphorins comprise a large family of secreted and transmembrane proteins, some of which function as repellents during axon guidance. Semaphorins fall into seven subclasses. Neuropilins are neuronal receptors for class III Semaphorins. In the immune system, VESPR, a member of the Plexin family, is a receptor for a viral-encoded Semaphorin. Here, we identify two Drosophila Plexins, both of which are expressed in the developing nervous system. We present evidence that Plexin A is a neuronal receptor for class I Semaphorins (Sema 1a and Sema 1b) and show that Plexin A controls motor and CNS axon guidance. Plexins, which themselves contain complete Semaphorin domains, may be both the ancestors of classical Semaphorins and binding partners for Semaphorins.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Turin, Sch Med, Inst Canc Res, Dept Mol Oncol, I-10060 Turin, Italy; Immunex Corp, Dept Mol Biol, Seattle, WA 98101 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Turin; Immunex Corporation; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goodman, CS (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Tamagnone, Luca/J-8948-2018	Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328	NICHD NIH HHS [HD21294] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021294, R01HD021294] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bagnard D, 1998, DEVELOPMENT, V125, P5043; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; ENSSER A, 1995, J GEN VIROL, V76, P1063, DOI 10.1099/0022-1317-76-4-1063; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herold C, 1996, J IMMUNOL, V157, P5262; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Roberts D. B, 1986, DROSOPHILA PRACTICAL; SATODA M, 1995, J NEUROSCI, V15, P942; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Wong JTW, 1997, DEVELOPMENT, V124, P3597; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X; Yu W, 1997, GENOME RES, V7, P353, DOI 10.1101/gr.7.4.353	42	372	378	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					903	916		10.1016/S0092-8674(00)81715-8	http://dx.doi.org/10.1016/S0092-8674(00)81715-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875845	Bronze			2022-12-28	WOS:000077759100006
J	McMurray, JE				McMurray, JE			For love of karaoke	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Wisconsin, Clin Sci Ctr J5210, Madison, WI 53762 USA	University of Wisconsin System; University of Wisconsin Madison	McMurray, JE (corresponding author), Univ Wisconsin, Clin Sci Ctr J5210, 600 Highland Ave, Madison, WI 53762 USA.							NERUDA P, 1973, COMPLETAS OBRAS	1	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1072	1073		10.7326/0003-4819-129-12-199812150-00016	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867765				2022-12-28	WOS:000077471900013
J	Gallo, RC				Gallo, RC			Biomedicine - The enigmas of Kaposi's sarcoma	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; TAT PROTEIN; HUMAN HERPESVIRUS-8; DNA-SEQUENCES; SPINDLE CELLS; LYMPHOCYTES; INDUCTION; CYTOKINES; AUTOCRINE		Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.	coleman@umbi.umd.edu						Ariyoshi K, 1998, J Hum Virol, V1, P193; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; CAPOBIANCHI MR, 1993, AIDS RES HUM RETROV, V9, P957, DOI 10.1089/aid.1993.9.957; CARUSO A, 1995, J ACQ IMMUN DEF SYND, V10, P462, DOI 10.1097/00042560-199512000-00010; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLOMBINI S, UNPUB; Desrosiers RC, 1997, J VIROL, V71, P9764, DOI 10.1128/JVI.71.12.9764-9769.1997; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Fiorelli V, 1998, BLOOD, V91, P956; Flamand L, 1996, J ACQ IMMUN DEF SYND, V13, P194, DOI 10.1097/00042560-199610010-00011; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gallo R C, 1998, J Natl Cancer Inst Monogr, P55; GALLO RC, 1989, P BIOM RES STRAT AID, P113; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gill PS, 1998, P NATL ACAD SCI USA, V95, P8257, DOI 10.1073/pnas.95.14.8257; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; Kaplan L D, 1989, Biotechnol Ther, V1, P229; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; LUNARDIISKANDER Y, UNPUB; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; Popescu NC, 1996, J NATL CANCER I, V88, P450, DOI 10.1093/jnci/88.7.450; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; Samaniego F, 1998, AM J PATHOL, V152, P1433; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851	33	167	178	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1837	1839		10.1126/science.282.5395.1837	http://dx.doi.org/10.1126/science.282.5395.1837			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9874635				2022-12-28	WOS:000077338100033
J	Kuttner, R				Kuttner, R			Employer-sponsored health coverage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		BUSS DD, 1998, WALL STREET J   1117, pA2; COOPER PF, 1997, HLTH AFF MILLWOOD, V16, P144; CUTLER DM, 1995, 5082 NBER; FRONSTIN P, 1998, FEATURES EMPLOYMENT, P1; FRONSTIN P, 1998, SOURCES HLTH INSURAN; *GEN ACC OFF, 1997, EMPL BAS HLTH INS CO, P2; *HEW ASS, 1996, SAL EMPL BEN PROV MA; LEVIT K, 1998, HLTH AFF MILLWOOD, V17, P108; MISHEL L, 1997, STATE WORKING AM 199; OBRIEN O, 1998, HJ KAISER FAMILY SEP, P2; *PHYS PAYM REV COM, 1996, ANN REP C 1996; 1998, EBRI NEWS       0925	12	47	47	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					248	252		10.1056/NEJM199901213400324	http://dx.doi.org/10.1056/NEJM199901213400324			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895408				2022-12-28	WOS:000078202900031
J	Wheeler, AP; Bernard, GR				Wheeler, AP; Bernard, GR			Treating patients with severe sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESPIRATORY-DISTRESS-SYNDROME; TUMOR-NECROSIS-FACTOR; CRITICALLY ILL PATIENTS; INFLAMMATORY RESPONSE SYNDROME; PLACEBO-CONTROLLED TRIAL; MULTIPLE ORGAN FAILURE; INHALED NITRIC-OXIDE; INTENSIVE-CARE UNIT; SEPTIC SHOCK; DOUBLE-BLIND		Vanderbilt Univ, Sch Med, Med Ctr No T1208, Dept Med,Ctr Lung Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Bernard, GR (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr No T1208, Dept Med,Ctr Lung Res, 221 Kirkland Hall, Nashville, TN 37232 USA.	gordon.bernard@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019153, R01HL043167] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07123, HL 19153, HL 43167] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P1095, DOI 10.1164/ajrccm/144.5.1095; BERNARD GR, 1995, AM J RESP CRIT CARE, V152, P4, DOI 10.1164/ajrccm.152.1.7599855; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BRUNBUISSON C, 1994, ARCH INTERN MED, V154, P2484; Bunnell E, 1996, CLIN CHEST MED, V17, P237, DOI 10.1016/S0272-5231(05)70311-7; CARLOS TM, 1994, BLOOD, V84, P2068; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P31; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CHERNOFF AE, 1995, J IMMUNOL, V154, P5492; CHRISTMAN JW, 1991, J CRIT CARE, V6, P172, DOI 10.1016/0883-9441(91)90008-H; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cook D, 1997, SEMIN RESP CRIT CARE, V18, P91, DOI 10.1055/s-2007-1009335; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; Darby JM, 1997, CRIT CARE MED, V25, P989, DOI 10.1097/00003246-199706000-00016; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; DHAINAUT JF, 1994, UPD INT CAR, V18, P397; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; Fekade D, 1996, NEW ENGL J MED, V335, P311, DOI 10.1056/NEJM199608013350503; FIELD S, 1982, AM REV RESPIR DIS, V126, P9; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; HARTMAN DL, 1997, AM J RESP CRIT CARE, V155, pA708; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; HERBERTSON MJ, 1995, AM J RESP CRIT CARE, V152, P480, DOI 10.1164/ajrccm.152.2.7633696; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Horn DL, 1996, SCAND J INFECT DIS, P9; Jain M, 1997, SEM RESP CRIT CARE M, V18, P79, DOI 10.1055/s-2007-1009334; KIEFT H, 1993, ARCH INTERN MED, V153, P2241, DOI 10.1001/archinte.153.19.2241; KORETZ RL, 1995, AM J RESP CRIT CARE, V151, P570, DOI 10.1164/ajrccm.151.2.7842222; LEDINGHAM IM, 1978, LANCET, V1, P1194; MARIK PE, 1994, JAMA-J AM MED ASSOC, V272, P1354, DOI 10.1001/jama.272.17.1354; Marini JJ, 1997, SEMIN RESP CRIT CARE, V18, P3, DOI 10.1055/s-2007-1009329; MARTY C, 1994, CRIT CARE MED, V22, P673, DOI 10.1097/00003246-199404000-00025; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; NEWMAN M, 1990, INT CRIT CARE DIG, V9, P3; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PASTOR CM, 1995, J CRIT CARE, V10, P183, DOI 10.1016/0883-9441(95)90010-1; Pittet D, 1996, AM J RESP CRIT CARE, V153, P684, DOI 10.1164/ajrccm.153.2.8564118; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Reinhart K, 1996, CRIT CARE MED, V24, P733, DOI 10.1097/00003246-199605000-00003; Reinhart K, 1996, CRIT CARE MED, V24, P1608; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; RUSSELL JA, 1994, AM J RESP CRIT CARE, V149, P533, DOI 10.1164/ajrccm.149.2.8306058; SCHINDLER R, 1990, BLOOD, V75, P40; SCHLAG G, 1994, SHOCK, V2, P10, DOI 10.1097/00024382-199407000-00002; SESSLER CN, 1995, AM J RESP CRIT CARE, V151, P1420, DOI 10.1164/ajrccm.151.5.7735595; SHENEP JL, 1984, J INFECT DIS, V150, P380, DOI 10.1093/infdis/150.3.380; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; STRIETER RM, 1994, J INVEST MED, V42, P640; Taylor RW, 1997, CRIT CARE MED, V25, P910; ten Cate H, 1993, New Horiz, V1, P312; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; Walmrath D, 1996, AM J RESP CRIT CARE, V153, P991, DOI 10.1164/ajrccm.153.3.8630585; WASHINGTON JA, 1986, REV INFECT DIS, V8, P792; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; Wheeler A, 1995, AM J RESP CRIT CAR S, V151, pA317; Wheeler A P, 1993, New Horiz, V1, P471; WHEELER AP, 1992, AM REV RESPIR DIS, V145, P632, DOI 10.1164/ajrccm/145.3.632; Wheeler AP, 1997, SEMIN RESP CRIT CARE, V18, P39, DOI 10.1055/s-2007-1009332; WHEELER AP, 1998, AM J RESP CRIT CAR S, V157, pA115; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; YU MH, 1993, CRIT CARE MED, V21, P1635, DOI 10.1097/00003246-199311000-00010; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; Zwissler B, 1996, AM J RESP CRIT CARE, V154, P1671, DOI 10.1164/ajrccm.154.6.8970353	91	733	785	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					207	214		10.1056/NEJM199901213400307	http://dx.doi.org/10.1056/NEJM199901213400307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895401				2022-12-28	WOS:000078202900007
J	Thiemens, MH				Thiemens, MH			Atmosphere science - Mass-independent isotope effects in planetary atmospheres and the early solar system	SCIENCE			English	Review							STRATOSPHERIC NITROUS-OXIDE; MARS VOLATILE EVOLUTION; HEAVY OZONE; MARTIAN ATMOSPHERE; CARBON-DIOXIDE; TROPOSPHERIC OZONE; GLOBAL PERSPECTIVE; OXYGEN ISOTOPES; FRACTIONATION; SYMMETRY	A class of isotope effects that alters isotope ratios on a mass-independent basis provides a toot for studying a wide range of processes in atmospheres of Earth and other planets as well as early processes in the solar nebula. The mechanism for the effect remains uncertain. Mass-independent isotopic compositions; have been observed in O-3, CO2, N2O, and CO in Earth's atmosphere and in carbonate from a martian meteorite, which suggests a role for mass-independent processes in the atmosphere of Mars. Observed mass-independent meteoritic oxygen and sulfur isotopic compositions may derive from chemical processes in the presolar nebula, and their distributions could provide insight into early solar system evolution.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Thiemens, MH (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	mht@chem.ucsd.edu						ABBAS MM, 1987, J GEOPHYS RES-ATMOS, V92, P13231, DOI 10.1029/JD092iD11p13231; Anderson R.B., 1956, CATALYSIS, VIV, P1; Anderson SM, 1997, J CHEM PHYS, V107, P5385, DOI 10.1063/1.474247; BAINSSAHOTA SK, 1989, J CHEM PHYS, V90, P6099, DOI 10.1063/1.456375; BAKER V, 1998, LUNAR PLANET SCI C, V29, P39; BARTH CA, 1986, PHOTOCHEMISTRY ATMOS, P337; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BHATTACHARYA SK, 1989, Z NATURFORSCH A, V44, P435; BIGELEISEN J, 1947, J CHEM PHYS, V15, P261, DOI 10.1063/1.1746492; BJORAAKER GL, 1989, B AM ASTRON SOC, V29, P991; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; Brenninkmeijer CAM, 1997, J GEOPHYS RES-ATMOS, V102, P25477, DOI 10.1029/97JD02291; Brenninkmeijer CAM, 1995, J GEOPHYS RES-ATMOS, V100, P26163, DOI 10.1029/95JD02528; BRENNINKMEIJER CAM, 1993, J GEOPHYS RES-ATMOS, V98, P10595, DOI 10.1029/93JD00587; CANTRELL CA, 1994, J GEOPHYS RES-ATMOS, V99, P3739, DOI 10.1029/93JD02659; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; Farquhar J, 1998, SCIENCE, V280, P1580, DOI 10.1126/science.280.5369.1580; GARNO T, 1989, TELLUS B, V41, P127; Gellene GI, 1996, SCIENCE, V274, P1344, DOI 10.1126/science.274.5291.1344; GELLENE GI, 1996, ADV GAS P I, V2, P161; GOLDMAN A, 1989, J GEOPHYS RES-ATMOS, V94, P8467, DOI 10.1029/JD094iD06p08467; GRIFFITH KS, 1992, J CHEM PHYS, V96, P4403, DOI 10.1063/1.462831; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; HODDER PS, 1994, US GEOL CIRC, V1107, P73; Houston PL, 1996, J GEOPHYS RES-ATMOS, V101, P18829, DOI 10.1029/96JD01664; Huff AK, 1998, GEOPHYS RES LETT, V25, P3509, DOI 10.1029/98GL02603; HUFF AK, 1996, EOS S            FAL, pF124; HULSTON JR, 1965, J GEOPHYS RES, V70, P3475, DOI 10.1029/JZ070i014p03475; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; HUTCHEON ID, 1994, ASTROPHYS J, V425, pL97, DOI 10.1086/187319; Hutchins KS, 1996, J GEOPHYS RES-PLANET, V101, P14933, DOI 10.1029/96JE00860; Irion FW, 1996, GEOPHYS RES LETT, V23, P2377, DOI 10.1029/96GL01695; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHNSTON JC, 1995, J GEOPHYS RES-ATMOS, V100, P16801, DOI 10.1029/95JD01646; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; KARLSSON KR, 1992, SCIENCE, V255, P1409, DOI 10.1126/science.11537889; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KAYE JA, 1983, J GEOPHYS RES-OCEANS, V88, P8447, DOI 10.1029/JC088iC13p08447; KERRIDGE JF, 1988, LUNAR PLANET SCI, V19, P599; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KIM KR, 1990, NATURE, V347, P58, DOI 10.1038/347058a0; KRANKOWSKY D, 1995, GEOPHYS RES LETT, V22, P1713, DOI 10.1029/95GL01436; KRASNOPOLSKY VA, 1996, ICARUS, V553; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; MAK JE, 1994, J GEOPHYS RES-ATMOS, V99, P22915, DOI 10.1029/94JD01931; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MAUERSBERGER K, 1981, GEOPHYS RES LETT, V8, P935, DOI 10.1029/GL008i008p00935; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MILLER RL, 1994, SCIENCE, V265, P1831, DOI 10.1126/science.265.5180.1831; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; MORTON J, 1989, CHEM PHYS LETT, V154, P143, DOI 10.1016/S0009-2614(89)87276-8; MORTON J, 1990, J GEOPHYS RES-ATMOS, V95, P901, DOI 10.1029/JD095iD01p00901; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAVON O, 1985, EARTH PLANET SC LETT, V73, P1, DOI 10.1016/0012-821X(85)90030-5; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; NIER AO, 1947, REV SCI INSTRUM, V18, P294, DOI 10.1063/1.1740940; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; NITTLER LR, 1997, AIP C P, V402, P59, DOI DOI 10.1063/1.53320; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; PRASAD JS, 1994, J GEOPHYS RES, V99, P5295; Prasad SS, 1998, GEOPHYS RES LETT, V25, P2173, DOI 10.1029/98GL01610; Prasad SS, 1997, J GEOPHYS RES-ATMOS, V102, P21537, DOI 10.1029/97JD00002; Rahn T, 1997, SCIENCE, V278, P1776, DOI 10.1126/science.278.5344.1776; RINSLAND CP, 1985, J GEOPHYS RES-ATMOS, V90, P10719, DOI 10.1029/JD090iD06p10719; ROBERT F, 1998, EARTH PLANET SCI, V91, P231; Rockmann T, 1998, J GEOPHYS RES-ATMOS, V103, P1463, DOI 10.1029/97JD02929; Rockmann T, 1998, SCIENCE, V281, P544, DOI 10.1126/science.281.5376.544; SCAMBOS TA, 1990, J GEOPHYS RES-SOLID, V95, P14779, DOI 10.1029/JB095iB09p14779; Sehested J, 1998, J GEOPHYS RES-ATMOS, V103, P3545, DOI 10.1029/97JD03124; STEVENS CM, 1972, EARTH PLANET SC LETT, V16, P147, DOI 10.1016/0012-821X(72)90183-5; Thiemen M.H, 1996, CHONDRULES PROTOPLAN, P107; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; THIEMENS MH, 1990, GEOPHYS RES LETT, V17, P717, DOI 10.1029/GL017i006p00717; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; UREY HC, 1947, J CHEM SOC, P562, DOI 10.1039/jr9470000562; VALENTINI JJ, 1987, J CHEM PHYS, V86, P6757, DOI 10.1063/1.452375; WAHLEN M, 1985, NATURE, V313, P780, DOI 10.1038/313780a0; WEN J, 1993, J GEOPHYS RES-ATMOS, V98, P12801, DOI 10.1029/93JD00565; WESTON RE, UNPUB CHEM REV; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; *WORLD MET ORG, 1995, 37 WORLD MET ORG, P2; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; Yoo RK, 1996, J CHEM PHYS, V105, P177, DOI 10.1063/1.471855; YOO RK, 1995, J CHEM PHYS, V102, P3227, DOI 10.1063/1.468633; Yoo RK, 1997, J CHEM PHYS, V106, P1294, DOI 10.1063/1.474089; YOSHIDA N, 1988, NATURE, V335, P528, DOI 10.1038/335528a0; YOSHINARI T, 1985, NATURE, V317, P349, DOI 10.1038/317349a0; YUNG YL, 1991, GEOPHYS RES LETT, V18, P13, DOI 10.1029/90GL02478; Yung YL, 1997, J GEOPHYS RES-ATMOS, V102, P10857, DOI 10.1029/97JD00528; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	104	298	309	7	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					341	345		10.1126/science.283.5400.341	http://dx.doi.org/10.1126/science.283.5400.341			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888843				2022-12-28	WOS:000078067000032
J	Ginzberg, E				Ginzberg, E			The uncertain future of managed care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, New York, NY 10027 USA	Columbia University	Ginzberg, E (corresponding author), Columbia Univ, New York, NY 10027 USA.							Reinhardt UE, 1997, JAMA-J AM MED ASSOC, V278, P1446, DOI 10.1001/jama.278.17.1446; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128	2	20	20	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					144	146		10.1056/NEJM199901143400212	http://dx.doi.org/10.1056/NEJM199901143400212			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887169				2022-12-28	WOS:000078016200012
J	Ibison, I				Ibison, I			Doctor suggests a young woman should smoke	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					116	116		10.1136/bmj.318.7176.116	http://dx.doi.org/10.1136/bmj.318.7176.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880289	Green Published			2022-12-28	WOS:000078087500032
J	Jefferson, T				Jefferson, T			What are the benefits of editorials and non-systematic reviews?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Minist Def, London, England		Jefferson, T (corresponding author), Minist Def, London, England.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240	1	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1999	318	7176					135	135		10.1136/bmj.318.7176.135	http://dx.doi.org/10.1136/bmj.318.7176.135			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880312	Green Published			2022-12-28	WOS:000078087500074
J	Zapotocky, M; Ramos, L; Poulin, P; Lubensky, TC; Weitz, DA				Zapotocky, M; Ramos, L; Poulin, P; Lubensky, TC; Weitz, DA			Particle-stabilized defect gel in cholesteric liquid crystals	SCIENCE			English	Article							FOCAL CONIC DOMAINS; RHEOLOGY; COPOLYMERS	Dispersions of colloidal particles in cholesteric liquid crystals form an unusual solid by stabilizing a network of linear defects under tension in the ideal layered structure of the cholesteric. The large length scales of the cholesteric liquid crystals allowed direct observation of the network structure, and its properties were correlated with rheological measurements of elasticity. This system serves as a model for a class of solids formed when particles are mixed with layered materials such as thermotropic and lyotropic smectic liquid crystals and block copolymers.	Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA	University of Pennsylvania	Lubensky, TC (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.		ramos, laurence/C-4610-2013; Zapotocky, Martin/B-8225-2008	Zapotocky, Martin/0000-0002-0437-2528; Poulin, Philippe/0000-0001-7748-8671				BOLTENHAGEN P, 1991, J PHYS II, V1, P1233, DOI 10.1051/jp2:1991130; Colby RH, 1997, RHEOL ACTA, V36, P498; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; JOWITT R, 1983, PHYSICAL CHEM FOODS; KAWASAKI K, 1990, PHYS REV A, V42, P3664, DOI 10.1103/PhysRevA.42.3664; Kleman M., 1983, POINTS LINES WALLS; LARSON RG, 1993, RHEOL ACTA, V32, P245, DOI 10.1007/BF00434188; LAVRENTOVICH OD, 1994, J PHYS II, V4, P377, DOI 10.1051/jp2:1994135; LUBENSKY TC, 1972, PHYS REV A, V6, P452, DOI 10.1103/PhysRevA.6.452; LUBENSKY TC, UNPUB; Mutel A., 1985, J POLYM ENG, DOI 10.1515/POLYENG.1985.5.4.293; Nielsen L. E., 1994, MECH PROPERTIES POLY; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; POULIN P, UNPUB; TRELOAR LRG, 1975, PHYSICS RUBBER ELAST; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969	16	207	208	0	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					209	212		10.1126/science.283.5399.209	http://dx.doi.org/10.1126/science.283.5399.209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880250				2022-12-28	WOS:000077976700035
J	Iglehart, JK				Iglehart, JK			The American health care system - Expenditures	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ECONOMICS											*ADV COMM INT REL, CHAR FED GRANT IN AI; Angell M, 1993, Kennedy Inst Ethics J, V3, P279; BARR S, 1998, WASH POST       0426, pA2; BERWICK DM, 1998, GOOD ITS HOULD GET M; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1003, DOI 10.1056/NEJM199804023381422; *BUR CENS, 1998, CURR POP REP HLTH IN; *C BUDG OFF, 1992, EC IMPL RIS HLTH CAR; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Ellwood MR, 1998, HEALTH AFFAIR, V17, P137, DOI 10.1377/hlthaff.17.3.137; *EV OFF PRES, 1998, BUDG US GOV AN PERSP; FUCHS VR, 1972, MILBANK MEML FUND Q, V50, P211, DOI 10.2307/3349445; Fuchs VR, 1996, AM ECON REV, V86, P1; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; FUCHS VR, 1997, CHALLENGES HLTH POLI; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; GREENBERG DS, 1998, WASHINGTON POST 1012, pA21; GROSS DJ, 1997, POCKET HLTH SPENDING; Guterman S, 1998, HEALTH AFFAIR, V17, P159, DOI 10.1377/hlthaff.17.1.159; Iglehart J K, 1996, N Engl J Med, V334, P203, DOI 10.1056/NEJM199601183340324; IGLEHART JK, 1982, NEW ENGL J MED, V306, P120, DOI 10.1056/NEJM198201143060235; *KAIS COMM MED UN, 1998, DECL MED SPEND GROWT; KRUEGER AB, 1994, HEALTH AFFAIR, V13, P34, DOI 10.1377/hlthaff.13.2.34; LAGNADO L, 1998, WALL STREET J   1117, pA1; Levit K, 1998, HEALTH AFFAIR, V17, P99, DOI 10.1377/hlthaff.17.6.99; LONG SH, 1998, WIDESPREAD MANAGED C, P12; *MED PAYM ADV COMM, 1998, REP C CONT CHANG MED; Neumann PJ, 1998, HEALTH AFFAIR, V17, P111, DOI 10.1377/hlthaff.17.6.111; *OECD, 1998, OECD HLTH DATA 1998; Pauly M, 1997, HLTH BENEFITS WORK E; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; Reinhardt UE, 1997, JAMA-J AM MED ASSOC, V278, P1446, DOI 10.1001/jama.278.17.1446; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; SAPOLSKY HM, 1981, MILBANK FUND Q, V59, P561, DOI 10.2307/3349741; SCHIEBER G, 1997, 365 WORLD BANK; SHEARER G, 1998, HIDDEN VIEW GROWING; Shortell SM, 1998, JAMA-J AM MED ASSOC, V280, P1102, DOI 10.1001/jama.280.12.1102; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; TANOUYE E, 1998, WALL STREET J   1116, pA1; VARMUS H, 1995, NEW ENGL J MED, V333, P811, DOI 10.1056/NEJM199509213331224	39	88	88	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					70	76		10.1056/NEJM199901073400122	http://dx.doi.org/10.1056/NEJM199901073400122			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155JQ	9878649				2022-12-28	WOS:000077943700033
J	Powell, M				Powell, M			Recent advances - Neurosurgery	BRITISH MEDICAL JOURNAL			English	Review							SURGERY; STIMULATION; NUCLEUS		UCL Hosp, Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Powell, M (corresponding author), UCL Hosp, Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.							Apuzzo MLJ, 1996, NEUROSURGERY, V38, P625; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; CHATTERJEE S, 1995, SPINE, V20, P734, DOI 10.1097/00007632-199503150-00016; Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008; GOLFINOS JG, 1995, J NEUROSURG, V83, P197, DOI 10.3171/jns.1995.83.2.0197; Jho HD, 1997, SURG NEUROL, V47, P213, DOI 10.1016/S0090-3019(96)00452-1; Jolesz FA, 1997, RADIOLOGY, V204, P601, DOI 10.1148/radiology.204.3.9280232; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Maciunas R J, 1996, Clin Neurosurg, V43, P353; Maeder P, 1998, BRIT J NEUROSURG, V12, P18, DOI 10.1080/02688699845456; Moriarty TM, 1996, NEUROSURG CLIN N AM, V7, P323; Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001; POWELL MP, 1998, BRIT MED J, V316, P1259; Quinn N, 1998, BRIT MED J, V316, P1259, DOI 10.1136/bmj.316.7140.1259; Sundaresan N, 1996, J NEUROSURG, V85, P438, DOI 10.3171/jns.1996.85.3.0438; SUNDARESAN N, 1995, J CLIN ONCOL, V13, P2330, DOI 10.1200/JCO.1995.13.9.2330; WATANABE E, 1987, SURG NEUROL, V27, P543, DOI 10.1016/0090-3019(87)90152-2	17	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					35	38						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872884				2022-12-28	WOS:000078013100027
J	Ikonomidou, C; Bosch, F; Miksa, M; Bittigau, P; Vockler, J; Dikranian, K; Tenkova, TI; Stefovska, V; Turski, L; Olney, JW				Ikonomidou, C; Bosch, F; Miksa, M; Bittigau, P; Vockler, J; Dikranian, K; Tenkova, TI; Stefovska, V; Turski, L; Olney, JW			Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain	SCIENCE			English	Article							CEREBELLAR GRANULE NEURONS; AMINO-ACID RECEPTORS; DEVELOPING RAT-BRAIN; CELL-DEATH; CAUTIONARY NOTE; MESSENGER-RNAS; GROWTH SPURT; ETHANOL; EXPRESSION; GLUTAMATE	Programmed cell death (apoptosis) occurs during normal development of the central nervous system. However, the mechanisms that determine which neurons will succumb to apoptosis are poorly understood. Blockade of N-methyl-D-aspartate (NMDA) glutamate receptors for only a few hours during late fetal or early neonatal Life triggered widespread apoptotic neurodegeneration in the developing rat brain, suggesting that the excitatory neurotransmitter glutamate, acting at NMDA receptors, controls neuronal survival. These findings may have relevance to human neurodevelopmental disorders involving prenatal (drug-abusing mothers) or postnatal (pediatric anesthesia) exposure to drugs that block NMDA receptors.	Humboldt Univ, Charite Virchow Clin, Dept Pediat Neurol, D-13353 Berlin, Germany; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; UCL, Eisai London Res Labs, London WC1E 6BT, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Washington University (WUSTL); Eisai Co Ltd; University of London; University College London	Ikonomidou, C (corresponding author), Humboldt Univ, Charite Virchow Clin, Dept Pediat Neurol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de			NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER; NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BALAZS R, 1990, INT J DEV NEUROSCI, V8, P347, DOI 10.1016/0736-5748(90)90068-D; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; COLES C D, 1987, Advances in Alcohol and Substance Abuse, V6, P87; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ishimaru M. J., 1997, Society for Neuroscience Abstracts, V23, P895; IZQUIERDO I, 1990, TRENDS PHARMACOL SCI, V11, P309, DOI 10.1016/0165-6147(90)90229-2; JEVTOVICTODOROV.V, 1998, NAT MED, V4, P450; JONES KL, 1973, LANCET, V2, P999; KAPPELLE AC, 1993, BRIT J PHARMACOL, V108, P780, DOI 10.1111/j.1476-5381.1993.tb12878.x; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KRISTENSEN JD, 1995, BRIT J ANAESTH, V74, P193, DOI 10.1093/bja/74.2.193; LEE HS, 1992, EXP NEUROL, V118, P284, DOI 10.1016/0014-4886(92)90185-S; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; Reynolds JD, 1995, CAN J PHYSIOL PHARM, V73, P1209, DOI 10.1139/y95-173; VALENTINE JL, 1994, J PHARMACOL EXP THER, V269, P1079; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; WHITE PF, 1976, J PHARMACOL EXP THER, V196, P545; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; ZHONG J, 1995, J NEUROCHEM, V64, P531	34	1514	1594	6	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					70	74		10.1126/science.283.5398.70	http://dx.doi.org/10.1126/science.283.5398.70			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872743				2022-12-28	WOS:000077976600051
J	Malik, RA; Williamson, S; Abbott, C; Carrington, AL; Iqbal, J; Schady, W; Boulton, AJM				Malik, RA; Williamson, S; Abbott, C; Carrington, AL; Iqbal, J; Schady, W; Boulton, AJM			Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised doubleblind controlled trial	LANCET			English	Article							PERIPHERAL NEUROPATHY; GLYCEMIC CONTROL; BACKGROUND RETINOPATHY; RISK-FACTORS; ABNORMALITIES; PROGRESSION; MULTICENTER; PREVALENCE; MELLITUS; NIDDM	Background Diabetes is a common cause of polyneuropathy. The development and progression of nephropathy, retinopathy, and neuropathy are closely related. Angiotensin-converting enzyme (ACE) inhibitors delay progression of both nephropathy and retinopathy. We investigated the effect of ACE inhibition on diabetic neuropathy. Methods We recruited 41 normotensive patients with type I or type II diabetes and mild neuropathy into a randomised double-blind placebo-controlled trial. Changes in the neuropathy symptom and deficit scores, vibration-perception threshold, peripheral-nerve electrophysiology, and cardiovascular autonomic function, were assessed at 6 and 12 months. The primary endpoint was the change in peroneal nerve motor conduction velocity. Findings We found no significant difference at baseline for age, HbA(1c), blood pressure, or severity of neuropathy between two groups. There was no change in HbA(1c) over the treatment period. Peroneal motor nerve conduction velocity (p=0.03) and M-wave amplitude (p=0.03) increased, and the F-wave latency (p=0.03) decreased and sural nerve action potential amplitude increased (p=0.04) significantly after 12 months of treatment with trandolapril compared with placebo. Vibration-perception threshold, autonomic function, and the neuropathy symptom and deficit score showed no improvement in either group. Interpretation The ACE inhibitor trandolapril may improve peripheral neuropathy in normotensive patients with diabetes. Larger clinical trials are needed to confirm these data before changes to clinical practice can be advocated.	Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Manchester Royal Infirm, Dept Neurol, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Malik, RA (corresponding author), Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.	humza@fsl.cmht.nwest.nhs.uk	Malik, Rayaz/H-9231-2019	Malik, Rayaz/0000-0002-7188-8903; Abbott, Caroline/0000-0002-4506-2235				Ahmad J, 1997, DIABETES CARE, V20, P1576, DOI 10.2337/diacare.20.10.1576; ALBERS JW, 1995, ANN NEUROL, V38, P478; ALMEMAR A, 1996, DIABET MED S38, V13, pP90; [Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; Boner G, 1996, DIABETOLOGIA, V39, P587; BOULTON AJM, 1997, TXB DIABETES, V58, P1; CAMERON NE, 1992, DIABETOLOGIA, V35, P12, DOI 10.1007/BF00400846; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; Dyck PJ, 1997, NEUROLOGY, V49, P229, DOI 10.1212/WNL.49.1.229; Forrest KYZ, 1997, DIABETES, V46, P665, DOI 10.2337/diabetes.46.4.665; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GIANNINI C, 1994, ANN NEUROL, V36, P408, DOI 10.1002/ana.410360312; HORROBIN DF, 1997, DIABETIC NEUROPATHY, P183; JANKA HU, 1989, DIABETES, V38, P460, DOI 10.2337/diabetes.38.4.460; MALIK RA, 1989, DIABETOLOGIA, V32, P92, DOI 10.1007/BF00505180; Malik RA, 1997, DIABETES, V46, pS50, DOI 10.2337/diab.46.2.S50; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MELTON LJ, 1987, DIABETIC NEUROPATHY, P27; Nicolucci A, 1996, DIABETIC MED, V13, P1017, DOI 10.1002/(SICI)1096-9136(199612)13:12<1017::AID-DIA252>3.0.CO;2-Z; PARTANEN J, 1995, NEW ENGL J MED, V333, P89, DOI 10.1056/NEJM199507133330203; PARVING HH, 1989, DIABETOLOGIA, V32, P440, DOI 10.1007/BF00271264; REJA A, 1995, DIABETIC MED, V12, P307, DOI 10.1111/j.1464-5491.1995.tb00482.x; Savage S, 1996, DIABETES CARE, V19, P1243, DOI 10.2337/diacare.19.11.1243; Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586; Tesfaye S, 1996, DIABETOLOGIA, V39, P329; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; VEVES A, 1991, DIABETIC MED, V8, P917, DOI 10.1111/j.1464-5491.1991.tb01530.x; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603	29	200	212	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1978	1981		10.1016/S0140-6736(98)02478-7	http://dx.doi.org/10.1016/S0140-6736(98)02478-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872248				2022-12-28	WOS:000077663000012
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Plant genomics - Plant genotoxicity	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Kovalchuk I, 1998, NAT BIOTECHNOL, V16, P1054, DOI 10.1038/3505; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x	2	0	0	3	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2214	2214		10.1126/science.282.5397.2214	http://dx.doi.org/10.1126/science.282.5397.2214			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890831				2022-12-28	WOS:000077645800034
J	Tonse, NKR				Tonse, NKR			The Nobel chronicles - 1930: Karl Landsteiner (1868-1943)	LANCET			English	Article									Univ Illinois, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tonse, NKR (corresponding author), Univ Illinois, Chicago, IL USA.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1944	1944		10.1016/S0140-6736(05)60452-7	http://dx.doi.org/10.1016/S0140-6736(05)60452-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863832				2022-12-28	WOS:000077544600076
J	Turnbull, D				Turnbull, D			Loss to follow-up of preterm and very preterm babies	LANCET			English	Editorial Material									Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5005, Australia	University of Adelaide	Turnbull, D (corresponding author), Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5005, Australia.							*AGPS, 1983, 22 AGPS; Crowther CA, 1997, PEDIATRICS, V99, P311, DOI 10.1542/peds.99.3.311; CROWTHER CA, 1995, LANCET, V345, P877; Holzman C, 1998, AM J PUBLIC HEALTH, V88, P183, DOI 10.2105/AJPH.88.2.183; McCormick MC, 1997, PEDIATRICS, V99, P476, DOI 10.1542/peds.99.3.476; *NAT HLTH MRC, 1995, UNPUB GUID PROT PRIV; WINT T, 1998, ARCH DIS CHILD, V79, pF83; WOLKE D, 1995, LANCET, V345, P447, DOI 10.1016/S0140-6736(95)90425-5	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1875	1876		10.1016/S0140-6736(05)60392-3	http://dx.doi.org/10.1016/S0140-6736(05)60392-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863782				2022-12-28	WOS:000077544600005
J	Franks, AL; Marks, JS				Franks, AL; Marks, JS			Introduction to supplement on iron overload, public health, and genetics	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEREDITARY HEMOCHROMATOSIS		Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Franks, AL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Mailstop K-24,4770 Buford Highway, Atlanta, GA 30341 USA.	alf1@cdc.gov						BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; Bradley L A, 1996, J Med Screen, V3, P178; Bradley L A, 1996, J Med Screen, V3, P171; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Haddow J E, 1994, J Med Screen, V1, P16; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	9	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					923	924		10.7326/0003-4819-129-11_Part_2-199812011-00001	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867743				2022-12-28	WOS:000077239200023
J	Werb, Z; Yan, YB				Werb, Z; Yan, YB			Cell biology - A cellular striptease act	SCIENCE			English	Editorial Material							GROWTH-FACTOR RECEPTOR; FACTOR-ALPHA; TNF-ALPHA; PROTEIN; CLEAVAGE; SURFACE		Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	zena@itsa.ucsf.edu; yan@cgl.ucsf.edu			NCI NIH HHS [CA72006] Funding Source: Medline; NICHD NIH HHS [HD26732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahonen M, 1998, CANCER RES, V58, P2310; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Gururajan R, 1998, GENOMICS, V52, P101, DOI 10.1006/geno.1998.5401; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	29	143	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1279	1280		10.1126/science.282.5392.1279	http://dx.doi.org/10.1126/science.282.5392.1279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9867633				2022-12-28	WOS:000076982200033
J	Brouqui, P; Lascola, B; Roux, V; Raoult, D				Brouqui, P; Lascola, B; Roux, V; Raoult, D			Chronic Bartonella quintana bacteremia in homeless patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAT-SCRATCH DISEASE; ROCHALIMAEA QUINTANA; BACILLARY ANGIOMATOSIS; HENSELAE; ENDOCARDITIS; SEROPREVALENCE; INFECTION	Background Infection with Bartonella quintana can cause french fever, endocarditis, bacillary angiomatosis, and peliosis. An outbreak of bacteremia due to B. quintana has been reported among homeless people in Seattle, and the seroprevalence is high among homeless people in both the United States and Europe. Body lice are known to be the vectors of B. quintana. Methods We studied all the homeless people who presented in 1997 to the emergency departments of the University Hospital, Marseiiles, France. Blood was collected for microimmunofluorescence testing for antibodies against B. quintana and for culture of the bacterium. Body lice were collected and analyzed by the polymerase chain reaction and sequencing of a portion of the citrate synthase gene of B. quintana. Results in 10 of 71 homeless patients (14 percent), blood cultures were positive for B. quintana, and 21 of the patients (30 percent) had high titers of antibody against the organism. A total of 17 patients (24 percent) had evidence of recent infection (bacteremia or seroconversion). Tests of lice from 3 of the 15 patients from whom they were collected were positive for B. quintana. The homeless people with B. quintana bacteremia were more likely to have been exposed to lice (P=0.002), were more likely to have headaches (P=0.03) and severe leg pain (P<0.001), and had lower platelet counts (P=0.006) than the homeless people who were seronegative for B. quintana and did not have bacteremia; 8 of the 10 patients with bacteremia were afebrile. Five patients had chronic bacteremia, as indicated by positive blood cultures over a period of several weeks. Conclusions in an outbreak of urban trench fever among homeless people in Marseiiles, B. quintana infections were associated with body lice in patients with nonspecific symptoms or no symptoms. (N Engl J Med 1999;340:184-9.) (C) 1999, Massachusetts Medical Society.	Fac Med Marseille, Unite Rickettsies, CNRS, UPRES A 6020, F-13885 Marseille, France; Assistance Publ Hop Marseille, Ctr Hosp Univ Felix Houphouet Boigny, Serv Malad Infect & Trop, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Brouqui, P (corresponding author), Fac Med Marseille, Unite Rickettsies, CNRS, UPRES A 6020, 27 Blvd J Moulin, F-13885 Marseille, France.		LA SCOLA, Bernard/P-6477-2016; RAOULT, Didier/A-8434-2008; Brouqui, Philippe/P-5771-2016	LA SCOLA, Bernard/0000-0001-8006-7704; RAOULT, Didier/0000-0002-0633-5974; 				AZAD AF, 1992, P NATL ACAD SCI USA, V89, P43, DOI 10.1073/pnas.89.1.43; Birtles RJ, 1996, INT J SYST BACTERIOL, V46, P891, DOI 10.1099/00207713-46-4-891; Brenner SA, 1997, J CLIN MICROBIOL, V35, P544, DOI 10.1128/JCM.35.3.544-547.1997; Brouqui P, 1996, CLIN INFECT DIS, V23, P756, DOI 10.1093/clinids/23.4.756; Byam W, 1919, TRENCH FEVER LOUSE B; CHOMEL BB, 1995, J CLIN MICROBIOL, V33, P2445, DOI 10.1128/JCM.33.9.2445-2450.1995; Comer JA, 1996, ARCH INTERN MED, V156, P2491, DOI 10.1001/archinte.156.21.2491; Drancourt M, 1996, J CLIN MICROBIOL, V34, P1158, DOI 10.1128/JCM.34.5.1158-1160.1996; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; Drancourt M, 1996, LANCET, V347, P441, DOI 10.1016/S0140-6736(96)90012-4; DRANCOURT M, 1996, LANCET, V347, P842; Jackson LA, 1996, J INFECT DIS, V173, P1023, DOI 10.1093/infdis/173.4.1023; Koehler JE, 1997, NEW ENGL J MED, V337, P1876, DOI 10.1056/NEJM199712253372603; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P1655, DOI 10.1128/JCM.33.6.1655-1656.1995; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P3245, DOI 10.1128/JCM.33.12.3245-3251.1995; KOSTRZEWSKI J, 1949, Bull Int Acad Pol Sci Let Cl Med, V7, P233; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; LaScola B, 1996, J CLIN MICROBIOL, V34, P2270, DOI 10.1128/JCM.34.9.2270-2274.1996; Maurin M, 1996, CLIN MICROBIOL REV, V9, P273, DOI 10.1128/CMR.9.3.273; MCNEE JW, 1916, BRIT MED J, V225, P34; MOOSER H, 1959, P 6 INT C TROP MED M, V5, P631; Raoult D, 1998, LANCET, V352, P353, DOI 10.1016/S0140-6736(97)12433-3; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; Raoult D, 1996, ANN INTERN MED, V125, P646, DOI 10.7326/0003-4819-125-8-199610150-00004; RAOULT D, 1997, ANN INTERN MED, V127, P249; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STEIN A, 1995, LANCET, V345, P450, DOI 10.1016/S0140-6736(95)90430-1; Swift HF, 1920, ARCH INTERN MED, V26, P76, DOI 10.1001/archinte.1920.00100010079006; VINSON JW, 1969, AM J TROP MED HYG, V18, P713, DOI 10.4269/ajtmh.1969.18.713; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	32	202	212	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					184	189		10.1056/NEJM199901213400303	http://dx.doi.org/10.1056/NEJM199901213400303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895398				2022-12-28	WOS:000078202900003
J	Drazen, JM; Israel, E; O'Byrne, PM				Drazen, JM; Israel, E; O'Byrne, PM			Treatment of asthma with drugs modifying the leukotriene pathway	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SLOW-REACTING SUBSTANCE; ASPIRIN-INDUCED ASTHMA; INDUCED AIRWAY RESPONSES; EXERCISE-INDUCED ASTHMA; ALLERGEN-INDUCED BRONCHOCONSTRICTION; RECEPTOR ANTAGONIST MK-0679; 5-LIPOXYGENASE INHIBITOR; SMOOTH-MUSCLE; D-4-RECEPTOR ANTAGONIST; MICROVASCULAR LEAKAGE		Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Partners Asthma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; McMaster University	Drazen, JM (corresponding author), Brigham & Womens Hosp, Resp Dis Div, 75 Francis St, Boston, MA 02115 USA.		Drazen, Jeffrey M/E-5841-2012	O'Byrne, Paul/0000-0003-0979-281X; Drazen, Jeffrey/0000-0003-2715-9890				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; [Anonymous], 1990, BRIT MED J, V301, P651; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; Barnes NC, 1997, THORAX, V52, P523, DOI 10.1136/thx.52.6.523; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; COHEN P, 1995, AM J PHYSIOL-LUNG C, V269, pL151, DOI 10.1152/ajplung.1995.269.2.L151; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAVIS C, 1982, J APPL PHYSIOL, V53, P1080, DOI 10.1152/jappl.1982.53.5.1080; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; DRAZEN JM, 1979, J CLIN INVEST, V63, P1, DOI 10.1172/JCI109262; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; Evans DJ, 1996, THORAX, V51, P1178, DOI 10.1136/thx.51.12.1178; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HUI KP, 1991, AM REV RESPIR DIS, V143, P1015, DOI 10.1164/ajrccm/143.5_Pt_1.1015; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JONES TR, 1982, CAN J PHYSIOL PHARM, V60, P638, DOI 10.1139/y82-087; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KNAPP HR, 1992, J LAB CLIN MED, V119, P48; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lazarus SC, 1997, AM J RESP CRIT CARE, V156, P1725, DOI 10.1164/ajrccm.156.6.9608006; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MACLOUF J, 1992, AM J PHYSIOL, V263, pH244, DOI 10.1152/ajpheart.1992.263.1.H244; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; MCCORMICK PA, 1990, BRIT MED J, V301, P924, DOI 10.1136/bmj.301.6757.924; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; *MERCK, 1998, SING MONT SOD; MINAMI M, 1987, J BIOL CHEM, V262, P13873; MUNOZ NM, 1995, AM J PHYSIOL-LUNG C, V268, pL446, DOI 10.1152/ajplung.1995.268.3.L446; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murphy RC, 1998, LUNG BIOL HEALTH DIS, V120, P87; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NASSER SMS, 1994, THORAX, V49, P743, DOI 10.1136/thx.49.8.743; *NAT ASTHM ED PROG, 1991, NIH PUBL; *NAT ASTHM ED PROG, 1997, NIH PUBL; *NAT HEART LUNG BL, 1995, NIH PUBL; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PASQUALE D, 1993, EXP HEMATOL, V21, P1361; PIACENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; PIPER PJ, 1983, BRIT MED BULL, V39, P255, DOI 10.1093/oxfordjournals.bmb.a071829; Porreca E, 1996, THROMB HAEMOSTASIS, V76, P99; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; RUBINSTEIN I, 1987, NEW ENGL J MED, V317, P482, DOI 10.1056/NEJM198708203170805; SALA A, 1990, J BIOL CHEM, V265, P21771; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Schwartz HJ, 1998, ARCH INTERN MED, V158, P141, DOI 10.1001/archinte.158.2.141; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; SPENCER DA, 1991, THORAX, V46, P441, DOI 10.1136/thx.46.6.441; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TAYLOR IK, 1992, J APPL PHYSIOL, V73, P743, DOI 10.1152/jappl.1992.73.2.743; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; WASSERMAN MA, 1995, ADV PROSTAG THROMB L, V23, P271; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; *ZYFLO FILMT, 1998, PHYS DESK REF, P474	111	615	643	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					197	206		10.1056/NEJM199901213400306	http://dx.doi.org/10.1056/NEJM199901213400306			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895400				2022-12-28	WOS:000078202900006
J	LaCasse, RA; Follis, KE; Trahey, M; Scarborough, JD; Littman, DR; Nunberg, JH				LaCasse, RA; Follis, KE; Trahey, M; Scarborough, JD; Littman, DR; Nunberg, JH			RETRACTED: Fusion-competent vaccines broad neutralization of primary isolates of HIV (Retracted article. See vol 296, pg 1025, 2002)	SCIENCE			English	Article; Retracted Publication							HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; ENVELOPE GLYCOPROTEINS; TYPE-1; GP120; PREVENTION; SEROTYPES; BINDING; PATHOGENESIS; IMMUNIZATION	Current recombinant human immunodeficiency virus (HIV) gp120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, "fusion-competent" HIV vaccine immunogens were generated that capture the transient envelope-CD4-coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E, Development of these fusion-dependent immunogens may Lead to a broadly effective HIV vaccine.	Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; NYU Med Ctr, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA	University of Montana System; University of Montana; University of Montana System; University of Montana; Howard Hughes Medical Institute; New York University	Nunberg, JH (corresponding author), Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA.	nunberg@selway.umt.edu			NIAID NIH HHS [AI41165, AI33856] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033856, R15AI041165] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475; Berger EA, 1997, AIDS, V11, pS3; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; COHEN J, 1994, SCIENCE, V264, P1839, DOI 10.1126/science.8009201; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1997, IMMUNOL RES, V16, P15, DOI 10.1007/BF02786321; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Follis KE, 1998, J VIROL, V72, P7603, DOI 10.1128/JVI.72.9.7603-7608.1998; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; Guillon C, 1995, AIDS RES HUM RETROV, V11, P1537, DOI 10.1089/aid.1995.11.1537; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288; Kostrikis LG, 1996, J VIROL, V70, P445, DOI 10.1128/JVI.70.1.445-458.1996; Krause RM, 1997, J INFECT DIS, V176, P549, DOI 10.1086/514074; LaCasse RA, 1998, J VIROL, V72, P2491, DOI 10.1128/JVI.72.3.2491-2495.1998; Langlois AJ, 1998, J VIROL, V72, P6950, DOI 10.1128/JVI.72.8.6950-6955.1998; Lee S, 1997, J VIROL, V71, P6037, DOI 10.1128/JVI.71.8.6037-6043.1997; Mascola JR, 1996, AIDS RES HUM RETROV, V12, P1319, DOI 10.1089/aid.1996.12.1319; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Montefiori DC, 1998, J VIROL, V72, P3427, DOI 10.1128/JVI.72.4.3427-3431.1998; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; MOORE JP, 1989, AIDS, V3, P155, DOI 10.1097/00002030-198903000-00006; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; PUTKONEN P, 1993, J MED PRIMATOL, V22, P100; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; SCARBOROUGH JD, 1993, EMBO J, V12, P1547; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1998, J VIROL, V72, P1876, DOI 10.1128/JVI.72.3.1876-1885.1998; VERSCHOOR EJ, 1995, VET IMMUNOL IMMUNOP, V46, P139, DOI 10.1016/0165-2427(94)07013-W; Weber J, 1996, J VIROL, V70, P7827, DOI 10.1128/JVI.70.11.7827-7832.1996; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995; YAMAMOTO JK, 1991, AIDS RES HUM RETROV, V7, P911, DOI 10.1089/aid.1991.7.911	50	192	229	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					357	362		10.1126/science.283.5400.357	http://dx.doi.org/10.1126/science.283.5400.357			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888845				2022-12-28	WOS:000078067000039
J	Kuttner, R				Kuttner, R			The American Health Care System - Health insurance coverage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*BUR CENS, 1998, DYN EC WELL BEING HL; *BUR CENS, 1998, CENS BRIEF CHILDR HL; *BUR CENS, 1998, HLTH INS COV 1997; *CA MAN RISK MED I, 1998, HEALTH FAM PROGR SUB; *DEP HLTH HUM SERV, 1997, RUL PACK IMPL, P72; *FAM US, 1997, ON OUT 3 KIDS HLTH I, P5; *FAM US, 1997, ONE OUT 3 KIDS HLTH; FREUDENHEIM M, 1998, NY TIMES        0424, pA1; FRONSTIN P, 1998, FEATURES EMPLOYMENT; GABEL J, 1998, FINANCIAL BURDEN SEL; *GEN ACC OFF, 1996, 96129 GAOHEHS; GREENBERG M, 1998, PARTICIPATION WELFAR; *HJ KAIS FAM FDN, 1988, NAT SURV SMALL BUS E; KILBORN P, 1998, NY TIMES        1205, pA7; Kuttner R, 1997, NEW ENGL J MED, V337, P64, DOI 10.1056/NEJM199707033370123; LAGNADO L, 1998, WALL STREET J   1117, pA1; *LEW GROUP, 1998, CURR KNOWL 3 PART OU, P7; *LEW GROUP, 1998, CURR KNOWL 3 PART OU, P4; *LEW GROUP, 1998, CURR KNOWL 3 PART OU, P19; *LEW GROUP, 1998, CURR KNOW 3 PART OUT, P13; *LEW GROUP, 1998, CURR KNOWL 3 PART OU; McCormack LA, 1996, HEALTH CARE FINANC R, V18, P157; MISHEL L, 1998, STATE WORKING AM 199, P243; Pear Robert, 1998, N Y Times Web, pA17; Pear Robert, 1998, NEW YORK TIMES  1226, pA20; Schoen C., 1998, WORKING FAMILIES RIS, P25; SCHOEN C, 1998, WORKING FAMILIES RIS; SHEARER G, 1998, HIDDEN VIEW GROWING, P9; TANOUYE E, 1998, WALL STREET J   1116, pA1; 1998, CLOSING HUGE HOLE ME	30	72	73	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					163	168		10.1056/NEJM199901143400226	http://dx.doi.org/10.1056/NEJM199901143400226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887170				2022-12-28	WOS:000078016200030
J	Nightingale, SL				Nightingale, SL			New requirement for patient labeling for selected prescription drug products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					27	27		10.1001/jama.281.1.27	http://dx.doi.org/10.1001/jama.281.1.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892435				2022-12-28	WOS:000077829300008
J	Goldbeck-Wood, S				Goldbeck-Wood, S			Evidence on peer review - scientific quality control or smokescreen?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION BIAS		BMJ, London WC1H 9HR, England		Goldbeck-Wood, S (corresponding author), BMJ, London WC1H 9HR, England.	10176.2501@compuserve.com						BAILAR JC, 1985, NEW ENGL J MED, V312, P654, DOI 10.1056/NEJM198503073121023; Black N, 1998, JAMA-J AM MED ASSOC, V280, P231, DOI 10.1001/jama.280.3.231; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Cho MK, 1998, JAMA-J AM MED ASSOC, V280, P243, DOI 10.1001/jama.280.3.243; Dickersin K, 1998, JAMA-J AM MED ASSOC, V280, P260, DOI 10.1001/jama.280.3.260; Goldbeck-Wood S, 1998, BRIT MED J, V316, P86; Joyce J, 1998, JAMA-J AM MED ASSOC, V280, P264, DOI 10.1001/jama.280.3.264; Junker CA, 1998, JAMA-J AM MED ASSOC, V280, P247, DOI 10.1001/jama.280.3.247; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; Link AM, 1998, JAMA-J AM MED ASSOC, V280, P246, DOI 10.1001/jama.280.3.246; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; Misakian AL, 1998, JAMA-J AM MED ASSOC, V280, P250, DOI 10.1001/jama.280.3.250; RENNIE D, 1990, JAMA-J AM MED ASSOC, V263, P1317, DOI 10.1001/jama.1990.03440100011001; Rennie D, 1998, JAMA-J AM MED ASSOC, V280, P214, DOI 10.1001/jama.280.3.214; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; van Rooyen S, 1999, BRIT MED J, V318, P23; Weber EJ, 1998, JAMA-J AM MED ASSOC, V280, P257, DOI 10.1001/jama.280.3.257; 1998, JAMA, V280, P203	21	55	57	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1999	318	7175					44	45						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872890				2022-12-28	WOS:000078013100031
J	Hoddinott, P; Pill, R				Hoddinott, P; Pill, R			Qualitative study of decisions about infant feeding among women in east end of London	BRITISH MEDICAL JOURNAL			English	Article								Objective To improve understanding of how first time mothers who belong to a socioeconomic group with particularly low rates of breast feeding decide whether or not to initiate breast feeding. Design Qualitative semistructured interviews early in pregnancy and 6-10 weeks after birth. Setting Women's homes in east end of London. Subjects 21 white, low income women expecting their first baby were interviewed mostly at home, often with their partner or a relative. Two focus groups were conducted. Results Women who had regularly seen a relative or friend successfully breast feed and described this experience positively were more confident about and committed to breast feeding. They were also more likely to succeed. Exposure to breast feeding, however, could be either a positive or a negative influence on the decision to breast feed, depending on the context Women who had seen breast feeding only by a stranger often described this as a negative influence, particularly if other people were present. All women knew that breast feeding has health benefits. Ownership of this knowledge, however, varied according to the woman's experience of seeing breast feeding. Conclusions The decision to initiate breast feeding is influenced more by embodied knowledge gained from seeing breast feeding than by theoretical knowledge about its benefits. Breast feeding involves performing a practical skill, often with others present The knowledge, confidence, and commitment necessary to breast feed may be more effectively gained through antenatal apprenticeship to a breastfeeding mother than from advice given in consultations or from books.	Macduff Med Practice, Macduff AB44 1PR, Banff, Scotland; Univ Wales, Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	Cardiff University	Hoddinott, P (corresponding author), Macduff Med Practice, Macduff AB44 1PR, Banff, Scotland.	hoddinott@dial.pipexcom	Hoddinott, Pat/F-9090-2011; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Hoddinott, Pat/0000-0002-4372-9681				BOND S, 1991, DEV VALIDATION INSTR; Foster K, 1997, INFANT FEEDING 1995; HALLY MR, 1984, ACTA PAEDIATR SCAND, V73, P33, DOI 10.1111/j.1651-2227.1984.tb09894.x; HASTRUP K, 1995, PASSAGE ANTHR EXPERI, P1; Henschel D, 1989, Nurs Stand, V4, P54; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; MACLEAN HM, 1989, HLTH PROMOTION, V3, P355; MANSTEAD ASR, 1983, J PERS SOC PSYCHOL, V44, P657, DOI 10.1037/0022-3514.44.4.657; MCINTOSH J, 1985, MIDWIFERY, V1, P213, DOI DOI 10.1016/S0266-6138(85)80019-X; Miles M., 2013, QUALITATIVE DATA ANA; *NAT BREASTF WORK, 1995, BREASTF GOOD PRACT G; Patton M. Q., 1990, QUALITATIVE EVALUATI; Potter J., 1995, ANAL QUALITATIVE DAT, P47; RENFREW MJ, 1995, COCHRANE LIBRARY; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [10.4324/9780203413081, DOI 10.4324/9780203413081_CHAPTER_9]; Strauss A., 1990, BASICS QUALITATIVE R; WHITE AS, 1992, INFANT FEEDING 1990; WHO/UNICEF, 1989, WHO UNICEF JOINT STA; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; WYLIE J, 1994, J HUM NUTR DIET, V7, P115, DOI 10.1111/j.1365-277X.1994.tb00418.x; [No title captured]	24	137	141	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					30	34						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872883	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078013100026
J	Marcus, GF; Vijayan, S; Rao, SB; Vishton, PM				Marcus, GF; Vijayan, S; Rao, SB; Vishton, PM			Rule learning by seven-month-old infants	SCIENCE			English	Article							LANGUAGE-ACQUISITION; SPEECH; WORDS	A fundamental task of language acquisition is to extract abstract algebraic rules. Three experiments show that 7-month-old infants attend longer to sentences with unfamiliar structures than to sentences with familiar structures. The design of the artificial language task used in these experiments ensured that this discrimination could not be performed by counting, by a system that is sensitive only to transitional probabilities, or by a popular class of simple neural network models. Instead, these results suggest that infants can represent, extract, and generalize abstract algebraic rules.	NYU, Dept Psychol, New York, NY 10003 USA; Amherst Coll, Dept Psychol, Amherst, MA 01002 USA	New York University; Amherst College	Marcus, GF (corresponding author), NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.							Bates E, 1996, SCIENCE, V274, P1849, DOI 10.1126/science.274.5294.1849; Berent I, 1997, COGNITION, V64, P39, DOI 10.1016/S0010-0277(97)00016-4; BIJELJACBABIC R, 1993, DEV PSYCHOL, V29, P711, DOI 10.1037/0012-1649.29.4.711; Chomsky N, 1980, RULES REPRESENTATION; DIENES Z, 1995, NEURAL COMPUTATION P; ELMAN JL, 1990, COGNITIVE SCI, V14, P179, DOI 10.1207/s15516709cog1402_1; GOMEZ RL, 1997, ANN M PSYCH SOC PHIL; GOMEZ RL, 1997, BOSTON U C LANGUAGE, V21, P194; GOODSITT JV, 1984, CHILD DEV, V55, P903, DOI 10.2307/1130141; Hummel JE, 1997, PSYCHOL REV, V104, P427, DOI 10.1037/0033-295X.104.3.427; JUSCZYK PW, 1995, COGNITIVE PSYCHOL, V29, P1, DOI 10.1006/cogp.1995.1010; MARCUS G, 1999, IN PRESS ALGEBRAIC M; Marcus G. F., 1995, COGNITIVE PSYCHOL, V29, P186; Marcus GF, 1998, COGNITION, V66, P153, DOI 10.1016/S0010-0277(98)00018-3; MARCUS GF, IN PRESS COGN PSYCHO; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; REBER AS, 1969, J EXP PSYCHOL, V81, P115, DOI 10.1037/h0027454; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Seidenberg MS, 1997, SCIENCE, V275, P1599, DOI 10.1126/science.275.5306.1599	20	735	742	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					77	80		10.1126/science.283.5398.77	http://dx.doi.org/10.1126/science.283.5398.77			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155ZH	9872745				2022-12-28	WOS:000077976600053
J	Vandenbroucke, JP				Vandenbroucke, JP			Medical journals and the shaping of medical knowledge	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; ORAL-CONTRACEPTIVES; VENOUS THROMBOEMBOLISM; CLINICAL-TRIALS; METAANALYSIS; RISK		Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Bldg 1,POB 9600, NL-2300 RC Leiden, Netherlands.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; [Anonymous], 1823, LANCET, V1, P1; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; BENSHLOMO Y, 1994, BRIT MED J, V309, P274, DOI 10.1136/bmj.309.6949.274; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CULLEN W, 1987, P R COLL PHYSICIANS, V18, P204; Davidoff F, 1998, ANN INTERN MED, V129, P327, DOI 10.7326/0003-4819-129-4-199808150-00011; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; FOX T, 1965, CRISIS COMMUNMICATIO; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Light RJ, 1984, SUMMING SCI REVIEWIN; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; LINDEGAARD O, 1998, CONTRACEPTION, V57, P291; Morabia A, 1996, J CLIN EPIDEMIOL, V49, P1327, DOI 10.1016/S0895-4356(96)00294-6; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x; Smith R, 1998, BMJ-BRIT MED J, V317, P291, DOI 10.1136/bmj.317.7154.291; SPITZER WO, 1996, BMJ-BRIT MED J, V312, P82; Thomas DP, 1997, THROMB HAEMOSTASIS, V78, P1422	23	67	70	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					2001	2006		10.1016/S0140-6736(98)10208-8	http://dx.doi.org/10.1016/S0140-6736(98)10208-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872263				2022-12-28	WOS:000077663000044
J	Kuttner, R				Kuttner, R			The risk-adjustment debate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		*AM SOC INT MED, 1995, ASS APPR PAT CAR UND, P18; Bertko J, 1998, INQUIRY-J HEALTH CAR, V35, P148; Dunn DL, 1998, INQUIRY-J HEALTH CAR, V35, P132; ENTHOVEN AC, 1980, HLTH PLAN ONLY PRACT, P81; FILES A, 1995, INQUIRY-J HEALTH CAR, V32, P300; GLENNERSTER H, 1994, INT J HEALTH SERV, V24, P231, DOI 10.2190/BLNN-D9NE-G3XQ-WPEW; GOLDFIELD N, 1996, PHYSCIAN PROFILING R, P120; Hornbrook M C, 1998, Eff Clin Pract, V1, P66; Iezzoni LI, 1998, NEW ENGL J MED, V339, P1933, DOI 10.1056/NEJM199812243392613; Knutson DL, 1998, INQUIRY-J HEALTH CAR, V35, P171; Kuttner R, 1998, NEW ENGL J MED, V338, P1558, DOI 10.1056/NEJM199805213382123; Newhouse JP, 1998, INQUIRY-J HEALTH CAR, V35, P122; PADGUG RA, 1995, J ACQ IMMUN DEF SYND, V8, pS67; SHMUELI A, 1998, GOVT HLTH SYSTEMS IM, P202; STARR P, 1992, LOGIC HLTH CARE REFO; STONE DA, 1993, J HEALTH POLIT POLIC, V18, P287, DOI 10.1215/03616878-18-2-287; SWARTZ K, 1995, INQUIRY-J HEALTH CAR, V32, P6; Swartz K, 1998, INQUIRY-J HEALTH CAR, V35, P101; Tollen L, 1998, INQUIRY-J HEALTH CAR, V35, P154; vanBarneveld EM, 1996, INQUIRY-J HEALTH CAR, V33, P133; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; Wilson VM, 1998, INQUIRY-J HEALTH CAR, V35, P178	22	34	34	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1952	1956		10.1056/NEJM199812243392625	http://dx.doi.org/10.1056/NEJM199812243392625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	150ZN	9874620				2022-12-28	WOS:000077696600032
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 66-year-old woman with ulcerative colitis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Peppercorn MA, 1998, JAMA-J AM MED ASSOC, V279, P949, DOI 10.1001/jama.279.12.949	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2118	2118		10.1001/jama.280.24.2118	http://dx.doi.org/10.1001/jama.280.24.2118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875881				2022-12-28	WOS:000077606100037
J	Wee, CC; Phillips, RS; Aurigemma, G; Erban, S; Kriegel, G; Riley, M; Douglas, PS				Wee, CC; Phillips, RS; Aurigemma, G; Erban, S; Kriegel, G; Riley, M; Douglas, PS			Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication	ANNALS OF INTERNAL MEDICINE			English	Article							MITRAL REGURGITATION; DOPPLER	Background: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market. Objective: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications. Design: Cohort study. Setting: Academic primary care practices. Patients: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy. Measurements: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one deg ree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation). Results: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease. One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation. The second patient developed new moderate aortic insufficiency. Conclusion: Users of diet medications are at risk for valvular heart disease. However, the incidence may be lower than that reported previously.	Beth Israel Deaconess Med Ctr, Div Gen Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Massachusetts, Med Ctr, Div Cardiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Wee, CC (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049	BHP HRSA HHS [5 T32 PE11001] Funding Source: Medline	BHP HRSA HHS		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; Klein A L, 1990, J Am Soc Echocardiogr, V3, P54; *MA MED SOC COMM N, 1996, OB TREATM US DRUG TH; OTTO CM, 1995, TXB CLIN ECHOCARDIOG, P247; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; REDFIELD MM, 1992, ANN INTERN MED, V117, P50, DOI 10.7326/0003-4819-117-1-50; REID CL, 1992, AM HEART J, V124, P657, DOI 10.1016/0002-8703(92)90274-Y; REID CL, 1994, CIRCULATION, V90, P1519; SPAIN MG, 1989, J AM COLL CARDIOL, V13, P585, DOI 10.1016/0735-1097(89)90597-4; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; WEYMAN AE, 1994, PRINCIPLES PRACTICE, P431	16	49	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819			ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					870	874		10.7326/0003-4819-129-11_Part_1-199812010-00005	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867728				2022-12-28	WOS:000077239200004
J	Bhalla, US; Iyengar, R				Bhalla, US; Iyengar, R			Emergent properties of networks of biological signaling pathways	SCIENCE			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; INOSITOL TRISPHOSPHATE; CATALYTIC ACTIVITY; ADENYLYL CYCLASES; ACTIVATES RAF-1; CYCLIC-AMP; AREA CA1; CALCIUM; PHOSPHORYLATION	Many distinct signaling pathways allow the cell to receive, process, and respond to information. Often, components of different pathways interact, resulting in signaling networks. Biochemical signaling networks were constructed with experimentally obtained constants and analyzed by computational methods to understand their role in complex biological processes. These ner:works exhibit emergent properties such as integration of signals across multiple time scales, generation of distinct outputs depending on input strength and duration, and self-sustaining feedback Loops. Feedback can result in bistable behavior with discrete steady-state activities, well-defined input thresholds for transition between states and prolonged signal output, and signal modulation in response to transient stimuli. These properties of signaling networks raise the possibility that information for "learned behavior" of biological systems may be stored within intracellular biochemical reactions that comprise signaling pathways.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Natl Ctr Biol Sci, Bangalore 560012, Karnataka, India	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BHALLA US, 1998, BOOK GENESIS EXPLORI, pCH10; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DESCHUTTER E, 1993, NEURAL COMPUT, V5, P681, DOI 10.1162/neco.1993.5.5.681; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HESTRIN S, 1990, J PHYSL, V422, P302; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KREBS EG, 1956, J BIOL CHEM, V218, P483; LAI CY, 1980, CRC CR REV BIOCH MOL, V9, P171, DOI 10.3109/10409238009105434; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PUEFFER T, 1977, J BIOL CHEM, V252, P7244; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Staubli U, 1996, J NEUROSCI, V16, P853; SUTHERLAND EW, 1955, NATURE, V175, P169, DOI 10.1038/175169a0; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TRAUB RD, 1991, J NEUROPHYSIOL, V66, P635, DOI 10.1152/jn.1991.66.2.635; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	57	1156	1205	3	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					381	387		10.1126/science.283.5400.381	http://dx.doi.org/10.1126/science.283.5400.381			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888852				2022-12-28	WOS:000078067000046
J	Talan, DA; Citron, DM; Abrahamian, FM; Moran, GJ; Goldstein, EJC				Talan, DA; Citron, DM; Abrahamian, FM; Moran, GJ; Goldstein, EJC		Emergency Med Anim Bite Infection Study Grp	Bacteriologic analysis of infected dog and cat bites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ANTIMICROBIAL AGENTS; WOUNDS; PASTEURELLA; HUMANS; SPARFLOXACIN; ANTIBIOTICS; HOMOLOGY; FLORA	Background and Methods To define better the bacteria responsible for infections of dog and cat bites, we conducted a prospective study at 18 emergency departments. To be eligible for enrollment, patients had to meet one of three major criteria for infection of a bite wound (fever, abscess, and lymphangitis) or four of five minor criteria (wound-associated erythema, tenderness at the wound site, swelling at the site, purulent drainage, and leukocytosis). Wound specimens were cultured for aerobic and anaerobic bacteria at a research microbiology laboratory and, in some cases, at local hospital laboratories. Results The infected wounds of 50 patients with dog bites and 57 patients with cat bites yielded a median of 5 bacterial isolates per culture (range, 0 to 16) at the reference laboratory. Significantly more isolates grew at the reference laboratory than at the local laboratories (median, 1; range, 0 to 5; P<0.001). Aerobes and anaerobes were isolated from 56 percent of the wounds, aerobes alone from 36 percent, and anaerobes alone from 1 percent; 7 percent of cultures had no growth. Pasteurella species were the most frequent isolates from both dog bites (50 percent) and cat bites (75 percent). Pasteurella canis was the most common isolate of dog bites, and Past. multocida subspecies multocida and septica were the most common isolates of cat bites. Other common aerobes included streptococci, staphylococci, moraxella, and neisseria. Common anaerobes included fusobacterium, bacteroides, porphyromonas, and prevotella. Isolates not previously identified as human pathogens included Reimerella anatipestifer from two cat bites and Bacteroides tectum, Prevotella heparinolytica, and several porphyromonas species from dog and cat bites. Erysipelothrix rhusiopathiae was isolated from two cat bites. Patients were most often treated with a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor, which, on the basis of the microbiologic findings, was appropriate therapy. Conclusions Infected dog and cat bites have a complex microbiologic mix that usually includes pasteurella species but may also include many other organisms not routinely identified by clinical microbiology laboratories and not previously recognized as bite-wound pathogens. (N Engl J Med 1999;340: 85-92.) (C) 1999, Massachusetts Medical Society.	Olive View UCLA Med Ctr, Dept Med, Div Emergency Med, Sylmar, CA 91342 USA; Olive View UCLA Med Ctr, Dept Med, Div Infect Dis, Sylmar, CA 91342 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Med Ctr, RM Alden Res Lab, Santa Monica, CA USA; Maricopa Integrated Hlth Syst, Dept Emergency Med, Tucson, AZ USA; Univ Arizona, Coll Med, Tucson, AZ USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Maricopa County General Hospital; University of Arizona	Talan, DA (corresponding author), Olive View UCLA Med Ctr, Dept Med, Div Emergency Med, 14445 Olive View Dr,N Annex, Sylmar, CA 91342 USA.							AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; Alexander CJ, 1997, J CLIN MICROBIOL, V35, P406, DOI 10.1128/JCM.35.2.406-411.1997; BAILIE WE, 1978, J CLIN MICROBIOL, V7, P223; BARON EJ, 1995, CLIN INFECT DIS, V20, pS174, DOI 10.1093/clinids/20.Supplement_2.S174; BIBERSTEIN EL, 1991, J VET DIAGN INVEST, V3, P319, DOI 10.1177/104063879100300408; BRACIS R, 1979, WESTERN J MED, V131, P438; BROOK I, 1987, PEDIATR INFECT DIS J, V6, P29, DOI 10.1097/00006454-198701000-00008; CALLAHAM M, 1980, ANN EMERG MED, V9, P410, DOI 10.1016/S0196-0644(80)80153-3; CALLAHAM ML, 1978, JACEP-J AM COLL EMER, V7, P83, DOI 10.1016/S0361-1124(78)80063-X; Citron DM, 1996, CLIN INFECT DIS, V23, pS78, DOI 10.1093/clinids/23.Supplement_1.S78; CUMMINGS P, 1994, ANN EMERG MED, V23, P535, DOI 10.1016/S0196-0644(94)70073-7; DOUGLAS LG, 1975, AM FAM PHYSICIAN, V11, P93; ELENBAAS RM, 1984, ANN EMERG MED, V13, P155, DOI 10.1016/S0196-0644(84)80604-6; ELLIOT DL, 1985, NEW ENGL J MED, V313, P985, DOI 10.1056/NEJM198510173131605; ESCANDE F, 1993, INT J MED MICROBIOL, V297, P131; FEDER HM, 1987, PEDIATR INFECT DIS J, V6, P24, DOI 10.1097/00006454-198701000-00007; GANIERE JP, 1993, COMP IMMUNOL MICROB, V16, P77, DOI 10.1016/0147-9571(93)90064-C; GOLDSTEIN EJC, 1993, ANTIMICROB AGENTS CH, V37, P1150, DOI 10.1128/AAC.37.5.1150; GOLDSTEIN EJC, 1988, ANTIMICROB AGENTS CH, V32, P1143, DOI 10.1128/AAC.32.8.1143; GOLDSTEIN EJC, 1978, J CLIN MICROBIOL, V8, P667; Goldstein EJC, 1998, ANTIMICROB AGENTS CH, V42, P1127, DOI 10.1128/AAC.42.5.1127; Goldstein EJC, 1998, J ANTIMICROB CHEMOTH, V41, P391, DOI 10.1093/jac/41.3.391; GOLDSTEIN EJC, 1995, ANTIMICROB AGENTS CH, V39, P1097, DOI 10.1128/AAC.39.5.1097; Goldstein EJC, 1997, ANTIMICROB AGENTS CH, V41, P1552, DOI 10.1128/AAC.41.7.1552; GOLDSTEIN EJC, 1988, ANTIMICROB AGENTS CH, V32, P3213; Holdeman L. V., 1997, ANAEROBE LAB MANUAL; HOLST E, 1992, J CLIN MICROBIOL, V30, P2984, DOI 10.1128/JCM.30.11.2984-2987.1992; Holt J., 1994, BERGEYS MANUAL DETER; Hudspeth MK, 1997, J CLIN MICROBIOL, V35, P2450, DOI 10.1128/JCM.35.10.2450-2453.1997; JONES DA, 1985, POSTGRAD MED J, V61, P593, DOI 10.1136/pgmj.61.717.593; LAUER EA, 1982, AM J DIS CHILD, V136, P202, DOI 10.1001/archpedi.1982.03970390016003; Lion C, 1996, EUR J EPIDEMIOL, V12, P521, DOI 10.1007/BF00144007; MURRAY PR, 1995, MANUL CLIN MICROBIOL; MUTTERS R, 1985, INT J SYST BACTERIOL, V35, P309, DOI 10.1099/00207713-35-3-309; SAPHIR DA, 1976, J CLIN MICROBIOL, V3, P344; SEGERS P, 1993, INT J SYST BACTERIOL, V43, P768, DOI 10.1099/00207713-43-4-768; SKURKA J, 1986, INFECTION, V14, P134, DOI 10.1007/BF01643478; Summanen P., 1993, WADSWORTH ANAEROBIC; TALAN DA, 1989, J CLIN MICROBIOL, V27, P78, DOI 10.1128/JCM.27.1.78-81.1989; THOMAS PR, 1987, MED J AUSTRALIA, V147, P536, DOI 10.5694/j.1326-5377.1987.tb133676.x; WEBER DJ, 1984, MEDICINE, V63, P133, DOI 10.1097/00005792-198405000-00001; Weiss HB, 1998, JAMA-J AM MED ASSOC, V279, P51, DOI 10.1001/jama.279.1.51; Weyant R. S., 1996, IDENTIFICATION UNUSU	43	500	533	3	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					85	92		10.1056/NEJM199901143400202	http://dx.doi.org/10.1056/NEJM199901143400202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887159				2022-12-28	WOS:000078016200002
J	Scalf, M; Westphall, MS; Krause, J; Kaufman, SL; Smith, LM				Scalf, M; Westphall, MS; Krause, J; Kaufman, SL; Smith, LM			Controlling charge states of large ions	SCIENCE			English	Article							PROTON-TRANSFER REACTIONS; IONIZATION MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; GAS-PHASE; PROTEINS; REDUCTION; OLIGONUCLEOTIDES; EVAPORATION; MOBILITY; ANIONS	The charge state of ions produced in electrospray ionization (ESI) was reduced in a controlled manner to yield predominantly singly charged species by exposure of the aerosol to a bipolar ionizing gas. Analysis of the resulting ions on an orthogonal time-of-flight mass spectrometer yielded mass spectra greatly simplified compared with conventional ESI spectra, The decreased spectral complexity afforded by the charge reduction facilitates the analysis of mixtures by ESI mass spectrometry.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Smith, LM (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000321, R01HG001808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01HG001808, R01HG00321] Funding Source: Medline; NIGMS NIH HHS [5T32GMO8349] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apffel A, 1997, ANAL CHEM, V69, P1320, DOI 10.1021/ac960916h; BOYLE JG, 1992, ANAL CHEM, V64, P2084, DOI 10.1021/ac00042a011; CHEN DR, 1995, J AEROSOL SCI, V26, P963, DOI 10.1016/0021-8502(95)00027-A; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; CHENG XH, 1995, ANAL CHEM, V67, P586, DOI 10.1021/ac00099a016; COOPER DW, 1973, J COLLOID INTERF SCI, V45, P17, DOI 10.1016/0021-9797(73)90239-7; Dawson J.H.J., 1989, RAPID COMMUN MASS SP, V3, P155, DOI [DOI 10.1002/RCM.1290030511, 10.1002/rcm.1290030511]; DOLE M, 1968, J CHEM PHYS, V49, P2240, DOI 10.1063/1.1670391; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fuchs N., 1963, GEOFIS PURA APPL, V56, P185, DOI [10.1007/BF01993343, DOI 10.1007/BF01993343]; IKONOMOU MG, 1991, J AM SOC MASS SPECTR, V2, P497, DOI 10.1016/1044-0305(91)80038-9; IRIBARNE JV, 1976, J CHEM PHYS, V64, P2287, DOI 10.1063/1.432536; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KAUFMAN S, UNPUB; Kaufman SL, 1996, ANAL CHEM, V68, P1895, DOI 10.1021/ac951128f; KAUFMAN SL, 1993, Patent No. 5247842; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; LEWIS KC, 1994, ANAL CHEM, V66, P2285, DOI 10.1021/ac00086a014; LIU BYH, 1974, J COLLOID INTERF SCI, V49, P305, DOI 10.1016/0021-9797(74)90366-X; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; MIRGORODSKAYA OA, 1994, ANAL CHEM, V66, P99, DOI 10.1021/ac00073a018; MIRZA UA, 1994, ANAL CHEM, V66, P2898, DOI 10.1021/ac00090a017; Mouradian S, 1997, ANAL CHEM, V69, P919, DOI 10.1021/ac960785k; Muddiman DC, 1996, J AM SOC MASS SPECTR, V7, P697, DOI 10.1016/1044-0305(96)80516-2; OGORZALEKLOO RR, 1991, J PHYS CHEM-US, V95, P6412; ROLLGEN FW, 1987, J PHYS-PARIS, V48, P253; SCHMELZEISENREDEKER G, 1989, INT J MASS SPECTROM, V90, P139, DOI 10.1016/0168-1176(89)85004-9; SMITH RD, 1990, J AM SOC MASS SPECTR, V1, P53, DOI 10.1016/1044-0305(90)80006-9; Stephenson JL, 1998, J AM SOC MASS SPECTR, V9, P585, DOI 10.1016/S1044-0305(98)00025-7; Stephenson JL, 1998, J MASS SPECTROM, V33, P664, DOI 10.1002/(SICI)1096-9888(199807)33:7<664::AID-JMS663>3.3.CO;2-G; Stephenson JL, 1996, ANAL CHEM, V68, P4026, DOI 10.1021/ac9605657; Stephenson JL, 1996, J AM CHEM SOC, V118, P7390, DOI 10.1021/ja9611755; Stephenson JL, 1997, J AM SOC MASS SPECTR, V8, P637, DOI 10.1016/S1044-0305(97)00023-8; Stephenson JL, 1997, RAPID COMMUN MASS SP, V11, P875, DOI 10.1002/(SICI)1097-0231(199705)11:8<875::AID-RCM934>3.0.CO;2-K; Stephenson JL, 1997, INT J MASS SPECTROM, V165, P419, DOI 10.1016/S0168-1176(97)00176-6; Stephenson JL, 1998, J AM SOC MASS SPECTR, V9, P957, DOI 10.1016/S1044-0305(98)00066-X; Stephenson JL, 1998, ANAL CHEM, V70, P3533, DOI 10.1021/ac9802832; STEPHENSON JL, 1998, RAPID COMMUN MASS SP, V70, P1198; THOMSON BA, 1979, J CHEM PHYS, V71, P4451, DOI 10.1063/1.438198; VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022; ZARRIN F, 1991, Patent No. 5076097; ZELENY J, 1915, P CAMB PHILOS SOC, V18, P71	43	143	156	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					194	197		10.1126/science.283.5399.194	http://dx.doi.org/10.1126/science.283.5399.194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880246				2022-12-28	WOS:000077976700031
J	Schofield, L; McConville, MJ; Hansen, D; Campbell, AS; Fraser-Reid, B; Grusby, MJ; Tachado, SD				Schofield, L; McConville, MJ; Hansen, D; Campbell, AS; Fraser-Reid, B; Grusby, MJ; Tachado, SD			CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells	SCIENCE			English	Article							PROMPTLY PRODUCE INTERLEUKIN-4; II-DEFICIENT MICE; NK1.1(+) T-CELLS; SIGNAL-TRANSDUCTION; ALPHA-CHAIN; ACTIVATION; CD4(+); CD1; RECOGNITION; LEISHMANIA	Immunoglobulin G (IgG) responses require major histocompatibility complex (MHC)-restricted recognition of peptide fragments by conventional CD4(+) helper T cells. Immunoglobulin G responses to glycosylphosphatidylinositol (GPI)-anchored protein antigens, however, were found to be regulated in part through CD1d-restricted recognition of the GPI moiety by thymus-dependent, interleukin-4-producing CD4(+), natural killer cell antigen 1.1 [(NK1.1)(+)] helper T cells. The CD1-NKT cell pathway regulated immunogobulin G responses to the GPI-anchored surface antigens of Plasmodium and Trypanosoma and may be a general mechanism for rapid, MHC-unrestricted antibody responses to diverse pathogens.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; INSMED Pharmaceut, Richmond, VA 23219 USA; Nat Prod & Glycotechnol, Durham, NC 27707 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Schofield, L (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	schofield@wehi.edu.au		Campbell, Anthony/0000-0001-5094-9714; Tachado, Souvenir/0000-0002-8368-6102	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040171, R21AI040171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041071] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40171] Funding Source: Medline; NIGMS NIH HHS [GM 41071] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; Brossay L, 1998, J IMMUNOL, V160, P3681; Brossay L, 1997, J IMMUNOL, V159, P1216; Brossay L, 1998, J IMMUNOL, V161, P5124; CAMPBELL AS, 1995, J AM CHEM SOC, V117, P10387, DOI 10.1021/ja00146a026; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Chen HJ, 1997, J IMMUNOL, V158, P5112; Chen HJ, 1997, J IMMUNOL, V159, P2240; CLARKE MW, 1985, MOL BIOCHEM PARASIT, V17, P19, DOI 10.1016/0166-6851(85)90125-2; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; JOYCE S, 1998, J IMMUNOL, V279, P1541; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Park SH, 1998, J IMMUNOL, V160, P3128; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; ROMERO PJ, 1988, EUR J IMMUNOL, V18, P1951, DOI 10.1002/eji.1830181213; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; WEISS WR, 1993, J IMMUNOL, V151, P2690; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	41	337	349	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					225	229		10.1126/science.283.5399.225	http://dx.doi.org/10.1126/science.283.5399.225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880256				2022-12-28	WOS:000077976700041
J	Levenstein, S; Ackerman, S; Kiecolt-Glaser, JK; Dubois, A				Levenstein, S; Ackerman, S; Kiecolt-Glaser, JK; Dubois, A			Stress and peptic ulcer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GASTRIC-ACID SECRETION; DUODENAL-ULCER; SERUM GASTRIN; PREDICTORS; ADULTS; RISK		Nuovo Regina Margherita Hosp, Dept Gastroenterol, Rome, Italy; St Lukes Roosevelt Hosp Ctr, Dept Psychiat, New York, NY USA; Ohio State Univ, Coll Med, Dept Psychiat, Columbus, OH 43210 USA; Uniformed Serv Univ Hlth Sci, Div Digest Dis, Bethesda, MD 20814 USA	Poliambulatorio Nuovo Regina Margherita; Mount Sinai St. Luke's; Mount Sinai West; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Levenstein, S (corresponding author), Via Templo 1A, I-00186 Rome, Italy.	slevenstein@compuserve.com	Kiecolt-Glaser, Janice K/A-3236-2009	Kiecolt-Glaser, Janice K/0000-0003-4900-9578				ACKERMAN SH, 1975, PSYCHOSOM MED, V37, P180, DOI 10.1097/00006842-197503000-00007; ANDA RF, 1992, ARCH INTERN MED, V152, P829, DOI 10.1001/archinte.152.4.829; Aoyama N, 1998, AM J GASTROENTEROL, V93, P311, DOI 10.1111/j.1572-0241.1998.00311.x; ARMSTRONG D, 1994, DIGEST DIS SCI, V39, P1425, DOI 10.1007/BF02088044; BRESNICK WH, 1993, J CLIN GASTROENTEROL, V17, P117, DOI 10.1097/00004836-199309000-00006; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P985; DUBOIS A, 1981, DIGEST DIS SCI, V26, P292, DOI 10.1007/BF01308367; FELDMAN M, 1992, GASTROENTEROLOGY, V102, P175, DOI 10.1016/0016-5085(92)91798-9; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; HOJGAARD L, 1989, GUT, V30, P782, DOI 10.1136/gut.30.6.782; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; LAM SK, 1995, J GASTROEN HEPATOL, V10, P570, DOI 10.1111/j.1440-1746.1995.tb01348.x; LEVENSTEIN S, 1995, J CLIN GASTROENTEROL, V21, P185, DOI 10.1097/00004836-199510000-00004; Levenstein S, 1996, J CLIN GASTROENTEROL, V22, P84, DOI 10.1097/00004836-199603000-00002; Levenstein S, 1997, J CLIN GASTROENTEROL, V24, P140, DOI 10.1097/00004836-199704000-00004; Levenstein S, 1998, BRIT MED J, V316, P538, DOI 10.1136/bmj.316.7130.538; Marucha PT, 1998, PSYCHOSOM MED, V60, P362, DOI 10.1097/00006842-199805000-00025; MIRSKY IA, 1958, AM J DIG DIS, V3, P285, DOI 10.1007/BF02232411; NATELSON BH, 1977, AM J DIG DIS, V22, P888, DOI 10.1007/BF01076165; Nice DS, 1996, JAMA-J AM MED ASSOC, V276, P375, DOI 10.1001/jama.276.5.375; Padgett DA, 1998, BRAIN BEHAV IMMUN, V12, P64, DOI 10.1006/brbi.1997.0512; PETERS MN, 1983, GASTROENTEROLOGY, V84, P114; PETERSON WL, 1997, GASTROINTESTINAL LIV, P604; POMAKOV P, 1993, J RADIOL, V74, P265; Spicer CC, 1944, LANCET, V1, P14; VELDHUIS JD, 1996, SLEEP S, V19, P5221; WEISS JM, 1971, J COMP PHYSIOL PSYCH, V77, P22, DOI 10.1037/h0031581	28	61	63	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					10	11		10.1001/jama.281.1.10	http://dx.doi.org/10.1001/jama.281.1.10			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892430				2022-12-28	WOS:000077829300002
J	Bosma, H; van de Mheen, HD; Mackenbach, JP				Bosma, H; van de Mheen, HD; Mackenbach, JP			Social class in childhood and general health in adulthood: questionnaire study of contribution of psychological attributes	BRITISH MEDICAL JOURNAL			English	Article							SELF-RATED HEALTH; LIVING-CONDITIONS; HEART-DISEASE; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC POSITION; MORTALITY; RISK; DETERMINANTS; DEPRESSION; HOSTILITY	Objective To determine the contribution of psychological attributes (personality characteristics and coping styles) to the association between social class in childhood and adult health among men and women. Design Partly retrospective, partly cross sectional study conducted in the framework of the Dutch GLOBE study. Subjects Sample of general population from south east Netherlands consisting of 2174 men and women aged 25-74 years. Baseline self reported data from 1991 provided information on childhood and adult social class, psychological attributes, and general health. Main outcome measure Self rated poor health. Results independent of adult social class, low childhood social class was related to self rated poor health (odds ratio 1.67 (95% confidence interval 1.02 to 2.75) for subjects whose fathers were unskilled manual workers versus subjects whose fathers were higher grade professionals). Subjects whose fathers were manual workers generally bad more unfavourable personality profiles and more negative coping styles. External locus of control, neuroticism, and the absence of active problem focused coping explained about half of the association between childhood social class and self rated poor health. The findings were independent of adult social class and height Conclusions A higher prevalence of negative personality profiles and adverse coping styles in subjects who grew up in lower social classes explains part of the association between social class in childhood and adult health. This finding underlines the importance of psychological mechanisms in the examination of the negative effects of adverse socioeconomic conditions in childhood.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bosma, H (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Bosma, Hans/A-6184-2013					Anderson JM, 1996, SOC SCI MED, V43, P697, DOI 10.1016/0277-9536(96)00153-0; ANDRIESSEN JHT, 1972, NEDERLANDS TIJDSCHRI, V27, P173; Appels A, 1996, SOC SCI MED, V42, P681, DOI 10.1016/0277-9536(95)00195-6; Barker DJP, 1992, FETAL INFANT ORIGINS; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; ERIKSON R, 1983, BRIT J SOCIOL, V34, P303, DOI 10.2307/590252; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P21, DOI 10.1016/0191-8869(85)90026-1; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; FRIEDMAN HS, 1993, J PERS SOC PSYCHOL, V65, P176, DOI 10.1037/0022-3514.65.1.176; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; Kohn M.L, 1977, CLASS CONFORMITY STU; Kubzansky LD, 1997, CIRCULATION, V95, P818; Lundberg O, 1997, SOC SCI MED, V44, P821, DOI 10.1016/S0277-9536(96)00184-0; LUNDBERG O, 1993, SOC SCI MED, V36, P1047, DOI 10.1016/0277-9536(93)90122-K; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; MACKENBACH JP, 1994, SOC SCI MED, V38, P299, DOI 10.1016/0277-9536(94)90399-9; McAdams DP, 1990, PERSON INTRO PERSONA; Meesters C, 1996, PERS INDIV DIFFER, V21, P271, DOI 10.1016/0191-8869(96)00044-X; MIROWSKY J, 1990, J HEALTH SOC BEHAV, V31, P71, DOI 10.2307/2137046; MOODY PM, 1972, PATIENTS PHYSICIANS; PECK MN, 1995, SOC SCI MED, V41, P733, DOI 10.1016/0277-9536(94)00379-8; Rahkonen O, 1997, SOC SCI MED, V44, P327, DOI 10.1016/S0277-9536(96)00102-5; Ranchor AV, 1997, J BEHAV MED, V20, P223, DOI 10.1023/A:1025538926879; ROSS CE, 1989, J HEALTH SOC BEHAV, V30, P206, DOI 10.2307/2137014; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976; Russek LG, 1997, J BEHAV MED, V20, P1, DOI 10.1023/A:1025525428213; SCHEIER MF, 1995, PSYCHOSOM MED, V57, P255, DOI 10.1097/00006842-199505000-00007; SCHREURS P, 1983, OUTWIKKELING UTRECHT; SCHWARTZ JE, 1995, AM J PUBLIC HEALTH, V85, P1237, DOI 10.2105/AJPH.85.9.1237; SHAFFER DR, 1994, SOCIAL PERSONALITY D; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; SMITS CHM, 1995, INT J AGING HUM DEV, V40, P237, DOI 10.2190/JH5F-2XWH-Y101-7EWF; Syme SL., 1989, STRESS, P3; TAX LCM, 1982, THESIS LISSE; van de Mheen H, 1998, INT J EPIDEMIOL, V27, P431, DOI 10.1093/ije/27.3.431; VANDEMHEEN H, IN PRESS SOC SCI MED; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WATSON D, 1984, PSYCHOL BULL, V96, P465, DOI 10.1037/0033-2909.96.3.465; WHEATON B, 1980, J HEALTH SOC BEHAV, V21, P100, DOI 10.2307/2136730	44	111	115	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					18	22						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	156QG	9872877				2022-12-28	WOS:000078013100020
J	Berlowitz, DR; Ash, AS; Hickey, EC; Friedman, RH; Glickman, M; Kader, B; Moskowitz, MA				Berlowitz, DR; Ash, AS; Hickey, EC; Friedman, RH; Glickman, M; Kader, B; Moskowitz, MA			Inadequate management of blood pressure in a hypertensive population	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; CARE; VALIDATION; MORBIDITY; QUALITY	Background Many patients with hypertension have inadequate control of their blood pressure. Improving the treatment of hypertension requires an understanding of the ways in which physicians manage this condition and a means of assessing the efficacy of this care. Methods We examined the care of 800 hypertensive men at five Department of Veterans Affairs sites in New England over a two-year period. Their mean (+/-SD) age was 65.5+/-9.1 years, and the average du ration of hypertension was 12.6+/-5.3 years. We used recursive partitioning to assess the probability that antihypertensive therapy would be increased at a given clinic visit using several variables. We then used these predictions to define the intensity of treatment for each patient during the study period, and we examined the associations between the intensity of treatment and the degree of control of blood pressure. Results Approximately 40 percent of the patients had a blood pressure of greater than or equal to 160/90 mm Hg despite an average of more than six hypertension-related visits per year. Increases in therapy occurred during 6.7 percent of visits. Characteristics associated with an increase in antihypertensive therapy included increased levels of both systolic and diastolic blood pressure at that visit (but not previous visits), a previous change in therapy, the presence of coronary artery disease, and a scheduled visit. Patients who had more intensive therapy had significantly (P<0.01) better control of blood pressure. During the two-year period, systolic blood pressure declined by 6.3 mm Hg among patients with the most intensive treatment, but increased by 4.8 mm Hg among the patients with the least intensive treatment. Conclusions In a selected population of older men, blood pressure was poorly controlled in many. Those who received more intensive medical therapy had better control. Many physicians are not aggressive enough in their approach to hypertension. (N Engl J Med 1998;339:1957-63.) (C) 1998, Massachusetts Medical Society.	Bedford Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, HSR&D Field Program, Bedford, MA 01730 USA; Boston Univ, Sch Med, Boston Med Ctr, Sect Gen Internal Med,Hlth Care Res Unit, Boston, MA 02118 USA; Boston Univ, Dept Math, Boston, MA 02215 USA	Boston Medical Center; Boston University; Boston University	Berlowitz, DR (corresponding author), Bedford Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, HSR&D Field Program, 200 Springs Rd, Bedford, MA 01730 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Friedman, Robert/0000-0002-9440-2443; Berlowitz, Dan/0000-0002-8783-5611; Glickman, Mark/0000-0003-3993-2801				Ahluwalia JS, 1997, J GEN INTERN MED, V12, P7, DOI 10.1046/j.1525-1497.1997.12107.x; ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; BEATTIE MC, 1993, DEP VETERANS AFFAIRS; Berlowitz DR, 1997, MED CARE, V35, P742, DOI 10.1097/00005650-199707000-00007; Berlowitz DR, 1998, MED CARE, V36, P928, DOI 10.1097/00005650-199806000-00015; Breiman L., 1984, CLASSIFICATION REGRE; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAYNES RB, 1982, CIRCULATION, V65, P28, DOI 10.1161/01.CIR.65.1.28; HAYNES RB, 1982, HYPERTENSION, V4, P415; KANE RL, 1977, MED CARE, V15, P961, DOI 10.1097/00005650-197711000-00010; Lohr K., 1990, MED STRATEGY QUALITY; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; *NAT CTR HLTH STAT, 1994, DHHS PUBL; NOBREGA FT, 1977, NEW ENGL J MED, V296, P145, DOI 10.1056/NEJM197701202960305; ROMM FJ, 1980, SOUTHERN MED J, V73, P564, DOI 10.1097/00007611-198005000-00006; ROSENBLATT RA, 1983, NEW ENGL J MED, V309, P892, DOI 10.1056/NEJM198310133091505; SHEA S, 1994, AM J PUBLIC HEALTH, V84, P1725, DOI 10.2105/AJPH.84.11.1725; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; *STAT SCI, 1995, S PLUS GUID STAT MAT; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; STOCKWELL DH, 1994, AM J PUBLIC HEALTH, V84, P1768, DOI 10.2105/AJPH.84.11.1768	26	705	720	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1957	1963		10.1056/NEJM199812313392701	http://dx.doi.org/10.1056/NEJM199812313392701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869666				2022-12-28	WOS:000077803800001
J	Schwartz, LB				Schwartz, LB			Infertility and pregnancy in epileptic women	LANCET			English	Editorial Material							TERATOGENESIS; METABOLISM; ACID		NYU Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, New York, NY 10016 USA	New York University	Schwartz, LB (corresponding author), NYU Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, New York, NY 10016 USA.							FINNELL RH, 1992, NEUROLOGY, V42, P25; FRIIS ML, 1986, NEUROLOGY, V36, P346, DOI 10.1212/WNL.36.3.346; KNIGHT AH, 1975, EPILEPSIA, V16, P99, DOI 10.1111/j.1528-1157.1975.tb04726.x; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MORRELL MJ, 1998, S SUMM NEW ORL LOUIS; MOUNTAIN KR, 1970, LANCET, V1, P265; WEBBER MP, 1986, EPILEPSIA, V27, P746, DOI 10.1111/j.1528-1157.1986.tb03605.x; WEGNER C, 1992, NEUROLOGY, V42, P17; YERBY M, 1985, EPILEPSIA, V26, P631, DOI 10.1111/j.1528-1157.1985.tb05703.x	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1952	1953		10.1016/S0140-6736(05)61325-6	http://dx.doi.org/10.1016/S0140-6736(05)61325-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872240				2022-12-28	WOS:000077663000004
J	Cummings, SR; Black, DM; Thompson, DE; Applegate, WB; Barrett-Connor, E; Musliner, TA; Palermo, L; Prineas, R; Rubin, SM; Scott, JC; Vogt, T; Wallace, R; Yates, AJ; LaCroix, AZ				Cummings, SR; Black, DM; Thompson, DE; Applegate, WB; Barrett-Connor, E; Musliner, TA; Palermo, L; Prineas, R; Rubin, SM; Scott, JC; Vogt, T; Wallace, R; Yates, AJ; LaCroix, AZ		Fracture Intervention Trial Res Grp	Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINERAL DENSITY; ELDERLY WOMEN; HIP FRACTURE; OSTEOPOROSIS; BISPHOSPHONATES; RESORPTION; PREVENTION	Context.-Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures. Objective.-To test the hypothesis that 4 years of alendronate would decrease the risk of clinical and vertebral fractures in women who have low bone mineral density (BMD) but no vertebral fractures. Design.-Randomized, blinded, placebo-controlled trial. Setting.-Eleven community-based clinical research centers. Subjects.-Women aged 54 to 81 years with a femoral neck BMD of 0.68 g/cm(2) or less (Hologic Inc, Waltham, Mass) but no vertebral fracture; 4432 were randomized to alendronate or placebo and 4272 (96%) completed outcome measurements at the final visit (an average of 4.2 years later). Intervention.-All participants reporting calcium intakes of 1000 mg/d or less received a supplement containing 500 mg of calcium and 250 IU of cholecalciferol. Subjects were randomly assigned to either placebo or 5 mg/d of alendronate sodium for 2 years followed by 10 mg/d for the remainder of the trial. Main Outcome Measures.-Clinical fractures confirmed by x-ray reports, new vertebral deformities detected by morphometric measurements on radiographs, and BMD measured by dual x-ray absorptiometry. Results.-Alendronate increased BMD at all sites studied (P<.001) and reduced clinical fractures from 312 in the placebo group to 272 in the intervention group, but not significantly so (14% reduction; relative hazard [RH], 0.86; 95% confidence interval [CI], 0.73-1.01). Alendronate reduced clinical fractures by 36% in women with baseline osteoporosis at the femoral neck (>2.5 SDs below the normal young adult mean; RH, 0.64; 95% CI, 0.50-0.82; treatment-control difference, 6.5%; number needed to treat [NNT], 15), but there was no significant reduction among those with higher BMD (RH, 1.08; 95% CI, 0.87-1.35). Alendronate decreased the risk of radiographic vertebral fractures by 44% overall (relative risk, 0.56; 95% CI, 0.39-0.80; treatment-control difference, 1.7%; NNT, 60). Alendronate did not increase the risk of gastrointestinal or other adverse effects. Conclusions.-In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity. Alendronate significantly reduced the risk of clinical fractures among women with osteoporosis but not among women with higher BMD.	Univ Calif San Francisco, Dept Epidemiol & Biostat, Prevent Sci Grp, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94105 USA; Merck Res Labs, Rahway, NJ USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Miami, Miami, FL 33152 USA; Univ Maryland, Baltimore, MD 21201 USA; Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA; Univ Iowa, Dept Prevent Med, Iowa City, IA 52242 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Merck & Company; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California San Diego; University of Miami; University System of Maryland; University of Maryland Baltimore; Cancer Research Center of Hawaii; University of Hawaii System; University of Iowa; Group Health Cooperative	Cummings, SR (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Prevent Sci Grp, Box 0886, San Francisco, CA 94105 USA.	scummings@psg.ucsf.edu						BLACK DM, 1993, OSTEOPOROSIS INT, V3, pS29; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BLACK DM, IN PRESS J BONE MINE; COOPER C, 1992, BRIT MED J, V304, P793, DOI 10.1136/bmj.304.6830.793; Cox D. R., 1984, ANAL SURVIVAL DATA; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Eddy DM, 1998, OSTEOPOROSIS INT S4, V8, P1; Fleisch H, 1997, HORM METAB RES, V29, P145, DOI 10.1055/s-2007-979008; Garnero P, 1996, J BONE MINER RES, V11, P1531; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; GENANT HK, 1995, VERTEBRAL FRACTURE O; HEANEY RP, 1993, CALCIFIED TISSUE INT, V53, pS3, DOI 10.1007/BF01673394; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; KOTOWICZ MA, 1994, J BONE MINER RES, V9, P599; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LOOKER AC, 1995, J BONE MINER RES, V10, P796; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Parfitt AM, 1996, J BONE MINER RES, V11, P150; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Riggs BL, 1996, BONE, V18, pS197, DOI 10.1016/8756-3282(95)00502-1; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; ROSS PD, 1994, J CLIN EPIDEMIOL, V47, P231, DOI 10.1016/0895-4356(94)90004-3; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002-9343(97)00130-7	28	1705	1759	0	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2077	2082		10.1001/jama.280.24.2077	http://dx.doi.org/10.1001/jama.280.24.2077			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875874	Bronze			2022-12-28	WOS:000077606100030
J	Landry, RF				Landry, RF			Four-wheel-drive medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2070	2070		10.1001/jama.280.24.2070-a	http://dx.doi.org/10.1001/jama.280.24.2070-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875863				2022-12-28	WOS:000077606100014
J	Shimada, M; Tritos, NA; Lowell, BB; Flier, JS; Maratos-Flier, E				Shimada, M; Tritos, NA; Lowell, BB; Flier, JS; Maratos-Flier, E			Mice lacking melanin-concentrating hormone are hypophagic and lean	NATURE			English	Article							TARGETED DISRUPTION; NEUROPEPTIDE-Y; MESSENGER-RNA; OBESE GENE; LEPTIN; AGOUTI; PROTEIN; WEIGHT	Feeding is influenced by hypothalamic neuropeptides that promote (orexigenic peptides) or inhibit feeding(1). Of these, neuropeptide Y (NPY) in the arcuate nucleus' and melanin-concentrating hormone (MCH)(3) and orexins/hypocretins(4,5) in the lateral hypothalamus have received attention because their expression is increased during fasting and because they promote feeding when administered centrally. Surprisingly, absence of the orexigenic neuropeptide NPY fails to alter feeding or body weight in normal mice(6). As deficiency of a single component of the pathway that limits food intake (such as leptin or receptors for melanocortin-4)(7,8) causes obesity, it has been suggested that orexigenic signals are more redundant than those limiting food intake(7,8). To define further the physiological role of MCH and to test the redundancy of orexigenic signals, we generated mice carrying a targeted deletion of the MCH gene. MCH-deficient mice have reduced body weight and leanness due to hypophagia (reduced feeding) and an inappropriately increased metabolic rate, despite their reduced amounts of both leptin and arcuate nucleus pro-opiomelanocortin messenger RNA. Our results show that MCH is a critical regulator of feeding and energy balance which acts downstream of leptin and the melanocortin system, and that deletion of a gene encoding a single orexigenic peptide can result in leanness.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center	Maratos-Flier, E (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	emarat@joslab.harvard.edu	Tritos, Nicholas/W-1594-2019; Flier, jeffrey/AAG-6223-2019	Tritos, Nicholas/0000-0001-8867-607X; 				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; BITTENCOURT JC, 1993, ANN NY ACAD SCI, V680, P462, DOI 10.1111/j.1749-6632.1993.tb19708.x; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DRYDEN S, 1994, EUR J CLIN INVEST, V24, P293, DOI 10.1111/j.1365-2362.1994.tb01089.x; ELIAS CF, IN PRESS J COMP NEUR; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MARKS DL, 1992, MOL CELL NEUROSCI, V3, P395, DOI 10.1016/1044-7431(92)90051-3; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TSUJII S, 1989, BRAIN RES BULL, V23, P165, DOI 10.1016/0361-9230(89)90142-1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	904	949	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					670	674		10.1038/25341	http://dx.doi.org/10.1038/25341			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872314				2022-12-28	WOS:000077694200052
J	Herman, J				Herman, J			The good old days	LANCET			English	Editorial Material									Assia Community Hlth Ctr, Netivot, Israel		Herman, J (corresponding author), 24 Megadim St, IL-96185 Jerusalem, Israel.							ANGRIST AA, 1977, NY STATE J MED, V88, P449; [Anonymous], 1978, WEBSTERS NEW 20 CENT, V2nd; DUBOVSKY SL, 1986, NEW ENGL J MED, V315, P1672, DOI 10.1056/NEJM198612253152609; FOX T, 1965, LANCET, V2, P801; GLICK SM, 1990, AM J MED, V88, P449, DOI 10.1016/0002-9343(90)90421-9; GRAEF I, 1977, NEW YORK STATE J MED, V77, P1454; Herman J, 1996, ISRAEL J MED SCI, V32, P259; NAUGHTON J, 1977, NEW YORK STATE J MED, V77, P1448; NORDLICHT S, 1977, NEW YORK STATE J MED, V77, P1452; PEABODY FW, 1965, LANCET, V2, P801; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; VOLPINTESTA EJ, 1992, ANN INTERN MED, V117, P700; 1996, MED LETT DRUGS THER, V38, P92	13	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1930	1931		10.1016/S0140-6736(98)09196-X	http://dx.doi.org/10.1016/S0140-6736(98)09196-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863805				2022-12-28	WOS:000077544600046
J	Brittenham, GM; Franks, AL; Rickles, FR				Brittenham, GM; Franks, AL; Rickles, FR			Research priorities in hereditary hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article							GENE	The Working Group on Research Priorities used a formal nominal group technique to identify and prioritize the specific aims of applied research needed to provide the scientific basis for population screening for iron overload disorders. The most important applied research goal was characterization of the natural history of the relation between genotype and phenotype in hereditary hemochromatosis and other iron overload disorders. Three other important research objectives were development of an optimal approach to screening for iron overload; analyses of the cost-effectiveness of screening; and assessment of the ethical, legal, and social implications of screening. To achieve these specific aims, two research studies were recommended as being of the highest priority: a multicenter, cross-sectional, population-based study of the natural history of iron overload and a multicenter, case-control study of patients with disease manifestations potentially attributable to hereditary hemochromatosis in primary care and subspecialty clinics.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, TB Lab Res, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Atlanta, GA 30341 USA	Columbia University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Brittenham, GM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, Harkness Pavil Room HP 550,630 W 168th St, New York, NY 10032 USA.							Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Bradley L A, 1996, J Med Screen, V3, P178; *CDCP, 1996, CDC GUID IMPR QUAL; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Reinke W, 1988, HLTH PLANNING EFFECT, P203; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	9	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					993	996		10.7326/0003-4819-129-11_Part_2-199812011-00011	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867753				2022-12-28	WOS:000077239200033
J	McDonnell, SM; Witte, DL; Cogswell, ME; McIntyre, R				McDonnell, SM; Witte, DL; Cogswell, ME; McIntyre, R			Strategies to increase detection of hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; GENETIC HEMOCHROMATOSIS; PRACTICE GUIDELINES; UNITED-STATES; FINANCIAL INCENTIVES; BLOOD-DONORS; PHYSICIANS; PREVALENCE; RECOMMENDATIONS; PERFORMANCE	As part of the iron Overload, Public Health and Genetics conference, sponsored by the Centers for Disease Control and Prevention in March 1997, a working group was convened to consider strategies to increase early case detection of hemochromatosis. This group emphasized that the primary public health goal should be to diagnose hemochromatosis before symptoms appear. To reach this goal, education and action need to be targeted to physicians and other health care workers, laboratorians, administrators, payers, and the public. Strategies to disseminate updated information and increase early case detection were prioritized according to expected effectiveness. Strategies targeting physicians are 1) to identify national and local physician-leaders and 2) to educate physicians about hemochromatosis in basic, graduate specialty, and continuing medical education. Strategies aimed at the health system are 1) to encourage laboratories to provide the transferrin saturation test as part of routine laboratory panels and 2) to work with policymakers and payers to allow reimbursement for case detection. Finally, public education is recommended to increase lay support for the early diagnosis of hemochromatosis. Attempts to educate the public should be aimed first at persons who receive diagnoses of hemochromatosis in order to ensure that they are properly treated and then at asymptomatic persons who could be screened as part of health appraisals. Although identifying physician-leaders and educating physicians are the highest priorities, physicians should not be targeted at the exclusion of payers and the public. Simultaneous efforts to reach all groups in appropriate ways should be initiated to provide the interest and infrastructure necessary to decrease morbidity and mortality from hemochromatosis.	Ctr Dis Control & Prevent, Div Int Hlth, Atlanta, GA 30303 USA; Lab Control Ltd, Ottumwa, IA USA	Centers for Disease Control & Prevention - USA	McDonnell, SM (corresponding author), Ctr Dis Control & Prevent, Div Int Hlth, Mailstop C-08,1600 Clifton Rd, Atlanta, GA 30303 USA.	sem0@cdc.gov						ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1996, SEMIN LIVER DIS, V16, P47, DOI 10.1055/s-2007-1007218; Alper J S, 1994, J Public Health Policy, V15, P345, DOI 10.2307/3342910; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Barton JC, 1997, AM J MED, V103, P498, DOI 10.1016/S0002-9343(97)00276-3; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; Blaine J R, 1997, Mo Med, V94, P612; BOTHWELL TH, 1982, CECILS TXB MED, P1128; Bradley L A, 1996, J Med Screen, V3, P178; BROOK RH, 1995, LANCET, V346, P132, DOI 10.1016/S0140-6736(95)91202-9; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Burke W, 1998, CLIN GENET, V54, P1; CARTWRIGHT GE, 1974, HARRISONS PRINCIPLES, P618; *CDCP, 1996, CDC GUID IMP QUAL; CLAYTON C, 1993, MED J AUSTRALIA, V159, P614, DOI 10.5694/j.1326-5377.1993.tb138051.x; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; CRAWFORD R, 1990, IRON ELEPHANT; CRECO PJ, 1993, NEW ENGL J MED, V329, P1271; CROSBY WH, 1987, HOSP PRACT, V22, P173, DOI 10.1080/21548331.1987.11707681; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; EDWARDS CQ, 1994, ADV EXP MED BIOL, V356, P303; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FLETCHER RH, 1990, ANN INTERN MED, V113, P645, DOI 10.7326/0003-4819-113-9-645; GABLE CB, 1992, J AM DIET ASSOC, V92, P208; GAMBINO R, 1991, HOSP PRACT, V26, P41; GEORGE DK, 1995, ANN CLIN BIOCHEM, V32, P521, DOI 10.1177/000456329503200601; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; Gunter EW, 1998, CLIN CHEM, V44, P361; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; KENNEDY M, 1995, QUAL LETT, V7, P1; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936; McDonnell SM, 1998, ANN INTERN MED, V129, P962, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00007; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; OLYNYK J, 1994, AUST NZ J MED, V24, P22, DOI 10.1111/j.1445-5994.1994.tb04420.x; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; PHELPS G, 1989, LANCET, V2, P233; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; WEINGARTEN S, 1995, J GEN INTERN MED, V10, P138, DOI 10.1007/BF02599668; Witte D L, 1991, J Insur Med, V23, P281; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Witte DL, 1997, CLIN CHEM, V43, P1535; WITTE DL, 1993, CLIN LAB MED, V13, P481, DOI 10.1016/S0272-2712(18)30450-5; WOLFE YL, 1997, PREVENTION       SEP, P58; WOLFE YL, 1997, PREVENTION       JUL, P88; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005; Yedidia MJ, 1996, J HEALTH SOC BEHAV, V37, P179, DOI 10.2307/2137272; 1997, COLL AM PATHOLOGISTS; 1982, COLL AM PATHOLOGISTS; 1996, MMWR MORB MORTAL WKL, V45, P991	65	15	15	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					987	992		10.7326/0003-4819-129-11_Part_2-199812011-00010	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867752				2022-12-28	WOS:000077239200032
J	Losick, R; Shapiro, L				Losick, R; Shapiro, L			DNA replication - Bringing the mountain to mohammed	SCIENCE			English	Editorial Material							BACILLUS-SUBTILIS; BIPOLAR LOCALIZATION; CHROMOSOME; PROTEIN; SEGREGATION; REGIONS; FOCI		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Harvard University; Stanford University	Losick, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Cook P, 1998, SCIENCE, V281, P1466, DOI 10.1126/science.281.5382.1466; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; MILLS AD, 1989, J CELL SCI, V94, P471; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Moriya S, 1998, MOL MICROBIOL, V29, P179, DOI 10.1046/j.1365-2958.1998.00919.x; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; Niki H, 1998, GENE DEV, V12, P1036, DOI 10.1101/gad.12.7.1036; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Teleman AA, 1998, CURR BIOL, V8, P1102, DOI 10.1016/S0960-9822(98)70464-6; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502	20	9	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1430	1431		10.1126/science.282.5393.1430	http://dx.doi.org/10.1126/science.282.5393.1430			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867650	Green Submitted			2022-12-28	WOS:000077110800030
J	Ruben, JA; Dal Sasso, C; Geist, NR; Hillenius, WJ; Jones, TD; Signore, M				Ruben, JA; Dal Sasso, C; Geist, NR; Hillenius, WJ; Jones, TD; Signore, M			Pulmonary function and metabolic physiology of theropod dinosaurs	SCIENCE			English	Article								Ultraviolet Light analysis of a fossil of the theropod dinosaur Scipionyx samniticus revealed that the Liver subdivided the visceral cavity into distinct anterior pleuropericardial and posterior abdominal regions. in addition, Scipionyx apparently had diaphragmatic musculature and a dorsally attached posterior colon. These features provide evidence that diaphragm-assisted lung ventilation was present in theropods and that these dinosaurs may have used a pattern of exercise physiology unlike that in any group of living tetrapods.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Museo Civico Storia Nat, I-20121 Milan, Italy; Coll Charleston, Dept Biol, Charleston, SC 29424 USA; Univ Bristol, Dept Geol, Bristol BS8 1RJ, Avon, England	Oregon State University; College of Charleston; University of Bristol	Ruben, JA (corresponding author), Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA.			Dal Sasso, Cristiano/0000-0001-6791-6601				BENNETT AF, 1985, J EXP BIOL, V118, P161; CARRIER D, 1990, J EXP BIOL, V152, P453; CARRIER DR, 1987, PALEOBIOLOGY, V13, P326; CHIASSON RB, COMMUNICATION; COLBERT EH, 1951, B AM MUS NAT HIST, V97, P143; Dal Sasso C, 1998, NATURE, V392, P383; DALSASSO C, 1998, 3 EUR WORKSH VERT PA, P23; DUNCKER HR, 1971, ERGEBNISSE ANATOMIE, V0045, P00001; DUNCKER HR, 1979, FORM FUNCTION BIRDS, V1, P39; Hengst R, 1998, SCIENCE, V281, P47; Hicks JW, 1998, SCIENCE, V281, P45; MCLELLAND J, 1989, FORM FUNCTION BIRDS, V0004, P00069; Reid R.E.H., 1997, P449; Romer A, 1956, OSTEOLOGY REPTILES; Ruben JA, 1997, SCIENCE, V278, P1267, DOI 10.1126/science.278.5341.1267; Ruben JA, 1998, SCIENCE, V281, P47; Ruben JA, 1996, SCIENCE, V273, P1204, DOI 10.1126/science.273.5279.1204; SCHEID P, 1989, ADV ANAL EMBRYOL CEL, V4, P369; SONG PS, 1973, J AM CHEM SOC, V95, P7892, DOI 10.1021/ja00804a069; WITH TK, 1968, BILE PIGMENTS	20	51	53	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					514	516		10.1126/science.283.5401.514	http://dx.doi.org/10.1126/science.283.5401.514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915693	Green Submitted			2022-12-28	WOS:000078203300029
J	Goldin, J				Goldin, J			A memorable patient - He was going to die anyway	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					185	185		10.1136/bmj.318.7177.185	http://dx.doi.org/10.1136/bmj.318.7177.185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888920	Green Published			2022-12-28	WOS:000078175100041
J	Teixeira, JMA; Fisk, NM; Glover, V				Teixeira, JMA; Fisk, NM; Glover, V			Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study	BRITISH MEDICAL JOURNAL			English	Article							DOPPLER ULTRASOUND; FETAL ORIGINS; STRESS; PREECLAMPSIA; PREDICTION; GESTATION; BEHAVIOR; DELIVERY; DISEASE	Objective To investigate whether maternal anxiety in the third trimester is associated with an increased uterine artery resistance index. Design Cohort based study. Subjects 100 pregnant women, with a mean gestation of 32 weeks. Outcome measures Self rating Spielberger questionnaire for state anxiety and trait anxiety, and uterine blood now waveform patterns as assessed by colour Doppler ultrasound. Results A significant association was found between uterine artery resistance index and scores for both Spielberger state anxiety and trait anxiety (r(s) = 0.31, P < 0.002 and 0.28 P < 0.005 respectively). Women with state anxiety scores > 40 (n = 15) had a higher mean uterine resistance index than those with scores less than or equal to 40 (mean difference with mean resistance index 24%, 95% confidence interval 12% to 38%; P < 0.0001), Similarly, women with trait anxiety scores >40 (n=32) had a higher mean resistance index than those with scores less than or equal to 40, although to a lesser extent. The presence of notches in the waveform pattern produced by uterine artery blood now was found in 4/15 (27%) women with high state anxiety scores compared with 4/85 (5%) with low anxiety scores (P < 0.02). Conclusions This study shows an association between maternal anxiety in pregnancy and increased uterine artery resistance index. It suggests a mechanism by which the psychological state of the mother may affect fetal development, and may explain epidemiological associations between maternal anxiety and low birth weight The influence of maternal anxiety may be one mechanism by which the intrauterine environment contributes to later disease in offspring.	Queen Charlottes & Chelsea Hosp, Div Paediat Obstet & Gynaecol, Ctr Fetal Care, London W6 0XG, England	Imperial College London	Glover, V (corresponding author), Queen Charlottes & Chelsea Hosp, Div Paediat Obstet & Gynaecol, Ctr Fetal Care, London W6 0XG, England.	vglover@rpms.ac.uk	Fisk, Nicholas M/B-2126-2009; Glover, Vivette/M-2711-2016	Fisk, Nicholas M/0000-0003-0031-7975; Glover, Vivette/0000-0001-6543-1651				BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1995, P ROY SOC B-BIOL SCI, V262, P37, DOI 10.1098/rspb.1995.0173; BOWER S, 1993, BRIT J OBSTET GYNAEC, V100, P989, DOI 10.1111/j.1471-0528.1993.tb15139.x; BOWER SJ, 1995, AM J OBSTET GYNECOL, V173, P502, DOI 10.1016/0002-9378(95)90273-2; Clarke AS, 1996, INFANT BEHAV DEV, V19, P451, DOI 10.1016/S0163-6383(96)90006-5; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; Ferber S.G., 2006, DEV PSYCHOPATHOL, V93, P117, DOI DOI 10.1017/S0954579400005290; FERREIRA AJ, 1965, J NERV MENT DIS, V141, P108, DOI 10.1097/00005053-196507000-00011; FRIED G, 1990, REGUL PEPTIDES, V28, P1, DOI 10.1016/0167-0115(90)90059-6; Frusca T, 1997, EARLY HUM DEV, V48, P177, DOI 10.1016/S0378-3782(96)01854-3; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Groome LJ, 1995, J DEV BEHAV PEDIATR, V16, P391; HACKETT GA, 1992, OBSTET GYNECOL, V79, P919; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; Harrington K, 1996, ULTRASOUND OBST GYN, V7, P182, DOI 10.1046/j.1469-0705.1996.07030182.x; HARRINGTON K, 1995, COLOUR ATLAS DOPPLER; Hedegaard M, 1996, EPIDEMIOLOGY, V7, P339, DOI 10.1097/00001648-199607000-00001; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; IANNIRUBERTO A, 1981, SEMIN PERINATOL, V5, P175; Lees C, 1996, OBSTET GYNECOL, V88, P14, DOI 10.1016/0029-7844(96)00070-1; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; MORISHIMA HO, 1978, AM J OBSTET GYNECOL, V131, P286, DOI 10.1016/0002-9378(78)90602-6; PERKIN MR, 1993, BRIT J OBSTET GYNAEC, V100, P629, DOI 10.1111/j.1471-0528.1993.tb14228.x; ROSENFIELD CR, 1976, AM J OBSTET GYNECOL, V127, P376; Spielberger C., 1983, STAI MANUAL; Spielberger C. D., 1983, MIND GARDEN; STARKMAN MN, 1990, PSYCHOSOM MED, V52, P129, DOI 10.1097/00006842-199003000-00001; WADWA PD, 1993, AM J OBSTET GYNECOL, V169, P858; WADWA PD, 1996, PSYCHOSOM MED, V58, P432; WEINSTEIN AM, 1995, BIOL PSYCHIAT, V37, P847, DOI 10.1016/0006-3223(94)00249-3; WOLF F, 1986, BRIT J OBSTET GYNAEC, V93, P1049	31	347	354	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					153	157		10.1136/bmj.318.7177.153	http://dx.doi.org/10.1136/bmj.318.7177.153			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888905	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078175100023
J	Ross, R				Ross, R			Mechanisms of disease - Atherosclerosis - An inflammatory disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; CORONARY-ARTERY DISEASE; C-REACTIVE PROTEIN; HYPERCHOLESTEROLEMIA-INDUCED ATHEROSCLEROSIS; HERITABLE HYPERLIPIDEMIC RABBIT; VASCULAR ENDOTHELIAL-CELLS; VITAMIN-E CONSUMPTION; CARDIOVASCULAR-DISEASE; HEART-DISEASE		Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Ross, R (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	ross@u.washington.edu	Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTHONY PP, 1977, B WORLD HEALTH ORGAN, V55, P521; Assoian RK, 1996, J CLIN INVEST, V98, P2436, DOI 10.1172/JCI119059; BABAEV VR, 1990, AM J PATHOL, V136, P1031; Badimon JJ, 1997, EUR J CLIN INVEST, V27, P568, DOI 10.1046/j.1365-2362.1997.1480697.x; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Breslow JL, 1997, NAT MED, V3, P600, DOI 10.1038/nm0697-600; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHANG MY, 1995, ARTERIOSCL THROM VAS, V15, P1631, DOI 10.1161/01.ATV.15.10.1631; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; CHOBANIAN AV, 1996, ATHEROSCLEROSIS CORO, V1, P237; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DAVIES MJ, 1990, CIRCULATION, V82, P38; de Villiers WJS, 1998, ARTERIOSCL THROM VAS, V18, P631, DOI 10.1161/01.ATV.18.4.631; DeCaterina R, 1997, ARTERIOSCL THROM VAS, V17, P2646, DOI 10.1161/01.ATV.17.11.2646; DeRisi J, 1996, NAT GENET, V14, P457; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Dimagno Eugene P., 1993, P665; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FALK E, 1996, ATHEROSCLEROSIS CORO, V2, P492; Folcik VA, 1997, ARTERIOSCL THROM VAS, V17, P1954, DOI 10.1161/01.ATV.17.10.1954; Frid MG, 1997, CIRC RES, V81, P940; Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GENG YJ, 1995, AM J PATHOL, V147, P251; Giachelli CM, 1998, AM J PATHOL, V152, P353; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOTLIEB AI, 1996, ATHEROSCLEROSIS CORO, V1, P595; Griendling KK, 1997, CIRCULATION, V96, P3264; HAJJAR DP, 1986, AM J PATHOL, V122, P62; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1996, ATHEROSCLEROSIS CORO, P557; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; HENDRIX MGR, 1990, AM J PATHOL, V136, P23; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Hwang SJ, 1997, CIRCULATION, V96, P4219; Hynes RO, 1996, J CLIN INVEST, V98, P2193, DOI 10.1172/JCI119027; Jackson LA, 1997, AM J PATHOL, V150, P1785; Johnson RJ, 1997, AM J PATHOL, V151, P1179; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1992, ARTERIOSCLER THROMB, V12, P1258, DOI 10.1161/01.ATV.12.11.1258; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Lacy F, 1998, J HYPERTENS, V16, P291, DOI 10.1097/00004872-199816030-00006; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LEVENSON J, 1995, ARTERIOSCL THROM VAS, V15, P1263, DOI 10.1161/01.ATV.15.9.1263; LIBBY P, 1991, LAB INVEST, V64, P5; Libby P, 1997, CIRCULATION, V96, P4095; LIBBY P, 1996, ATHEROSCLEROSIS CORO, V1, P585; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Lukacs NW, 1996, ADV IMMUNOL, V62, P257, DOI 10.1016/S0065-2776(08)60432-0; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, CIRCULATION, V96, P396; MAGIL AB, 1989, LAB INVEST, V61, P404; MAHER JJ, 1990, SEMIN LIVER DIS, V10, P66, DOI 10.1055/s-2008-1040458; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; MALINOW MR, 1995, CLIN CHEM, V41, P173; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCMILLAN DE, 1985, STROKE, V16, P582, DOI 10.1161/01.STR.16.4.582; MELNICK JL, 1993, EUR HEART J, V14, P30; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; MOREL DW, 1983, J LIPID RES, V24, P1070; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MUDD SH, 1985, AM J HUM GENET, V37, P1; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; National Cholesterol Education Program, 1993, NIH PUBL; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NEHLER MR, 1995, CARDIOVASC SURG, V6, P559; Nicholson AC, 1998, ARTERIOSCL THROM VAS, V18, P339, DOI 10.1161/01.ATV.18.3.339; Nunes GL, 1997, CIRCULATION, V96, P3593; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Omenn GS, 1998, CIRCULATION, V97, P421; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; PALKAMA T, 1993, FEBS LETT, V319, P100, DOI 10.1016/0014-5793(93)80045-V; PEDERSEN TR, 1994, LANCET, V344, P1383; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Qiao JH, 1997, AM J PATHOL, V150, P1687; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAINES EW, 1996, ATHEROSCLEROSIS CORO, P539; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, AM J PATHOL, V143, P987; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ross R, 1996, ATHEROSCLEROSIS CORO, V1, P441; SARLES H, 1989, ANNU REV MED, V40, P453; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; SEWELL KL, 1993, LANCET, V341, P283, DOI 10.1016/0140-6736(93)92627-6; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Smith RE, 1997, J LEUKOCYTE BIOL, V62, P612, DOI 10.1002/jlb.62.5.612; Springer TA., 1996, ATHEROSCLEROSIS CORO, VVol 1, P511; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; Stary HC, 1996, ATHEROSCLEROSIS CORO, V1, P463; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; Swei A, 1997, HYPERTENSION, V30, P1628, DOI 10.1161/01.HYP.30.6.1628; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Tormey VJ, 1997, IMMUNOLOGY, V90, P463, DOI 10.1046/j.1365-2567.1997.00207.x; Toss H, 1997, CIRCULATION, V96, P4204; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; VANDERWAL AC, 1989, LAB INVEST, V61, P166; Vanhoutte P M, 1995, Hypertens Res, V18, P87, DOI 10.1291/hypres.18.87; VERHOEF P, 1995, NUTR REV, V53, P283, DOI 10.1111/j.1753-4887.1995.tb01478.x; Wesley RB, 1998, ARTERIOSCL THROM VAS, V18, P432, DOI 10.1161/01.ATV.18.3.432; Wick G, 1997, FASEB J, V11, P1199, DOI 10.1096/fasebj.11.13.9367355; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	148	16796	18258	54	2588	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					115	126		10.1056/NEJM199901143400207	http://dx.doi.org/10.1056/NEJM199901143400207			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887164				2022-12-28	WOS:000078016200007
J	Birger, Y; Shemer, R; Perk, J; Razin, A				Birger, Y; Shemer, R; Perk, J; Razin, A			The imprinting box of the mouse Igf2r gene	NATURE			English	Article							DNA METHYLATION; MECHANISMS; EXPRESSION; PATTERN; EMBRYO; ISLAND	Genomic imprinting is a phenomenon characterized by parent-of-origin-specific expression. The imprint is a mark established during germ-cell development to distinguish between the paternal and maternal copies of the imprinted genes. This imprint is maintained throughout embryo development and erased in the embryonic gonads to set the stage for a new imprint(1). DNA methylation is essential in this process as shown by the presence of differentially methylated regions (DMRs) in all imprinted genes(2) and by the loss of imprinting in mice that are deficient in DNA. methylation(3) or upon deletion of DMRs(4-6). Here we show that a DMR in the imprinted Igf2r gene (which encodes the receptor for insulin-like growth factor type-2) that has been shown to be necessary for imprinting(5) includes a 113-base-pair sequence that constitutes a methylation imprinting box. We identify two new cis-acting elements in this box that bind specific proteins: a de novo methylation signal and an allele-discrimination signal. We propose that this regulatory system, which we show to be involved in the establishment of differential methylation in the Igf2r DMR, represents a critical element in the imprinting process.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Razin, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, POB 12272, IL-91120 Jerusalem, Israel.							Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	17	106	109	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					84	88		10.1038/16291	http://dx.doi.org/10.1038/16291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892358				2022-12-28	WOS:000077959400053
J	Reynolds, CF; Frank, E; Perel, JM; Imber, SD; Cornes, C; Miller, MD; Mazumdar, S; Houck, PR; Dew, MA; Stack, JA; Pollock, BG; Kupfer, DJ				Reynolds, CF; Frank, E; Perel, JM; Imber, SD; Cornes, C; Miller, MD; Mazumdar, S; Houck, PR; Dew, MA; Stack, JA; Pollock, BG; Kupfer, DJ			Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression - A randomized controlled trial in patients older than 59 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVALENCE; RELAPSE; SCALE; LIFE	Context Elderly patients with major depression are at high risk for recurrence, increased mortality, and chronic disability. Objective To determine the efficacy of maintenance nortriptyline hydrochloride and interpersonal psychotherapy (IPT) in preventing recurrence of major depressive episodes in patients older than 59 years. Design A 2 x 2 randomized, double-blind, placebo-controlled clinical trial, stratified by therapist. Setting University-based psychiatric research clinic. Patients Of atotalof 187 patients with recurrent nonpsychotic unipolar major depression (average age, 67 years; one third aged greater than or equal to 70 years) recruited through clinical referral and media announcements, 107 were fully recovered after open acute and treatment continuation with nortriptyline and IPT. These patients were randomly assigned to 1 of 4 maintenance therapy conditions, Interventions Monthly medication clinic with nortriptyline hydrochloride (80-120 ng/mL steady-state levels) (n = 24); medication clinic with placebo (n = 29); monthly maintenance IPT with placebo (n = 21), and monthly maintenance IPT with nortriptyline (n = 22). Main Outcome Measure Recurrence of major depressive episode. Results The time to recurrence of a major depressive episode for all 3 active treatments was significantly better than for placebo. Recurrence rates over 3 years were as follows: nortriptyline and IPT, 20% (95% confidence interval [CI], 4%-36%); nortriptyline and medication clinic visits, 43% (95% CI, 25%-61%); IPT and placebo, 64% (95% CI, 45%-83%); and placebo and medication clinic visits, 90% (95% CI, 79% 100%), Combined treatment with nortriptyline and IPT was superior to IPT and placebo and showed a trend to superior efficacy over nortriptyline monotherapy (Wald chi(2) = 3.56; P = .06), Subjects aged 70 years and older had a higher and more rapid rate of recurrence than those aged 60 to 69 years. Conclusion In geriatric patients with recurrent major depression, maintenance treatment with nortriptyline or IPT is superior to placebo in preventing or delaying recurrence. Combined treatment using both appears to be the optimal clinical strategy in preserving recovery.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Mental Hlth Clin Res Ctr Late & Midlife Mood Diso, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Reynolds, CF (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Mental Hlth Clin Res Ctr Late & Midlife Mood Diso, 3811 Ohara St, Pittsburgh, PA 15213 USA.	Reynoldscf@msx.upmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH052247, R37MH043832, P30MH030915] Funding Source: NIH RePORTER; NIMH NIH HHS [P30 MH30915, R37 MH43832, P30 MH52247] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGST J, 1974, CLASSIFICATION PREDI; ASBERG M, 1986, J AFFECT DISORD S, V2, pS1; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beekman ATF, 1995, J AFFECT DISORDERS, V36, P65, DOI 10.1016/0165-0327(95)00061-5; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BORSON S, 1986, J AM GERIATR SOC, V34, P341, DOI 10.1111/j.1532-5415.1986.tb04316.x; CONWELL Y, 1996, DIAGNOSIS TREATMENT, P397; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P46; FLINT A, 1998, 1998 AM ASS GER PSYC; FOGLIA JP, 1987, CLIN CHEM, V33, P1024; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; GEORGOTAS A, 1988, ARCH GEN PSYCHIAT, V45, P929; GEORGOTAS A, 1989, ARCH GEN PSYCHIAT, V46, P783; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JACOBY R, 1993, BRIT J PSYCHIAT, V162, P175; KELLER MB, 1983, JAMA-J AM MED ASSOC, V250, P3299, DOI 10.1001/jama.250.24.3299; Klerman GL, 1984, INTERPERSONAL PSYCHO; Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186; Little JT, 1998, AM J PSYCHIAT, V155, P1035, DOI 10.1176/ajp.155.8.1035; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; MURPHY E, 1983, BRIT J PSYCHIAT, V142, P111, DOI 10.1192/bjp.142.2.111; Murray C. J. L., 1996, GLOBAL BURDEN DIS; PEREL JM, 1994, DIAGNOSIS TREATMENT, P245; POST F, 1998, PSYCHIAT ASPECTS NEU, P99; Reynolds CF, 1996, AM J PSYCHIAT, V153, P1288; REYNOLDS CF, IN PRESS AM J GERIAT; REYNOLDS CF, 1995, DIAGNOSIS TREATMENT, P463; ROVNER BW, 1993, AM J MED S5A, V94, P19; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; STACK JA, 1995, PSYCHIAT RES, V56, P17, DOI 10.1016/0165-1781(94)02617-R; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WAGNER EF, 1992, J PSYCHOTHERAPY PRAC, V22, P281; WILLIAMSON GM, 1990, PSYCHOL AGING, V5, P502, DOI 10.1037/0882-7974.5.4.502; Zis A P, 1980, Psychopharmacol Bull, V16, P47	38	415	422	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					39	45		10.1001/jama.281.1.39	http://dx.doi.org/10.1001/jama.281.1.39			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153JE	9892449				2022-12-28	WOS:000077829300033
J	Bonfanti, L; Mironov, AA; Martinez-Menarguez, JA; Martella, O; Fusella, A; Baldassarre, M; Buccione, R; Geuze, HJ; Mironov, AA; Luini, A				Bonfanti, L; Mironov, AA; Martinez-Menarguez, JA; Martella, O; Fusella, A; Baldassarre, M; Buccione, R; Geuze, HJ; Mironov, AA; Luini, A			Procollagen traverses the Golgi stack without leaving the lumen of Cisternae: Evidence for cisternal maturation	CELL			English	Article							COLLAGEN TRIPLE-HELIX; ELECTRON-MICROSCOPY; I COLLAGEN; TRANSPORT; CELLS; MEMBRANE; SECRETION; VESICLES; COMPLEX; ORGANIZATION	Newly synthesized procollagen type I (PC) assembles into 300 nm rigid, rod-like triple helices in the lumen of the endoplasmic reticulum. This oligomeric complex moves to the Golgi and forms large electron-dense aggregates. We have monitored the transport of PC along the secretory pathway. We show that PC moves across the Golgi stacks without ever leaving the lumen of the Golgi cisternae. During transport from the endoplasmic reticulum to the Golgi, PC is found within tubular-saccular structures greater than 300 nm in length. Thus, supermolecular cargoes such as PC do not utilize the conventional vesicle-mediated transport to traverse the Golgi stacks. Our results imply that PC moves in the anterograde direction across the Golgi complex by a process involving progressive maturation of Golgi cisternae.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Morphol, I-66030 Chieti, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Mol Neurobiol Lab, I-66030 Chieti, Italy; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Utrecht University; Utrecht University	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy.	mironov@cmns.mnegri.it; luini@cmns.mnegri.it	Baldassarre, Massimiliano/AAI-6581-2021; Luini, Alberto/L-1372-2013; Baldassarre, Massimiliano/E-6236-2011	Baldassarre, Massimiliano/0000-0002-2498-4767; Luini, Alberto/0000-0002-8729-2549; Baldassarre, Massimiliano/0000-0002-2498-4767; Buccione, Roberto/0000-0001-9210-5261; Mironov, Aleksandr/0000-0002-1497-328X				AYALA J, 1994, J CELL SCI, V107, P753; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Beck K, 1996, J BIOL CHEM, V271, P21566, DOI 10.1074/jbc.271.35.21566; BECKER B, 1995, TRENDS CELL BIOL, V5, P305, DOI 10.1016/S0962-8924(00)89047-9; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Buccione R, 1996, J BIOL CHEM, V271, P3523; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FOELLMER HG, 1983, EUR J BIOCHEM, V134, P183, DOI 10.1111/j.1432-1033.1983.tb07549.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; HARWOOD R, 1976, BIOCHEM J, V156, P81, DOI 10.1042/bj1560081; Jantti J, 1997, EUR J CELL BIOL, V74, P150; KAO WWY, 1977, J BIOL CHEM, V252, P8391; Kim YR, 1997, J CELL BIOCHEM, V67, P338, DOI 10.1002/(SICI)1097-4644(19971201)67:3<338::AID-JCB6>3.0.CO;2-X; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; OHTANI H, 1992, J HISTOCHEM CYTOCHEM, V40, P1139, DOI 10.1177/40.8.1619278; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARRAS MP, 1991, DEV BIOL, V148, P495, DOI 10.1016/0012-1606(91)90267-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; TRELSTAD RL, 1979, DEV BIOL, V71, P228, DOI 10.1016/0012-1606(79)90166-0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	33	300	309	1	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					993	1003		10.1016/S0092-8674(00)81723-7	http://dx.doi.org/10.1016/S0092-8674(00)81723-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875853	Bronze			2022-12-28	WOS:000077759100014
J	Nussenzweig, MC				Nussenzweig, MC			Immune receptor editing: Revise and select	CELL			English	Review							MATURE B-CELLS; LYMPHOCYTES		Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019					BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURNET FM, 1959, CLONAL SELECTION THE; Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; McMahan CJ, 1998, IMMUNITY, V9, P637, DOI 10.1016/S1074-7613(00)80661-5; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wang FP, 1998, P NATL ACAD SCI USA, V95, P11834, DOI 10.1073/pnas.95.20.11834	19	80	85	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					875	878		10.1016/S0092-8674(00)81711-0	http://dx.doi.org/10.1016/S0092-8674(00)81711-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875841	Bronze			2022-12-28	WOS:000077759100002
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Transplantation - Brain transplants?	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2213	2213		10.1126/science.282.5397.2213a	http://dx.doi.org/10.1126/science.282.5397.2213a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890829				2022-12-28	WOS:000077645800032
J	Adams, J				Adams, J			Benchmarking international research	NATURE			English	Editorial Material									Univ Leeds, Ctr Policy Studies Educ, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Adams, J (corresponding author), Univ Leeds, Ctr Policy Studies Educ, Leeds LS2 9JT, W Yorkshire, England.		Adams, Jonathan/A-5224-2009	Adams, Jonathan/0000-0002-0325-4431				ADAMS J, 1998, BENCHMARKING INT STA; Hicks D, 1997, 6 STEEP U SUSS; HILLS G, 1998, CHEM IND, V7, P284; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; May RM, 1998, SCIENCE, V281, P49, DOI 10.1126/science.281.5373.49; *OFF SCI TECHN, 1997, AN QUAL UK SCI BAS	6	63	66	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					615	618		10.1038/25219	http://dx.doi.org/10.1038/25219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872303				2022-12-28	WOS:000077694200021
J	Read, RC				Read, RC			Treating influenza with zanamivir	LANCET			English	Editorial Material							NEURAMINIDASE; EFFICACY; SAFETY		Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2RX, S Yorkshire, England; Royal Hallamshire Hosp, Dept Infect & Trop Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; University of Sheffield	Read, RC (corresponding author), Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2RX, S Yorkshire, England.			Read, Robert/0000-0002-4297-6728				Goto H, 1997, VIROLOGY, V238, P265, DOI 10.1006/viro.1997.8810; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Schmid ML, 1998, BRIT MED J, V316, P275, DOI 10.1136/bmj.316.7127.275; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0	7	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1872	1873		10.1016/S0140-6736(98)00087-7	http://dx.doi.org/10.1016/S0140-6736(98)00087-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863779				2022-12-28	WOS:000077544600002
J	Derynck, R; Zhang, Y; Feng, XH				Derynck, R; Zhang, Y; Feng, XH			Smads: Transcriptional activators of TGF-beta responses	CELL			English	Review							TUMOR-SUPPRESSOR; PROTEINS; DNA		Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601				Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	29	924	967	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					737	740		10.1016/S0092-8674(00)81696-7	http://dx.doi.org/10.1016/S0092-8674(00)81696-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865691	Bronze			2022-12-28	WOS:000077498800003
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Molecular barbells	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1439	1439		10.1126/science.282.5393.1439	http://dx.doi.org/10.1126/science.282.5393.1439			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867653				2022-12-28	WOS:000077110800035
J	Yu, ZY; Lennon, VA				Yu, ZY; Lennon, VA			Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IGG CATABOLISM; RECEPTOR; TRANSPORT		Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Yu, ZY (corresponding author), Mayo Clin, Rochester, MN 55905 USA.							BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0; Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008; Geha R. S., 1996, THERAPEUTIC IMMUNOLO, P280; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Junghans RP, 1997, BLOOD, V90, P3815, DOI 10.1182/blood.V90.10.3815; MARTIN MG, 1993, J CLIN INVEST, V91, P2844, DOI 10.1172/JCI116528; MASSON PL, 1993, J AUTOIMMUN, V6, P683, DOI 10.1006/jaut.1993.1057; SELL S, 1964, J IMMUNOL, V93, P81	9	311	330	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					227	228		10.1056/NEJM199901213400311	http://dx.doi.org/10.1056/NEJM199901213400311			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895405				2022-12-28	WOS:000078202900011
J	Sacco, RL; Elkind, M; Boden-Albala, B; Lin, IF; Kargman, DE; Hauser, WA; Shea, S; Paik, MC				Sacco, RL; Elkind, M; Boden-Albala, B; Lin, IF; Kargman, DE; Hauser, WA; Shea, S; Paik, MC			The protective effect of moderate alcohol consumption on ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	22nd International Joint Conference on Stroke and Cerebral Circulation	FEB 06-08, 1997	ANAHEIM, CALIFORNIA	Natl Inst Neurol Disorders & Stroke, Amer Heart Assoc			HIGH-DENSITY-LIPOPROTEIN; RISK-FACTORS; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; CEREBRAL-HEMORRHAGE; CIGARETTE-SMOKING; DRINKING HABITS; HEART-DISEASE; FOLLOW-UP; QUESTIONNAIRE	Context Moderate alcohol consumption has been shown to be protective for coronary heart disease, but the relationship between moderate alcohol consumption and ischemic stroke is more controversial. Objective To determine the association between alcohol consumption and risk of ischemic stroke. Design Population-based case-control study conducted between July 1993 and June 1997. Setting Multiethnic population in northern Manhattan, New York, NY, aged 40 years or older. Patients and Other Participants Cases (n = 677) had first ischemic stroke and were matched to community controls (n = 1139) derived through random digit dialing by age, sex, and race/ethnicity. Mean +/- SD age of cases was 70.0 +/- 12.7 years; 55.8% were women; 19.5% were white, 28.4% black, and 50.7% Hispanic. Main Outcome Measure First ischemic stroke (fatal or nonfatal). Results Moderate alcohol consumption, up to 2 drinks per day, was significantly protective for ischemic stroke after adjustment for cardiac disease, hypertension, diabetes, current smoking, body mass index, and education (odds ratio [OR], 0.51; 95% confidence interval [CI], 0.39-0.67). This protective effect of alcohol consumption was detected in both younger and older groups, in men and women, and in whites, blacks, and Hispanics. In a quadratic model of stroke risk, increased risk of ischemic stroke was statistically significant among those consuming 7 or more drinks per day (OR, 2.96; 95% CI, 1.05-8.29). Conclusions Moderate alcohol consumption was independently associated with a decreased risk of ischemic stroke in our elderly, multiethnic, urban subjects, while heavy alcohol consumption had deleterious effects. Our data support the National Stroke Association Stroke Prevention Guidelines regarding the beneficial effects of moderate alcohol consumption.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY USA; Columbia Univ, Sch Publ Hlth, Div Sociomed Sci, New York, NY USA; Columbia Univ, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Sacco, RL (corresponding author), Neurol Inst, 710 W 168th St, New York, NY 10032 USA.		Albala, Bernadette Boden/J-5703-2013; Hauser, W Allen/AAB-5277-2020; Tuluc, Petronel/C-2527-2011; Sacco, Ralph/Y-9278-2019	Albala, Bernadette Boden/0000-0001-5664-2342; Boden-Albala, Bernadette/0000-0002-3752-329X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517, R01NS029993, T32NS007153] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 29993, R01 NS 27517, T32 NS 07153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUZEID HAH, 1977, STROKE, V8, P106, DOI 10.1161/01.STR.8.1.106; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; Aull S, 1996, AM J MED, V101, P291, DOI 10.1016/S0002-9343(96)00199-4; BEGHI E, 1995, STROKE, V26, P1691, DOI 10.1161/01.STR.26.9.1691; BENSHLOMO Y, 1992, STROKE, V23, P1093, DOI 10.1161/01.STR.23.8.1093; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; Fang J, 1996, NEW ENGL J MED, V335, P1545, DOI 10.1056/NEJM199611213352101; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; Gentry E M, 1985, Am J Prev Med, V1, P9; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; GORELICK P B, 1986, Current Concepts of Cerebrovascular Disease and Stroke, V21, P21; GORELICK PB, 1989, NEUROLOGY, V39, P339, DOI 10.1212/WNL.39.3.339; HANSAGI H, 1995, STROKE, V26, P1768, DOI 10.1161/01.STR.26.10.1768; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; HASELAGER EM, 1977, LANCET, V1, P774; HENRICH JB, 1989, ARCH INTERN MED, V149, P1413, DOI 10.1001/archinte.149.6.1413; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; JAMROZIK K, 1994, STROKE, V25, P51, DOI 10.1161/01.STR.25.1.51; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; KLATSKY AL, 1989, STROKE, V20, P741, DOI 10.1161/01.STR.20.6.741; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZAREVIC D, 1983, INT J EPIDEMIOL, V12, P145, DOI 10.1093/ije/12.2.145; Maclure M, 1990, Epidemiology, V1, P441, DOI 10.1097/00001648-199011000-00005; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MarquesVidal P, 1996, AM J EPIDEMIOL, V143, P1089, DOI 10.1093/oxfordjournals.aje.a008683; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; *NAT STROK ASS STR, 1998, J STROKE CEREBROVASC, V7, P162; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; Rimm EB, 1996, AM J EPIDEMIOL, V143, P1094; RODGERS H, 1993, STROKE, V24, P1473, DOI 10.1161/01.STR.24.10.1473; ROMELSJO A, 1995, INT J EPIDEMIOL, V24, P929, DOI 10.1093/ije/24.5.929; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; Sacco RL, 1997, STROKE, V28, P929, DOI 10.1161/01.STR.28.5.929; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEMMERMANN GN, 1984, STROKE, V15, P23, DOI 10.1161/01.STR.15.1.23; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WOLF PA, 1988, ANN NEUROL, V24, P177	63	367	373	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					53	60		10.1001/jama.281.1.53	http://dx.doi.org/10.1001/jama.281.1.53			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892451	Bronze			2022-12-28	WOS:000077829300035
J	Laredo, J; Thurer, RL; Burke, PA; Archer, SY				Laredo, J; Thurer, RL; Burke, PA; Archer, SY			A 70-year-old man with an empyema	LANCET			English	Article							LAPAROSCOPIC CHOLECYSTECTOMY		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Div Gen Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Div Cardiothorac Surg, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Archer, SY (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Div Gen Surg, Boston, MA 02215 USA.			Burke, Peter/0000-0002-0329-5436				BARNARD SP, 1995, ANN THORAC SURG, V60, P1100, DOI 10.1016/0003-4975(95)00404-9; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; Horton M, 1998, AM J SURG, V175, P375, DOI 10.1016/S0002-9610(98)00048-8; LESLIE KA, 1994, CAN J SURG, V37, P240; Noda S, 1998, ANN THORAC SURG, V65, P1465, DOI 10.1016/S0003-4975(98)00102-7	5	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1982	1982		10.1016/S0140-6736(98)09328-3	http://dx.doi.org/10.1016/S0140-6736(98)09328-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872249				2022-12-28	WOS:000077663000013
J	El-Sadr, WM; Murphy, RL; Yurik, RM; Luskin-Hawk, R; Cheung, TW; Balfour, HH; Eng, R; Hooton, TM; Kerkering, TM; Schutz, M; van der Horst, C; Hafner, R				El-Sadr, WM; Murphy, RL; Yurik, RM; Luskin-Hawk, R; Cheung, TW; Balfour, HH; Eng, R; Hooton, TM; Kerkering, TM; Schutz, M; van der Horst, C; Hafner, R		Community Program Clin Res AIDS AIDS Clin Trial	Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PROPHYLAXIS; SULFAMETHOXAZOLE; METAANALYSIS; ENCEPHALITIS; INTOLERANT; EFFICACY; 566C80; AIDS	Background Although trimethoprim-sulfamethoxazole is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tolerate it and must switch to an alternative agent. Methods We conducted a multicenter, open-label, randomized trial comparing daily atovaquone (1500-mg suspension) with daily dapsone (100 mg) for the prevention of P. carinii pneumonia among patients infected with the human immunodeficiency virus who could not tolerate trimethoprim-sulfamethoxazole. The median follow-up period was 27 months. Results Of 1057 patients enrolled, 298 had a history of P. carinii pneumonia. P. carinii pneumonia developed in 122 of 536 patients assigned to atovaquone (15.7 cases per 100 person-years), as compared with 135 of 521 in the dapsone group (18.4 cases per 100 person-years; relative risk for atovaquone vs, dapsone, 0.85; 95 percent confidence interval, 0.67 to 1.09; P = 0.20). The relative risk of death was 1.07 (95 percent confidence interval, 0.89 to 1.30; P = 0.45), and the relative risk of discontinuation of the assigned medication because of adverse events was 0.94 (95 percent confidence interval, 0.74 to 1.19; P = 0.59). Among the 546 patients who were receiving dapsone at base line, the relative risk of discontinuation because of adverse events was 3.78 for atovaquone as compared with dapsone (95 percent confidence interval, 2.37 to 6.01; P < 0.001); among those not receiving dapsone at base line, it was 0.42 (95 percent confidence interval, 0.30 to 0.58; P < 0.001). Conclusions Among patients who cannot tolerate trimethoprim-sulfamethoxazole, atovaquone and dapsone are similarly effective for the prevention of Fi carinii pneumonia. Our results support the continuation of dapsone prophylaxis among patients who are already receiving it. However, among those not receiving dapsone, atovaquone is better tolerated and may be the preferred choice for prophylaxis against Fl carinii pneumonia. (N Engl J Med 1998;339:1889-95.) (C) 1998, Massachusetts Medical Society.	Harlem Hosp Med Ctr, Div Infect Dis, New York, NY 10037 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; St Josephs Med Ctr, Chicago, IL USA; Mt Sinai Med Ctr, New York, NY 10029 USA; E Orange Vet Affairs Hosp, E Orange, NJ USA; Univ Washington, Seattle, WA 98195 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Illinois Masonic Med Ctr, Chicago, IL 60657 USA; Univ N Carolina, Chapel Hill, NC USA; NIAID, Div AIDS, Bethesda, MD 20892 USA	Columbia University; Northwestern University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle; Virginia Commonwealth University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	El-Sadr, WM (corresponding author), Harlem Hosp Med Ctr, Div Infect Dis, Rm 3107,506 Lenox Ave, New York, NY 10037 USA.			Murphy, Robert/0000-0003-3936-2052				[Anonymous], 1997, MMWR Recomm Rep, V46, P1; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Bucher HC, 1997, J ACQ IMMUN DEF SYND, V15, P104, DOI 10.1097/00042560-199706010-00002; Chaisson RE, 1997, J ACQ IMMUN DEF SYND, V16, pS14, DOI 10.1097/00042560-199701001-00003; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CHENE G, 1997, 37 INT C ANT AG CHEM, P269; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GLUCKSTEIN D, 1995, CLIN INFECT DIS, V20, P849, DOI 10.1093/clinids/20.4.849; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; JORDE UP, 1993, AIDS, V7, P355, DOI 10.1097/00002030-199303000-00008; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; LEOUNG G, 1997, 37 INT C ANT AG CHEM, P10; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MASUR H, 1993, NEW ENGL J MED, V328, P1136; MURPHY R, 1998, P 5 C RETR OPP INF C, P113; OPRAVIL M, 1995, CLIN INFECT DIS, V20, P531, DOI 10.1093/clinids/20.3.531; PARA MF, 1997, P 4 C RETR OPP INF W, P65; SalmonCeron C, 1996, J INFECT DIS, V173, P277	20	110	113	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1889	1895		10.1056/NEJM199812243392604	http://dx.doi.org/10.1056/NEJM199812243392604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862944				2022-12-28	WOS:000077696600004
J	Solomon, DH; Hashimoto, H; Daltroy, L; Liang, MH				Solomon, DH; Hashimoto, H; Daltroy, L; Liang, MH			Techniques to improve physicians' use of diagnostic tests - A new conceptual framework	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TEST-ORDERING BEHAVIOR; RANDOMIZED CONTROLLED TRIAL; CONTINUING MEDICAL-EDUCATION; OTTAWA ANKLE RULES; LABORATORY TESTS; COST-CONTAINMENT; GENERAL-PRACTITIONERS; HOUSE STAFF; MULTICENTER TRIAL; INAPPROPRIATE USE	Objectives.-To review the published literature on interventions aimed at improving physicians' testing practices and propose methodologic standards for these studies and to review selected studies using the PRECEDE framework, a behavioral model that helps categorize interventions based on which behavioral factors are being affected. Data Sources.-MEDLINE, EMBASE, and HEALTHStar databases were searched for the years 1966 to January 1, 1998, for English-language articles pertaining to diagnostic testing behavior; bibliographies were scanned to identify articles of potential interest; and researchers in health services, health behavior, and behavior modification were contacted for proprietary and other unpublished articles. Study Selection.-A total of 102 articles were identified that described the results of interventions aimed at changing physicians' testing practices. We included the 49 studies that compared diagnostic testing practices in intervention and control groups. Data Extraction.-Two investigators independently reviewed each article in a blinded fashion using a standard data collection form to obtain a methodologic score and to abstract the key elements of each intervention. Data Synthesis.-On a 38-point methodologic criteria scale, the mean +/- SD score was 13 +/- 4.4. The desired behavior change was reported in the intervention group in 37 (76%) of 49 studies. Twenty-four (86%) of 28 interventions targeted at many behavioral factors were successful, while 13 (62%) of 21 studies aimed at a single behavioral factor were successful (P=.12). Conclusions.-A majority of interventions to improve physicians' testing practices reported in the literature claimed success, with interventions based on multiple behavioral factors trending toward being more successful. While methodologic flaws hamper drawing strong conclusions from this literature, application of a behavioral framework appears to be useful in explaining interventions that are successful and can facilitate interpretation of intervention results.	Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, RB Brigham Multipurp Arthrit & Musculosk Dis Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Solomon, DH (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 221 Longwood Ave,Suite 341, Boston, MA 02115 USA.	dhsolomon@bics.bwh.harvard.edu			NIAID NIH HHS [AI31599] Funding Source: Medline; NIAMS NIH HHS [AR07530-10, AR36038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, U01AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABBOTT JA, 1977, WESTERN J MED, V126, P173; APPLEGATE WB, 1983, MED CARE, V21, P486, DOI 10.1097/00005650-198305000-00002; Auleley GR, 1997, JAMA-J AM MED ASSOC, V277, P1935; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; BALAS EA, 1995, MED CARE, V33, P687, DOI 10.1097/00005650-199507000-00005; BAREFORD D, 1990, BRIT MED J, V301, P1305, DOI 10.1136/bmj.301.6764.1305; BASS EB, 1995, ARCH OPHTHALMOL-CHIC, V113, P27, DOI 10.1001/archopht.1995.01100010029018; Bates DW, 1997, ARCH INTERN MED, V157, P2501, DOI 10.1001/archinte.157.21.2501; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; BILLI JE, 1987, J GEN INTERN MED, V2, P306, DOI 10.1007/BF02596163; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; Bree RL, 1996, JAMA-J AM MED ASSOC, V276, P1595, DOI 10.1001/jama.276.19.1595; CASSCELLS W, 1978, NEW ENGL J MED, V299, P999, DOI 10.1056/NEJM197811022991808; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COHEN DI, 1982, MED CARE, V20, P286, DOI 10.1097/00005650-198203000-00005; DANIELS M, 1977, MED CARE, V15, P482, DOI 10.1097/00005650-197706000-00004; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; DIXON RH, 1974, ARCH INTERN MED, V134, P1064, DOI 10.1001/archinte.134.6.1064; DOWLING PT, 1989, ACAD MED, V64, P410, DOI 10.1097/00001888-198907000-00017; EISENBERG JM, 1977, MED CARE, V15, P915, DOI 10.1097/00005650-197711000-00005; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; EISENBERG JM, 1977, J MED EDUC, V52, P578; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FORREST JB, 1981, SURGERY, V90, P154; FOWKES FGR, 1986, LANCET, V1, P367; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; Freemantle N, 1996, HEALTH POLICY, V38, P71, DOI 10.1016/0168-8510(96)00837-8; GAMA R, 1992, J CLIN PATHOL, V45, P248, DOI 10.1136/jcp.45.3.248; GANS KM, 1993, AM J PREV MED, V9, P101, DOI 10.1016/S0749-3797(18)30748-7; GOLDEN WE, 1987, ARCH INTERN MED, V147, P1045, DOI 10.1001/archinte.147.6.1045; GORTMAKER SL, 1988, MED CARE, V26, P631, DOI 10.1097/00005650-198806000-00011; Green L.W., 1991, HLTH PROMOTION PLANN; GRIVELL AR, 1982, MED J AUSTRALIA, V2, P326, DOI 10.5694/j.1326-5377.1982.tb132452.x; GROOPMAN DS, 1992, ANN EMERG MED, V21, P524, DOI 10.1016/S0196-0644(05)82518-1; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; *HLTH CAR FIN ADM, 1997, HLTH CARE FINANCIN S, P150; Kanouse D E, 1988, Int J Technol Assess Health Care, V4, P27; KROENKE K, 1987, MED CARE, V25, P928, DOI 10.1097/00005650-198710000-00002; LYLE CB, 1979, J MED EDUC, V54, P856; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; McKinlay JB, 1996, SOC SCI MED, V42, P769, DOI 10.1016/0277-9536(95)00342-8; MOSKOWITZ MA, 1986, CLIN LAB MED, V6, P387, DOI 10.1016/S0272-2712(18)30820-5; MOZES B, 1989, ARCH INTERN MED, V149, P1836, DOI 10.1001/archinte.149.8.1836; MURRAY DM, 1988, AM J PREV MED, V4, P331, DOI 10.1016/S0749-3797(18)31142-5; NARDELLA A, 1994, ARCH PATHOL LAB MED, V118, P965; NOVICH M, 1985, AM J CLIN PATHOL, V84, P756, DOI 10.1093/ajcp/84.6.756; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; POP P, 1989, J ROY COLL GEN PRACT, V39, P507; POZEN MW, 1976, SOC SCI MED, V10, P491, DOI 10.1016/0037-7856(76)90117-7; PUGH JA, 1989, ARCH INTERN MED, V149, P426, DOI 10.1001/archinte.149.2.426; RATNAIKE S, 1993, MED J AUSTRALIA, V159, P666, DOI 10.5694/j.1326-5377.1993.tb138081.x; RHYNE RL, 1979, J FAM PRACTICE, V8, P1003; SCHECTMAN JM, 1991, ARCH INTERN MED, V151, P2163, DOI 10.1001/archinte.151.11.2163; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SCHROEDER SA, 1973, JAMA-J AM MED ASSOC, V225, P969, DOI 10.1001/jama.225.8.969; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; SPIEGEL JS, 1989, ARCH INTERN MED, V149, P549, DOI 10.1001/archinte.149.3.549; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; SUSSMAN E, 1984, MED CARE, V22, P569, DOI 10.1097/00005650-198406000-00007; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WACHTEL TJ, 1990, J GEN INTERN MED, V5, P335, DOI 10.1007/BF02600402; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WILLIAMS SV, 1986, J GEN INTERN MED, V1, P8, DOI 10.1007/BF02596318; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; WONG ET, 1983, JAMA-J AM MED ASSOC, V249, P3076, DOI 10.1001/jama.249.22.3076; YOUNG DW, 1988, POSTGRAD MED J, V64, P283, DOI 10.1136/pgmj.64.750.283; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	76	253	255	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2020	2027		10.1001/jama.280.23.2020	http://dx.doi.org/10.1001/jama.280.23.2020			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146YW	9863854				2022-12-28	WOS:000077462300033
J	Lloyd-Jones, DM; Martin, DO; Larson, MG; Levy, D				Lloyd-Jones, DM; Martin, DO; Larson, MG; Levy, D			Accuracy of death certificates for coding coronary heart disease as the cause of death	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; death certificates; cause of death; mortality; epidemiologic methods	MORTALITY; AUTOPSY; POPULATION; TRENDS; COMPLETION; STATISTICS; DECLINE; ERRORS; MEN	Background: Death certificates are widely used in epidemiologic and clinical investigations and for national statistics. Objective: To examine the accuracy of death certificates for coding coronary heart disease as the underlying cause of death. Design: Community-based inception cohort followed since 1948. Setting: Framingham, Massachusetts. Patients: 2683 deceased Framingham Heart Study participants. Measurements: Sensitivity, specificity, and predictive values of the death certificate. The reference standard was cause of death adjudicated by a panel of three physicians. Results: Among 2683 decedents, the death certificate coded coronary heart disease as the underlying cause of death for 942; the physician panel assigned coronary heart disease for 758. The death certificate had a sensitivity of 83.8% (95% CI, 81.1% to 86.4%), positive predictive value of 67.4% (CI, 64.4% to 70.4%), specificity of 84.1% (CI, 82.4% to 85.7%1), and negative predictive value of 92.9% (CI, 91.7% to 94.1 %) for coronary heart disease. The death certificate assigned coronary heart disease in 51.2% of 242 deaths (9.0% of total deaths) for which the physician panel could not determine a ca use. Compared with the physician panel, the death certificate attributed 24.3% more deaths to coronary heart disease overall and more than twice as many deaths to coronary heart disease in decedents who were at least 85 years of age. When deaths that were assigned unknown cause by the physician panel were excluded, the death certificate still assigned more deaths to coronary heart disease (7.9% overall and 43.1% in the oldest age group). Conclusions: Coronary heart disease may be overrepresented as a cause of death on death certificates. National mortality statistics, which are based on death certificate data, may overestimate the frequency of coronary heart disease by 7.9% to 24.3% overall and by as much as twofold in older persons.	NHLBI, NIH, Bethesda, MD 20892 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Levy, D (corresponding author), Framingham Heart Dis Epidemiol Study, 5 Thurber St, Framingham, MA 01702 USA.		Lloyd-Jones, Donald M/C-5899-2009; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254; Lloyd-Jones, Donald/0000-0003-0847-6110	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R, 1995, MONTHLY VITAL STA S2, V45; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; BRITTON M, 1974, ACTA MED SCAND, V196, P203; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COUGHLIN SS, 1992, J CLIN EPIDEMIOL, V45, P1, DOI 10.1016/0895-4356(92)90180-U; DAVIS BR, 1987, CONTROL CLIN TRIALS, V8, P110, DOI 10.1016/0197-2456(87)90036-5; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; ENGEL LW, 1980, AM J EPIDEMIOL, V111, P99, DOI 10.1093/oxfordjournals.aje.a112879; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JORDAN JM, 1993, CLIN INVEST MED, V16, P249; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KULLER LH, 1989, CIRCULATION, V80, P261, DOI 10.1161/01.CIR.80.2.261; LINDAHL BIB, 1994, SCAND J SOC MED, V22, P145, DOI 10.1177/140349489402200211; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAUSNER JS, 1974, EPIDEMIOLOGY INTRO T, P245; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; *NAT CTR HLTH STAT, 1989, ADV REP FIN MORT STA; *NAT HEART LUNG BL, 1996, MORB MORT; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PARK CB, 1991, J CLIN EPIDEMIOL, V44, P519, DOI 10.1016/0895-4356(91)90215-U; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; SAS Institute, 1996, SAS STAT SOFTW CHANG; SEXTON PT, 1992, AUST NZ J MED, V22, P114, DOI 10.1111/j.1445-5994.1992.tb02788.x; SORLIE PD, 1987, AM J PUBLIC HEALTH, V77, P148, DOI 10.2105/AJPH.77.2.148; STEHBENS WE, 1987, LANCET, V1, P606; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; WHO, 1995, WORLD HLTH STAT ANN; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; ZUMWALT RE, 1987, POSTGRAD MED, V81, P245, DOI 10.1080/00325481.1987.11699876	37	360	365	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1020	+		10.7326/0003-4819-129-12-199812150-00005	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	147DC	9867756				2022-12-28	WOS:000077471900004
J	Kandela, P				Kandela, P			The Great War	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1914, LANCET          1121, P1185; 1914, LANCET          0905, P659; 1915, LANCET          0102, P44; 1915, LANCET          0116, P168; 1914, LANCET          1003, P857; 1914, LANCET          0808, P428	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1947	1947		10.1016/S0140-6736(05)60457-6	http://dx.doi.org/10.1016/S0140-6736(05)60457-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863833				2022-12-28	WOS:000077544600077
J	Wiebers, D; Whisnant, J; Forbes, G; Meissner, I; Brown, R; Piepgras, D; Huston, J; Nichols, D; O'Fallon, W; Peacock, J; Jaeger, L; Kassell, N; Kongable-Beckman, G; Torner, J; Rajput, M; Drake, C; Kurtzke, J; Marler, J; Walker, M; Meyer, F; Atkinson, J; Marsh, W; Thielen, K; Ferguson, G; Barr, H; Lownie, S; Hachinski, V; Fox, A; Sahjpaul, R; Parrent, A; Mayer, C; Lindsay, K; Teasdale, E; Bone, I; Fatukasi, J; Lindsay, M; Cail, W; Sagher, O; Davis, M; Sengupta, R; Bates, D; Gholkar, A; Murdy, J; Wilson, S; Praharaj, S; Partridge, G; Reynolds, C; Hind, N; Ogilvy, C; Crowell, R; Gress, D; Schaefer, P; Choi, I; Buckley, D; Sloan, K; King, D; Giannotta, S; Ameriso, S; Teitelbaum, T; Thomson, E; Fishback, D; Vajda, J; Nyary, I; Czirjak, S; Horvath, M; Szikora, I; Pasztor, E; Varady, P; Erdos, A; Edner, G; Wahlgren, N; Lindqvist, M; Antonsson, A; Da Pian, R; Pasqualin, A; Chioffi, F; Beltramello, A; Zampieri, G; Benati, A; Rossi, G; Ronkainen, A; Hernesniemi, J; Vapalahti, M; Rinne, J; Luukkonen, M; Vihavainen, M; Savolainen, S; Koivisto, T; Leivo, S; Helin, K; Steinberg, G; Marks, M; Vanefsky, M; Norbash, A; Thompson, R; Bell, T; Marcellus, M; Meyer, A; Kerr, R; Adams, C; Molyneux, A; Vinden, S; Bacon, F; Shrimpton, J; Parker, S; Day, A; Nadeau, S; Stachniak, J; Friedman, W; Fessler, R; Peters, K; Jacob, R; Roper, S; Smith, A; LaFrentz, P; Howard, M; Loftus, C; Adams, H; Crosby, D; Rogers, M; Broderick, J; Tew, J; Brott, T; van Loveren, H; Yeh, H; Zuccarello, M; Tomsick, T; Gaskill-Shipley, M; Minneci, L; McMahon, N; Castel, J; Orgogozo, J; Loiseau, H; Bourgeois, P; Berge, J; Dousset, V; Cuny, E; Richard, M; Agbi, C; Hugenholtz, H; Benoit, B; Morrish, W; Wee, R; Grahovac, S; Pratt, L; Mortensen, M; Andreoli, A; Testa, C; Comani, V; Trevisan, C; Limoni, P; Carlucci, F; Leonardi, M; Sturiale, C; Pendl, G; Eder, H; Klein, G; Eder, M; Leber, K; Horner, T; Leipzig, T; Payner, T; Denardo, A; Scott, J; Redelman, K; Fisher, W; Rosner, M; Vitek, G; Hand, M; Flack, WF; Sichez, J; Pertuiset, B; Fohanno, D; Marsault, C; Casasco, A; Biondi, A; Capelle, L; Duffau, H; Winn, H; Grady, M; Newell, D; Longstreth, W; Thompson, P; Bybee, H; Jones, D; Findlay, J; Petruk, K; Steinke, D; Ashforth, R; Stenerson, P; Schindel, D; Vanderhoven, H; Neves, J; Zager, E; Flamm, E; Raps, E; Hurst, R; Parrott, S; Sellers, M; Torchia, M; Anderson, B; West, M; Fewer, D; Hill, N; Sutherland, G; Ross, I; McClarty, B; Brownstone, R; Williams, O; Narotam, P; Christane, L; McGinn, G; Gladish, D; Kirkpatrick, P; Pickard, J; Antoun, N; Simpson, D; Higgins, N; Turner, C; Tebbs, S; Holness, R; Malloy, D; Phillips, S; Maloney, W; Molina-de-Orozco, V; Baxter, B; Connolly-Campbell, K; MacDougall, A; Gentili, F; Wallace, M; ter Brugge, K; Willinsky, R; Tymianski, M; Rickards, L; Tucker, W; Lambert, C; Montanera, W; Rychlewski, C; Flood, C; Villani, R; Sganzerla, E; Tomei, G; Bettinelli, A; Leonardi, M; Ceccarelli, G; Righini, A; Bello, L; Marras, C; Nelson, R; Lewis, T; Renowden, C; Clarke, Y; Varian, L; Chyatte, D; Sila, C; Perl, J; Masaryk, T; Porterfield, R; Shaw, M; Foy, P; Nixon, T; Dunn, L; Clitheroe, N; Smith, T; Eldridge, P; Humphrey, P; Wiseman, J; Hawkins, K; Owen, L; Ost, K; Saminaden, S; Mohr, G; Schondorf, R; Carlton, J; Maleki, M; Just, N; Brien, S; Entis, S; Tampieri, D; Simons, N; Mooij, J; Metzemackers, J; Hew, J; Beks, J; van der Veen, A; Bosma, I; Sprengers, M; Rinkel, G; van Gijn, J; Ramos, L; Tulleken, C; Greebe, P; van Vliet, F; Borgesen, S; Jespersen, B; Boge-Rasmussen, T; Willumsen, L; Homer, D; Eller, T; Carpenter, J; Meyer, J; Munson, R; Small, B; Nussbaum, E; Heros, R; Latchaw, R; Camarata, P; Lundgren, J; Mattsen, N; Whittle, I; Sellar, R; O'Sullivan, M; Steers, A; Statham, P; Malcolm, G; Price, R; Hoffman, B; Yonas, H; Wechsler, L; Thompson-Dobkin, J; Jungreis, C; Kassam, A; Kirby, L; Parent, A; Lewis, A; Azordegan, P; Smith, R; Alexander, L; Gordon, D; Russell, W; Brown, R; Benashvili, G; Perry, R; Scalzo, D; Mandybur, G; Morgan, C; Karanjia, P; Madden, K; Kelman, D; Gallant, T; Vanderspek, H; Choucair, A; Neal, J; Mancl, K; Saveland, H; Brandt, L; Holtas, S; Trulsson, B; Macdonald, R; Weir, B; Mojtahedi, S; AMidei, C; Vermeulen, M; Bosch, D; Hulsmans, F; Albrecht, K; Roos, Y; Vet, A; Gorissen, A; Mechielsen, M; Martin, N; Gobin, Y; Saver, J; Vinuela, F; Duckwiler, G; Kelly, D; Frazee, J; da Graca, R; Gravori, T; Illingworth, R; Richards, P; Wade, J; Colquhoun, I; Bashir, E; Shortt, S; Weaver, J; Fisher, M; Stone, B; Chaturvedi, S; Davidson, R; Davidson, K; Giombini, S; Solero, C; Boiardi, A; Cimino, C; Valentini, S; Silvani, A; Alberts, M; Friedman, A; Gentry, A; Hoffman, K; Hughes, R; Lillihei, K; Earnest, M; Nichols, J; Kindt, G; Anderson, A; Levy, S; Nichols, J; Smith, R; Breeze, R; Noonan, V; Gress, D; Dowd, C; Vanwestrop, J; Wilson, C; Berger, M; Hannegan, L; Heros, R; Marcos, J; Ugarte, L; Kitchen, N; Taylor, W; Kumar, M; Grieve, J; Durity, F; Boyd, M; Fairholm, D; Griesdale, D; Honey, C; Redekop, G; Toyota, B; Turnbull, I; Woodhurst, W; Zwimpfer, T; Teal, P; Grabe, D; Brevner, A; Piepgras, A; Schmiedek, P; Schwartz, A; Weber, T; Biller, J; Brem, S; Cybulski, G; Chadwick, L; Bronstein, K; Pietila, T; Brock, M; Krug, D; Krznaric, I; Hernesniemi, J; Kivisaari, R				Wiebers, D; Whisnant, J; Forbes, G; Meissner, I; Brown, R; Piepgras, D; Huston, J; Nichols, D; O'Fallon, W; Peacock, J; Jaeger, L; Kassell, N; Kongable-Beckman, G; Torner, J; Rajput, M; Drake, C; Kurtzke, J; Marler, J; Walker, M; Meyer, F; Atkinson, J; Marsh, W; Thielen, K; Ferguson, G; Barr, H; Lownie, S; Hachinski, V; Fox, A; Sahjpaul, R; Parrent, A; Mayer, C; Lindsay, K; Teasdale, E; Bone, I; Fatukasi, J; Lindsay, M; Cail, W; Sagher, O; Davis, M; Sengupta, R; Bates, D; Gholkar, A; Murdy, J; Wilson, S; Praharaj, S; Partridge, G; Reynolds, C; Hind, N; Ogilvy, C; Crowell, R; Gress, D; Schaefer, P; Choi, I; Buckley, D; Sloan, K; King, D; Giannotta, S; Ameriso, S; Teitelbaum, T; Thomson, E; Fishback, D; Vajda, J; Nyary, I; Czirjak, S; Horvath, M; Szikora, I; Pasztor, E; Varady, P; Erdos, A; Edner, G; Wahlgren, N; Lindqvist, M; Antonsson, A; Da Pian, R; Pasqualin, A; Chioffi, F; Beltramello, A; Zampieri, G; Benati, A; Rossi, G; Ronkainen, A; Hernesniemi, J; Vapalahti, M; Rinne, J; Luukkonen, M; Vihavainen, M; Savolainen, S; Koivisto, T; Leivo, S; Helin, K; Steinberg, G; Marks, M; Vanefsky, M; Norbash, A; Thompson, R; Bell, T; Marcellus, M; Meyer, A; Kerr, R; Adams, C; Molyneux, A; Vinden, S; Bacon, F; Shrimpton, J; Parker, S; Day, A; Nadeau, S; Stachniak, J; Friedman, W; Fessler, R; Peters, K; Jacob, R; Roper, S; Smith, A; LaFrentz, P; Howard, M; Loftus, C; Adams, H; Crosby, D; Rogers, M; Broderick, J; Tew, J; Brott, T; van Loveren, H; Yeh, H; Zuccarello, M; Tomsick, T; Gaskill-Shipley, M; Minneci, L; McMahon, N; Castel, J; Orgogozo, J; Loiseau, H; Bourgeois, P; Berge, J; Dousset, V; Cuny, E; Richard, M; Agbi, C; Hugenholtz, H; Benoit, B; Morrish, W; Wee, R; Grahovac, S; Pratt, L; Mortensen, M; Andreoli, A; Testa, C; Comani, V; Trevisan, C; Limoni, P; Carlucci, F; Leonardi, M; Sturiale, C; Pendl, G; Eder, H; Klein, G; Eder, M; Leber, K; Horner, T; Leipzig, T; Payner, T; Denardo, A; Scott, J; Redelman, K; Fisher, W; Rosner, M; Vitek, G; Hand, M; Flack, WF; Sichez, J; Pertuiset, B; Fohanno, D; Marsault, C; Casasco, A; Biondi, A; Capelle, L; Duffau, H; Winn, H; Grady, M; Newell, D; Longstreth, W; Thompson, P; Bybee, H; Jones, D; Findlay, J; Petruk, K; Steinke, D; Ashforth, R; Stenerson, P; Schindel, D; Vanderhoven, H; Neves, J; Zager, E; Flamm, E; Raps, E; Hurst, R; Parrott, S; Sellers, M; Torchia, M; Anderson, B; West, M; Fewer, D; Hill, N; Sutherland, G; Ross, I; McClarty, B; Brownstone, R; Williams, O; Narotam, P; Christane, L; McGinn, G; Gladish, D; Kirkpatrick, P; Pickard, J; Antoun, N; Simpson, D; Higgins, N; Turner, C; Tebbs, S; Holness, R; Malloy, D; Phillips, S; Maloney, W; Molina-de-Orozco, V; Baxter, B; Connolly-Campbell, K; MacDougall, A; Gentili, F; Wallace, M; ter Brugge, K; Willinsky, R; Tymianski, M; Rickards, L; Tucker, W; Lambert, C; Montanera, W; Rychlewski, C; Flood, C; Villani, R; Sganzerla, E; Tomei, G; Bettinelli, A; Leonardi, M; Ceccarelli, G; Righini, A; Bello, L; Marras, C; Nelson, R; Lewis, T; Renowden, C; Clarke, Y; Varian, L; Chyatte, D; Sila, C; Perl, J; Masaryk, T; Porterfield, R; Shaw, M; Foy, P; Nixon, T; Dunn, L; Clitheroe, N; Smith, T; Eldridge, P; Humphrey, P; Wiseman, J; Hawkins, K; Owen, L; Ost, K; Saminaden, S; Mohr, G; Schondorf, R; Carlton, J; Maleki, M; Just, N; Brien, S; Entis, S; Tampieri, D; Simons, N; Mooij, J; Metzemackers, J; Hew, J; Beks, J; van der Veen, A; Bosma, I; Sprengers, M; Rinkel, G; van Gijn, J; Ramos, L; Tulleken, C; Greebe, P; van Vliet, F; Borgesen, S; Jespersen, B; Boge-Rasmussen, T; Willumsen, L; Homer, D; Eller, T; Carpenter, J; Meyer, J; Munson, R; Small, B; Nussbaum, E; Heros, R; Latchaw, R; Camarata, P; Lundgren, J; Mattsen, N; Whittle, I; Sellar, R; O'Sullivan, M; Steers, A; Statham, P; Malcolm, G; Price, R; Hoffman, B; Yonas, H; Wechsler, L; Thompson-Dobkin, J; Jungreis, C; Kassam, A; Kirby, L; Parent, A; Lewis, A; Azordegan, P; Smith, R; Alexander, L; Gordon, D; Russell, W; Brown, R; Benashvili, G; Perry, R; Scalzo, D; Mandybur, G; Morgan, C; Karanjia, P; Madden, K; Kelman, D; Gallant, T; Vanderspek, H; Choucair, A; Neal, J; Mancl, K; Saveland, H; Brandt, L; Holtas, S; Trulsson, B; Macdonald, R; Weir, B; Mojtahedi, S; AMidei, C; Vermeulen, M; Bosch, D; Hulsmans, F; Albrecht, K; Roos, Y; Vet, A; Gorissen, A; Mechielsen, M; Martin, N; Gobin, Y; Saver, J; Vinuela, F; Duckwiler, G; Kelly, D; Frazee, J; da Graca, R; Gravori, T; Illingworth, R; Richards, P; Wade, J; Colquhoun, I; Bashir, E; Shortt, S; Weaver, J; Fisher, M; Stone, B; Chaturvedi, S; Davidson, R; Davidson, K; Giombini, S; Solero, C; Boiardi, A; Cimino, C; Valentini, S; Silvani, A; Alberts, M; Friedman, A; Gentry, A; Hoffman, K; Hughes, R; Lillihei, K; Earnest, M; Nichols, J; Kindt, G; Anderson, A; Levy, S; Nichols, J; Smith, R; Breeze, R; Noonan, V; Gress, D; Dowd, C; Vanwestrop, J; Wilson, C; Berger, M; Hannegan, L; Heros, R; Marcos, J; Ugarte, L; Kitchen, N; Taylor, W; Kumar, M; Grieve, J; Durity, F; Boyd, M; Fairholm, D; Griesdale, D; Honey, C; Redekop, G; Toyota, B; Turnbull, I; Woodhurst, W; Zwimpfer, T; Teal, P; Grabe, D; Brevner, A; Piepgras, A; Schmiedek, P; Schwartz, A; Weber, T; Biller, J; Brem, S; Cybulski, G; Chadwick, L; Bronstein, K; Pietila, T; Brock, M; Krug, D; Krznaric, I; Hernesniemi, J; Kivisaari, R		Int Study Unruptured Intracranial Aneurysms Inv	Unruptured intracranial aneurysms - Risk of rupture and risks of surgical intervention	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SACCULAR ANEURYSMS; NATURAL-HISTORY; SURGERY; MORTALITY	Background The management of unruptured intracranial aneurysms requires knowledge of the natural history of these lesions and the risks of repairing them. Methods A total of 2621 patients at 53 participating centers in the United States, Canada, and Europe were enrolled in the study, which had retrospective and prospective components. In the retrospective component, we assessed the natural history of unruptured intracranial aneurysms in 1449 patients with 1937 such aneurysms; 727 of the patients had no history of subarachnoid hemorrhage from a different aneurysm (group 1), and 722 had a history of subarachnoid hemorrhage from a different aneurysm that had been repaired successfully (group 2). In the prospective component, we assessed treatment-related morbidity and mortality in 1172 patients with newly diagnosed unruptured intracranial aneurysms. Results In group 1, the cumulative rate of rupture of aneurysms that were less than 10 mm in diameter at diagnosis was less than 0.05 percent per year, and in group 2, the rate was approximately 11 times as high (0.5 percent per year). The rupture rate of aneurysms that were 10 mm or more in diameter was less than 1 percent per year in both groups, but in group 1, the rate was 6 percent the first year for giant aneurysms (greater than or equal to 25 mm in diameter). The size and location of the aneurysm were independent predictors of rupture. The overall rate of surgery-related morbidity and mortality was 17.5 percent in group 1 and 13.6 percent in group 2 at 30 days and was 15.7 percent and 13.1 percent, respectively, at 1 year. Age independently predicted surgical outcome. Conclusions The likelihood of rupture of unruptured intracranial aneurysms that were less than 10 mm in diameter was exceedingly low among patients in group 1 and was substantially higher among those in group 2. The risk of morbidity and mortality related to surgery greatly exceeded the 7.5-year risk of rupture among patients in group 1 with unruptured intracranial aneurysms smaller than 10 mm in diameter. (N Engl J Med 1998;339:1725-33.) (C) 1998, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, ISUIA Coordinating Ctr, Rochester, MN 55905 USA	Mayo Clinic	Wiebers, D (corresponding author), Mayo Clin & Mayo Fdn, ISUIA Coordinating Ctr, 200 1st St SW, Rochester, MN 55905 USA.		Bello, Lorenzo/AAB-2884-2022; Schaefer, Pamela/AAA-1323-2019; Roos, Yvo BWEM/B-9843-2013; ameriso, sebastian/AAV-2296-2020; Gobin, Yves Pierre/A-8008-2008; Biondi, Andrea/K-9997-2016; Friedman, William/GLR-1220-2022; van Gijn, Jan/A-9444-2008; Nussbaum, E/AAA-1371-2022; Silvani, Antonio/AAA-4600-2019; whittle, ian/AAX-7309-2021; Wechsler, Lawrence/AAB-9176-2020	Bello, Lorenzo/0000-0001-6797-7105; Silvani, Antonio/0000-0002-4791-1042; Steinberg, Gary/0000-0001-6374-1058	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028492] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-28492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHASON JL, 1958, NEUROLOGY, V8, P41, DOI 10.1212/WNL.8.1.41; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes G, 1996, AM J NEURORADIOL, V17, P1407; HEISKANEN O, 1986, J NEUROSURG, V65, P451, DOI 10.3171/jns.1986.65.4.0451; HOUSEPIAN EM, 1958, J NEUROPATH EXP NEUR, V17, P409, DOI 10.1097/00005072-195807000-00001; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; JAKUBOWSKI J, 1978, J NEUROL NEUROSUR PS, V41, P972, DOI 10.1136/jnnp.41.11.972; Jellinger K, 1977, Zentralbl Neurochir, V38, P29; JOMIN M, 1987, ACTA NEUROCHIR, V84, P85, DOI 10.1007/BF01418829; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MCCORMICK WF, 1970, J NEUROSURG, V33, P422, DOI 10.3171/jns.1970.33.4.0422; NISHIMOTO A, 1985, STROKE, V16, P48, DOI 10.1161/01.STR.16.1.48; RANKIN J, 1957, Scott Med J, V2, P200; RICE BJ, 1990, J NEUROSURG, V73, P165, DOI 10.3171/jns.1990.73.2.0165; STEHBENS WE, 1963, ARCH PATHOL, V75, P45; WIEBERS DO, 1992, NEW ENGL J MED, V327, P953, DOI 10.1056/NEJM199209243271310; WIEBERS DO, 1981, NEW ENGL J MED, V304, P696, DOI 10.1056/NEJM198103193041203; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; WIRTH FP, 1983, NEUROSURGERY, V12, P507, DOI 10.1227/00006123-198305000-00005; 1981, N ENGL J MED, V305, P99; 1987, J NEUROSURG, V67, P475	23	1236	1272	3	63	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1725	1733		10.1056/nejm199812103392401	http://dx.doi.org/10.1056/nejm199812103392401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9867550	Bronze			2022-12-28	WOS:000077459700001
J	Ledent, C; Valverde, O; Cossu, C; Petitet, F; Aubert, LF; Beslot, F; Bohme, GA; Imperato, A; Pedrazzini, T; Roques, BP; Vassart, G; Fratta, W; Parmentier, M				Ledent, C; Valverde, O; Cossu, C; Petitet, F; Aubert, LF; Beslot, F; Bohme, GA; Imperato, A; Pedrazzini, T; Roques, BP; Vassart, G; Fratta, W; Parmentier, M			Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice	SCIENCE			English	Article							MORPHINE; ACTIVATION; WITHDRAWAL; LACKING; GENE	The function of the central cannabinoid receptor (CB1) was investigated by invalidating its gene. Mutant mice did not respond to cannabinoid drugs, demonstrating the exclusive role of the CB1 receptor in mediating analgesia, reinforcement, hypothermia, hypolocomotion, and hypotension, The acute effects of opiates were unaffected, but the reinforcing properties of morphine and the severity of the withdrawal syndrome were strongly reduced. These observations suggest that the CB1 receptor is involved in the motivational properties of opiates and in the development of physical dependence and extend the concept of an interconnected role of CB1 and opiate receptors in the brain areas mediating addictive behavior.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Univ Paris 05, Dept Pharmacochim Mol & Struct, CNRS,URA D1500, INSERM,U266, F-75270 Paris, France; Univ Cagliari, Bernard B Brodie Dept Neurosci, I-09124 Cagliari, Italy; Rhone Poulenc Rorer SA, Ctr Rech Vitry Alfortville, F-94403 Vitry, France; Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cagliari; Sanofi-Aventis; University of Lausanne; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium.	mparment@ulb.ac.be	Valverde, Olga/D-8654-2012	Valverde, Olga/0000-0003-2264-7852; Parmentier, Marc/0000-0001-8081-4685				Abood ME, 1996, INT REV NEUROBIOL, V39, P197, DOI 10.1016/S0074-7742(08)60667-4; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hutcheson DM, 1998, BRIT J PHARMACOL, V125, P1567, DOI 10.1038/sj.bjp.0702228; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; KUZMIN A, 1992, PHARMACOL BIOCHEM BE, V41, P497, DOI 10.1016/0091-3057(92)90363-K; LAHTI RA, 1982, LIFE SCI, V31, P2257, DOI 10.1016/0024-3205(82)90132-1; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; Martellotta MC, 1998, NEUROSCIENCE, V85, P327, DOI 10.1016/S0306-4522(98)00052-9; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SMITH PB, 1994, J PHARMACOL EXP THER, V268, P1381; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; WAY EL, 1993, OPIOIDS, V2, P573; WELCH SP, 1992, J PHARMACOL EXP THER, V262, P10	24	1017	1044	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					401	404		10.1126/science.283.5400.401	http://dx.doi.org/10.1126/science.283.5400.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888857				2022-12-28	WOS:000078067000051
J	Beral, V; Hermon, C; Kay, C; Hannaford, P; Darby, SA; Reeves, G				Beral, V; Hermon, C; Kay, C; Hannaford, P; Darby, SA; Reeves, G			Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe the long term effects of the use of oral contraceptives on mortality Design Cohort study with 25 year follow up. Details of oral contraceptive use and of morbidity and mortality were reported six monthly by general practitioners. 75% of the original cohort was "flagged" on the NHS central registers. Setting 1400 general practices throughout Britain. Subjects 46 000 women, half of whom were using oral contraceptives at recruitment in 1968-9. Median age at end of follow up was 49 years. Main outcome measures Relative risks of death adjusted for age, parity, social class, and smoking. Results Over the 25 year follow up 1599 deaths were Research reported. Over the entire period of follow up the risk of death from all causes was similar in ever users and never users of oral contraceptives (relative risk = 1.0, 95% confidence interval 0.9 to 1.1; P = 0.7) and the risk of death for most specific causes did not differ significantly in the two groups, However, among current and recent (within 10 years) users the relative risk of death from ovarian cancer was 0.2 (0.1 to 0.8; P = 0.01), from cervical cancer 2.5 (1.1 to 6.1; P = 0.04), and from cerebrovascular disease 1.9 (1.2 to 3.1, P = 0.009). By contrast, for women who had stopped use greater than or equal to 10 years previously there were no significant excesses or deficits either overall or for any specific cause of death. Conclusion Oral contraceptives seem to have their main effect on mortality while they are being used and in the 10 years after use ceases. Ten or more years after use ceases mortality in past users is similar to that in never users.	Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England; Royal Coll Gen Practitioners, Manchester Res Unit, Manchester M22 4DB, Lancs, England	Radcliffe Infirmary; University of Oxford	Beral, V (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England.	beral@icrf.icnet.uk	Hannaford, Philip C/B-7867-2012					Beral V, 1996, EVIDENCE GUIDED PRES, P327; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; COLDITZ GA, 1994, ANN INTERN MED, V120, P821, DOI 10.7326/0003-4819-120-10-199405150-00002; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; OWENSMITH V, IN PRESS J EPIDEMIOL; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; PRESTON D. L., 1993, EPICURE USERS GUIDE; *ROYAL COLL GEN PR, 1974, OR CONTR HLTH; *ROYAL COLL GEN PR, 1983, J R COLL GEN PRACT, V33, P75; VESSEY M, 1976, Journal of Biosocial Science, V8, P373; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P1221; *WHO SCI GROUP, 1998, WHO TECH REP SER, V877; WINGRAVE SJ, 1981, J EPIDEMIOL COMMUN H, V35, P51, DOI 10.1136/jech.35.1.51; World Health Organization, 1967, INT CLASS DIS INJ CA	16	164	174	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					96	100		10.1136/bmj.318.7176.96	http://dx.doi.org/10.1136/bmj.318.7176.96			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880284	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078087500027
J	Strle, F; Nadelman, RB; Cimperman, J; Nowakowski, J; Picken, RN; Schwartz, I; Maraspin, V; Aguero-Rosenfeld, ME; Varde, S; Lotric-Furlan, S; Wormser, GP				Strle, F; Nadelman, RB; Cimperman, J; Nowakowski, J; Picken, RN; Schwartz, I; Maraspin, V; Aguero-Rosenfeld, ME; Varde, S; Lotric-Furlan, S; Wormser, GP			Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York state and by Borrelia afzelii in Slovenia	ANNALS OF INTERNAL MEDICINE			English	Article							EARLY LYME-DISEASE; CLINICAL MANIFESTATIONS; LATO; SKIN	Background: The clinical manifestations of Lyme borreliosis in North America and Europe seem to differ, but a systematic comparison has never been done. Objective: To compare European and U.S. patients with culture-confirmed erythema migrans. Design: Prospective, clinical cohort study. Setting: University medical centers in Westchester County, New York, and Ljubljana, Slovenia. Patients: 119 U.S. patients with Borrelia burgdorferi sensu stricto infection and 85 Slovenian patients with B. afzelii infection. Measurements: Interview, physical examination, and laboratory assays. Results: Compared with Slovenian patients, U.S. patients had erythema migrans for a briefer duration (median duration, 4 days compared with 14 days; P < 0.001) but were more likely to have systemic symptoms (P = 0.01), abnor mal findings on physical examination (P < 0.001), and seroreactivity (P < 0.001). Central clearing of erythema migrans lesions was more likely in Slovenian patients (P < 0.001). Conclusions: Erythema migrans caused by B. afzelii in Slovenia and erythema migrans caused by B. burgdorferi in New York have distinct clinical presentations. Caution should be used when clinical and laboratory experience from one side of the Atlantic is applied to patients on the other.	Westchester Cty Med Ctr, Div Infect Dis, Valhalla, NY 10595 USA; Univ Ljubljana, Ljubljana, Slovenia; New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Rush Med Coll, Chicago, IL 60612 USA; Westchester Cty Med Ctr, Clin Labs, Valhalla, NY 10595 USA	Westchester Medical Center; University of Ljubljana; New York Medical College; Rush University; Westchester Medical Center	Nadelman, RB (corresponding author), Westchester Cty Med Ctr, Div Infect Dis, Macy Pavill 209SE, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041508] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41508] Funding Source: Medline; PHS HHS [U50/CCU 210280, U50/CCU 210286] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; ASBRINK E, 1985, ACTA DERM-VENEREOL, V65, P43; ASBRINK E, 1986, ZBL BAKT-INT J MED M, V263, P229; BALMELLI T, 1995, RES MICROBIOL, V146, P329, DOI 10.1016/0923-2508(96)81056-4; BELFAIZA J, 1993, J CLIN MICROBIOL, V31, P2873, DOI 10.1128/JCM.31.11.2873-2877.1993; GARCIAMONCO JC, 1993, LYME DIS, P219; KUIPER H, 1994, J CLIN MICROBIOL, V32, P715, DOI 10.1128/JCM.32.3.715-720.1994; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; Ohlenbush A, 1996, J INFECT DIS, V174, P421, DOI 10.1093/infdis/174.2.421; Picken RN, 1996, EUR J CLIN MICROBIOL, V15, P313, DOI 10.1007/BF01695664; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; Strle F, 1996, CLIN INFECT DIS, V23, P61, DOI 10.1093/clinids/23.1.61; VANDAM AP, 1993, CLIN INFECT DIS, V17, P708, DOI 10.1093/clinids/17.4.708; WEBER K, 1986, ZBL BAKT-INT J MED M, V263, P209; WILSKE B, 1984, INFECTION, V12, P331, DOI 10.1007/BF01651147; Wormser GP, 1998, INFECTION, V26, P208, DOI 10.1007/BF02962365; 1991, MMWR MORB MORTAL WKL, V40, P417	21	153	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					32	36		10.7326/0003-4819-130-1-199901050-00006	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890847				2022-12-28	WOS:000077744500005
J	Basov, DN; Woods, SI; Katz, AS; Singley, EJ; Dynes, RC; Xu, M; Hinks, DG; Homes, CC; Strongin, M				Basov, DN; Woods, SI; Katz, AS; Singley, EJ; Dynes, RC; Xu, M; Hinks, DG; Homes, CC; Strongin, M			Sum rules and interlayer conductivity of High-T-c cuprates	SCIENCE			English	Article							CHARGE DYNAMICS; OPTICAL CONDUCTIVITY; AXIS RESPONSE; CUO2 PLANES; PSEUDOGAP; SUPERCONDUCTORS; LA2-XSRXCUO4; YBA2CU3O6+X; TRANSPORT; MODELS	Analysis of the interlayer infrared conductivity of cuprate high-transition temperature superconductors reveals an anomalously large energy scale extending up to midinfrared frequencies that can be attributed to formation of the superconducting condensate. This unusual effect is observed in a variety of materials, including Tl2Ba2CuO6+x, La2-xSrxCuO4, and YBa2Cu3O6.6, which show an incoherent interlayer response in the normal state. Midinfrared range condensation was examined in the context of sum rules that can be formulated for the complex conductivity. One possible interpretation of these experiments is in terms of a kinetic energy change associated with the superconducting transition.	Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Argonne Natl Lab, Dept Mat Sci, Argonne, IL 60439 USA; Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA	University of California System; University of California San Diego; University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory	Basov, DN (corresponding author), Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA.							Abrikosov AA, 1996, PHYS REV B, V54, P12003, DOI 10.1103/PhysRevB.54.12003; Anderson P.W., 1998, THEORY SUPERCONDUCTI; Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; ANDERSON PW, 1991, PHYS C, V11, P185; BASOV DN, 1994, PHYS REV B, V50, P3511, DOI 10.1103/PhysRevB.50.3511; BASOV DN, 1995, PHYS REV B, V52, P13141, DOI 10.1103/PhysRevB.52.R13141; Bernhard C, 1998, PHYS REV LETT, V80, P1762, DOI 10.1103/PhysRevLett.80.1762; Chakravarty S, 1998, EUR PHYS J B, V5, P337, DOI 10.1007/s100510050451; COOPER SL, 1994, PHYSICAL PROPERTIES, V4, P61; Das Sarma S, 1998, PHYS REV LETT, V80, P4753, DOI 10.1103/PhysRevLett.80.4753; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; EMERY VJ, UNPUB; HIRSCH JE, 1992, PHYSICA C, V199, P305, DOI 10.1016/0921-4534(92)90415-9; HOMES CC, 1995, PHYSICA C, V254, P265, DOI 10.1016/0921-4534(95)00579-X; HOMES CC, 1993, PHYS REV LETT, V71, P1645, DOI 10.1103/PhysRevLett.71.1645; Kim EH, 1998, PHYS REV B, V58, P2452, DOI 10.1103/PhysRevB.58.2452; Leggett AJ, 1996, SCIENCE, V274, P587, DOI 10.1126/science.274.5287.587; LEGGETT AJ, IN PRESS J PHYS CHEM; LORAM JW, 1993, PHYS REV LETT, V71, P1740, DOI 10.1103/PhysRevLett.71.1740; MALDAGUE PF, 1977, PHYS REV B, V16, P2437, DOI 10.1103/PhysRevB.16.2437; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; PALMER LH, 1968, PHYS REV, V165, P588, DOI 10.1103/PhysRev.165.588; RADTKE RJ, 1995, PHYSICA C, V250, P282, DOI 10.1016/0921-4534(95)00359-2; Schutzmann J, 1997, PHYS REV B, V55, P11118, DOI 10.1103/PhysRevB.55.11118; SCHUTZMANN J, 1994, PHYS REV LETT, V73, P174, DOI 10.1103/PhysRevLett.73.174; Shafranjuk SE, 1997, PHYS REV B, V55, P8425, DOI 10.1103/PhysRevB.55.8425; SHEN ZX, 1995, SCIENCE, V267, P343, DOI 10.1126/science.267.5196.343; Shibata H, 1997, PHYS REV B, V56, P14275, DOI 10.1103/PhysRevB.56.R14275; SINGLEY EJ, UNPUB; Tajima S, 1997, PHYS REV B, V55, P6051, DOI 10.1103/PhysRevB.55.6051; TAKENAKA K, 1994, PHYS REV B, V50, P6534, DOI 10.1103/PhysRevB.50.6534; TAMASAKU K, 1992, PHYS REV LETT, V69, P1455, DOI 10.1103/PhysRevLett.69.1455; TINKHAM M, 1959, PHYS REV LETT, V2, P331, DOI 10.1103/PhysRevLett.2.331; Tsvetkov AA, 1998, NATURE, V395, P360, DOI 10.1038/26439; Uchida S, 1996, PHYS REV B, V53, P14558, DOI 10.1103/PhysRevB.53.14558; WALSTEDT RE, 1990, PHYS REV B, V41, P9574, DOI 10.1103/PhysRevB.41.9574; WARREN WW, 1989, PHYS REV LETT, V62, P1193, DOI 10.1103/PhysRevLett.62.1193	39	205	206	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	1999	283	5398					49	52		10.1126/science.283.5398.49	http://dx.doi.org/10.1126/science.283.5398.49			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872736				2022-12-28	WOS:000077976600044
J	Gao, YJ; Sun, Y; Frank, KM; Dikkes, P; Fujiwara, Y; Seidl, KJ; Sekiguchi, JM; Rathbun, GA; Swat, W; Wang, JY; Bronson, RT; Malynn, BA; Bryans, M; Zhu, CM; Chaudhuri, J; Davidson, L; Ferrini, R; Stamato, T; Orkin, SH; Greenberg, ME; Alt, FW				Gao, YJ; Sun, Y; Frank, KM; Dikkes, P; Fujiwara, Y; Seidl, KJ; Sekiguchi, JM; Rathbun, GA; Swat, W; Wang, JY; Bronson, RT; Malynn, BA; Bryans, M; Zhu, CM; Chaudhuri, J; Davidson, L; Ferrini, R; Stamato, T; Orkin, SH; Greenberg, ME; Alt, FW			A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis	CELL			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; LIGASE-IV; GENE RECOMBINATION; MAMMALIAN-CELLS; NERVOUS-SYSTEM; DEFICIENT MICE; IN-VIVO; BCL-X; REARRANGEMENT	XRCC4 was identified via a complementation cloning method that employed an ionizing radiation (IR)-sensitive hamster cell line. By gene-targeted mutation, we show that XRCC4 deficiency in primary murine cells causes growth defects, premature senescence, IR sensitivity, and inability to support V(D)J recombination. In mice, XRCC4 deficiency causes late embryonic lethality accompanied by defective lymphogenesis and defective neurogenesis manifested by extensive apoptotic death of newly generated postmitotic neuronal cells. We find similar neuronal developmental defects in embryos that lack DNA ligase IV, an XRCC4-associated protein. Our findings demonstrate that differentiating lymphocytes and neurons strictly require the XRCC4 and DNA ligase IV end-joining proteins and point to the general stage of neuronal development in which these proteins are necessary.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Dept Pediat, Boston, MA 02115 USA; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 812, Japan; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Lankenau Med Res Ctr, Wynnewood, PA 19096 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Kyushu University; Tufts University; Tufts University; Lankenau Medical Center; Lankenau Institute for Medical Research	Alt, FW (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Ctr Blood Res, Boston, MA 02115 USA.			Sekiguchi, JoAnn/0000-0002-7178-4258	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047, K08AI001428, P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35714, AI20047, AI01428] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayer S.A., 1991, NEOCORTICAL DEV; Behrens TW, 1997, IMMUNOL RES, V16, P149, DOI 10.1007/BF02786359; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CHANG Y, 1995, IMMUNITY, V2, P607, DOI 10.1016/1074-7613(95)90005-5; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; CHUN JJ, 1993, NEURONAL CELL DEATH, P283; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DATTA SR, 1998, HORMONES SIGNALING, V1, P94; Errami A, 1996, MOL CELL BIOL, V16, P1519; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Shortman K, 1990, Semin Immunol, V2, P3; STAMATO T, 1993, RADIAT RES, V133, P60, DOI 10.2307/3578257; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tourigny MR, 1997, J EXP MED, V185, P1549, DOI 10.1084/jem.185.9.1549; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	46	554	565	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					891	902		10.1016/S0092-8674(00)81714-6	http://dx.doi.org/10.1016/S0092-8674(00)81714-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875844	Bronze			2022-12-28	WOS:000077759100005
J	Labauge, P; Laberge, S; Brunereau, L; Levy, C; Tournier-Lasserve, E				Labauge, P; Laberge, S; Brunereau, L; Levy, C; Tournier-Lasserve, E		Soc Francaise Neurochirurg	Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families	LANCET			English	Article							CHROMOSOME 7Q; NATURAL-HISTORY; MALFORMATIONS; LOCUS; INTERVAL; BRAIN; MAPS; CCM1	Background Cavernous angiomas, which are vascular malformations mostly located in the central nervous system, may be inherited as an autosomal dominant disorder known as familiar cerebral cavernoma (FCC). FCC has been studied in Hispanoamerican families, in which a strong founder effect was shown. We studied the families of 57 non-Hispanic patients with cavernous angiomas. Methods All 28 neurosurgery centres in France collaborated in the study. Inclusion criteria were: families of index patients known to have at least one clinically affected relative, and families of index patients with multiple cavernous angiomas who initially presented as sporadic cases. Clinical and cerebral magnetic resonance imaging (MRI) investigations were done in all patients and in other at-risk individuals who consented to take part. Findings On MRI, 16 of 22 sporadic index patients had relatives with cavernous angiomas. 51 multiple-case families, including 100 patients with symptoms and 164 symptom-free individuals had MRI lesions. Most FCC patients had multiple lesions and there was a strong correlation between number of lesions and age (p<0.01). The sensitivity of gradient-echo sequences was higher than that of standard MRI for detection of small cavernous angiomas. Pattern of inheritance was autosomal dominant, with incomplete clinical penetrance. The occurence of denovo mutations was strongly suggested in some families. Interpretation Neuroimaging penetrance of FCC is much higher than clinical penetrance. 75% of sporadic cases with multiple lesions are in fact familial cases. The proportion of patients developing clinical symptoms is higher in the hereditary form than in the sporadic form of the disorder.	Fac Med Necker Enfants Malad, INSERM, U25, F-75730 Paris, France; Hop Lariboisiere, F-75475 Paris, France; CHU Bretonneau, Serv Neuroradiol, F-37044 Tours, France; CHU St Antoine, Serv Radiol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Tournier-Lasserve, E (corresponding author), Fac Med Necker Enfants Malad, INSERM, U25, 156 Rue Vangirard, F-75730 Paris, France.	tournier@necker.fr	Tournier-Lasserve, Elisabeth/N-7134-2017; Laberge, Sophie/ABD-7353-2020	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Laberge, Sophie/0000-0003-4722-0361				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; GilNagel A, 1996, ANN NEUROL, V39, P807, DOI 10.1002/ana.410390619; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; Gunel M, 1996, NEUROSURGERY, V38, P1265; Headache Classification Committee of the International Headache Society, 1998, CEPHALALGIA S7, V8, P19; HSU FPK, 1993, CAVERNOUS MALFORMATI, P13; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; KATTAPONG VJ, 1995, NEUROLOGY, V45, P492, DOI 10.1212/WNL.45.3.492; KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820; LEJEUNE JP, 1989, NEUROCHIRURGIE, V35, P11; MALIK S, 1992, ARCH NEUROL-CHICAGO, V49, P170, DOI 10.1001/archneur.1992.00530260072023; MARCHUK DA, 1995, GENOMICS, V28, P311, DOI 10.1006/geno.1995.1147; Notelet L, 1997, J NEUROL NEUROSUR PS, V63, P40, DOI 10.1136/jnnp.63.1.40; OFTEN P, 1989, NEUROCHIRURGIE, V35, P82; Polymeropoulos MH, 1997, NEUROLOGY, V48, P752, DOI 10.1212/WNL.48.3.752; Pozzati E, 1996, NEUROSURGERY, V38, P662, DOI 10.1227/00006123-199604000-00006; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; ROBINSON JR, 1993, NEUROSURGERY, V32, P730, DOI 10.1227/00006123-199305000-00005; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; SIMARD JM, 1986, NEUROSURGERY, V18, P162; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	25	187	190	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1998	352	9144					1892	1897		10.1016/S0140-6736(98)03011-6	http://dx.doi.org/10.1016/S0140-6736(98)03011-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863787				2022-12-28	WOS:000077544600010
J	Montaner, JSG; Hogg, R; Raboud, J; Harrigan, R; O'Shaughnessy, M				Montaner, JSG; Hogg, R; Raboud, J; Harrigan, R; O'Shaughnessy, M			Antiretroviral treatment in 1998	LANCET			English	Review							IMMUNODEFICIENCY-VIRUS INFECTION; HIV-1 INFECTION; THERAPY; RECOMMENDATIONS; RESERVOIR; INDINAVIR; PLASMA; PANEL; AIDS		Univ British Columbia, St Pauls Hosp, BC Ctr Excellence HIV AIDS, Canadian HIV Trials Network, Vancouver, BC V6Z IY6, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, BC Ctr Excellence HIV AIDS, Canadian HIV Trials Network, Vancouver, BC V6Z IY6, Canada.		Hogg, Robert S/B-2783-2012; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; 				Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015; [Anonymous], 1996, Lancet, V348, P283; [Anonymous], 1998, LANCET, V351, P1825; BORLEFFS JC, 1998, 5 C RETR OPP INF FEB; CAMERON DW, 1998, 5 C RETR OPP INF FEB; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CHESNEY M, 1997, P ANN M AIDS CLIN TR; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLUMECK N, 1998, P 5 C RETR OPP INF F; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DEWOLF F, 1998, P 12 WORLD AIDS C JU; FERTHING C, 1998, P 38 INT C ANT AG CH; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL M, 1998, P 12 WORLD AIDS C JU; GERSTOFT J, 1997, P INT C ANT AG CHEM; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARBERL A, 1998, P 12 WORLD AIDS C JU; HARRIGAN PR, 1998, P 2 INT WORKSH HIV D; Harris M, 1998, J INFECT DIS, V177, P1514, DOI 10.1086/515317; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HOGG RS, 1998, IN PRESS AIDS; JOHNSON M, 1998, 5 C RETR OPP INF FEB; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MONTANER J, 1998, P 12 WORLD AIDS C JU; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Montaner JSG, 1998, AIDS, V12, pS15; MONTANER JSG, 1998, IN PRESS DRUG RESIST; MONTANER JSG, 1998, P 38 INT C ANT AG CH; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PATRIK AK, 1998, P 2 INT WORKSH HIV D; PAUWELS R, 1998, P 2 INT WORKSH HIV D; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; RENAUD M, 1998, P WORLD AIDS C JUN 2; Rhone SA, 1998, J INFECT DIS, V178, P662, DOI 10.1086/515365; SEKALY RP, 1998, P 12 WORLD AIDS C JU; SENSION M, 1998, 5 C RETR OPP INF FEB; SHAEFER M, 1998, P 12 WORLD AIDS C JU; STASZEWSKI S, 1998, P WORLD AIDS C JUN 2; WINSLOW D, 1998, P 12 WORLD AIDS C JU; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZOLOPA AR, 1998, P 12 WORLD AIDS C JU	55	73	74	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1998	352	9144					1919	1922		10.1016/S0140-6736(98)07532-1	http://dx.doi.org/10.1016/S0140-6736(98)07532-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863802				2022-12-28	WOS:000077544600043
J	Henry, MD; Campbell, KP				Henry, MD; Campbell, KP			A role for dystroglycan in basement membrane assembly	CELL			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; EMBRYONIC STEM-CELLS; BETA-1 INTEGRIN; EPITHELIAL MORPHOGENESIS; NEUROMUSCULAR-JUNCTION; FIBRONECTIN MATRIX; AGRIN RECEPTOR; LAMININ; EXPRESSION; COLLAGEN	Basement membranes are composed of ordered arrays of characteristic extracellular matrix proteins, but little is known about the assembly of these structures in vivo. We have investigated the function of dystroglycan, a cell-surface laminin receptor expressed by cells contacting basement membranes in developing and adult tissues. We find that dystroglycan is required for the formation of a basement membrane in embryoid bodies. Our results further indicate that dystroglycan-laminin interactions are prerequisite for the deposition of other basement membrane proteins. Dystroglycan may exert its influence on basement membrane assembly by binding soluble laminin and organizing it on the cell surface. These data establish a role for dystroglycan in the assembly of basement membranes and suggest fundamental mechanisms underlying this process.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Neurol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Kevin-campbell@uiowa.edu		Henry, Michael/0000-0002-7871-245X; Campbell, Kevin/0000-0003-2066-5889	NHLBI NIH HHS [HL07121] Funding Source: Medline; NIDDK NIH HHS [DK09712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; DARRIBERE T, 1986, CELL TISSUE RES, V246, P45, DOI 10.1007/BF00218997; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1996, MATRIX BIOL, V15, P397, DOI 10.1016/S0945-053X(96)90159-6; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; EKBLOM P, 1996, LAMININS, P185; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fleischmajer R, 1998, J CELL SCI, V111, P1929; FORM DM, 1986, LAB INVEST, V55, P521; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; Montanaro F, 1998, J NEUROSCI, V18, P1250; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Sasaki T, 1998, EXP CELL RES, V238, P70, DOI 10.1006/excr.1997.3837; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; THOMAS T, 1993, EXP CELL RES, V208, P54, DOI 10.1006/excr.1993.1222; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VRACKO R, 1974, AM J PATHOL, V77, P314; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; Yurchenco PD., 1994, EXTRACELLULAR MATRIX, P351; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	54	324	330	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					859	870		10.1016/S0092-8674(00)81708-0	http://dx.doi.org/10.1016/S0092-8674(00)81708-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865703	Bronze			2022-12-28	WOS:000077498800015
J	Noji, H				Noji, H			Amersham Pharmacia Biotech & Science Prize - The rotary enzyme of the cell: The rotation of F1-ATPase	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; ATP SYNTHASE; PROTEIN		Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, Kawasaki, Kanagawa, Japan	Teikyo University	Noji, H (corresponding author), Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, Kawasaki, Kanagawa, Japan.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1996, J BIOENERG BIOMEMBR, V28, P451, DOI 10.1007/BF02113988; RYRIE IJ, 1972, J BIOL CHEM, V247, P4453; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	11	25	25	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1844	1845		10.1126/science.282.5395.1844	http://dx.doi.org/10.1126/science.282.5395.1844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9874637				2022-12-28	WOS:000077338100037
J	Barton, JC; McDonnell, SM; Adams, PC; Brissot, P; Powell, LW; Edwards, CQ; Cook, JD; Kowdley, KV				Barton, JC; McDonnell, SM; Adams, PC; Brissot, P; Powell, LW; Edwards, CQ; Cook, JD; Kowdley, KV		Hemochromatosis Management Working Grp	Management of hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; GENETIC HEMOCHROMATOSIS; HEPATOCELLULAR-CARCINOMA; HYPOGONADOTROPIC HYPOGONADISM; TRANSFERRIN SATURATION; LIVER-TRANSPLANTATION; CHRONIC HEPATITIS; IRON DEPLETION	The complications of iron overload in hemochromatosis can be avoided by early diagnosis and appropriate management. Therapeutic phlebotomy is used to remove excess iron and maintain low normal body iron stores, and it should be initiated in men with serum ferritin levels of 300 mu g/L or more and in women with serum ferritin levels of 200 mu g/L or more, regardless of the presence or absence of symptoms. Typically, therapeutic phlebotomy consists of 1) removal of 1 unit (450 to 500 mL) of blood weekly until the serum ferritin level is 10 to 20 mu g/L and 2) maintenance of the serum ferritin level at 50 mu g/L or less thereafter by periodic removal of blood. Hyperferritinemia attributable to iron overload is resolved by therapeutic phlebotomy. When applied before iron overload becomes severe, this treatment also prevents complications of iron overload, including hepatic cirrhosis, primary liver cancer, diabetes mellitus, hypogonadotrophic hypogonadism, joint disease, and cardiomyopathy. In patients with established iron overload disease, weakness, fatigue, increased hepatic enzyme concentrations, right upper quadrant pain, and hyperpigmentation are often substantially alleviated by therapeutic phlebotomy. Patients with liver disease, joint disease, diabetes mellitus and other endocrinopathic abnormalities, and cardiac abnormalities often require additional, specific management. Dietary management of hemochromatosis includes avoidance of medicinal iron, mineral supplements, excess vitamin C, and uncooked seafoods. This can reduce the rate of iron reaccumulation; reduce retention of nonferrous metals; and help reduce complications of liver disease, diabetes mellitus, and Vibrio infection. This comprehensive approach to the management of hemochromatosis can decrease the frequency and severity of iron overload, improve quality of life, and increase longevity.	So Iron Overload Disorders Ctr, Birmingham, AL 35209 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA; London Hlth Sci Ctr, Dept Med, London, ON N6A 5A5, Canada; Hop Univ Pontchaillou, INSERM, U49, Clin Malad Foie, Rennes, France; Univ Queensland, Bancroft Ctr, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Utah, Coll Med, Salt Lake City, UT 84143 USA; Univ Utah, Latter Day St Hosp, Outpatient Clin, Salt Lake City, UT 84143 USA; Univ Kansas, Med Ctr, Div Hematol, Kansas City, KS 66103 USA; Univ Washington, Div Gastroenterol & Hepatol, Seattle, WA 98195 USA	Centers for Disease Control & Prevention - USA; London Health Sciences Centre; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); QIMR Berghofer Medical Research Institute; University of Queensland; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Kansas; University of Kansas Medical Center; University of Washington; University of Washington Seattle	Barton, JC (corresponding author), So Iron Overload Disorders Ctr, Suite G-105,2022 Brookwood Med Ctr Dr, Birmingham, AL 35209 USA.	ironmd@mem.po.com	Kowdley, Kris/AAF-5202-2019	Barton, James/0000-0003-2876-8276				ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; ADAMS PC, 1991, CLIN INVEST MED, V14, P16; ALTSTATT LB, 1967, P SOC EXP BIOL MED, V124, P353, DOI 10.3181/00379727-124-31741; ASKARI AD, 1983, AM J MED, V75, P957, DOI 10.1016/0002-9343(83)90875-6; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; Barton JC, 1997, AM J MED, V103, P498, DOI 10.1016/S0002-9343(97)00276-3; Barton JC, 1997, ANN INTERN MED, V126, P738, DOI 10.7326/0003-4819-126-9-199705010-00015; BARTON JC, 1994, J LAB CLIN MED, V124, P193; BARTON JC, 1991, HOSP PRACT, V26, P46; Barton JC, 1996, BLOOD CELL MOL DIS, V22, P195, DOI 10.1006/bcmd.1996.0100; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; BILGRAMI S, 1993, ACTA HAEMATOL-BASEL, V89, P141; BLUMBERG RS, 1988, GASTROENTEROLOGY, V95, P1399, DOI 10.1016/0016-5085(88)90379-4; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; Bothwell TH., IRON METABOLISM MAN, P256; BRADBEAR RA, 1985, J NATL CANCER I, V75, P81; BRISSOT P, 1978, DIGESTION, V17, P469, DOI 10.1159/000198153; BRISSOT P, 1981, GASTROENTEROLOGY, V80, P557; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; BULLEN JJ, 1991, ARCH INTERN MED, V151, P1606, DOI 10.1001/archinte.151.8.1606; BUTT EM, 1960, METAL BINDING MEDICI, P43; CANDELLRIERA J, 1983, AM J CARDIOL, V52, P824, DOI 10.1016/0002-9149(83)90422-8; CELADA A, 1979, BLOOD, V54, P906; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; CONRAD ME, 1980, SEMIN HEMATOL, V17, P149; CONRAD ME, 1981, AM J HEMATOL, V10, P199, DOI 10.1002/ajh.2830100212; CUTLER DJ, 1980, AM J MED, V69, P923, DOI 10.1016/S0002-9343(80)80020-9; DAVIS WD, 1952, J LAB CLIN MED, V39, P526; DEALARCON PA, 1979, NEW ENGL J MED, V300, P5, DOI 10.1056/NEJM197901043000102; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; EDWARDS CQ, 1983, ARCH INTERN MED, V143, P1890, DOI 10.1001/archinte.143.10.1890; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1989, J INTERN MED, V226, P373, DOI 10.1111/j.1365-2796.1989.tb01411.x; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; EDWARDS CQ, 1991, AM J MED SCI, V301, P50, DOI 10.1097/00000441-199101000-00009; FARGION S, 1994, HEPATOLOGY, V20, P1426, DOI 10.1002/hep.1840200608; FARINA G, 1995, HAEMATOLOGICA, V80, P335; FARRELL FJ, 1994, HEPATOLOGY, V20, P404, DOI 10.1002/hep.1840200221; HADDY TB, 1988, AM J PEDIAT HEMATOL, V10, P23; HAYASHI H, 1994, AM J GASTROENTEROL, V89, P986; Hlady WG, 1996, J INFECT DIS, V173, P1176, DOI 10.1093/infdis/173.5.1176; KAIKOV Y, 1992, PEDIATRICS, V90, P37; KALTWASSER JP, 1988, ANN NY ACAD SCI, V526, P339, DOI 10.1111/j.1749-6632.1988.tb55521.x; KELLNER H, 1992, Z GASTROENTEROL, V30, P779; KELLY TM, 1984, ANN INTERN MED, V101, P629, DOI 10.7326/0003-4819-101-5-629; KNAUER CM, 1965, GASTROENTEROLOGY, V49, P667; Kowdley K V, 1995, Liver Transpl Surg, V1, P237, DOI 10.1002/lt.500010408; LESAGE GD, 1983, GASTROENTEROLOGY, V84, P1471; Liu CL, 1997, AM J SURG, V173, P358, DOI 10.1016/S0002-9610(96)00384-4; LUFKIN EG, 1987, MAYO CLIN PROC, V62, P473, DOI 10.1016/S0025-6196(12)65472-X; LUNDVALL O, 1982, ACTA DERM-VENEREOL, P107; MCLARAN CJ, 1982, AUST NZ J MED, V12, P187, DOI 10.1111/j.1445-5994.1982.tb02457.x; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; MOHLER DN, 1986, AM J MED SCI, V292, P320, DOI 10.1097/00000441-198611000-00014; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; MUENCH KH, 1989, AM J MED, V87, pN40; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; Nonami T, 1997, AM J SURG, V173, P288, DOI 10.1016/S0002-9610(96)00399-6; OLATUNBOSUN D, 1977, J LAB CLIN MED, V75, P754; Piperno A, 1996, LIVER, V16, P248; Pippard MJ, 1982, ADV RED BLOOD CELL B, P103; Poulos JE, 1996, DIGEST DIS, V14, P316, DOI 10.1159/000171562; POWELL LW, 1970, AUSTRALAS ANN MED, V19, P54; POWELL LW, 1986, HEPATOLOGY, V6, P1423, DOI 10.1002/hep.1840060636; POWELL LW, 1992, J HEPATOL, V16, P259, DOI 10.1016/S0168-8278(05)80654-3; Powell W.L., 1994, IRON METABOLISM HLTH; RIVERS J, 1987, AM HEART J, V113, P216, DOI 10.1016/0002-8703(87)90039-1; Roberts AG, 1997, LANCET, V349, P321, DOI 10.1016/S0140-6736(96)09436-6; Sampietro M, 1998, HEPATOLOGY, V27, P181, DOI 10.1002/hep.510270128; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SCHUMACHER HR, 1988, ANN NY ACAD SCI, V526, P224, DOI 10.1111/j.1749-6632.1988.tb55508.x; SEARLE J, 1993, PATHOLOGY LIVER, P219; Sham RL, 1997, BLOOD CELL MOL DIS, V23, P314, DOI 10.1006/bcmd.1997.0148; SIMINOSKI K, 1990, J ENDOCRINOL INVEST, V13, P849, DOI 10.1007/BF03349640; Skinke B, 1994, IRON METABOLISM HLTH, P151; SPENCER H, 1988, ANN NY ACAD SCI, V526, P336, DOI 10.1111/j.1749-6632.1988.tb55520.x; STREMMEL W, 1988, ANN NY ACAD SCI, V526, P209, DOI 10.1111/j.1749-6632.1988.tb55507.x; WEINTRAUB LR, 1966, MED CLIN N AM, V50, P1579, DOI 10.1016/S0025-7125(16)33106-6; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; WOHLER F, 1963, ACTA HAEMATOL-BASEL, V30, P65, DOI 10.1159/000208110	84	206	210	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					932	939		10.7326/0003-4819-129-11_Part_2-199812011-00003	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867745				2022-12-28	WOS:000077239200025
J	Cogswell, ME; McDonnell, SM; Khoury, MJ; Franks, AL; Burke, W; Brittenham, G				Cogswell, ME; McDonnell, SM; Khoury, MJ; Franks, AL; Burke, W; Brittenham, G			Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			HUMAN GENOME PROJECT; LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; COST-EFFECTIVENESS; DIABETIC-PATIENTS; BLOOD-DONORS; HLA-H; MUTATION ANALYSIS; SERUM FERRITIN	Population screening for hemochromatosis done by using the transferrin saturation test has been advocated by experts to permit the initiation of therapeutic phlebotomy before the onset of clinical disease. The discovery of a gene associated with hemochromatosis has made DNA testing another option for screening and diagnosis. In this paper, U.S. Preventive Services Task Force criteria are used to evaluate the evidence for the usefulness of population screening done by using iron measures or genetic testing. Published clinical research offers little evidence to suggest that population screening for hemochromatosis done by using genetic testing improves clinical outcomes. Although one recently discovered mutation, C282Y, accounts for 60% to 92% of cases of the disease in series of patients with hemochromatosis, uncertainties remain about the clinical penetrance of various genotypes; the accuracy of genetic testing; and the ethical, legal, and social effects of genetic testing. Before population screening for hemochromatosis done by using transferrin saturation testing can be recommended, laboratory standardization needs to be addressed and questions about risk for clinical disease in asymptomatic persons with mutations or early biochemical expression of disease require resolution. Evidence from case series suggests that hemochromatosis may be associated with liver cancer, other liver disease, diabetes, bradyarrhythmias, and arthritis. In ail studies but one, however, estimation of the magnitude and significance of this risk is limited by lack of adequate comparison groups. The need for population data to answer questions about penetrance among asymptomatic persons should not impede efforts to increase the detection and treatment of hemochromatosis in persons found to have elevated iron measures, a family history of hemochromatosis, or consistent early signs and symptoms of the disease.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA; Univ Washington, Womens Hlth Care Ctr, Seattle, WA 98195 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA	Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; Case Western Reserve University	Cogswell, ME (corresponding author), Ctr Dis Control & Prevent, Mailstop K-25,4770 Buford Highway NE, Atlanta, GA 30341 USA.	mec0@cdc.gov						Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Adams PC, 1998, AM J HEMATOL, V58, P16, DOI 10.1002/(SICI)1096-8652(199805)58:1<16::AID-AJH3>3.0.CO;2-3; Adams PC, 1997, GASTROENTEROLOGY, V112, pA1207; Alper J S, 1994, J Public Health Policy, V15, P345, DOI 10.2307/3342910; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BASSETT ML, 1988, ANN NY ACAD SCI, V526, P274, DOI 10.1111/j.1749-6632.1988.tb55512.x; BEATON GH, 1989, AM J CLIN NUTR, V50, P575, DOI 10.1093/ajcn/50.3.575; BELL H, 1994, J INTERN MED, V236, P315, DOI 10.1111/j.1365-2796.1994.tb00802.x; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P95, DOI 10.1006/bcmd.1997.0125; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BOMFORD A, 1976, Q J MED, V45, P611; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Bradley L A, 1996, J Med Screen, V3, P178; Bradley L A, 1996, J Med Screen, V3, P171; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; CARTWRIGHT GE, 1974, HARRISONS PRINCIPLES, P618; CHAKRABORTY R, 1992, AM J HUM GENET, V50, P145; Conte D, 1998, ANN INTERN MED, V128, P370, DOI 10.7326/0003-4819-128-5-199803010-00005; CZINK E, 1991, DIABETES CARE, V14, P929, DOI 10.2337/diacare.14.10.929; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; Franks AL, 1998, ANN INTERN MED, V129, P923, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00001; GARVER KL, 1994, AM J HUM GENET, V54, P148; GAYLE CB, 1992, J AM DIET ASSOC, V92, P208; GEORGE DK, 1995, ANN CLIN BIOCHEM, V32, P521, DOI 10.1177/000456329503200601; GRINDON AJ, 1993, JAMA-J AM MED ASSOC, V270, P880; GUYER MS, 1995, P NATL ACAD SCI USA, V92, P10841, DOI 10.1073/pnas.92.24.10841; Haddow J E, 1994, J Med Screen, V1, P16; Holtzman NA., 1998, PROMOTING SAFE EFFEC; HSIEH CL, 1992, ANN HUM GENET, V56, P105, DOI 10.1111/j.1469-1809.1992.tb01137.x; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; *I MED, 1994, ASS GEN RISKS IMPL H; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; KAYE TB, 1993, J DIABETES COMPLICAT, V7, P246, DOI 10.1016/0891-6632(93)90008-5; Launois B, 1996, ANN GASTROENT HEPATO, V32, P35; LEDERLE FA, 1989, J GEN INTERN MED, V4, P61, DOI 10.1007/BF02596494; LILIENFELD DE, 1994, FDN EPIDEMIOLOGY, P118; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; MANACHINO D, 1994, MAYO CLIN PROC, V69, P913, DOI 10.1016/S0025-6196(12)61803-5; McDonnell SM, 1998, ANN INTERN MED, V129, P962, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00007; Mercier B, 1997, NAT GENET, V15, P234; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; MILDER MS, 1980, MEDICINE, V59, P34, DOI 10.1097/00005792-198001000-00002; MILMAN N, 1991, EUR J HAEMATOL, V47, P292; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OBRIEN T, 1990, DIABETES CARE, V13, P532, DOI 10.2337/diacare.13.5.532; OLYNYK J, 1994, AUST NZ J MED, V24, P22, DOI 10.1111/j.1445-5994.1994.tb04420.x; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; PHELPS G, 1989, LANCET, V2, P233; Piperno A, 1995, EUR J GASTROEN HEPAT, V7, P1203; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; POWELL LW, 1970, POSTGRAD MED J, V46, P200, DOI 10.1136/pgmj.46.534.200; ROSENQVIST M, 1989, EUR HEART J, V10, P473, DOI 10.1093/oxfordjournals.eurheartj.a059512; SACKETT DL, 1985, CLIN EPDIEMIOLOGY BA; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; SINGH BM, 1992, DIABETIC MED, V9, P730, DOI 10.1111/j.1464-5491.1992.tb01881.x; Stuart KE, 1996, CANCER, V77, P2217, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M; TOBKES AI, 1995, DIGEST DIS, V13, P267, DOI 10.1159/000171507; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P231; Wetterhall SF, 1998, ANN INTERN MED, V129, P980, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00009; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492; 1996, MMWR MORB MORTAL WKL, V45, P991	80	95	95	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					971	979		10.7326/0003-4819-129-11_Part_2-199812011-00008	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867750				2022-12-28	WOS:000077239200030
J	French, AL; Welbel, SF; Dietrich, SE; Mosher, LB; Breall, PS; Paul, WS; Kocka, FE; Weinstein, RA				French, AL; Welbel, SF; Dietrich, SE; Mosher, LB; Breall, PS; Paul, WS; Kocka, FE; Weinstein, RA			Use of DNA fingerprinting to assess tuberculosis infection control	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIDRUG-RESISTANT TUBERCULOSIS; CDC TB SURVEY; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; MEMBER HOSPITALS; CONTROL PROGRAMS; EPIDEMIOLOGY; OUTBREAK; POPULATION; CULTURES	Background: DNA fingerprinting establishes the genetic relatedness of Mycobacterium tuberculosis isolates and has become a powerful tool in tuberculosis epidemiology. Objective: To use DNA fingerprinting to assess the efficacy of current tuberculosis infection-control practices. Design: Retrospective molecular and descriptive epidemiologic study. Setting: A 700-bed urban public hospital that follows the Centers for Disease Control and Prevention (CDC) guidelines for tuberculosis infection control. Patients: 183 patients who had positive cultures for M. tuberculosis from 1 April 1995 to 31 March 1996. Results: 173 of 183 M. tuberculosis isolates from the study period underwent DNA fingerprinting. Fingerprinting revealed that five isolates represented false-positive cultures and that 91 (54%) of the remaining 168 isolates were in 15 DNA fingerprinting clusters, which ranged in size from 2 to 29 isolates. Risk factors for clustering were birth in the United States, African-American ethnicity, homelessness, substance abuse, and male sex. Retrospective epidemiologic analysis of inpatient and outpatient visits by the 91 patients who had clustered isolates revealed only one possible instance of patient-to-patient transmission. Conclusions: The DNA fingerprinting of all M. tuberculosis isolates from a 1-year period revealed one possible instance of nosocomial transmission and five false-positive M. tuberculosis cultures. However, these results did not lead to changes in infection-control practices or in clinical care. The study findings do not support the use of DNA fingerprinting for nosocomial tuberculosis surveillance, but they suggest that compliance with the CDC tuberculosis infection-control guidelines may control patient-to-patient transmission in high-risk urban hospitals.	Cook Cty Hosp, Div Infect Dis, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA; Chicago Dept Publ Hlth, Chicago, IL 60612 USA; Michigan Dept Community Hlth, Div Lab Serv, Lansing, MI 48909 USA	John H Stroger Junior Hospital Cook County; Rush University; Chicago Department of Public Health; MDHHS - Michigan Department of Health & Human Services	French, AL (corresponding author), Cook Cty Hosp, Div Infect Dis, Durand 115,1835 W Harrison St, Chicago, IL 60612 USA.			French, Audrey/0000-0002-9776-8934				ABRUTYN E, 1998, SHEAS RESPONSE OSHA; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1997, FED REG, V62, P54160; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; Braden CR, 1997, CLIN INFECT DIS, V24, P35, DOI 10.1093/clinids/24.1.35; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P321, DOI 10.1164/ajrccm.155.1.9001331; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WELBEL SF, 1996, 34 ANN M INF DIS SOC; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; 1994, MMWR MORB MORTAL WKL, V44	24	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					856	861		10.7326/0003-4819-129-11_Part_1-199812010-00003	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867726				2022-12-28	WOS:000077239200002
J	McDonnell, SM; Phatak, PD; Felitti, V; Hover, A; McLaren, GD				McDonnell, SM; Phatak, PD; Felitti, V; Hover, A; McLaren, GD			Screening for hemochromatosis in primary care settings	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			HEREDITARY HEMOCHROMATOSIS; IRON OVERLOAD; GENETIC HEMOCHROMATOSIS; COST-EFFECTIVENESS; AFRICAN-AMERICANS; PHENOTYPIC-EXPRESSION; BLOOD-DONORS; PREVALENCE; AGE; MEN	Interest in including screening for hemochromatosis in the routine medical care of adults has grown in recent years. In March 1997, at a meeting on iron overload at the Centers for Disease Control and Prevention, the directors of four hemochromatosis screening programs described the major challenges that they faced and the lessons that they learned in implementing their programs. Seven issues were consistently described as important challenges: 1) changes in case definitions of hemochromatosis, 2) selection of screening threshold values and identification of false-positive cases, 3) variability and lack of standardization in screening test measurements, 4) physician education, 5) informed consent and concerns about medical and genetic discrimination, 6) patient compliance with screening and therapy, and 7) incidental detection of iron deficiency. The two programs that have been completed report a prevalence of iron overload from hemochromatosis of 4.2 to 4.5 per 1000 persons screened; this is consistent with findings in the recent literature. All programs report that screening is feasible and propose that hemochromatosis be defined by repeated elevated serum transferrin saturation values (with or without DNA test results) rather than by the clinical outcome of excessive iron in tissue. The goal of screening programs is to diagnose iron status disorders, particularly hemochromatosis, before they lead to iron overload and chronic disease states. Further research is needed on the ability of genetic and phenotypic tests to predict the clinical expression of hemochromatosis. The experiences outlined in this report highlight practical issues that need to be addressed when iron status screening for hemochromatosis is implemented. It is hoped that this information will facilitate similar efforts in other health care settings.	Ctr Dis Control & Prevent, Div Int Hlth, Epidemiol Program Off, Atlanta, GA 30303 USA; Rochester Gen Hosp, Rochester, NY 14621 USA; Kaiser Permanente Med Care Program, San Diego, CA 92111 USA; St Johns Hlth Syst, Springfield, MO 65807 USA; Univ N Dakota, Sch Med & Hlth Sci, Fargo, ND USA; Vet Affairs Med Ctr, Hematol Oncol Sect 11111H, Fargo, ND USA	Centers for Disease Control & Prevention - USA; Rochester General Hospital; Kaiser Permanente; University of North Dakota Grand Forks; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonnell, SM (corresponding author), Ctr Dis Control & Prevent, Div Int Hlth, Epidemiol Program Off, Mailstop C-108,1600 Clifton Rd, Atlanta, GA 30303 USA.	sem0@cdc.gov			AHRQ HHS [R01 HS07616] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; Barton JC, 1997, AM J MED, V103, P498, DOI 10.1016/S0002-9343(97)00276-3; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BORWEIN ST, 1983, CLIN INVEST MED, V6, P171; Bradley L A, 1996, J Med Screen, V3, P178; Bradley L A, 1996, J Med Screen, V3, P171; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; CLAYTON C, 1993, MED J AUSTRALIA, V159, P614, DOI 10.5694/j.1326-5377.1993.tb138051.x; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; CRAWFORD R, 1990, IRON ELEPHANT; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; *EXP SCI WORK GROU, 1985, AM J CLIN NUTR, V42, P318; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Freeman V, 1996, AM J PREV MED, V12, P177, DOI 10.1016/S0749-3797(18)30339-8; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GRUNBAUM JA, 1993, J ADOLESCENT HEALTH, V14, P99, DOI 10.1016/1054-139X(93)90092-4; Gunter EW, 1998, CLIN CHEM, V44, P361; HALLBERG L, 1989, J INTERN MED, V225, P249, DOI 10.1111/j.1365-2796.1989.tb00074.x; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1988, NEW ENGL J MED, V319, P1548; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; McDonnell SM, 1997, POSTGRAD MED, V102, P83, DOI 10.3810/pgm.1997.12.378; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; MEYER T, 1990, J INTERN MED, V227, P397, DOI 10.1111/j.1365-2796.1990.tb00178.x; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; OLSSON KS, 1983, ACTA MED SCAND, V213, P145; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; TANNER AR, 1985, GUT, V26, P1139; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P231; Wilson JMB, 1968, 34 WHO; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wurapa RK, 1996, AM J MED, V101, P9, DOI 10.1016/S0002-9343(96)00053-8; 1996, MMWR MORB MORTAL WKL, V45, P991	48	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					962	970		10.7326/0003-4819-129-11_Part_2-199812011-00007	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867749				2022-12-28	WOS:000077239200029
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Treating with HIV	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998	2	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1438	1438						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867652				2022-12-28	WOS:000077110800033
J	Duguid, JKM; Minards, J; Bolton-Maggs, PHB				Duguid, JKM; Minards, J; Bolton-Maggs, PHB			Incompatible plasma transfusions and haemolysis in children	BRITISH MEDICAL JOURNAL			English	Article									Natl Blood Serv, Mersey & N Wales Ctr, Liverpool L7 8TW, Merseyside, England; Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Duguid, JKM (corresponding author), Wrexham Maelor Hosp, Dept Haematol, Wrexham LL13 7TD, Clwyd, Wales.							CONTRERAS M, 1992, TRANSFUSION MED, V2, P57; CONWAY LT, 1984, TRANSFUSION, V24, P413, DOI 10.1046/j.1537-2995.1984.24585017836.x; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; MURPHY MF, 1992, TRANSFUSION MED, V2, P311, DOI 10.1111/j.1365-3148.1992.tb00175.x; PIERCE RN, 1985, TRANSFUSION, V25, P60, DOI 10.1046/j.1537-2995.1985.25185116506.x	5	19	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					176	177		10.1136/bmj.318.7177.176	http://dx.doi.org/10.1136/bmj.318.7177.176			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888915	Green Published			2022-12-28	WOS:000078175100036
J	Moss, PJ; Beeching, NJ				Moss, PJ; Beeching, NJ			Provision of health advice for UK medical students planning to travel overseas for their elective study period: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Beeching, NJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ELLIS CJ, 1993, BRIT MED J, V307, P1008, DOI 10.1136/bmj.307.6910.1008-c; *EXP ADV GROUP AID, 1997, GUID POST PROPH HLTH; Gilks CF, 1998, BRIT MED J, V316, P1158, DOI 10.1136/bmj.316.7138.1158; *UNAIDS, 1998, REP GLOB HIV AIDS EP, P63	4	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					161	162		10.1136/bmj.318.7177.161	http://dx.doi.org/10.1136/bmj.318.7177.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888909	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078175100026
J	Sachs, BP; Kobelin, C; Castro, MA; Frigoletto, F				Sachs, BP; Kobelin, C; Castro, MA; Frigoletto, F			The risks of lowering the cesarean-delivery rate	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VAGINAL BIRTH; TRIAL; LABOR; ANALGESIA; PROGRAM; SECTION		Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital	Sachs, BP (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							*AM COLL OBST GYN, 1998, AM COLL OBST GYN PRA, V2; Ames M., 1995, American Journal of Obstetrics and Gynecology, V172, P288; BERNSTEIN S, 1998, LOS ANGELES TIM 0125; Bickell NA, 1996, OBSTET GYNECOL, V87, P664, DOI 10.1016/0029-7844(96)00024-5; Bofill JA, 1996, OBSTET GYNECOL, V88, P1007; COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; *DEP HLTH, 1996, MONTHL STAT STAT REP, V44; *DHHS, 1990, DHHS PUBL, P378; *DIV HLTH CAR QUAL, 1997, HOSP VAL SURV; *FDA PUBL HLTH ADV, 1998, NEED CANT US VAC ASS; FLAMM BL, 1990, OBSTET GYNECOL, V76, P750, DOI 10.1097/00006250-199011000-00004; *FLOR DEP HLTH, 1996, FLOR VIT STAT ANN RE; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P1163; GOVEART P, 1993, CRANIAL HEMORRHAGE T, V23, P25; JOHNSON AT, 1993, OPHTHALMOLOGY, V100, P524; KELLY JV, 1963, AM J OBSTET GYNECOL, V85, P687, DOI 10.1016/0002-9378(63)90317-X; Lieberman E, 1998, OBSTET GYNECOL, V92, P1; Macfarlane A, 1998, BRIT MED J, V316, P566, DOI 10.1136/bmj.316.7131.566; McMahon MJ, 1996, NEW ENGL J MED, V335, P689, DOI 10.1056/NEJM199609053351001; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; *NAT CTR HLTH STAT, 1996, MON VIT STAT REP S, V44, P11; *NAT CTR HLTH STAT, 1997, MON VIT STAT REP S, V45, P66; *NAT CTR HLTH STAT, 1997, VITAL STAT REP S3, V45; *NY STAT DPT PUBL, SPARCS MONTH VIT S S, V46; OGRADY JP, 1987, VACUUM EXTRACTION MO, P84; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Studnicki J, 1997, Am J Med Qual, V12, P62, DOI 10.1177/0885713X9701200111; The Lancet, 1997, LANCET, V349, P815; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; 1995, MMWR MORB MORTAL WKL, V44, P303	31	175	177	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					54	57		10.1056/NEJM199901073400112	http://dx.doi.org/10.1056/NEJM199901073400112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878648				2022-12-28	WOS:000077943700012
J	Beecham, L				Beecham, L			Government plans shake up in NHS pay	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					10	10						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872870				2022-12-28	WOS:000078013100012
J	Harada, A; Kataoka, K				Harada, A; Kataoka, K			Chain length recognition: Core-shell supramolecular assembly from oppositely charged block copolymers	SCIENCE			English	Article							GLYCOL)	Molecular recognition based on length was found to occur between oppositely charged pairs of flexible and randomly coiled block copolymers in an aqueous milieu. Matched pairs with the same block lengths of polyanions and polycations exclusively formed even in mixtures with different block lengths. These assemblies of the charged segments with matched chain lengths then formed larger core-shell-type supramolecular assemblies with an extremely,narrow size distribution due to the strict phase separation between core- and shell-forming segments.	Univ Tokyo, Grad Sch Engn, Dept Mat Sci, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Kataoka, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Mat Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Kataoka, Kazunori/K-7108-2012	Kataoka, Kazunori/0000-0002-8591-413X				AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; DAGANI R, 1991, CHEM ENG NEWS, V69, P24, DOI 10.1021/cen-v069n002.p024; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; Harada A, 1996, MACROMOLECULES, V29, P6183, DOI 10.1021/ma960487p; HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019; Jenekhe SA, 1998, SCIENCE, V279, P1903, DOI 10.1126/science.279.5358.1903; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; Percec V, 1998, NATURE, V391, P161, DOI 10.1038/34384; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777	12	530	558	1	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					65	67		10.1126/science.283.5398.65	http://dx.doi.org/10.1126/science.283.5398.65			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872741				2022-12-28	WOS:000077976600049
J	Westendorp, RGJ; Kirkwood, TBL				Westendorp, RGJ; Kirkwood, TBL			Human longevity at the cost of reproductive success	NATURE			English	Article							DROSOPHILA-MELANOGASTER; SENESCENCE; EVOLUTION	The disposable soma theory on the evolution of ageing states that longevity requires investments in somatic maintenance that reduce the resources available for reproduction(1,2), Experiments in Drosophila melanogaster indicate that trade-offs of this kind exist in non-human species(3-7). We have determined the interrelationship between longevity and reproductive success in Homo sapiens using a historical data set from the British aristocracy. The number of progeny was small when women died at an early age, increased with the age of death, reaching a plateau through the sixth, seventh and eighth decades of life, but decreased again in women who died at an age of 80 years or over. Age at first childbirth was lowest in women who died early and highest for women who died at the oldest ages. When account was taken only of women who had reached menopause, who were aged 60 years and over, female longevity was negatively correlated with number of progeny and positively correlated with age at first childbirth. The findings show that human life histories involve a trade-off between longevity and reproduction.	Leiden Univ, Med Ctr CO P, Dept Gen Internal Med & Clin Epidemiol, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Dept Geriatr Med, Biol Gerontol Grp, Manchester M13 9PT, Lancs, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Manchester; University of Manchester	Westendorp, RGJ (corresponding author), Leiden Univ, Med Ctr CO P, Dept Gen Internal Med & Clin Epidemiol, Sect Gerontol & Geriatr, POB 9600, NL-2300 RC Leiden, Netherlands.	RudiWestendorp@compuserv.ecom						CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Finch CE, 1990, LONGEVITY SENESCENCE; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; Gavrilova NS, 1998, HUM BIOL, V70, P799; GIBBS V, 1910, COMPLETE PEERAGE ENG; GIBBS V, 1910, COMPLETE PEERAGE BAR; HOLLINGWOOD TH, 1977, POPULATION S, V18, P323; Khoury M, 1993, FUNDAMENTALS GENETIC; KIDD C, 1994, DEBRETTS PEERAGE BAR; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; Medawar P., 1952, UNSOLVED PROBLEM BIO; MONCREIFFE I, 1982, ROYAL HIGHNESS ANCES; MORBY JE, 1994, WORDSWORTH HDB KINGS; PAGET G, 1977, LINEAGE ANCESTRY HRH; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; Perls TT, 1997, NATURE, V389, P133, DOI 10.1038/38148; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; TOWNSEND P, 1963, BURKES GENEALOGICAL; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.2307/2410318; 1996, WHITTAKERS ALMANACK	25	359	363	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					743	746		10.1038/25519	http://dx.doi.org/10.1038/25519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874369				2022-12-28	WOS:000077742800030
J	Galanakis, E				Galanakis, E			Apgar score and Soranus of Ephesus	LANCET			English	Article							ROMAN		Univ Crete, Dept Paediat, GR-71110 Iraklion, Greece	University of Crete	Galanakis, E (corresponding author), Univ Crete, Dept Paediat, POB 1352, GR-71110 Iraklion, Greece.							[Anonymous], 1986, PEDIATRICS, V78, P1148; APGAR V, 1953, Curr Res Anesth Analg, V32, P260; BACHMANN GA, 1990, J REPROD MED, V35, P839; BUTTERFIELD J, 1962, JAMA-J AM MED ASSOC, V181, P353, DOI 10.1001/jama.1962.03050300073025; DRABKIN I. E., 1951, BULL HIST MED, V25, P503; DUNN PM, 1995, ARCH DIS CHILD-FETAL, V73, pF51, DOI 10.1136/fn.73.1.F51; GERDTZ J, 1994, HOSP COMMUNITY PSYCH, V45, P485; GOLDSTEIN A, 1969, PSYCHIAT QUART, V43, P535, DOI 10.1007/BF01564267; JAMES LS, 1975, PEDIATRICS, V55, P1; MARMELZAT WL, 1987, CLIN DERMATOL, V5, P1, DOI 10.1016/0738-081X(87)90023-X; PRIORESCHI P, 1995, MED HYPOTHESES, V44, P447, DOI 10.1016/0306-9877(95)90505-7; SORANOS DEPHESE, 1988, MALADIES FEMMES; Soranus, 1991, GYNECOLOGY; Thomasen A L, 1980, Clio Med, V15, P5	14	12	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					2012	2013		10.1016/S0140-6736(98)06038-3	http://dx.doi.org/10.1016/S0140-6736(98)06038-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872266				2022-12-28	WOS:000077663000047
J	Neeman, R; Keller, N; Barzilai, A; Korenman, Z; Sela, S				Neeman, R; Keller, N; Barzilai, A; Korenman, Z; Sela, S			Prevalence of internalisation-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers	LANCET			English	Article							FIBRONECTIN-BINDING PROTEIN; RESPIRATORY EPITHELIAL-CELLS; SFB PROTEIN; PYOGENES; ADHESIN; PHARYNGOTONSILLITIS; PENICILLIN; ADHERENCE; DOMAIN; PCR	Background The failure of antibiotic treatment to eradicate group-A streptococci in up to 30% of patients with pharyngotonsillitis is unexplained. Some strains of group-A streptococci can enter respiratory epithelial cells, where they would be inaccessible to antibiotics unable to penetrate the cell membrane, such as penicillins. The fibronectin-binding proteins, F1 and SfbI, are needed for this process. We hypothesised, therefore, that an intracellular reservoir of group-A streptococci could account, at least partly, for failure to eradicate throat carriage, and that the presence of the gene for fibronectin-binding protein (F1) might be linked to the ability of a strain to persist in the throat after therapy. Methods We investigated the frequency of prtF1-containing strains among 67 patients with pharyngotonsillitis. All patients were clinically cured, although 13 of them continued to carry group-A streptococci in the throat during or after therapy, To distinguish between persisting and recolonising strains, isolates from the 13 patients were serologically tested and compared by polymorphic DNA-amplification technique. Findings 12 (92%) of the 13 patients with symptomless carriage had prfF1-containing strains in the throat, compared with 16 (30%) of the 54 patients with successful eradication (p=0.0001). Three of the 13 eradication-failure patients were recolonised with strains that differed from the pretreatment strains. Nine of the ten (90%) persisting strains carried prtF1 (p=0.0009). Interpretation Our findings suggest that protein-F1-mediated entry to cells is involved in the causative process of the carriage stale.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Tel Hashomer Hosp, Dept Clin Microbiol, Jerusalem, Israel; Chaim Sheba Med Ctr, Tel Hashomer Hosp, Dept Pediat, Jerusalem, Israel; Israeli Streptococcal Reference Ctr, Cent Labs, Jerusalem, Israel	Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Sela, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	shlomos@post.tau.ac.il		Sela (Saldinger), Shlomo/0000-0002-9141-9696				BISNO AL, 1990, INFECT DIS, P1519; CARAPETIS J, 1995, J CLIN MICROBIOL, V33, P1471, DOI 10.1128/JCM.33.6.1471-1472.1995; GARDINER D, 1995, PCR METH APPL, V4, P288; GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539; GRECO R, 1995, RES MICROBIOL, V146, P551, DOI 10.1016/0923-2508(96)80561-4; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HANSKI E, 1992, INFECT IMMUN, V60, P5119, DOI 10.1128/IAI.60.12.5119-5125.1992; HOLM SE, 1994, PEDIATR INFECT DIS J, V13, pS66, DOI 10.1097/00006454-199401001-00015; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Kiska DL, 1997, J INFECT DIS, V176, P992, DOI 10.1086/516540; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; MARKOWITZ M, 1993, J PEDIATR-US, V123, P679, DOI 10.1016/S0022-3476(05)80840-6; Maurin Max, 1993, P23; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; MOODY M D, 1965, Health Lab Sci, V2, P149; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; OKADA N, 1994, J CLIN INVEST, V94, P965, DOI 10.1172/JCI117463; Osterlund A, 1997, LARYNGOSCOPE, V107, P640; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; PCHICHERO ME, 1991, PEDIATR INFECT DIS J, V10, pS50; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; STOLLERMAN GH, 1995, HOSP PRACT, V30, P80, DOI 10.1080/21548331.1995.11443168; Stollerman GH, 1996, MT SINAI J MED, V63, P144; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; VALENTINWEIGAND P, 1994, MICROB PATHOGENESIS, V17, P111, DOI 10.1006/mpat.1994.1057; WANG G, 1993, NUCLEIC ACIDS RES, V21, P5930, DOI 10.1093/nar/21.25.5930	27	115	119	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1974	1977		10.1016/S0140-6736(97)12452-7	http://dx.doi.org/10.1016/S0140-6736(97)12452-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872247				2022-12-28	WOS:000077663000011
J	Anderson, DG; Kowalczykowski, SC				Anderson, DG; Kowalczykowski, SC			Reconstitution of an SOS response pathway: Derepression of transcription in response to DNA breaks	CELL			English	Article							COLI RECA PROTEIN; HOT-SPOT-CHI; ESCHERICHIA-COLI; RECBCD ENZYME; PAIRING SEQUENCES; LEXA REPRESSOR; RECOMBINATION; MECHANISM; INDUCTION; CLEAVAGE	E. coli responds to DNA damage by derepressing the transcription of about 20 genes that make up the SOS pathway. Genetic analyses have shown that SOS induction in response to double-stranded DNA (dsDNA) breaks requires LexA repressor, and the RecA and RecBCD enzymes - proteins best known for their role as initiators of dsDNA break repair and homologous recombination. Here we demonstrate that purified RecA protein, RecBCD enzyme, single-stranded DNA-binding (SSB) protein, and LexA repressor respond to dsDNA breaks in vitro by derepressing transcription from an SOS promoter. Interestingly, derepression is more rapid if the DNA containing the dsDNA break has a chi recombination hot spot (5'-GCTGGTGG-3'), suggesting a novel regulatory role for one of the most overrepresented octamers in the E. coli genome.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; Eggleston AK, 1997, CURR BIOL, V7, pR745, DOI 10.1016/S0960-9822(06)00394-0; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; Sambrook J., 2002, MOL CLONING LAB MANU; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Tracy RB, 1997, CELL, V90, P205, DOI 10.1016/S0092-8674(00)80328-1; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4	25	43	43	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					975	979		10.1016/S0092-8674(00)81721-3	http://dx.doi.org/10.1016/S0092-8674(00)81721-3			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875851	Bronze			2022-12-28	WOS:000077759100012
J	Xong, HV; Vanhamme, L; Chamekh, M; Chimfwembe, CE; Van Den Abbeele, J; Pays, A; Van Meirvenne, N; Hamers, R; De Baetselier, P; Pays, E				Xong, HV; Vanhamme, L; Chamekh, M; Chimfwembe, CE; Van Den Abbeele, J; Pays, A; Van Meirvenne, N; Hamers, R; De Baetselier, P; Pays, E			A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense	CELL			English	Article							SURFACE GLYCOPROTEIN GENES; AFRICAN TRYPANOSOMES; BRUCEI-RHODESIENSE; ANTIGEN GENE; T-BRUCEI; TRANSCRIPTION; DISRUPTION; PROTEIN; FAMILY; CLONES	Infectivity of Trypanosoma brucei rhodesiense to humans is due to its resistance to a lytic factor present in human serum. In the ETat 1 strain this character was associated with antigenic variation, since expression of the ETat 1.10 variant surface glycoprotein was required to generate resistant (R) clones. In addition, in this strain transcription of a gene termed SRA was detected in R clones only. We show that the ETat 1.10 expression site is the one selectively transcribed in R variants. This expression site contains SRA as an expression site-associated gene (ESAG) and is characterized by the deletion of several ESAGs. Transfection of SRA into T.b. brucei was sufficient to confer resistance to human serum, identifying this gene as one of those responsible for T.b. rhodesiense adaptation to humans.	Free Univ Brussels, Mol Parasitol Lab, B-1640 Rhode St Genese, Belgium; Free Univ Brussels VIB, Cellular Immunol Lab, B-1640 Rhode St Genese, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Institute of Tropical Medicine (ITM)	Pays, E (corresponding author), Free Univ Brussels, Mol Parasitol Lab, 67 Rue Chevaux, B-1640 Rhode St Genese, Belgium.	epays@dbm.uib.ac.be	De Baetselier, Patrick/D-3866-2014	Van Den Abbeele, Jan/0000-0002-4533-4480				BERNARDS A, 1985, MOL CELL BIOL, V5, P545, DOI 10.1128/MCB.5.3.545; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; Carruthers VB, 1996, MOL BIOCHEM PARASIT, V81, P65, DOI 10.1016/0166-6851(96)02672-2; CROSS GAM, 1978, PROC R SOC SER B-BIO, V202, P55, DOI 10.1098/rspb.1978.0057; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; DOTHI CD, 1991, MOL BIOCHEM PARASIT, V48, P199; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MURPHY NB, 1987, J MOL BIOL, V195, P855, DOI 10.1016/0022-2836(87)90490-6; Navarro M, 1996, MOL CELL BIOL, V16, P3615; PAYS E, 1983, NUCLEIC ACIDS RES, V11, P8137, DOI 10.1093/nar/11.23.8137; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PAYS E, 1981, NATURE, V292, P265, DOI 10.1038/292265a0; RIFKIN MR, 1994, MOL BIOCHEM PARASIT, V66, P211, DOI 10.1016/0166-6851(94)90148-1; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; Webb H, 1997, J CELL BIOL, V139, P103, DOI 10.1083/jcb.139.1.103	27	279	283	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					839	846						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865701	Bronze			2022-12-28	WOS:000077498800013
J	de Visser, JAGM; Zeyl, CW; Gerrish, PJ; Blanchard, JL; Lenski, RE				de Visser, JAGM; Zeyl, CW; Gerrish, PJ; Blanchard, JL; Lenski, RE			Diminishing returns from mutation supply rate in asexual populations	SCIENCE			English	Article							TERM EXPERIMENTAL EVOLUTION; ESCHERICHIA-COLI; ADAPTIVE EVOLUTION; MISMATCH REPAIR; ADAPTATION; SELECTION; BACTERIA	Mutator genotypes with increased mutation rates may be especially important in microbial-evolution if genetic adaptation is generally Limited by the supply of mutations. In experimental populations of the bacterium Escherichia coli, the rate of evolutionary adaptation was proportional to the mutation supply rate only in particular circumstances of small or initially well-adapted populations. These experiments also demonstrate a "speed limit" on adaptive evolution in asexual populations, one that is independent of the mutation supply rate.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Ctr Dis Control, Atlanta, GA 30333 USA	Michigan State University; Wake Forest University; University of Oregon; Centers for Disease Control & Prevention - USA	de Visser, JAGM (corresponding author), Wageningen Univ Agr, Microbiol Lab, Wageningen, Netherlands.		de Visser, Arjan/GLU-3870-2022; Gerrish, Philip/AAE-7346-2019; Blanchard, Jeffrey/AAA-5173-2020	Blanchard, Jeffrey/0000-0002-7310-9678; de Visser, Arjan/0000-0002-5098-6686; Gerrish, Philip/0000-0001-6393-0553; Lenski, Richard/0000-0002-1064-8375				BURCH C, IN PRESS GENETICS; Fisher R.A., 1930, GENETICAL THEORY NAT; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; KONDRASHOV AS, 1995, GENET RES, V66, P53, DOI 10.1017/S001667230003439X; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; MALMBERG RL, 1977, GENETICS, V86, P607; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; MOXON ER, 1978, P NATL ACAD SCI USA, V75, P1534, DOI 10.1073/pnas.75.3.1534; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Otto SP, 1997, GENETICS, V147, P879; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; ZYSKIND J, 1989, RECOMBINANT DNA LAB	23	278	281	4	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					404	406		10.1126/science.283.5400.404	http://dx.doi.org/10.1126/science.283.5400.404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888858				2022-12-28	WOS:000078067000052
J	Schwartz, P; Gaulton, GN				Schwartz, P; Gaulton, GN			Addressing the needs of basic and clinical research: Analysis of graduates of the University of Pennsylvania MD-PhD program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCIENTIST TRAINING-PROGRAM		Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Schwartz, P (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Bradford WD, 1996, ACAD MED, V71, P484, DOI 10.1097/00001888-199605000-00019; FRIEDEN C, 1991, ACAD MED, V66, P162, DOI 10.1097/00001888-199103000-00008	2	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					96	+		10.1001/jama.281.1.96	http://dx.doi.org/10.1001/jama.281.1.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892459				2022-12-28	WOS:000077829300047
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Cell biology - Gentle slam	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Laffafian I, 1998, BIOPHYS J, V75, P2558, DOI 10.1016/S0006-3495(98)77700-8	1	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2213	2214		10.1126/science.282.5397.2213b	http://dx.doi.org/10.1126/science.282.5397.2213b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890830				2022-12-28	WOS:000077645800033
J	Cheung, BMY; Kumana, CR				Cheung, BMY; Kumana, CR			Natriuretic peptides - Relevance in cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; CHRONIC HEART-FAILURE; PLASMA-LEVELS; ATRIAL; SYSTEM; HYPERTENSION; ENDOCRINE; INFUSION		Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China	University of Hong Kong	Cheung, BMY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				ARAKAWA N, 1994, CARDIOLOGY, V85, P334, DOI 10.1159/000176706; BEVAN EG, 1992, J HYPERTENS, V10, P607; Cheung BMY, 1997, CLIN EXP PHARMACOL P, V24, P966, DOI 10.1111/j.1440-1681.1997.tb02729.x; CHEUNG BMY, 1994, CLIN SCI, V86, P723, DOI 10.1042/cs0860723; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; deBold AJ, 1996, CARDIOVASC RES, V31, P7, DOI 10.1016/S0008-6363(95)00121-2; HOLMES SJ, 1993, J CLIN ENDOCR METAB, V76, P91, DOI 10.1210/jc.76.1.91; LANG CC, 1992, CLIN SCI, V83, P519, DOI 10.1042/cs0830519; LAVILLA G, 1994, PACE, V17, P953; Levin ER, 1998, NEW ENGL J MED, V339, P321; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Marcus LS, 1996, CIRCULATION, V94, P3184, DOI 10.1161/01.CIR.94.12.3184; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; NAKAO K, 1992, J HYPERTENS, V10, P907; NORTHRIDGE DB, 1990, AM J HYPERTENS, V3, P682, DOI 10.1093/ajh/3.9.682; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Tsutamoto T, 1997, CIRCULATION, V96, P509; TUNNY TJ, 1993, J HYPERTENS, V11, pS222; Wallen T, 1997, HEART, V77, P264, DOI 10.1136/hrt.77.3.264; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988	23	117	133	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					1983	1984		10.1001/jama.280.23.1983	http://dx.doi.org/10.1001/jama.280.23.1983			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863839				2022-12-28	WOS:000077462300011
J	Greengold, NL				Greengold, NL			First attending rounds	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					1987	1988		10.1001/jama.280.23.1987	http://dx.doi.org/10.1001/jama.280.23.1987			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863840				2022-12-28	WOS:000077462300012
J	Goldenberg, RL; Vermund, SH; Goepfert, AR; Andrews, WW				Goldenberg, RL; Vermund, SH; Goepfert, AR; Andrews, WW			Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED TRIAL; BACTERIAL VAGINOSIS; INFECTION; METRONIDAZOLE; ZIDOVUDINE; REDUCTION; MEMBRANES; OUTCOMES; TYPE-1	The obstetric risk factors for perinatal transmission of HIV-1 include preterm birth, prolonged rupture of the chorioamniotic membranes, and clinical and histological bacterial chorioamnionitis. A chronic chorioamnionitis precedes many cases of preterm labour and spontaneous rupture of membranes, whereas an acute chorioamnionitis is more common after rupture of the membranes at term. Amniotic fluid cytokines are raised in the presence of term and preterm intrauterine bacterial infections, and various cytokines seem able to attract HIV-1-infected leucocytes into the amniotic cavity and to increase replication of HIV-1. We postulate that the association of preterm birth and prolonged rupture of membranes with perinatal transmission of HIV-1 may result from an associated chronic or acute bacterial chorioamnionitis marked by the migration of HIV-1-infected maternal leucocytes into the amniotic cavity. Antibiotic treatment could prevent this sequence of events.	Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Goldenberg, RL (corresponding author), Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA.		Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698	PHS HHS [290-92-0055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREWS G, 1995, BEHAV HEALTHC TOM, V4, P19; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; Fiscella K, 1996, PUBLIC HEALTH REP, V111, P104; GIAQUINTO C, 1992, LANCET, V339, P1007; Goldenberg RL, 1997, CLIN PERINATOL, V24, P23, DOI 10.1016/S0095-5108(18)30182-9; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P656, DOI 10.1016/0029-7844(96)00034-S; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; MANDELBROT L, PREINATAL HIV 1 TRAN; Mansergh G, 1996, JAMA-J AM MED ASSOC, V276, P139, DOI 10.1001/jama.276.2.139; Melendez-Guerrero LM, 1994, TROPHOBLAST RES, V8, P33; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; MINKOFF H, 1995, AM J OBSTET GYNECOL, V173, P585, DOI 10.1016/0002-9378(95)90286-4; MOFENSONLM, 1997, ACTA PAEDIAT S, V491, P1; MUNDY DC, 1987, LANCET, V2, P549; NORMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P404, DOI 10.1111/j.1471-0528.1994.tb11912.x; NYONGO A, 1909, INT C AIDS, V8, pB165; POPEK EJ, 1997, 4 C RETR OPP INF, P158; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; SCHAEFER A, 1998, 12 WORLD AIDS C GEN; SCHAFER AP, 1993, INT C AIDS, V9, P91; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TAHA TF, 1998, 11 WORLD AIDS C GEN; Vuthipongse P, 1998, JAMA-J AM MED ASSOC, V279, P1061	25	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1927	1930		10.1016/S0140-6736(98)04453-5	http://dx.doi.org/10.1016/S0140-6736(98)04453-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863804				2022-12-28	WOS:000077544600045
J	Adams, MWW; Stiefel, EI				Adams, MWW; Stiefel, EI			Biochemistry - Biological hydrogen production: Not so elementary	SCIENCE			English	Editorial Material							DESULFOVIBRIO-GIGAS; BREATH HYDROGEN; CRYSTAL-STRUCTURE; NIFE HYDROGENASE; NICKEL; IRON; LIGANDS		Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Exxon Res & Engn Co, Corp Res, Annandale, NJ 08801 USA	University System of Georgia; University of Georgia; Exxon Mobil Corporation	Adams, MWW (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.		Cai, Jinling/M-3943-2013	Cai, Jinling/0000-0003-0588-6456; Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1980, BIOCHIM BIOPHYS ACTA, V594, P105, DOI 10.1016/0304-4173(80)90007-5; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALANI FT, 1986, J ORGANOMET CHEM, V307, pC31, DOI 10.1016/0022-328X(86)80485-5; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Barber DE, 1996, INORG CHEM, V35, P4635, DOI 10.1021/ic951124t; Benemann J, 1996, NAT BIOTECHNOL, V14, P1101, DOI 10.1038/nbt0996-1101; Brandt P. F., 1997, INORG SYNTH, V31, P112; BRUUN E, 1995, GUT, V37, P256, DOI 10.1136/gut.37.2.256; CAMMACK R, 1982, FEBS LETT, V142, P289, DOI 10.1016/0014-5793(82)80154-3; Casellas F, 1998, PANCREAS, V16, P481, DOI 10.1097/00006676-199805000-00004; Chen JB, 1996, J ORGANOMET CHEM, V522, P21, DOI 10.1016/0022-328X(96)06242-0; CHEN JS, 1974, BIOCHIM BIOPHYS ACTA, V371, P283, DOI 10.1016/0005-2795(74)90025-7; CHENIER PJ, 1992, SURVEY IND CHEM, P60; Crabtree R. H., 1994, ORGANOMETALLIC CHEM; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; FRIEDRICH CG, 1982, J BACTERIOL, V152, P42; GEST H, 1954, BACTERIOL REV, V18, P43, DOI 10.1128/MMBR.18.1.43-73.1954; GRAF EG, 1981, FEBS LETT, V136, P165, DOI 10.1016/0014-5793(81)81238-0; GRAY CT, 1965, SCIENCE, V148, P186, DOI 10.1126/science.148.3667.186; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; HOEKSTRA JH, 1995, EUR J PEDIATR, V154, P362, DOI 10.1007/BF02072103; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; JANNASCH HW, 1985, SCIENCE, V229, P717, DOI 10.1126/science.229.4715.717; LEGALL J, 1982, BIOCHEM BIOPH RES CO, V106, P610, DOI 10.1016/0006-291X(82)91154-8; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Minocha A, 1997, DIGEST DIS SCI, V42, P672, DOI 10.1023/A:1018832117482; MORTENSON LE, 1974, MICROBIAL IRON METAB, P232; NAKOS G, 1971, BIOCHIM BIOPHYS ACTA, V227, P576, DOI 10.1016/0005-2744(71)90008-8; PECK HD, 1956, P NATL ACAD SCI USA, V42, P13, DOI 10.1073/pnas.42.1.13; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; SEYFERTH D, 1979, J AM CHEM SOC, V101, P508, DOI 10.1021/ja00496a053; Thomas CE, 1998, INT J HYDROGEN ENERG, V23, P507, DOI 10.1016/S0360-3199(97)00102-X; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Wachtershauser G, 1998, THERMOPHILES KEYS MO, P47; WEATHERILL TD, 1986, INORG CHEM, V25, P1466, DOI 10.1021/ic00229a033	37	228	236	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1842	1843		10.1126/science.282.5395.1842	http://dx.doi.org/10.1126/science.282.5395.1842			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9874636				2022-12-28	WOS:000077338100036
J	Grisso, JA; Battistini, M; Ryan, L				Grisso, JA; Battistini, M; Ryan, L			Women's health textbooks: Codifying science and calling for change	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIANS		Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Pennsylvania	Grisso, JA (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Blockley Hall,Room 920,423 Guardian Dr, Philadelphia, PA 19104 USA.							BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; CARLSON KJ, 1995, PRIMARY CARE WOMEN; CARR PL, 1995, MED CARE WOMEN; LEMCKE DP, 1995, PRIMARY CARE WOMEN; Leppert PC, 1997, PRIMARY CARE WOMEN; ROTER D, 1991, MED CARE, V29, P1083; Ruiz MT, 1997, J EPIDEMIOL COMMUN H, V51, P106, DOI 10.1136/jech.51.2.106; SELTZER VL, 1995, WOMENS PRIMARY HLTH; [No title captured]; [No title captured]	10	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					916	918		10.7326/0003-4819-129-11_Part_1-199812010-00025	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867742				2022-12-28	WOS:000077239200021
J	Alward, RD; Detling, JK; Milchunas, DG				Alward, RD; Detling, JK; Milchunas, DG			Grassland vegetation changes and nocturnal global warming	SCIENCE			English	Article							TEMPERATURE; PRECIPITATION; GREENHOUSE; GROWTH	Global minimum temperatures (T-MIN) are increasing faster than maximum temperatures, but the ecological consequences of this are Largely unexplored. Long-term data sets from the shortgrass steppe were used to identify correlations between T-MIN and several vegetation variables. This ecosystem is potentially sensitive to increases in T-MIN. Most notably, increased spring T-MIN was correlated with decreased net primary production by the dominant C-4 grass (Bouteloua gracilis) and with increased abundance and production by exotic and native C-3 forbs. Reductions in B. gracilis may make this system more vulnerable to invasion by exotic species and less tolerant of drought and grazing.	Colorado State Univ, Grad Degree Program Ecol, Ft Collins, CO 80523 USA; Colorado State Univ, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Rangeland Ecosyst Sci, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University; Colorado State University	Alward, RD (corresponding author), Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA.		Detling, James K/I-1691-2013					Cohen AN, 1998, SCIENCE, V279, P555, DOI 10.1126/science.279.5350.555; Coughenour MB, 1997, ECOL APPL, V7, P802, DOI 10.2307/2269435; Dai A, 1997, NATURE, V386, P665, DOI 10.1038/386665b0; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Henderson-Sellers A., 1992, GeoJournal, V27, P255, DOI 10.1007/BF02482666; *INT PAN CLIM CHAN, 1995, CLIM CHANG 1995 SCI; KARL TR, 1994, TRENDS 93 COMPENDIUM, P686; KERR RA, 1995, SCIENCE, V268, P1567, DOI 10.1126/science.268.5217.1567; KERR RA, 1995, SCIENCE, V270, P1565, DOI 10.1126/science.270.5242.1565; KERR RA, 1992, SCIENCE, V255, P682, DOI 10.1126/science.255.5045.682; KUKLA G, 1994, ASYMMETRIC CHANGE DA; LAUENROTH WK, 1991, ECOSYSTEMS WORLD A, V8; Manunta P, 1996, J AGRON CROP SCI, V176, P267, DOI 10.1111/j.1439-037X.1996.tb00471.x; MILCHUNAS DG, 1990, J VEG SCI, V1, P375, DOI 10.2307/3235714; MILCHUNAS DG, 1994, J RANGE MANAGE, V47, P133, DOI 10.2307/4002821; MILCHUNAS DG, 1995, ECOL APPL, V5, P452, DOI 10.2307/1942035; MILCHUNAS DG, 1992, ECOLOGY, V73, P593, DOI 10.2307/1940765; MILCHUNAS DG, 1989, VEGETATIO, V80, P11, DOI 10.1007/BF00049137; MOONEY HA, 1994, ASYMMETRIC CHANGE DA, P467; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; RICE RW, 1971, 103 US IBP COL STAT; SALA OE, 1988, ECOLOGY, V69, P40, DOI 10.2307/1943158; SEDDIGH M, 1989, CROP SCI, V29, P400, DOI 10.2135/cropsci1989.0011183X002900020033x; STOHIGREN TJ, IN PRESS ECOL MONOGR; Wedin DA, 1996, SCIENCE, V274, P1720, DOI 10.1126/science.274.5293.1720; YANG YL, 1995, OECOLOGIA, V104, P225, DOI 10.1007/BF00328587; Zeiher C.A., 1994, COTTON, P89	27	265	316	8	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					229	231		10.1126/science.283.5399.229	http://dx.doi.org/10.1126/science.283.5399.229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880257	Green Published			2022-12-28	WOS:000077976700042
J	[Anonymous]				[Anonymous]			BMA calls for guidelines on new and expensive drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1999	318	7175					63	63						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872908				2022-12-28	WOS:000078013100079
J	Kuner, R; Kohr, G; Grunewald, S; Eisenhardt, G; Bach, A; Kornau, HC				Kuner, R; Kohr, G; Grunewald, S; Eisenhardt, G; Bach, A; Kornau, HC			Role of heteromer formation in GABA(B) receptor function	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN SLICES; PHYSIOLOGICAL-ROLE; ABSENCE SEIZURES; BASIC MECHANISMS; K+ CHANNELS; PROTEIN; MODULATION; EXPRESSION; CLONING	Recently, GBR1, a seven-transmembrene domain protein with high affinity for gamma-aminobutyric acid (GABA)(B) receptor antagonists, was identified. Here, a GBR1-related protein, GBR2, was shown to be coexpressed with GBR1 in many brain regions and to interact with it through a short domain in the carboxyl-terminal cytoplasmic tail. Heterologously expressed GBR2 mediated inhibition of adenylyl cyclase; however, inwardly rectifying potassium channels were activated by GABA(B) receptor agonists only upon coexpression with GBR1 and GBR2, Thus, the interaction of these receptors appears to be crucial for important physiological effects of GABA and provides a mechanism in receptor signaling pathways that involve a heterotrimeric GTP-binding protein.	BASF LYNX Biosci AG, Dept Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	BASF; Max Planck Society	Kornau, HC (corresponding author), BASF LYNX Biosci AG, Dept Neurosci, Neuenheimer Feld 515, D-69120 Heidelberg, Germany.	kornau@basf-lynx.de	Kuner, Rohini/AGU-0204-2022					ALGER BE, 1979, NATURE, V281, P315, DOI 10.1038/281315a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BONANNO G, 1993, TRENDS PHARMACOL SCI, V14, P259, DOI 10.1016/0165-6147(93)90124-3; BOWERY NG, 1987, NEUROSCIENCE, V20, P365, DOI 10.1016/0306-4522(87)90098-4; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; Caddick SJ, 1996, MOL NEUROBIOL, V13, P23, DOI 10.1007/BF02740750; CHU DCM, 1990, NEUROSCIENCE, V34, P341, DOI 10.1016/0306-4522(90)90144-S; Dichter MA, 1997, EPILEPSIA, V38, pS2, DOI 10.1111/j.1528-1157.1997.tb05200.x; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HILL DR, 1985, BRIT J PHARMACOL, V84, P249; Jarolimek W, 1998, J NEUROSCI, V18, P4001; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Knight AR, 1996, NEUROPHARMACOLOGY, V35, P703, DOI 10.1016/0028-3908(96)84642-9; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNER R, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; STOFFEL M, 1995, BIOCHEM BIOPH RES CO, V212, P894, DOI 10.1006/bbrc.1995.2053; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOICIK WJ, 1984, MOL PHARMACOL, V25, P24	35	471	505	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					74	77		10.1126/science.283.5398.74	http://dx.doi.org/10.1126/science.283.5398.74			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872744				2022-12-28	WOS:000077976600052
J	Ye, XH; Rivera, VM; Zoltick, P; Cerasoli, F; Schnell, MA; Gao, GP; Hughes, JV; Gilman, M; Wilson, JM				Ye, XH; Rivera, VM; Zoltick, P; Cerasoli, F; Schnell, MA; Gao, GP; Hughes, JV; Gilman, M; Wilson, JM			Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer	SCIENCE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; SUSTAINED EXPRESSION; IMMUNOCOMPETENT MICE; SKELETAL-MUSCLE; ERYTHROPOIETIN; TRANSDUCTION; SECRETION; EFFICIENT; PLASMID; SYSTEM	Stable delivery of a therapeutic protein under pharmacologic control was achieved through in vivo somatic gene transfer. This system was based on the expression of two chimeric, human-derived proteins that were reconstituted by rapamycin into a transcription factor complex. A mixture of two adeno-associated virus vectors, one expressing the transcription factor chimeras and one containing erythropoietin (Epo) under the control of a promoter responsive to the transcription factor, was injected into skeletal muscle of immune-competent mice. Administration of rapamycin resulted in 200-fold induction of plasma Epo, Stable engraftment of this humanized system in immune-competent mice was achieved for 6 months with similar results for at least 3 months in a rhesus monkey.	Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA; Univ Penn, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Wistar Inst, Philadelphia, PA 19104 USA; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Wilson, JM (corresponding author), Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	Wilson, James M/F-9220-2011; Wilson, Matthew H/K-3193-2013	Wilson, James M/0000-0002-9630-3131; Rivera, Victor/0000-0002-7258-3001	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR/NS43648-03] Funding Source: Medline; NIDDK NIH HHS [P30 DK47757-05] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohl D, 1997, HUM GENE THER, V8, P195, DOI 10.1089/hum.1997.8.2-195; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Gao GP, 1998, HUM GENE THER, V9, P2353, DOI 10.1089/hum.1998.9.16-2353; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Naffakh N, 1996, HUM GENE THER, V7, P11, DOI 10.1089/hum.1996.7.1-11; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Ye X., UNPUB; Ye XH, 1996, J BIOL CHEM, V271, P3639	25	258	294	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					88	91		10.1126/science.283.5398.88	http://dx.doi.org/10.1126/science.283.5398.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872748				2022-12-28	WOS:000077976600056
J	Achenbach, S; Moshage, W; Ropers, D; Nossen, J; Daniel, WG				Achenbach, S; Moshage, W; Ropers, D; Nossen, J; Daniel, WG			Value of electron-beam computed tomography for the noninvasive detection of high-grade coronary-artery stenoses and occlusions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTRAST AGENT; MR-ANGIOGRAPHY; CT; CALCIFICATION; DISEASE	Background Reliable noninvasive assessment of coronary-artery stenoses and occlusions would constitute an advantage in the care of patients with known or suspected coronary artery disease. We investigated the accuracy of contrast-enhanced electron-beam computed tomography (CT) for the detection of high-grade coronary-artery stenoses and occlusions. Methods Electron-beam CT was performed in 125 patients. After intravenous injection of a contrast agent, 40 cross-sectional images of the heart were acquired during inspiration, triggered by the electrocardiogram in diastole. Three-dimensional reconstructions of the heart and coronary arteries were rendered to facilitate evaluation of the images. The proximal and middle segments of the major coronary arteries were evaluated for the presence or absence of high-grade stenoses and occlusions, The results were compared with those of invasive coronary angiography in a blinded fashion. Results Because of technical problems that impaired the quality of the images, 124 (25 percent) of the 500 coronary arteries studied (left main, left anterior descending, left circumflex, and right coronary) in a total of 125 patients were excluded from evaluation. No vessels could be evaluated in 19 patients (15 percent), and another 28 patients (22 percent) had one, two, or three vessels that could not be evaluated. In the remaining coronary arteries with adequate image quality, electron-beam CT permitted visualization of 69 of 75 high-grade stenoses and occlusions (sensitivity, 92 percent), whereas in 282 of 301 arteries, the absence of high-grade stenoses and occlusions was correctly detected (specificity, 94 percent). Conclusions When image quality is adequate, electron-beam CT may be useful to detect or rule out high-grade coronary-artery stenoses and occlusions. (N Engl J Med 1998;339:1964-71.) (C) 1998, Massachusetts Medical Society.	Univ Erlangen Nurnberg, Med Klin & Poliklin 2, Dept Internal Med 2, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Achenbach, S (corresponding author), Univ Erlangen Nurnberg, Med Klin & Poliklin 2, Dept Internal Med 2, Ostliche Stadtmauerstr 29, D-91054 Erlangen, Germany.							Achenbach S, 1997, CIRCULATION, V96, P2785, DOI 10.1161/01.CIR.96.9.2785; AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; *AM HEART ASS, 1993, 1993 HEART STROK FAC, P8; *AM HEART ASS COMM, 1975, CIRCULATION, V51, P5; Arad Y, 1996, CIRCULATION, V93, P1951, DOI 10.1161/01.CIR.93.11.1951; BOYD DP, 1979, IEEE T NUCL SCI, V26, P2724, DOI 10.1109/TNS.1979.4330523; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; Budoff M. J., 1997, Journal of the American College of Cardiology, V29, p393A; Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898; Caiati C, 1996, J AM COLL CARDIOL, V27, P1413, DOI 10.1016/0735-1097(96)81521-X; Chernoff DM, 1997, AM J ROENTGENOL, V169, P93, DOI 10.2214/ajr.169.1.9207507; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Detrano R, 1996, J AM COLL CARDIOL, V27, P285, DOI 10.1016/0735-1097(95)00460-2; DUERINCKX AJ, 1995, TOP MAGN RESON IMAG, V7, P267; Feigenbaum H, 1989, J Am Soc Echocardiogr, V2, P253; GOULD RG, 1992, ULTRAFAST COMPUTED T, P1; Hamm CW, 1996, HERZ, V21, P127; Hozumi T, 1998, CIRCULATION, V97, P1557, DOI 10.1161/01.CIR.97.16.1557; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; Kessler W, 1997, AM J CARDIOL, V80, P989, DOI 10.1016/S0002-9149(97)00590-0; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MANNING WJ, 1993, MAGN RESON QUART, V9, P131; MANNING WJ, 1994, NEW ENGL J MED, V330, P152; MCCONNELL MV, 1995, CIRCULATION, V92, P3158, DOI 10.1161/01.CIR.92.11.3158; Mohiaddin RH, 1996, CORONARY ARTERY DIS, V7, P591, DOI 10.1097/00019501-199608000-00006; MOSHAGE WEL, 1995, RADIOLOGY, V196, P707, DOI 10.1148/radiology.196.3.7644633; Muller MF, 1997, J MAGN RESON IMAGING, V7, P644, DOI 10.1002/jmri.1880070406; Mulvagh SL, 1996, J AM COLL CARDIOL, V27, P1519, DOI 10.1016/0735-1097(95)00619-2; Nakanishi T, 1997, J COMPUT ASSIST TOMO, V21, P121, DOI 10.1097/00004728-199701000-00024; Neubauer S, 1998, EUR HEART J, V19, P19; Pennell DJ, 1996, HEART, V75, P127, DOI 10.1136/hrt.75.2.127; POST JC, 1995, CIRCULATION, V92, P3163, DOI 10.1161/01.CIR.92.11.3163; Post JC, 1996, AM J ROENTGENOL, V166, P1399, DOI 10.2214/ajr.166.6.8633453; REDDY GP, 1997, RADIOLOGY S, V205, P459; RUBENSTEIN E, 1994, SYNCHROTRON RADIATION IN THE BIOSCIENCES, P639; RUMBERGER J A, 1991, American Journal of Cardiac Imaging, V5, P29; Rumberger JA, 1996, MAYO CLIN PROC, V71, P369, DOI 10.4065/71.4.369; Schmermund A, 1998, J AM COLL CARDIOL, V31, P1547, DOI 10.1016/S0735-1097(98)00132-6; STANFORD W, 1993, AM J ROENTGENOL, V161, P1139, DOI 10.2214/ajr.161.6.8249716; TARDIF JC, 1994, J AM COLL CARDIOL, V24, P909, DOI 10.1016/0735-1097(94)90849-4; Taylor AM, 1996, CURR OPIN CARDIOL, V11, P635, DOI 10.1097/00001573-199611000-00013; VANDERWALL EE, 1997, INT J CARDIAC IMAG, V13, P79; 1991, LANCET, V337, P1449	43	278	286	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1964	1971		10.1056/NEJM199812313392702	http://dx.doi.org/10.1056/NEJM199812313392702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869667				2022-12-28	WOS:000077803800002
J	Gillespie, SH				Gillespie, SH			Failure of penicillin in Streptococcus pyogenes pharyngeal infection	LANCET			English	Editorial Material							GROUP-A STREPTOCOCCI; RESISTANCE; TONSILLOPHARYNGITIS; ERYTHROMYCIN; EXPRESSION; EFFICACY		UCL Royal Free & Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England	University of London; University College London; UCL Medical School	Gillespie, SH (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England.							Adam D, 1996, EUR J CLIN MICROBIOL, V15, P712, DOI 10.1007/BF01691957; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; FERRETTI JJ, 1992, NEW PERSPECTIVES S S, V22, P329; GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539; GUTMANN L, 1982, ANTIMICROB AGENTS CH, V22, P128, DOI 10.1128/AAC.22.1.128; HYDER SL, 1978, J INFECT DIS, V138, P281, DOI 10.1093/infdis/138.3.281; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; MARKOWITZ M, 1993, J PEDIATR-US, V123, P679, DOI 10.1016/S0022-3476(05)80840-6; McLaughlin R E, 1995, Methods Mol Biol, V47, P185; MILATOVIC D, 1989, EUR J CLIN MICROBIOL, V8, P282, DOI 10.1007/BF01963451; PICHICHERO ME, 1987, PEDIATR INFECT DIS J, V6, P635, DOI 10.1097/00006454-198707000-00004; Poyart C, 1997, ANTIMICROB AGENTS CH, V41, P24, DOI 10.1128/AAC.41.1.24; RAVDONIKAS LE, 1983, ACTA PATH MICRO IM B, V91, P55; ROOS K, 1993, SCAND J INFECT DIS, V25, P31, DOI 10.3109/00365549309169666; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SMITH TD, 1987, J PEDIATR-US, V110, P777, DOI 10.1016/S0022-3476(87)80023-9; Standaert BB, 1998, PEDIATR INFECT DIS J, V17, P39, DOI 10.1097/00006454-199801000-00009; STEVENS DL, 1993, J INFECT DIS, V167, P1401, DOI 10.1093/infdis/167.6.1401	18	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1954	1956		10.1016/S0140-6736(05)61327-X	http://dx.doi.org/10.1016/S0140-6736(05)61327-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872242				2022-12-28	WOS:000077663000006
J	Farkouh, ME; Smars, PA; Reeder, GS; Zinsmeister, AR; Evans, RW; Meloy, TD; Kopecky, SL; Allen, M; Allison, TG; Gibbons, RJ; Gabriel, SE				Farkouh, ME; Smars, PA; Reeder, GS; Zinsmeister, AR; Evans, RW; Meloy, TD; Kopecky, SL; Allen, M; Allison, TG; Gibbons, RJ; Gabriel, SE		Chest Pain Evaluat Emergency Room Invest	Clinical trial of a chest-pain observation unit for patients with unstable angina	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ACUTE CARDIAC ISCHEMIA; DIAGNOSTIC PROTOCOL; EMERGENCY	Background Nearly half of patients hospitalized with unstable angina eventually receive a non-cardiac-related diagnosis, yet 5 percent of patients with myocardial infarction are inappropriately discharged from the emergency department. We evaluated the safety, efficacy, and cost of admission to a chest-pain observation unit (CPU) located in the emergency department for such patients. Methods We performed a community-based, prospective, randomized trial of the safety, efficacy, and cost of admission to a CPU as compared with those of regular hospital admission for patients with unstable angina who were considered to be at intermediate risk for cardiovascular events in the short term. A total of 424 eligible patients were randomly assigned to routine hospital admission (a monitored bed under the care of the cardiology service) or admission to the CPU (where patients were cared for according to a strict protocol including aspirin, heparin, continuous ST-segment monitoring, determination of creatine kinase isoenzyme levels, six hours of observation, and a study of cardiac function). The CPU was managed by the emergency department staff. Patients whose test results were negative were discharged, and the others were hospitalized. Primary outcomes (nonfatal myocardial infarction, death, acute congestive heart failure, stroke, or out-of-hospital cardiac arrest) and use of resources were compared between the two groups. Results The 212 patients in the hospital-admission group had 15 primary events (13 myocardial infarctions and 2 cases of congestive heart failure), and the 212 patients in the CPU group had 7 events (5 myocardial infarctions, 1 death from cardiovascular causes, and 1 case of congestive heart failure). There was no significant difference in the rate of cardiac events between the two groups (odds ratio for the CPU group as compared with the hospital-admission group, 0.50; 95 percent confidence interval, 0.20 to 1.24). No primary events occurred among the 97 patients who were assigned to the CPU and discharged. Resource use during the first six months was greater among patients assigned to hospital admission than among those assigned to the CPU (P = 0.003 by the rank-sum test). Conclusions A CPU located in the emergency-department can be a safe, effective, and cost-saving means of ensuring that patients with unstable angina who are considered to be at intermediate risk of cardiovascular events receive appropriate care. (N Engl J Med 1998;339:1882-8.) (C) 1998, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Div Emergency Med Serv & Internal Med, Rochester, MN 55905 USA; Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Sect Hlth Serv Evaluat, Rochester, MN 55905 USA; Cent Utah Med Clin, Div Cardiol, Provo, UT USA	Mayo Clinic; Icahn School of Medicine at Mount Sinai; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smars, PA (corresponding author), Mayo Clin & Mayo Fdn, Div Emergency Med Serv & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.							Barish R A, 1997, J Healthc Qual, V19, P6; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COLLINSON PO, 1992, ANN CLIN BIOCHEM, V29, P43, DOI 10.1177/000456329202900105; FARKOUH ME, 1996, CIRCULATION S1, V94, P1; GIBLER WB, 1992, ANN EMERG MED, V21, P504; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; *HCIA, 1997, DRG HDB COMP CLIN FI; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KIRK JD, 1995, J AM COLL CARDIOL, V25, pA171; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; Nichol G, 1997, ANN INTERN MED, V127, P996, DOI 10.7326/0003-4819-127-11-199712010-00009; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; Stussman BJ, 1997, DHHS PUBLICATION; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; Zalenski RJ, 1997, ARCH INTERN MED, V157, P1085, DOI 10.1001/archinte.157.10.1085	20	394	405	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1882	1888		10.1056/NEJM199812243392603	http://dx.doi.org/10.1056/NEJM199812243392603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862943				2022-12-28	WOS:000077696600003
J	Halpern, SH; Leighton, BL; Ohlsson, A; Barrett, JFR; Rice, A				Halpern, SH; Leighton, BL; Ohlsson, A; Barrett, JFR; Rice, A			Effect of epidural vs parenteral opioid analgesia on the progress of labor - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CESAREAN-SECTION; RISK-FACTORS; INTRAMUSCULAR PETHIDINE; OPERATIVE DELIVERY; NULLIPAROUS WOMEN; MATERNAL OPINION; RANDOMIZED TRIAL; CLINICAL-TRIALS; TEMPERATURE; ANESTHESIA	Context.-Epidural labor analgesia, if selected by the patient, is associated with high cesarean delivery rates. Results of randomized trials comparing rates of cesarean delivery using epidural anesthesia vs parenteral opioids are inconsistent. Objective.-To review the effects of epidural vs parenteral opioid analgesia on cesarean delivery rates. Data Sources.-Studies were identified by searching MEDLINE from January 1966 through January 1998, the Cochrane Database of Perinatal Trials, and relevant nonindexed journals and abstracts. Study Selection.-We included all studies that randomized patients to epidural vs parenteral opioid labor analgesia. Data Extraction.-Two authors independently extracted data from 10 trials enrolling 2369 patients. Odds ratios (ORs) for categorical data, weighted mean differences (WMDs) for continuous data, and 95% confidence intervals (CIs) were calculated using a random-effects model. Data Synthesis.-The risk of cesarean delivery did not differ between patients receiving epidural (8.2%) vs parenteral opioid (5.6%) analgesia (OR, 1.5; 95% CI, 0.81-2.76). Epidural patients had longer first (WMD, 42 minutes; 95% CI, 17-68 minutes) and second (WMD, 14 minutes; 95% CI, 5-23 minutes) labor stages. While epidural patients were more likely to have instrumented delivery (OR, 2.19; 95% CI, 1.32-7.78), they were no more likely to have instrumented delivery for dystocia (OR, 0.68; 95% CI, 0.31-1.49). After epidural analgesia, neonates were less likely to have low 5-minute Apgar scores (OR, 0.38; 95% CI, 0.18-0.81) or to need naloxone (OR, 0.24; 95% CI, 0.07-0.77). Women receiving epidural analgesia had lower pain scores during the first (WMD, -40 mm on a 100-mm scale; 95% CI, -42 to -38 mm) and second (WMD, -29 mm; 95% CI, -38 to -21 mm) stages of labor. The odds of dissatisfaction were lower with epidural analgesia (OR, 0.25; 95% CI, 0.20-0.32). Conclusions.-Epidural labor analgesia is not associated with increased rates of instrumented vaginal delivery for dystocia or cesarean delivery. Patients receiving epidural analgesia have longer labors. Patient satisfaction and neonatal outcome are better after epidural than parenteral opioid analgesia.	Womens Coll Hosp, Dept Anaesthesia, Toronto, ON M5S 1B2, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Dept Newborn & Dev Paediat, Toronto, ON, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University of Toronto; University of Toronto	Halpern, SH (corresponding author), Womens Coll Hosp, Dept Anaesthesia, 76 Grenville St, Toronto, ON M5S 1B2, Canada.	halpern@ftn.net	Halpern, Stephen H/K-8304-2012	Halpern, Stephen H/0000-0002-7480-5122				*AM COLL OBST GYN, 1997, GUID PER CAR; AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; BARRY D, 1997, SOC OBST AN PER APR; Bofill JA, 1997, AM J OBSTET GYNECOL, V177, P1465, DOI 10.1016/S0002-9378(97)70092-9; Breslow NE, 1980, STATISTICAL METHODS, V1, P136; BUTLER J, 1993, AM J OBSTET GYNECOL, V168, P1407, DOI 10.1016/S0002-9378(11)90773-X; CAMANN WR, 1991, BRIT J ANAESTH, V67, P565, DOI 10.1093/bja/67.5.565; CAMMU H, 1994, ACTA OBSTET GYN SCAN, V73, P235, DOI 10.3109/00016349409023446; Cheek TG, 1996, BRIT J ANAESTH, V77, P632, DOI 10.1093/bja/77.5.632; Chestnut DH, 1997, ANESTHESIOLOGY, V87, P472, DOI 10.1097/00000542-199709000-00003; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fogel ST, 1998, ANESTH ANALG, V87, P119, DOI 10.1097/00000539-199807000-00026; FUSI L, 1989, LANCET, V1, P1250, DOI 10.1016/S0140-6736(89)92341-6; GLEESON NC, 1989, LANCET, V2, P861; GLOSTEN B, 1992, ANESTHESIOLOGY, V77, P10, DOI 10.1097/00000542-199207000-00003; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; GRIBBLE RK, 1991, OBSTET GYNECOL, V78, P231; HANNAH P, 1992, BRIT J PSYCHIAT, V160, P777, DOI 10.1192/bjp.160.6.777; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; HENDOLIN H, 1982, ANN CLIN RES, V14, P181; HOWELL CJ, 1998, PREGNANCY CHILDBIRTH; Jacob J, 1997, OBSTET GYNECOL, V89, P217, DOI 10.1016/S0029-7844(96)00430-9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHNSON S, 1995, J FAM PRACTICE, V40, P244; KROLL L, 1994, EUR J OBSTET GYN R B, V55, P175, DOI 10.1016/0028-2243(94)90034-5; LEIGHTON BL, 1993, OBSTET ANESTHESIA, P615; Lieberman E, 1996, OBSTET GYNECOL, V88, P993, DOI 10.1016/S0029-7844(96)00359-6; Lyon DS, 1997, OBSTET GYNECOL, V90, P135, DOI 10.1016/S0029-7844(97)00214-7; MORTON SC, 1994, OBSTET GYNECOL, V83, P1045, DOI 10.1097/00006250-199406000-00029; Muir Holly, 1996, Canadian Journal of Anaesthesia, V43, pA60; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; PETITTI DB, 1994, MONOGR EPIDEMIOL BIO, V24, P55; PHILIPSEN T, 1989, EUR J OBSTET GYN R B, V30, P27, DOI 10.1016/0028-2243(89)90090-7; PHILIPSEN T, 1990, EUR J OBSTET GYN R B, V34, P205, DOI 10.1016/0028-2243(90)90072-9; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Reynolds F, 1997, LANCET, V349, P4, DOI 10.1016/S0140-6736(05)62156-3; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x; RYDING EL, 1993, ACTA OBSTET GYN SCAN, V72, P280, DOI 10.3109/00016349309068038; Sharma SK, 1997, ANESTHESIOLOGY, V87, P487, DOI 10.1097/00000542-199709000-00006; SHNIDER SM, 1993, ANESTHESIA OBSTET, P135; THORP JA, 1991, AM J PERINAT, V8, P402, DOI 10.1055/s-2007-999426; THORP JA, 1989, AM J OBSTET GYNECOL, V161, P670, DOI 10.1016/0002-9378(89)90377-3; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Turcot L, 1997, AM J OBSTET GYNECOL, V176, P395, DOI 10.1016/S0002-9378(97)70505-2; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	46	203	216	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2105	2110		10.1001/jama.280.24.2105	http://dx.doi.org/10.1001/jama.280.24.2105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875879				2022-12-28	WOS:000077606100035
J	White, JH; Wise, A; Main, MJ; Green, A; Fraser, NJ; Disney, GH; Barnes, AA; Emson, P; Foord, SM; Marshall, FH				White, JH; Wise, A; Main, MJ; Green, A; Fraser, NJ; Disney, GH; Barnes, AA; Emson, P; Foord, SM; Marshall, FH			Heterodimerization is required for the formation of a functional GABA(B) receptor	NATURE			English	Article							DIMERIZATION; EXPRESSION; CLONING	GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the mammalian central nervous system, where it exerts its effects through ionotropic (GABA(A/C)) receptors to produce fast synaptic inhibition and metabotropic (GABA(B)) receptors to produce slow prolonged inhibitory signals. The gene encoding a GABA(B) receptor (GABA(B)R1) has been cloned(1); however, when expressed in mammalian cells this receptor is retained as an immature glycoprotein on intracellular membranes(2) and exhibits low affinity for agonists compared with the endogenous receptor on brain membranes. Here we report the cloning of a complementary DNA encoding a new subtype of the GABA(B) receptor (GABA(B)R2), which we identified by mining expressed-sequence-tag databases. Yeast two-hybrid screening showed that this new GABA(B)R2-receptor subtype forms heterodimers with GABA(B)R1 through an interaction at their intracellular carboxy-terminal tails. Upon expression with GABA(B)R2 in HEK293T cells, GABA(B)R1 is terminally glycosylated and expressed at the cell surface. Go-expression of the two receptors produces a fully functional GABA(B) receptor at the cell surface; this receptor binds GABA with a high affinity equivalent to that of the endogenous brain receptor. These results indicate that, in vivo, functional brain GABA(B) receptors may be heterodimers composed of GABA(B)R1 and GABA(B)R2.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Receptor Syst, Stevenage SG1 2NY, Herts, England; Babraham Inst, Dept Neurobiol, Cambridge CB2 4AT, England	GlaxoSmithKline; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Marshall, FH (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Receptor Syst, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	fhm27375@glaxowellcome.co.uk	Marshall, Fiona/AAZ-9626-2020	Marshall, Fiona/0000-0002-8681-005X				BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Bittiger H, 1992, PHARM COMMUN, V2, P23; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; HARPUR LL, 1995, EXP AGING RES, V21, P1, DOI 10.1080/03610739508254264; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SIMMONS D, 1988, J IMMUNOL, V141, P2797; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; WIELAND T, 1994, METHOD ENZYMOL, V237, P3	18	954	1027	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					679	682		10.1038/25354	http://dx.doi.org/10.1038/25354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872316				2022-12-28	WOS:000077694200054
J	Silagy, C; Campion, K; Keene, O; Cooper, C; Bolton, P; Watts, R; Liaw, T; Narayan, K; Delooze, F; Narayan, K; Dunne, J; Stewart, R; Gilzan, C; Cooper, C; Bolton, P; Mira, M; Lavis, S; Batey, C; Liaw, T; Scarfo, M; Silagy, C; Wesslinghe, S; Girke, T; Roberts, P; Watts, R; Stanley, J; Cook, N; Delooze, F; McKeirnan, M; Hartl, G; Peterson, V; Becker, M; Drewry, A; Ratima, K; Sauer, F; Clark, M; Wright, L				Silagy, C; Campion, K; Keene, O; Cooper, C; Bolton, P; Watts, R; Liaw, T; Narayan, K; Delooze, F; Narayan, K; Dunne, J; Stewart, R; Gilzan, C; Cooper, C; Bolton, P; Mira, M; Lavis, S; Batey, C; Liaw, T; Scarfo, M; Silagy, C; Wesslinghe, S; Girke, T; Roberts, P; Watts, R; Stanley, J; Cook, N; Delooze, F; McKeirnan, M; Hartl, G; Peterson, V; Becker, M; Drewry, A; Ratima, K; Sauer, F; Clark, M; Wright, L		Management Influenza So Hemisphere Triali	Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections	LANCET			English	Article							NEURAMINIDASE; INHIBITOR; RIMANTADINE; RESISTANCE; AMANTADINE	Background Influenza affects many people worldwide each year and has many troublesome symptoms. We investigated the efficacy and safety of the inhaled antiviral agent zanamivir as a treatment fbr influenza A and B infection. Methods In a randomised, double-blind, placebo-controlled trial, we recruited 455 patients aged 12 years and older with influenza-like symptoms of 36 h duration or less who lived in Australia, New Zealand, and South Africa. Eligible patients were randomly assigned 10 mg inhaled zanamivir (n=227) or placebo (n=228) twice daily for 5 days. All patients recorded symptoms on diary cards four times daily during treatment and twice daily for 9 days after treatment. We analysed all patients by intention to treat, influenza-positivity, and high risk of developing complications. Findings Compared with placebo, zanamavir relieved influenza symptoms a median of 1.5 days earlier in the intention-to-treat population (p=0.011), in influenza-positive patients (p=0.004), and in patients who were febrile at entry (p<0.001). In high-risk patients treated with zanamivir, symptoms were alleviated a median of 2.5 days earlier (p=0.048), fewer had complications (p=0.004), and fewer used complication-associated antibiotics (p=0.025) compared with placebo. The adverse event profiles were similar for zanamivir and placebo. Interpretation Zanamivir was well-tolerated and effective in shortening the duration and severity of influenza symptoms and, in high-risk patients, the rate of complications. Our findings need to be confirmed in future studies because of the small number of patients.	Flinders Med Ctr, Dept Evidence Based Med & Gen Practice, Bedford Pk, Vic 3155, Australia; Glaxo Wellcome Res & Dev, Res Triangle Pk, NC USA; Univ Sydney, Sydney, NSW 2006, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Box Hill Hosp, Box Hill, Vic, Australia; Univ Queensland, St Lucia, Qld 4067, Australia; Univ Auckland, Auckland 1, New Zealand	Flinders Medical Centre; GlaxoSmithKline; University of Sydney; University of Melbourne; Box Hill Hospital; University of Queensland; University of Auckland	Silagy, C (corresponding author), Flinders Med Ctr, Dept Evidence Based Med & Gen Practice, Bedford Pk, Vic 3155, Australia.			Keene, Oliver/0000-0003-0016-9773				BARNETT J, 1997, 37 INT C ANT AG CHEM, P230; BELSHE RB, 1989, J INFECT DIS, V159, P430, DOI 10.1093/infdis/159.3.430; CATE TR, 1987, AM J MED, V82, P15, DOI 10.1016/0002-9343(87)90555-9; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; DOLIN R, 1998, HARRISONS PRINCIPLES, P1112; Efron B, 1993, INTRO BOOTSTRAP, P178; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HAYDEN FG, 1994, ANTIVIR RES, V25, P123, DOI 10.1016/0166-3542(94)90101-5; HAYDEN FG, 1994, CURR OPIN INFECT DIS, V7, P674, DOI 10.1097/00001432-199412000-00008; HAYDEN FG, 1996, OPTIONS CONTROL INFL, V3, P718; LIU CG, 1993, VIROLOGY, V194, P403, DOI 10.1006/viro.1993.1276; Luo Ming, 1997, Journal of Infectious Diseases, V176, pS62, DOI 10.1086/514178; Monto Arnold S., 1997, Journal of Infectious Diseases, V176, pS32, DOI 10.1086/514172; MONTO AS, 1987, AM J MED, V82, P20, DOI 10.1016/0002-9343(87)90556-0; OSTERHAUS ADM, 1998, 38 INT C ANT AG CHEM, P11; RYAN DM, 1994, ANTIMICROB AGENTS CH, V38, P2770; SCHOENBAUM SC, 1987, AM J MED, V82, P26, DOI 10.1016/0002-9343(87)90557-2; Van Voris L P, 1992, Semin Respir Infect, V7, P61; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WOODS JM, 1993, ANTIMICROB AGENTS CH, V37, P1473, DOI 10.1128/AAC.37.7.1473	22	291	299	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1877	1881						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863784				2022-12-28	WOS:000077544600007
J	Cheng, AM; Saxton, TM; Sakai, R; Kulkarni, S; Mbamalu, G; Vogel, W; Tortorice, CG; Cardiff, RD; Cross, JC; Muller, WJ; Pawson, T				Cheng, AM; Saxton, TM; Sakai, R; Kulkarni, S; Mbamalu, G; Vogel, W; Tortorice, CG; Cardiff, RD; Cross, JC; Muller, WJ; Pawson, T			Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; MIDDLE T-ANTIGEN; ADAPTER PROTEIN; SH3 DOMAINS; RAS PATHWAY; SIGNAL-TRANSDUCTION; SH3-SH2-SH3 PROTEIN; BINDING-DOMAIN	Proteins with SH2 and SH3 domains link tyrosine kinases to intracellular pathways. To investigate the biological functions of a mammalian SH2/SH3 adaptor, we have introduced a null mutation into the mouse gene for Grb2. Analysis of mutant embryonic stem cells, embryos, and chimeras reveals that Grb2 is required during embyrogenesis for the differentiation of endodermal cells and formation of the epiblast. Grb2 acts physiologically as an adaptor, since replacing the C terminus of the Ras activator Sos1 with the Grb2 SH2 domain yields a fusion protein that largely rescues the defects caused by the Grb2 mutation. Furthermore, Grb2 is rate limiting for mammary carcinomas induced by polyomavirus middle T antigen. These data provide genetic evidence for a mammalian Grb2-Ras signaling pathway, mediated by SH2/SH3 domain interactions, that has multiple functions in embryogenesis and cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; McMaster University; University of California System; University of California Davis	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Cross, James/F-4814-2011; Pawson, Tony J/E-4578-2013; Cross, James/AAU-2973-2020	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378; Sakai, Ryuichi/0000-0001-6833-1103				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BHATNAGAR P, 1995, DEVELOPMENT, V121, P1333; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Byrne JL, 1996, ONCOGENE, V13, P2055; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSHIMA RG, 1983, DEV BIOL, V99, P447, DOI 10.1016/0012-1606(83)90294-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	288	299	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					793	803		10.1016/S0092-8674(00)81702-X	http://dx.doi.org/10.1016/S0092-8674(00)81702-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865697	Bronze			2022-12-28	WOS:000077498800009
J	Spear, PG				Spear, PG			Microbiology - A welcome mat for leprosy and lassa fever	SCIENCE			English	Editorial Material							DYSTROGLYCAN		Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.							Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Matsumura K, 1997, HISTOL HISTOPATHOL, V12, P195; Nations SP, 1998, SEMIN NEUROL, V18, P113, DOI 10.1055/s-2008-1040867; PETERS CJ, 1996, FIELDS VIROLOGY, V8, P1521; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Wewer UM, 1996, NEUROMUSCULAR DISORD, V6, P409, DOI 10.1016/S0960-8966(96)00384-7; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831	9	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					1999	2000		10.1126/science.282.5396.1999	http://dx.doi.org/10.1126/science.282.5396.1999			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9874652				2022-12-28	WOS:000077467100029
J	Tecott, LH; Heberlein, U				Tecott, LH; Heberlein, U			Y do we drink?	CELL			English	Review							NEUROPEPTIDE-Y; ALCOHOL PREFERENCE; MICE; ABUSE; RATS		Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurobiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tecott, LH (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.							Ault DT, 1998, J PHARMACOL EXP THER, V284, P553; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Carr LG, 1998, ALCOHOL CLIN EXP RES, V22, P884, DOI 10.1097/00000374-199806000-00017; CICERO TJ, 1980, ALCOHOL TOLERANCE DE; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; EHLERS CL, 1998, ALCOHOL CLIN EXPER R, V22, P884; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FRANKISH HM, 1995, PEPTIDES, V16, P757, DOI 10.1016/0196-9781(94)00200-P; HEILIG M, 1994, TRENDS NEUROSCI, V17, P80, DOI 10.1016/0166-2236(94)90079-5; HUA XY, 1991, J PHARMACOL EXP THER, V258, P243; JEWETT DC, 1992, PHARMACOL BIOCHEM BE, V42, P207, DOI 10.1016/0091-3057(92)90517-J; JOSSELYN SA, 1993, PHARMACOL BIOCHEM BE, V46, P543, DOI 10.1016/0091-3057(93)90542-2; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LI TK, 1993, BEHAV GENET, V23, P163, DOI 10.1007/BF01067421; Melo JA, 1996, NAT GENET, V13, P147, DOI 10.1038/ng0696-147; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; VALLEE BL, 1994, MOL BASIS ALCOHOL US; WEHNER JM, 1995, ALCOHOL CLIN EXP RES, V19, P811, DOI 10.1111/j.1530-0277.1995.tb00951.x	22	18	18	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					733	735		10.1016/S0092-8674(00)81695-5	http://dx.doi.org/10.1016/S0092-8674(00)81695-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865690	Bronze			2022-12-28	WOS:000077498800002
J	Annas, GJ				Annas, GJ			Human rights and health - The universal declaration of human rights at 50	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				ANNAN K, 1998, NY TIMES        0927, P16; Annas G., 1993, STANDARD CARE LAW AM; Annas G., 1998, SOME CHOICE LAW MED; Bassiouni M.C., 1992, CRIMES HUMANITY INT; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Benatar SR, 1998, AM J PUBLIC HEALTH, V88, P295, DOI 10.2105/AJPH.88.2.295; Gruskin S, 1998, JAMA-J AM MED ASSOC, V280, P462; Knox Bernard, 1984, SOPHOCLES 3 THEBAN P; Kunz JosefL., 1949, AM J INT LAW, V43, P316; Maier Pauline, 1997, AM SCRIPTURE MAKING; Mann J, 1996, J MARSHALL LAW REV, V30, P195; MANN J, IN PRESS HLTH HUMAN; Mann JM, 1997, HASTINGS CENT REP, V27, P6, DOI 10.2307/3528660; Mann Jonathan M, 1994, Health Hum Rights, V1, P6; Meron T, 1998, AM J INT LAW, V92, P462, DOI 10.2307/2997918; Palmer J, 1998, LANCET, V351, P1940, DOI 10.1016/S0140-6736(05)78631-1; Petersen A. R., 1996, NEW PUBLIC HLTH DISC; PODGERS J, 1998, ABA J            SEP, P64; Simma Bruno, 1994, CHARTER UN A COMMENT; Somerville MA, 1998, AM J PUBLIC HEALTH, V88, P301, DOI 10.2105/AJPH.88.2.301; Steiner Henry, 1996, INT HUMAN RIGHTS CON; Steiner Henry J, 1998, HARVARD MAGAZINE SEP, P45; Stephenson J, 1998, JAMA-J AM MED ASSOC, V280, P587, DOI 10.1001/jama.280.7.587; STEPHENSON J, 1998, JAMA-J AM MED ASSOC, V280, P590; Wills Garry, 1992, LINCOLN GETTYSBURG W; *WORLD BANK, 1993, WORLD DEV REP 1993 I; 1998, JAMA, V280, P469	27	24	24	3	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1778	1781		10.1056/NEJM199812103392411	http://dx.doi.org/10.1056/NEJM199812103392411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	146XU	9867552	Green Published			2022-12-28	WOS:000077459700011
J	de Marquiegui, A; Huish, N				de Marquiegui, A; Huish, N			ABC of sexual health - A woman's sexual life after an operation	BRITISH MEDICAL JOURNAL			English	Review									Barnet Hosp, Barnet Healthcare NHS Trust, Barnet, England		de Marquiegui, A (corresponding author), Barnet Hosp, Barnet Healthcare NHS Trust, Barnet, England.							CROWTHER ME, 1994, BRIT MED J, V308, P869, DOI 10.1136/bmj.308.6933.869	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					178	181		10.1136/bmj.318.7177.178	http://dx.doi.org/10.1136/bmj.318.7177.178			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888917	Green Published			2022-12-28	WOS:000078175100038
J	Gilley, J				Gilley, J			Meeting the information and budgetary requirements of primary care groups	BRITISH MEDICAL JOURNAL			English	Article									Gen Practitioners Comm, London WC1H 9JR, England		Gilley, J (corresponding author), Gen Practitioners Comm, BMA House, London WC1H 9JR, England.			Majeed, Azeem/0000-0002-2357-9858				*SECR STAT HLTH, 1997, CMND3807	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					168	169		10.1136/bmj.318.7177.168	http://dx.doi.org/10.1136/bmj.318.7177.168			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888913	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078175100030
J	Hayashi, T; Umemori, H; Mishina, M; Yamamoto, T				Hayashi, T; Umemori, H; Mishina, M; Yamamoto, T			The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn	NATURE			English	Article							CEREBELLAR GRANULE CELLS; LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; PURKINJE-CELLS; SRC; EXPRESSION; HIPPOCAMPUS; FYN; ASSOCIATION; ACTIVATION	Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. The ionotropic glutamate receptors are classified into two groups, NMDA (N-methyl-D-aspartate) receptors and AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, The AMPA receptor is a ligand-gated postsynaptic currents in the central nervous system(1,2). Here we report that AMPA receptors function not only as ion channels but also as cell-surface signal transducers by means of their interaction with the Src-family non-receptor protein tyrosine kinase Lyn. In the cerebellum, Lyn is physically associated with the AMPA receptor and is rapidly activated following stimulation of the receptor. Activation of Lyn is independent of Ca2+ and Na+ influx through AMPA receptors. As a result of activation of Lyn, the mitogen-activated protein kinase (MAPK) signalling pathway is activated, and the expression of brain-derived neurotrophic factor (BDNF) messenger RNA is increased in a Lyn-kinase-dependent manner. Thus, AMPA receptors generate intracellular signals from the cell surface to the nucleus through the Lyn-MAPK pathway, which may contribute to synaptic plasticity by regulating the expression of BDNF.	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Univ Tokyo, Sch Med, Dept Mol Neurobiol & Pharmacol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.			Hayashi, Takashi/0000-0003-3591-2109; Umemori, Hisashi/0000-0001-7198-2062				BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; Chen S, 1996, DEV BRAIN RES, V92, P140, DOI 10.1016/0165-3806(95)00208-1; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIRANO T, 1986, P NATL ACAD SCI USA, V83, P4957, DOI 10.1073/pnas.83.13.4957; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUDOL M, 1988, ONCOGENE RES, V2, P345; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; Wang YZ, 1997, NATURE, V389, P502, DOI 10.1038/39062; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMASHITA H, 1992, ANAL SCI, V8, P251, DOI 10.2116/analsci.8.251; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	28	239	248	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					72	76		10.1038/16269	http://dx.doi.org/10.1038/16269			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892356				2022-12-28	WOS:000077959400050
J	Schiff, ER				Schiff, ER			Update in hepatology	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Miami, Sch Med, Ctr Liver Dis, Div Hepatol, Miami, FL 33136 USA; Madrona Med Grp, Bellingham, WA 98226 USA; Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	University of Miami; American College of Physicians	Schiff, ER (corresponding author), Univ Miami, Sch Med, Ctr Liver Dis, Div Hepatol, 1500 NW 12th Ave,Suite 1101, Miami, FL 33136 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					52	57		10.7326/0003-4819-130-1-199901050-00010	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890851				2022-12-28	WOS:000077744500009
J	Venema, LC; Wildoer, JWG; Janssen, JW; Tans, SJ; Tuinstra, HLJT; Kouwenhoven, LP; Dekker, C				Venema, LC; Wildoer, JWG; Janssen, JW; Tans, SJ; Tuinstra, HLJT; Kouwenhoven, LP; Dekker, C			Imaging electron wave functions of quantized energy levels in carbon nanotubes	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPE; SURFACE; TUBULES; ROPES	Carbon nanotubes provide a unique system for studying one-dimensional quantization phenomena. Scanning tunneling microscopy was used to observe the electronic wave functions that correspond to quantized energy Levels in short metallic carbon nanotubes. Discrete electron waves were apparent from periodic oscillations in the differential conductance as a function of the position along the tube axis, with a period that differed from that of the atomic Lattice. Wave functions could be observed for several electron states at adjacent discrete energies. The measured wavelengths are in good agreement with the calculated Fermi wavelength for armchair nanotubes.	Delft Univ Technol, Dept Appl Phys, NL-2628 CJ Delft, Netherlands; Delft Univ Technol, DIMES, NL-2628 CJ Delft, Netherlands	Delft University of Technology; Delft University of Technology	Venema, LC (corresponding author), Delft Univ Technol, Dept Appl Phys, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.		Tans, Sander/AAS-2901-2020	Venema, Liesbeth/0000-0002-5896-1766; Dekker, Cees/0000-0001-6273-071X				Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; CROMMIE MF, 1993, NATURE, V363, P424; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; DUBOIS JGA, 1993, PHYS REV B, V48, P11260, DOI 10.1103/PhysRevB.48.11260; HAMADA N, 1992, PHYS REV LETT, V68, P1579, DOI 10.1103/PhysRevLett.68.1579; HASEGAWA Y, 1993, PHYS REV LETT, V71, P1071, DOI 10.1103/PhysRevLett.71.1071; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; RUBIO A, UNPUB; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; SCOTT WT, 1966, PHYSICS ELECT MAGNET, P163; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Venema LC, 1997, APPL PHYS LETT, V71, P2629, DOI 10.1063/1.120161; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; WILDOER JWG, 1994, REV SCI INSTRUM, V65, P2849, DOI 10.1063/1.1144626; WILKINS R, 1989, PHYS REV LETT, V63, P801, DOI 10.1103/PhysRevLett.63.801	19	287	292	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					52	55		10.1126/science.283.5398.52	http://dx.doi.org/10.1126/science.283.5398.52			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872737	Green Submitted			2022-12-28	WOS:000077976600045
J	Kennedy, CR; Kimm, L; Dees, DC; Campbell, MJ; Thornton, ARD; Bamber, J; Innes, V; Lloyd-Hughes, S; Parish, R; Woodhead, C; Allison, G; Chittenden, J; Ivens, D; Wood, A; Richardson, J; Aylett, E; Lutman, M; Stevens, JC; Reed, D; Reid, A; Richards, S; Thomas, H; Williamson, T; Owen, V				Kennedy, CR; Kimm, L; Dees, DC; Campbell, MJ; Thornton, ARD; Bamber, J; Innes, V; Lloyd-Hughes, S; Parish, R; Woodhead, C; Allison, G; Chittenden, J; Ivens, D; Wood, A; Richardson, J; Aylett, E; Lutman, M; Stevens, JC; Reed, D; Reid, A; Richards, S; Thomas, H; Williamson, T; Owen, V		Wessex Universal Neonatal Hearing Screening Tri	Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment	LANCET			English	Article							EVOKED OTOACOUSTIC EMISSIONS; DEAFNESS; INFANTS; NEWBORN; FEASIBILITY; CHILDREN	Background Congenital permanent childhood hearing impairment (PCHI) impairs communication skills and, possibly, mental health and employment prospects. Management within 1 year of birth can alleviate most of its adverse effects. Neonatal screening for this disorder is feasible but its benefit for all babies is disputed. We investigated whether neonatal screening of all babies born in hospital, in addition to the standard health visitor distraction test, would increase the rates of early referral, confirmation, and management. Methods Between 1993 and 1996, two teams of four part-time testers and equipment moved between two pairs of hospitals to achieve four periods with neonatal screening and four without neonatal screening, each of 4-6 months' duration. Babies did or did not undergo neonatal screening dependent on during which periods they were born. We used a transient evoked otoacoustic emissions test and, in babies who failed this test, an automated auditory brainstem response test on the same day. We referred babies with positive results for audiological assessment. Findings 53 781 babies were included in the trial, and 25 609 were born during periods with neonatal screening. Neonatal screening achieved 87% coverage of births, with a false-alarm rate of 1.5%, and an overall yield of 90 cases of bilateral PCHI of 40 dB or more relative to hearing threshold level per 100 000 target population, equivalent to 80% of the expected prevalence of the disorder in the population. 71 more babies with moderate or severe PCHI per 100 000 target population were referred before age 6 months during periods with neonatal screening than during periods without. Early confirmation and management of PCHI were significantly increased. The rate of false-negative results from neonatal screening was significantly lower than that for the distraction test (4 vs 27% p=0.041). Interpretation Neonatal screening is effective in identification of congenital PCHI early and may be particularly useful for babies with moderate and severe PCHI for whom early management may have the most benefit.	Southampton Gen Hosp, Dept Paediat Neurol, Southampton SO16 6YD, Hants, England	University of Southampton	Kennedy, CR (corresponding author), Southampton Gen Hosp, Dept Paediat Neurol, Mailpoint 21, Southampton SO16 6YD, Hants, England.		Owen, Victoria/GSE-2297-2022; Bamber, Jeffrey C/B-8839-2014	Bamber, Jeffrey C/0000-0001-9436-1832	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNOLD B, 1995, LARYNGO RHINO OTOL, V74, P172, DOI 10.1055/s-2007-997713; Baille MF, 1996, ARCH DIS CHILD, V75, P129, DOI 10.1136/adc.75.2.129; Bamford J, 1998, ARCH DIS CHILD-FETAL, V79, pF73, DOI 10.1136/fn.79.1.F73; BESS FH, 1994, PEDIATRICS, V93, P330; BESS FH, 1994, PEDIATRICS, V94, P959; BONFILS P, 1995, ARCH PEDIATRIE, V2, P685, DOI 10.1016/0929-693X(96)81228-0; CURNOCK D, 1993, BRIT MED J, V307, P1225, DOI 10.1136/bmj.307.6914.1225; Davis A, 1997, HEALTH TECHNOL ASSES, V1, P1; ELBERLING C, 1985, ACTA OTO-LARYNGOL, P77; HAGGARD MP, 1991, SCREENIGN CHILDRENS; HUNTER MF, 1994, BRIT J AUDIOL, V28, P47, DOI 10.3109/03005369409077912; *JOINT COMM INF HE, 1994, ASHA, V36, P38; KENNEDY CR, 1991, ARCH DIS CHILD-FETAL, V66, P1124, DOI 10.1136/adc.66.10_Spec_No.1124; Lang DV, 1996, ARCH DIS CHILD-FETAL, V75, pF143, DOI 10.1136/fn.75.2.F143-a; Mason JA, 1998, PEDIATRICS, V101, P221, DOI 10.1542/peds.101.2.221; Maxon A B, 1995, J Am Acad Audiol, V6, P271; MAXON AB, 1993, BRIT J AUDIOL, V27, P149, DOI 10.3109/03005369309077906; Mehl AL, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e4; *NAT DEAF CHILDR S, 1994, NAT DEAF CHILD SOC, V1, P1; National Institutes of Health, 1994, AM J OTOL, V15, P130; *NIH, 1993, EARL ID HEAR IMP INF; PARRY G, 1995, INVESTIGATION EFFECT; Parving A, 1996, AUDIOLOGY, V35, P158; PRESCOTT CAJ, 1995, S AFR MED J, V85, P7; Robinson R, 1998, BMJ-BRIT MED J, V316, P1; Salamy A, 1996, EAR HEARING, V17, P42, DOI 10.1097/00003446-199602000-00005; SCHORN K, 1993, BRIT J AUDIOL, V27, P143, DOI 10.3109/03005369309077905; Sheldon T., 1998, EFFECTIVE HLTH CARE, V4, P1; Stevens JC, 1998, ARCH DIS CHILD, V78, P14, DOI 10.1136/adc.78.1.14; *STEWARTBROWN S, 1987, BMJ-BRIT MED J, V294, P1387; THORNTON ARD, 1994, BRIT J AUDIOL, V28, P99, DOI 10.3109/03005369409077920; THORNTON ARD, 1998, BRIT J AUDIOL, V27, P319; TUCKER SM, 1992, ARCH DIS CHILD, V67, P911, DOI 10.1136/adc.67.7.911; Vohr BR, 1996, J PEDIATR-US, V128, P710, DOI 10.1016/S0022-3476(96)80143-0; WATKIN PM, 1995, BRIT J AUDIOL, V29, P259, DOI 10.3109/03005369509076740; Watkin PM, 1996, ARCH DIS CHILD-FETAL, V75, pF158, DOI 10.1136/fn.75.3.F158; Watkin PM, 1998, BRIT J AUDIOL, V32, P27, DOI 10.3109/03005364000000048; WelzlMuller K, 1997, HNO, V45, P227, DOI 10.1007/s001060050109; WHITE KR, 1995, INT J PEDIATR OTORHI, V32, P201, DOI 10.1016/0165-5876(95)01165-8; Yoshinaga-Itano C, 1998, PEDIATRICS, V102, P1161, DOI 10.1542/peds.102.5.1161	40	153	156	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1957	1964						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872244				2022-12-28	WOS:000077663000008
J	Cleeman, JI; Lenfant, C				Cleeman, JI; Lenfant, C			The National Cholesterol Education Program - Progress and prospects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; MYOCARDIAL-INFARCTION; MEN; PRAVASTATIN; PREVALENCE; PREVENTION; MORTALITY; STROKE	The National Cholesterol Education Program (NCEP) is a prime example of the role the National Heart, Lung, and Blood institute has played, in its 50 years; of existence, as a catalyst for translating research advances into improved clinical and public health practices. Since its inception in 1985, the NCEP has adhered to 2 principles in mounting educational campaigns for professionals and the public: building on a strong science base and working in partnership with other organizations. In slightly more than a decade, the NCEP has made significant progress toward its goal of reducing the prevalence of high blood cholesterol. The impact of cholesterol education is clearly visible in 4 major trends: increasing professional and public cholesterol awareness; declining dietary intakes of saturated fat, total fat, and cholesterol; falling serum cholesterol levels; and a continuing decline in coronary heart disease (CHD) mortality rates. Nevertheless, cholesterol levels are still being undertreated, especially in patients with CHD, and substantial scientific and educational challenges remain. bs it looks forward to the 21st century, the NCEP plans to make continued progress by using emerging scientific developments and pursuing the powerful combination of cholesterol lowering in CHD patients and in primary prevention.	NHLBI, Natl Cholesterol Educ Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cleeman, JI (corresponding author), NHLBI, Natl Cholesterol Educ Program, 31 Ctr Dr,Bldg 31,Room 4A16, Bethesda, MD 20892 USA.	cleemanj@gwgate.nhlbi.nih.gov						BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; *DHHS, 1997, DHHS PUBL PHS, P191; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Ernst ND, 1997, AM J CLIN NUTR, V66, P965; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; Expert Panel on Detection, 1994, CIRCULATION, V89, P1329; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V1; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V2; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HICKMAN TB, IN PRESS PREV MED; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kuller LH, 1998, CIRCULATION, V98, P196, DOI 10.1161/01.CIR.98.3.196; KULLER LH, 1991, NIH PUBL; LAROSA JC, 1992, CIRCULATION, V85, P1229, DOI 10.1161/01.CIR.85.3.1229; MCDOWELL MA, 1994, NATL CTR HLTH STAT P, V255; Nachman RL, 1997, CIRCULATION, V96, P2485; *NAT CHOL ED PROGR, 1995, NIH PUBL; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; *NAT CHOL ED PROGR, 1990, NIH PUBL; *NAT HEART LUNG BL, 1996, MORD MORT 1996 CHART; *NAT HEART LUNG BL, 1990, NIH PUBL; *NAT HEART LUNG BL, 1995, CHOL AW SURV; National Cholesterol Education Program, 1993, NIH PUBL; National Heart Lung and Blood Institute, 1998, NAT HEART LUNG BLOOD; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259	44	99	99	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2099	2104		10.1001/jama.280.24.2099	http://dx.doi.org/10.1001/jama.280.24.2099			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875878	Green Published			2022-12-28	WOS:000077606100034
J	Dye, C; Garnett, GP; Sleeman, A; Williams, BG				Dye, C; Garnett, GP; Sleeman, A; Williams, BG			Prospects for worldwide tuberculosis control under the WHO DOTS strategy	LANCET			English	Article							TRANSMISSION; HISTORY; DISEASE; MODELS; AGE	Background WHO advocates the use of directly observed treatment with a short-course drug regimen as part of the DOTS strategy, but the potential effect of this strategy worldwide has not been investigated. Methods We developed an age-structured mathematical model to explore the characteristics of tuberculosis control under DOTS, and to forecast the effect of improved case finding and cure on tuberculosis epidemics for each of the six WHO regions. Findings In countries where the incidence of tuberculosis is stable and HIV-1 absent, a control programme that reaches the WHO targets of 70% case detection and 85% cure would reduce the incidence rate by 11% (range 8-12) per year and the death rate by 12% (9-13) per year. If tuberculosis has been in decline for some years, the same case detection and cure rates would have a smaller effect on incidence. DOTS saves a greater proportion of deaths than cases, and this difference is bigger in the presence of HIV-1. HIV-1 epidemics cause an increase in tuberculosis incidence, but do not substantially reduce the preventable proportion of cases and deaths. Without greater effort to control tuberculosis, the annual incidence of the disease is expected to increase by 41% (21-61) between 1998 and 2020 (from 7.4 million to 10.6 million cases per year). Achievement of WHO targets by 2010 would prevent 23% (15-30) or 48 million cases by 2020. Interpretation The potential effect of chemotherapy (delivered as DOTS) on tuberculosis is greater in many developing countries now than it was in developed countries 50 years ago. To exploit this potential, case detection and cure rates urgently need to be improved in the main endemic areas.	WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland; Ctr Epidemiol & Infect Dis, Oxford, England; Epidemiol Res Unit, Johannesburg, South Africa	World Health Organization; University of Oxford	Dye, C (corresponding author), WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland.		Garnett, Geoffrey P/A-9312-2008; Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; Williams, Brian/0000-0002-3174-4876				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CAUTHEN G, 1998, WHOTB88154; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; FOX W, 1975, AM REV RESPIR DIS, V111, P325; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Harries AD, 1997, PHARMACOL THERAPEUT, V73, P1, DOI 10.1016/S0163-7258(96)00115-5; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; OBRIEN RJ, 1994, TUBERCULOSIS BACK FU, P151; Organization WH, 1997, WHOTB97229; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; Rieder HL, 1993, TUBERCULOSIS COMPREH, P167; Styblo K, 1991, TUBERCULOSIS SURVEIL, V2, P60; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; *UNAIDS, 1997, REP GLOB HIV AIDS EP; *UNPD, 1996, WORLD POP PROSP; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; VYNNYCKY E, 1996, THESIS U LONDON LOND; *WHO, 1996, INV HLTH RES DEV, P35; *WHO, 1998, WHOTB98237; World Health Organization, 1994, FRAM EFF TUB CONTR	24	353	359	1	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1886	1891		10.1016/S0140-6736(98)03199-7	http://dx.doi.org/10.1016/S0140-6736(98)03199-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863786				2022-12-28	WOS:000077544600009
J	Mayer, KFX; Schoof, H; Haecker, A; Lenhard, M; Jurgens, G; Laux, T				Mayer, KFX; Schoof, H; Haecker, A; Lenhard, M; Jurgens, G; Laux, T			Role of WUSCHEL in regulating stem cell fate in the Arabidopsis shoot meristem	CELL			English	Article							PROTEIN PHOSPHATASE; SEQUENCE-ANALYSIS; ANALYSIS SOFTWARE; HOMEOBOX GENES; C-ELEGANS; THALIANA; CLAVATA1; EMBRYOGENESIS; HOMEODOMAIN; EMBRYO	The shoot meristem gives rise to the aerial parts of higher plants by continuously initiating new organs. The basis of this activity is its ability to maintain a pool of pluripotent stem cells, which are the ultimate source of all tissues of the shoot. In Arabidopsis plants mutant for the WUSCHEL (WUS) gene, the stem cells are misspecified and appear to undergo differentiation. Here, we show that WUS encodes a novel homeodomain protein which presumably acts as a transcriptional regulator. The pattern of WUS expression suggests that stem cells in the shoot meristem are specified by an underlying cell group which is established in the 16-cell embryo and becomes localized to its prospective domain of function by asymmetric cell divisions.	Univ Tubingen, Lehrstuhl Entwicklungsgenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Laux, T (corresponding author), Univ Tubingen, Lehrstuhl Entwicklungsgenet, Auf Morgenstelle 1, D-72076 Tubingen, Germany.	thomas.laux@uni-tuebingen.de	Schoof, Heiko/Y-7073-2018; Mayer, Klaus FX/M-7941-2015; Lenhard, Michael/J-1554-2015	Schoof, Heiko/0000-0002-1527-3752; Mayer, Klaus FX/0000-0001-6484-1077; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barlow PW, 1978, STEM CELLS TISSUE HO, P87; BARTON MK, 1993, DEVELOPMENT, V119, P823; BOEHM U, 1995, PLANT J, V7, P441, DOI 10.1046/j.1365-313X.1995.7030441.x; BOWMAN J, 1994, ARABIDOPSIS ATLAS MI; Brown JWS, 1996, PLANT J, V10, P771, DOI 10.1046/j.1365-313X.1996.10050771.x; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; Clark SE, 1997, PLANT CELL, V9, P1067, DOI 10.1105/tpc.9.7.1067; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HAKE S, 1995, PHILOS T R SOC B, V350, P45, DOI 10.1098/rstb.1995.0136; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Jackson DP, 1991, MOL PLANT PATHOL, P163; JURGENS G, 1994, COLOUR ATLAS DEV EMB, P7; Kaplan DR, 1997, PLANT CELL, V9, P1903, DOI 10.1105/tpc.9.11.1903; KAPLAN DR, 1969, PHYTOMORPHOLOGY, V19, P253; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Laux T, 1998, SEMIN CELL DEV BIOL, V9, P195, DOI 10.1006/scdb.1997.0208; Laux T, 1997, TRENDS PLANT SCI, V2, P325, DOI 10.1016/S1360-1385(97)84613-4; Laux T, 1996, DEVELOPMENT, V122, P87; Laux T, 1997, PLANT CELL, V9, P989, DOI 10.1105/tpc.9.7.989; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Long JA, 1998, DEVELOPMENT, V125, P3027; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Matallana E., 1992, Methods in Arabidopsis research., P144; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; NEWMAN I. V., 1965, J LINN SOC LONDON BOT, V59, P185; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUTH J, 1985, AM J BOT, V72, P1127, DOI 10.2307/2443459; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; SPURR AR, 1949, AM J BOT, V36, P629, DOI 10.2307/2437856; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEWART RN, 1970, AM J BOT, V57, P816, DOI 10.2307/2441339; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Williams RW, 1997, P NATL ACAD SCI USA, V94, P10467, DOI 10.1073/pnas.94.19.10467; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; WU L, 1995, PLANT J, V8, P323, DOI 10.1046/j.1365-313X.1995.08030323.x	56	1198	1305	12	245	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					805	815		10.1016/S0092-8674(00)81703-1	http://dx.doi.org/10.1016/S0092-8674(00)81703-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865698	Bronze			2022-12-28	WOS:000077498800010
J	Danino, C				Danino, C			Emmanuel Andrew Danino - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					197	197		10.1136/bmj.318.7177.197	http://dx.doi.org/10.1136/bmj.318.7177.197			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888937	Green Published			2022-12-28	WOS:000078175100068
J	Gamester, CF; Tilzey, AJ; Banatvala, JE				Gamester, CF; Tilzey, AJ; Banatvala, JE			Medical students' risk of infection with bloodborne viruses at home and abroad: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine risks of exposure to and prevention of bloodborne virus infections among medical students during their elective period. Design Questionnaire study of students returning from their electives in 1997-8. Setting Urban teaching hospital. Subjects 220 final year medical students. Results 148 students (67%) returned questionnaires; all had been vaccinated against hepatitis B. 65 respondents (44%) had visited areas of relatively high endemicity for HIV, although 27 (42%) of these, all of whom had visited areas other than sub-Saharan Africa, were unaware of this. AU but one had discussed their elective with advisers. Four students experienced percutaneous or mucosal exposure to potentially infectious body fluids, three in areas with a high prevalence of HIV infection. 44 respondents (30%) had experienced at least one such exposure during their clinical training; 75% of these exposures were unreported. 34% (13/38) students who visited areas known to have a high prevalence of HIV infection took with them a starter pack of zidovudine for post-exposure prophylaxis; 53% (20) took latex gloves and 63% (24) a medi-kit None of the 27 students who were unaware that the areas they visited had a relatively high prevalence of HIV infection took zidovudine; only 15% (4) took gloves and 30% (8) a medi-kit. Conclusions Medical schools should produce, regularly update, and implement guidelines regarding protection from bloodborne viruses during clinical studies, including electives. Education and training in infection control should start at the earliest opportunity.	Guys Kings Coll & St Thomass Sch Med, London SE1 7EH, England	University of London; King's College London	Tilzey, AJ (corresponding author), Guys Kings Coll & St Thomass Sch Med, St Thomass Campus, London SE1 7EH, England.							Balter M, 1998, SCIENCE, V280, P1864, DOI 10.1126/science.280.5371.1864; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BANATVALA N, 1997, STUDENT BMJ, V5, P354; BERNARD RP, 1997, GLOBAL VIEW HIV INFE; Gottlieb S, 1998, BRIT MED J, V317, P11; GUST ID, 1982, P 3 INT S VIR HEP NE; *PUBL HLTH LAB SER, 1997, CRD, V7, P461; *PUBL HLTH LAB SER, 1998, CDR, V8, P227; Tereskerz PM, 1996, NEW ENGL J MED, V335, P1150, DOI 10.1056/NEJM199610103351512; *UK HLTH DEP, 1997, GUID POST PROPH HLTH; *UK HLTH DEP, 1994, AIDS HIV INF HLTH CA; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P365; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P193	15	33	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					158	160		10.1136/bmj.318.7177.158	http://dx.doi.org/10.1136/bmj.318.7177.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888908	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078175100025
J	Chakraborty, S; Knoche, R; Schulze, H; Rubie, DC; Dobson, D; Ross, NL; Angel, RJ				Chakraborty, S; Knoche, R; Schulze, H; Rubie, DC; Dobson, D; Ross, NL; Angel, RJ			Enhancement of cation diffusion rates across the 410-kilometer discontinuity in Earth's mantle	SCIENCE			English	Article							FE-MG INTERDIFFUSION; SAN-CARLOS OLIVINE; ALUMINOSILICATE GARNETS; TRACER DIFFUSION; TRANSITION ZONE; GPA; FORSTERITE; PHASE	Rates of cation diffusion (magnesium, iron, and nickel) have been determined in olivine and its high-pressure polymorph, wadsleyite, at 9 to 15 gigapascals and 1100 degrees to 1400 degrees C for compositions that are relevant to Earth's mantle. Diffusion in olivine becomes strongly dependent on composition at high pressure. In wadsleyite, diffusion is one to two orders of magnitude faster than in olivine, depending on temperature. Homogenization of mantle heterogeneities (chemical mixing) and mineral transformations involving a magnesium-iron exchange will therefore occur considerably faster in the transition zone than at depths of Less than 410 kilometers.	Univ Cologne, Inst Mineral & Geochem, D-50674 Cologne, Germany; Univ Innsbruck, Inst Mineral & Petrog, A-6020 Innsbruck, Austria; Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; Univ London Univ Coll, Dept Geol Sci, Mantle Petrol Grp, London WC1E 6BT, England	University of Cologne; University of Innsbruck; University of Bayreuth; University of London; University College London	Chakraborty, S (corresponding author), Ruhr Univ Bochum, Inst Mineral, D-44780 Bochum, Germany.	Sumit.Chakraborty@rz.ruhr-uni.bochum.de	Angel, Ross J/K-9924-2015; Ross, Nancy L/S-1409-2017	Angel, Ross J/0000-0003-0861-398X; Ross, Nancy L/0000-0002-3745-8133; Dobson, David/0000-0002-0890-0121				BINA CR, 1993, PHYS EARTH PLANET IN, V76, P329, DOI 10.1016/0031-9201(93)90021-Z; BUENING DK, 1973, J GEOPHYS RES, V78, P6852, DOI 10.1029/JB078i029p06852; Chakraborty S, 1997, J GEOPHYS RES-SOL EA, V102, P12317, DOI 10.1029/97JB00208; CHAKRABORTY S, 1994, PHYS CHEM MINER, V21, P489; CHAKRABORTY S, 1992, CONTRIB MINERAL PETR, V111, P74, DOI 10.1007/BF00296579; Chakraborty S, 1996, CONTRIB MINERAL PETR, V122, P406, DOI 10.1007/s004100050136; CONSTABLE S, 1990, J GEOPHYS RES-SOLID, V95, P6967, DOI 10.1029/JB095iB05p06967; Crank J., 1975, MATH DIFFUSION; Dohmen R, 1998, AM MINERAL, V83, P970; FARBER DL, 1994, NATURE, V371, P693, DOI 10.1038/371693a0; FUJINO K, 1981, ACTA CRYSTALLOGR B, V37, P513, DOI 10.1107/S0567740881003506; Ganguly J, 1998, CONTRIB MINERAL PETR, V131, P171, DOI 10.1007/s004100050386; HORIUCHI H, 1981, AM MINERAL, V66, P568; JAOUL O, 1995, PHYS EARTH PLANET IN, V89, P199, DOI 10.1016/0031-9201(94)03008-7; KELLOGG LH, 1990, J GEOPHYS RES-SOLID, V95, P421, DOI 10.1029/JB095iB01p00421; KOHLSTEDT DL, 1995, J GEOPHYS RES-SOL EA, V100, P17587, DOI 10.1029/95JB01460; LIEBERMANN RC, 1992, GEOPHYS MONOGR SER, V67, P19; MACKWELL SJ, 1988, PHILOS MAG A, V57, P779, DOI 10.1080/01418618808209920; NAKAMURA A, 1984, BER BUNSEN PHYS CHEM, V88, P140, DOI 10.1002/bbpc.19840880212; ONEILL HSC, 1993, AM MINERAL, V78, P456; Robie R. A., 1979, US GEOL SURV B, V1452; RUBIE DC, 1993, AM MINERAL, V78, P574; RUBIE DC, 1993, PHYS CHEM MINER, V20, P315; SOLOMATOV VS, 1994, EARTH PLANET SC LETT, V125, P267, DOI 10.1016/0012-821X(94)90220-8; SULL DR, 1971, JANAF THERMOCHEMICAL; WANAMAKER BJ, 1994, GEOPHYS RES LETT, V21, P21, DOI 10.1029/93GL02790; Xu YS, 1998, SCIENCE, V280, P1415, DOI 10.1126/science.280.5368.1415	27	43	43	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					362	365		10.1126/science.283.5400.362	http://dx.doi.org/10.1126/science.283.5400.362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888846				2022-12-28	WOS:000078067000040
J	Butcher, J				Butcher, J			ABC of sexual health - Female sexual problems II: sexual pain and sexual fears	BRITISH MEDICAL JOURNAL			English	Article									Univ Cent Lancashire, Preston PR1 2HE, Lancs, England; Withington Hosp, Manchester M20 8LR, Lancs, England	University of Central Lancashire	Butcher, J (corresponding author), Univ Cent Lancashire, Preston PR1 2HE, Lancs, England.								0	20	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					110	112		10.1136/bmj.318.7176.110	http://dx.doi.org/10.1136/bmj.318.7176.110			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880287	Green Published			2022-12-28	WOS:000078087500030
J	Ashton, CM; Petersen, MPHNJ; Souchek, J; Menke, TJ; Yu, HJ; Pietz, K; Eigenbrodt, ML; Barbour, G; Kizer, KW; Wray, NP				Ashton, CM; Petersen, MPHNJ; Souchek, J; Menke, TJ; Yu, HJ; Pietz, K; Eigenbrodt, ML; Barbour, G; Kizer, KW; Wray, NP			Geographic variations in utilization rates in Veterans Affairs hospitals and clinics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; PREVENTABLE HOSPITALIZATIONS; OUTCOMES; MEDICARE; VA	Background in the United States, geographic variation in hospital use is common. It is uncertain whether there are similar geographic variations in the health care system of the Department of Veterans Affairs (VA), which differs from the private sector because it predominantly serves men with annual incomes below $20,000, has a central system of administration, and uses salaried physicians. Thus, it might be less likely to have geographic variations. Methods We used VA data bases to obtain information on patients treated for eight diseases (chronic obstructive pulmonary disease, pneumonia, congestive heart failure, angina, diabetes, chronic renal failure, bipolar disorder, and major depression). We analyzed their use of hospital and outpatient services by assessing the risk-adjusted numbers of hospital days (the average number of days a patient spent in the hospital per 12 months of follow-up, regardless of the number of hospital stays), hospital-discharge rates, and clinic-visit rates from 1991 through 1995 for the entire system and within the 22 geographically based health care networks. Results We found substantial geographic variation in hospital use for all eight cohorts of patients and all the years studied. Variations in the numbers of hospital days per person-year among the networks were greatest among patients with chronic obstructive pulmonary disease (ranging from a factor of 2.7 to a factor of 3.1) during a given year and smallest among patients with angina (ranging from a factor of 1.5 to a factor of 2.1). Levels of hospital use were highest in the Northeast and lowest in the West. The variation in the rates of clinic visits for principal medical care among the networks ranged from a factor of approximately 1.6 to a factor of 4.0; variations in the rates were greatest among patients with chronic renal failure and smallest among patients with congestive heart failure. There was no clear geographic pattern in the rates of outpatient-clinic use. Conclusions There are significant geographic variations in the use of hospital and outpatient services in the VA health care system. Because VA physicians are unable to increase their income by changing their patterns of practice, our findings suggest that their practice styles are similar to those of other physicians in their geographic regions. (N Engl J Med 1999;340:32-9.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Vet Hlth Adm, Dept Vet Affairs, Washington, DC USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ashton, CM (corresponding author), Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA.							[Anonymous], 1996, ICD9CM; Ashton CM, 1998, MED CARE, V36, P793, DOI 10.1097/00005650-199806000-00003; ASHTON CM, IN PRESS AM J MED QU; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; *CTR EV CLIN SCI, 1996, DARTM ATL HLTH CAR; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; FRISS L, 1989, SOC SCI MED, V28, P347, DOI 10.1016/0277-9536(89)90036-1; GORNICK M, 1977, SOC SECUR BULL, V40, P22; GRAVES EJ, 1995, VITAL HLTH STAT SERI, V13; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; Iglehart JK, 1996, NEW ENGL J MED, V335, P1407, DOI 10.1056/NEJM199610313351821; Kizer K W, 1997, Minn Med, V80, P24; Kizer KW, 1997, HOSP HEALTH SERV ADM, V42, P283; Kizer KW, 1997, ANN EMERG MED, V30, P804, DOI 10.1016/S0196-0644(97)70053-2; KIZER KW, 1997, COMP HLTH C, P3; Kizer KW, 1995, VISION CHANGE PLAN R; KIZER KW, 1997, VETERANS EQUITABLE R; KIZER KW, 1996, PRESCRIPTION CHANGE; KNICKMAN JR, 1985, INQUIRY-J HEALTH CAR, V22, P45; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; *NAT CTR VET AN ST, 1995, PUBL NAT SURV VET; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; POKRAS R, 1965, VITAL HLTH STAT SERI, V13; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; Restuccia J, 1996, HEALTH AFFAIR, V15, P156, DOI 10.1377/hlthaff.15.4.156; SCHAPPERT SM, 1991, VITAL HLTH STAT SERI, V13; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Snedecor G.W., 1980, STATISTICAL METHODS, P365; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; Wray NP, 1997, MED CARE, V35, P768, DOI 10.1097/00005650-199708000-00003	36	188	191	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					32	39		10.1056/NEJM199901073400106	http://dx.doi.org/10.1056/NEJM199901073400106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155JQ	9878643				2022-12-28	WOS:000077943700006
J	Wallace, H; Shorvon, S; Tallis, R				Wallace, H; Shorvon, S; Tallis, R			Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2052922 and age-specific fertility rates of women with epilepsy	LANCET			English	Article							SEIZURES	Background There are no data on prevalence or incidence of treated epilepsy, and no data on fertility of women with epilepsy from an unselected UK population. Methods We used the General Practice Research Database to ascertain the incidence and prevalence of people with treated epilepsy in an unselected population of 2 052 922 people in England and Wales, and also age-specific fertility rates. We defined period prevalence of treated epilepsy as the number of people with epilepsy taking an antiepileptic drug per 100 000 people during 1995. The incidence of treated epilepsy was defined as the number of new cases of treated epilepsy per 100 000 people during the same period. We calculated fertility rates among women with treated epilepsy between 1991 and 1995 and compared these rates with the population rates for England and Wales in 1993. Findings The period prevalence of treated epilepsy in 1995 was 5.15 per 1000 people (95% CI 5.05-5.25). The prevalence was lower in children (age 5-9 years 3.16 [2.86-3.48]; 10-14 years 4.05 [3.70-4.42]), and higher in older people (65-69 years 6.01 [5.50-6.57]; 70-74 years 6.53 [5.97-7.14]; 75-79 years 7.39 [6.73-8.11]); 80-84 years 7.54 [6.78-8.39]; 85 years and older 7.73 [6.98-8.66]. The incidence of treated epilepsy was 80.8 per 100 000 people (76.9-84.7). The incidence was lower in children (5-9 years 63.2 [50.5-79.1]; 10-14 years 53.8 [42.4-68.31) and higher in older people (65-69 years 85.9 [68.5-107.3]; 70-74 years 82.8 [65.0-105.2]; 75-79 years 114.5 [116.9-179.2]; 80-84 years 159 [125.2-202.6]; greater than or equal to 85 years 135.4 [100.4-178.7]). Fertility was lower among women with treated epilepsy, with an overall rate of 47.1 livebirths per 1000 women aged 15-44 per year (42.3-52.2), compared with a national rate of 62.6 in the same age-group. The standardised fertility ratios were significantly lower between the ages of 25 and 39 years in women with epilepsy (p<0.001). Interpretation Compared with previous studies, we found that the incidence of epilepsy was higher in elderly people and lower in children. The prevalence rates also increase with age. Women aged 25-39 years with treated epilepsy have significantly lower fertility rates than those in the general population. Research is needed to identify any potentially preventable causes for the low fertility rates.	UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol, Epilepsy Res Grp, London WC1N 3BG, England; Univ Manchester, Hope Hosp, Dept Geriatr Med, Salford M6 8HD, Lancs, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Manchester	Shorvon, S (corresponding author), UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol, Epilepsy Res Grp, London WC1N 3BG, England.		Shorvon, Simon D/A-2019-2009					COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; CROMBIE DL, 1960, BRIT MED J, V2, P416; DANSKY LV, 1980, EPILEPSIA, V21, P261, DOI 10.1111/j.1528-1157.1980.tb04072.x; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HARVALD B, 1951, ACTA PSYCH NEUROL, V26, P339, DOI 10.1111/j.1600-0447.1951.tb09678.x; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P341, DOI 10.1001/archneur.1986.00520040029014; HOLLOWELL J, 1994, GEN PRACTICE RES DAT; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; *OFF NAT STAT, 1997, SERIES FM1, V24, pR15; *OFF POP CENS SURV, 1994, 1991 CENS MIGR GB TO; Olafsson E, 1998, NEUROLOGY, V51, P71, DOI 10.1212/WNL.51.1.71; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; TALLIS RC, 1998, BOCKLEHURSTS TXB GER, P435; WEBBER MP, 1986, EPILEPSIA, V27, P746, DOI 10.1111/j.1528-1157.1986.tb03605.x	15	250	257	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1970	1973		10.1016/S0140-6736(98)04512-7	http://dx.doi.org/10.1016/S0140-6736(98)04512-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872246				2022-12-28	WOS:000077663000010
J	Horvath, MP; Schweiker, VL; Bevilacqua, JM; Ruggles, JA; Schultz, SC				Horvath, MP; Schweiker, VL; Bevilacqua, JM; Ruggles, JA; Schultz, SC			Crystal structure of the Oxytricha nova telomere end binding protein complexed with single strand DNA	CELL			English	Article							COCRYSTAL STRUCTURE; MACRONUCLEAR DNA; EUPLOTES-CRASSUS; BETA-SUBUNIT; 3' TERMINUS; IN-VITRO; RESOLUTION; GENES; YEAST; SENESCENCE	Telomeres are specialized protein-DNA complexes that compose the ends of eukaryotic chromosomes. Telomeres protect chromosome termini from degradation and recombination and act together with telomerase to ensure complete genome replication. We have determined the crystal structure of the two-subunit Oxytricha nova telomere end binding protein (On-TEBP) complexed with single strand telomeric DNA at 2.8 Angstrom resolution. The structure reveals four oligonucleotide/oligosaccharide-binding folds, three of which form a deep cleft that binds the ssDNA, and a fourth that forms an unusual protein-protein interaction between the alpha and beta subunits. This structure provides a molecular description of how the two subunits of OnTEBP recognize and bind ssDNA to form a sequence-specific, telomeric nucleoprotein complex that caps the very 3' ends of chromosomes.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; H Lundback AS, Dept Clin Pharmacol, Copenhagen, Denmark	University of Colorado System; University of Colorado Boulder; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Schultz, SC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	schultz@mmol.colorado.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017155] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 F32 GM17155-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brunger A. T., 1993, X PLOR MANUAL VERSIO; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUSCHLBAUER W, 1972, EUR J BIOCHEM, V31, P1, DOI 10.1111/j.1432-1033.1972.tb02493.x; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saenger W., 1984, PRINCIPLES NUCL ACID; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; SON TD, 1972, J AM CHEM SOC, V94, P7903; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VERMEESCH JR, 1994, MOL CELL BIOL, V14, P554, DOI 10.1128/MCB.14.1.554; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	54	229	236	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					963	974		10.1016/S0092-8674(00)81720-1	http://dx.doi.org/10.1016/S0092-8674(00)81720-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875850	Bronze			2022-12-28	WOS:000077759100011
J	Steele, PM; Medina, JF; Nores, WL; Mauk, MD				Steele, PM; Medina, JF; Nores, WL; Mauk, MD			Using genetic mutations to study the neural basis of behavior	CELL			English	Review							CEREBELLUM; MEMORY		Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Keck Ctr Neurobiol Learning & Memory, Houston, TX 77030 USA	University of Texas System; University of Texas System	Steele, PM (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA.			Medina, Javier/0000-0001-8708-5315				ABELIOVICH A, 1993, CELL, V79, P365; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Garcia KS, 1998, NEUROPHARMACOLOGY, V37, P471, DOI 10.1016/S0028-3908(98)00055-0; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MAUK MD, 1997, LEARN MEMORY, V3, P130; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Silva AJ, 1997, ANNU REV GENET, V31, P527, DOI 10.1146/annurev.genet.31.1.527; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Watanabe D, 1998, CELL, V95, P17, DOI 10.1016/S0092-8674(00)81779-1; YEO CH, 1984, BEHAV BRAIN RES, V13, P261, DOI 10.1016/0166-4328(84)90168-2; ZIMMER A, 1992, ANNU REV NEUROSCI, V15, P115, DOI 10.1146/annurev.neuro.15.1.115	16	19	19	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					879	882		10.1016/S0092-8674(00)81712-2	http://dx.doi.org/10.1016/S0092-8674(00)81712-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875842	Bronze			2022-12-28	WOS:000077759100003
J	Wintemute, GJ; Drake, CM; Beaumont, JJ; Wright, MA; Parham, CA				Wintemute, GJ; Drake, CM; Beaumont, JJ; Wright, MA; Parham, CA			Prior misdemeanor convictions as a risk factor for later violent and firearm-related criminal activity among authorized purchasers of handguns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARREST	Context.-Under current federal law, many persons with prior convictions for misdemeanor offenses pass criminal records background checks and legally purchase handguns. Objective.-To determine whether authorized handgun purchasers with prior misdemeanor convictions are more likely than those with no criminal history to be charged with new crimes, particularly offenses involving firearms and violence. Design.-Retrospective cohort study. Setting and Participants.-A total of 5923 authorized purchasers of handguns in California in 1977 who were younger than 50 years, identified by random sample. Main Outcome Measures.-Incidence and relative risk (RR) of first charges for new criminal offenses after handgun purchase. Results.-Of the 5923 authorized purchasers, 3128 had at least 1 conviction for a misdemeanor offense prior to handgun purchase, and 2795 had no prior criminal history. Follow-up to the end of the 15-year observation period or to death was available for 77.8% of study subjects and for a median 8.9 years for another 9.6%. Handgun purchasers with at least 1 prior misdemeanor conviction were more than 7 times as likely as those with no prior criminal history to be charged with a new offense after handgun purchase (RR, 7.5; 95% confidence interval [CI], 6.6-8.7). Among men, those with 2 or more prior convictions for misdemeanor violence were at greatest risk for nonviolent firearm-related offenses such as weapon carrying (RR, 11.7; 95% CI, 6.8-20.0), violent offenses generally (RR, 10.4; 95% CI, 6.9-15.8), and Violent Crime Index offenses (murder or non-negligent manslaughter, forcible rape, robbery, or aggravated assault) (RR, 15.1; 95% CI, 9.4-24.3). However, even handgun purchasers with only 1 prior misdemeanor conviction and no convictions for offenses involving firearms or violence were nearly 5 times as likely as those with no prior criminal history to be charged with new offenses involving firearms or violence. Conclusions.-Handgun purchasers with prior misdemeanor convictions are at increased risk for future criminal activity, including violent and firearm-related crimes.	Univ Calif Davis, Med Ctr, Violence Prevent Res Program, Sacramento, CA 95817 USA	University of California System; University of California Davis	Wintemute, GJ (corresponding author), Univ Calif Davis, Med Ctr, Violence Prevent Res Program, 2315 Stockton Blvd, Sacramento, CA 95817 USA.		drake, christiana/W-7161-2019; Drake, Christiana M/M-9791-2015	drake, christiana/0000-0002-0096-1800; 	PHS HHS [R49/CCR903549] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELKIN J, 1973, J CRIM JUST, V1, P7, DOI 10.1016/0047-2352(73)90003-2; BLUMSTEIN A, 1979, J CRIM LAW CRIM, V70, P561, DOI 10.2307/1142642; BLUMSTEIN A, 1981, LAW SOC REV, V16, P265; Blumstein Alfred, 1986, CRIMINAL CAREERS CAR, V1, P55; Breslow NE., 1987, STAT METHODS CANC RE, P81; Cook PJ, 1996, GUNS AM RESULTS COMP; COOK PJ, 1981, ANN AM ACAD POLIT SS, V445, P80; *CRIM REC PURG UN, 1990, CRIM REC PURG SEAL H; *CTR GUN POL RES N, 1997, NAT GUN POL SURV; FARRINGTON DP, 1987, PREDICTION CLASSIFIC; GREENBERG DF, 1991, CRIMINOLOGY, V29, P17, DOI 10.1111/j.1745-9125.1991.tb01057.x; Maltz M., 1984, RECIDIVISM; MANSON D, 1997, US BUREAU JUSTICE ST; MANSON D, 1998, US BUREAU JUSTICE ST; RAND MR, 1997, US BUREAU JUSTICE ST; TAYLOR BM, 1997, US BUREAU JUSTICE ST; Teret SP, 1998, NEW ENGL J MED, V339, P813, DOI 10.1056/NEJM199809173391206; TIEN JM, 1990, US BUR JUST STAT PUB; TILLMAN R, 1987, CRIMINOLOGY, V25, P561, DOI 10.1111/j.1745-9125.1987.tb00811.x; Tracy PE, 1990, DELINQUENCY CAREERS; *US BUR AL TOB FIR, 1994, PUBL ATF; *US BUR JUST STAT, 1981, US BUR JUST STAT PUB; *US FED BUR INV, 1997, UN CRIM REP US 1996; *US FED BUR INV, 1996, CRIM US 1995; *US GEN ACC OFF, 1996, US GEN ACC OFF PUBL; *US OFF TECHN ASS, 1991, PUBL US OFF TECHN AS; Visher C. A., 1986, CRIMINAL CAREERS CAR, P211; VISHER CA, 1991, CRIMINOLOGY, V29, P329, DOI 10.1111/j.1745-9125.1991.tb01070.x; WRIGHT MA, IN PRESS AM J PUBLIC	29	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2083	2087		10.1001/jama.280.24.2083	http://dx.doi.org/10.1001/jama.280.24.2083			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149LE	9875875	Bronze			2022-12-28	WOS:000077606100031
J	Arrigo, KR; Robinson, DH; Worthen, DL; Dunbar, RB; DiTullio, GR; VanWoert, M; Lizotte, MP				Arrigo, KR; Robinson, DH; Worthen, DL; Dunbar, RB; DiTullio, GR; VanWoert, M; Lizotte, MP			Phytoplankton community structure and the drawdown of nutrients and CO2 in the Southern Ocean	SCIENCE			English	Article							SEA	Data from recent oceanographic cruises show that phytoplankton community structure in the floss Sea is related to mixed layer depth. Diatoms dominate in highly stratified waters, whereas Phaeocystis antarctica assemblages dominate where waters an more deeply mixed. The drawdown of both carbon dioxide (CO2) and nitrate per mole of phosphate and the rate of new production by diatoms are much Lower than that measured for P. antarctica. Consequently, the capacity of the biological community to draw down atmospheric CO2 and transport it to the deep ocean could diminish dramatically if predicted increases in upper ocean stratification due to climate warming should occur.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; San Francisco State Univ, Romberg Tuburon Ctr Environm Studies, Tiburon, CA 94920 USA; Sci Syst & Applicat, Lanham, MD 20706 USA; Stanford Univ, Stanford, CA 94305 USA; Univ Charleston, Grice Marine Lab, Charleston, SC 29412 USA; NOAA, Natl Environm Satellite Data & Informat Serv, Washington, DC 20233 USA; Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California State University System; San Francisco State University; Stanford University; College of Charleston; National Oceanic Atmospheric Admin (NOAA) - USA; University of Wisconsin System	Arrigo, KR (corresponding author), NASA, Goddard Space Flight Ctr, Code 971-0, Greenbelt, MD 20771 USA.			Dunbar, Robert/0000-0002-9728-5609; Arrigo, Kevin/0000-0002-7364-876X				Carlson CA, 1998, LIMNOL OCEANOGR, V43, P375, DOI 10.4319/lo.1998.43.3.0375; DiTullio GR, 1996, J GEOPHYS RES-OCEANS, V101, P18467, DOI 10.1029/96JC00034; Dugdale RC, 1998, NATURE, V391, P270, DOI 10.1038/34630; El-Sayed Sayed Z., 1993, P65; HUCHINS DA, 1998, NATURE, V393, P561; SAMBROTTO RN, 1993, NATURE, V363, P248, DOI 10.1038/363248a0; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; Sedwick PN, 1997, GEOPHYS RES LETT, V24, P2515, DOI 10.1029/97GL02596; WRIGHT SW, 1991, MAR ECOL PROG SER, V77, P183, DOI 10.3354/meps077183	9	595	607	3	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					365	367		10.1126/science.283.5400.365	http://dx.doi.org/10.1126/science.283.5400.365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888847				2022-12-28	WOS:000078067000041
J	McCulloch, MT; Tudhope, AW; Esat, TM; Mortimer, GE; Chappell, J; Pillans, B; Chivas, AR; Omura, A				McCulloch, MT; Tudhope, AW; Esat, TM; Mortimer, GE; Chappell, J; Pillans, B; Chivas, AR; Omura, A			Coral record of equatorial sea-surface temperatures during the penultimate deglaciation at Huon Peninsula	SCIENCE			English	Article							LAST INTERGLACIAL PERIOD; GREAT-BARRIER-REEF; PAPUA-NEW-GUINEA; MASS-SPECTROMETRY; SOUTHERN-OSCILLATION; WESTERN-AUSTRALIA; LEVEL CHANGES; OCEAN; CLIMATE; PACIFIC	Uplifted coral terraces at Huon Peninsula, Papua New Guinea, preserve a record of sea level, sea-surface temperature, and salinity from the penultimate deglaciation. Remnants have been found of a shallow-water reef that formed during a pause, similar to the Younger Dryas, in the penultimate deglaciation at 130,000 +/- 2000 years ago, when sea Level was 60 to 80 meters lower than it is today. Porites coral, which grew during this period, has oxygen isotopic values and strontium/calcium ratios that indicate that sea-surface temperatures were much cooler (22 degrees +/- 2 degrees C) than either Last Interglacial or present-day tropical temperatures (29 degrees +/- 1 degrees C). These observations provide further evidence for a major cooling of the equatorial western Pacific followed by an extremely rapid rise in sea level during the Latter stages of Termination II.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Edinburgh, Dept Geol & Geophys, Edinburgh EH9 3JW, Midlothian, Scotland; Kanazawa Univ, Dept Earth Sci, Kanazawa, Ishikawa 920, Japan	Australian National University; University of Edinburgh; Kanazawa University	McCulloch, MT (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.	Malcolm.McCulloch@anu.edu.au	McCulloch, Malcolm T/C-3651-2009; Chivas, Allan/B-4242-2013	McCulloch, Malcolm T/0000-0003-1538-1558; Pillans, Bradley/0000-0002-8373-635X; Chivas, Allan/0000-0002-1459-6330; Esat, Tezer/0000-0001-5331-6568; Esat, Sevilay/0000-0002-7257-4009				Alibert C, 1997, PALEOCEANOGRAPHY, V12, P345, DOI 10.1029/97PA00318; BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Beck JW, 1997, NATURE, V385, P705, DOI 10.1038/385705a0; BERGER AL, 1978, QUATERNARY RES, V9, P139, DOI 10.1016/0033-5894(78)90064-9; Broecker WS, 1989, PALEOCEANOGRAPHY, V4, P207, DOI 10.1029/PA004i002p00207; BROECKER WS, 1986, QUATERNARY RES, V26, P121, DOI 10.1016/0033-5894(86)90087-6; Bush ABG, 1998, SCIENCE, V279, P1341, DOI 10.1126/science.279.5355.1341; CHAPPELL J, 1974, GEOL SOC AM BULL, V85, P553, DOI 10.1130/0016-7606(1974)85<553:GOCTHP>2.0.CO;2; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; COLE JE, 1993, SCIENCE, V260, P1790, DOI 10.1126/science.260.5115.1790; Colonna M, 1996, QUATERNARY RES, V46, P335, DOI 10.1006/qres.1996.0071; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; EDWARDS LR, 1986, EARTH PLANET SC LETT, V81, P175; EDWARDS RL, 1987, SCIENCE, V236, P1547, DOI 10.1126/science.236.4808.1547; Esat TM, 1999, SCIENCE, V283, P197, DOI 10.1126/science.283.5399.197; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; GAGAN MK, 1994, EARTH PLANET SC LETT, V121, P549, DOI 10.1016/0012-821X(94)90090-6; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; GUILDERSON TP, 1994, SCIENCE, V263, P633; HAMELIN B, 1991, EARTH PLANET SC LETT, V106, P169, DOI 10.1016/0012-821X(91)90070-X; HANSEN J, 1993, RES EXPLOR, V9, P142; Linsley BK, 1996, NATURE, V380, P234, DOI 10.1038/380234a0; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P151, DOI 10.1016/0016-7037(89)90282-2; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P2747, DOI 10.1016/0016-7037(94)90142-2; OHKOUCHI N, 1994, GEOPHYS RES LETT, V21, P2207, DOI 10.1029/94GL01991; PHILANDER SG, 1990, EL NINO LA NINA SO O; Prahl FG, 1989, PALEOCEANOGRAPHY, V4, P495, DOI 10.1029/PA004i005p00495; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; STEIN M, 1993, GEOCHIM COSMOCHIM AC, V57, P2541, DOI 10.1016/0016-7037(93)90416-T; STIRLING CH, 1995, EARTH PLANET SC LETT, V135, P115, DOI 10.1016/0012-821X(95)00152-3; Stoll HM, 1998, GEOCHIM COSMOCHIM AC, V62, P1107, DOI 10.1016/S0016-7037(98)00042-8; SZABO BJ, 1994, SCIENCE, V266, P93, DOI 10.1126/science.266.5182.93; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; THUNELL R, 1994, QUATERNARY RES, V41, P255, DOI 10.1006/qres.1994.1029; Tudhope AW, 1995, EARTH PLANET SC LETT, V136, P575, DOI 10.1016/0012-821X(95)00156-7; Webb RS, 1997, NATURE, V385, P695, DOI 10.1038/385695a0; WEBSTER PJ, 1978, QUATERNARY RES, V10, P279, DOI 10.1016/0033-5894(78)90024-8; ZHU ZR, 1993, EARTH PLANET SC LETT, V118, P281, DOI 10.1016/0012-821X(93)90173-7	39	111	116	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					202	204		10.1126/science.283.5399.202	http://dx.doi.org/10.1126/science.283.5399.202			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880248				2022-12-28	WOS:000077976700033
J	Nightingale, SL				Nightingale, SL			New rule requires labeling information for pediatric use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					27	27		10.1001/jama.281.1.27	http://dx.doi.org/10.1001/jama.281.1.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892435				2022-12-28	WOS:000077829300007
J	Ohlmeyer, JT; Kalderon, D				Ohlmeyer, JT; Kalderon, D			Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator	NATURE			English	Article							KINESIN-RELATED PROTEIN; DROSOPHILA-MELANOGASTER; SIGNAL-TRANSDUCTION; WINGLESS; GENE; COMPARTMENT; ENCODES; BOUNDARIES; EXPRESSION; SUPPRESSOR	In Drosophila, signalling by the protein Hedgehog (Hh) alters the activity of the transcription factor Cubitus interruptus (Ci) by inhibiting the proteolysis of full-length Ci (Ci-155) to its shortened Ci-75 form(1,2). Ci-75 is found largely in the nucleus and is thought to be a transcriptional repressor(1), whereas there is evidence(3-5) to indicate that Ci-155 may be a transcriptional activator(1,2,6). However, Ci-155 is detected only in the cytoplasm, where it is associated with the protein kinase Fused (Fu), with Suppressor of Fused (Su(fu)), and with the microtubule-binding protein Costal-2 (refs 1,7-9), It is not clear how Ci-155 might become a nuclear activator. We show here that mutations in Su(fu) cause an increase in the expression of Hh-target genes in a dose-dependent manner while simultaneously reducing Ci-155 concentration by some mechanism other than proteolysis to Ci-75, Conversely, eliminating Fu kinase activity reduces Hh-target gene expression while increasing Ci-155 concentration. We propose that Fu kinase activity is required for Hh to stimulate the maturation of Ci-155 into a short-lived nuclear transcriptional activator and that Su(fu) opposes this maturation step through a stoichiometric interaction with Ci-155.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Kalderon, D (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; Blair SS, 1997, DEVELOPMENT, V124, P4053; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUSSON D, 1988, ROUX ARCH DEV BIOL, V197, P221, DOI 10.1007/BF02439429; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; FORBES AJ, 1993, DEVELOPMENT, P115; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; PREAT T, 1992, GENETICS, V132, P725; PREAT T, 1993, GENETICS, V135, P1047; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Strigini M, 1997, DEVELOPMENT, V124, P4697; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; THEROND P, 1993, MECH DEVELOP, V44, P165; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0	30	256	258	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 31	1998	396	6713					749	753		10.1038/25533	http://dx.doi.org/10.1038/25533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874371				2022-12-28	WOS:000077742800032
J	Rosenbaum, S; Frankford, DM; Moore, B; Borzi, P				Rosenbaum, S; Frankford, DM; Moore, B; Borzi, P			Who should determine when health care is medically necessary?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TECHNOLOGY		George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20006 USA; Rutgers State Univ, Sch Law, Camden, NJ 08102 USA; George Washington Univ, Med Ctr, Washington, DC 20006 USA	George Washington University; Rutgers State University Camden; Rutgers State University New Brunswick; George Washington University	Rosenbaum, S (corresponding author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20006 USA.							Bergthold LA, 1995, HEALTH AFFAIR, V14, P180, DOI 10.1377/hlthaff.14.4.180; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P817, DOI 10.1001/jama.272.10.817; Finkelstein BS, 1998, JAMA-J AM MED ASSOC, V279, P663, DOI 10.1001/jama.279.9.663; FRANKLIN C, 1993, INTENS CARE MED, V19, P117, DOI 10.1007/BF01708374; HAVIGHURST CC, 1992, U PENN LAW REV, V140, P1755, DOI 10.2307/3312430; *MILL ROB, 1996, HEALTHC MAN GUID; *PRES ADV COMM CON, 1998, QUAL FIRST BETT HLTH; Steiner CA, 1996, J GEN INTERN MED, V11, P294, DOI 10.1007/BF02598272	8	65	65	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					229	232		10.1056/NEJM199901213400312	http://dx.doi.org/10.1056/NEJM199901213400312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159YJ	9895406				2022-12-28	WOS:000078202900012
J	Raw, M; McNeill, A; West, R				Raw, M; McNeill, A; West, R			Smoking cessation: evidence based recommendations for the healthcare system	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Hlth Educ Author, London SW1P 2HW, England; Kings Coll London, Sch Med & Dent, London SE5 9PJ, England; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	University of London; King's College London; St Georges University London	McNeill, A (corresponding author), Hlth Educ Author, Trevelyan House, London SW1P 2HW, England.	ann.mcneill@hea.org.uk	West, Robert/B-5414-2009; West, Robert/B-5414-2009	West, Robert/0000-0002-0291-5760; West, Robert/0000-0001-6398-0921; McNeill, Ann/0000-0002-6223-4000				ABBOT NC, 1998, COCHRANE LIBR; Benowitz NL, 1998, NICOTINE SAFETY TOXI; CALLUM C, 1998, SMOKING EPIDEMIC; *DEP HLTH, 1998, CMND4177; FIORE MC, 1996, PUBLICATION US DEP H; Glynn TJ, 1989, HELP YOUR PATIENTS S; GOURLAY SG, 1998, COCHRANE LIBR; HAJEK P, 1989, BRIT J ADDICT, V84, P591; HAJEK P, 1998, COCHRANE LIBR; LANCASTER T, 1998, COCHRANE LIBR; MANT D, 1997, RES DEV PRIMARY CARE; Parrott S, 1998, THORAX, V53, pAS1; Raw M, 1998, THORAX, V53, pS1, DOI 10.1136/thx.53.2008.S1; SILAGY C, 1998, COCHRANE LIBR; STEAD LF, 1998, COCHRANE LIBR; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Thomas M, 1998, LIVING BRITAIN RESUL; WHITE AR, 1998, COCHRANE LIBR	18	100	104	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1999	318	7177					182	185		10.1136/bmj.318.7177.182	http://dx.doi.org/10.1136/bmj.318.7177.182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888919	Green Published			2022-12-28	WOS:000078175100040
J	Roche, N				Roche, N			Pulmonary medicine	BRITISH MEDICAL JOURNAL			English	Review							VOLUME REDUCTION SURGERY; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; COMMUNITY-ACQUIRED PNEUMONIA; SELF-ADMINISTERED THERAPY; COST-EFFECTIVENESS; UNFRACTIONATED HEPARIN; COPD PATIENTS; REDUCES DYSPNEA; ASTHMA		Hop Ambroise Pare, Serv Pneumol, F-92104 Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Roche, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England.	bnroche@club-internet.fr	Roche, Nicolas/AAP-4445-2021; Roche, Nicolas/AAE-9206-2021	roche, nicolas/0000-0002-3162-5033				Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; Bousquet J, 1998, EUR RESPIR J, V11, p42S; Burman WJ, 1997, CHEST, V112, P63, DOI 10.1378/chest.112.1.63; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; *COPD GUID GROUP S, 1997, THORAX S5, V52, pS1; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Cydulka RK, 1997, AM J RESP CRIT CARE, V156, P1807, DOI 10.1164/ajrccm.156.6.9611008; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Donner CF, 1997, EUR RESPIR J, V10, P744; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Gosselink R, 1997, EUR RESPIR J, V10, P2884, DOI 10.1183/09031936.97.10122884; Gustafsson LE, 1998, EUR RESPIR J, V11, p49S; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; Horwitz RJ, 1998, AM J RESP CRIT CARE, V157, P1363, DOI 10.1164/ajrccm.157.5.9706059; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; KEATINGS V, 1997, AM J RESP CRIT CARE, V155, P548; Keller CA, 1997, AM J RESP CRIT CARE, V156, P60, DOI 10.1164/ajrccm.156.1.9609101; Koivula I, 1997, AM J MED, V103, P281, DOI 10.1016/S0002-9343(97)00149-6; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Mannino DM, 1997, AM J RESP CRIT CARE, V156, P814, DOI 10.1164/ajrccm.156.3.9702026; Martinez FJ, 1997, AM J RESP CRIT CARE, V155, P1984, DOI 10.1164/ajrccm.155.6.9196106; McFadden ER, 1997, ANN INTERN MED, V127, P142, DOI 10.7326/0003-4819-127-2-199707150-00009; Moore RD, 1996, AM J RESP CRIT CARE, V154, P1013, DOI 10.1164/ajrccm.154.4.8887600; National Heart Lung and Blood Institute World Health Organization, 1995, GLOB STRAT ASTHM MAN, P1; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Perrier A, 1997, AM J RESP CRIT CARE, V156, P492, DOI 10.1164/ajrccm.156.2.9702032; RamirezVenegas A, 1997, CHEST, V112, P336, DOI 10.1378/chest.112.2.336; Reed CE, 1998, J ALLERGY CLIN IMMUN, V101, P14, DOI 10.1016/S0091-6749(98)70187-3; Roy A, 1996, EUR RESPIR J, V9, P226, DOI 10.1183/09031936.96.09020226; Russi EW, 1997, EUR RESPIR J, V10, P208, DOI 10.1183/09031936.97.10010208; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Szekely LA, 1997, CHEST, V111, P550, DOI 10.1378/chest.111.3.550; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Tschernko EM, 1997, THORAX, V52, P545, DOI 10.1136/thx.52.6.545; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540, DOI 10.1164/ajrccm.157.2.9703060; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067	48	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					171	176		10.1136/bmj.318.7177.171	http://dx.doi.org/10.1136/bmj.318.7177.171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888914	Green Published			2022-12-28	WOS:000078175100035
J	Hartmann, LC; Schaid, DJ; Woods, JE; Crotty, TP; Myers, JL; Arnold, PG; Petty, PM; Sellers, TA; Johnson, JL; McDonnell, SK; Frost, MH; Jenkins, RB				Hartmann, LC; Schaid, DJ; Woods, JE; Crotty, TP; Myers, JL; Arnold, PG; Petty, PM; Sellers, TA; Johnson, JL; McDonnell, SK; Frost, MH; Jenkins, RB			Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCUTANEOUS MASTECTOMY; BRCA1; RISK; PROBABILITY; MUTATIONS	Background Options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes for surveillance and prophylactic mastectomy are incomplete. Methods We conducted a retrospective study of all women with a family history of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. The women were divided into two groups - high risk and moderate risk - on the basis of family history. A control study of the sisters of the high-risk probands and the Gall model were used to predict the number of breast cancers expected in these two groups in the absence of prophylactic mastectomy. Results We identified 639 women with a family history of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at moderate risk. The median length of follow-up was 14 years. The median age at prophylactic mastectomy was 42 years. According to the Gall model, 37.4 breast cancers were expected in the moderate-risk group; 4 breast cancers occurred (reduction in risk, 89.5 percent; P<0.001). We compared the numbers of breast cancers among the 214 high-risk probands with the numbers among their 403 sisters who had not undergone prophylactic mastectomy. Of these sisters, 38.7 percent (156) had been given a diagnosis of breast cancer (115 cases were diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, and the time of the diagnosis was unknown in 3 cases). By contrast, breast cancer was diagnosed in 1.4 percent (3 of 214) of the probands. Thus, prophylactic mastectomy was associated with a reduction in the incidence of breast cancer of at least 90 percent. Conclusions In women with a high risk of breast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the incidence of breast cancer. (N Engl J Med 1999;340:77-84.) (C) 1999, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Plast & Reconstruct Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Clin Epidemiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University College Dublin	Hartmann, LC (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; McDonnell, Shannon/0000-0001-6201-369X	NATIONAL CANCER INSTITUTE [U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [U10 CA37404-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM SOC PLAST REC, 1994, PROPH MAST; [Anonymous], 1980, DHHS PUBL; Benichou J, 1996, J CLIN ONCOL, V14, P103, DOI 10.1200/JCO.1996.14.1.103; Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227; BILIMORIA MM, 1995, CA-CANCER J CLIN, V45, P263, DOI 10.3322/canjclin.45.5.263; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; *DHHS, 1970, DHHS PUBL; ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0; ERNSTER VL, 1997, DUCTAL CARCINOMA IN, P23; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fonseca R, 1997, ANN INTERN MED, V127, P1013, DOI 10.7326/0003-4819-127-11-199712010-00013; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; Grann VR, 1998, J CLIN ONCOL, V16, P979, DOI 10.1200/JCO.1998.16.3.979; Hicken NF, 1940, ARCH SURG-CHICAGO, V40, P6, DOI 10.1001/archsurg.1940.04080010009002; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KOSARY CL, 1995, NIH PUBLICATION; LEVITAN M, 1977, TXB HUMAN GENETICS, P410; Lopez MJ, 1996, SURG CLIN N AM, V76, P231, DOI 10.1016/S0039-6109(05)70436-9; *NAT CANC I, 1995, NIH PUBL; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OLOPADE OI, 1996, PRINCIPLES PRACTICE, V10, P1; PENNISI VR, 1986, AESTHET PLAST SURG, V10, P101, DOI 10.1007/BF01575276; PENNISI VR, 1989, AESTHET PLAST SURG, V13, P15, DOI 10.1007/BF01570320; PENNISI VR, 1977, PLAST RECONSTR SURG, V59, P53, DOI 10.1097/00006534-197701000-00009; *PHS, 1964, PHS PUBL, V1252; Powles T, 1998, LANCET, V352, P98; Schaid DJ, 1997, J NATL CANCER I, V89, P1632, DOI 10.1093/jnci/89.21.1632-a; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; SHAM P, 1995, STAT HUMAN GENETICS, P32; STEFANEK ME, 1995, PREV MED, V24, P412, DOI 10.1006/pmed.1995.1066; Veronesi U, 1998, LANCET, V352, P93; WOODS JE, 1983, ANN PLAS SURG, V11, P541, DOI 10.1097/00000637-198312000-00016; *WOODS JE, 1986, MAYO CLIN P, V61, P579; ZIEGLER LD, 1991, AM J CLIN ONCOL-CANC, V14, P451, DOI 10.1097/00000421-199110000-00018	39	901	914	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					77	84		10.1056/NEJM199901143400201	http://dx.doi.org/10.1056/NEJM199901143400201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887158				2022-12-28	WOS:000078016200001
J	Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E; Bernasconi, M; Parrinello, M				Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E; Bernasconi, M; Parrinello, M			Superionic and metallic states of water and ammonia at giant planet conditions	SCIENCE			English	Article							HIGH-PRESSURE; MAGNETIC-FIELDS; ELECTRICAL-CONDUCTIVITY; MOLECULAR-DYNAMICS; URANUS; ICE; NEPTUNE; PHASE; MBAR; TEMPERATURE	The phase diagrams of water and ammonia were determined by constant pressure ab initio molecular dynamic simulations at pressures (30 to 300 gigapascal) and temperatures (300 to 7000 kelvin) of relevance for the middle ice layers of the giant planets Neptune and Uranus. Along the planetary isentrope water and ammonia behave as fully dissociated ionic, electronically insulating fluid phases, which turn metallic at temperatures exceeding 7000 kelvin for water and 5500 kelvin for ammonia. At lower temperatures, the phase diagrams of water and ammonia exhibit a superionic solid phase between the solid and the ionic liquid. These simulations improve our understanding of the properties of the middle ice Layers of Neptune and Uranus.	Ist Nazl Fis Mat, I-34014 Trieste, Italy; Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy; SISSA, I-34014 Trieste, Italy; Abdus Salaam Int Ctr Theoret Phys, I-34014 Trieste, Italy; Univ Milan, Dipartimento Sci Mat, I-20126 Milan, Italy; INFM, I-20126 Milan, Italy; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; International School for Advanced Studies (SISSA); International School for Advanced Studies (SISSA); Abdus Salam International Centre for Theoretical Physics (ICTP); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Max Planck Society	Chiarotti, GL (corresponding author), Ist Nazl Fis Mat, Via Beirut 4, I-34014 Trieste, Italy.	guido@sissa.it	Chiarotti, Guido/A-9909-2012; Scandolo, Sandro/AAC-9081-2019	Scandolo, Sandro/0000-0003-3826-4813				Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; Aoki K, 1996, PHYS REV LETT, V76, P784, DOI 10.1103/PhysRevLett.76.784; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Benoit M, 1998, NATURE, V392, P258, DOI 10.1038/32609; Benoit M, 1996, PHYS REV LETT, V76, P2934, DOI 10.1103/PhysRevLett.76.2934; Bernasconi M, 1998, PHYS REV LETT, V81, P1235, DOI 10.1103/PhysRevLett.81.1235; BERNASCONI M, 1995, J PHYS CHEM SOLIDS, V56, P501, DOI 10.1016/0022-3697(94)00228-2; Datchi F., 1998, KOATSURYOKU NO KAGAK, P778; DEMONTIS P, 1988, PHYS REV LETT, V60, P2284, DOI 10.1103/PhysRevLett.60.2284; FOCHER P, 1994, EUROPHYS LETT, V26, P345, DOI 10.1209/0295-5075/26/5/005; Goncharov AF, 1996, SCIENCE, V273, P218, DOI 10.1126/science.273.5272.218; HEMLEY RJ, 1987, NATURE, V330, P737, DOI 10.1038/330737a0; HIRSCH KR, 1984, PHYS LETT A, V101, P142, DOI 10.1016/0375-9601(84)90510-3; HOBBS PV, 1974, ICE PHYSICS; Hubbard WB, 1997, SCIENCE, V275, P1279, DOI 10.1126/science.275.5304.1279; HUBBARD WB, 1980, J GEOPHYS RES, V85, P225, DOI 10.1029/JB085iB01p00225; Hubbard WB, 1995, SPACE SCI S, P109; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; Loveday JS, 1996, PHYS REV LETT, V76, P74, DOI 10.1103/PhysRevLett.76.74; MITCHELL AC, 1982, J CHEM PHYS, V76, P6273, DOI 10.1063/1.443030; Nellis WJ, 1997, J CHEM PHYS, V107, P9096, DOI 10.1063/1.475200; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; NESS NF, 1986, SCIENCE, V233, P85, DOI 10.1126/science.233.4759.85; NESS NF, 1989, SCIENCE, V246, P1473, DOI 10.1126/science.246.4936.1473; Podolak M, 1995, PLANET SPACE SCI, V43, P1517, DOI 10.1016/0032-0633(95)00061-5; PRUZAN P, 1993, J CHEM PHYS, V99, P9842, DOI 10.1063/1.465467; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993	33	362	373	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	1999	283	5398					44	46		10.1126/science.283.5398.44	http://dx.doi.org/10.1126/science.283.5398.44			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872734				2022-12-28	WOS:000077976600042
J	Gau, H; Herminghaus, S; Lenz, P; Lipowsky, R				Gau, H; Herminghaus, S; Lenz, P; Lipowsky, R			Liquid morphologies on structured surfaces: From microchannels to microchips	SCIENCE			English	Article							INSTABILITY	Liquid microchannels on structured surfaces are built up using a wettability pattern consisting of hydrophilic stripes on a hydrophobic substrate, These channels undergo a shape instability at a certain amount of adsorbed volume, from a homogeneous state with a spatially constant cross section to a state with a single bulge. This instability is quite different from the classical Rayleigh Plateau instability and represents a bifurcation between two different morphologies of constant mean curvature. The bulge state can be used to construct channel networks that could be used as fluid microchips or microreactors.	MPI Colloids & Interfaces, D-14513 Teltow, Germany; MPI Colloids & Interfaces, D-12489 Berlin, Germany	Max Planck Society; Max Planck Society	Lipowsky, R (corresponding author), MPI Colloids & Interfaces, Kantstr 55, D-14513 Teltow, Germany.		Lenz, Peter/L-5980-2013; Herminghaus, Stephan/D-1904-2009	Lenz, Peter/0000-0001-7705-3950; Lipowsky, Reinhard/0000-0001-8417-8567				BARZIV R, 1994, PHYS REV LETT, V73, P1392, DOI 10.1103/PhysRevLett.73.1392; CHANDRASEKHAR S., 1981, HYDRODYNAMIC HYDROMA; DRELICH J, 1994, COLLOID SURFACE A, V93, P1, DOI 10.1016/0927-7757(94)02940-7; Goldstein RE, 1996, J PHYS II, V6, P767, DOI 10.1051/jp2:1996210; JACBOS K, 1997, IN PRESS P 2 EUR COA; Lenz P, 1998, PHYS REV LETT, V80, P1920, DOI 10.1103/PhysRevLett.80.1920; LOPEZ GP, 1993, SCIENCE, V260, P647, DOI 10.1126/science.8480175; Moller G, 1998, LANGMUIR, V14, P4955, DOI 10.1021/la980400o; Morhard F, 1997, ELEC SOC S, V97, P1058; QUERE D, 1990, SCIENCE, V249, P1256, DOI 10.1126/science.249.4974.1256; Rowlinson J. S., 1982, MOL THEORY CAPILLARI; STRUWE M, 1988, PLATEAUS PROBLEM CAL; Sullivan JM, 1996, INT J MATH, V7, P833, DOI 10.1142/S0129167X9600044X; Van Dyke, 1982, ALBUM FLUID MOTION; Wang R, 1997, NATURE, V388, P431, DOI 10.1038/41233; [No title captured]; 19748295	17	897	938	7	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					46	49		10.1126/science.283.5398.46	http://dx.doi.org/10.1126/science.283.5398.46			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872735				2022-12-28	WOS:000077976600043
J	Hebestreit, K; Stutz, J; Rosen, D; Matveiv, V; Peleg, M; Luria, M; Platt, U				Hebestreit, K; Stutz, J; Rosen, D; Matveiv, V; Peleg, M; Luria, M; Platt, U			DOAS measurements of tropospheric bromine oxide in mid-latitudes	SCIENCE			English	Article							BOUNDARY-LAYER; BRO	Episodes of elevated bromine oxide (BrO) concentration are known to occur at high Latitudes in the Arctic boundary layer and to lead to catalytic destruction of ozone at those latitudes; these events have not been observed at Lower latitudes. With the use of differential optical absorption spectroscopy (DOAS), Locally high BrO concentrations were observed at mid-latitudes at the Dead Sea, Israel, during spring 1997. Mixing ratios peaked daily at around 80 parts per trillion around noon and were correlated with Low boundary-layer ozone mixing ratios.	Univ Heidelberg, Inst Umweltphys, D-69120 Heidelberg, Germany; Hebrew Univ Jerusalem, Sch Appl Sci, IL-91904 Jerusalem, Israel	Ruprecht Karls University Heidelberg; Hebrew University of Jerusalem	Stutz, J (corresponding author), Univ Heidelberg, Inst Umweltphys, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Stutz, Jochen/K-7159-2014					ALICKE B, IN PRESS NATURE; BOTTENHEIM JW, 1986, GEOPHYS RES LETT, V13, P113, DOI 10.1029/GL013i002p00113; FAN SM, 1992, NATURE, V359, P522, DOI 10.1038/359522a0; Ferlemann F, 1998, GEOPHYS RES LETT, V25, P3847, DOI 10.1029/1998GL900020; FINLAYSONPITTS BJ, 1988, ATMOS ENVIRON, V22, P1107, DOI 10.1016/0004-6981(88)90340-X; Hausmann M., 1994, J GEOPHYS RES, V99, P25, DOI [10.1029/94JD01314, DOI 10.1029/94JD01314]; HEINTZ F, 1996, J GEOPHYS RES, V101, P891; Kreher K, 1997, GEOPHYS RES LETT, V24, P3021, DOI 10.1029/97GL02997; Niemi T. M., 1997, OXFORD MONOGRAPHS GE, V36; OLTMANS SJ, 1986, J GEOPHYS RES-ATMOS, V91, P5229, DOI 10.1029/JD091iD04p05229; Platt U, 1995, FARADAY DISCUSS, V100, P175, DOI 10.1039/fd9950000175; Platt U., 1983, SPRINGER SER OPTICAL, V39, P95; PLATT U, 1998, HALOTROP FINAL REPOR; Platt U., 1994, CHEM ANAL SERIES, P27; Richter A, 1998, GEOPHYS RES LETT, V25, P2683, DOI 10.1029/98GL52016; Stutz J, 1996, APPL OPTICS, V35, P6041, DOI 10.1364/AO.35.006041; Tuckermann M, 1997, TELLUS B, V49, P533, DOI 10.1034/j.1600-0889.49.issue5.9.x; Vogt R, 1996, NATURE, V383, P327, DOI 10.1038/383327a0; Wagenbach D, 1998, J GEOPHYS RES-ATMOS, V103, P10961, DOI 10.1029/97JD01804; Wagner T, 1998, NATURE, V395, P486, DOI 10.1038/26723; WAHNER A, 1988, CHEM PHYS LETT, V152, P507, DOI 10.1016/0009-2614(88)80450-0; WAYNE RP, 1995, ATMOS ENVIRON, V29, P2675, DOI 10.1016/1352-2310(95)90286-4; [No title captured]	23	132	138	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					55	57		10.1126/science.283.5398.55	http://dx.doi.org/10.1126/science.283.5398.55			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872738				2022-12-28	WOS:000077976600046
J	Espinel, CH				Espinel, CH			Art and neuroscience: how the brain sees Vermeer's Woman Holding a Balance	LANCET			English	Article							PERCEPTION		Blood Pressure Ctr, Washington, DC USA; Georgetown Univ, Dept Med, Arlington, VA 22205 USA; Georgetown Univ, Ctr Clin Bioeth, Arlington, VA 22205 USA	Georgetown University; Georgetown University	Espinel, CH (corresponding author), Blood Pressure Ctr, Washington, DC USA.							[Anonymous], GENESIS; Arnheim R., 1984, ART VISUAL PERCEPTIO; BLANKERT A, 1978, J VERMEER DELFT 1932; BROOS B, 1995, J VERMEER EXHIBITION, P47; Carstensen R, 1971, DTSCH ARZTEBLATT ARZ, V68, P1; CAVANAGH P, 1985, PERCEPTION, V14, P151, DOI 10.1068/p140151; CUNNINGHAM FG, 1997, WILLIAMS OBSTET, P1; DELACROIX H, 1991, RENAISSANCE MODERN A, V2; ESPINEL CH, 1994, LANCET, V344, P1750, DOI 10.1016/S0140-6736(94)92891-6; Espinel CH, 1995, LANCET, V346, P1684, DOI 10.1016/S0140-6736(95)92846-4; GIFFORD M, 1997, RECENT OBSERVATIONS, P186; Gombrich E. H., 1994, IMAGE EYE; Hubel David H, 1995, EYE BRAIN VISION, P6; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P400; Kemp Martin, 1990, SCI ART, P9; KUHN H, 1968, REPORT STUDIES HIST; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; WADUM J, 1998, CONTOURS VERMEER, P201; WHEELOCK AK, 1995, VERMMER ART PAINTING, P97; WRIGHT C, 1976, VERMEER; Zeki S., 1990, DISCUSS NEUROSCI, VVI, P1	21	10	10	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2007	2009		10.1016/S0140-6736(98)10102-2	http://dx.doi.org/10.1016/S0140-6736(98)10102-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872264	hybrid			2022-12-28	WOS:000077663000045
J	Paraf, F				Paraf, F			"Smiling" alveolar macrophage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Hosp Univ Dupuytren, F-87042 Limoges, France	CHU Limoges	Paraf, F (corresponding author), Ctr Hosp Univ Dupuytren, F-87042 Limoges, France.			Paraf, Francois/0000-0002-3930-2618					0	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1896	1896		10.1056/NEJM199812243392605	http://dx.doi.org/10.1056/NEJM199812243392605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862945				2022-12-28	WOS:000077696600005
J	Manoury, B; Hewitt, EW; Morrice, N; Dando, PM; Barrett, AJ; Watts, C				Manoury, B; Hewitt, EW; Morrice, N; Dando, PM; Barrett, AJ; Watts, C			An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation	NATURE			English	Article							INNATE IMMUNITY; PURIFICATION; RECOGNITION; COMPLEXES	Foreign protein antigens must be broken down within endosomes or lysosomes to generate suitable peptides that will form complexes with class II major histocompatibility complex molecules for presentation to T cells. However, it is not known which proteases are required for antigen processing. To investigate this, we exposed a domain of the microbial tetanus toxin antigen (TTCF) to disrupted lysosomes that had been purified from a human B-cell line. Here we show that the dominant processing activity is not one of the known lysosomal cathepsins, which are generally believed to be the principal enzymes involved in antigen processing, but is instead an asparagine-specific cysteine endopeptidase. This enzyme seems similar or identical to a mammalian homologue(1) of the legumain/haemoglobinase asparaginyl endopeptidases found originally in plants' and parasites(3). We designed competitive peptide inhibitors of B-cell asparaginyl endopeptidase (AEP) that specifically block its proteolytic activity and inhibit processing of TTCF in vitro. In vivo, these inhibitors slow TTCF presentation to T cells, whereas preprocessing of TTCF with AEP accelerates its presentation, indicating that this enzyme performs a key step in TTCF processing. We also show that N-glycosylation of asparagine residues blocks AEP action in vitro. This indicates that N-glycosylation could eliminate sites of processing by AEP in mammalian proteins, allowing preferential processing of microbial antigens.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Babraham Inst, Dept Immunol, MRC, Peptidase Lab, Cambridge CB2 4AT, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Watts, C (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Wellcome Sci Bldg, Dundee DD1 5EH, Scotland.			Hewitt, Eric/0000-0002-6238-6303; Manoury, Benedicte/0000-0001-7784-3389; Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BOTARELLI P, 1991, J IMMUNOL, V147, P3128; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fineschi B, 1997, TRENDS BIOCHEM SCI, V22, P377, DOI 10.1016/S0968-0004(97)01116-X; Harlow E., 1988, ANTIBODIES LAB MANUA; Hewitt EW, 1997, J IMMUNOL, V159, P4693; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lu JY, 1996, CARBOHYD RES, V296, P1, DOI 10.1016/S0008-6215(96)00240-6; MAKOFF AJ, 1989, BIO-TECHNOL, V7, P1043; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Pond L, 1997, J IMMUNOL, V159, P543; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	21	300	308	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					695	699		10.1038/25379	http://dx.doi.org/10.1038/25379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872320				2022-12-28	WOS:000077694200058
J	Burgio, KL; Locher, JL; Goode, PS; Hardin, JM; McDowell, BJ; Dombrowski, M; Candib, D				Burgio, KL; Locher, JL; Goode, PS; Hardin, JM; McDowell, BJ; Dombrowski, M; Candib, D			Behavioral vs drug treatment for urge urinary incontinence in older women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PELVIC MUSCLE EXERCISE; FECAL INCONTINENCE; BIOFEEDBACK	Context.-Urinary incontinence is a common condition caused by many factors with several treatment options. Objective.-To compare the effectiveness of biofeedback-assisted behavioral treatment with drug treatment and a placebo control condition for the treatment of urge and mixed urinary incontinence in older community-dwelling women. Design.-Randomized placebo-controlled trial conducted from 1989 to 1995. Setting.-University-based outpatient geriatric medicine clinic. Patients.-A volunteer sample of 197 women aged 55 to 92 years with urge urinary incontinence or mixed incontinence with urge as the predominant pattern. Subjects had to have urodynamic evidence of bladder dysfunction, be ambulatory, and not have dementia, Intervention.-Subjects were randomized to 4 sessions (8 weeks) of biofeedback-assisted behavioral treatment, drug treatment (with oxybutynin chloride, possible range of doses, 2.5 mg daily to 5.0 mg 3 times daily), or a placebo control condition. Main Outcome Measures.-Reduction in the frequency of incontinent episodes as determined by bladder diaries, and patients' perceptions of improvement and their comfort and satisfaction with treatment. Results.-For all 3 treatment groups, reduction of incontinence was most pronounced early in treatment and progressed more gradually thereafter. Behavioral treatment, which yielded a mean 80.7% reduction of incontinence episodes, was significantly more effective than drug treatment (mean 68.5% reduction; P=.04) and both were more effective than the placebo control condition (mean 39.4% reduction; P<.001 and P=.009, respectively). Patient-perceived improvement was greatest for behavioral treatment (74.1% "much better" vs 50.9% and 26.9% for drug treatment and placebo, respectively). Only 14.0% of patients receiving behavioral treatment wanted to change to another treatment vs 75.5% in each of the other groups. Conclusion.-Behavioral treatment is a safe and effective conservative intervention that should be made more readily available to patients as a first-line treatment for urge and mixed incontinence.	Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA; Univ Alabama, Sch Hlth Related Profess, Dept Hlth Serv Adm, Birmingham, AL USA; Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; Allegheny Gen Hosp, Dept Med, Pittsburgh, PA 15212 USA; St Vincent Hlth Ctr, Family Practice Residency Program, Erie, PA USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Allegheny General Hospital	Burgio, KL (corresponding author), 2001 3rd Ave S LNB 1081, Birmingham, AL 35233 USA.	kburgio@Aging.dom.uab.edu		Locher, Julie/0000-0002-2639-6459	NIA NIH HHS [AG 08010] Funding Source: Medline; PHS HHS [KO4 00431] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008010] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAIGISSMITH J, 1989, GERONTOLOGIST, V29, P229, DOI 10.1093/geront/29.2.229; BURGIO KL, 1986, AM J OBSTET GYNECOL, V154, P58; BURGIO KL, 1989, J UROLOGY, V141, P303, DOI 10.1016/S0022-5347(17)40747-6; Burgio KL, 1989, STAYING DRY PRACTICA; BURNS PA, 1993, J GERONTOL, V48, pM167; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; CARDOZO L, 1978, BRIT J UROL, V50, P250, DOI 10.1111/j.1464-410X.1978.tb02819.x; CARDOZO LD, 1978, BR J UROL, V50, P27; CERULLI MA, 1979, GASTROENTEROLOGY, V76, P742; Conover W.J., 1981, AM STAT, V35, P125; *CYT SOFTW CORP, 1989, STATXACT US MAN; DIOKNO AC, 1986, J UROLOGY, V136, P1022; ELLIOTT JM, 1989, JAMA-J AM MED ASSOC, V261, P2685; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FANTL JA, 1996, AHCPR PUBLICATION; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; JARVIS GJ, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322-a; Johnson M A, 1982, J Gerontol Nurs, V8, P641; JOHNSON MJ, 1982, J GERONTOL NURS, V8, P54; KEGEL A H, 1956, J Int Coll Surg, V25, P487; KEGEL AH, 1948, AM J OBSTET GYNECOL, V56, P238, DOI 10.1016/0002-9378(48)90266-X; Kirk R. E., 1982, EXPT DESIGN; MCDOWELL BJ, 1992, J AM GERIATR SOC, V40, P370, DOI 10.1111/j.1532-5415.1992.tb02137.x; MEYHOFF HH, 1983, BRIT J UROL, V55, P34, DOI 10.1111/j.1464-410X.1983.tb07075.x; MIDDAUGH SJ, 1989, BIOFEEDBACK SELF-REG, V14, P3, DOI 10.1007/BF00999338; PENGELLY AW, 1980, BRIT J UROL, V52, P463, DOI 10.1111/j.1464-410X.1980.tb03091.x; TAYLOR MC, 1979, BRIT J UROL, V51, P504, DOI 10.1111/j.1464-410X.1979.tb03588.x; WELLS TJ, 1991, J AM GERIATR SOC, V39, P785, DOI 10.1111/j.1532-5415.1991.tb02701.x; WYMAN JF, 1988, OBSTET GYNECOL, V71, P812; [No title captured]	31	395	401	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					1995	2000		10.1001/jama.280.23.1995	http://dx.doi.org/10.1001/jama.280.23.1995			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146YW	9863850	Bronze			2022-12-28	WOS:000077462300029
J	O'Hollaren, MT				O'Hollaren, MT			Update in allergy and immunology	ANNALS OF INTERNAL MEDICINE			English	Review							LATEX		Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA	Oregon Health & Science University	O'Hollaren, MT (corresponding author), Oregon Hlth & Sci Univ, Dept Med, 0P30,3181 SW Sam Jackson Pk, Portland, OR 97201 USA.							DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7	5	4	4	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1036	1043		10.7326/0003-4819-129-12-199812150-00008	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867759				2022-12-28	WOS:000077471900007
J	Odorizzi, G; Babst, M; Emr, SD				Odorizzi, G; Babst, M; Emr, SD			Fab1p PtdIns(3)P 5-kinase function essential for protein sorting in the multivesicular body	CELL			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; PREVACUOLAR COMPARTMENT; ALKALINE-PHOSPHATASE; TRANSPORT; MEMBRANE; PATHWAY; MUTANTS	Sorting of signal-transducing cell surface receptors within multivesicular bodies (MVBs) is required for their rapid down-regulation and degradation within lysosomes. Yeast mutants defective in late stages of transport to the vacuole/lysosome accumulate MVBs. We demonstrate that the membrane glycoprotein carboxypeptidase S and the G protein-coupled receptor Ste2p are targeted into the vacuole lumen, and this process requires a subset of VPS gene products essential for normal endosome function. The PtdIns(3)P B-kinase activity of Fab1p, which converts the product of the Vps34p PtdIns 3-kinase PtdIns(3)P into PtdIns(3,5)P-2, also is required for cargo-selective sorting into the vacuole lumen. These findings demonstrate a role for phosphoinositide signaling at distinct stages of vacuolar/lysosomal protein transport and couple PtdIns(3,5)P-2 synthesis to regulation of MVB sorting.	Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Emr, SD (corresponding author), Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA.			Odorizzi, Greg/0000-0002-1143-1098	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; MORANO KA, 1994, J CELL SCI, V107, P2813; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	52	541	544	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					847	858		10.1016/S0092-8674(00)81707-9	http://dx.doi.org/10.1016/S0092-8674(00)81707-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865702	Bronze			2022-12-28	WOS:000077498800014
J	Rudnick, DL; Ferrari, R				Rudnick, DL; Ferrari, R			Compensation of horizontal temperature and salinity gradients in the ocean mixed layer	SCIENCE			English	Article							NORTH PACIFIC; THERMOCLINE; FLUXES; FRONTS; MODEL; WATER; FLOW	Establishment of the temperature-salinity relationship in the ocean has concerned oceanographers for decades because of its importance for understanding ocean circulation. High-resolution measurements in the ocean mixed Layer are used to show that temperature and salinity gradients on horizontal scales of 20 meters to 10 kilometers tend to compensate in their effect on density. These observations support the notion of a horizontal mixing in the mixed Layer that depends on density gradient.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Rudnick, DL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Ferrari, Raffaele/C-9337-2013; Rudnick, Daniel L/J-8948-2016	Ferrari, Raffaele/0000-0002-3736-1956; Rudnick, Daniel L/0000-0002-2624-7074				Anderson SP, 1996, J CLIMATE, V9, P3056, DOI 10.1175/1520-0442(1996)009<3056:SBFATM>2.0.CO;2; BRAINERD KE, 1993, J GEOPHYS RES-OCEANS, V98, P22645, DOI 10.1029/93JC02297; CHEN LAG, 1995, J PHYS OCEANOGR, V25, P691, DOI 10.1175/1520-0485(1995)025<0691:MLDRFT>2.0.CO;2; Chen LG, 1995, J PHYS OCEANOGR, V25, P3064, DOI 10.1175/1520-0485(1995)025<3064:DCTGAD>2.0.CO;2; Daubechies I., 1992, 10 LECT WAVELETS, V61; FARGE M, 1992, ANNU REV FLUID MECH, V24, P395, DOI 10.1146/annurev.fl.24.010192.002143; Ferrari R, 1997, J MAR RES, V55, P1069, DOI 10.1357/0022240973224094; GREGG MC, 1989, J GEOPHYS RES-OCEANS, V94, P9686, DOI 10.1029/JC094iC07p09686; ISELIN CO, 1939, T AM GEOPHYSICAL UNI, V20, P414; Langmuir I, 1938, SCIENCE, V87, P119, DOI 10.1126/science.87.2250.119; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; Lueck R. G., 1990, Journal of Atmospheric and Oceanic Technology, V7, P756, DOI 10.1175/1520-0426(1990)007<0756:TIOCCO>2.0.CO;2; LUYTEN JR, 1983, J PHYS OCEANOGR, V13, P292, DOI 10.1175/1520-0485(1983)013<0292:TVT>2.0.CO;2; POLLARD R, 1986, NATURE, V323, P433, DOI 10.1038/323433a0; RODEN GI, 1975, J PHYS OCEANOGR, V5, P557, DOI 10.1175/1520-0485(1975)005<0557:ONPTSS>2.0.CO;2; RODEN GI, 1984, ANN GEOPHYS, V2, P399; Rudnick DL, 1996, J GEOPHYS RES-OCEANS, V101, P923, DOI 10.1029/95JC02867; SAMELSON RM, 1988, J GEOPHYS RES-OCEANS, V93, P2237, DOI 10.1029/JC093iC03p02237; SCHMITT RW, 1994, ANNU REV FLUID MECH, V26, P255, DOI 10.1146/annurev.fl.26.010194.001351; SCHMITT RW, 1981, J PHYS OCEANOGR, V11, P1015, DOI 10.1175/1520-0485(1981)011<1015:FOTTSR>2.0.CO;2; SCHMITT RW, 1989, J PHYS OCEANOGR, V19, P1208, DOI 10.1175/1520-0485(1989)019<1208:EMPADF>2.0.CO;2; STOMMEL H, 1979, P NATL ACAD SCI USA, V76, P3051, DOI 10.1073/pnas.76.7.3051; STOMMEL HM, 1993, J PHYS OCEANOGR, V23, P151, DOI 10.1175/1520-0485(1993)023<0151:TAROAS>2.0.CO;2; STOMMEL HM, 1993, J PHYS OCEANOGR, V23, P142, DOI 10.1175/1520-0485(1993)023<0142:ACRMFD>2.0.CO;2; WELLER RA, 1985, SCIENCE, V227, P1552, DOI 10.1126/science.227.4694.1552; YOUNG WR, 1994, J PHYS OCEANOGR, V24, P1812, DOI 10.1175/1520-0485(1994)024<1812:TSMLA>2.0.CO;2	26	138	139	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					526	529		10.1126/science.283.5401.526	http://dx.doi.org/10.1126/science.283.5401.526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915697				2022-12-28	WOS:000078203300033
J	Zubarev, ER; Pralle, MU; Li, LM; Stupp, SI				Zubarev, ER; Pralle, MU; Li, LM; Stupp, SI			Conversion of supramolecular clusters to macromolecular objects	SCIENCE			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; 2-DIMENSIONAL POLYMERS; MOLECULAR RECOGNITION; DENDRIMERS; CHEMISTRY; PORE; POLYBUTADIENE; MUTAGENESIS; COPOLYMERS; RESIDUES	In a reaction proceeding within a nanoscopic volume, supramolecular clusters were transformed to polymer objects while retaining their shape and size. Spatial isolation of the cross-linkable blocks of oligobutadiene that were involved in this stitching reaction was achieved by self-assembly of the molecules that made up the clusters. Thermal activation of cross-linking yielded macromolecules (molecular weight of 70,000) with a narrow size distribution that was similar to that of the supramolecular clusters. The macromolecules obtained have an anisotropic shape (2 nanometers by 8 nanometers), as determined by electron microscopy and small-angle x-ray scattering, and form materials that exhibit a Liquid crystalline state.	Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Mat Res Lab, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Visualizat Lab, Urbana, IL 61801 USA; Univ Illinois, Ctr Electron Microscopy, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Stupp, SI (corresponding author), Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA.		Stupp, Samuel/B-6737-2009; Zubarev, Eugene R./C-9288-2011; Stupp, Samuel/AGV-1942-2022	Li, Leiming/0000-0003-2073-6632; Zubarev, Eugene/0000-0002-6401-3287				Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; Bell TW, 1996, SCIENCE, V271, P1077, DOI 10.1126/science.271.5252.1077; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; DOSKOCILOVA D, 1993, POLYMER, V34, P437, DOI 10.1016/0032-3861(93)90104-I; EATON DF, 1990, J AM CHEM SOC, V112, P2821, DOI 10.1021/ja00163a065; Fang Y, 1997, BIOCHEMISTRY-US, V36, P9518, DOI 10.1021/bi970600j; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; GOLUB MA, 1973, POLYM LETT, V11, P129; GRASSIE N, 1974, J POLYM SCI POL LETT, V12, P89, DOI 10.1002/pol.1974.130120206; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; LEHN JM, 1994, PURE APPL CHEM, V66, P1961, DOI 10.1351/pac199466101961; MCNEILL IC, 1978, J POLYM SCI POL CHEM, V16, P2169, DOI 10.1002/pol.1978.170160907; MOORE JS, 1994, MACROMOL SYMP, V77, P295, DOI 10.1002/masy.19940770131; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; NEWKOME GR, 1993, J ORG CHEM, V58, P3123, DOI 10.1021/jo00063a036; NEWKOME GR, 1991, ANGEW CHEM INT EDIT, V30, P1176, DOI 10.1002/anie.199111761; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; Percec V, 1996, J AM CHEM SOC, V118, P9855, DOI 10.1021/ja9615738; Percec V., 1993, J CHEM SOC PERK T, V1, P411; Smart B. E., 1994, ORGANOFLUORINE CHEM, P57, DOI DOI 10.1007/978-1-4899-1202-2_3; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; STUPP SI, 1995, J AM CHEM SOC, V117, P5212, DOI 10.1021/ja00124a005; Tew GN, 1998, J AM CHEM SOC, V120, P5601, DOI 10.1021/ja9727732; TOMALIA DA, 1993, TOP CURR CHEM, V165, P193; VANHEST JCM, 1995, SCIENCE, V268, P1592, DOI 10.1126/science.268.5217.1592; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095; ZUBAREV ER, UNPUB	30	166	178	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					523	526		10.1126/science.283.5401.523	http://dx.doi.org/10.1126/science.283.5401.523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915696				2022-12-28	WOS:000078203300032
J	Fuchs, CS; Giovannucci, EL; Colditz, GA; Hunter, DJ; Stampfer, MJ; Rosner, B; Speizer, FE; Willett, WC				Fuchs, CS; Giovannucci, EL; Colditz, GA; Hunter, DJ; Stampfer, MJ; Rosner, B; Speizer, FE; Willett, WC			Dietary fiber and the risk of colorectal cancer and adenoma in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-ADMINISTERED QUESTIONNAIRE; COLON-CANCER; ALCOHOL-CONSUMPTION; NUTRITIONAL FACTORS; RANDOMIZED TRIAL; MEN; FAT; RECTUM; HYPERTENSION; EPIDEMIOLOGY	Background A high intake of dietary fiber has been thought to reduce the risk of colorectal cancer and adenoma. Methods We conducted a prospective study of 88,757 women, who were 34 to 59 years old and had no history of cancer, inflammatory bowel disease, or familial polyposis, who completed a dietary questionnaire in 1980. During a 16-year follow-up period, 787 cases of colorectal cancer were documented. In addition, 1012 patients with adenomas of the distal colon and rectum were found among 27,530 participants who underwent endoscopy during the followup period. Results After adjustment for age, established risk factors, and total energy intake, we found no association between the intake of dietary fiber and the risk of colorectal cancer; the relative risk for the highest as compared with the lowest quintile group with respect to fiber intake was 0.95 (95 percent confidence interval, 0.73 to 1.25). No protective effect of dietary fiber was observed when we omitted adjustment for total energy intake, when events during the first six years of follow-up were excluded, or when we excluded women who altered their fiber intake during the follow-up period. No significant association between fiber intake and the risk of colorectal adenoma was found. Conclusions Our data do not support the existence of an important protective effect of dietary fiber against colorectal cancer or adenoma. (N Engl J Med 1999;340:169-76.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Fuchs, CS (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356, CA 66385] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, K07CA066385, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDOORI WH, 1994, AM J CLIN NUTR, V60, P757, DOI 10.1093/ajcn/60.5.757; Ascherio A, 1996, HYPERTENSION, V27, P1065, DOI 10.1161/01.HYP.27.5.1065; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; *DEP AGR, 1963, AGR HDB, V8; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P385; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; GOLDBOHM RA, 1994, CANCER CAUSE CONTROL, V5, P95, DOI 10.1007/BF01830255; HEILBRUN LK, 1989, INT J CANCER, V44, P1, DOI 10.1002/ijc.2910440102; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P345, DOI 10.1097/00008469-199510000-00003; LANZA E, 1987, AM J CLIN NUTR, V46, P790, DOI 10.1093/ajcn/46.5.790; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; *NAT I HLTH, 1984, NIH PUBL; Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Southgate D A, 1976, J Hum Nutr, V30, P303; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	37	454	469	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					169	176		10.1056/NEJM199901213400301	http://dx.doi.org/10.1056/NEJM199901213400301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895396	Bronze			2022-12-28	WOS:000078202900001
J	Baron, JA; Beach, M; Mandel, JS; van Stolk, RU; Haile, RW; Sandler, RS; Rothstein, R; Summers, RW; Snover, DC; Beck, GJ; Bond, JH; Greenberg, ER				Baron, JA; Beach, M; Mandel, JS; van Stolk, RU; Haile, RW; Sandler, RS; Rothstein, R; Summers, RW; Snover, DC; Beck, GJ; Bond, JH; Greenberg, ER		Calcium Polyp Prevention Study Grp	Calcium supplements for the prevention of colorectal adenomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPITHELIAL-CELL PROLIFERATION; RECTAL MUCOSAL PROLIFERATION; VITAMIN-D; DIETARY CALCIUM; COLON-CANCER; SPORADIC ADENOMA; DAIRY-PRODUCTS; RISK-FACTORS; BILE-ACIDS; CARCINOGENESIS	Background and Methods Laboratory, clinical, and epidemiologic evidence suggests that calcium may help prevent colorectal adenomas. We conducted a randomized, double-blind trial of the effect of supplementation with calcium carbonate on the recurrence of colorectal adenomas. We randomly assigned 930 subjects (mean age, 61 years; 72 percent men) with a recent history of colorectal adenomas to receive either calcium carbonate (3 g [1200 mg of elemental calcium] dairy) or placebo, with follow-up colonoscopies one and four years after the qualifying examination. The primary end point was the proportion of subjects in whom at least one adenoma was detected after the first follow-up endoscopy but up to (and including) the second follow-up examination. Risk ratios for the recurrence of adenomas were adjusted for age, sex, lifetime number of adenomas before the study, clinical center, and length of the surveillance period. Results The subjects in the calcium group had a lower risk of recurrent adenomas. Among the 913 subjects who underwent at least one study colonoscopy, the adjusted risk ratio for any recurrence of adenoma with calcium as compared with placebo was 0.85 (95 percent confidence interval, 0.74 to 0.98; P=0.03). The main analysis was based on the 832 subjects (409 in the calcium group and 423 in the placebo group) who completed both follow-up examinations. At least one adenoma was diagnosed between the first and second follow-up endoscopies in 127 subjects in the calcium group (31 percent) and 159 subjects in the placebo group (38 percent); the adjusted risk ratio was 0.81 (95 percent confidence interval, 0.67 to 0.99; P=0.04). The adjusted ratio of the average number of adenomas in the calcium group to that in the placebo group was 0.76 (95 percent confidence interval, 0.60 to 0.96; P=0.02). The effect of calcium was independent of initial dietary fat and calcium intake. Conclusions Calcium supplementation is associated with a significant - though moderate - reduction in the risk of recurrent colorectal adenomas. (N Engl J Med 1999;340:101-7) (C) 1999, Massachusetts Medical Society.	Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Community & Family Med, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Anesthesia, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Vet Affairs Med Ctr, White River Junction, VT USA; Univ Minnesota, Sch Publ Hlth, Dept Environm & Occupat Hlth, Minneapolis, MN USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Pathol, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Minneapolis, MN USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gastroenterol, Ctr Colon Polyps & Colon Canc, Cleveland, OH 44195 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ Iowa, Coll Med, James A Clifton Ctr Digest Dis, Dept Internal Med, Iowa City, IA USA; Fairview Southdale Hosp, Dept Pathol, Minneapolis, MN USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of Iowa	Baron, JA (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, 7927 Rubin Bldg,1 Med Ctr Dr, Lebanon, NH 03756 USA.				NATIONAL CANCER INSTITUTE [U01CA037287, P30CA023108] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108, CA37287] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts DS, 1996, JNCI-J NATL CANCER I, V88, P81, DOI 10.1093/jnci/88.2.81; ALDER RJ, 1993, AM J EPIDEMIOL, V138, P804, DOI 10.1093/oxfordjournals.aje.a116784; ARMITAGE NC, 1995, BRIT J CANCER, V71, P186, DOI 10.1038/bjc.1995.38; BARON JA, 1995, JNCI-J NATL CANCER I, V87, P1303, DOI 10.1093/jnci/87.17.1303; Bautista D, 1997, CANCER EPIDEM BIOMAR, V6, P57; BergsmaKadijk JA, 1996, EPIDEMIOLOGY, V7, P590, DOI 10.1097/00001648-199611000-00005; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BOSTICK RM, 1993, AM J EPIDEMIOL, V137, P1302, DOI 10.1093/oxfordjournals.aje.a116640; BOSTICK RM, 1995, JNCI-J NATL CANCER I, V87, P1307, DOI 10.1093/jnci/87.17.1307; Boutron MC, 1996, BRIT J CANCER, V74, P145, DOI 10.1038/bjc.1996.330; CATS A, 1995, JNCI-J NATL CANCER I, V87, P598, DOI 10.1093/jnci/87.8.598; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; GREGOIRE RC, 1989, GUT, V30, P376, DOI 10.1136/gut.30.3.376; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; KAMPMAN E, 1994, CANCER RES, V54, P3186; KAMPMAN E, 1994, AM J EPIDEMIOL, V139, P16, DOI 10.1093/oxfordjournals.aje.a116931; Kearney J, 1996, AM J EPIDEMIOL, V143, P907, DOI 10.1093/oxfordjournals.aje.a008834; LAPRE JA, 1993, CANCER RES, V53, P248; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; LLOR X, 1991, CANCER RES, V51, P4305; Lupton JR, 1996, J NUTR, V126, P1421, DOI 10.1093/jn/126.5.1421; Martinez ME, 1996, JNCI-J NATL CANCER I, V88, P1375, DOI 10.1093/jnci/88.19.1375; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MCSHERRY CK, 1989, CANCER RES, V49, P6039; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; Neugut AI, 1996, CANCER-AM CANCER SOC, V78, P723, DOI 10.1002/(SICI)1097-0142(19960815)78:4<723::AID-CNCR5>3.0.CO;2-F; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; PEIPINS LA, 1994, EPIDEMIOL REV, V16, P273, DOI 10.1093/oxfordjournals.epirev.a036154; PENCE BC, 1988, CARCINOGENESIS, V9, P187, DOI 10.1093/carcin/9.1.187; PENCE BC, 1993, MUTAT RES, V290, P87, DOI 10.1016/0027-5107(93)90036-F; Pritchard RS, 1996, CANCER EPIDEM BIOMAR, V5, P897; Sandler RS, 1996, GASTROENTEROL CLIN N, V25, P717, DOI 10.1016/S0889-8553(05)70271-5; SITRIN MD, 1991, CANCER RES, V51, P5608; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P504, DOI 10.1093/oxfordjournals.aje.a114998; Snedecor GW, 1980, STAT METHODS, V7th; STERN HS, 1990, SURGERY, V108, P528; Tseng M, 1996, AM J EPIDEMIOL, V144, P1005, DOI 10.1093/oxfordjournals.aje.a008871; VanderMeer R, 1997, CANCER LETT, V114, P75, DOI 10.1016/S0304-3835(97)04629-6; WARGOVICH MJ, 1992, GASTROENTEROLOGY, V103, P92, DOI 10.1016/0016-5085(92)91100-I; WHITTEMORE AS, 1990, JNCI-J NATL CANCER I, V82, P915, DOI 10.1093/jnci/82.11.915; Willett W., 1990, NUTR EPIDEMIOLOGY	45	610	637	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					101	107		10.1056/NEJM199901143400204	http://dx.doi.org/10.1056/NEJM199901143400204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887161	Green Published, Bronze			2022-12-28	WOS:000078016200004
J	Farmer, D; Armi, L				Farmer, D; Armi, L			The generation and trapping of solitary waves over topography	SCIENCE			English	Article							LINEAR INTERNAL WAVES; 2-LAYER FLOW; SEA	Observations of tidal flow over a sill show that upstream solitary wave generation occurred in conjunction with the downstream movement of a streamline bifurcation over the obstacle crest. Solitary waves appeared upstream of the bifurcation, riding on the surface stratification. Shear flow instabilities on the plunging interface were also evident and may contribute to wave generation through subharmonic interaction. Nonlinear waves generated downstream of an internal control became trapped in the supercritical flow.	Fisheries Oceans Canada Inst Ocean Sci, Sidney, BC V8L 4B2, Canada; Scripps Inst Oceanog, La Jolla, CA 92093 USA	Fisheries & Oceans Canada; University of California System; University of California San Diego; Scripps Institution of Oceanography	Farmer, D (corresponding author), Fisheries Oceans Canada Inst Ocean Sci, POB 6000, Sidney, BC V8L 4B2, Canada.	farmerd@dfo-mpo.gc.ca.edu; larmi@ucsd.edu						APEL JR, 1985, J PHYS OCEANOGR, V15, P1625, DOI 10.1175/1520-0485(1985)015<1625:TSSISE>2.0.CO;2; ARMI L, 1986, J FLUID MECH, V163, P27, DOI 10.1017/S0022112086002197; BAINES PG, 1984, J FLUID MECH, V146, P127, DOI 10.1017/S0022112084001798; FARMER DM, 1978, J PHYS OCEANOGR, V8, P63, DOI 10.1175/1520-0485(1978)008<0063:OOLNIW>2.0.CO;2; FARMER DM, IN PRESS P R SOC L A; GRIMSHAW RHJ, 1986, J FLUID MECH, V169, P429, DOI 10.1017/S002211208600071X; Grue J, 1997, J FLUID MECH, V351, P223, DOI 10.1017/S0022112097007428; LEE CY, 1974, J GEOPHYS RES, V79, P453, DOI 10.1029/JC079i003p00453; Liu AK, 1998, J GEOPHYS RES-OCEANS, V103, P7995, DOI 10.1029/97JC01918; LIU PLF, 1990, SEA OCEAN ENG SCI, V9, P27; MAXWORTHY T, 1980, J FLUID MECH, V96, P47, DOI 10.1017/S0022112080002017; MAXWORTHY T, 1979, J GEOPHYS RES-OCEANS, V84, P338, DOI 10.1029/JC084iC01p00338; MELVILLE WK, 1987, J FLUID MECH, V178, P31, DOI 10.1017/S0022112087001101; OSBORNE AR, 1980, SCIENCE, V208, P451, DOI 10.1126/science.208.4443.451; SMITH RK, 1982, Q J ROY METEOR SOC, V108, P937, DOI 10.1002/qj.49710845813; THORPE SA, 1978, J FLUID MECH, V85, P7, DOI 10.1017/S0022112078000518; WINANT CD, 1974, J FLUID MECH, V63, P237, DOI 10.1017/S0022112074001121	17	156	160	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					188	190		10.1126/science.283.5399.188	http://dx.doi.org/10.1126/science.283.5399.188			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880244				2022-12-28	WOS:000077976700029
J	Nightingale, SL				Nightingale, SL			Categories of research eligible for expedited review by IRBs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					27	27		10.1001/jama.281.1.27	http://dx.doi.org/10.1001/jama.281.1.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892435				2022-12-28	WOS:000077829300009
J	Lin, JL; Ho, HH; Yu, CC				Lin, JL; Ho, HH; Yu, CC			Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM CREATININE; EXPOSURE; NEPHROPATHY; DISEASE; IMPAIRMENT; EXCRETION; DIET; PLAY	Background: Nephropathy is known to occur in persons exposed to high levels of lead, but the question of whether long-term exposure to low levels of environmental lead is associated with impaired renal function remains controversial. Objective: To examine whether chelation therapy stows the progression of renal insufficiency in patients with mildly elevated body lead burden. Design: Randomized, controlled trial. Setting: Academic medical center in Taiwan. Patients: 32 patients with chronic renal insufficiency (serum creatinine level > 132.6 mu mol/L [1.5 mg/dL] and < 353.8 mu mol/L [4.0 mg/dL]), mildly elevated body lead burden (>0.72 mu mol [150 mu g] of lead per 72-hour urine collection and < 2.90 mu mol [600 mu g] of lead per 72-hour urine collection [EDTA mobilization tests]), and no history of heavy lead exposure. Intervention: The treatment group received 2 months of chelation therapy; the control group received no therapy. Measurements: The reciprocal of serum creatinine (1/Cr) was used as an index of progressive renal insufficiency. Results: Rates of progression of renal insufficiency were similar in the treatment group and the control group during a 12-month baseline observation period (1/Cr, 0.000054 L/mu mol per month compared with 0.000046 L/mu mol per month; P > 0.2). After the 2-month treatment period, improvement in renal function was greater in the treatment group than in the control group. In the 12 months after the treatment period, renal insufficiency progressed more slowly in the treatment group than in the control group (1/Cr, 0.000033 +/- 0.00038 L/mu mol per month compared with 0.000045 +/- 0.000038 L/mu mol per month; P = 0.0030). Conclusion: Chelation therapy seems to slow the progression of renal insufficiency in patients with mildly elevated body lead burden. This implies that long-term exposure to low levels of environmental lead may be associated with impaired renal function in patients with chronic renal disease.	Chang Gung Mem Hosp, Div Nephrol, Taipei, Taiwan; Chang Gung Mem Hosp, Poison Ctr, Taipei, Taiwan; Chang Gung Mem Hosp, Div Rheumatol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Lin, JL (corresponding author), Chang Gung Mem Hosp, Div Nephrol, 199 Tung Hwa N Rd, Taipei, Taiwan.							ALVESTRAND A, 1983, CLIN NEPHROL, V19, P67; BATUMAN V, 1981, NEW ENGL J MED, V304, P520, DOI 10.1056/NEJM198102263040905; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; HENDERSON DA, 1958, MED J AUSTRALIA, V1, P377; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; KHALILMANESH F, 1992, ENVIRON RES, V58, P35, DOI 10.1016/S0013-9351(05)80203-8; Kim R, 1996, JAMA-J AM MED ASSOC, V275, P1177, DOI 10.1001/jama.275.15.1177; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; LIM VS, 1990, KIDNEY INT, V37, P131, DOI 10.1038/ki.1990.18; LIN JL, 1993, AM J NEPHROL, V13, P442, DOI 10.1159/000168661; LIN JL, 1992, AM J NEPHROL, V12, P457, DOI 10.1159/000168498; LIN JL, 1994, J HUM HYPERTENS, V8, P495; LIN JL, 1994, J RHEUMATOL, V21, P705; LIN JL, 1992, MINER ELECTROL METAB, V18, P1; MITCH WE, 1976, LANCET, V2, P1326; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; POLLOCK CA, 1988, INT J ARTIF ORGANS, V11, P75, DOI 10.1177/039139888801100204; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; WEDEEN RP, 1979, ARCH INTERN MED, V139, P53, DOI 10.1001/archinte.139.1.53; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7	24	49	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					7	13		10.7326/0003-4819-130-1-199901050-00003	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890856				2022-12-28	WOS:000077744500002
J	Johnson, RT; Gibes, CJ				Johnson, RT; Gibes, CJ			Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FATAL FAMILIAL INSOMNIA; PRION DISEASES; PERSON TRANSMISSION; CEREBROSPINAL-FLUID; MINK ENCEPHALOPATHY; HUMAN-BLOOD; VARIANT; SCRAPIE; PROTEIN; MICE		Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Natl Neurosci Inst Singapore, Singapore, Singapore; NIH, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Neuroscience Institute (NNI); National Institutes of Health (NIH) - USA	Johnson, RT (corresponding author), Johns Hopkins Hosp, Meyer 6-181, Baltimore, MD 21287 USA.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Anderson RM, 1997, NATURE, V386, P302, DOI 10.1038/386302b0; Antoine JC, 1997, NEUROLOGY, V48, P1451, DOI 10.1212/WNL.48.5.1451; BERNOULLI C, 1977, LANCET, V1, P478; BERNOULLI CC, 1979, SLOW TRANSMISSIBLE D, V1, P229; Bons N, 1996, LANCET, V348, P55, DOI 10.1016/S0140-6736(96)24027-9; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; Brown P, 1998, NEUROLOGY, V50, P684, DOI 10.1212/WNL.50.3.684; BROWN P, 1996, PRION DIS, P139; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUDKA H, 1995, BRAIN PATHOL, V5, P319, DOI 10.1111/j.1750-3639.1995.tb00609.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; CHIOFALO N, 1980, ARCH NEUROL-CHICAGO, V37, P143, DOI 10.1001/archneur.1980.00500520041005; Collee JG, 1997, LANCET, V349, P636, DOI 10.1016/S0140-6736(96)01310-4; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; CREANGE A, 1995, ANN NEUROL, V38, P269, DOI 10.1002/ana.410380223; CUILLE J., 1936, Compte Rendu de l'Academie des Sciences, V203, P1552; Defebvre L, 1997, NEUROLOGY, V48, P1470, DOI 10.1212/WNL.48.5.1470; DUFFY P, 1974, NEW ENGL J MED, V290, P692; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GIBBS CJ, 1980, J INFECT DIS, V142, P205, DOI 10.1093/infdis/142.2.205; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GIBBS CJ, 1996, BOVINE SPONGIFORM EN; GIBBS CJ, 1978, SENILE DEMENTIA BIOM, V3, P115; GOLDFARB LG, 1991, EUR J EPIDEMIOL, V7, P477, DOI 10.1007/BF00143125; GRAY JR, 1996, PRION DIS, P199; HADLOW WJ, 1959, LANCET, V2, P289; Hadlow WJ, 1979, SLOW TRANSMISSIBLE D, V2, P3; HAINFELLNER JA, 1996, LANCET, V348, P616; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; Haywood AM, 1997, NEW ENGL J MED, V337, P1821, DOI 10.1056/NEJM199712183372508; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Holman RC, 1996, EMERG INFECT DIS, V2, P333, DOI 10.3201/eid0204.960409; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Hourrigan JL, 1996, BOVINE SPONGIFORM EN, P59; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; KIMBERLIN RH, 1980, J GEN VIROL, V51, P183, DOI 10.1099/0022-1317-51-1-183; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KLEIN R, 1993, LANCET, V341, P768, DOI 10.1016/0140-6736(93)90549-V; KURODA Y, 1983, INFECT IMMUN, V41, P154, DOI 10.1128/IAI.41.1.154-161.1983; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MANUELIDIS EE, 1985, LANCET, V2, P896; MARSH RF, 1991, J GEN VIROL, V72, P589, DOI 10.1099/0022-1317-72-3-589; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; Masters CL., 1982, RECENT ADV NEUROPATH, Vvol 2, P139; McKenzie D, 1996, SEMIN VIROL, V7, P201, DOI 10.1006/smvy.1996.0025; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NEVIN S, 1960, BRAIN, V83, P519, DOI 10.1093/brain/83.4.519; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1991, NATURE, V352, P547, DOI 10.1038/352547a0; PATTERSON WJ, 1995, J PUBLIC HEALTH MED, V17, P261; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Prusiner SB, 1996, CURR TOP MICROBIOL, V207, P1; Ricketts MN, 1997, EMERG INFECT DIS, V3, P155, DOI 10.3201/eid0302.970208; Ridley RM, 1996, J GEN VIROL, V77, P2895, DOI 10.1099/0022-1317-77-12-2895; SARRADET M, 1883, REV VET, V3, P310; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; TATEISHI J, 1985, LANCET, V2, P1074; Verdrager J, 1998, LANCET, V351, P112, DOI 10.1016/S0140-6736(05)78148-4; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; Wientjens DPWM, 1996, NEUROLOGY, V46, P1287, DOI 10.1212/WNL.46.5.1287; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; Zerr I, 1998, ANN NEUROL, V43, P32, DOI 10.1002/ana.410430109	82	230	239	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1994	2004		10.1056/NEJM199812313392707	http://dx.doi.org/10.1056/NEJM199812313392707			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869672				2022-12-28	WOS:000077803800007
J	Iezzoni, LI; Ayanian, JZ; Bates, DW; Burstin, HR				Iezzoni, LI; Ayanian, JZ; Bates, DW; Burstin, HR			Paying more fairly for Medicare capitated care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROSPECTIVE-PAYMENT SYSTEM; RISK ADJUSTMENT; ACCURACY; PLANS; HMO		Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Iezzoni, LI (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, East Campus,LY-326,330 Brookline Ave, Boston, MA 02215 USA.							Ash A, 1989, Health Care Financ Rev, V10, P17; ASH A, 1990, 18C98526103 HLTH POL; Bertko J, 1998, INQUIRY-J HEALTH CAR, V35, P148; CARTER GM, 1991, R3826 HCFA RAND CORP; *CTR EV CLIN STUD, 1996, DARTM ATL HLTH CAR; *DEP HHS, 1998, FED REGISTER, V63, P45706; *DEP HHS, 1998, FED REGISTER, V63, P35004; DONALDSON MS, 1994, HLTH DATA INFORMATIO; Dunn DL, 1998, INQUIRY-J HEALTH CAR, V35, P132; Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101; Ellis RP, 1996, DIAGNOSTIC COST GROU; Fowles J B, 1995, Health Care Financ Rev, V16, P189; Greenwald LM, 1998, INQUIRY-J HEALTH CAR, V35, P193; Hellinger FJ, 1998, ARCH INTERN MED, V158, P833, DOI 10.1001/archinte.158.8.833; Holtzman J, 1998, J AM GERIATR SOC, V46, P629; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; JOHNSSON J, 1996, AM MED NEWS     0624, P28; Knutson DL, 1998, INQUIRY-J HEALTH CAR, V35, P171; *MED PAY ADV COMM, 1998, REP C MED PAYM POL, V1; *MED PAYM ADV COMM, 1998, HLTH CAR SPEND MED P, P35; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; Neuman P, 1998, HEALTH AFFAIR, V17, P132, DOI 10.1377/hlthaff.17.4.132; Newhouse JP, 1998, INQUIRY-J HEALTH CAR, V35, P122; Newhouse JP, 1996, J ECON LIT, V34, P1236; Newhouse JP, 1997, HEALTH AFFAIR, V16, P26, DOI 10.1377/hlthaff.16.5.26; Pear Robert, 1998, N Y Times Web, pA17; Riley G, 1996, HEALTH CARE FINANC R, V17, P65; Rogal DL, 1998, INQUIRY-J HEALTH CAR, V35, P115; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; Sing M, 1998, INQUIRY-J HEALTH CAR, V35, P210; Tollen L, 1998, INQUIRY-J HEALTH CAR, V35, P154; Wilson VM, 1998, INQUIRY-J HEALTH CAR, V35, P178; 1995, AM MED NEWS     0725, P26	35	62	62	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1933	1938		10.1056/NEJM199812243392613	http://dx.doi.org/10.1056/NEJM199812243392613			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	150ZN	9862953				2022-12-28	WOS:000077696600013
J	Marszalek, PE; Oberhauser, AF; Pang, YP; Fernandez, JM				Marszalek, PE; Oberhauser, AF; Pang, YP; Fernandez, JM			Polysaccharide elasticity governed by chair-boat transitions of the glucopyranose ring	NATURE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; ALPHA-D-GLUCOSE; FORCE MICROSCOPY; ADHESION; WALLS	Many common, biologically important polysaccharides contain pyranose rings made of five carbon atoms and one oxygen atom. They occur in a variety of cellular structures, where they are often subjected to considerable tensile stress(1-6). The polysaccharides are thought to respond to this stress by elastic deformation, but the underlying molecular rearrangements allowing such a response remain poorly understood. It is typically assumed, however, that the pyranose ring structure is inelastic and locked into a chair-like conformation. Here we describe single-molecule force measurements(7-12) on individual polysaccharides that identify the pyranose rings as the structural unit controlling the molecule's elasticity. In particular, we find that the enthalpic component of the polymer elasticity(10,11,13,14) Of amylose, dextran and pullulan is eliminated once their pyranose rings are cleaved. We interpret these observations as indicating that the elasticity of the three polysaccharides results from a force-induced elongation of the ring structure and a final transition from a chair-like to a boat-like conformation. We expect that the force-induced deformation of pyranose rings reported here plays an important role in accommodating mechanical stresses and modulating ligand binding in biological systems.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, 200 1st St SW, Rochester, MN 55905 USA.	fernandez.julio@mayo.edu		Pang, Yuan-Ping/0000-0003-0838-2560				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BARTON DHR, 1970, SCIENCE, V169, P539, DOI 10.1126/science.169.3945.539; BOBBITT JM, 1956, ADV CARBOHYD CHEM, V11, P1; BRADY JW, 1986, J AM CHEM SOC, V108, P8153, DOI 10.1021/ja00286a006; BRADY JW, 1987, CARBOHYD RES, V165, P306, DOI 10.1016/0008-6215(87)80107-6; BROWN GM, 1979, ACTA CRYSTALLOGR B, V35, P656, DOI 10.1107/S0567740879004374; BROWN GM, 1965, SCIENCE, V147, P1038, DOI 10.1126/science.147.3661.1038-a; Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; Cosgrove DJ, 1997, PLANT CELL, V9, P1031, DOI 10.1105/tpc.9.7.1031; Drickamer K, 1997, STRUCTURE, V5, P465, DOI 10.1016/S0969-2126(97)00202-5; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; *GAUSS INC, 1994, GAUSS 94; JOSHI NV, 1979, BIOPOLYMERS, V18, P2993, DOI 10.1002/bip.1979.360181207; Kellis G.M., 1974, TOP STEREOCHEM, V8, P225; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Li HB, 1998, ADV MATER, V10, P316; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; *MOL SIM, 1997, QUANT 97 CHARMM; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SMITH NM, 1992, CHILD NERV SYST, V8, P258, DOI 10.1007/BF00300792; SMITH SM, 1995, ENG APPL ARTIF INTEL, V8, P271, DOI 10.1016/0952-1976(95)00013-Q; THWAITES JJ, 1985, P NATL ACAD SCI USA, V82, P2163, DOI 10.1073/pnas.82.7.2163	30	379	393	5	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					661	664		10.1038/25322	http://dx.doi.org/10.1038/25322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872313				2022-12-28	WOS:000077694200049
J	Baeuerle, PA				Baeuerle, PA			I kappa B-NF-kappa B structures: At the interface of inflammation control	CELL			English	Review							TRANSCRIPTION FACTOR; PROTEINS; NUCLEUS; ALPHA; DNA		Micromet GmbH, D-82152 Planegg Martinsried, Germany	Amgen; Amgen Research Munich GmbH	Baeuerle, PA (corresponding author), Micromet GmbH, Am Klopferspitz 19, D-82152 Planegg Martinsried, Germany.							ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BAUMGARTNER R, 1998, CURR BIOL, V6, P1279; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; THOMPSON JE, 1995, CELL, V80, P572; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	17	398	424	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					729	731		10.1016/S0092-8674(00)81694-3	http://dx.doi.org/10.1016/S0092-8674(00)81694-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865689	Bronze			2022-12-28	WOS:000077498800001
J	Looker, AC; Johnson, CL				Looker, AC; Johnson, CL			Prevalence of elevated serum transferrin saturation in adults in the United States	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS; COST-EFFECTIVENESS; AFRICAN-AMERICANS; DEFICIENCY; MEN; POPULATION; FERRITIN	Background: A population-based hemochromatosis screening program that uses serum transferrin saturation has been proposed, but few data exist on the number of U.S. adults that such a program would identify for further testing. Objective: To determine the prevalence of an initially elevated serum transferrin saturation and the prevalence of concurrently elevated serum transferrin saturation and serum ferritin levels in the adult population of the United States. Design: Nationally representative cross-sectional survey of the noninstitutionalized U.S. civilian population. Participants: 15 839 men and nonpregnant women 20 years of age and older who were examined in the third National Health and Nutrition Examination Survey (1988-1994). Measurements: Single measurements of serum transferrin saturations and serum ferritin levels. Cut-off values used to define elevated serum transferrin saturation ranged from greater than 45% to greater than 62%. Results: The prevalence of initially elevated serum transferrin saturation ranged from 1% to 6%. Approximately 11% to 22% of those with elevated serum transferrin saturation had concurrently elevated serum ferritin levels. The prevalence of elevated serum transferrin saturation was lower in women than in men when the same cut-off value was used to define elevated serum transferrin saturation. The prevalence of elevated serum transferrin saturation in non-Hispanic black persons and Mexican-Americans was similar to or slightly less than that in non-Hispanic white persons. The prevalence of elevated serum transferrin saturation in persons 20 to 49 years of age was as high as or higher than that in older adults. Conclusions: A hemochromatosis screening program that uses a cut-off value of greater than 60% to define elevated serum transferrin saturation would identify an estimated 1.4 to 2.5 million U.S. adults for further testing.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Looker, AC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd, Hyattsville, MD 20782 USA.							BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Bradley L A, 1996, J Med Screen, V3, P178; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; CROSBY WH, 1984, JAMA-J AM MED ASSOC, V251, P1986, DOI 10.1001/jama.251.15.1986; CUSTER EM, 1995, J LAB CLIN MED, V126, P88; EDWARDS CQ, 1989, J INTERN MED, V226, P373, DOI 10.1111/j.1365-2796.1989.tb01411.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; EZZATI T, 1992, 1992 P AM STAT ASS S, P339; EZZATI T, 1992, VITAL HLTH STAT, V2; GUNTER EW, 1994, LAB METHODS USED 3 N; HAMILTON LD, 1950, P SOC EXP BIOL MED, V75, P65; Hulthen L, 1998, EUR J CLIN NUTR, V52, P376, DOI 10.1038/sj.ejcn.1600573; JONSSON JJ, 1991, J CLIN EPIDEMIOL, V44, P1289, DOI 10.1016/0895-4356(91)90090-V; KARLSSON M, 1988, ACTA MED SCAND, V224, P385; LammiKeefe CJ, 1996, J AM DIET ASSOC, V96, P247, DOI 10.1016/S0002-8223(96)00075-2; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1985, ACTA MED SCAND, V218, P299; LOOKER AC, 1995, NUTR REV, V53, P246, DOI 10.1111/j.1753-4887.1995.tb05481.x; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; *METH SUBC HNIS NC, 1996, AN REP GUID 3 NAT HL; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; MOHADJER L, 1996, NATL HTLH NUTR EXAMI; Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; OLSSON KS, 1984, ACTA MED SCAND, V215, P105; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; SHAH BV, 1991, SUDAAN USERS MANUAL; STATLAND BE, 1976, CLIN BIOCHEM, V9, P26, DOI 10.1016/S0009-9120(76)80008-2; WITTE DL, 1991, CLIN CHEM, V37, P484; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wurapa RK, 1996, AM J MED, V101, P9, DOI 10.1016/S0002-9343(96)00053-8; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; 1996, MMWR MORB MORTAL WKL, V45, P991	38	44	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					940	945		10.7326/0003-4819-129-11_Part_2-199812011-00004	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867746				2022-12-28	WOS:000077239200026
J	Phatak, PD; Sham, RL; Raubertas, RF; Dunnigan, K; O'Leary, MT; Braggins, C; Cappuccio, JD				Phatak, PD; Sham, RL; Raubertas, RF; Dunnigan, K; O'Leary, MT; Braggins, C; Cappuccio, JD			Prevalence of hereditary hemochromatosis in 16,031 primary care patients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			IRON OVERLOAD; PHENOTYPIC-EXPRESSION; COST-EFFECTIVENESS; SCREENING-TESTS; GENE; MEN; AGE	Background: Despite evidence from screening studies in northern European populations, the prevalence of hemochromatosis in primary care populations in the United States remains speculative. Objective: To establish the feasibility of screening for hemochromatosis and to estimate the prevalence of hemochromatosis in a large primary care population. Design: Cross-sectional prevalence study. Setting: 22 primary care practices in the Rochester, New York, area. Patients: 16 031 ambulatory patients without a previous diagnosis of hemochromatosis. Intervention: Serum transferrin saturation screening tests were offered to all adult patients in participating primary care practices. Measurements: Patients with a serum transferrin saturation of 45% or more on initial testing had a serum transferrin saturation test done under fasting conditions and had serum ferritin levels measured. Those who had a fasting serum transferrin saturation of 55% or more and a serum ferritin level of 200 mu g/L or more with no other apparent cause were presumed to have hemochromatosis and were offered liver biopsy to confirm the diagnosis. Results: 25 patients had biopsy-proven hemochromatosis; 22 patients met the clinical criteria for hemochromatosis but declined liver biopsy and were classified as having clinically proven hemochromatosis; and 23 patients had a serum transferrin saturation of 55% or more with no identifiable cause, indicating probable hemochromatosis. The prevalence of clinically proven and biopsy-proven hemochromatosis combined was 4.5 per 1000 (95% CI, 3.3 to 5.8 per 1000) in the total sample and 5.4 per 1000 (CI, 4.0 to 7.1 per 1000) in white persons. The prevalence was higher in men than in women (ratio, 1.8:1). Conclusions: Hemochromatosis is relatively common among white persons. Routine screening of white persons for hemochromatosis should be considered by primary care physicians.	Rochester Gen Hosp, Hematol Unit, Mary M Gooley Hemophilia Ctr Inc, Rochester, NY 14621 USA; Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA	Rochester General Hospital; University of Rochester	Phatak, PD (corresponding author), Rochester Gen Hosp, Hematol Unit, Mary M Gooley Hemophilia Ctr Inc, 1425 Portland Ave, Rochester, NY 14621 USA.				AHRQ HHS [R01 HS07616] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BORWEIN S, 1984, CAN MED ASSOC J, V131, P895; BORWEIN ST, 1983, CLIN INVEST MED, V6, P171; Bradley L A, 1996, J Med Screen, V3, P178; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Cox D. R., 1984, ANAL SURVIVAL DATA; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; HALLBERG L, 1989, J INTERN MED, V225, P249, DOI 10.1111/j.1365-2796.1989.tb00074.x; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1988, NEW ENGL J MED, V319, P1548; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; MEYER T, 1990, J INTERN MED, V227, P397, DOI 10.1111/j.1365-2796.1990.tb00178.x; OLSSON KS, 1983, ACTA MED SCAND, V213, P145; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; TANNER AR, 1985, GUT, V26, P1139; THOMAS DR, 1975, J AM STAT ASSOC, V70, P865, DOI 10.2307/2285449; 1996, MMWR MORB MORTAL WKL, V45, P991	27	90	93	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					954	961		10.7326/0003-4819-129-11_Part_2-199812011-00006	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867748				2022-12-28	WOS:000077239200028
J	Schneider, T; Stallmach, A; von Herbay, A; Marth, T; Strober, W; Zeitz, M				Schneider, T; Stallmach, A; von Herbay, A; Marth, T; Strober, W; Zeitz, M			Treatment of refractory Whipple disease with interferon-gamma	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Saarland, D-66421 Homburg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; NIAID, Mucosal Immun Sect, NIH, Bethesda, MD 20892 USA	Saarland University; Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zeitz, M (corresponding author), Univ Saarland, D-66421 Homburg, Germany.							BJERKNES R, 1988, SCAND J GASTROENTERO, V23, P611, DOI 10.3109/00365528809093921; ECTOERS N, 1992, GASTROENTEROLOGY, V106, pA676; FELDMAN M, 1980, ANN INTERN MED, V93, P709, DOI 10.7326/0003-4819-93-5-709; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; MAIZEL H, 1970, MEDICINE, V49, P175, DOI 10.1097/00005792-197005000-00001; MARTH T, 1994, CLIN IMMUNOL IMMUNOP, V72, P217, DOI 10.1006/clin.1994.1134; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; MARTIN FF, 1972, GASTROENTEROLOGY, V63, P6; PAULLEY JW, 1952, GASTROENTEROLOGY, V22, P128; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; vonHerbay A, 1997, GASTROENTEROLOGY, V113, P434, DOI 10.1053/gast.1997.v113.pm9247461; vonHerbay A, 1996, GASTROENTEROLOGY, V110, P1735, DOI 10.1053/gast.1996.v110.pm8964398	17	59	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					875	877		10.7326/0003-4819-129-11_Part_1-199812010-00006	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867729				2022-12-28	WOS:000077239200005
J	Hoang, U				Hoang, U			Researchers discover new mutant gene	BRITISH MEDICAL JOURNAL			English	News Item													Hoang, Uy/AAD-9445-2022; Hoang, Uy/G-3012-2011	Hoang, Uy/0000-0002-8428-5140; Hoang, Uy/0000-0002-8428-5140				Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					146	146		10.1136/bmj.318.7177.146	http://dx.doi.org/10.1136/bmj.318.7177.146			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888897	Green Published			2022-12-28	WOS:000078175100015
J	Suzuki, H; Terauchi, Y; Fujiwara, M; Aizawa, S; Yazaki, Y; Kadowaki, T; Koyasu, S				Suzuki, H; Terauchi, Y; Fujiwara, M; Aizawa, S; Yazaki, Y; Kadowaki, T; Koyasu, S			Xid-like immunodeficiency in mice with disruption of the p85 alpha subunit of phosphoinositide 3-kinase	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; RECEPTOR TYROSINE KINASES; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; SIGNALING SYSTEM; GENETIC-CONTROL; INSULIN; EXPRESSION	Mice with a targeted gene disruption of p85 alpha, a regulatory subunit of phosphoinositide 3-kinase, had impaired B cell development at the pro-B cell stage, reduced numbers of mature B cells and peritoneal CD5(+) Ly-1 B cells, reduced B cell proliferative responses, and no T cell-independent antibody production. These phenotypes are nearly identical to those of Btk(-/-) or rid (X-Linked immunodeficiency) mice. These results provide evidence that p85 alpha is functionally Linked to the Btk pathway in antigen receptor-mediated signal transduction and is pivotal in B cell development and functions.	Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan	Keio University; University of Tokyo; Kumamoto University	Koyasu, S (corresponding author), Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	koyasu@sun.microb.med.keio.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Suzuki, Harumi/L-1271-2013; Koyasu, Shigeo/J-5583-2015	Suzuki, Harumi/0000-0003-3616-9361; Koyasu, Shigeo/0000-0001-9585-3038				ALLMAN DM, 1992, J IMMUNOL, V149, P2533; AMSBAUGH DF, 1972, J EXP MED, V136, P931, DOI 10.1084/jem.136.4.931; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BRUTON OC, 1952, PEDIATRICS, V9, P722; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; KADOWAKI T, 1996, ENDOCR J, V43, P33; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; PONS S, 1995, MOL CELL BIOL, V15, P4453; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHER I, 1982, IMMUNOL REV, V64, P117, DOI 10.1111/j.1600-065X.1982.tb00421.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUZUKI H, UNPUB; TERAUCHI Y, IN PRESS NATURE GENE; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	37	403	407	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					390	392		10.1126/science.283.5400.390	http://dx.doi.org/10.1126/science.283.5400.390			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888854				2022-12-28	WOS:000078067000048
J	Feely, M				Feely, M			Drug treatment of epilepsy	BRITISH MEDICAL JOURNAL			English	Review							ANTIEPILEPTIC DRUGS; CARBAMAZEPINE; VALPROATE; LAMOTRIGINE; PHENYTOIN; TRIAL		Univ Leeds, Gen Infirm, Div Med, Clin Pharmacol Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Feely, M (corresponding author), Univ Leeds, Gen Infirm, Div Med, Clin Pharmacol Unit, Leeds LS1 3EX, W Yorkshire, England.	mfeely@ulth.northy.nhs.uk						*BRIT EP ASS, 1996, TREATM EP PAT VIEWP; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brodie MJ, 1997, SEIZURE-EUR J EPILEP, V6, P159, DOI 10.1016/S1059-1311(97)80001-5; BRODIE MJ, 1994, EPILEPSIA, V35, pS41, DOI 10.1111/j.1528-1157.1994.tb05966.x; BROWNE TR, 1989, BRIT J CLIN PHARMACO, V27, pS95, DOI 10.1111/j.1365-2125.1989.tb03468.x; *COMM ADV TROP MED, 1998, CAN COMMUN DIS REP, V24, P1; CRAIG I, 1994, EPILEPSIA, V35, P381, DOI 10.1111/j.1528-1157.1994.tb02448.x; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; DICHTER MA, 1994, HARRISONS PRINCIPLES, V2, P2223; Faught E, 1996, NEUROLOGY, V46, P1684, DOI 10.1212/WNL.46.6.1684; FEELY M, 1984, J NEUROL NEUROSUR PS, V47, P1279, DOI 10.1136/jnnp.47.12.1279; Marson AG, 1996, BMJ-BRIT MED J, V313, P1169, DOI 10.1136/bmj.313.7066.1169; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; OOMMEN K, 1993, NEUROLOGY, V43, P2292; RICHENS A, 1993, TXB EPILEPSY; Roberts SJ, 1998, SEIZURE-EUR J EPILEP, V7, P127; Stephen L.J., 1998, PRESCRIBERS J, V38, P98; *UK GAB STUD GROUP, 1990, LANCET, V335, P114	19	34	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					106	109		10.1136/bmj.318.7176.106	http://dx.doi.org/10.1136/bmj.318.7176.106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880286	Green Published			2022-12-28	WOS:000078087500029
J	Kvaerner, KJ; Aasland, OG; Botten, GS				Kvaerner, KJ; Aasland, OG; Botten, GS			Female medical leadership: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; GENDER	Objective To assess the relation between male and female medical leadership. Design Cross sectional study on predictive factors for female medical leadership with data on sex, age, specialty, and occupational status of Norwegian physicians. Setting Oslo, Norway. Subjects 13 844 non-retired Norwegian physicians. Main outcome measure Medical leaders, defined as physicians holding a leading position in hospital medicine, public health, academic medicine, or private health care. Results 14.6% (95% confidence interval 14.0% to 15.4%) of the men were leaders compared with 5.1% (4.4% to 5.9%) of the women. Adjusted for age men had a higher estimated probability of leadership in all categories of age and job, the highest being in academic medicine with 0.57 (0.42 to 0.72) for men aged ol el 54 years compared with 0.39 (0.21 to 0.63) for women in the same category Among female hospital physicians there was a positive relation between the proportion of women in their specialty and the probability of leadership. Conclusion Women do not reach senior positions as easily as men. Medical specialties with high proportions of women have more female leaders.	Univ Oslo, Ulleval Hosp, Dept Otorhinolaryngol, N-0407 Oslo, Norway; Norwegian Med Assoc, Res Inst, N-0107 Oslo, Norway; Univ Oslo, Natl Hosp, Ctr Hlth Adm, N-0027 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway	Kvaerner, KJ (corresponding author), Univ Oslo, Ulleval Hosp, Dept Otorhinolaryngol, N-0407 Oslo, Norway.							Allen, 1988, DOCTORS THEIR CAREER; Allen I., 1994, DOCTORS THEIR CAREER; ALTEKRUSE JM, 1987, FEMINISM SCI HLTH PR, P65; HARRIS M, 1981, J AM MED WOMEN ASSOC, V36, P82; Hofoss Dag, 1994, Tidsskrift for den Norske Laegeforening, V114, P3059; HORNER MS, 1972, J SOC ISSUES, V28, P157, DOI 10.1111/j.1540-4560.1972.tb00023.x; Kane-Berman J, 1989, Curationis, V12, P5; Kanter R.M., 1977, MEN WOMEN CORPORATIO; Kuhn A., 1978, FEMINISM MAT; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; Leonard JC, 1996, ACAD MED, V71, P502, DOI 10.1097/00001888-199605000-00023; LEVINSON W, 1991, WESTERN J MED, V154, P423; LORBER J, 1993, GENDER WORK MED WOME, P62; Lyness KS, 1997, J APPL PSYCHOL, V82, P359, DOI 10.1037/0021-9010.82.3.359; MARTIN SC, 1988, J HEALTH SOC BEHAV, V29, P333, DOI 10.2307/2136867; RISKA E, 1993, GENDER WORK MED WOME, P77; *STAT SENTR, 1998, SOS UTS 1998 STAT AN; TERBORG JR, 1977, ACAD MANAGE J, V20, P89, DOI 10.2307/255464; Wiers-Jenssen J, 1997, Tidsskr Nor Laegeforen, V117, P2807	19	62	64	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					91	94						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157XT	9880281				2022-12-28	WOS:000078087500024
J	Galtier, N; Tourasse, N; Gouy, M				Galtier, N; Tourasse, N; Gouy, M			A nonhyperthermophilic common ancestor to extant life forms	SCIENCE			English	Article							DNA-SEQUENCES; G+C-CONTENT; ORGANISMS; ORIGIN; PROKARYOTES; CENANCESTER; EUKARYOTES; TRANSITION; RATES; SITES	The G + C nucleotide content of ribosomal RNA (rRNA) sequences is strongly correlated with the optimal growth temperature of prokaryotes. This property allows inference of the environmental temperature of the common ancestor to all life forms from knowledge of the C + C content of its rRNA sequences. A model of sequence evolution, assuming varying C + C content among lineages and unequal substitution rates among sites, was devised to estimate ancestral base compositions. This method was applied to rRNA sequences of various species representing the major lineages of life. The inferred C+C content of the common ancestor to extant life forms appears incompatible with survival at high temperature. This finding challenges a widely accepted hypothesis about the origin of life.	Univ Lyon 1, Lab Biometrie Genet & Biol Populat, F-69622 Villeurbanne, France; Univ Montpellier 2, Lab Genome & Populat, F-34095 Montpellier, France; Univ Texas, Ctr Human Genet, Houston, TX 77030 USA	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; University of Texas System	Galtier, N (corresponding author), Univ Lyon 1, Lab Biometrie Genet & Biol Populat, F-69622 Villeurbanne, France.							Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; DeRijk P, 1996, NUCLEIC ACIDS RES, V24, P92, DOI 10.1093/nar/24.1.92; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Forterre P, 1996, CELL, V85, P789, DOI 10.1016/S0092-8674(00)81262-3; Galtier N, 1998, MOL BIOL EVOL, V15, P871, DOI 10.1093/oxfordjournals.molbev.a025991; GALTIER N, 1995, P NATL ACAD SCI USA, V92, P11317, DOI 10.1073/pnas.92.24.11317; Galtier N, 1997, J MOL EVOL, V44, P632, DOI 10.1007/PL00006186; Gogarten JP, 1996, SCIENCE, V274, P1750; Gu X, 1997, MOL BIOL EVOL, V14, P861, DOI 10.1093/oxfordjournals.molbev.a025827; Hasegawa M, 1996, SCIENCE, V274, P1750, DOI 10.1126/science.274.5293.1750; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; RZHETSKY A, 1995, GENETICS, V141, P771; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; TAMURA K, 1992, MOL BIOL EVOL, V9, P678; Tourasse NJ, 1997, MOL BIOL EVOL, V14, P287, DOI 10.1093/oxfordjournals.molbev.a025764; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; YANG ZH, 1995, MOL BIOL EVOL, V12, P451	19	269	280	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					220	221		10.1126/science.283.5399.220	http://dx.doi.org/10.1126/science.283.5399.220			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880254				2022-12-28	WOS:000077976700039
J	Mueller, LJ; Weitekamp, DP				Mueller, LJ; Weitekamp, DP			Quantum statistical corrections to dynamic nuclear magnetic resonance	SCIENCE			English	Article							NMR-SPECTRA	A quantum statistical treatment of the chemical exchange between molecular eigenstates or conformations revealed previously unsuspected dynamic terms in the spin Hamiltonian operator that describes fast exchange. These terms resulted from the effect of nuclear spin on rotational and vibrational relaxation. With the traditional theory, an interpretation of new carbon-13 nuclear magnetic resonance measurements of the chemical shift of methylcyclohexane in solution showed fast-exchange equilibrium constants that were inconsistent with the slow-exchange free-energy difference and were spread over a range of 30 percent for the various carbon-13 positions. Modeling of the new terms indicated that they have the correct magnitude and temperature dependence to reconcile these inconsistencies.	CALTECH, Arthur Amos Noyes Lab Chem Phys, Pasadena, CA 91125 USA	California Institute of Technology	Weitekamp, DP (corresponding author), CALTECH, Arthur Amos Noyes Lab Chem Phys, 127-72, Pasadena, CA 91125 USA.	weitekamp@caltech.edu		Mueller, Leonard/0000-0002-2607-9875				Abragam A, 1961, INT SERIES MONOGRAPH; ALEXANDER S, 1962, J CHEM PHYS, V37, P967, DOI 10.1063/1.1733254; ANET FAL, 1993, CHEM PHYS LETT, V208, P187, DOI 10.1016/0009-2614(93)89059-Q; BASUS VJ, 1975, THESIS U CALIFORNIA; Bevington P. R, 1969, DATA REDUCTION ERROR; BINSCH G, 1980, ANGEW CHEM INT EDIT, V19, P411, DOI 10.1002/anie.198004113; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; Cohen-Tannoudji C., 1998, ATOM PHOTON INTERACT; DODDRELL DM, 1982, J MAGN RESON, V48, P323, DOI 10.1016/0022-2364(82)90286-4; GUTOWSKY HS, 1953, J CHEM PHYS, V21, P279, DOI 10.1063/1.1698874; HAHN EL, 1952, PHYS REV, V88, P1070, DOI 10.1103/PhysRev.88.1070; JEENER J, 1982, ADV MAGN RESON, V10, P1; JOHNSON CS, 1964, J CHEM PHYS, V41, P3277, DOI 10.1063/1.1725724; Johnston ER, 1998, J AM CHEM SOC, V120, P1489, DOI 10.1021/ja970281j; Lynden-Bell R. M., 1967, PROG NMR SPECTROSC, V2, P163; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MORRIS GA, 1988, J MAGN RESON, V80, P547, DOI 10.1016/0022-2364(88)90253-3; MUELLER LJ, UNPUB; MUELLER LJ, 1997, THESIS CALIFORNIA I; OHARA KE, 1994, J MAGN RESON SER A, V109, P74, DOI 10.1006/jmra.1994.1136; Redfield A., 1965, ADV MAGN RESON, V1, P1, DOI [10.1016/B978-1-4832-3114-3.50007-6, DOI 10.1016/B978-1-4832-3114-3.50007-6]; SQUILLACOTE ME, 1987, MAGN RESON CHEM, V25, P53, DOI 10.1002/mrc.1260250113; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; VEGA AJ, 1974, J MAGN RESON, V19, P21; Werbelow L, 1996, CONCEPT MAGNETIC RES, V8, P325, DOI 10.1002/(SICI)1099-0534(1996)8:5<325::AID-CMR2>3.0.CO;2-0; WERBELOW LG, 1979, J CHEM PHYS, V70, P5381, DOI 10.1063/1.437471; [No title captured]; [No title captured]	28	4	5	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					61	65		10.1126/science.283.5398.61	http://dx.doi.org/10.1126/science.283.5398.61			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872740				2022-12-28	WOS:000077976600048
J	Kulkarni, A; Colburn, HS				Kulkarni, A; Colburn, HS			Role of spectral detail in sound-source localization	NATURE			English	Article								Sounds heard over headphones are typically perceived inside the head(1) (internalized), unlike real sound sources which are perceived outside the head (externalized). If the acoustical waveforms from a real sound source are reproduced precisely using headphones, auditory images are appropriately externalized and localized(1-4) The filtering (relative boosting, attenuation and delaying of component frequencies) of a sound by the head and outer ear provides information about the location of a sound source by means of the differences in the frequency spectra between the ears as well as the overall spectral shape. This location-dependent filtering is explicitly described by the head-related transfer function (HRTF) from sound source to ear canal. Here we present sounds to subjects through open-canal tube-phones and investigate how accurately the HRTFs must be reproduced to achieve true three-dimensional perception of auditory signals in anechoic space. Listeners attempted to discriminate between 'real' sounds presented from a loudspeaker and 'virtual' sounds presented over tube-phones. Our results show that the HRTFs can be smoothed significantly in frequency without affecting the perceived location of a sound. Listeners cannot distinguish real from virtual sources until the HRTF has lost most of its detailed variation in frequency, at which time the perceived elevation of the image is the reported cue.	Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University	Kulkarni, A (corresponding author), Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA.	abhijit@enga.bu.edu						Hartmann WM, 1996, J ACOUST SOC AM, V99, P3678, DOI 10.1121/1.414965; KISTLER DJ, 1992, J ACOUST SOC AM, V91, P1637, DOI 10.1121/1.402444; KULKARNI A, UNPUB J ACOUST SOC A; Loomis J. M., 1996, P SOC INF DISPL 1996, P965; Oppenheim A. V., 1975, DIGITAL SIGNAL PROCE; Shaw E. A. G., 1997, BINAURAL SPATIAL HEA, P25; Wenzel Elizabeth M., 1992, PRES TELEOP VIRT ENV, V1, P80, DOI [10.1162/pres.1992.1.1.80, DOI 10.1162/PRES.1992.1.1.80]; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P858, DOI 10.1121/1.397557; ZAHORIK P, 1995, P AC SPEECH SIGN PRO	9	143	155	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					747	749		10.1038/25526	http://dx.doi.org/10.1038/25526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874370				2022-12-28	WOS:000077742800031
J	Taylor, AJ; O'Malley, PG				Taylor, AJ; O'Malley, PG			Self-referral of patients for electron-beam computed tomography to screen for coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREDICTIVE VALUE; ATHEROSCLEROSIS; CALCIFICATION; CALCIUM		Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Serv Cardiol, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Taylor, AJ (corresponding author), Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Serv Cardiol, Bldg 2,Rm 4A, Washington, DC 20307 USA.							Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; Arad Y, 1996, CIRCULATION, V93, P1951, DOI 10.1161/01.CIR.93.11.1951; Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898; Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; Detrano R, 1997, CIRCULATION, V95, P534; DETRANO RC, 1997, CIRCULATION, V96, P404; KAJINAMI K, 1995, J AM COLL CARDIOL, V26, P1209, DOI 10.1016/0735-1097(95)00314-2; OMALLEY PG, IN PRESS AM HEART J; Rumberger JA, 1998, CIRCULATION, V97, P2095, DOI 10.1161/01.CIR.97.20.2095; Rumberger JA, 1997, J AM COLL CARDIOL, V29, P1542, DOI 10.1016/S0735-1097(97)00093-4; Rumberger JA, 1996, MAYO CLIN PROC, V71, P369, DOI 10.4065/71.4.369; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; Wong ND, 1996, AM J CARDIOL, V78, P1220, DOI 10.1016/S0002-9149(96)00599-1; WONG ND, 1994, AM HEART J, V127, P422, DOI 10.1016/0002-8703(94)90133-3	14	23	23	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					2018	2020		10.1056/NEJM199812313392711	http://dx.doi.org/10.1056/NEJM199812313392711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869676				2022-12-28	WOS:000077803800011
J	Shah, S				Shah, S			Why leeches influence my physical examination	LANCET			English	Article											Shah, S (corresponding author), 420 E 70th St,6J, New York, NY 10021 USA.							EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406	1	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2014	2015		10.1016/S0140-6736(98)09291-5	http://dx.doi.org/10.1016/S0140-6736(98)09291-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872267				2022-12-28	WOS:000077663000048
J	Lengauer, C; Kinzler, KW; Vogelstein, B				Lengauer, C; Kinzler, KW; Vogelstein, B			Genetic instabilities in human cancers	NATURE			English	Review							NONPOLYPOSIS COLORECTAL-CANCER; DNA-MISMATCH REPAIR; MITOTIC CHROMOSOME TRANSMISSION; CARCINOMA CELL-LINES; WILD-TYPE P53; COLON-CANCER; MICROSATELLITE INSTABILITY; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; XERODERMA PIGMENTOSUM	Whether and how human tumours are genetically unstable has been debated for decades. There is now evidence that most cancers may indeed be genetically unstable, but that the instability exists at two distinct levels. In a small subset of tumours, the instability is observed at the nucleotide level and results in base substitutions or deletions or insertions of a few nucleotides. in most other cancers, the instability is observed at the chromosome level, resulting in losses and gains of whole chromosomes or large portions thereof. Recognition and comparison of these instabilities are leading to new insights into tumour pathogenesis.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute	Lengauer, C (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X				AALTONEN LA, 1994, CANCER RES, V54, P1645; Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AUER GU, 1994, VIRCHOWS ARCH, V424, P343; BAKER SJ, 1990, CANCER RES, V50, P7717; Bardi G, 1997, BRIT J CANCER, V76, P765, DOI 10.1038/bjc.1997.459; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bomme L, 1998, CANCER GENET CYTOGEN, V106, P66, DOI 10.1016/S0165-4608(98)00047-8; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; BRODEUR GM, 1998, GENETIC BASIS HUMAN, V1, P161; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CAIRNS J, 1981, NATURE, V289, P353, DOI 10.1038/289353a0; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAMS E, 1995, CANCER RES, V55, P1547; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; FEINBERG AP, 1982, CANCER RES, V42, P3252; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1985, GENETICS, V110, P381; HARVEY M, 1993, ONCOGENE, V8, P2457; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johansson B, 1996, GENE CHROMOSOME CANC, V16, P155, DOI 10.1002/(SICI)1098-2264(199607)16:3<155::AID-GCC1>3.0.CO;2-Y; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEBEAU MM, 1986, ADV HUM GENET, V15, P1; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MITELMAN F, 1994, CATALOG CHROMOSOME A, V2; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nowell PC, 1997, CANCER GENET CYTOGEN, V94, P13, DOI 10.1016/S0165-4608(96)00227-0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Owens AH, 1982, TUMOR CELL HETEROGEN; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Perucho M, 1996, BIOL CHEM, V377, P675; Phear G, 1996, MOL CELL BIOL, V16, P6516; RADFORD DM, 1995, CANCER RES, V55, P3399; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; SILVERSTEIN MJ, 1995, DUCTAL CARCINOMA IN; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; SPENCER F, 1990, GENETICS, V124, P237; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang SI, 1997, CANCER RES, V57, P4183; Williams C, 1998, CANCER RES, V58, P2449; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	92	3173	3284	3	264	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					643	649		10.1038/25292	http://dx.doi.org/10.1038/25292			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872311				2022-12-28	WOS:000077694200044
J	Stein, TS				Stein, TS			In between	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Dept Phys Educ & Dev, Oakland, CA 94612 USA		Stein, TS (corresponding author), Dept Phys Educ & Dev, 1800 Harrison,21st Floor, Oakland, CA 94612 USA.	Terry.Stein@ncal.kaiperm.org							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1074	1074		10.7326/0003-4819-129-12-199812150-00018	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867766				2022-12-28	WOS:000077471900014
J	Monath, TP; Cordon, LK				Monath, TP; Cordon, LK			Biological warfare - Strengthening the biological weapons convention	SCIENCE			English	Editorial Material									OraVax Inc, Cambridge, MA 02139 USA		Monath, TP (corresponding author), OraVax Inc, 230 Albany St, Cambridge, MA 02139 USA.								0	6	6	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1423	1423		10.1126/science.282.5393.1423	http://dx.doi.org/10.1126/science.282.5393.1423			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867648				2022-12-28	WOS:000077110800024
J	Froehner, SC				Froehner, SC			Neuroscience - Gathering glycine receptors at synapses	SCIENCE			English	Editorial Material							ACETYLCHOLINE-RECEPTOR; PROTEIN; PHOSPHORYLATION; GEPHYRIN; TUBULIN; PSD-95		Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Froehner, SC (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA.							Colledge M, 1998, CURR OPIN NEUROBIOL, V8, P357, DOI 10.1016/S0959-4388(98)80061-5; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; Megeath LJ, 1998, J NEUROSCI, V18, P672; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q	20	2	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1277	1279		10.1126/science.282.5392.1277	http://dx.doi.org/10.1126/science.282.5392.1277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9867632				2022-12-28	WOS:000076982200032
J	Thomas, MD; Cook, LJ				Thomas, MD; Cook, LJ			Fever associated with cyclosporin for treating atopic dermatitis	BRITISH MEDICAL JOURNAL			English	Letter									St Marys Hosp, Portsmouth PO3 6AD, Hants, England		Thomas, MD (corresponding author), St Marys Hosp, Portsmouth PO3 6AD, Hants, England.							Douglas S, 1987, ANNA J, V14, P97; FEUTREN G, 1989, CURR OPIN IMMUNOL, V2, P239, DOI 10.1016/0952-7915(89)90194-5; OTA B, 1983, TRANSPLANT P, V15, P3150	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1291	1291		10.1136/bmj.317.7168.1291b	http://dx.doi.org/10.1136/bmj.317.7168.1291b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9867383	Green Published			2022-12-28	WOS:000076963800028
J	Ryan, K				Ryan, K			A salutary lesson - Learning from our mistakes	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					177	177		10.1136/bmj.318.7177.177	http://dx.doi.org/10.1136/bmj.318.7177.177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888916	Green Published			2022-12-28	WOS:000078175100037
J	Bakin, AV; Curran, T				Bakin, AV; Curran, T			Role of DNA 5-methylcytosine transferase in cell transformation by fos	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; OSTEO-SARCOMA VIRUS; C-FOS; NIH3T3 CELLS; MORPHOLOGICAL TRANSFORMATION; SIGNALING PATHWAY; EXPRESSION; PROTEIN; METHYLATION; GENE	The Fos and Jun oncoproteins form dimeric complexes that stimulate transcription of genes containing activator protein-1 regulatory elements. We found, by representational difference analysis, that expression of DNA 5-methylcytosine transferase (dnmt1) in fos-transformed cells is three times the expression in normal fibroblasts and that fos-transformed cells contain about 20 percent more 5-methylcytosine than normal fibroblasts. Transfection of the gene encoding Dnmt1 induced morphological transformation, whereas inhibition of dnmt1 expression or activity resulted in reversion of fos transformation. Inhibition of histone deacetylase, which associates with methylated DNA, also caused reversion. These results suggest that fos may transform cells through alterations in DNA methylation and in histone deacetylation.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale, Memphis, TN 38105 USA.	fos1@aol.com	Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; Baylin SB, 1998, ADV CANCER RES, V72, P141; BRASELMANN S, 1992, J CELL SCI, P97; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; Curran T, 1988, ONCOGENE HDB, P307; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JOOSS KU, 1995, ONCOGENE, V10, P603; JOSEPH L, 1987, NUCLEIC ACIDS RES, V15, P3186, DOI 10.1093/nar/15.7.3186; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; Kho CJ, 1996, CELL GROWTH DIFFER, V7, P1157; KOISTINAHO J, 1995, MOL BRAIN RES, V29, P53, DOI 10.1016/0169-328X(94)00218-4; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MIETZ JA, 1990, P NATL ACAD SCI USA, V87, P2269, DOI 10.1073/pnas.87.6.2269; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUBERG M, 1991, ONCOGENE, V6, P1325; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; TROEN BR, 1988, J BIOL CHEM, V263, P254; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	51	206	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					387	390		10.1126/science.283.5400.387	http://dx.doi.org/10.1126/science.283.5400.387			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888853				2022-12-28	WOS:000078067000047
J	Hyett, J; Perdu, M; Sharland, G; Snijders, R; Nicolaides, KH				Hyett, J; Perdu, M; Sharland, G; Snijders, R; Nicolaides, KH			Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; CHROMOSOMAL DEFECTS; GREAT-ARTERIES; TRIMESTER; ECHOCARDIOGRAPHY; ABNORMALITIES; DIAGNOSIS; FETUSES; ULTRASONOGRAPHY; PREGNANCY	Objectives To examine the utility of measuring fetal nuchal translucency thickness in screening for major defects of the heart and great arteries at 10-14 week of gestation. Design Population based cohort study. Subjects 29 154 singleton pregnancies with chromosomally normal fetuses at 10-14 weeks of gestation. Setting Fetal medicine centre in London. Main outcome measure Prevalence of major defects of the heart and great arteries. Results Of 50 cases with major defects of the heart and great arteries (prevalence 1.7 pet 1000 pregnancies) 28 (56%, 95% confidence interval 42% to 70%) were in the subgroup of 1822 pregnancies with fetal nuchal translucency thicknesses above the 95th centile of the normal range. The positive and negative predictive values for this cut off point of nuchal translucency thickness were 1.5% and 99.9% respectively. Conclusions Measurement of fetal nuchal translucency thickness-traditionally used to identify fetuses at high risk of aneuploidy-at 10-14 weeks of gestation can identify a large proportion of fetuses with major defects of the heart and great arteries.	Univ London Kings Coll Hosp, Sch Med, Dept Obstet & Gynaecol, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England; Guys Hosp, Fetal Cardiol Unit, London SE1 9RT, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Nicolaides, KH (corresponding author), Univ London Kings Coll Hosp, Sch Med, Dept Obstet & Gynaecol, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England.			Snijders, Rosalinde/0000-0003-1809-7886; Nicolaides, Kypros/0000-0003-1266-0711				ACHIRON R, 1994, OBSTET GYNECOL, V84, P69; ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; BRONSHTEIN M, 1990, PRENATAL DIAG, V10, P697, DOI 10.1002/pd.1970101103; Carvalho JS, 1998, LANCET, V351, P1023, DOI 10.1016/S0140-6736(97)08406-7; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P618; DOLKART LA, 1991, AM J OBSTET GYNECOL, V165, P688, DOI 10.1016/0002-9378(91)90310-N; FERENCZ C, 1985, AM J EPIDEMIOL, V121, P31, DOI 10.1093/oxfordjournals.aje.a113979; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Hyett J, 1996, ULTRASOUND OBST GYN, V7, P245, DOI 10.1046/j.1469-0705.1996.07040245.x; Hyett J, 1997, AM J MED GENET, V69, P207, DOI 10.1002/(SICI)1096-8628(19970317)69:2<207::AID-AJMG18>3.0.CO;2-P; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; MeyerWittkopf M, 1996, ULTRASOUND OBST GYN, V8, P8, DOI 10.1046/j.1469-0705.1996.08010008.x; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; RUSTICO MA, 1995, ULTRASOUND OBST GYN, V6, P313, DOI 10.1046/j.1469-0705.1995.06050313.x; Sharland G, 1998, LANCET, V351, P1662, DOI 10.1016/S0140-6736(05)77722-9; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Snijders RJM, 1996, ULTRASOUND OBST GYN, V7, P216, DOI 10.1046/j.1469-0705.1996.07030216.x; TAIPALE P, 1997, NEW ENGL J MED, V337, P165; TEGNANDER E, 1995, ULTRASOUND OBST GYN, V5, P72	26	380	397	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					81	85		10.1136/bmj.318.7176.81	http://dx.doi.org/10.1136/bmj.318.7176.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880278	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078087500021
J	Petty, GW; Brown, RD; Whisnant, JP; Sicks, JD; O'Fallon, WM; Wiebers, DO				Petty, GW; Brown, RD; Whisnant, JP; Sicks, JD; O'Fallon, WM; Wiebers, DO			Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention - A population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; GASTROINTESTINAL HEMORRHAGE; CEREBRAL-ISCHEMIA; RISK-FACTORS; ANTICOAGULATION; EPIDEMIOLOGY; TRIAL; OUTPATIENTS; INFARCTION; PREDICTION	Background: Complication rates of medical therapy for secondary stroke prevention derived from clinical trials may or may not be applicable to patients with cerebrovascular disease in the general population. Objective: To determine complication rates for aspirin, warfarin, and intravenous heparin administered for secondary stroke prevention after first episodes of ischemic stroke, transient ischemic attack, or amaurosis fugax in a community. Design: Population-based historical cohort study. Setting: Rochester, Minnesota. Patients: All residents of Rochester who, between 1985 and 1989, received aspirin (n = 339) or warfarin (n = 145) within 2 years after first ischemic stroke, transient ischemic attack, or amaurosis fugax or received intravenous heparin (n = 201) within 2 weeks after first ischemic stroke, transient ischemic attack, or amaurosis fugax. Measurements: Occurrence of major complications caused by therapy. Results: Twenty aspirin-associated complications (1 fatal) occurred during an average 1.7 years of treatment, 8 warfarin-associated complications occurred during an average 0.7 years of treatment, and 3 heparin-associated complications (1 fatal) occurred during an average 5.1 days of treatment. Complication rates were 3.5 per 100 person-years (95% CI, 2.1 to 5.4) for aspirin, 7.9 per 100 person-years (CI, 3.4 to 15.6) for warfarin, and 0.30 (CI, 0.06 to 0.86) per 100 person-days for heparin. Rates of fatal complications were 0.2 per 100 person-years (CI, 0 to 1.0) for aspirin, 0 per 100 person-years (CI, 0 to 3.6) for warfarin, and 0.10 per 100 person-days (0 to 0.55) for heparin. Conclusions: Complication rates for warfarin and intravenous heparin given as therapy for secondary stroke prevention in Rochester, Minnesota, were lower than rates reported from earlier trials and observational studies. However, complication rates for warfarin were higher than in more recent referral-based studies and multicenter randomized trials. After adjustment for duration of therapy, complication rates for heparin were higher than those for aspirin or warfarin. These rates can be used to judge the applicability of complication rates derived from ongoing clinical trials.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Petty, GW (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006663] Funding Source: NIH RePORTER; NINDS NIH HHS [NS06663] Funding Source: Medline; PHS HHS [282910028] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1991, Lancet, V338, P1345; BAKER RN, 1962, NEUROLOGY, V12, P823, DOI 10.1212/WNL.12.12.823; BILLER J, 1989, STROKE, V20, P441, DOI 10.1161/01.STR.20.4.441; BRODERICK JP, 1992, STROKE, V23, P1250, DOI 10.1161/01.STR.23.9.1250; Brown RD, 1996, STROKE, V27, P373; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; ENGER E, 1965, ACTA MED SCAND, VS178, P7; ERIKSSON SE, 1985, ACTA NEUROL SCAND, V71, P485; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GROCH SN, 1961, ANN INTERN MED, V55, P358, DOI 10.7326/0003-4819-55-3-358; HAKIM AM, 1983, STROKE, V14, P668; HALEY EC, 1988, STROKE, V19, P10, DOI 10.1161/01.STR.19.1.10; HILL AB, 1962, BRIT MED J, P1003, DOI 10.1136/bmj.2.5311.1003; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KEITH DS, 1987, MAYO CLIN PROC, V62, P1101, DOI 10.1016/S0025-6196(12)62503-8; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P206; Longstreth GF, 1997, AM J GASTROENTEROL, V92, P419; MCDOWELL FLETCHER, 1965, P185; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; ORENCIA AJ, 1993, STROKE POPULATIONS C, P238; PEARCE JMS, 1965, LANCET, V1, P6; PESSIN MS, 1993, NEUROLOGY, V43, P1298, DOI 10.1212/WNL.43.7.1298; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; Petty GW, 1998, NEUROLOGY, V50, P208, DOI 10.1212/WNL.50.1.208; PUTMAN SF, 1985, ARCH NEUROL-CHICAGO, V42, P960, DOI 10.1001/archneur.1985.04060090042011; RAMIREZLASSEPAS M, 1986, ARCH NEUROL-CHICAGO, V43, P386, DOI 10.1001/archneur.1986.00520040066022; RANKIN J, 1957, Scott Med J, V2, P127; SHERMAN DG, 1995, CHEST, V108, pS444, DOI 10.1378/chest.108.4_Supplement.444S; SULLIVAN LW, 1992, NATL STROKE ASS  SPR, V9, P1; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; *VET ADM COOP STUD, 1961, NEUROLOGY, V11, P132; 1997, STROKE, V28, P475	43	69	71	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					14	22		10.7326/0003-4819-130-1-199901050-00004	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890845				2022-12-28	WOS:000077744500003
J	Finch, EA; Augustine, GJ				Finch, EA; Augustine, GJ			Local calcium signalling by inositol-1,4, 5-trisphosphate in Purkinje cell dendrites	NATURE			English	Article							RAT CEREBELLAR SLICES; LONG-TERM DEPRESSION; GLUTAMATE RECEPTORS; ACTIVATION; TRISPHOSPHATE; NEURONS; 1,4,5-TRISPHOSPHATE; CA2+; POTENTIATION; LOCALIZATION	The second messenger inositol-1,4,5-trisphosphate (InsP(3)) releases Ca2+ from intracellular Ca2+ stores by activating specific receptors on the membranes of these stores(1). In many cells, InsP(3) is a global signalling molecule that liberates Ca2+ throughout the cytoplasm(1,2) . However, in neurons the situation might be different(3,4), because synaptic activity may produce InsP(3) at discrete locations. Here we characterize InsP(3) signalling in postsynaptic cerebellar Purkinje neurons, which have a high level of InsP(3) receptors(5). We find that repetitive activation of the synapse between parallel fibres and Purkinje cells causes InsP(3)-mediated Ca2+ release in the Purkinje cells. This Ca2+ release is restricted to individual postsynaptic spines, where both metabotropic glutamate receptors(6,7) and InsP3 receptors(5) are located, or to multiple spines and adjacent dendritic shafts. Focal photolysis of caged InsP(3) (ref. 8) in Purkinje cell dendrites also produces Ca2+ signals that spread only a few micrometres from the site of InsP(3) production. Uncaged InsP(3) produces a long-lasting depression of parallel-fibre synaptic transmission that is limited to synapses where the Ca2+ concentration is raised. Thus, in Purkinje cells InP3 acts within a restricted spatial range that allows it to regulate the function of local groups of parallel-fibre synapses.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University	Augustine, GJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, POB 3209, Durham, NC 27710 USA.	georgea@neuro.duke.edu	Augustine, George James/J-9228-2013					BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BATCHELOR AM, 1994, NEUROSCIENCE, V63, P911, DOI 10.1016/0306-4522(94)90558-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; Dichiara TJ, 1995, J PHYSIOL-LONDON, V489, P403, DOI 10.1113/jphysiol.1995.sp021061; Doroshenko PA, 1997, NEUROPHARMACOLOGY, V36, P865, DOI 10.1016/S0028-3908(97)00032-4; Eilers J, 1997, LEARN MEMORY, V4, P159, DOI 10.1101/lm.4.1.159; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Hartell NA, 1996, NEURON, V16, P601, DOI 10.1016/S0896-6273(00)80079-3; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JAFFE DB, 1994, J NEUROPHYSIOL, V72, P471, DOI 10.1152/jn.1994.72.1.471; KHODAKHAH K, 1995, J PHYSIOL-LONDON, V487, P343, DOI 10.1113/jphysiol.1995.sp020884; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WANG BZ, 1995, IEEE MICROW GUIDED W, V5, P15, DOI 10.1109/75.382374; WANG SSH, UNPUB P NATL ACAD SC; YAMADA M, 1992, BRAIN RES, V578, P41, DOI 10.1016/0006-8993(92)90227-Z	29	427	431	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					753	756		10.1038/25541	http://dx.doi.org/10.1038/25541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874372				2022-12-28	WOS:000077742800033
J	Hollman, A; Treasure, T				Hollman, A; Treasure, T			Pulmonary valvotomy - 50 years ago	LANCET			English	Editorial Material									Sea Bank, Hastings TN35 4EQ, E Sussex, England; St George Hosp, Sch Med, Dept Cardiothorac Surg, London, England	St Georges University London	Hollman, A (corresponding author), Sea Bank, Chick Hill, Hastings TN35 4EQ, E Sussex, England.							BLALOCK A, 1945, JAMA-J AM MED ASSOC, V128, P189, DOI 10.1001/jama.1945.02860200029009; BROCK RC, 1948, BRIT MED J, V1, P1121, DOI 10.1136/bmj.1.4562.1121; Cutler EC, 1929, ARCH SURG-CHICAGO, V18, P403, DOI 10.1001/archsurg.1929.04420020225016; Hurt R., 1996, HIST CARDIOTHORACIC; SELLORS TH, 1948, LANCET, V254, P988; TREASURE T, 1995, ANN ROY COLL SURG, V77, P145	6	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1956	1956		10.1016/S0140-6736(05)61328-1	http://dx.doi.org/10.1016/S0140-6736(05)61328-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872243				2022-12-28	WOS:000077663000007
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Editorial Material									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2028	2028		10.1016/S0140-6736(05)61387-6	http://dx.doi.org/10.1016/S0140-6736(05)61387-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872291				2022-12-28	WOS:000077663000079
J	Schroeder, BC; Kubisch, C; Stein, V; Jentsch, TJ				Schroeder, BC; Kubisch, C; Stein, V; Jentsch, TJ			Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; FAMILIAL NEONATAL CONVULSIONS; POTASSIUM-CHANNEL; KVLQT1 MUTATIONS; PROTEINS; K(V)LQT1; FORM; RAT	Epilepsy affects more than 0.5% of the world's population and has a large genetic component(1). It is due to an electrical hyperexcitability in the central nervous system. Potassium channels are important regulators of electrical signalling, and benign familial neonatal convulsions (BFNC), an autosomal dominant epilepsy of infancy, is caused by mutations in the KCNQ2 or the KCNQ3 potassium channel genes(2-4), Here we show that KCNQ2 and KCNQ3 are distributed broadly in brain with expression patterns that largely overlap. Expression in Xenopus oocytes indicates the formation of heteromeric KCNQ2/KCNQ3 potassium channels with currents that are at least tenfold larger than those of the respective homomeric channels. KCNQ2/KCNQ3 currents can be increased by intracellular cyclic AMP, an effect that depends on an intact phosphorylation site in the KCNQ2 amino terminus. KCNQ2 and KCNQ3 mutations identified in BFNC pedigrees compromised the function of the respective subunits, but exerted no dominant-negative effect on KCNQ2/KCNQ3 heteromeric channels. We predict that a 25% loss of heteromeric KCNQ2/ KCNQ3-channel function is sufficient to cause the electrical hyperexcitability in BFNC, Drugs raising intracellular cAMP may prove beneficial in this form of epilepsy.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de	Stein, Valentin/A-8025-2008; Kubisch, Christian/F-1893-2011	Stein, Valentin/0000-0003-1222-4928; Kubisch, Christian/0000-0003-4220-0978; Jentsch, Thomas/0000-0002-3509-2553				BARAISTER M, 1990, OXF MONOGR MED GENET, V18, P96; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943	19	407	436	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					687	690		10.1038/25367	http://dx.doi.org/10.1038/25367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872318				2022-12-28	WOS:000077694200056
J	Kullo, IJ; Edwards, WD; Schwartz, RS				Kullo, IJ; Edwards, WD; Schwartz, RS			Vulnerable plaque: Pathobiology and clinical implications	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; PLASMA-CHOLESTEROL CONCENTRATIONS; HUMAN ATHEROSCLEROTIC PLAQUES; POSITRON EMISSION TOMOGRAPHY; RABBIT CAROTID ARTERIES; SUDDEN ISCHEMIC DEATH; NITRIC-OXIDE SYNTHASE; VITAMIN-E CONSUMPTION; HEART-DISEASE	Purpose: To review the pathobiology and clinical implications of vulnerable coronary atherosclerotic plaques and to discuss the identification of vulnerable plaques and mechanisms of plaque stabilization. Data Sources:: English-language articles in the MEDLINE database that were published from 1966 to the present, identified by using the terms atherosclerotic plaque, myocardial revascularization, and plaque stabilization. Selected references cited in identified articles were reviewed. Study Selection: Experimental, clinical, and basic research studies related to coronary atherosclerotic plaques. Data Synthesis: Rupture at the site of a vulnerable atherosclerotic plaque is the most frequent cause of acute coronary syndromes. Typically, such plaque does not cause high-grade stenosis and has a large lipid core and a thin fibrous cap that is often infiltrated by inflammatory cells. Mechanical stresses contribute to plaque vulnerability, and certain triggers may cause plaque disruption directly. The most important: consequence of plaque rupture is thrombosis. No method reliably identifies plaques prone to rupture. The reduction of coronary events by lipid-lowering agents despite only modest luminal changes suggests that these agents have a plaque-stabilizing effect. Surgical or percutaneous revascularization does not address the basic biology of coronary atherosclerosis and therefore may have little effect on plaque vulnerability. Conclusions: Improved understanding of the biology of atheromatous plaques has led to the concept of plaque vulnerability. Identification and stabilization of vulnerable plaques are important new directions in the treatment of coronary atherosclerosis. The relative benefits of aggressive medical therapy aimed at plaque stabilization should be compared with those of revascularization in the management of chronic coronary artery disease.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Kullo, IJ (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.							Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; Andrews TC, 1997, CIRCULATION, V95, P324; ARMSTRONG ML, 1975, CIRC RES, V36, P256, DOI 10.1161/01.RES.36.2.256; ARMSTRONG ML, 1972, CIRC RES, V30, P675, DOI 10.1161/01.RES.30.6.675; BADIMON JJ, 1991, ARTERIOSCLER THROMB, V11, P395, DOI 10.1161/01.ATV.11.2.395; Benson RL, 1926, ARCH PATHOL LAB MED, V2, P876; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BROWN BG, 1986, CIRCULATION, V73, P653, DOI 10.1161/01.CIR.73.4.653; Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; Chamberlain DA, 1997, LANCET, V350, P461; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; CLARKSON TB, 1981, EXP MOL PATHOL, V34, P345, DOI 10.1016/0014-4800(81)90052-6; Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265; CONSTANT.P, 1966, J ATHEROSCLER RES, V6, P1, DOI 10.1016/S0368-1319(66)80056-X; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAVIES MJ, 1981, PHILOS T R SOC B, V294, P225, DOI 10.1098/rstb.1981.0101; DAVIES MJ, 1976, BRIT HEART J, V38, P659; DAVIES MJ, 1979, J PATHOL, V127, P99, DOI 10.1002/path.1711270208; DAVIES MJ, 1993, BRIT HEART J, V69, P377; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; deDivitiis M, 1996, AM J CARDIOL, V78, P763, DOI 10.1016/S0002-9149(96)00417-1; DEFEYTER PJ, 1995, CIRCULATION, V92, P1408, DOI 10.1161/01.CIR.92.6.1408; Demer LL, 1997, CIRCULATION, V95, P297; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Edwards W D, 1995, Monogr Pathol, V37, P12; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EICHSTADT HW, 1995, AM J CARDIOL, V76, pA122, DOI 10.1016/S0002-9149(05)80033-5; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; Forrester JS, 1997, CIRCULATION, V96, P1360, DOI 10.1161/01.CIR.96.4.1360; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRISHMAN WH, 1990, AM J CARDIOL, V66, pG66, DOI 10.1016/0002-9149(90)90401-L; FRYE RL, 1987, PROG CARDIOVASC DIS, V30, P1, DOI 10.1016/0033-0620(87)90008-9; GERTZ SD, 1990, AM J CARDIOL, V66, P1368, DOI 10.1016/0002-9149(90)91170-B; GINSBERG HN, 1990, ARTERIOSCLEROSIS, V10, P256, DOI 10.1161/01.ATV.10.2.256; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOULD KL, 1995, JAMA-J AM MED ASSOC, V274, P894, DOI 10.1001/jama.274.11.894; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HANSSON GK, 1988, ATHEROSCLEROSIS, V72, P135, DOI 10.1016/0021-9150(88)90074-3; HODGSON JM, 1993, J AM COLL CARDIOL, V21, P35, DOI 10.1016/0735-1097(93)90714-C; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; JAY RH, 1990, ATHEROSCLEROSIS, V85, P249, DOI 10.1016/0021-9150(90)90117-2; KERENSKY R, 1991, AM J CARDIOL, V68, P967, DOI 10.1016/0002-9149(91)90421-G; Kullo IJ, 1997, CIRCULATION, V96, P2254; Kullo IJ, 1997, HYPERTENSION, V30, P314, DOI 10.1161/01.HYP.30.3.314; KULLO IJ, IN PRESS ARTERIOSCLE; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LEE RT, 1994, J AM COLL CARDIOL, V23, P1289, DOI 10.1016/0735-1097(94)90369-7; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIN CS, 1988, ANGIOLOGY, V39, P535; LITTLE WC, 1990, AM J CARDIOL, V65, P808, DOI 10.1016/0002-9149(90)91394-L; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; LOREE HM, 1994, ARTERIOSCLER THROMB, V14, P230, DOI 10.1161/01.ATV.14.2.230; MACISAAC AI, 1993, J AM COLL CARDIOL, V22, P1228, DOI 10.1016/0735-1097(93)90442-4; Madsen JK, 1997, CIRCULATION, V96, P748; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; McCormick LS, 1997, AM J CARDIOL, V80, P1130, DOI 10.1016/S0002-9149(97)00627-9; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RICHARDSON PD, 1989, LANCET, V2, P941; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Romer TJ, 1998, CIRCULATION, V97, P878, DOI 10.1161/01.CIR.97.9.878; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; SANG KHLQ, 1995, ARTERIOSCL THROM VAS, V15, P759, DOI 10.1161/01.ATV.15.6.759; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SEILER C, 1993, CIRCULATION, V88, P2139, DOI 10.1161/01.CIR.88.5.2139; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEIN PD, 1994, AM J CARDIOL, V73, P431, DOI 10.1016/0002-9149(94)90671-8; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TERRIN ML, 1993, J AM COLL CARDIOL, V22, P1763, DOI 10.1016/0735-1097(93)90755-P; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Toussaint JF, 1996, CIRCULATION, V94, P932, DOI 10.1161/01.CIR.94.5.932; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; vanBoven AJ, 1996, CIRCULATION, V94, P1503, DOI 10.1161/01.CIR.94.7.1503; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WADA H, 1992, CLIN THER, V14, P829; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8; Yokoyama I, 1996, CIRCULATION, V94, P3232, DOI 10.1161/01.CIR.94.12.3232; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Zoldhelyi P, 1996, CIRCULATION, V93, P10, DOI 10.1161/01.CIR.93.1.10	116	135	146	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1050	1060		10.7326/0003-4819-129-12-199812150-00010	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867761				2022-12-28	WOS:000077471900009
J	Criqui, M				Criqui, M			Alcohol in the myocardial infarction patient	LANCET			English	Editorial Material							CARDIOVASCULAR-DISEASE; MORTALITY											CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; Hennekens CH, 1997, CIRCULATION, V96, P2751, DOI 10.1161/01.CIR.96.8.2751; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Muldoon MF, 1997, BRIT MED J, V315, P1554, DOI 10.1136/bmj.315.7122.1554; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367	8	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1873	1873		10.1016/S0140-6736(05)60390-X	http://dx.doi.org/10.1016/S0140-6736(05)60390-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863780				2022-12-28	WOS:000077544600003
J	Sharma, K; Sheng, HZ; Lettieri, K; Li, H; Karavanov, A; Potter, S; Westphal, H; Pfaff, SL				Sharma, K; Sheng, HZ; Lettieri, K; Li, H; Karavanov, A; Potter, S; Westphal, H; Pfaff, SL			LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons	CELL			English	Article							HOMEOBOX GENE LHX3; CHICK SPINAL-CORD; SONIC HEDGEHOG; NEUROENDOCRINE TISSUES; PROJECTION PATTERNS; FLOOR PLATE; EXPRESSION; SPECIFICATION; PITUITARY; ORGANIZATION	The circuits that control movement are comprised of discrete subtypes of motor neurons. How motor neuron subclasses develop and extend axons to their correct targets is still poorly understood. We show that LIM homeodomain factors Lhx3 and Lhx4 are expressed transiently in motor neurons whose axons emerge ventrally from the neural tube (V-MN). Motor neurons develop in embryos deficient in both Lhx3 and Lhx4, but v-MN cells switch their subclass identity to become motor neurons that extend axons dorsally from the neural tube (d-MN). Conversely, the misexpression of Lhx3 in dorsal-exiting motor neurons is sufficient to reorient their axonal projections ventrally. Thus, Lhx3 and Lhx4 act in a binary fashion during a brief period in development to specify the trajectory of motor axons from the neural tube.	Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA; NICHHD, Lab Mammalian Genet & Dev, Bethesda, MD 20892 USA; NICHHD, Mol Genet Lab, Bethesda, MD 20892 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan; Childrens Hosp, Cincinnati, OH 45229 USA	Salk Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Academia Sinica - Taiwan; Cincinnati Children's Hospital Medical Center	Pfaff, SL (corresponding author), Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037116] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37116] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Appel B, 1995, DEVELOPMENT, V121, P4117; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BRICHTA AM, 1987, J COMP NEUROL, V255, P351, DOI 10.1002/cne.902550304; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; Ensini M, 1998, DEVELOPMENT, V125, P969; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Fedtsova N, 1997, DEV BIOL, V190, P18, DOI 10.1006/dbio.1997.8691; FRITZSCH B, 1993, ACTA ANAT, V148, P96; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; Hobert O, 1998, J NEUROSCI, V18, P2084; Hogan B, 1994, MANIPULATING MOUSE E; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LEBER SM, 1995, J NEUROSCI, V15, P1236; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1996, DEVELOPMENT, V122, P659; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Pfaff S, 1998, CURR OPIN NEUROBIOL, V8, P27, DOI 10.1016/S0959-4388(98)80005-6; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAUER B, 1993, GUIDE TECHNIQUES MOU, P890; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHARMA K, 1994, DEVELOPMENT, V120, P1315; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WETTS R, 1994, NEUROSCIENCE, V63, P1117, DOI 10.1016/0306-4522(94)90577-0; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	55	351	360	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					817	828		10.1016/S0092-8674(00)81704-3	http://dx.doi.org/10.1016/S0092-8674(00)81704-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865699	Bronze			2022-12-28	WOS:000077498800011
J	Stewart, J				Stewart, J			The Wisheart affairs: A patient's perspective	BRITISH MEDICAL JOURNAL			English	Article									Blue Haze, Sidmouth EX10 8JD, Devon, England		Stewart, J (corresponding author), Blue Haze, Hillside Rd, Sidmouth EX10 8JD, Devon, England.							Dunn PM, 1998, BRIT MED J, V317, P1144; *GEN MED COMM, 1998, TRANSCR PROF COND CO; SHARMA AK, 1985, J THORAC CARDIOV SUR, V90, P45	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1581	1582						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9890763				2022-12-28	WOS:000077451700036
J	Hin, H; Bird, G; Fisher, P; Mahy, N; Jewell, D				Hin, H; Bird, G; Fisher, P; Mahy, N; Jewell, D			Coeliac disease in primary care: case finding study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE	Objectives To provide evidence of underdiagnosis of coeliac disease and to describe the main presenting symptoms of coeliac disease in primary care. Design Case finding in a primary care setting by testing for coeliac disease by using the endomysial antibody test. Setting Nine surgeries in and around a market town in central England, serving a population of 70 000. Participants First 1000 patients screened from October 1996 to October 1997. Outcome measures Determination of endomysial antibody titre of patients fulfilling the study criteria, followed by small intestine biopsy of those with positive results. Results The 30 patients (out of 1000 samples) with positive results on the endomysial antibody test all had histological confirmation on small intestine biopsy The commonest mode of presentation (15/30) was anaemia of varying severity. Most patients (25/30) presented with non-gastrointestinal symptoms. Specificity of the endomysial antibody test was 30/30. Conclusions Underdiagnosis and misdiagnosis of coeliac disease are common in general practice and often result in protracted and unnecessary morbidity. Serological screening in primary care will uncover a large proportion of patients with this condition and should be made widely available and publicised. Coeliac disease should be considered in patients who have anaemia or are tired all the time, especially when there is a family history of the disease.	Horton Hosp, Banbury OX16 9AL, Oxon, England; Radcliffe Infirm, Oxford OX2 6HE, England	Radcliffe Infirmary	Hin, H (corresponding author), Hightown Surg, Banbury, Oxon, England.	HaroldHin@pgec-horton.demon.co.uk						CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; FERGUSON A, 1993, GUT, V34, P150, DOI 10.1136/gut.34.2.150; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Gee S., 1888, ST BARTHOLOMEWS HOSP, V24, P17; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HANKEY GL, 1994, GUT, V35, P65, DOI 10.1136/gut.35.1.65; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; JERRETT WA, 1981, PRACTITIONER, V225, P731; Johnston SD, 1996, ACTA PAEDIATR, V85, P61, DOI 10.1111/j.1651-2227.1996.tb14255.x; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; MCMILLAN SA, 1991, BRIT MED J, V303, P1163, DOI 10.1136/bmj.303.6811.1163; MYLOTTE M, 1973, BMJ-BRIT MED J, V1, P703, DOI 10.1136/bmj.1.5855.703; RIDSDALE L, 1996, BRIT MED J, V307, P103; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; SWINSON CM, 1980, BRIT MED J, V281, P1258, DOI 10.1136/bmj.281.6250.1258; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; Unsworth DJ, 1996, J CLIN PATHOL, V49, P704, DOI 10.1136/jcp.49.9.704; UNSWORTH DJ, 1994, GUT, V35, P61, DOI 10.1136/gut.35.1.61	19	252	261	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1999	318	7177					164	167		10.1136/bmj.318.7177.164	http://dx.doi.org/10.1136/bmj.318.7177.164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888912	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000078175100029
J	Sponheimer, M; Lee-Thorp, JA				Sponheimer, M; Lee-Thorp, JA			Isotopic evidence for the diet of an early hominid, Australopithecus africanus	SCIENCE			English	Article							CALCIUM RATIOS SR/CA; BODY-SIZE; SWARTKRANS; ETHIOPIA; ROBUSTUS; KENYA; MICROWEAR; BABOONS; BRAIN; TOOLS	Current consensus holds that the 3-million-year-old hominid Australopithecus africanus subsisted on fruits and Leaves, much as the modern chimpanzee does. Stable carbon isotope analysis of A. africanus from Makapansgat Limeworks, South Africa, demonstrates that this early hominid ate not only fruits and Leaves but also Large quantities of carbon-13-enriched foods such as grasses and sedges or animals that ate these plants, or both. The results suggest that early hominids regularly exploited relatively open environments such as woodlands or grasslands for food. They may also suggest that hominids consumed high-quality animal foods before the development of stone tools and the origin of the genus Homo.	Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08901 USA; Univ Cape Town, Dept Archaeol, ZA-7701 Rondebosch, South Africa	Rutgers State University New Brunswick; University of Cape Town	Sponheimer, M (corresponding author), Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08901 USA.		Sponheimer, Matt/A-6075-2013	Sponheimer, Matt/0000-0002-8743-1123				AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; BLUMENSCHINE RJ, 1987, CURR ANTHROPOL, V28, P383, DOI 10.1086/203544; BUNN HT, 1981, NATURE, V291, P574, DOI 10.1038/291574a0; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; CLARKE RJ, 1995, SCIENCE, V269, P521, DOI 10.1126/science.7624772; Dart RA, 1949, AM J PHYS ANTHROP-NE, V7, P1, DOI 10.1002/ajpa.1330070103; DUNBAR RIM, 1991, PRIMATES, V32, P1, DOI 10.1007/BF02381596; DUNBAR RIM, 1983, J HUM EVOL, V12, P647, DOI 10.1016/S0047-2484(83)80004-9; Fleagle JG, 1988, PRIMATE ADAPTATION E; GRINE FE, 1988, NATURE, V333, P765, DOI 10.1038/333765a0; GRINE FE, 1986, J HUM EVOL, V15, P783, DOI 10.1016/S0047-2484(86)80010-0; HARDING RSO, 1976, FOLIA PRIMATOL, V25, P143, DOI 10.1159/000155711; JOLLY CJ, 1970, MAN, V5, P5, DOI 10.2307/2798801; Kimbel WH, 1996, J HUM EVOL, V31, P549, DOI 10.1006/jhev.1996.0079; Kummer H., 1968, SOCIAL ORG HAMADRYAS; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; Lee-Thorp J, 1997, B SOC GEOL FR, V168, P767; LEETHORP JA, 1989, J ARCHAEOL SCI, V16, P585, DOI 10.1016/0305-4403(89)90024-1; LEETHORP JA, 1994, J HUM EVOL, V27, P361, DOI 10.1006/jhev.1994.1050; LEETHORP JA, UNPUB; LEONARD WR, 1994, AM J HUM BIOL, V6, P77, DOI 10.1002/ajhb.1310060111; McFadden P.L., 1980, Palaeontologia Africana, V23, P35; McGrew W.C., 1992, CHIMPANZEE MAT CULTU; McHenry HM, 1998, J HUM EVOL, V35, P1, DOI 10.1006/jhev.1997.0197; RAYNER RJ, 1993, J HUM EVOL, V24, P219, DOI 10.1006/jhev.1993.1016; REED K, 1996, THESIS STATE U NEW Y; ROBINSON JT, 1954, EVOLUTION, V8, P324, DOI 10.2307/2405779; Schick K. D., 1993, MAKING SILENT STONES; Semaw S, 1997, NATURE, V385, P333, DOI 10.1038/385333a0; SILLEN A, 1992, J HUM EVOL, V23, P495, DOI 10.1016/0047-2484(92)90049-F; SILLEN A, 1995, J HUM EVOL, V28, P277, DOI 10.1006/jhev.1995.1020; SMITH BN, 1971, PLANT PHYSIOL, V47, P380, DOI 10.1104/pp.47.3.380; TEAFORD MF, 1992, THEROPITHECUS RISE F, P331; Tobias P.V, 1967, OLDUVAI GORGE, V2; VOGEL JC, 1978, S AFR J SCI, V74, P209; Vrba E. S., 1985, ANCESTORS HARD EVIDE; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; Wallace J.A., 1975, P203; WHITE TD, 1981, S AFR J SCI, V77, P445; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOLPOFF MH, 1973, AM J PHYS ANTHROPOL, V39, P375, DOI 10.1002/ajpa.1330390306; [No title captured]; [No title captured]	43	247	259	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					368	370		10.1126/science.283.5400.368	http://dx.doi.org/10.1126/science.283.5400.368			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	157MV	9888848				2022-12-28	WOS:000078067000042
J	Ellis, H				Ellis, H			Lord Smith of Marlow - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		SMITH R, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					129	129		10.1136/bmj.318.7176.129	http://dx.doi.org/10.1136/bmj.318.7176.129			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880305	Green Published			2022-12-28	WOS:000078087500065
J	Molmenti, EP; Thompson, RW				Molmenti, EP; Thompson, RW			Meckel's diverticulum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Baylor Univ, Med Ctr, Dallas, TX 75246 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Baylor University; Baylor University Medical Center; Washington University (WUSTL)	Molmenti, EP (corresponding author), Baylor Univ, Med Ctr, Dallas, TX 75246 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					31	31		10.1056/NEJM199901073400105	http://dx.doi.org/10.1056/NEJM199901073400105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878642				2022-12-28	WOS:000077943700005
J	Bromley, E				Bromley, E			The evolving relationship between the physician and the scientist in the 20th century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bromley, E (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							Bliss M., 1982, DISCOVERY INSULIN; BONNER TN, 1997, SICKNESS HLTH AM REA, P189; KENNEDY TJ, 1994, ACAD MED, V69, P779, DOI 10.1097/00001888-199410000-00001; LIPPARD VW, 1974, HALF CENTURY AM MED, P74; Numbers Ronald L., 1987, SCI COLONIALISM CROS, p[200, 191]; ROSENBERG CE, 1976, NO OTHER GODS SCI AM; ROTHSTEIN WG, 1987, AM MED SCH PRACTICE, P246; [No title captured]	8	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					95	+		10.1001/jama.281.1.95	http://dx.doi.org/10.1001/jama.281.1.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892458	hybrid			2022-12-28	WOS:000077829300046
J	Lederle, FA; Simel, DL				Lederle, FA; Simel, DL			Does this patient have abdominal aortic aneurysm?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL VASCULAR-DISEASE; POSITIVE PREDICTIVE VALUE; PHYSICAL-EXAMINATION; CLINICAL SUSPICION; ARTERIAL-DISEASE; HIGH PREVALENCE; ULTRASONOGRAPHY; MANAGEMENT; ULTRASOUND; DIAGNOSIS	In the physical examination of abdominal aortic aneurysm (AAA), the only maneuver of demonstrated value is abdominal palpation to detect abnormal widening of the aortic pulsation. Palpation of AAA appears to be safe and has not been reported to precipitate rupture. The best evidence on the accuracy of abdominal palpation comes from 15 studies of patients not previously known to have AAA who were screened with both abdominal palpation and ultrasound. When results from these studies are pooled, the sensitivity of abdominal palpation increases significantly with AAA diameter (P<.001), ranging from 29% for AAAs of 3.0 to 3.9 cm to 50% for AAAs of 4.0 to 4.9 cm and 76% for AAAs of 5.0 cm or greater. Positive and negative likelihood ratios with 95% confidence intervals (Cls) using a cutoff point for AAAs of 3.0 cm or greater are 12.0 (95% CI, 7.4-19.5) and 0.72 (95% CI, 0.65-0.81), respectively, and for AAAs of 4.0 cm or greater are 15.6 (95% CI, 8.6-28.5) and 0.51 (95% CI, 0.38-0.67). The positive predictive value of palpation for AAA of 3.0 cm or greater in these studies was 43%. Limited data suggest that abdominal obesity decreases the sensitivity of palpation. Abdominal palpation specifically directed at measuring aortic width has moderate sensitivity for detecting an AAA that would be large enough to be referred for surgery but cannot be relied on to exclude AAA, especially if rupture is a possibility.	Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA; Duke Univ, Durham Vet Affairs Med Ctr, Dept Med, Durham, NC USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Lederle, FA (corresponding author), Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Dept Med, 1 Vet Dr, Minneapolis, MN 55417 USA.	vhaminlederf@med.va.gov						al-Zahrani H A, 1996, Cardiovasc Surg, V4, P87, DOI 10.1016/0967-2109(96)83791-4; ALLARDICE JT, 1988, BRIT J SURG, V75, P240, DOI 10.1002/bjs.1800750318; ALLEN PIM, 1987, LANCET, V2, P736; ANDERSSON AP, 1991, VASCULAR SURG, V25, P516, DOI 10.1177/153857449102500702; [Anonymous], 1991, CAN MED ASSOC J, V145, P783; Arnell TD, 1996, AM SURGEON, V62, P861; Ballard DJ, 1992, ABDOMINAL AORTIC ANE; BEEDE SD, 1990, ARCH INTERN MED, V150, P549, DOI 10.1001/archinte.150.3.549; BERGAN JJ, 1974, ARCH SURG-CHICAGO, V109, P80; BREWSTER DC, 1977, CIRCULATION, V56, P164; BREWSTER DC, 1975, NEW ENGL J MED, V292, P822, DOI 10.1056/NEJM197504172921602; BUXTON B, 1978, AUST NZ J SURG, V48, P387, DOI 10.1111/j.1445-2197.1978.tb04882.x; CABELLON S, 1983, AM J SURG, V146, P575, DOI 10.1016/0002-9610(83)90290-8; CHERVU A, 1995, SURGERY, V117, P454, DOI 10.1016/S0039-6060(05)80067-4; COLLIN J, 1988, LANCET, V2, P613; CRAIG SR, 1993, BRIT J SURG, V80, P450, DOI 10.1002/bjs.1800800413; CRONENWETT JL, 1990, J VASC SURG, V11, P260, DOI 10.1067/mva.1990.16697; Donaldson M C, 1985, Conn Med, V49, P3; EDDY DM, 1992, FAST PRO V1 8 SOFTWA, P91; FOWLER NO, 1985, CECIL TXB MED, P345; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; FRIEDMAN SA, 1967, J AMER MED ASSOC, V200, P1147, DOI 10.1001/jama.200.13.1147; GAYLIS H, 1980, SURGERY, V87, P300; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; GORDONSMITH IC, 1978, BRIT J SURG, V65, P834, DOI 10.1002/bjs.1800651203; GRAEVE AH, 1982, AM J SURG, V144, P627, DOI 10.1016/0002-9610(82)90539-6; Guarino J R, 1975, J Kans Med Soc, V76, p15A; GUARINO JR, 1975, J KANSAS MED SOC, V76, pA15; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HERTZER NR, 1978, JAMA-J AM MED ASSOC, V240, P1966; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOYCE JW, 1992, VASC MED, P401; Kahn CE, 1996, J GEN INTERN MED, V11, P756, DOI 10.1007/BF02598992; KARANJIA PN, 1994, STROKE, V25, P627, DOI 10.1161/01.STR.25.3.627; KARP W, 1978, ACTA RADIOL DIAGN, V19, P955, DOI 10.1177/028418517801900610; Kiev J, 1997, VASCULAR SURG, V31, P143, DOI 10.1177/153857449703100205; LEDERLE FA, 1994, AM J MED, V96, P163, DOI 10.1016/0002-9343(94)90137-6; LEDERLE FA, 1994, J VASC SURG, V20, P296, DOI 10.1016/0741-5214(94)90019-1; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lederle FA, 1997, J VASC SURG, V26, P595, DOI 10.1016/S0741-5214(97)70057-0; LEE KR, 1975, SURGERY, V78, P195; LEE TG, 1977, AM J ROENTGENOL, V128, P273, DOI 10.2214/ajr.128.2.273; LOFGREN RP, 1987, J GEN INTERN MED, V2, P452, DOI 10.1007/BF02596381; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; MCGREGOR JC, 1976, BRIT J SURG, V63, P113, DOI 10.1002/bjs.1800630206; MCGREGOR JC, 1975, SCOT MED J, V20, P133, DOI 10.1177/003693307502000313; Molnar L J, 1995, Rev Assoc Med Bras (1992), V41, P43; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; NUSBAUM JW, 1971, ARCH SURG-CHICAGO, V102, P385; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; OHMAN EM, 1985, IRISH MED J, V78, P127; Osler W, 1905, LANCET, V2, P1089; OTTINGER LW, 1975, JAMA-J AM MED ASSOC, V233, P147, DOI 10.1001/jama.233.2.147; PRYOR JP, 1972, BRIT MED J, V3, P735, DOI 10.1136/bmj.3.5829.735; ROBERTS A, 1974, AUST NZ J SURG, V44, P360, DOI 10.1111/j.1445-2197.1974.tb03904.x; ROBICSEK F, 1981, SURGERY, V89, P275; Robicsek F, 1971, Ann Thorac Surg, V11, P538; SHAPIRA OM, 1990, J CARDIOVASC SURG, V31, P170; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SPIRIDONOV AA, 1992, GRUDNAIA SERDECHNO S, V9, P33; TWOMEY A, 1986, INT ANGIOL, V5, P269; VOLPETTI G, 1976, SURG GYNECOL OBSTET, V142, P321; WALSH JA, 1992, MED J AUSTRALIA, V156, P138; WILLIAMS RD, 1972, AM J SURG, V123, P698, DOI 10.1016/0002-9610(72)90357-1	66	114	116	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					77	82		10.1001/jama.281.1.77	http://dx.doi.org/10.1001/jama.281.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892455				2022-12-28	WOS:000077829300039
J	van Rooyen, S; Godlee, F; Evans, S; Black, N; Smith, R				van Rooyen, S; Godlee, F; Evans, S; Black, N; Smith, R			Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial	BRITISH MEDICAL JOURNAL			English	Article							ANONYMITY	Objectives To examine the effect on peer review of asking reviewers to have their identity revealed to the authors of the paper. Design Randomised trial. Consecutive eligible papers were sent to two reviewers who were randomised to have their identity revealed to the authors or to remain anonymous. Editors and authors were blind to the intervention. Main outcome measures The quality of the reviews was independently rated by two editors and the corresponding author using a validated instrument Additional outcomes were the time taken to complete the review and the recommendation regarding publication. A questionnaire survey was undertaken of the authors of a cohort of manuscripts submitted for publication to find out their views on open peer review. Results Two editors' assessments were obtained for 113 out of 125 manuscripts, and the corresponding author's assessment was obtained for 105. Reviewers randomised to be asked to be identified were 12% (95% confidence interval 0.2% to 24%) more likely to decline to review than reviewers randomised to remain anonymous (35% v 23%). There was no significant difference in quality (scored on a scale of 1 to 5) between anonymous reviewers (3.06 (SD 0.72)) and identified reviewers (3.09 (0.68)) (P = 0.68, 95% confidence interval for difference -0.19 to 0.12), and no significant difference in the recommendation regarding publication or time taken to review the paper. The editors' quality score for reviews (3.05 (SD 0.70)) was significantly higher than that of authors (2.90 (0.87)) (P < 0.005, 95% confidence interval for difference -0.26 to -0.03). Most authors were in favour of open peer review. Conclusions Asking reviewers to consent to being identified to the author had no important effect on the quality of the review, the recommendation regarding publication, or the time taken to review, but it significantly increased the likelihood of reviewers declining to review.	BMJ, London WC1H 9JR, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	van Rooyen, S (corresponding author), BMJ, BMA House, London WC1H 9JR, England.			Evans, Stephen/0000-0002-1474-2596				Black N, 1998, JAMA-J AM MED ASSOC, V280, P231, DOI 10.1001/jama.280.3.231; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Godlee F, 1998, JAMA-J AM MED ASSOC, V280, P237, DOI 10.1001/jama.280.3.237; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; LOCK S, 1994, CARDIOVASC RES, V28, P1141; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; RENNIE D, 1994, CARDIOVASC RES, V28, P1142; SMITH R, 1994, CARDIOVASC RES, V28, P1144; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; VANROOYEN S, IN PRESS J CLIN EPID	11	262	264	1	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					23	27						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872878				2022-12-28	WOS:000078013100021
J	Mutton, P				Mutton, P			Early identification of deaf babies	LANCET			English	Editorial Material									New Childrens Hosp, Deafness Ctr, Westmead, NSW 2145, Australia	University of Sydney	Mutton, P (corresponding author), New Childrens Hosp, Deafness Ctr, Westmead, NSW 2145, Australia.							BENCH J, 1992, COMMUNICATION SKILLS; DAVIS A, 1993, PAEDIAT AUDIOLOGY 0; DAVIS JM, 1986, J SPEECH HEAR DISORD, V51, P53, DOI 10.1044/jshd.5101.53; Downs Marion P., 1994, Seminars in Hearing, V15, P76, DOI 10.1055/s-0028-1083757; LEVITT H, 1987, INTERRELATIONSHIPS S, P123; MARKIDES A, 1986, British Journal of Audiology, V20, P165, DOI 10.3109/03005368609079011; Schein J.D., 1974, DEAF POPULATION US; Schildroth A.N., 1986, DEAF CHILDREN AM; STEWART L, 1997, AUDIOLOGY ED	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1951	1952		10.1016/S0140-6736(05)61324-4	http://dx.doi.org/10.1016/S0140-6736(05)61324-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872239				2022-12-28	WOS:000077663000003
J	Drachman, DA				Drachman, DA			A 69-year-old man with chronic dizziness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEAD-SHAKING NYSTAGMUS; DIZZY PATIENT; VERTIGO; OSCILLOPSIA; PREVALENCE		Univ Massachusetts, Med Ctr, Dept Neurol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Drachman, DA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ADAMS RD, 1996, PRINCIPLES NEUROLOGY; [Anonymous], 1995, PHYS DESK REF; Asawavichianginda S, 1997, J OTOLARYNGOL, V26, P20; BALOH RW, 1995, OTOLARYNG HEAD NECK, V112, P3, DOI 10.1016/S0194-5998(95)70299-7; Baloh RW, 1996, NEUROL CLIN, V14, P85, DOI 10.1016/S0733-8619(05)70244-9; BALOH RW, 1990, CLIN NEUROPHYSIOL, P301; Benarroch EE, 1993, CLIN AUTONOMIC DISOR, P209; BENDER MB, 1965, ARCH NEUROL-CHICAGO, V13, P204, DOI 10.1001/archneur.1965.00470020094013; Burgio D L, 1992, J Vestib Res, V2, P221; CLARK DB, 1994, AM J PSYCHIAT, V151, P1223; COLLEDGE NR, 1994, AGE AGEING, V23, P117, DOI 10.1093/ageing/23.2.117; Corsten M, 1997, J OTOLARYNGOL, V26, P361; Cowand JL, 1998, OTOLARYNG HEAD NECK, V118, P49, DOI 10.1016/S0194-5998(98)70374-2; DIX MR, 1952, ANN OTO RHINOL LARYN, V61, P987, DOI 10.1177/000348945206100403; DRACHMAN D, 1994, CURRENT DIAGNOSIS NE, P264; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; EPLEY JM, 1995, OTOLARYNG HEAD NECK, V112, P154, DOI 10.1016/S0194-5998(95)70315-2; Epley JM, 1996, OTOLARYNG CLIN N AM, V29, P323; Furman JM, 1997, NEUROLOGY, V48, P1161, DOI 10.1212/WNL.48.5.1161; Gizzi M, 1996, ARCH NEUROL-CHICAGO, V53, P1299, DOI 10.1001/archneur.1996.00550120111024; Gomez CR, 1996, NEUROLOGY, V47, P94, DOI 10.1212/WNL.47.1.94; GOODHILL V, 1979, EAR DIS DEAFNESS DIZ, P526; GRAD A, 1989, ARCH NEUROL-CHICAGO, V46, P281, DOI 10.1001/archneur.1989.00520390047014; HALL SF, 1992, J OTOLARYNGOL, V21, P209; HART CW, 1983, LARYNGOSCOPE, V93, P1160; ISHIKAWA K, 1985, AM J OTOLARYNG, V6, P290, DOI 10.1016/S0196-0709(85)80057-0; JACOB RG, 1988, PSYCHIAT CLIN N AM, V11, P361; Jeka JJ, 1997, EXP BRAIN RES, V113, P475, DOI 10.1007/PL00005600; Kinney WC, 1998, AM J OTOL, V19, P341; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; Lee C S, 1995, Ear Nose Throat J, V74, P527; LONGRIDGE NS, 1987, ACTA OTO-LARYNGOL, V103, P273, DOI 10.3109/00016488709107794; MADLONKAY DJ, 1985, J FAM PRACTICE, V21, P109; Murakami S, 1998, ACTA OTO-LARYNGOL, V118, P145; OJALA M, 1988, ACTA NEUROL SCAND, V78, P26, DOI 10.1111/j.1600-0404.1988.tb03614.x; Oliva M, 1998, Acta Otorrinolaringol Esp, V49, P275; Olshansky B, 1998, SYNCOPE: MECHANISMS AND MANAGEMENT, P15; PAGE NGR, 1985, J NEUROL NEUROSUR PS, V48, P729, DOI 10.1136/jnnp.48.8.729; SCHONE H, 1984, PRINCETON SERIES NEU, P347; SHARPE J, 1995, NEUROOPHTHALMOLOGICA, P253; Shea JJ, 1997, OTOLARYNG CLIN N AM, V30, P1051; Slattery WH, 1997, OTOLARYNG CLIN N AM, V30, P1027; SLOANE PD, 1994, J AM GERIATR SOC, V42, P847, DOI 10.1111/j.1532-5415.1994.tb06556.x; STEIN MB, 1994, AM J PSYCHIAT, V151, P1697; SULLIVAN M, 1993, ARCH INTERN MED, V153, P1479, DOI 10.1001/archinte.153.12.1479; Unrug A, 1997, NEUROPSYCHOBIOLOGY, V36, P42, DOI 10.1159/000119359; *US DEP HHS, 1988, VITAL HLTH STAT 13, V13, P1754; Wade MG, 1997, PHYS THER, V77, P619, DOI 10.1093/ptj/77.6.619; WIST ER, 1983, BRAIN, V106, P153, DOI 10.1093/brain/106.1.153; Yardley L, 1998, BRIT J GEN PRACT, V48, P1131	50	33	36	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2111	2118		10.1001/jama.280.24.2111	http://dx.doi.org/10.1001/jama.280.24.2111			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875880				2022-12-28	WOS:000077606100036
J	Skehel, JJ; Wiley, DC				Skehel, JJ; Wiley, DC			Coiled coils in both intracellular vesicle and viral membrane fusion	CELL			English	Review							INFLUENZA HEMAGGLUTININ; GP41		Natl Inst Med Res, London NW7 1AA, England; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Childrens Hosp, Howard Hughes Med Inst, Dept Med, Mol Med Lab, Boston, MA 02115 USA	MRC National Institute for Medical Research; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Skehel, JJ (corresponding author), Natl Inst Med Res, Mill Hill,The Ridgeway, London NW7 1AA, England.							BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weis WI, 1998, NATURE, V395, P328, DOI 10.1038/26354; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	19	363	378	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					871	874		10.1016/S0092-8674(00)81710-9	http://dx.doi.org/10.1016/S0092-8674(00)81710-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875840	Bronze			2022-12-28	WOS:000077759100001
J	Wong, JB; Bennett, WG; Koff, RS; Pauker, SG				Wong, JB; Bennett, WG; Koff, RS; Pauker, SG			Pretreatment evaluation of chronic hepatitis C - Risks, benefits, and costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS LIVER-BIOPSY; NON-B-HEPATITIS; RECOMBINANT INTERFERON-ALFA; TERM FOLLOW-UP; CHRONIC NON-A; VIRUS GENOTYPES; PROGNOSTIC FACTORS; COMPENSATED CIRRHOSIS; RANDOMIZED TRIAL; NATURAL-HISTORY	Context.-Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response. Objective.-To examine the cost-effectiveness of alternative pretreatment management strategies for patients with CHC. Design.-Decision and cost-effectiveness analysis using a Markov model to examine prevalence of genotypes, viral load, and histological characteristics in relation to the sustained response rate with treatment. Data were based on a previously published decision model and a MEDLINE literature search for hepatitis C, biopsy, and liver from 1966 to 1996. Patients.-A hypothetical population of patients with CHC infection and elevated serum alanine aminotransferase level. Interventions.-Combinations of liver biopsy, genotyping, and quantitative viral load determination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and conservative management. Main Outcome Measures.-Proportion of sustained responders, lifetime costs, life expectancy, and quality-adjusted life expectancy. Results.-Strategies involving hepatitis C virus (HCV) RNA testing had marginal cost-effectiveness ratios up to $4400 per discounted quality-adjusted life-year gained but would miss up to 36% of sustained responders. Empirical interferon treatment had a marginal cost-effectiveness ratio of $12 400 per discounted quality-adjusted life-year gained and reached all potential sustained responders. Strategies involving liver biopsy were more expensive and would miss 6% of sustained responders and yield slightly lower life expectancies. Conclusions.-Routine liver biopsy before treatment with interferon increases the cost of managing patients with CHC without improving health outcomes. Using quantitative HCV RNA testing to guide therapy misses some potential sustained responders. Empirical interferon treatment has a marginal cost-effectiveness ratio within the bounds of other commonly accepted therapies and misses none of the sustained responders.	Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Decis Making Informat & Telemed, Boston, MA 02111 USA; Metrowest Med Ctr, Dept Med, Framingham, MA USA	Tufts Medical Center; Tufts University	Wong, JB (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Decis Making Informat & Telemed, 750 Washington St,Box 302, Boston, MA 02111 USA.	john.wong@es.nemc.org		Wong, John/0000-0003-4203-9010				Alter M J, 1997, Clin Liver Dis, V1, P559, DOI 10.1016/S1089-3261(05)70321-4; ANGELINI G, 1995, DIGESTION, V56, P199, DOI 10.1159/000201243; [Anonymous], 1997, HEPATOLOGY, V26, pS2; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BATTEZZATI PM, 1992, ITAL J GASTROENTEROL, V24, P481; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CHRISTENSEN E, 1989, SCAND J GASTROENTERO, V24, P999, DOI 10.3109/00365528909089247; CIMINO L, 1991, ITAL J GASTROENTEROL, V23, P399; COLCHER MD, 1994, HEPATOLOGY, V20, P618; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, J HEPATOL, V11, pS72, DOI 10.1016/0168-8278(90)90168-Q; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DETRE K, 1995, LIVER TRANSPLANTATIO; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; FROEHLICH F, 1993, DIGEST DIS SCI, V38, P1480, DOI 10.1007/BF01308607; GILMORE IT, 1995, GUT, V36, P437, DOI 10.1136/gut.36.3.437; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Gold MR, 1996, COST EFFECTIVENESS H; GORDON SC, 1994, AM J GASTROENTEROL, V89, P1458; GRETCH DR, 1995, ANN INTERN MED, V123, P321, DOI 10.7326/0003-4819-123-5-199509010-00001; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; JANES CH, 1993, ANN INTERN MED, V118, P96, DOI 10.7326/0003-4819-118-2-199301150-00003; Kaplan MM, 1993, DIS LIVER, V7, P108; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KILPE VE, 1993, TRANSPLANTATION, V56, P554, DOI 10.1097/00007890-199309000-00012; Kim WR, 1997, ANN INTERN MED, V127, P866, DOI 10.7326/0003-4819-127-10-199711150-00002; KNAUER CM, 1978, GASTROENTEROLOGY, V74, P101; Koff RS, 1997, ANN INTERN MED, V127, P918, DOI 10.7326/0003-4819-127-10-199711150-00011; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LeGuen B, 1997, HEPATOLOGY, V25, P1250, DOI 10.1002/hep.510250531; LEVEY AS, 1987, ANN INTERN MED, V107, P697, DOI 10.7326/0003-4819-107-5-697; LINDNER H, 1967, DEUT MED WOCHENSCHR, V92, P1751, DOI 10.1055/s-0028-1106036; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MARCELLIN P, 1995, J HEPATOL, V22, P364, DOI 10.1016/0168-8278(95)80291-6; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MATTSSON L, 1989, THESIS KAROLINSKA I; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; McQuillan G., 1996, American Journal of Epidemiology, V143, pS32; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; PAGLIARO L, 1994, HEPATOLOGY, V19, P820, DOI 10.1002/hep.1840190404; PEREZ R, 1993, GUT, V34, pS139, DOI 10.1136/gut.34.2_Suppl.S139; PERRAULT J, 1978, GASTROENTEROLOGY, V74, P103; PIAZZA M, 1993, GUT, V34, pS128, DOI 10.1136/gut.34.2_Suppl.S128; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; PICCIOTTO A, 1995, LIVER, V15, P20; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1996, HEPATOLOGY, V24, P778; Prati D, 1996, GASTROENTEROLOGY, V110, P178, DOI 10.1053/gast.1996.v110.pm8536854; QU D, 1994, J HEPATOL, V21, P70, DOI 10.1016/S0168-8278(94)80139-8; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SERFATY L, 1994, J HEPATOL, V21, P12, DOI 10.1016/S0168-8278(94)80130-4; SHERLOCK S, 1985, J HEPATOL, V1, P75, DOI 10.1016/S0168-8278(85)80070-2; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; Tarantino G, 1993, Clin Ter, V143, P489; TERRY R, 1952, BRIT MED J, V1, P1102, DOI 10.1136/bmj.1.4768.1102; THALER H., 1964, WIENER KLIN WOCHENSCH, V76, P533; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; *UNOS DIV ORG TRAN, 1995, UNOS UPDATE, V11, P15; Watson JP, 1996, GUT, V38, P269, DOI 10.1136/gut.38.2.269; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Younossi Z, 1996, GASTROENTEROLOGY, V110, pA47; Zein NN, 1996, MAYO CLIN PROC, V71, P458, DOI 10.4065/71.5.458; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1993, MMWR MORB MORTAL WKL, V41, P969	82	148	151	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2088	2093		10.1001/jama.280.24.2088	http://dx.doi.org/10.1001/jama.280.24.2088			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875876	Bronze			2022-12-28	WOS:000077606100032
J	Heyland, DK; MacDonald, S; Keefe, L; Drover, JW				Heyland, DK; MacDonald, S; Keefe, L; Drover, JW			Total parenteral nutrition in the critically ill patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE RANDOMIZED TRIAL; THERMALLY INJURED PATIENTS; CLINICAL-TRIALS; POSTOPERATIVE PERIOD; ABDOMINAL-SURGERY; SEPTIC MORBIDITY; MAJOR SURGERY; AMINO-ACIDS; SUPPORT; CARCINOMA	Context.-Nutritional support has become a standard of care for hospitalized patients, but whether total parenteral nutrition (TPN) affects morbidity and mortality is unclear. Objective.-To examine the relationship between TPN and complication and mortality rates in critically ill patients. Data Sources.-Computerized search of published research on MEDLINE from 1980 to 1998, personal files, and review of relevant reference lists. Study Selection.-We reviewed 210 titles, abstracts, and papers. Primary studies were included if they were randomized clinical trials of critically ill or surgical patients that evaluated the effect of TPN (compared with standard care) on complication and mortality rates. We excluded studies comparing TPN with enteral nutrition. Data Extraction.-Relevant data were abstracted on the methodology and outcomes of primary studies. Data were abstracted in duplicate, independently. Data Synthesis.-There were 26 randomized trials of 2211 patients comparing the use of TPN with standard care (usual oral diet plus intravenous dextrose) in surgical and critically ill patients. When the results of these trials were aggregated, TPN had no effect on mortality (risk ratio [RR], 1.03; 95% confidence interval [CI], 0.81-1.31). Patients who received TPN tended to have a lower complication rate, but this result was not statistically significant (RR, 0.84; 95% CI, 0.64-1.09), We examined several a priori hypotheses and found that studies including only malnourished patients were associated with lower complication rates but no difference in mortality when compared with studies of nonmalnourished patients, Studies published since 1989 and studies with a higher methods score showed no treatment effect, while studies published in 1988 or before and studies with a lower methods score demonstrated a significant treatment effect. Complication rates were lower in studies that did not use lipids; however, there was no difference in mortality rates between studies that did not use lipids and those studies that did, Studies limited to critically ill patients demonstrated a significant increase in complication and mortality rates compared with studies of surgical patients. Conclusions.-Total parenteral nutrition does not influence the overall mortality rate of surgical or critically ill patients. It may reduce the complication rate, especially in malnourished patients, but study results are influenced by patient population, use of lipids, methodological quality, and year of publication.	Kingston Gen Hosp, Nutr Serv, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Surg, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Heyland, DK (corresponding author), Kingston Gen Hosp, Nutr Serv, 76 Stuart St,Angada 3, Kingston, ON K7L 2V7, Canada.	dkh@post.queensu.ca						ABEL RM, 1976, ARCH SURG-CHICAGO, V111, P45; ASKANAZI J, 1986, ANN SURG, V203, P236, DOI 10.1097/00000658-198603000-00002; *ASPEN BOARD DIR, 1993, JPEN J PARENTER EN S, V17; BASTTISTELLA ED, 1997, J TRAUMA, V43, P52; BEALE RJ, 1997, INTENSIVE CARE ME S1, V23, P5128; BELLANTONE R, 1988, ACTA CHIR SCAND, V154, P249; BELLANTONE R, 1988, JPEN-PARENTER ENTER, V12, P195, DOI 10.1177/0148607188012002195; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BONAU RA, 1984, JPEN-PARENTER ENTER, V8, P622, DOI 10.1177/0148607184008006622; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BOWER RH, 1986, ANN SURG, V203, P13, DOI 10.1097/00000658-198601000-00003; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; BROWN RO, 1990, CRIT CARE MED, V18, P1096, DOI 10.1097/00003246-199010000-00009; BUCHMAN AL, 1995, JPEN-PARENTER ENTER, V19, P453, DOI 10.1177/0148607195019006453; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Chiarelli A G, 1996, Minerva Anestesiol, V62, P1; COLLINS JP, 1978, LANCET, V1, P788; CULEBRASFERNANDEZ JM, 1987, INFUS KLIN ERN, V14, P202; DEITCH EA, 1987, ANN SURG, V205, P681, DOI 10.1097/00000658-198706000-00010; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; Doglietto GB, 1996, ANN SURG, V223, P357, DOI 10.1097/00000658-199604000-00003; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; FAN ST, 1989, CLIN NUTR, V8, P23, DOI 10.1016/0261-5614(89)90021-6; FIGUERAS J, 1988, ACTA CHIR SCAND, V154, P435; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; FORD WDA, 1984, SURGERY, V96, P527; FREEMAN J, 1990, NEW ENGL J MED, V323, P301, DOI 10.1056/NEJM199008023230504; FREUND H, 1979, ANN SURG, V190, P18, DOI 10.1097/00000658-197907000-00004; GARDEN OJ, 1983, BRIT J SURG, V70, P79, DOI 10.1002/bjs.1800700208; GYS T, 1990, ACTA CHIR BELG, P234; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; HANSELL DT, 1989, JPEN-PARENTER ENTER, V13, P349, DOI 10.1177/0148607189013004349; HEATLEY RV, 1979, POSTGRAD MED J, V55, P541, DOI 10.1136/pgmj.55.646.541; HENSLE TW, 1978, J UROLOGY, V119, P355, DOI 10.1016/S0022-5347(17)57489-3; Herndon D N, 1989, J Burn Care Rehabil, V10, P309, DOI 10.1097/00004630-198907000-00004; HERNDON DN, 1987, J TRAUMA, V27, P195, DOI 10.1097/00005373-198702000-00018; HEYLAND DK, 1993, INTENS CARE MED, V19, P435, DOI 10.1007/BF01711083; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; HOGBIN BM, 1984, JPEN-PARENTER ENTER, V8, P511, DOI 10.1177/0148607184008005511; HOLTER AR, 1977, J SURG RES, V23, P31, DOI 10.1016/0022-4804(77)90186-X; HUGHES CA, 1980, CLIN SCI, V59, P317, DOI 10.1042/cs0590317; HWANG TL, 1993, JPEN-PARENTER ENTER, V17, P254, DOI 10.1177/0148607193017003254; JENSEN S, 1985, MED ONCOL TUMOR PHAR, V2, P225; JIMENEZ FJJ, 1995, CLIN NUTR, V14, P88, DOI 10.1016/S0261-5614(95)80028-X; KORETZ RL, 1995, AM J RESP CRIT CARE, V151, P570, DOI 10.1164/ajrccm.151.2.7842222; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; LEVINE GM, 1974, GASTROENTEROLOGY, V67, P975; LO CW, 1989, NUTR REV, V47, P193, DOI 10.1111/j.1753-4887.1989.tb02837.x; MEGUID MM, 1988, BRIT J CLIN PRACT, V42, P53; MEZEY E, 1991, HEPATOLOGY, V14, P1090, DOI 10.1016/0270-9139(91)90134-H; MOGHISSI K, 1977, BRIT J SURG, V64, P125, DOI 10.1002/bjs.1800640211; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MULLER JM, 1986, WORLD J SURG, V10, P53; MULLER JM, 1982, LANCET, V1, P68; NAYLOR AF, 1967, BIOMETRICS, V23, P349, DOI 10.2307/2528167; NEUVONEN P, 1986, JPEN-PARENTER ENTER, V10, P160, DOI 10.1177/0148607186010002160; NORDENSTROM J, 1979, AM J CLIN NUTR, V32, P2416, DOI 10.1093/ajcn/32.12.2416; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PRESHAW RM, 1979, CAN J SURG, V22, P437; REILLY J, 1990, JPEN-PARENTER ENTER, V14, P386, DOI 10.1177/0148607190014004386; ROTHMAN JR, 1986, MODERN EPIDEMIOLOGY, P177; ROTHMAN KJ, 1979, EPIDEMIOLOGICAL ANAL; SACKS HS, 1983, NEW ENGL J MED, V309, P1353; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; SCHROEDER D, 1981, JPEN J PARENTER ENTE, V15, P376; SEIDNER DL, 1989, JPEN-PARENTER ENTER, V13, P614, DOI 10.1177/0148607189013006614; SIMMS JM, 1980, JPEN, V4, P422; SMITH RC, 1988, JPEN-PARENTER ENTER, V12, P587, DOI 10.1177/0148607188012006587; THOMPSON BR, 1981, J SURG RES, V30, P497, DOI 10.1016/0022-4804(81)90096-2; VENTE JP, 1991, WORLD J SURG, V15, P128, DOI 10.1007/BF01658984; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WARNOLD I, 1984, ANN SURG, V199, P299, DOI 10.1097/00000658-198403000-00009; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; WOOLFSON AMJ, 1989, CLIN NUTR, V8, P15, DOI 10.1016/0261-5614(89)90020-4; YAMADA N, 1983, BRIT J SURG, V70, P267, DOI 10.1002/bjs.1800700508	81	365	376	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2013	2019		10.1001/jama.280.23.2013	http://dx.doi.org/10.1001/jama.280.23.2013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863853				2022-12-28	WOS:000077462300032
J	Aractingi, S; Berkane, N; Bertheau, P; Le Goue, C; Dausset, J; Uzan, S; Carosella, ED				Aractingi, S; Berkane, N; Bertheau, P; Le Goue, C; Dausset, J; Uzan, S; Carosella, ED			Fetal DNA in skin of polymorphic eruptions of pregnancy	LANCET			English	Article							MATERNAL BLOOD; PERIPHERAL-BLOOD; CELLS; WOMEN; MICRODISSECTION; AMPLIFICATION; DERMATOSES; PCR	Background Polymorphic eruptions of pregnancy (PEP) are common cutaneous disorders of unknown origin that occur usually after week 34 of gestation. Since pregnancy is associated with peripheral-blood chimerism, particularly during the third trimester, we studied the role of fetal cells in the development of the skin lesions. Methods We studied samples of skin from ten women with PEP who were carrying male fetuses and 26 women with normal skin or non-PEP skin disorders (13 carrying male and 13 carrying female fetuses). Epidermis and dermis were dissected from the samples, and the DNA was extracted. PCR with primers specific for the SRY gene was used to detect male DNA. Findings Male DNA was detected in dermis or epidermis from skin lesions of six of the ten women with PEP. No male DNA was detected in any of the 26 women without PEP. Interpretation Fetal cells can migrate to skin during gestation, where they seem to be associated with the development of cutaneous disorders of pregnancy.	Hop Tenon, Unite Dermatol, F-75020 Paris, France; Hop Tenon, Serv Gynecol Obstet & Med Reprod, F-75020 Paris, France; Hop Tenon, UPRES EA 236, F-75020 Paris, France; CEA DRM DSV, Ctr Hayem, Serv Rech Hematoimmunol, Paris, France; Hop St Louis, Anat Pathol Lab, Paris, France; Hop St Louis, Fdn Dausset, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Aractingi, S (corresponding author), Hop Tenon, Unite Dermatol, Ap Hp,4 Rue Chine, F-75020 Paris, France.			Aractingi, Selim/0000-0002-7766-2673				Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; BORRADORI L, 1994, ARCH DERMATOL, V130, P778, DOI 10.1001/archderm.130.6.778; DAHL MV, 1984, J INVEST DERMATOL, V82, P132, DOI 10.1111/1523-1747.ep12259679; GANHIRST D, 1995, CURR OPIN GYNECOL OB, V7, P103; HALL JM, 1994, ANN NY ACAD SCI, V731, P115, DOI 10.1111/j.1749-6632.1994.tb55754.x; HOLMES RC, 1982, CLIN EXP DERMATOL, V7, P65, DOI 10.1111/j.1365-2230.1982.tb02387.x; HOLZGREVE W, 1990, LANCET, V335, P1220, DOI 10.1016/0140-6736(90)92741-Y; KAO SM, 1992, AM J OBSTET GYNECOL, V166, P1013, DOI 10.1016/0002-9378(92)91381-J; LAWLEY TJ, 1979, JAMA-J AM MED ASSOC, V241, P1696, DOI 10.1001/jama.241.16.1696; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; MUELLER UW, 1990, LANCET, V336, P197, DOI 10.1016/0140-6736(90)91731-O; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; ROGER D, 1994, ARCH DERMATOL, V130, P734, DOI 10.1001/archderm.130.6.734; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; RUBINOW A, 1978, ANN INTERN MED, V88, P781, DOI 10.7326/0003-4819-88-6-781; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P441, DOI 10.1136/ard.47.6.441; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	24	133	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1898	1901		10.1016/S0140-6736(98)05121-6	http://dx.doi.org/10.1016/S0140-6736(98)05121-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863788				2022-12-28	WOS:000077544600011
J	George, JN; Raskob, GE; Shah, SR; Rizvi, MA; Hamilton, SA; Osborne, S; Vondracek, T				George, JN; Raskob, GE; Shah, SR; Rizvi, MA; Hamilton, SA; Osborne, S; Vondracek, T			Drug-induced thrombocytopenia: A systematic review of published case reports	ANNALS OF INTERNAL MEDICINE			English	Review							THERAPY; PURPURA	Purpose: To determine the strength of clinical evidence for individual drugs as a cause of thrombocytopenia. Data Sources: All English-language reports on drug-induced thrombocytopenia. Study Selection: Articles describing thrombocytopenia caused by heparin were excluded from review. Of the 581 articles reviewed, 20 were excluded because they contained no patient case reports. The remaining 561 articles reported on 774 patients. Data Extraction: Two of the authors used a priori criteria to independently review each patient case report. Two hundred fifty-nine patient case reports were excluded from further review because of lack of evaluable data, platelet count of 100 000 cells/mu L or more, use of cytotoxic or nontherapeutic agents, occurrence of drug-induced systemic disease, or occurrence of disease in children. For the remaining 515 patient case reports, a level of evidence for the drug as the cause of thrombocytopenia was assigned. Data on bleeding complications and clinical course were recorded. Data Synthesis: The evidence supported a definite or probable causal role for the drug in 247 patient case reports (48%). Among the 98 drugs described in these reports, quinidine was mentioned in 38 case reports, gold in 11, and trimethoprim-sulfamethoxazole in 10. Of the 247 patients described in the case reports, 23 (9%) had major bleeding and 2 (0.8%) died of bleeding. Conclusions: Many reports of drug-induced thrombocytopenia do not provide evidence supporting a definite or probable causal relation between the disease and the drug. Future patient case reports should incorporate standard criteria to clearly establish the etiologic role of the drug.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Box 26901, Oklahoma City, OK 73190 USA.							*AHFS, 1997, AHFS DRUG INF; Berkowitz SD, 1997, CIRCULATION, V95, P809; COBLYN JS, 1981, ANN INTERN MED, V95, P178, DOI 10.7326/0003-4819-95-2-178; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; DEREN B, 1974, ARCH INTERN MED, V134, P1012, DOI 10.1001/archinte.134.6.1012; FREIMAN JP, 1990, ANN INTERN MED, V112, P308, DOI 10.7326/0003-4819-112-4-308; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1995, WILLIAMS HEMATOLOGY, P1315; Graafsma YP, 1997, THROMB HAEMOSTASIS, V78, P1189; KAUFMAN DW, 1993, BLOOD, V82, P2714; MCCRAE KR, 1994, THROMBOSIS HEMORRHAG, P545; *MICR INC, 1997, MART EXTR PHARM EL V; PedersenBjergaard U, 1997, EUR J CLIN PHARMACOL, V52, P183, DOI 10.1007/s002280050272; Simoons ML, 1997, LANCET, V349, P1429; Suh JS, 1998, BLOOD, V91, P916, DOI 10.1182/blood.V91.3.916.916_916_922; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; WARKENTIN TE, 1995, BLOOD PRINCIPLES PRA, P973; 1997, DRUG FACTS COMP	18	302	314	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					886	890		10.7326/0003-4819-129-11_Part_1-199812010-00009	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867731				2022-12-28	WOS:000077239200007
J	Rodbell, DT; Seltzer, GO; Anderson, DM; Abbott, MB; Enfield, DB; Newman, JH				Rodbell, DT; Seltzer, GO; Anderson, DM; Abbott, MB; Enfield, DB; Newman, JH			An similar to 15,000-year record of El Nino-driven alluviation in southwestern Ecuador	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; SOUTHERN OSCILLATION; EARLY HISTORY; NORTHERN PERU; VARIABILITY; CLIMATE	Debris flows have deposited inorganic Laminae in an alpine lake that is 75 kilometers east of the Pacific Ocean, in Ecuador. These storm-induced events were dated by radiocarbon, and the age of laminae that are Less than 200 years old matches the historic record of El Nino events. From about 15,000 to about 7000 calendar years before the present, the periodicity of elastic deposition is greater than or equal to 15 years; thereafter, there is a progressive increase in frequency to periodicities of 2 to 8.5 years. This is the modern El Nino periodicity, which was established about 5000 calendar years before the present. This may reflect the onset of a steeper zonal sea surface temperature gradient, which was driven by enhanced trade winds.	Union Coll, Dept Geol, Schenectady, NY 12308 USA; Syracuse Univ, Dept Earth Sci, Syracuse, NY 13244 USA; NOAA, Boulder, CO 80303 USA; Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA; NOAA, Atlantic Oceanog & Meteorol Lab, Miami, FL 33149 USA	Union College; Syracuse University; National Oceanic Atmospheric Admin (NOAA) - USA; University of Massachusetts System; University of Massachusetts Amherst; National Oceanic Atmospheric Admin (NOAA) - USA; Atlantic Oceanographic & Meteorological Laboratory (AOML)	Rodbell, DT (corresponding author), Union Coll, Dept Geol, Schenectady, NY 12308 USA.		anderson, david/E-6416-2011; Enfield, David/I-2112-2013	Enfield, David/0000-0001-8107-5079				BERGER AL, 1978, QUATERNARY RES, V9, P139, DOI 10.1016/0033-5894(78)90064-9; CANE MA, 1985, SCIENCE, V228, P1085, DOI 10.1126/science.228.4703.1085; COLE JE, 1993, SCIENCE, V260, P1790, DOI 10.1126/science.260.5115.1790; CUCALON E, 1987, J GEOPHYS RES-OCEANS, V92, P14309, DOI 10.1029/JC092iC13p14309; DeVries TJ, 1997, SCIENCE, V276, P965, DOI 10.1126/science.276.5314.965; DEVRIES TJ, 1987, J GEOPHYS RES-OCEANS, V92, P14471, DOI 10.1029/JC092iC13p14471; Diaz HF, 1992, EL NINO HIST PALEOCL; DUNBAR RB, 1994, PALEOCEANOGRAPHY, V9, P291, DOI 10.1029/93PA03501; ENFIELD DB, 1991, J CLIMATE, V4, P1137, DOI 10.1175/1520-0442(1991)004<1137:LFCIEN>2.0.CO;2; ENFIELD DB, 1989, REV GEOPHYS, V27, P159, DOI 10.1029/RG027i001p00159; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; GOLDBERG RA, 1987, J GEOPHYS RES-OCEANS, V92, P14225, DOI 10.1029/JC092iC13p14225; GRAHAM NE, 1988, SCIENCE, V240, P1293, DOI 10.1126/science.240.4857.1293; HOREL JD, 1986, MON WEATHER REV, V114, P2091, DOI 10.1175/1520-0493(1986)114<2091:CATCON>2.0.CO;2; Jenkins G., 1968, SPECTRAL ANAL ITS AP; KUSHNIR Y, 1994, J CLIMATE, V7, P141, DOI 10.1175/1520-0442(1994)007<0141:IVINAS>2.0.CO;2; MARTIN L, 1993, QUATERNARY RES, V39, P338, DOI 10.1006/qres.1993.1040; MCGLONE MS, 1992, EL NINO HIST PALEOCL, P434; MCPHADEN MJ, 1990, SCIENCE, V250, P1385, DOI 10.1126/science.250.4986.1385; McPhaden MJ, 1998, J GEOPHYS RES-OCEANS, V103, P14169, DOI 10.1029/97JC02906; Noller JS., 1993, THESIS U COLORADO CO; PHILANDER SGH, 1985, J ATMOS SCI, V42, P2652, DOI 10.1175/1520-0469(1985)042<2652:ENALN>2.0.CO;2; PICKARD GL, 1982, DESCRIPTIVE PHYSICAL; Quinn WH, 1992, CLIMATE AD 1500, V1500, P623, DOI DOI 10.1002/JOC.3370130411; RASMUSSON EM, 1982, MON WEATHER REV, V110, P354, DOI 10.1175/1520-0493(1982)110<0354:VITSST>2.0.CO;2; RODBELL DT, 1993, GEOL SOC AM BULL, V105, P923, DOI 10.1130/0016-7606(1993)105<0923:TTOTLD>2.3.CO;2; Sandweiss DH, 1997, SCIENCE, V276, P966; SHULMEISTER J, 1995, HOLOCENE, V5, P10, DOI 10.1177/095968369500500102; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; SUN DZ, IN PRESS EL NINO SO; THOMPSON LG, 1984, SCIENCE, V226, P50, DOI 10.1126/science.226.4670.50; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; THOMSON DJ, 1990, PHILOS T R SOC A, V330, P601, DOI 10.1098/rsta.1990.0041; Trenberth KE, 1997, B AM METEOROL SOC, V78, P2771, DOI 10.1175/1520-0477(1997)078<2771:TDOENO>2.0.CO;2; VAUTARD R, 1992, PHYSICA D, V58, P95, DOI 10.1016/0167-2789(92)90103-T; WELLS LE, 1990, GEOLOGY, V18, P1134, DOI 10.1130/0091-7613(1990)018<1134:HHOTEN>2.3.CO;2; Wells LE, 1997, SCIENCE, V276, P966; [No title captured]	38	524	566	4	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					516	520		10.1126/science.283.5401.516	http://dx.doi.org/10.1126/science.283.5401.516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915694				2022-12-28	WOS:000078203300030
J	Gainetdinov, RR; Wetsel, WC; Jones, SR; Levin, ED; Jaber, M; Caron, MG				Gainetdinov, RR; Wetsel, WC; Jones, SR; Levin, ED; Jaber, M; Caron, MG			Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity	SCIENCE			English	Article							DOPAMINE TRANSPORTER; MICE LACKING; D-AMPHETAMINE; ATTENTION; DISORDER; BEHAVIOR; COCAINE; BRAIN; NOREPINEPHRINE; INHIBITION	The mechanism by which psychostimulants act as calming agents in humans with attention-deficit hyperactivity disorder (ADHD) or hyperkinetic disorder is currently unknown. Mice Lacking the gene encoding the plasma membrane dopamine transporter (DAT) have elevated dopaminergic tone and are hyperactive. This activity was exacerbated by exposure to a novel environment. Additionally, these mice were impaired in spatial cognitive fund:ion, and they showed a decrease in locomotion in response to psychostimulants. This paradoxical calming effect of psychostimulants depended on serotonergic neurotransmission. The parallels between the DAT knockout mice and individuals with ADHD suggest that common mechanisms may underlie some of their behaviors and responses to psychostimulants.	Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Endocrinol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA.		Levin, Edward/GLV-2991-2022; Jones, Sara R/K-4816-2014; Gainetdinov, Raul R/G-5875-2011	Jones, Sara R/0000-0002-3424-7576; Gainetdinov, Raul R/0000-0003-2951-6038; Jaber, Mohamed/0000-0003-2536-1913	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040159, P30MH040159] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-40159] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Barkley R. A., 1998, ATTENTION DEFICIT HY, V2nd; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Baumgarten HG, 1995, PHARMACOPSYCHIATRY, V28, P73, DOI 10.1055/s-2007-979623; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; BRASE DA, 1975, LIFE SCI, V16, P1005, DOI 10.1016/0024-3205(75)90184-8; BREESE GR, 1975, PSYCHOPHARMACOLOGIA, V44, P5, DOI 10.1007/BF00421175; Broderick PA, 1997, NEUROSCI BIOBEHAV R, V21, P227, DOI 10.1016/S0149-7634(96)00048-6; BRODIE BB, 1957, ANN NY ACAD SCI, V66, P631, DOI 10.1111/j.1749-6632.1957.tb40753.x; Carlsson A., 1987, PSYCHOPHARMACOLOGY 3, P39; Collins P, 1998, J COGNITIVE NEUROSCI, V10, P332, DOI 10.1162/089892998562771; COOK EH, 1995, AM J HUM GENET, V56, P993; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gainetdinov RR, 1998, BRAIN RES REV, V26, P148, DOI 10.1016/S0165-0173(97)00063-5; GAINETDINOV RR, UNPUB; Geyer MA, 1996, BEHAV BRAIN RES, V73, P31; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; Gingerich KJ, 1998, J CLIN PSYCHOL, V54, P415, DOI 10.1002/(SICI)1097-4679(199806)54:4<415::AID-JCLP3>3.0.CO;2-M; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GREEN TK, 1974, J PHARMACOL EXP THER, V190, P109; GREENHILL LL, 1992, PSYCHIAT CLIN N AM, V15, P1; HARLOW H F, 1948, Res Publ Assoc Res Nerv Ment Dis, V27 (1 vol.), P446; HECHTMAN L, 1994, J PSYCHIATR NEUROSCI, V19, P193; HEFFNER TG, 1982, BRAIN RES, V244, P81, DOI 10.1016/0006-8993(82)90906-4; HOLLISTER AS, 1976, J PHARMACOL EXP THER, V198, P12; Hornig M, 1998, J CLIN PSYCHIAT, V59, P69; JAFFE SL, 1991, J AM ACAD CHILD PSY, V30, P773, DOI 10.1097/00004583-199109000-00012; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1672, DOI 10.1097/00004583-199712000-00015; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Jones SR, 1998, J NEUROSCI, V18, P1979; KOKKINIDIS L, 1980, PSYCHOL BULL, V88, P551; KOSTRZEWA RM, 1994, BRAIN RES BULL, V34, P161, DOI 10.1016/0361-9230(94)90013-2; KOYUNCUOGLU H, 1975, PSYCHOPHARMACOLOGIA, V45, P163, DOI 10.1007/BF00429055; Kuczenski R, 1997, J NEUROCHEM, V68, P2032; LEHNERT H, 1993, PSYCHOTHER PSYCHOSOM, V60, P18, DOI 10.1159/000288676; LeMarquand DG, 1998, NEUROPSYCHOPHARMACOL, V19, P333; Levin ED, 1997, ENVIRON HEALTH PERSP, V105, P1320, DOI 10.2307/3433751; Lucki I, 1998, BIOL PSYCHIAT, V44, P151, DOI 10.1016/S0006-3223(98)00139-5; MABRY PD, 1973, BRAIN RES, V49, P381, DOI 10.1016/0006-8993(73)90429-0; MILSON JA, 1976, BRIT J PHARMACOL, V56, P77, DOI 10.1111/j.1476-5381.1976.tb06961.x; Popper CW, 1997, J CLIN PSYCHIAT, V58, P14; Reith MEA, 1997, NEUROTRANSMITTER TRA; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; Robbins TW, 1998, ANN NY ACAD SCI, V846, P222, DOI 10.1111/j.1749-6632.1998.tb09740.x; ROBBINS TW, 1979, NEUROPHARMACOLOGY, V18, P931, DOI 10.1016/0028-3908(79)90157-6; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; Seiden L.S., 1995, HDB NEUROTOXICOLOGY, P825; SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pa.33.040193.003231; SHUSTER L, 1982, PSYCHOPHARMACOLOGY, V77, P31, DOI 10.1007/BF00436096; SNYDER SH, 1973, ANN NY ACAD SCI, V205, P310, DOI 10.1111/j.1749-6632.1973.tb43188.x; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; Swanson J, 1998, CURR OPIN NEUROBIOL, V8, P263, DOI 10.1016/S0959-4388(98)80150-5; SWANSON JM, 1996, CURR OPIN PSYCHIATR, V10, P300; TAGLIAMONTE A, 1973, LIFE SCI 2-BIOCH GEN, V12, P277, DOI 10.1016/0024-3205(73)90361-5; TAYLOR D, 1978, RES COMMUN CHEM PATH, V21, P67; TAYLOR KM, 1971, BRAIN RES, V28, P295, DOI 10.1016/0006-8993(71)90661-5; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; WESTERINK BHC, 1991, J NEUROCHEM, V56, P228, DOI 10.1111/j.1471-4159.1991.tb02585.x; WETSEL WC, UNPUB; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Young SN, 1996, NEUROSCI BIOBEHAV R, V20, P313, DOI 10.1016/0149-7634(95)00022-4	70	629	650	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					397	401		10.1126/science.283.5400.397	http://dx.doi.org/10.1126/science.283.5400.397			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	157MV	9888856				2022-12-28	WOS:000078067000050
J	Kelley, SO; Barton, JK				Kelley, SO; Barton, JK			Electron transfer between bases in double helical DNA	SCIENCE			English	Article							DISTANCE DEPENDENCE; DUPLEX DNA; FLUORESCENCE; ADENOSINE; 2-AMINOPURINE; POTENTIALS; OXIDATION; GUANOSINE; GUANINE; MOMENTS	Fluorescent analogs of adenine that selectively oxidize guanine were used to investigate photoinduced electron transfer through the DNA pi-stack as a function of reactant stacking and energetics. Small variations in these factors led to profound changes in the kinetics and distance dependences of DNA-mediated electron-transfer reactions. Values of beta, a parameter reflecting the dependence of electron transfer on distance, ranged from 0.1 to 1.0 per angstrom. Strong stacking interactions result in the fastest electron-transfer kinetics. Electrons are thus transported preferentially through an intrastrand rather than interstrand pathway. Reactant energetics also modulate the distance dependence of DNA-mediated charge transport. These studies may resolve the range of disparate results previously reported, and paradigms must now be developed to describe these properties of the DNA pi-stack, which can range from insulator- to "wire"-like.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Barton, JK (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.		Kelley, Shana/ABA-7403-2021; Kelley, Shana/H-5856-2015	Kelley, Shana/0000-0003-3360-5359	NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Arkin MR, 1997, CHEM BIOL, V4, P389, DOI 10.1016/S1074-5521(97)90129-0; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; Broo A, 1998, J PHYS CHEM A, V102, P526, DOI 10.1021/jp9713625; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Dandliker PJ, 1998, BIOCHEMISTRY-US, V37, P6491, DOI 10.1021/bi980041w; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FELTS AK, 1995, J PHYS CHEM-US, V99, P2929, DOI 10.1021/j100009a057; Fukui K, 1998, ANGEW CHEM INT EDIT, V37, P158, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<158::AID-ANIE158>3.0.CO;2-L; Gasper SM, 1997, J AM CHEM SOC, V119, P12762, DOI 10.1021/ja972496z; Georghiou S, 1996, BIOPHYS J, V70, P1909, DOI 10.1016/S0006-3495(96)79755-2; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; Hall DB, 1997, J AM CHEM SOC, V119, P5045, DOI 10.1021/ja970366k; HOLMEN A, 1994, J PHYS CHEM-US, V98, P13460, DOI 10.1021/j100102a006; Holmen A, 1997, J AM CHEM SOC, V119, P3114, DOI 10.1021/ja9635600; HOLMLIN RE, 1997, ANGEW CHEM INT EDIT, V36, P2714; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; Kelley SO, 1997, J AM CHEM SOC, V119, P9861, DOI 10.1021/ja9714651; KELLEY SO, IN PRESS MET IONS BI; KELLEY SO, IN PRESS ANGEW CHEM; KELLEY SO, 1997, CHEM BIOL, V8, P413; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1820, DOI 10.1021/bi00221a014; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEADE TJ, 1995, ANGEW CHEM INT EDIT, V34, P352, DOI 10.1002/anie.199503521; Meggers E, 1998, ANGEW CHEM INT EDIT, V37, P460, DOI 10.1002/(SICI)1521-3773(19980302)37:4<460::AID-ANIE460>3.0.CO;2-U; MURPHY CJ, 1994, P NATL ACAD SCI USA, V91, P5315, DOI 10.1073/pnas.91.12.5315; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; NORLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095; Okada A, 1998, J PHYS CHEM A, V102, P1241, DOI 10.1021/jp972918r; Priyadarshy S, 1998, J BIOL INORG CHEM, V3, P196, DOI 10.1007/s007750050221; REGAN JJ, 1995, CHEM BIOL, V2, P489, DOI 10.1016/1074-5521(95)90266-X; Saenger W., 1984, PRINCIPLES NUCL ACID; SANTHOSH C, 1991, SPECTROCHIM ACTA A, V47, P1685, DOI 10.1016/0584-8539(91)80006-5; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; Seidel CAM, 1996, J PHYS CHEM-US, V100, P5541, DOI 10.1021/jp951507c; SPENCER RD, 1974, EUR J BIOCHEM, V45, P425, DOI 10.1111/j.1432-1033.1974.tb03566.x; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Stemp EDA, 1997, J AM CHEM SOC, V119, P2921, DOI 10.1021/ja963606p; WARD DC, 1969, J BIOL CHEM, V244, P1228; WOITELLIER S, 1989, INORG CHEM, V28, P758, DOI 10.1021/ic00303a029	44	804	818	2	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					375	381		10.1126/science.283.5400.375	http://dx.doi.org/10.1126/science.283.5400.375			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888851				2022-12-28	WOS:000078067000045
J	Phillips, KA; Glendon, G; Knight, JA				Phillips, KA; Glendon, G; Knight, JA			Putting the risk of breast cancer in perspective	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERCEIVED RISK; WOMEN; AGE; TRENDS		Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Canc Care Ontario, Toronto, ON M5G 2L7, Canada; Ontario Canc Genet Networks, Toronto, ON M5G 2L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cancer Care Ontario	Phillips, KA (corresponding author), Peter MacCallum Canc Inst, Dept Med Oncol & Hematol, Locked Bag 1,A Becket St, Melbourne, Vic 3000, Australia.		Knight, Julia/R-5617-2019; Knight, Julia/A-6843-2012	Knight, Julia/0000-0002-7610-7635; Phillips, Kelly-Anne/0000-0002-0475-1771				Alexander NE, 1996, J GEN INTERN MED, V11, P92, DOI 10.1007/BF02599584; *AM CANC SOC, 1998, CANC FACTS FIG 1998, P4; BAINES CJ, 1992, CAN MED ASSOC J, V146, P2147; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Dolan NC, 1997, CANCER, V80, P413; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; Hebert-Croteau N, 1997, CAN J PUBLIC HEALTH, V88, P392, DOI 10.1007/BF03403913; *NAT COUNC AG, 1997, MYTHS PERC AG WOM HL; *NCI CAN, 1998, CAN CANC STAT; Smith BL, 1996, SURGERY, V120, P297, DOI 10.1016/S0039-6060(96)80301-1; WUN LM, 1995, CANCER CAUSE CONTROL, V6, P135, DOI 10.1007/BF00052774; 1997, LANCET, V350, P1563	13	83	83	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					141	144		10.1056/NEJM199901143400211	http://dx.doi.org/10.1056/NEJM199901143400211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887168				2022-12-28	WOS:000078016200011
J	Ramsey, BW; Pepe, MS; Quan, JM; Otto, KL; Montgomery, AB; Williams-Warren, J; Vasiljev-K, M; Borowitz, D; Bowman, CM; Marshall, BC; Marshall, S; Smith, AL				Ramsey, BW; Pepe, MS; Quan, JM; Otto, KL; Montgomery, AB; Williams-Warren, J; Vasiljev-K, M; Borowitz, D; Bowman, CM; Marshall, BC; Marshall, S; Smith, AL		Cystic Fibrosis Inhaled Tobramycin Study Grp	Intermittent administration of inhaled tobramycin in patients with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PSEUDOMONAS-AERUGINOSA; EXACERBATIONS; DISEASE	Background and Methods We conducted two multicenter, double-blind, placebo-controlled trials of intermittent administration of inhaled tobramycin in patients with cystic fibrosis and Pseudomonas aeruginosa infection. A total of 520 patients (mean age, 21 years) were randomly assigned to receive either 300 mg of inhaled tobramycin or placebo twice daily for four weeks, followed by four weeks with no study drug. Patients received treatment or placebo in three on-off cycles for a total of 24 weeks. The end points included pulmonary function, the density of Fl aeruginosa in sputum, and hospitalization. Results The patients treated with inhaled tobramycin had an average increase in forced expiratory volume in one second (FEV1) of 10 percent at week 20 as compared with week 0, whereas the patients receiving placebo had a 2 percent decline in FEV1 (P<0.001). In the tobramycin group, the density of Fl aeruginosa decreased by an average of 0.8 log(10) colony-forming units (CFU) per gram of expectorated sputum from week 0 to week 20, as compared with an increase of 0.3 log(10) CFU per gram in the placebo group (P<0.001). The patients in the tobramycin group were 26 percent (95 percent confidence interval, 2 to 43 percent) less likely to be hospitalized than those in the placebo group. Inhaled tobramycin was not associated with detectable ototoxic or nephrotoxic effects or with accumulation of the drug in serum. The proportion of patients with Fl aeruginosa isolates for which the minimal inhibitory concentration of tobramycin was 8 mu g per milliliter or higher increased from 25 percent at week 0 to 32 percent at week 24 in the tobramycin group, as compared with a decrease from 20 percent at week 0 to 17 percent at week 24 in the placebo group. Conclusions In a 24-week study of patients with cystic fibrosis, intermittent administration of inhaled tobramycin was well tolerated and improved pulmonary function, decreased the density of Fl aeruginosa in sputum, and decreased the risk of hospitalization. (N Engl J Med 1999;340:23-30.). (C) 1999, Massachusetts Medical Society.	Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; PathoGenesis, Seattle, WA USA; SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA; Univ So Calif, Dept Pediat, Los Angeles, CA 90089 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Missouri, Sch Med, Dept Mol Microbiol, Columbia, MO USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Southern California; Utah System of Higher Education; University of Utah; University of Missouri System; University of Missouri Columbia	Ramsey, BW (corresponding author), Childrens Hosp & Med Ctr, CH-18,POB C-5371, Seattle, WA 98105 USA.		Smith, Adam/GPS-8322-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00037] Funding Source: Medline; NIDDK NIH HHS [P30-DK47754] Funding Source: Medline; PHS HHS [MO1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Burns JL, 1998, CLIN INFECT DIS, V27, P158, DOI 10.1086/514631; *CYST FIBR FDN, 1997, CYST FIBR FDN PAT RE; DALTONBUNNOW MF, 1985, AM J HOSP PHARM, V42, P2220, DOI 10.1093/ajhp/42.10.2220; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Eisenberg J, 1997, CHEST, V111, P955, DOI 10.1378/chest.111.4.955; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GRIMWOOD K, 1993, PEDIATR PULM, V15, P135, DOI 10.1002/ppul.1950150302; HODSON ME, 1981, LANCET, V2, P1137; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MACLUSKY IB, 1989, PEDIATR PULM, V7, P42, DOI 10.1002/ppul.1950070110; RAMSEY BW, 1993, NEW ENGL J MED, V328, P1740, DOI 10.1056/NEJM199306173282403; RAMSEY BW, 1994, J PEDIATR-US, V124, P177, DOI 10.1016/S0022-3476(94)70301-9; STEINKAMP G, 1989, PEDIATR PULM, V6, P91, DOI 10.1002/ppul.1950060207; THOMASSEN MJ, 1979, J INFECT DIS, V140, P873, DOI 10.1093/infdis/140.6.873; TURPIN SV, 1993, CYSTIC FIBROSIS, V64, P277; WALL MA, 1983, LANCET, V1, P1325; WOLFF RK, 1994, J AEROSOL MED, V7, P89, DOI 10.1089/jam.1994.7.89	21	968	1021	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					23	30		10.1056/NEJM199901073400104	http://dx.doi.org/10.1056/NEJM199901073400104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878641	Green Published			2022-12-28	WOS:000077943700004
J	Leviton, LC; Goldenberg, RL; Baker, CS; Schwartz, RM; Freda, MC; Fish, LJ; Cliver, SP; Rouse, DJ; Chazotte, C; Merkatz, IR; Raczynski, JM				Leviton, LC; Goldenberg, RL; Baker, CS; Schwartz, RM; Freda, MC; Fish, LJ; Cliver, SP; Rouse, DJ; Chazotte, C; Merkatz, IR; Raczynski, JM			Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; EDUCATIONAL OUTREACH; DELIVERY; SURVIVAL; OPINION	Context Antenatal corticosteroids for fetal maturation have been underused, despite evidence for their benefits in cases of preterm birth. Objective To evaluate dissemination strategies aimed at increasing appropriate use of this therapy. Design and Setting Twenty-seven tertiary care institutions were randomly assigned to either usual dissemination of practice recommendations (n = 14) or usual dissemination plus an active, focused dissemination effort (n = 13), Subjects Obstetricians and their preterm delivery cases at participating hospitals. Intervention Recommendations by a National Institutes of Health (NIH) Consensus Conference held in late February-early March 1994 were disseminated in early May 1994. Usual dissemination was publication of the recommendations and endorsement by the American College of Obstetricians and Gynecologists. Active dissemination was a year-long educational effort led by an influential physician and a nurse coordinator at each facility, consisting of grand rounds, a chart reminder system, group discussion of case scenarios, monitoring, and feedback. Main Outcome Measure Use or nonuse of antenatal corticosteroids was abstracted from medical records of eligible women delivering at the participating hospitals in the 12 months immediately prior to release of the NIH recommendations (average number of records abstracted, 130) and in the 12 months following their release (average number of records abstracted, 122). Results Active dissemination significantly increased the odds of corticosteroid use after the conference. Use increased from 33.0% of eligible patients receiving corticosteroids to 57.6%, or by 75% over baseline, in usual dissemination hospitals. Use increased from 32.9% to 68.3%, or an 108% increase, in active dissemination hospitals. Gestational age and maternal diagnosis affected use of the therapy in complex ways. Conclusion An active, focused dissemination effort increased the effectiveness of usual dissemination methods when combined with key principles to change physician practices.	Univ Alabama, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Obstet & Gynecol, Birmingham, AL USA; Natl Perinatal Informat Ctr, Providence, RI USA; Yeshiva Univ, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, New York, NY 10033 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yeshiva University	Leviton, LC (corresponding author), Univ Alabama, Sch Publ Hlth, Dept Hlth Behav, Ryals Bldg,1665 Univ Blvd, Birmingham, AL 35294 USA.	lleviton@hb.soph.uab.edu			PHS HHS [290-92-0055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AG HLTH CAR POL R, 1992, ANN BIBL INF DISS HL; *AM COLL OBST GYN, 1994, COMM OP, V147; BRONSTEIN JM, 1995, AM J OBSTET GYNECOL, V173, P296, DOI 10.1016/0002-9378(95)90217-1; Bronstein JM, 1998, HEALTH SERV RES, V32, P825; BRYK AS, 1993, HIERARCHICAL LINEAR; Burack RC, 1996, CANCER, V78, P1708, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1708::AID-CNCR11>3.3.CO;2-9; Coleman J. S., 1966, MED INNOVATION DIFFU; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; GILSTRAP LC, 1995, AM J OBSTET GYNECOL, V173, P246; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Gould C, 1996, BRIT J OBSTET GYNAEC, V103, P534; GROGAARD JB, 1990, J PEDIATR-US, V117, P139, DOI 10.1016/S0022-3476(05)72462-8; HACK M, 1991, PEDIATRICS, V87, P587; HAYWOOD JL, 1994, AM J OBSTET GYNECOL, V171, P432, DOI 10.1016/0002-9378(94)90279-8; KANOUSE DE, 1992, CHANGING MED PRACTIC; LEVITON LC, 1995, AM J OBSTET GYNECOL, V173, P312, DOI 10.1016/0002-9378(95)90220-1; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; *NAT I HLTH, 1994, NIH CONS STAT, V12, P1; Naylor D., 1998, JAMA-J AM MED ASSOC, V279, P1392; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; SOUMERAI SB, 1993, JAMA-J AM MED ASSOC, V270, P961, DOI 10.1001/jama.270.8.961; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; VanAmringe M, 1992, QRB Qual Rev Bull, V18, P397; WRIGHT LL, 1995, AM J OBSTET GYNECOL, V173, P263, DOI 10.1016/0002-9378(95)90211-2	26	90	90	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					46	52		10.1001/jama.281.1.46	http://dx.doi.org/10.1001/jama.281.1.46			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892450				2022-12-28	WOS:000077829300034
J	Rich, JD; Merriman, NA; Mylonakis, E; Greenough, TC; Flanigan, TP; Mady, BJ; Carpenter, CCJ				Rich, JD; Merriman, NA; Mylonakis, E; Greenough, TC; Flanigan, TP; Mady, BJ; Carpenter, CCJ			Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: A case series	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS; ANTIBODY; DONORS; BLOOD	Background: The availability of sensitive assays for plasma HIV viral load and the trend toward earlier and more aggressive treatment of HIV infection has led to the inappropriate use of these assays as primary tools for the diagnosis of acute HIV infection. Objective: To describe limitations in the use of plasma viral load testing for the diagnosis of HIV infection. Design: Case series. Setting: Academic medical centers in Providence, Rhode Island, and Worcester, Massachusetts. Patients: Three persons in whom HIV infection was falsely diagnosed by plasma viral load testing. Measurements: Laboratory measures and clinical outcomes. Results: Two cases of false-positive results obtained by using branched-chain DNA plasma viral load assays and one case of a false-positive result obtained by using reverse transcriptase-polymerase chain reaction plasma viral load assay are reported. All three plasma Viral load tests yielded positive results with low values (1254 copies/mL, 1574 copies/mL, and 1300 copies/mL). Infection with HIV was initially diagnosed in all three patients, but each patient subsequently tested negative by HIV-1 enzyme-linked immunosorbent assay and repeated plasma viral load testing. Conclusion: Physicians should exercise caution when using plasma Viral load assays to detect primary HIV infection, particularly when the pretest probability of infection is low.	Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	Brown University; University of Massachusetts System; University of Massachusetts Worcester	Rich, JD (corresponding author), Brown Univ, Miriam Hosp, Sch Med, Dept Med, 164 Summit Ave, Providence, RI 02906 USA.	josiah_rich@Brown.edu			NATIONAL INSTITUTE ON DRUG ABUSE [K20DA000268] Funding Source: NIH RePORTER; NIDA NIH HHS [K20 DA00268] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P380; Brown AE, 1997, TRANSFUSION, V37, P926, DOI 10.1046/j.1537-2995.1997.37997454019.x; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Harrigan R, 1995, J ACQ IMMUN DEF SYND, V10, pS34; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; Niu MT, 1998, J INFECT DIS, V178, P80, DOI 10.1086/515612; Saah AJ, 1997, ANN INTERN MED, V126, P91, DOI 10.7326/0003-4819-126-1-199701010-00026; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; Schwartz DH, 1997, LANCET, V350, P256, DOI 10.1016/S0140-6736(97)01500-6; 1997, MED LETT DRUGS THER, V39, P81	16	70	75	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					37	39		10.7326/0003-4819-130-1-199901050-00007	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890848				2022-12-28	WOS:000077744500006
J	Qi, HL; Rand, MD; Wu, XH; Sestan, N; Wang, WY; Rakic, P; Xu, T; Artavanis-Tsakonas, S				Qi, HL; Rand, MD; Wu, XH; Sestan, N; Wang, WY; Rakic, P; Xu, T; Artavanis-Tsakonas, S			Processing of the Notch ligand delta by the metalloprotease kuzbanian	SCIENCE			English	Article							CELL FATE; DROSOPHILA; RECEPTOR; PROTEIN; SERRATE; CHOICE	Signaling by the Notch surface receptor controls cell fate determination in a broad spectrum of tissues. This signaling is triggered by the interaction of the Notch protein with what, so far, have been thought to be transmembrane ligands expressed on adjacent cells. Here biochemical and genetic analyses show that the ligand Delta is cleaved on the surface, releasing an extracellular fragment capable of binding to Notch and acting as an agonist of Notch activity. The ADAM disintegrin metalloprotease Kuzbanian is required for this processing event. These observations raise the possibility that Notch signaling in vivo is modulated by soluble forms of the Notch ligands.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China; Yale Univ, Sch Med, Boyer Ctr Mol Med, Neurobiol Sect, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Fudan University; Yale University	Artavanis-Tsakonas, S (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084, R01NS014841] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14841, NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Klueg KM, 1998, MOL BIOL CELL, V9, P1709, DOI 10.1091/mbc.9.7.1709; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; QI H, UNPUB; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, THESIS YALE U; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SESTAN N, UNPUB; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sun X, 1997, DEVELOPMENT, V124, P3439; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wu X., UNPUB	21	368	380	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					91	94		10.1126/science.283.5398.91	http://dx.doi.org/10.1126/science.283.5398.91			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872749				2022-12-28	WOS:000077976600057
J	Glick, BS; Malhotra, V				Glick, BS; Malhotra, V			The curious status of the Golgi apparatus	CELL			English	Review							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; PROTEIN-TRANSPORT; COMPLEX; CELLS; SECRETION; ORGANIZATION; MEMBRANES; MECHANISM; RETRIEVAL		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of California System; University of California San Diego; University of Chicago	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	malhotra@biomail.ucsd.edu	Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; Beams H. W., 1968, International Review of Cytology, V23, P209, DOI 10.1016/S0074-7696(08)60273-9; Becker B, 1996, MICROBIOL REV, V60, P697, DOI 10.1128/MMBR.60.4.697-721.1996; BIRKY CW, 1983, INT REV CYTOL, P49; CLERMONT Y, 1993, ANAT REC, V235, P363, DOI 10.1002/ar.1092350305; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; Fullekrug J, 1998, BBA-MOL CELL RES, V1404, P77, DOI 10.1016/S0167-4889(98)00048-2; Gaynor EC, 1998, BBA-MOL CELL RES, V1404, P33, DOI 10.1016/S0167-4889(98)00045-7; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KREIS TE, 1997, GOLGI APPARATUS, P179; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; MOLLENHAUER HH, 1991, J ELECTRON MICR TECH, V17, P2, DOI 10.1002/jemt.1060170103; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALADE GE, 1983, METHOD ENZYMOL, V96, pR29; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RABOUILLE C, 1997, GOLGI APPARATUS, P195; Rambourg A., 1997, GOLGI APPARATUS, P37; Reynolds TB, 1998, J CELL BIOL, V143, P935, DOI 10.1083/jcb.143.4.935; ROTH J, 1997, GOLGI APPARATUS, P131; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHNEPF E, 1993, PROTOPLASMA, V172, P3, DOI 10.1007/BF01403716; SCHWANINGER R, 1992, METHOD ENZYMOL, V219, P110; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Staehelin L. A, 1997, GOLGI APPARATUS, P275, DOI [DOI 10.1007/978-3-0348-8876-9_10, 10.1007/978-3-0348-8876-9_10]; STORRIE B, 1998, IN PRESS J CELL BIOL, V143; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Whaley W.B., 1975, GOLGI APPARATUS; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	70	184	187	2	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					883	889		10.1016/S0092-8674(00)81713-4	http://dx.doi.org/10.1016/S0092-8674(00)81713-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875843	Bronze			2022-12-28	WOS:000077759100004
J	Fletcher, SW; Fletcher, RH				Fletcher, SW; Fletcher, RH			Development of clinical guidelines	LANCET			English	Editorial Material									Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fletcher, SW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA.							BROOK RH, 1996, LANCET, V348, P1001; Coley CM, 1997, ANN INTERN MED, V126, P480; Day P., 1998, NUFFIELD TRUST SERIE, V4; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; EASTMAN P, 1997, J NATL CANCER I, V89, P8; *NIH CONS DEV PAN, 1997, MONOGR NATL CANC I, V22, pR7	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1876	1876		10.1016/S0140-6736(05)60393-5	http://dx.doi.org/10.1016/S0140-6736(05)60393-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863783				2022-12-28	WOS:000077544600006
J	Barondess, JA				Barondess, JA			Care of the medical ethos: Reflections on social Darwinism, racial hygiene, and the Holocaust	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Conference on Medical Research Ethics at the End of the 20th-Century - What Have We Learned	MAR 30, 1998	NIH, BETHESDA, MD		NIH		CANCER	The core values of medicine-healing, relief of suffering, and compassion-have ancient roots and have been reiterated on countless occasions over the millennia. Most physicians have adopted these values and use them to guide clinical practice. However, these principles, which reflect the ethical priorities of medicine in most western societies, are vulnerable to distortion and subversion by Various forces. The eugenics movement of the early 20th century, based on flawed and simplistic science, was one such force; it led medicine to adversely affect the lives of tens of thousands of persons in the United States, Great Britain, and elsewhere. The most egregious distortions of the medical ethos took place in Nazi Germany in the 1930s and 1940s, when state policies led German biomedicine to depart radically from the traditional values. Recent decades have seen heightened sensitivity to the idea that the medical ethos is not immutable; rather, upholding it requires concerned attention and ongoing care. Such views have been sharpened not only by reports of ethically flawed research but by striking inequalities in access to and quality of health care among socioeconomic and ethnic groups in the U.S. population. Specific efforts are needed to ra ise awareness of the central importance of the medical ethos as an active guide across the range of activities of biomedicine.	New York Acad Med, New York, NY 10029 USA	New York Academy of Medicine	Barondess, JA (corresponding author), New York Acad Med, 1216 5th Ave, New York, NY 10029 USA.							BARONDESS JA, 1997, T AM CLIN CLIM ASS, V109, P174; Barondess JA, 1994, T AM CLIN CLIMAT ASS, V106, P1; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CYNKAR RJ, 1981, COLUMBIA LAW REV, V81, P1418, DOI 10.2307/1122204; Ernst E, 1996, AM J MED, V100, P579, DOI 10.1016/S0002-9343(96)00006-X; ERNST E, 1995, ANN INTERN MED, V122, P789, DOI 10.7326/0003-4819-122-10-199505150-00009; FERRERO GL, 1972, CRIMINAL MAN ACCORDI; Harrington A, 1996, DAEDALUS, V125, P181; HAYCRAFT JB, 1895, DARWINISM RACE PROGR, P51; Holstein M, 1997, ACAD MED, V72, P848, DOI 10.1097/00001888-199710000-00007; JONSEN A, 1990, NEW MED OLD ETHICS, P70; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KATER MH, 1979, HIST Z, V228, P572; Katz J., 1994, MED ETHICS 3 REICH H, P73; KEVLES DJ, 1985, NAME EUGENICS GENETI, P47; Langer LL, 1996, DAEDALUS, V125, P47; LERNER BH, 1995, ANN INTERN MED, V122, P793, DOI 10.7326/0003-4819-122-10-199505150-00010; McLaren Angus, 1990, OUR OWN MASTER RACE, DOI DOI 10.3138/9781442623316; Mitscherlich A, 1949, DOCTORS INFAMY STORY; Morton S.G., 1839, CRANIA AM; MULLERHILL B, 1988, MURDEROUS SCI, P89; OLIVER JH, 1939, B HIST MED, V7, P315; PLOETZ A, 1895, GRUNDLINIEN EINER RA, V1; Polubinskaya SV, 1996, INT J LAW PSYCHIAT, V19, P143, DOI 10.1016/0160-2527(96)00002-7; PROCTOR R, 1988, RACIAL HYGIENE MED N, P161; PROCTOR R, 1988, RACIAL HYGIENE MED N, P15; Proctor RN, 1997, B HIST MED, V71, P435, DOI 10.1353/bhm.1997.0139; Proctor RN, 1988, RACIAL HYGIENE MED N, P64; REILLY PR, 1985, GENETICS LAW, V3, P236; ROCTOR R, 1988, RACIAL HYGIENE MED N, P14; STRAUSS MB, 1968, FAMILIAR MED QUOTATI, P410; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056	34	27	27	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					891	898		10.7326/0003-4819-129-11_Part_1-199812010-00010	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867732				2022-12-28	WOS:000077239200008
J	Powell, LW; George, DK; McDonnell, SM; Kowdley, KV				Powell, LW; George, DK; McDonnell, SM; Kowdley, KV			Diagnosis of hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			HEPATIC IRON INDEX; HEREDITARY HEMOCHROMATOSIS; GENETIC HEMOCHROMATOSIS; BLOOD-DONORS; HLA-H; PREVALENCE; OVERLOAD		Univ Queensland, Brisbane, Qld, Australia; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Washington, Seattle, WA 98195 USA	University of Queensland; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle	Powell, LW (corresponding author), Univ Queensland, Brisbane, Qld, Australia.		Kowdley, Kris/AAF-5202-2019; Kalantar-Zadeh, Kamyar/Q-4734-2018	Kalantar-Zadeh, Kamyar/0000-0002-8666-0725				ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130; Barton JC, 1997, AM J MED, V103, P498, DOI 10.1016/S0002-9343(97)00276-3; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Bradley L A, 1996, J Med Screen, V3, P178; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; Conte D, 1998, ANN INTERN MED, V128, P370, DOI 10.7326/0003-4819-128-5-199803010-00005; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; GEORGE DK, 1995, ANN CLIN BIOCHEM, V32, P521, DOI 10.1177/000456329503200601; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Kowdley KV, 1997, GASTROENTEROLOGY, V113, P1270, DOI 10.1053/gast.1997.v113.pm9322522; KUSHNER JP, 1995, GASTROENTEROLOGY, V109, P315, DOI 10.1016/0016-5085(95)90300-3; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LLOYD HM, 1964, LANCET, V2, P555; MACDONALD RA, 1965, AM J MED SCI, V249, P62; MacDONALD RICHARD A., 1966, PROGR HEMATOLIN PROGRESS IN HEMATOLOGY, V5, P324; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; Moirand R, 1997, LANCET, V349, P95, DOI 10.1016/S0140-6736(96)06034-5; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; OLYNYK J, 1994, AUST NZ J MED, V24, P22, DOI 10.1111/j.1445-5994.1994.tb04420.x; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Powell LW, 1996, GASTROENTEROLOGY, V110, P1304, DOI 10.1053/gast.1996.v110.agast961304; Powell W.L., 1994, IRON METABOLISM HLTH; RUBIN RB, 1995, DIGEST DIS, V13, P223, DOI 10.1159/000171504; Sheldon J. H., 1935, HAEMOCHROMATOSIS; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; VONRECKLINGHAUS.F, 1889, 62 TAG VERSLG DTSCH, P324; WIGGERS P, 1991, J INTERN MED, V230, P265, DOI 10.1111/j.1365-2796.1991.tb00441.x; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005	40	136	141	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					925	931		10.7326/0003-4819-129-11_Part_2-199812011-00002	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867744				2022-12-28	WOS:000077239200024
J	Yang, QH; McDonnell, SM; Khoury, MJ; Cono, J; Parrish, RG				Yang, QH; McDonnell, SM; Khoury, MJ; Cono, J; Parrish, RG			Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of multiple-cause mortality data	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			ISCHEMIC-HEART-DISEASE; BODY IRON STORES; HEREDITARY HEMOCHROMATOSIS; RISK; DEATH; GENE; EXPRESSION; PREVALENCE; MORBIDITY; OVERLOAD	Background: Hemochromatosis, which can lead to serious chronic diseases resulting from iron overload, has an estimated prevalence of 50 to 80 cases per 10 000 persons. However, little population-based information is available on the impact of hemochromatosis on morbidity and mortality. Objective: To evaluate trends over 14 years in deaths and medical conditions associated with hemochromatosis in the United States. Design: We searched Multiple-Cause Mortality Files compiled by the National Center for Health Statistics for the years 1979 to 1992 for all records listing hemochromatosis. We used these data to calculate age-adjusted and age-specific mortality rates, identify medical conditions associated with a known diagnosis of hemochromatosis at death, and calculate proportionate mortality ratios for these medical conditions. Results: The listing of hemochromatosis on death certificates increased 60% from 1979 to 1992. Decedents with hemochromatosis were 23, 13, and 5 times more likely to have liver neoplasms, liver disease, and cardiomyopathy, respectively, than were decedents without hemochromatosis. Conversely, decedents with liver neoplasms, liver disease, and cardiomyopathy were 26, 14, and 5 times more likely, respectively, to have hemochromatosis than were decedents without these conditions. Hemochromatosis was 82 times more likely in persons with the combination of liver neoplasms and diabetes and 43 times more likely in those with the combination of liver disease and diabetes than in those without these conditions. Conclusions: Comparison of the reported prevalence of hemochromatosis among decedents with estimates of prevalence in the general U.S. population suggests that either the penetrance or the recognition of hemochromatosis, or both, is low. Nevertheless, substantial mortality resulting from liver disease, liver neoplasms, cardiomyopathy, and a combination of liver disease and diabetes in patients with hemochromatosis argues for the improved diagnosis and treatment of hemochromatosis in persons with these conditions.	Ctr Dis Control & Prevent, Div Int Hlth, Atlanta, GA 30333 USA; Emory Univ, Egleston Childrens Hosp, Dept Gen Pediat, Atlanta, GA 30312 USA	Centers for Disease Control & Prevention - USA; Emory University	McDonnell, SM (corresponding author), Ctr Dis Control & Prevent, Div Int Hlth, Mailstop C-08,1600 Clifton Rd, Atlanta, GA 30333 USA.	sem0@cdc.gov						Adams PC, 1996, SEMIN LIVER DIS, V16, P47, DOI 10.1055/s-2007-1007218; Ahlbom A, 1993, BIOSTATISTICS EPIDEM; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Baur M.P., 1980, HISTOCOMPATIBILITY T, P955; BOTHWELL TH, 1995, NUTR REV, V53, P237, DOI 10.1111/j.1753-4887.1995.tb05480.x; Bradley L A, 1996, J Med Screen, V3, P178; Carella M, 1997, AM J HUM GENET, V60, P828; CARTWRIGHT GE, 1974, HARRISONS PRINCIPLES, P618; CONRAD ME, 1991, AM J HEMATOL, V38, P150, DOI 10.1002/ajh.2830380217; CROSBY WH, 1987, HOSP PRACT, V22, P173, DOI 10.1080/21548331.1987.11707681; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; GABLE CB, 1992, J AM DIET ASSOC, V92, P208; GITTELSOHN A, 1978, 2300032 NCHS HRA; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HURWITZ ES, 1995, AM J PUBLIC HEALTH, V85, P1256, DOI 10.2105/AJPH.85.9.1256; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KNEKT P, 1994, INT J CANCER, V56, P379, DOI 10.1002/ijc.2910560315; Knisely A S, 1992, Adv Pediatr, V39, P383; KULLER LH, 1995, AM J PUBLIC HEALTH, V85, P1198, DOI 10.2105/AJPH.85.9.1198; Lynch SR, 1996, J NUTR, V126, pS2404; MACDONALD RA, 1965, AM J MED SCI, V249, P62; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; ROUAULT TA, 1993, JAMA-J AM MED ASSOC, V269, P3152, DOI 10.1001/jama.269.24.3152; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; Sempos CT, 1996, NUTR REV, V54, P73, DOI 10.1111/j.1753-4887.1996.tb03875.x; STEVENS RG, 1994, INT J CANCER, V56, P364, DOI 10.1002/ijc.2910560312; SULLIVAN JL, 1992, CIRCULATION, V86, P1036, DOI 10.1161/01.CIR.86.3.1036; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Yang QH, 1997, GENET EPIDEMIOL, V14, P493, DOI 10.1002/(SICI)1098-2272(1997)14:5<493::AID-GEPI4>3.0.CO;2-2; 1996, MMWR MORB MORTAL WKL, V45, P991	42	125	128	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					946	953		10.7326/0003-4819-129-11_Part_2-199812011-00005	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867747				2022-12-28	WOS:000077239200027
J	Fruman, DA; Snapper, SB; Yballe, CM; Davidson, L; Yu, JY; Alt, FW; Cantley, LC				Fruman, DA; Snapper, SB; Yballe, CM; Davidson, L; Yu, JY; Alt, FW; Cantley, LC			Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85 alpha	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; FAMILY; GENE; SPECIFICITY; MICE; CD28	Phosphoinositide 3-kinase (PI3K) activation has been implicated in many cellular responses, including fibroblast growth, transformation, survival, and chemotaxis, Although PI3K is activated by several agents that stimulate T and B cells, the role of PI3K in Lymphocyte function is not clear. The mouse gene encoding the PI3K adapter subunit p85 alpha and its splice variants p55 alpha and p50 alpha was disrupted. Most p85 alpha-p55 alpha-p50 alpha(-/-) mice die within days after birth. Lymphocyte development and function was studied with the use of the RAG2-deficient blastocyst complementation system. Chimeric mice had reduced numbers of peripheral mature B cells and decreased serum immunoglobulin. The B cells that developed had diminished proliferative responses to antibody to immunoglobulin M, antibody to CD40, and Lipopolysaccharide stimulation and decreased survival after incubation with interleukin-A In contrast, T cell development and proliferation was normal. This phenotype is similar to defects observed in mice lacking the tyrosine kinase Btk.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Med Serv, Gastrointestinal Unit, Boston, MA 02114 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Fruman, DA (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DUCKWORTH BC, 1996, HANDB LIP R, V8, P125; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; FRUMAN DA, UNPUB; Hutchcroft JE, 1996, J IMMUNOL, V156, P4071; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRUITT KE, 1995, J IMMUNOL, V155, P4702; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Woodland RT, 1996, J IMMUNOL, V156, P2143; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	24	546	556	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					393	397		10.1126/science.283.5400.393	http://dx.doi.org/10.1126/science.283.5400.393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888855				2022-12-28	WOS:000078067000049
J	Hingorani, AD; Vallance, P				Hingorani, AD; Vallance, P			A simple computer program for guiding management of cardiovascular risk factors and prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PRIMARY PREVENTION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HYPERTENSION; PRAVASTATIN; PROFILE; STROKE; TABLE	Objective To describe, and to test against trial data, a simple and flexible computer program for calculating cardiovascular risk in individual patients as an aid to managing risk factors and prescribing drugs to lower cholesterol concentration and blood pressure. Design Descriptive comparison of actual cardiovascular risk in randomised controlled trials of cholesterol reduction with risk predicted by a computer program based on the Framingham risk equation. Comparison of the program's performance with that of tables and guidelines by means of hypothetical case examples. Main outcome measures Average risk of coronary heart disease and myocardial infarction. Results The computer program accurately predicted baseline absolute risk in a UK population as well as the relative and absolute reduction in risk from cholesterol lowering for primary prevention of coronary heart disease. The program also allowed a more refined estimate of absolute risk of coronary heart disease than some existing tables and enabled the impact of prescribing decisions to be quantified and costed. Conclusions This simple computer program to estimate individuals' cardiovascular disease risk and display the benefits of intervention should help clinicians and patients decide on the most effective packages of risk reduction and identify those most likely to benefit from modulation of risk factors.	UCL, Wolfson Inst Biomed Res, Ctr Clin Pharmacol, London W1P 9LN, England	University of London; University College London	Hingorani, AD (corresponding author), UCL, Wolfson Inst Biomed Res, Ctr Clin Pharmacol, London W1P 9LN, England.	a.hingorani@ucl.ac.uk		Hingorani, Aroon/0000-0001-8365-0081				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; FREMANTLE N, 1997, BRIT MED J, V315, P826; Gould AL, 1998, CIRCULATION, V97, P946; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; Haq IU, 1996, CLIN SCI, V91, P773; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JACKSON R, 1995, LANCET, V346, P1440, DOI 10.1016/S0140-6736(95)92466-3; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; Muldoon MF, 1997, BRIT MED J, V315, P1554, DOI 10.1136/bmj.315.7122.1554; Packard CJ, 1998, CIRCULATION, V97, P1440; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Ramsay LE, 1996, LANCET, V348, P1251, DOI 10.1016/S0140-6736(05)65536-5; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SCAND SIMV SURV S, 1995, LANCET, V344, P1883; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Skolbekken JA, 1998, BMJ-BRIT MED J, V316, P1956, DOI 10.1136/bmj.316.7149.1956; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WIYNARD G, 1997, SMAC STATE USE STATI; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	25	96	99	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1999	318	7176					101	105		10.1136/bmj.318.7176.101	http://dx.doi.org/10.1136/bmj.318.7176.101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880285	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078087500028
J	Stiner, MC; Munro, ND; Surovell, TA; Tchernov, E; Bar-Yosef, O				Stiner, MC; Munro, ND; Surovell, TA; Tchernov, E; Bar-Yosef, O			Paleolithic population growth pulses evidenced by small animal exploitation	SCIENCE			English	Article							MT-CARMEL; ORIGINS; CAVE	Variations in small game hunting along the northern and eastern rims of the Mediterranean Sea and results from predator-prey simulation modeling indicate that human population densities increased abruptly during the late Middle Paleolithic and again during the Upper and Epi-Paleolithic periods. The demographic pulses are evidenced by increasing reliance on agile, fast-reproducing partridges, hares, and rabbits at the expense of slow-reproducing but easily caught tortoises and marine shellfish and, concurrently, climate-independent size diminution in tortoises and shellfish. The results indicate that human populations of the early Middle Paleolithic were exceptionally small and highly dispersed.	Univ Arizona, Dept Anthropol, Tucson, AZ 85721 USA; Hebrew Univ Jerusalem, Dept Evolut Systemat & Ecol, IL-91904 Jerusalem, Israel; Harvard Univ, Peabody Museum, Dept Anthropol, Cambridge, MA 02138 USA	University of Arizona; Hebrew University of Jerusalem; Harvard University	Stiner, MC (corresponding author), Univ Arizona, Dept Anthropol, Bldg 30, Tucson, AZ 85721 USA.	mstiner@u.arizona.edu		Surovell, Todd/0000-0001-6587-8621; Munro, Natalie/0000-0003-1690-6133				BAMBLE C, 1986, PALAEOLITHIC SETTLEM; Bar-Yosef O, 1981, PREHISTORIE LEVANT C, P389; BARYOSEF O, 1992, CURR ANTHROPOL, V33, P497, DOI 10.1086/204112; BarYosef O, 1996, J ARCHAEOL SCI, V23, P297, DOI 10.1006/jasc.1996.0028; BARYOSEF O, 1989, J WORLD PREHIST, V3, P447, DOI 10.1007/BF00975111; BarYosef O, 1996, INTERD CONT, P61; Binford L.R., 1968, NEW PERSPECTIVES ARC, P313; Botkin S., 1980, MODELING CHANGE PREH, P121; BOTTEMA S, 1987, CHRONOLOGIES NEAR E, P295; Cassoli P. F., 1976, QUATERNARIA, V19, P187; Clark G.A., 1983, HUNTER GATHERER EC P, P131; COHEN MN, 1977, FOOD CRISIS PREHISTO; EDWARDS PC, 1989, ANTIQUITY, V63, P225, DOI 10.1017/S0003598X00075955; Flannery K. V., 1969, The domestication and exploitation of plants and animals., P73; HARPENDING H, 1975, AM ANTIQUITY, V40, P82; Henry DO., 1989, FORAGING AGR LEVANT; Keeley LH, 1995, SCH AM RES, V354, P243; KLEIN RG, 1986, J ARCHAEOL SCI, V13, P515, DOI 10.1016/0305-4403(86)90038-5; Klein RG, 1989, HUMAN CAREER HUMAN B; Kuhn SL, 1998, CURR ANTHROPOL, V39, pS175, DOI 10.1086/204694; KUHN SL, 1998, CREATIVITY HUMAN EVO, P143; KUHN SL, 1998, REPORT 1997 EXCAVATI; LONG JC, 1993, ANNU REV ANTHROPOL, V22, P251; NEELEY MP, 1993, HUNTING ANIMAL EXPLO, V4, P221, DOI DOI 10.1525/AP3A.1993.4.1.221; Oswalt W. H, 1976, ANTHR ANAL FOOD GETT; Palma di Cesnola A., 1965, RIV SCI PREISTORICHE, V25, P3; Palma di Cesnola A., 1969, ESTRATTO DAGLI SCRIT, P95; Pichon J, 1987, FAUNE GISEMENT NATOU, P115; Radmilli A.M., 1974, SCAVI NELLA GROTTA P; Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119; Shackleton N. J., 1973, Quaternary Research, V3, P39, DOI 10.1016/0033-5894(73)90052-5; SHERRY ST, 1994, HUM BIOL, V66, P761; Stephens D.W., 1986, pi; STEWARD JH, 1938, B BUREAU AM ETHNOLOG, V120; Stiner M.C., 1994, HONOR THIEVES ZOOARC; Stiner Mary C., 1991, Quaternaria Nova, V1, P333; Stiner MC, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P241; STINER MC, 1992, CURR ANTHROPOL, V33, P433, DOI 10.1086/204095; STINER MC, 1993, HUNTING ANIMAL EXPLO, V4, P101; STINER MC, IN PRESS CURR ANTHR; TCHERNOV E, 1992, EVOLUTION DISPERSAL, P149; Tchernov E., 1994, LATE QUATERNARY CHRO, P333; Tchernov E, 1998, PALEORIENT, V23, P209; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; Watson PJ, 1995, SCH AM RES, V354, P21	45	347	363	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					190	194		10.1126/science.283.5399.190	http://dx.doi.org/10.1126/science.283.5399.190			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155ZJ	9880245				2022-12-28	WOS:000077976700030
J	Butcher, J				Butcher, J			ABC of sexual health - Female sexual problems I: Loss of desire - what about the fun?	BRITISH MEDICAL JOURNAL			English	Review									Univ Cent Lancashire, Preston PR1 2HE, Lancs, England; Withington Hosp, Manchester M20 8LR, Lancs, England	University of Central Lancashire	Butcher, J (corresponding author), Univ Cent Lancashire, Preston PR1 2HE, Lancs, England.							[Anonymous], 1985, SEX THERAPY PRACTICA; BANCROFT J, 1998, HUMAN SEXUALITY ITS; CROWE M, 1990, THERAPY COUPLES; DICKSON A, 1985, MIRROR; GOODWIN AJ, 1997, WOMANS GUIDE OVERCOM; Heiman J, 1976, BECOMING ORGASMIC SE; Kaplan H.S., 1995, SEXUAL DESIRE DISORD; KITZINGER S, 1985, WOMENS EXPERIENCE SE; Masters W., 1970, HUMAN SEXUAL INADEQU	9	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					41	43						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872888				2022-12-28	WOS:000078013100030
J	Gallardo, BS; Gupta, VK; Eagerton, FD; Jong, LI; Craig, VS; Shah, RR; Abbott, NL				Gallardo, BS; Gupta, VK; Eagerton, FD; Jong, LI; Craig, VS; Shah, RR; Abbott, NL			ELectrochemical principles for active control of liquids on submillimeter scales	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; ASPERGILLUS-NIGER; AQUEOUS-SOLUTIONS; WATER-INTERFACE; GLUCOSE-OXIDASE; SURFACTANTS; ADSORPTION; SURFACES; FILMS; GOLD	Electrochemical methods were combined with redox-active surfactants to actively control the motions and positions of aqueous and organic liquids on millimeter and smaller scales. Surfactant species generated at one electrode and consumed at another were used to manipulate the magnitude and direction of spatial gradients in surface tension and guide droplets of organic liquids through simple fluidic networks. Solid microparticles could be transported across unconfined surfaces. Electrochemical control of the position of surface-active species within aqueous films of liquid supported on homogeneous surfaces was used to direct these films into periodic arrays of droplets with deterministic shapes and sizes.	Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Abbott, NL (corresponding author), Univ Wisconsin, Dept Chem Engn, 1415 Johnson Dr, Madison, WI 53706 USA.		CRAIG, Vincent Stuart James/A-6607-2008	CRAIG, Vincent Stuart James/0000-0002-8048-8397				ABBOTT NL, 1994, LANGMUIR, V10, P1493, DOI 10.1021/la00017a029; ABBOTT NL, 1995, LANGMUIR, V11, P16, DOI 10.1021/la00001a005; ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; Bard A.J., 1994, INTEGRATED CHEM SYST; Bennett DE, 1996, J AM CHEM SOC, V118, P6499, DOI 10.1021/ja960902t; Brinck J, 1996, LANGMUIR, V12, P5042, DOI 10.1021/la960260n; Carre A, 1996, NATURE, V379, P432, DOI 10.1038/379432a0; CAZABAT AM, 1990, NATURE, V346, P824, DOI 10.1038/346824a0; Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diamant H, 1996, J PHYS CHEM-US, V100, P13732, DOI 10.1021/jp960377k; DLUHY RA, 1986, J PHYS CHEM-US, V90, P1373, DOI 10.1021/j100398a033; Eskilsson K, 1998, LANGMUIR, V14, P2444, DOI 10.1021/la971066j; Fluitman J, 1996, SENSOR ACTUAT A-PHYS, V56, P151, DOI 10.1016/0924-4247(96)01276-9; Frank B, 1996, COLLOID SURFACE A, V116, P31, DOI 10.1016/0927-7757(96)03622-9; FRASER DM, 1992, BIOCHIM BIOPHYS ACTA, V1099, P91, DOI 10.1016/0167-4838(92)90457-O; Gallardo BS, 1996, LANGMUIR, V12, P4116, DOI 10.1021/la960199m; GALLARDO BS, UNPUB; GORMAN CB, 1995, LANGMUIR, V11, P2242, DOI 10.1021/la00006a063; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Hu K, 1997, LANGMUIR, V13, P5114, DOI 10.1021/la9700782; Kovacs GTA., 1998, MICROMACHINED TRANSD; Petersen K, 1996, SENSOR ACTUAT A-PHYS, V56, P143, DOI 10.1016/0924-4247(96)01289-7; SAJI T, 1991, J AM CHEM SOC, V113, P450, DOI 10.1021/ja00002a011; SalimiMoosavi H, 1997, J AM CHEM SOC, V119, P8716, DOI 10.1021/ja971735f; SAUDAN P, 1994, BIOTECHNOL BIOENG, V44, P407, DOI 10.1002/bit.260440403; Young T., 1805, PHILOS T R SOC LONDO, V95, P65, DOI [10.1098/rstl.1805.0005, DOI 10.1098/RSTL.1805.0005]	27	376	397	4	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					57	60		10.1126/science.283.5398.57	http://dx.doi.org/10.1126/science.283.5398.57			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872739				2022-12-28	WOS:000077976600047
J	Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H				Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H			Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)	LANCET			English	Article							CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BREAST-CANCER; RISK; HEALTH	Background Advantages and disadvantages of postmenopausal oestrogen replacement therapy (ERT) are still not clear. We aimed to analyse the relation between postmenopausal oestrogen replacement therapy (ERT), cardiovascular disease, and cancer. Methods We examined 7944 women born between 1923 and 1930, who participated in a mammography screening for breast cancer, and who were followed up from 1987 to 1995, The follow-up consisted of 53 305 person-years. 988 women were current users and 757 were former users of ERT. Information about hormone use and health events was obtained through biennial questionnaires and recording and linking information from the hospital discharge registers of the region, the national cancer register, the social insurance reimbursement register, and the national death register. We used proportional-hazards models to calculate risk ratios and 95% CIs, adjusted for eight confounding variables. Findings Current ERT was associated with decreased cardiovascular mortality and a decrease in sudden cardiac death. Adjusted risk ratio (RR) for cardiovascular mortality in current users was 0.21 (95% CI 0.08-0.59) and in former users 0.75 (0.41-1.37). Absolute risk per 1000 person-years for deaths from acute myocardial infarction (AMI) was 1.1 in never users, 1.2 in former users, and 0.45 in current users (p=0.197). Corresponding absolute risk for other coronary-artery-disease (CAD) deaths was 1.0, 0.81, and 0 (p=0.009), and for deaths from stroke 1.2, 1.0, and 0.15 (p=0.012), Absolute risk for sudden cardiac death was 1.6 in never users, 1.0 in former users, and 0 in current users (p<0.001). Cardiovascular morbidity was not decreased by ERT: the RR for current use was 1.07 (0.86-1.32) and for former use 1.11 (0.89-1.39). Incidence of cardiovascular disease per 1000 person-years was 24.9 in never users, 23.4 in former users, and 20.9 in current users (p=0.153). Breast-cancer morbidity did not increase with current ERT--the RR was 0.57 (0.27-1.20). Incidence of breast cancer was 1.8, 1.6, and 1.0 in never, former, and current users (p=0.242). Endometrial cancer increased with current ERT-the RR was 5.06 (2.47-10.41). Incidence of endometrial cancer was 0.52 in never users, 0.51 in former users, and 2.1 in current users (p<0.001). Interpretation Current ERT reduced primarily sudden cardiac death and predicted reduced cardiovascular mortality, but did not reduce morbidity. ERT did not increase the risk of breast cancer, but associated with increased risk of endometrial cancer.	Univ Turku, Dept Geriatr, Turku 20700, Finland; Univ Turku, Dept Obstet & Gynaecol, Turku 20700, Finland; Univ Turku, Dept Biostat, Turku 20700, Finland	University of Turku; University of Turku; University of Turku	Sourander, L (corresponding author), Univ Turku, Dept Geriatr, Kunnallissairaalantie 20, Turku 20700, Finland.							AKHTAR M, 1994, SUDDEN CARDIAC DEATH; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; *CENTR STAT OFF FI, 1974, OFF STAT FINL, V9; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Collett D., 1994, MODELING SURVIVAL DA; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Huikuri HV, 1996, CIRCULATION, V94, P122, DOI 10.1161/01.CIR.94.2.122; KATSOUYANNI K, 1997, J CLIN ENDOCR METAB, V82, P1549; LOBO RA, 1992, AM J OBSTET GYNECOL, V166, P1997, DOI 10.1016/0002-9378(92)91401-U; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Matthews KA, 1996, AM J EPIDEMIOL, V143, P983; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; PUKKALA E, 1995, CONTRIBUTION EPIDEMI, V7; SISMOND P, 1996, EUR MENOPAUSE J, V3, P227; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; *STAT FINL, 1996, CAUS DATH; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	25	147	148	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1965	1969		10.1016/S0140-6736(98)05066-1	http://dx.doi.org/10.1016/S0140-6736(98)05066-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872245				2022-12-28	WOS:000077663000009
J	Bozzette, SA; Berry, SH; Duan, NJ; Frankel, MR; Leibowitz, AA; Lefkowitz, D; Emmons, CA; Senterfitt, JW; Berk, ML; Morton, SC; Shapiro, MF				Bozzette, SA; Berry, SH; Duan, NJ; Frankel, MR; Leibowitz, AA; Lefkowitz, D; Emmons, CA; Senterfitt, JW; Berk, ML; Morton, SC; Shapiro, MF		HIV Cost Services Utilization Study Consortium	The care of HIV-infected adults in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS	Background and Methods In order to elucidate the medical care of patients with human immunodeficiency virus (HIV) infection in the United States, we randomly sampled HIV-infected adults receiving medical care in the contiguous United States at a facility other than a military, prison, or emergency department facility during the first two months of 1996. We interviewed 76 percent of 4042 patients selected from among the patients receiving care from 145 providers in 28 metropolitan areas and 51 providers in 25 rural areas. Results During the first two months of 1996, an estimated 231,400 HIV-infected adults (95 percent confidence interval, 162,800 to 300,000) received care. Fifty-nine percent had the acquired immunodeficiency syndrome according to the case definition of the Centers for Disease Control and Prevention, and 91 percent had CD4+ cell counts of less than 500 per cubic millimeter. Eleven percent were 50 years of age or older, 23 percent were women, 33 percent were black, and 49 percent were men who had had sex with men. Forty-six percent had incomes of less than $10,000 per year, 68 percent had public health insurance or no insurance, and 30 percent received care at teaching institutions. The estimated annual direct expenditures for the care of the patients seen during the first two months of 1996 were $5.1 billion; the expenditures for the estimated 335,000 HIV-infected adults seen at least as often as every six months were $6.7 billion, which is about $20,000 per patient per year. Conclusions In this national survey we found that most HIV-infected adults who were receiving medical care had advanced disease. The patient population was disproportionately male, black, and poor. Many Americans with diagnosed or undiagnosed HIV infection are not receiving medical care at least as often as every six months. The total cost of medical care for HIV-infected Americans accounts for less than 1 percent of all direct personal health expenditures in the United States. (N Engl J Med 1998;339:1897-904.) (C) 1998, Massachusetts Medical Society.	Rand Corp, HCSUS Off, Hlth, Santa Monica, CA 90407 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; CUNY Bernard M Baruch Coll, New York, NY 10010 USA; Project Hope, Bethesda, MD USA; US Dept HHS, Agcy Hlth Care Policy & Res, Rockville, MD 20852 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of Chicago; City University of New York (CUNY) System; Baruch College (CUNY); Agency for Healthcare Research & Quality	Bozzette, SA (corresponding author), Rand Corp, HCSUS Off, Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Harding, Richard/G-9729-2012	Duan, Naihua/0000-0001-9411-2924	AHRQ HHS [U-01HS08578] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERRY SH, HCSUS BASELINE PAT; *BUR CENS, 1997, CURR POP REP SER P, V60; Campbell P., 1997, POPULATION PROJECTIO; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; *CDCP, 1997, HIV AIDS SURV REP, V9, P24; DAY J, 1996, CURRENT POPULATION P, V20; *DEP HLTH HUM SERV, 1998, ANN INTERN MED, V128, P1079; *DEP JUST, 1997, CORR POP US 1995; DUAN N, IN PRESS HCSUS BASEL; FINGERHUT LA, 1997, INJURY CHARTBOOK HLT; FRANEKL MR, IN PRESS HLTH SERV R; HAMMETT TM, 1995, UPDATE HIV AIDS STDS; HELLINGER FJ, 1994, HEALTH SERV RES, V29, P569; KALTON G, 1983, COMPENSATING MISSING; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; KISH L, 1965, SURVEY SAMPLING, V16, P643; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pamuk E., 1998, SOCIOECONOMIC STATUS; SHAPIRO MF, 1997, HLTH SERV RES; Smith D, 1998, J ACQ IMMUN DEF SYND, V17, pS17, DOI 10.1097/00042560-199801001-00006; WINSLOW C, IN PRESS HIV CARE; 1992, MMWR MORB MOTAL WKLY, V41, P1; 1990, MMWR MORB MOTAL WKLY, V39, P1	26	401	407	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1897	1904		10.1056/NEJM199812243392606	http://dx.doi.org/10.1056/NEJM199812243392606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862946				2022-12-28	WOS:000077696600006
J	Lu, XW; Horvitz, HR				Lu, XW; Horvitz, HR			lin-35 and lin-53, two genes that antagonize a C-elegans Ras pathway, encode proteins similar to Rb and its binding protein RbAp48	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATOR; TRANSCRIPTIONAL REPRESSION; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; VULVAR DEVELOPMENT; LEADER SEQUENCE; MESSENGER-RNA	The Ras signaling pathway for vulval induction in Caenorhabditis elegans is antagonized by the activity of the synthetic multivulva (synMuv) genes, which define two functionally redundant pathways. We have characterized two genes in one of these pathways. lin-35 encodes a protein similar to the tumor suppressor Rb and the closely related proteins p107 and p130. lin-53 encodes a protein similar to RbAp48, a mammalian protein that binds Rb. In mammals, Rb and related proteins act as regulators of E2F transcription factors, and RbAp48 may act with such proteins as a transcriptional corepressor. We propose that LIN-35 and LIN-53 antagonize the Ras signaling pathway in C. elegans by repressing transcription in the vulval precursor cells of genes required for the expression of vulval cell fates.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.	horvitz@mit.edu						Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEITEL GJ, 1994, THESIS MIT CAMBRIDGE; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1994, GENETICS, V137, P987; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELLIS RE, 1995, GENETICS, V139, P561; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEDGECOCK EM, 1995, GENETICS, V141, P989; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Priess J. R., 1997, C ELEGANS 2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BD, 1992, GENETICS, V131, P609; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	64	257	281	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					981	991		10.1016/S0092-8674(00)81722-5	http://dx.doi.org/10.1016/S0092-8674(00)81722-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875852	Bronze			2022-12-28	WOS:000077759100013
J	Greenhill, LJ; Gwinn, CR; Schwartz, C; Moran, JM; Diamond, PJ				Greenhill, LJ; Gwinn, CR; Schwartz, C; Moran, JM; Diamond, PJ			Coexisting conical bipolar and equatorial outflows from a high-mass protostar	NATURE			English	Article							STAR-FORMING REGION; HERBIG-HARO OBJECTS; ORION-KL; SUBARCSECOND-RESOLUTION; PROPER MOTIONS; EMISSION; NEBULA; FLOWS; DISKS; IRC2	The BN/KL region in the Orion molecular cloud(1) is an archetype for the study of the formation of stars much more massive than the Sun(2). This region contains luminous young stars and protostars but, like most star-forming regions, is difficult to study in detail because of the obscuring effects of dust and gas. Our basic expectations are shaped to some extent by the present theoretical picture of star formation, the cornerstone of which is that protostars accrete gas from rotating equatorial disks and shed angular momentum by ejecting gas in bipolar outflows. The main source of the outflow in the BN/KL region(3-5) may be an object known as radio source I (ref. 6), which is commonly believed to be surrounded by a rotating disk of molecular material(7-9). Here we report high-resolution observations of silicon monoxide (SiO) and water maser emission from the gas surrounding source I. We show that within 60 AU of the source (about the size of the Solar System), the region is dominated by a conical bipolar outflow rather than the expected disk A slower outflow, close to the equatorial plane of the protostellar system, extends to radii of 1,000 AU.	Ctr Astrophys, Cambridge, MA 02138 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Maria Mitchell Observ, Nantucket, MA 02554 USA; Natl Radio Astron Observ, Socorro, NM 87801 USA	University of California System; University of California Santa Barbara; National Radio Astronomy Observatory (NRAO)	Greenhill, LJ (corresponding author), Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.			Moran, James/0000-0002-3882-4414				ALLEN DA, 1993, NATURE, V363, P54, DOI 10.1038/363054a0; BARVAINIS R, 1984, ASTROPHYS J, V279, P358, DOI 10.1086/161896; CHANDLER CJ, 1995, ASTROPHYS J, V455, pL67, DOI 10.1086/309814; CHURCHWELL E, 1987, ASTROPHYS J, V321, P516, DOI 10.1086/165648; DANCHI WC, 1994, ASTRON J, V107, P1469, DOI 10.1086/116960; DOUGADOS C, 1993, ASTROPHYS J, V406, P112, DOI 10.1086/172424; GARAY G, 1989, ASTROPHYS J, V338, P244, DOI 10.1086/167195; Gaume RA, 1998, ASTROPHYS J, V493, P940, DOI 10.1086/305161; GENZEL R, 1981, ASTROPHYS J, V244, P884, DOI 10.1086/158764; GENZEL R, 1989, ANNU REV ASTRON ASTR, V27, P41, DOI 10.1146/annurev.aa.27.090189.000353; GEZARI DY, 1992, ASTROPHYS J, V396, pL43, DOI 10.1086/186513; GEZARI DY, 1995, ASTROPHYS SPACE SCI, V224, P45; GREENHILL LJ, 1988, IMPACT VLBI ASTROPHY, P253; Hu XH, 1996, ASTRON J, V112, P2712, DOI 10.1086/118215; JONES BF, 1985, ASTRON J, V90, P1320, DOI 10.1086/113837; KLEINMAN.DE, 1967, ASTROPHYS J, V149, pL1, DOI 10.1086/180039; LUCAS R, 1992, ASTRON ASTROPHYS, V262, P491; MENTEN KM, 1995, ASTROPHYS J, V445, pL157, DOI 10.1086/187913; MIGENES V, 1989, ASTROPHYS J, V347, P294, DOI 10.1086/168118; MORITA R, 1991, CANCER RES, V51, P3; PHAMBCK RL, 1990, ASTROPHYS J, V348, pL65; PLAMBECK RL, 1995, ASTROPHYS J, V455, pL189, DOI 10.1086/309830; Rao R, 1998, ASTROPHYS J, V502, pL75, DOI 10.1086/311485; Schleuning DA, 1998, ASTROPHYS J, V493, P811, DOI 10.1086/305139; SHU FH, 1995, ASTROPHYS J, V455, pL155, DOI 10.1086/309838; SUGAI H, 1995, ASTROPHYS J, V442, P674, DOI 10.1086/175472; THRONSON HA, 1986, ASTRON J, V91, P1350, DOI 10.1086/114110; Torrelles JM, 1998, ASTROPHYS J, V505, P756, DOI 10.1086/306205; WARDLE M, 1993, ASTROPHYS J, V410, P218, DOI 10.1086/172739; WRIGHT MCH, 1995, ASTROPHYS J, V455, pL185, DOI 10.1086/309829; Wright MCH, 1996, ASTROPHYS J, V469, P216, DOI 10.1086/177773; ZENSUS JA, 1995, VERY LONG BASELINE L	32	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					650	653		10.1038/25299	http://dx.doi.org/10.1038/25299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872312	Green Submitted			2022-12-28	WOS:000077694200045
J	Hung, LW; Wang, IXY; Nikaido, K; Liu, PQ; Ames, GFL; Kim, SH				Hung, LW; Wang, IXY; Nikaido, K; Liu, PQ; Ames, GFL; Kim, SH			Crystal structure of the ATP-binding subunit of an ABC transporter	NATURE			English	Article							PERIPLASMIC HISTIDINE PERMEASE; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; TRAFFIC ATPASE; PROTEIN; IDENTIFICATION; RESOLUTION; HYDROLYSIS; HUMANS	ABC transporters (also known as traffic ATPases) form a large family of proteins responsible for the translocation of a variety of compounds across membranes of both prokaryotes and eukaryotes'. The recently completed Escherichia coli genome sequence revealed that the largest family of paralogous E. coli proteins is composed of ABC transporters(2), Many eukaryotic proteins of medical significance belong to this family, such as the cystic fibrosis transmembrane conductance regulator (CFTR), the P-glycoprotein (or multidrug-resistance protein) and the heterodimeric transporter associated with antigen processing (Tap1-Tap2). Here we report the crystal structure at 1.5 Angstrom resolution of HisP, the ATP-binding subunit of the histidine permease, which is an ABC transporter from Salmonella typhimurium, We correlate the details of this structure with the biochemical, genetic and biophysical properties of the wild-type and several mutant HisP proteins. The structure provides a basis for understanding properties of ABC transporters and of defective CFTR proteins.	Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.	shkim@lbl.gov						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM SH, 1993, HDB EXPT PHARM, P177; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKIN DL, 1993, CELLS HEPATIC SINUSO, V4, P26; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pal E.F., 1989, NATURE, V341, P209; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	30	596	604	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					703	707		10.1038/25393	http://dx.doi.org/10.1038/25393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872322				2022-12-28	WOS:000077694200060
J	Kaptchuk, TJ; Eisenberg, DM				Kaptchuk, TJ; Eisenberg, DM			The persuasive appeal of alternative medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PREVALENCE; DISEASE	Alternative medicine has a major presence and persuasive attraction in the industrialized western world. The extent to which these practices have clinical efficacy according to biomedical criteria is a matter of ongoing research and debate. It may be that independent of any such efficacy, the attraction of alternative medicine is related to the power of its underlying shared beliefs and cultural assumptions. The fundamental premises are an advocacy of nature, vitalism, "science," and spirituality. These themes offer patients a participatory experience of empowerment, authenticity, and enlarged self-identity when illness threatens their sense of intactness and connection to the world. A discussion of these themes may enable conventionally trained clinicians to better understand their patients' attraction to and acceptance of alternative medical therapies.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, 330 Brookline Ave,LW-600, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1982, CRUSADERS FITNESS HI; APPLE RD, 1996, VITAMIA VITAMINS AM; Barbour Ian G., 1966, ISSUES SCI RELIG; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; BRADER CS, 1973, SPIRITS REBELLION RI; BRODY H, 1994, LIT MED, V13, P79; BROWN PS, 1985, MED HIST, V29, P71, DOI 10.1017/S0025727300043751; Bynum W.F, 1987, MED FRINGE MED ORTHO; CAMPBELL A, 1984, 2 FACES HOMEOPATHY; Campbell B.F., 1980, ANCIENT WISDOM REVIV; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; Cooter Roger, 1988, STUDIES HIST ALTERNA; CSORDAS T J, 1988, Medical Anthropology Quarterly, V2, P121, DOI 10.1525/maq.1988.2.2.02a00030; CSORDAS TJ, 1983, CULT MED PSYCHIAT, V7, P333, DOI 10.1007/BF00052238; DUBISCH J, 1981, AM DIMENSION CULTURA; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Felker M. E, 1983, ANTHR MED CULTURE ME; Filliozat Jean, 1964, CLASSICAL DOCTRINE I; Frank J.D., 1961, PERSUASION HEALING C; Fuller R., 1989, ALTERNATIVE MED AM R; Fuller R.C., 1982, MESMERISM AM CURE SO; GEVITZ N, 1995, MT SINAI J MED, V62, P127; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLIK DC, 1988, SOC SCI MED, V27, P1197, DOI 10.1016/0277-9536(88)90349-8; GOLDSTEIN MS, 1988, SOC SCI MED, V26, P853, DOI 10.1016/0277-9536(88)90178-5; GORDON DR, 1988, BIOMEDICINE EXAMINED; GRIM P, 1982, PHILOS SCI OCCULT; HAHNEMANN S, 1980, ORGANON MED; Haigh E, 1975, Bull Hist Med, V49, P72; Haller Jr John S., 1994, MED PROTESTANTS ECLE; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; Ingelfinger F J, 1977, N Engl J Med, V296, P1167, DOI 10.1056/NEJM197705192962013; KANDEL RF, 1980, NUTR ANTHR CONT APPR; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; Kaptchuk TJ, 1998, NUTRITION, V14, P471; KAPTCHUK TJ, 1996, FUNDAMENTALS COMPLEM; KAPTCHUK TJ, 1996, COMPLEMENTARY MED EF; KIRMAYER LJ, 1993, CULT MED PSYCHIAT, V17, P161, DOI 10.1007/BF01379325; KLEINMAN AM, 1973, INQUIRY, V16, P206, DOI 10.1080/00201747308601685; KNIPSCHILD P, 1989, BRIT MED J, V299, P491, DOI 10.1136/bmj.299.6697.491; KOPELMAN L, 1981, J MED PHILOS, V6, P209, DOI 10.1093/jmp/6.2.209; LEDERMANN EK, 1986, PHILOS MED; LILIENFELD AM, 1982, B HIST MED, V56, P1; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Luhrmann T.M., 1989, PERSUASIONS WITCHS C; Lyng Stephen, 1990, HOLISTIC HLTH BIOMED; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; MARTIN SC, 1994, ISIS, V85, P207, DOI 10.1086/356807; MARTIN SC, 1993, TECHNOL CULT, V34, P808, DOI 10.2307/3106416; Marwick C, 1997, JAMA-J AM MED ASSOC, V278, P1725, DOI 10.1001/jama.1997.03550210021013; MAUSKOPF S, 1979, RECEPTION UNCONVENTI; Mauskopf SH, 1980, ELUSIVE SCI ORIGINS; MCCLENON J, 1984, DEVIANT SCI CASE PAR; MCGUIRE MB, 1983, CULT MED PSYCHIAT, V7, P221, DOI 10.1007/BF00049311; Meyer Donald, 1965, POSITIVE THINKERS ST; NEUBURGER M, 1933, DOCTRIN HEALING POWE; Nissenbaum Stephen, 1980, SEX DIET DEBILITY JA; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oppenheim J., 1985, OTHER WORLD SPIRITUA; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALMER DD, 1910, CHIROPRACTIC; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; ROTHSTEIN W, 1972, AM PHYSICIANS 19 CEN; SCHAFER R, 1975, J AM DIET ASSOC, V66, P129; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Shumaker, 1972, OCCULT SCI RENAISSAN; SIMON A, 1979, JAMA-J AM MED ASSOC, V242, P1385, DOI 10.1001/jama.242.13.1385; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; SULLIVAN M, 1986, CULT MED PSYCHIAT, V10, P331, DOI 10.1007/BF00049269; SULLIVAN MD, 1993, J MED PHILOS, V18, P213, DOI 10.1093/jmp/18.2.213; Tambiah S.J., 1990, MAGIC SCI RELIG SCOP; TURNER BS, 1982, BRIT J SOCIOL, V33, P254, DOI 10.2307/589935; TWIGG J, 1979, RELIGION, V9, P13, DOI 10.1016/0048-721X(79)90051-4; TYLER VE, 1987, PLANTA MED, P1; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; WALLIS R, 1979, MARGINS SCI SOCIAL C; Warner J. H, 1978, PERSPECTIVES AM HIST, V11, P291; WHEELER R, 1939, VITALISM; Whorton J C, 1977, J Hist Med Allied Sci, V32, P115; WILLIAM J, 1961, VARIETIES RELIG EXPE	84	171	173	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1061	1065		10.7326/0003-4819-129-12-199812150-00011	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	147DC	9867762				2022-12-28	WOS:000077471900010
J	Kearon, C; Ginsberg, JS; Hirsh, J				Kearon, C; Ginsberg, JS; Hirsh, J			The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article							TIME COMPRESSION ULTRASONOGRAPHY; VEIN THROMBOSIS; IMPEDANCE PLETHYSMOGRAPHY; DUPLEX ULTRASOUND; ACCURACY; MANAGEMENT; VENOGRAPHY; LEG; SURVEILLANCE; OUTPATIENTS	This paper describes the role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Inability to compress the common femoral or popliteal vein is usually diagnostic of a first episode of deep venous thrombosis in symptomatic patients (positive predictive value of about 97%). Full compressibility of both of these sites excludes proximal deep venous thrombosis in symptomatic patients (negative predictive value of about 98%). In patients with suspected deep venous thrombosis or in those who present with suspected pulmonary embolism but have a nondiagnostic lung scan, the subsequent risk for symptomatic venous thromboembolism is very low (<2% during 6 months of follow-up) provided that ultrasonography of the proximal veins remains normal in the course of 1 week (suspected deep venous thrombosis) or 2 weeks (suspected pulmonary embolism). Anticoagulation and further diagnostic testing can usually be safely withheld in these situations. Venous ultrasonography is much less reliable for the diagnosis of asymptomatic, isolated distal, and recurrent deep venous thrombosis than for the diagnosis of a first episode of proximal deep venous thrombosis in symptomatic patients. Clinical evaluation of the probability of deep venous thrombo!;is or pulmonary embolism, preferably by using a validated clinical model, complements venous ultrasonographic findings and helps to identify patients who would benefit from additional (often invasive) diagnostic testing. Thus, venous ultrasonography is thought to be a very valuable test for the diagnosis and management of patients with suspected deep venous thrombosis or pulmonary embolism.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Kearon, C (corresponding author), Henderson Gen Hosp, McMaster Med Unit, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		ginsberg, jeffrey s/ABC-1065-2020					AGNELLI G, 1990, ANGIOLOGY, V41, P559, DOI 10.1177/000331979004100709; AGNELLI G, 1993, THROMB HAEMOSTASIS, V70, P266; ALPERT JS, 1994, PROG CARDIOVASC DIS, V36, P417, DOI 10.1016/S0033-0620(94)80050-2; Anand SS, 1998, JAMA-J AM MED ASSOC, V279, P1094, DOI 10.1001/jama.279.14.1094; Atri M, 1996, AM J ROENTGENOL, V166, P1361, DOI 10.2214/ajr.166.6.8633448; BARRITT DW, 1960, LANCET, V1, P1309; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BRADLEY MJ, 1993, CLIN RADIOL, V47, P399, DOI 10.1016/S0009-9260(05)81060-8; Burke P, 1994, J IRISH COLLEGE PHYS, V23, P105; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DALEN JE, 1993, ARCH INTERN MED, V153, P1415, DOI 10.1001/archinte.153.12.1415; ELIAS A, 1987, INT ANGIOL, V6, P175; FLINN WR, 1989, ARCH SURG-CHICAGO, V124, P901; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, ARCH INTERN MED, V152, P1901, DOI 10.1001/archinte.152.9.1901; HEIJBOER H, 1992, ACTA RADIOL, V33, P297; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; KAKKAR VV, 1969, LANCET, V2, P230; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LAGERSTEDT CI, 1985, LANCET, V2, P515; Lensing AWA, 1997, ARCH INTERN MED, V157, P765, DOI 10.1001/archinte.157.7.765; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MITCHELL DC, 1991, BRIT J SURG, V78, P611, DOI 10.1002/bjs.1800780528; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NICOLAIDES AN, 1971, BRIT J RADIOL, V44, P653, DOI 10.1259/0007-1285-44-525-653; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; QUINTAVALLA R, 1992, EUR J RADIOL, V15, P32, DOI 10.1016/0720-048X(92)90199-J; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; SCHINDLER JM, 1990, BRIT MED J, V301, P1369, DOI 10.1136/bmj.301.6765.1369; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; STEWART JH, 1992, MAYO CLIN PROC, V67, P1186, DOI 10.1016/S0025-6196(12)61150-1; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; WHITE RH, 1990, J BONE JOINT SURG AM, V72A, P495, DOI 10.2106/00004623-199072040-00004	56	315	332	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1044	1049		10.7326/0003-4819-129-12-199812150-00009	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867760				2022-12-28	WOS:000077471900008
J	Bateman, DE; Pople, I				Bateman, DE; Pople, I			Brown-Sequard at a theme park	LANCET			English	Article							SPINAL ENTEROGENOUS CYSTS		Royal United Hosp, Dept Neurol, Bath BA1 3NG, Avon, England; Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England		Bateman, DE (corresponding author), Royal United Hosp, Dept Neurol, Bath BA1 3NG, Avon, England.							BIOUSSE V, 1995, LANCET, V346, P767, DOI 10.1016/S0140-6736(95)91525-7; HOLMES GL, 1978, AM J DIS CHILD, V132, P906, DOI 10.1001/archpedi.1978.02120340082018; Rao MB, 1996, CLIN NEUROL NEUROSUR, V98, P32, DOI 10.1016/0303-8467(95)00076-3; Schievink WI, 1996, LANCET, V347, P1409, DOI 10.1016/S0140-6736(96)91048-X	4	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1902	1902		10.1016/S0140-6736(98)08248-8	http://dx.doi.org/10.1016/S0140-6736(98)08248-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863789				2022-12-28	WOS:000077544600012
J	Hut, P; Makino, J				Hut, P; Makino, J			Computational physics - Astrophysics on the GRAPE family of special-purpose computers	SCIENCE			English	Review							SMOOTHED PARTICLE HYDRODYNAMICS; GLOBULAR-CLUSTER EVOLUTION; CENTRAL BLACK-HOLES; GRAVOTHERMAL OSCILLATIONS; COLLAPSE EVOLUTION; GALACTIC NUCLEI; CORE COLLAPSE; GALAXIES; PLANETESIMALS; SIMULATION	The GRAPE-4 the world's fastest computer in 1995-1997, has produced some major scientific results through a wide diversity of large-scale simulations in astrophysics. I Applications have included planetary formation, the evolution of star clusters and galactic nuclei, and the formation of galaxies and clusters of galaxies.	Inst Adv Study, Princeton, NJ 08540 USA; Univ Tokyo, Coll Arts & Sci, Dept Gen Syst Study, Meguro Ku, Tokyo 1538902, Japan	Institute for Advanced Study - USA; University of Tokyo	Hut, P (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.		Makino, Junichiro/A-9525-2014; Makino, Junichiro/K-5260-2019	Makino, Junichiro/0000-0002-0411-4297; 				Aarseth SJ, 1998, MON NOT R ASTRON SOC, V297, P794, DOI 10.1046/j.1365-8711.1998.01521.x; AARSETH SJ, 1974, ASTRON ASTROPHYS, V37, P183; Athanassoula E, 1998, MON NOT R ASTRON SOC, V293, P369, DOI 10.1046/j.1365-8711.1998.01102.x; BARNES J, 1986, NATURE, V324, P446, DOI 10.1038/324446a0; Bartelmann M, 1996, MON NOT R ASTRON SOC, V283, P431, DOI 10.1093/mnras/283.2.431; BEGELMAN MC, 1980, NATURE, V287, P307, DOI 10.1038/287307a0; BETTWIESER E, 1984, MON NOT R ASTRON SOC, V208, P493; BREEDEN JL, 1994, ASTROPHYS J, V421, P195, DOI 10.1086/173636; BREEDEN JL, 1995, ASTROPHYS J, V448, P672, DOI 10.1086/175996; COHN H, 1989, ASTROPHYS J, V342, P814, DOI 10.1086/167638; EBISUZAKI T, 1991, NATURE, V354, P212, DOI 10.1038/354212a0; FUKUSHIGE T, 1995, MON NOT R ASTRON SOC, V276, P206; FUNATO Y, 1993, PUBL ASTRON SOC JPN, V45, P289; FUNATO Y, UNPUB; GOODMAN J, 1987, ASTROPHYS J, V313, P576, DOI 10.1086/164998; Guhathakurta P, 1996, ASTRON J, V111, P267, DOI 10.1086/117779; Haehnelt MG, 1998, ASTROPHYS J, V495, P647, DOI 10.1086/305323; HAEHNELT MG, 1995, APJ, V465, pL95; Henon M., 1961, ANN ASTROPHYS, V24, P369; Klessen RS, 1998, ASTROPHYS J, V501, pL205, DOI 10.1086/311471; Komeiji Y, 1997, J COMPUT CHEM, V18, P1546, DOI 10.1002/(SICI)1096-987X(199709)18:12<1546::AID-JCC11>3.0.CO;2-I; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; Lauer TR, 1995, ASTRON J, V110, P2622, DOI 10.1086/117719; Makino J, 1996, ASTROPHYS J, V471, P796, DOI 10.1086/178007; MAKINO J, 1987, PUBL ASTRON SOC JPN, V39, P589; MAKINO J, 1991, PUBL ASTRON SOC JPN, V43, P621; Makino J, 1996, ASTROPHYS J, V465, P527, DOI 10.1086/177439; Makino J, 1997, ASTROPHYS J, V478, P58, DOI 10.1086/303773; MAKINO J, IN PRESS NEW ASTRON; Makino J, 1996, IAU S, V174, P151; Navarro JF, 1997, ASTROPHYS J, V478, P13, DOI 10.1086/303763; Spurzem R, 1996, MON NOT R ASTRON SOC, V282, P19, DOI 10.1093/mnras/282.1.19; SPURZEM R, 1993, ASTR SOC P, V50, P135; Steinmetz M, 1996, MON NOT R ASTRON SOC, V278, P1005, DOI 10.1093/mnras/278.4.1005; STEINMETZ M, 1995, MON NOT R ASTRON SOC, V276, P549, DOI 10.1093/mnras/276.2.549; SUGIMOTO D, 1990, NATURE, V345, P33, DOI 10.1038/345033a0; SUGIMOTO D, 1983, MNRAS, V204, P19; Suginohara T, 1998, ASTROPHYS J, V507, P16, DOI 10.1086/306326; Taiji M, 1998, SCI SIMULATIONS SPEC; UMEMURA M, 1993, PUBL ASTRON SOC JPN, V45, P311; WETHERILL GW, 1989, ICARUS, V77, P330, DOI 10.1016/0019-1035(89)90093-6; ZWART SP, 1998, IN PRESS ASTRON ASTR, V297, P794; [No title captured]	47	39	40	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					501	505		10.1126/science.283.5401.501	http://dx.doi.org/10.1126/science.283.5401.501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915691	Green Submitted			2022-12-28	WOS:000078203300027
J	Launer, J				Launer, J			A narrative approach to mental health in general practice	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOTHERAPY		Tavistock Clin, Child & Family Dept, London NW3 5BA, England		Launer, J (corresponding author), Tavistock Clin, Child & Family Dept, London NW3 5BA, England.							Anderson H., 1992, THERAPY SOCIAL CONST, P25; Armstrong D, 1996, PRIMARY CARE PSYCHIA, V2, P119; Brown B, 1996, SOC SCI MED, V43, P1569, DOI 10.1016/S0277-9536(96)00053-6; BURCK C, 1997, MULTIPLE VOICES NARR, P64; DAVID R, 1983, LACAN NARRATION PSYC; ELDER A, 1993, OUTLINE PSYCHOTHERAP, P74; FROSH S, 1995, J FAM THER, V17, P175, DOI 10.1111/j.1467-6427.1995.tb00012.x; Gordon P, 1996, EXTENDING PRIMARY CA, P1; Hoffman L., 1992, THERAPY SOCIAL CONST, P7; Keeney B.P., 1983, AESTHETICS OF CHANGE; Kleinman A., 1980, PATIENTS HEALERS CON; Launer J, 1997, BRIT J GEN PRACT, V47, P453; Launer J, 1995, FAMILY SYSTEMS MED, V13, P379; LAUNER J, 1986, J FAM THER, V18, P255; Lupton D., 2022, COVID SOC THEORISING; Masson Jeffrey, 1989, THERAPY; McNamee Sheila, 1992, THERAPY SOCIAL CONST; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; PAPADOPOULOS R, 1997, MULTIPLE VOICES NARR; Shapiro J., 1993, FAM SYST MED, V11, P47; Stevens A., 1996, EVOLUTIONARY PSYCHIA	21	50	51	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					117	119		10.1136/bmj.318.7176.117	http://dx.doi.org/10.1136/bmj.318.7176.117			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157XT	9880290	Green Published			2022-12-28	WOS:000078087500033
J	Upshaw, CB; Silverman, ME				Upshaw, CB; Silverman, ME			The Wenckebach phenomenon: A salute and comment on the Centennial of its original description	ANNALS OF INTERNAL MEDICINE			English	Article									Piedmont Hosp, Atlanta, GA USA; Emory Univ, Sch Med, Atlanta, GA USA	Emory University	Upshaw, CB (corresponding author), 35 Collier Rd NW,Suite 425, Atlanta, GA 30309 USA.								0	22	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					58	63		10.7326/0003-4819-130-1-199901050-00011	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890852				2022-12-28	WOS:000077744500010
J	Lawson, M; Thomas, M				Lawson, M; Thomas, M			Vitamin D concentrations in Asian children aged 2 years living in England: population survey	BRITISH MEDICAL JOURNAL			English	Article									Inst Child Hlth, Childrens Nutr Res Ctr, London WC1N 1EH, England; Off Natl Stat, London SW1V 2QQ, England	University of London; University College London	Thomas, M (corresponding author), Inst Child Hlth, Childrens Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.							ARNAUD SB, 1976, PEDIATRICS, V57, P221; Gregory JR, 1995, NATL DIET NUTR SURVE, V1; GRINDULIS H, 1986, ARCH DIS CHILD, V61, P843, DOI 10.1136/adc.61.9.843; Lawson MS, 1998, ARCH DIS CHILD, V78, P420, DOI 10.1136/adc.78.5.420; THOMAS M, 1997, INFANT FEEDING ASIAN	5	87	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					28	28						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872879	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000078013100022
J	Schneck, SA				Schneck, SA			"Doctoring" doctors and their families	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS CHILDREN; PSYCHIATRIC ILLNESS; OWN FAMILIES; PATIENT; SUICIDE; HOUSE	Being selected to provide medical care to other physicians or their family members represents not only a gratifying professional recognition of competence by one's peers but also a challenge. Many personal and psychological factors may influence the medical care of physicians. III physicians may have difficulty with role reversal and "the VIP syndrome," while treating physicians may have to deal with their own anxiety and issues such as confidentiality, privacy, empathy, and intrusion by a physician-relative into the care of medical family members. Based on experience with more than 200 physician-patients and many adult family members of physicians, suggestions are offered for care of these patient groups.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schneck, SA (corresponding author), 1722 Crestridge Dr, Greenwood Village, CO 80121 USA.							Allibone A, 1981, J R Coll Gen Pract, V31, P728; AOUN H, 1992, ANN INTERN MED, V116, P335, DOI 10.7326/0003-4819-116-4-335; ARNETZ BB, 1987, ACTA PSYCHIAT SCAND, V75, P139, DOI 10.1111/j.1600-0447.1987.tb02765.x; BASS LW, 1978, NEW ENGL J MED, V299, P772, DOI 10.1056/NEJM197810052991410; BLACHLY PH, 1963, NEW ENGL J MED, V268, P1278, DOI 10.1056/NEJM196306062682307; BLACHLY PH, 1968, B SUICIDOLOGY, V4, P1; BOIKO PE, 1984, J FAM PRACTICE, V6, P891; BOWES D, 1984, CAN MED ASSOC J, V131, P1343; BYNDER H, 1968, MED CARE, V6, P157, DOI 10.1097/00005650-196803000-00007; CRAWSHAW R, 1980, JAMA-J AM MED ASSOC, V243, P1915; CRAWSHAW R, 1992, WESTERN J MED, V157, P201; Crosbie S, 1972, Rocky Mt Med J, V69, P49; DEARLOVE J, 1982, BRIT MED J, V285, P187, DOI 10.1136/bmj.285.6336.187; Diekema DS, 1996, AM J EMERG MED, V14, P6, DOI 10.1016/S0735-6757(96)90002-9; DUFFY JC, 1967, EMOTIONAL HLTH PHYSI, P35; DUSDIEKER LB, 1993, AM J DIS CHILD, V147, P146, DOI 10.1001/archpedi.1993.02160260036018; EDELSTEIN EL, 1984, PSYCHOPATHOLOGY, V17, P213, DOI 10.1159/000284054; EDELSTEIN EL, 1982, PSYCHIAT CLIN, V15, P177, DOI 10.1159/000283938; ELLARD J, 1974, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1974.tb70807.x; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; GOLD N, 1972, AUST NZ J PSYCHIAT, V6, P209, DOI 10.3109/00048677209159712; Hjemmen Arne, 1993, Tidsskrift for den Norske Laegeforening, V113, P961; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; Keoun B, 1996, J NATL CANCER I, V88, P1616, DOI 10.1093/jnci/88.22.1616; KHANTZIAN EJ, 1985, JAMA-J AM MED ASSOC, V254, P249, DOI 10.1001/jama.254.2.249; Kirsch M, 1996, AM J GASTROENTEROL, V91, P1299; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; Lindeman S, 1996, BRIT J PSYCHIAT, V168, P274, DOI 10.1192/bjp.168.3.274; MAIN TF, 1957, BRIT J MED PSYCHOL, V30, P129, DOI 10.1111/j.2044-8341.1957.tb01193.x; Mandell H, 1987, DOCTORS GET SICK; MANDELL HN, 1987, POSTGRAD MED, V82, P20, DOI 10.1080/00325481.1987.11699942; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; MARZUK PM, 1987, NEW ENGL J MED, V317, P1409, DOI 10.1056/NEJM198711263172209; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; Meissner W W, 1978, Int J Psychoanal Psychother, V7, P437; MURRAY RM, 1978, J ROY COLL PHYS LOND, V12, P403; MURRAY RM, 1974, LANCET, V1, P1211; NESS DE, 1994, JAMA-J AM MED ASSOC, V272, P1777, DOI 10.1001/jama.272.22.1777; OSMOND H, 1977, PRACTITIONER, V218, P834; PEARSON MM, 1960, AM J PSYCHIAT, V116, P915, DOI 10.1176/ajp.116.10.915; PEARSON MM, 1982, PSYCHIAT ANN, V12, P194, DOI 10.3928/0048-5713-19820201-07; Pensack R., 1994, RAISING LAZARUS; PHILIPS JB, 1983, NEW ENGL J MED, V308, P1542; PINNER M, 1952, DOCTORS ARE PATIENTS; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; RHOADS JM, 1977, JAMA-J AM MED ASSOC, V237, P2615, DOI 10.1001/jama.237.24.2615; RICH CL, 1979, AM J PSYCHIAT, V136, P1089; ROBBINS GF, 1953, CANCER, V6, P624, DOI 10.1002/1097-0142(195305)6:3<624::AID-CNCR2820060320>3.0.CO;2-0; Rosenbaum EE., 1988, TASTE MY OWN MED DOC; ROSENBAUM EE, 1988, TASTE MY OWN MED DOC, P14; Rutle Olav, 1993, Tidsskrift for den Norske Laegeforening, V113, P964; Sacks O, 1984, LEG STAND; SCARLETT EP, 1965, ARCH INTERN MED, V115, P351, DOI 10.1001/archinte.1965.03860150095018; SIMON W, 1968, J NERV MENT DIS, V147, P105, DOI 10.1097/00005053-196808000-00002; SOUTHWICK FS, 1995, BEING DOCTOR, P35; SPIRO HM, 1987, PERSPECT BIOL MED, V31, P117; SPIRO JH, 1978, J MED EDUC, V53, P997; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; VAILLANT GE, 1970, NEW ENGL J MED, V282, P365, DOI 10.1056/NEJM197002122820705; VINCENT MO, 1969, CAN MED ASSOC J, V100, P403; WARING EM, 1974, COMPR PSYCHIAT, V15, P519, DOI 10.1016/0010-440X(74)90007-8; WASSERMAN RC, 1989, PEDIATRICS, V83, P319; WATTERSON DJ, 1976, CAN MED ASSOC J, V115, P311; WEINBERG RB, 1995, BEING DOCTOR, P45; WEINTRAUB W, 1964, J NERV MENT DIS, V138, P181, DOI 10.1097/00005053-196402000-00012; WHITE RB, 1963, DIS NERV SYST, V24, P304; 1993, LANCET, V342, P1249; 1972, MED WORLD NEWS, V13, P56; 1970, JAMA, V212, P147; 1983, LANCET, V2, P201	74	58	58	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2039	2042		10.1001/jama.280.23.2039	http://dx.doi.org/10.1001/jama.280.23.2039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146YW	9863860	Bronze			2022-12-28	WOS:000077462300039
J	van Walraven, C; Goel, V; Chan, B				van Walraven, C; Goel, V; Chan, B			Effect of population-based interventions on laboratory utilization - A time-series analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; TESTS; EDUCATION; BEHAVIOR; SERVICES; FORM	Context.-Previous studies have identified methods of decreasing laboratory utilization. However, most were hospital-based, relatively small, single-centered, or of limited duration. Objective.-To determine the effect of 3 population-based interventions (physician guidelines, laboratory requisition form modification, and changes to funding policy) on laboratory utilization in Ontario. Design.-Interventional time-series analysis in which data analysis was based on all claims made to the Ontario Health Insurance Program between July 1, 1991, and April 1997 for laboratory tests affected by the interventions. Setting.-All clinical laboratories (not based in hospitals) in Ontario. Interventions.-Physician guidelines, modification of laboratory requisition form, and changes in funding policy for the use of the erythrocyte sedimentation rate test (ESR), microscopic urinalysis, tests for renal function, iron stores, serum urea, and serum iron determinations, and tests for thyroid dysfunction (total thyroxine and thyroid-stimulating hormone [TSH]). Main Outcome Measures.-Change from 1991 to 1997 in utilization rates of ESR, microscopic urinalysis, serum urea and iron determinations, and tests for total thyroxine and TSH. Results.-Age- and sex-standardized rates for laboratory tests unaffected by the interventions were stable during the study period. Utilization of ESR and urea determination decreased by 58% (P<.001) and 57% (P<.001), respectively, after they were removed from the requisition form and guidelines discouraging their use were disseminated. Rates for urinalyses without microscopy increased by 1700% (P<.001), while microscopic urinalysis decreased by 14% (P<.001), after a policy change eliminated microscopic urinalysis from routine urinalysis. Rates of iron determination declined by 80% (P<.001) and ferritin rates increased by 34% (P=.05) when policy changes eliminated iron testing when ordered with ferritin and guidelines advocating ferritin alone for investigating iron deficiency were disseminated. Utilization of total thyroxine testing declined by 96% (P =.02) when the provincial health plan stopped its funding. When TSH was removed from the laboratory requisition form, a 12% decline (P=.03) in its use was observed. Through April 1997, these interventions saved more than 625 000 tests or $210 400. Conclusions.-The combination of guideline dissemination, laboratory requisition form modification, and changes to funding policy was associated with significant reductions in laboratory utilization.	Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Univ Toronto, Toronto, ON, Canada; Price Waterhouse, Toronto, ON, Canada; Inst Clin Evaluat Sci, N York, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto	van Walraven, C (corresponding author), Ottawa Civic Hosp, Clin Epidemiol Unit, Civic Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.			Goel, Vivek/0000-0002-1389-2007				AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DIXON RH, 1974, ARCH INTERN MED, V134, P1064, DOI 10.1001/archinte.134.6.1064; DURANDZALESKI I, 1993, LANCET, V342, P150, DOI 10.1016/0140-6736(93)91349-Q; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; LEESE B, 1991, IS THERE TOO MUCH LA, P79; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P3075, DOI 10.1001/jama.249.22.3075; MACDONALD D, 1992, REPORT WORKING PARTY; MENON D, 1992, INFLUENCE ED INTERVE; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MOZES B, 1989, ARCH INTERN MED, V149, P1836, DOI 10.1001/archinte.149.8.1836; NOVICH M, 1985, AM J CLIN PATHOL, V84, P756, DOI 10.1093/ajcp/84.6.756; Ohkubo A, 1995, Rinsho Byori, V43, P647; *ONT MIN HLTH, 1995, SAL FEAT LAB IND ONT; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PUTNAM RW, 1989, CAN MED ASSOC J, V140, P806; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; THOMPSON RS, 1983, PREV MED, V12, P385, DOI 10.1016/0091-7435(83)90247-5; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P550, DOI 10.1001/jama.280.6.550; WONG ET, 1983, JAMA-J AM MED ASSOC, V249, P3076, DOI 10.1001/jama.249.22.3076; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	24	94	94	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2028	2033		10.1001/jama.280.23.2028	http://dx.doi.org/10.1001/jama.280.23.2028			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863855	Bronze			2022-12-28	WOS:000077462300034
J	Masera, G; Baez, F; Biondi, A; Cavalli, F; Conter, V; Flores, A; Fontana, G; Bellani, FF; Lanfranco, P; Malta, A; Mendez, G; Ocampo, E; Pacheco, C; Riva, L; Sala, A; Silva, F; Sessa, C; Tognoni, G				Masera, G; Baez, F; Biondi, A; Cavalli, F; Conter, V; Flores, A; Fontana, G; Bellani, FF; Lanfranco, P; Malta, A; Mendez, G; Ocampo, E; Pacheco, C; Riva, L; Sala, A; Silva, F; Sessa, C; Tognoni, G			North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD; FEATURES; HEALTH; ONSET	We describe the La Mascota twinning programme between La Mascota paediatric hospital in Managua, Nicaragua, and hospitals in Monza and Milan, Italy, and Bellinzona, Switzerland, The programme was based on the belief that an attempt to reduce the gap in mortality from cancer in childhood between developed and less developed countries should become an integral part of the care and research activity of a haemato-oncological department of a developed country and not simply an exercise in solidarity. This programme for acute lymphoblastic leukaemia shows that intellectual, organisational, and financial resources can be generated by a twinning programme, What is vital for such programmes is a long-term commitment to a comprehensive and holistic strategy that incorporates supply of drugs, training and supervision of health professionals, and the care of the children and of their parents.	Univ Milan, S Gerardo Hosp, Pediat Clin, I-20052 Monza, Italy; Manuel Jesus Rivera La Mascota Hosp, Paediat Hematooncol Dept, Managua, Nicaragua; S Giovanni Hosp, Dept Oncol, Bellinzona, Switzerland; Ist Nazl Tumori, Dept Paediat Oncol, I-20133 Milan, Italy; Ist Ric Farmacol Mario Negri, Milan, Italy	University of Milan; Regional Hospital of Bellinzona & Valleys, San Giovanni; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Masera, G (corresponding author), Univ Milan, S Gerardo Hosp, Pediat Clin, I-20052 Monza, Italy.		Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016	Biondi, Andrea/0000-0002-6757-6173; 				ALBER JL, 1997, ANNU REV PUBL HEALTH, V18, P463; Baez F, 1997, ANN ONCOL, V8, P247, DOI 10.1023/A:1008200210674; CHANDY M, 1995, MED PEDIATR ONCOL, V25, P197, DOI 10.1002/mpo.2950250307; COREA AM, 1993, ANN ONCOL, V4, P892, DOI 10.1093/oxfordjournals.annonc.a058400; Flores A, 1996, MED PEDIATR ONCOL, V26, P258, DOI 10.1002/(SICI)1096-911X(199604)26:4<258::AID-MPO7>3.0.CO;2-I; HALLORAN ME, 1989, AM J PUBLIC HEALTH, V79, P424, DOI 10.2105/AJPH.79.4.424; HALPERIN DC, 1982, NEW ENGL J MED, V307, P388, DOI 10.1056/NEJM198208053070634; Howson CP, 1998, LANCET, V351, P586, DOI 10.1016/S0140-6736(97)11452-0; Jareg P, 1998, LANCET, V351, P819, DOI 10.1016/S0140-6736(97)11454-4; Lamontagne JF, 1998, SOC SCI MED, V46, P403, DOI 10.1016/S0277-9536(97)00184-6; Magrath I, 1993, PRINCIPLES PRACTICE, P1225; Malta A, 1997, INT J PEDIAT HEM ONC, V4, P121; MASERA G, 1993, ANN ONCOL, V4, P37, DOI 10.1093/oxfordjournals.annonc.a058354; PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408; PIZZO PA, 1993, PRINCIPLES PRACTICE, P1226; Reading R, 1997, ARCH DIS CHILD, V76, P463, DOI 10.1136/adc.76.5.463; ROBERTS H, 1997, BMJ-BRIT MED J, V314, P122; TOGNONI G, 1993, ANN ONCOL, V4, P7, DOI 10.1093/oxfordjournals.annonc.a058366; WAGNER HP, ANN NY ACAD, V824, P193; Walt G, 1998, LANCET, V351, P434, DOI 10.1016/S0140-6736(97)05546-3; *WORLD BANK, 1993, WORLD DEV REP 1993 I; 1997, SIOP NEWS, V17, P32	22	90	90	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1998	352	9144					1923	1926		10.1016/S0140-6736(98)07077-9	http://dx.doi.org/10.1016/S0140-6736(98)07077-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863803				2022-12-28	WOS:000077544600044
J	Muntwyler, J; Hennekens, CH; Buring, JE; Gaziano, JM				Muntwyler, J; Hennekens, CH; Buring, JE; Gaziano, JM			Mortality and light to moderate alcohol consumption after myocardial infarction	LANCET			English	Article							CORONARY HEART-DISEASE; U-SHAPED CURVE; BLOOD-PRESSURE; RISK; MORBIDITY; ETHANOL	Background Although heavy alcohol consumption increases total mortality, light to moderate consumption decreases cardiovascular and all-cause mortality in apparently healthy people. Since data are sparse on the relation of light to moderate alcohol intake to mortality in patients with previous myocardial infarction, we did a prospective study of mortality in men. Methods Of 90 150 men in the Physicians' Health Study enrolment cohort who provided information on alcohol intake and who had no history of cancer, stroke, or liver disease, 5358 had a previous myocardial infarction. We estimated alcohol consumption by food-frequency questionnaire. Findings During a mean follow-up of 5 years, 920 men died. After adjustment for several potential confounders, moderate alcohol intake was associated with a significant decrease in total mortality (p=0.016). Compared with men who rarely or never drank alcohol, those who drank one to four drinks per month had a relative risk for total mortality of 0.85 (95% CI 0.69-1.05); for two to four drinks per week, the relative risk was 0.72 (0.58-0.89); for one drink per day 0.79 (0.64-9.96); and for two or more drinks per day 0.84 (0.55-1.26). Interpretation Men with previous myocardial infarction who consume small to moderate amounts of alcohol have a lower total mortality.	Vet Affairs Med Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med & Cardiovasc Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gaziano, JM (corresponding author), Vet Affairs Med Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr, 1600 VFW Pkwy, W Roxbury, MA 02132 USA.	gaziano@maveric.org			NHLBI NIH HHS [HL-42441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKWRIGHT PD, 1982, CIRCULATION, V66, P60, DOI 10.1161/01.CIR.66.1.60; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; Longnecker MP, 1996, CLIN CHIM ACTA, V246, P121, DOI 10.1016/0009-8981(96)06232-8; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MARMOT MG, 1981, LANCET, V1, P580; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; SHAPER AG, 1988, LANCET, V2, P1267; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; THOMAS AP, 1994, ALCOHOL CLIN EXP RES, V18, P121, DOI 10.1111/j.1530-0277.1994.tb00891.x; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	23	139	142	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1882	1885		10.1016/S0140-6736(98)06351-X	http://dx.doi.org/10.1016/S0140-6736(98)06351-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863785				2022-12-28	WOS:000077544600008
J	Jacobs, MD; Harrison, SC				Jacobs, MD; Harrison, SC			Structure of an I kappa B alpha/NF-kappa B complex	CELL			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DNA-BINDING ACTIVITY; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; CYTOPLASMIC RETENTION; STRUCTURE REFINEMENT; PROTEIN; SIGNAL; P50; ACTIVATION	The inhibitory protein, I kappa B alpha, sequesters the transcription factor, NF-kappa B, as an inactive complex in the cytoplasm. The structure of the I kappa B alpha ankyrin repeat domain, bound to a partially truncated NF-kappa B heterodimer (p50/p65), has been determined by X-ray crystallography at 2.7 Angstrom resolution. It shows a stack of six I kappa B alpha ankyrin repeats facing the C-terminal domains of the NF-kappa B Rel homology regions. Contacts occur in discontinuous patches, suggesting a combinatorial quality for ankyrin repeat specificity. The first two repeats cover an alpha helically ordered segment containing the p65 nuclear localization signal. The position of the sixth ankyrin repeat shows that full-length I kappa B alpha Will occlude the NF-kappa B DNA-binding cleft. The orientation of I kappa B alpha in the complex places its N- and C-terminal regions in appropriate locations for their known regulatory functions.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	harrison@crystal.harvard.edu						ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1992, X PLOR VERSION 3 0 S; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OTWINOSKI Z, 1993, DATA COLLECTION PROC; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1095, DOI 10.1016/S0960-894X(00)80294-2; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1089, DOI 10.1016/S0960-894X(00)80293-0; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	63	660	691	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					749	758		10.1016/S0092-8674(00)81698-0	http://dx.doi.org/10.1016/S0092-8674(00)81698-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865693	Bronze			2022-12-28	WOS:000077498800005
J	Locher, KP; Rees, B; Koebnik, R; Mitschler, A; Moulinier, L; Rosenbusch, JP; Moras, D				Locher, KP; Rees, B; Koebnik, R; Mitschler, A; Moulinier, L; Rosenbusch, JP; Moras, D			Transmembrane signaling across the ligand-gated FhuA receptor: Crystal structures of free and ferrichrome-bound states reveal allosteric changes	CELL			English	Article							ESCHERICHIA-COLI K-12; MICROBIAL IRON TRANSPORT; COMPLETE GENOME SEQUENCE; OUTER-MEMBRANE PROTEIN; ELECTRON-DENSITY MAPS; CELL-ENVELOPE; ANOMALOUS DIFFRACTION; PHAGE T5; BINDING; TONB	FhuA protein facilitates ligand-gated transport of ferrichrome-bound iron across Escherichia coli outer membranes. X-ray analysis at 2.7 Angstrom resolution reveals two distinct conformations in the presence and absence of ferrichrome. The monomeric protein consists of a hollow, 22-stranded, antiparallel beta barrel (residues 160-714), which is obstructed by a plug (residues 19-159). The binding site of ferrichrome, an aromatic pocket near the cell surface, undergoes minor changes upon association with the ligand. These are propagated and amplified across the plug, eventually resulting in substantially different protein conformations at the periplasmic face. Our findings reveal the mechanism of signal transmission and suggest how the energy-transducing Tons complex senses ligand binding.	ULP, Struct Biol Lab, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67400 Illkirch Graffenstaden, France; Univ Basel, Biozentrum, Dept Microbiol, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Basel	Moras, D (corresponding author), ULP, Struct Biol Lab, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, 1 Rue Laurent Fries, F-67400 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Koebnik, Ralf/J-5627-2014	Koebnik, Ralf/0000-0002-4419-0542				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRAUN V, 1973, FEBS LETT, V34, P77, DOI 10.1016/0014-5793(73)80707-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DOHERTY AJ, 1995, NUCLEIC ACIDS RES, V23, P2074, DOI 10.1093/nar/23.11.2074; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DREW HR, 1982, P NATL ACAD SCI-BIOL, V79, P4040, DOI 10.1073/pnas.79.13.4040; EDMAN P, 1956, ACTA CHEM SCAND, V10, P761, DOI 10.3891/acta.chem.scand.10-0761; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; HANTKE K, 1975, FEBS LETT, V49, P301, DOI 10.1016/0014-5793(75)80771-X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KILLMANN H, 1995, J BACTERIOL, V177, P694, DOI 10.1128/jb.177.3.694-698.1995; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Locher KP, 1997, EUR J BIOCHEM, V247, P770, DOI 10.1111/j.1432-1033.1997.t01-1-00770.x; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; NAUCORNELISSEN C, 1994, MOL MICROBIOL, V40, P843; NAUCORNELISSEN C, 1998, MOL MICROBIOL, V27, P611; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plancon L, 1997, J BIOL CHEM, V272, P16868, DOI 10.1074/jbc.272.27.16868; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; SCHIEPEK G, 1995, PSYCHOTHERAPIE FORUM, V3, P1; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Stevens MK, 1996, INFECT IMMUN, V64, P1724, DOI 10.1128/IAI.64.5.1724-1735.1996; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; VANDERHELM D, 1980, J AM CHEM SOC, V102, P4224, DOI 10.1021/ja00532a039; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0	47	445	456	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					771	778		10.1016/S0092-8674(00)81700-6	http://dx.doi.org/10.1016/S0092-8674(00)81700-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865695				2022-12-28	WOS:000077498800007
J	Nonaka, S; Tanaka, Y; Okada, Y; Takeda, S; Harada, A; Kanai, Y; Kido, M; Hirokawa, N				Nonaka, S; Tanaka, Y; Okada, Y; Takeda, S; Harada, A; Kanai, Y; Kido, M; Hirokawa, N			Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein	CELL			English	Article							KINESIN-LIKE PROTEIN; ORGANELLE TRANSPORT; SITUS-INVERSUS; NERVOUS-SYSTEM; MOUSE EMBRYOS; DYNEIN ARMS; EXPRESSION; GENE; MEMBRANE; MOTILITY	Microtubule-dependent motor, murine KIF3B, was disrupted by gene targeting. The null mutants did not survive beyond midgestation, exhibiting growth retardation, pericardial sac ballooning, and neural tube disorganization. Prominently, the left-right asymmetry was randomized in the heart loop and the direction of embryonic turning, lefty-2 expression was either bilateral or absent. Furthermore, the node lacked monocilia while the basal bodies were present. Immunocytochemistry revealed KIF3B localization in wildtype nodal cilia. Video microscopy showed that these cilia were motile and generated a leftward flow. These data suggest that KIF3B is essential for the left-right determination through intraciliary transportation of materials for ciliogenesis of motile primary cilia that could produce a gradient of putative morphogen along the left-right axis in the node.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, 7-3-1 Hongo, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp	Takeda, Sen/I-8462-2012; Okada, Yasushi/N-5067-2015; Nonaka, Shigenori/I-2132-2013; Kanai, Yoshimitsu/W-3486-2019	Takeda, Sen/0000-0001-7090-2139; Okada, Yasushi/0000-0003-2601-3689; Nonaka, Shigenori/0000-0002-8093-0325; Tanaka, Yosuke/0000-0001-5376-5726; Kanai, Yoshimitsu/0000-0002-0375-6853				AFZELIUS BA, 1975, J CELL BIOL, V66, P225, DOI 10.1083/jcb.66.2.225; Afzelius BA, 1995, INT J DEV BIOL, V39, P839; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Beech PL, 1996, J CELL SCI, V109, P889; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1990, DEVELOPMENT, V109, P1; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Dufort D, 1998, DEVELOPMENT, V125, P3015; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HANDEL MA, 1984, J HERED, V75, P498, DOI 10.1093/oxfordjournals.jhered.a109995; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; ODOR DL, 1985, AM J ANAT, V174, P437, DOI 10.1002/aja.1001740407; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; SHAKIR MA, 1993, NEUROREPORT, V4, P891, DOI 10.1097/00001756-199307000-00013; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TAM PPL, 1980, J EMBRYOL EXP MORPH, V59, P131; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TANAKA Y, 1995, J CELL SCI, V108, P1883; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; WOOD M J, 1987, P255; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387	47	1190	1219	0	105	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					829	837		10.1016/S0092-8674(00)81705-5	http://dx.doi.org/10.1016/S0092-8674(00)81705-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865700	Bronze			2022-12-28	WOS:000077498800012
J	Guzick, DS; Carson, SA; Coutifaris, C; Overstreet, JW; Factor-Litvak, P; Steinkampf, MP; Hill, JA; Mastroianni, L; Buster, JE; Nakajima, ST; Vogel, DL; Canfield, RE				Guzick, DS; Carson, SA; Coutifaris, C; Overstreet, JW; Factor-Litvak, P; Steinkampf, MP; Hill, JA; Mastroianni, L; Buster, JE; Nakajima, ST; Vogel, DL; Canfield, RE		Natl Cooperative Reproductive Med Network	Efficacy of superovulation and intrauterine insemination in the treatment of infertility	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Induction of superovulation with gonadotropins and intrauterine insemination are frequently used to treat infertility. We conducted a large, randomized, controlled clinical trial of these treatments. Methods We studied 932 couples in which the woman had no identifiable infertility factor and the man had motile sperm. The couples were randomly assigned to receive intracervical insemination, intrauterine insemination, superovulation and intracervical insemination, or superovulation and intrauterine insemination. Treatment continued for four cycles unless pregnancy was achieved. Results The 231 couples in the group treated with superovulation and intrauterine insemination had a higher rate of pregnancy (33 percent) than the 234 couples in the intrauterine-insemination group (18 percent), the 234 couples in the group treated with superovulation and intracervical insemination (19 percent), or the 233 couples in the intracervical-insemination group (10 percent). Stratified, discrete-time Cox proportional-hazards analysis showed that the couples in the group treated with superovulation and intrauterine insemination were 3.2 times as likely to become pregnant as those in the intracervical-insemination group (95 percent confidence interval, 2.0 to 5.3) and 1.7 times as likely as those in the intrauterine-insemination group (95 percent confidence interval, 1.2 to 2.6). The couples in the intrauterine-insemination group and in the group treated with superovulation and intracervical insemination were nearly twice as likely to conceive as those in the intracervical-insemination group. Conclusions Among infertile couples, treatment with induction of superovulation and intrauterine insemination is three times as likely to result in pregnancy as is intracervical insemination and twice as likely to result in pregnancy as is treatment with either superovulation and intracervical insemination or intrauterine insemination alone. (N Engl J Med 1999; 340:177-83.) (C) 1999, Massachusetts Medical Society.	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Univ Rochester, Rochester, NY USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Univ Calif Davis, Sacramento, CA 95817 USA; Columbia Univ, New York, NY USA; Univ Alabama, Birmingham, AL USA; Harvard Univ, Boston, MA 02115 USA; NIH, Bethesda, MD 20892 USA	Baylor College of Medicine; University of Rochester; University of Pennsylvania; University of California System; University of California Davis; Columbia University; University of Alabama System; University of Alabama Birmingham; Harvard University; National Institutes of Health (NIH) - USA	Guzick, DS (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, 6550 Fannin 801, Houston, TX 77030 USA.				NICHD NIH HHS [U10 HD26975, U10 HD26981, U10 HD27006] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD026975, U10HD026981, U10HD027006] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABT K, 1981, CONTROL CLIN TRIALS, V1, P377, DOI 10.1016/0197-2456(81)90042-8; COX DR, 1972, J R STAT SOC B, V34, P187; Dourron NE, 1996, SEMIN REPROD ENDOCR, V14, P355, DOI 10.1055/s-2008-1067980; EVANS MI, 1995, AM J OBSTET GYNECOL, V172, P1750, DOI 10.1016/0002-9378(95)91407-2; Guzick DS, 1998, FERTIL STERIL, V70, P207, DOI 10.1016/S0015-0282(98)00177-0; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Overstreet JW, 1997, INFERTILITY MALE, P487; Paulson RJ, 1996, J ASSIST REPROD GEN, V13, P751, DOI 10.1007/BF02066492; Revised American Fertility Society, 1985, FERTIL STERIL, V43, P351; Tummon IS, 1997, FERTIL STERIL, V68, P8, DOI 10.1016/S0015-0282(97)81467-7; VanVoorhis BJ, 1997, FERTIL STERIL, V67, P830, DOI 10.1016/S0015-0282(97)81393-3; World Health Organization, 1992, WHO LAB MAN EX HUM S	12	383	395	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					177	183		10.1056/NEJM199901213400302	http://dx.doi.org/10.1056/NEJM199901213400302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895397				2022-12-28	WOS:000078202900002
J	Neelon, FA; Harvey, EN				Neelon, FA; Harvey, EN			The Babinski sign	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Duke Univ, Med Ctr, Durham, NC 27710 USA; Family Serv Greater Lowell, Lowell, MA 01852 USA	Duke University	Neelon, FA (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					196	196		10.1056/NEJM199901213400305	http://dx.doi.org/10.1056/NEJM199901213400305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895399				2022-12-28	WOS:000078202900005
J	Esat, TM; McCulloch, MT; Chappell, J; Pillans, B; Omura, A				Esat, TM; McCulloch, MT; Chappell, J; Pillans, B; Omura, A			Rapid fluctuations in sea level recorded at Huon Peninsula during the penultimate deglaciation	SCIENCE			English	Article							BAHAMIAN ISLAND GEOLOGY; LAST INTERGLACIAL PERIOD; PAPUA-NEW-GUINEA; QUATERNARY TECTONIC MOVEMENTS; MASS-SPECTROMETRY; CORAL REEFS; WESTERN-AUSTRALIA; OXYGEN ISOTOPES; HEINRICH EVENTS; NORTH-ATLANTIC	About 140,000 years ago, the breakup of large continental ice sheets initiated the Last Interglacial period. Sea level rose and peaked around 135,000 years ago about 14 meters below present Levels. A record of Last Interglacial sea Levels between 116,000 years to 136,000 years ago is preserved at reef VII of the uplifted coral terraces of Huon Peninsula in Papua New Guinea. However, corals from a cave situated about 90 meters below the crest of reef VII are 130,000 +/- 2000 years old and appear to have grown in conditions that were 6 degrees C cooler than those at present. These observations imply a drop in sea level of 60 to 80 meters. After 130,000 years, sea level began rising again in response to the major insolation maximum at 126,000 to 128,000 years ago. The early (about 140,000 years ago) start of the penultimate deglaciation, well before the peak in insolation, is consistent with the Devils Hole chronology.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Kanazawa Univ, Kanazawa, Ishikawa 920, Japan	Australian National University; Kanazawa University	Esat, TM (corresponding author), Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia.		McCulloch, Malcolm T/C-3651-2009	McCulloch, Malcolm T/0000-0003-1538-1558; Esat, Tezer/0000-0001-5331-6568; Pillans, Bradley/0000-0002-8373-635X; Esat, Sevilay/0000-0002-7257-4009				AHARON P, 1986, PALAEOGEOGR PALAEOCL, V56, P337, DOI 10.1016/0031-0182(86)90101-X; ANDREWS JT, 1992, GEOLOGY, V20, P1087, DOI 10.1130/0091-7613(1992)020<1087:DCRSNL>2.3.CO;2; BAKER PA, 1975, EARTH PLANET SC LETT, V27, P57, DOI 10.1016/0012-821X(75)90160-0; BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; BERGER WH, 1994, P WORKSH ROYAL NETH, P61; BLOOM AL, 1974, QUATERNARY RES, V4, P185, DOI 10.1016/0033-5894(74)90007-6; BLOOM AL, 1990, SEA LEVEL CHANGE, P104; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; BROECKER WS, 1994, NATURE, V372, P421, DOI 10.1038/372421a0; Carew JL, 1997, GEOLOGY, V25, P572, DOI 10.1130/0091-7613(1997)025<0572:RSLCAT>2.3.CO;2; Cathles L.M., 1975, VISCOSITY EARTHS MAN; Chapman MR, 1998, EARTH PLANET SC LETT, V159, P57, DOI 10.1016/S0012-821X(98)00068-5; CHAPPELL J, 1974, GEOL SOC AM BULL, V85, P553, DOI 10.1130/0016-7606(1974)85<553:GOCTHP>2.0.CO;2; CHAPPELL J, 1991, NATURE, V349, P147, DOI 10.1038/349147a0; CHAPPELL J, 1986, NATURE, V324, P137, DOI 10.1038/324137a0; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; CHAPPELL J, 1978, GEOL SOC AM BULL, V89, P356, DOI 10.1130/0016-7606(1978)89<356:LQTMAS>2.0.CO;2; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; COLLINS LB, 1993, MAR GEOL, V110, P203, DOI 10.1016/0025-3227(93)90085-A; CROWLEY TJ, 1981, MAR MICROPALEONTOL, V6, P97, DOI 10.1016/0377-8398(81)90001-3; CROWLEY TJ, 1994, PALEOCEANOGRAPHY, V9, P1, DOI 10.1029/93PA02558; Denton G. H., 1981, LAST GREAT ICE SHEET; DODGE RE, 1983, SCIENCE, V219, P1423, DOI 10.1126/science.219.4591.1423; EDWARDS RL, 1987, SCIENCE, V236, P1547, DOI 10.1126/science.236.4808.1547; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; Esat TM, 1999, SCIENCE, V283, P197, DOI 10.1126/science.283.5399.197; ESAT TM, 1995, INT J MASS SPECTROM, V148, P159, DOI 10.1016/0168-1176(95)04234-C; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FAIRBRIDGE RW, 1960, SCI AM, V202, P70, DOI 10.1038/scientificamerican0560-70; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; Growley T.J., 1991, OXFORD MONOGRAPHS GE, V16; HAMELIN B, 1991, EARTH PLANET SC LETT, V106, P169, DOI 10.1016/0012-821X(91)90070-X; Hearty PJ, 1997, GEOLOGY, V25, P574; HillaireMarcel C, 1996, QUATERNARY SCI REV, V15, P53, DOI 10.1016/0277-3791(95)00079-8; Imbrie J., 1979, ICE AGES SOLVING MYS; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; KONISHI K, 1974, P 2 INT COR REEF S B, P595; Kukla G, 1978, T NEBRASKA ACADEMY S, P57; KUKLA GJ, 1977, EARTH-SCI REV, V13, P307, DOI 10.1016/0012-8252(77)90125-8; Ludwig KR, 1996, GEOLOGY, V24, P211, DOI 10.1130/0091-7613(1996)024<0211:SLRAKF>2.3.CO;2; McCabe AM, 1998, NATURE, V392, P373, DOI 10.1038/32866; Milankovitch M.K., 1941, CANON INSOLATION ICE; Mylroie JE, 1997, GEOLOGY, V25, P573; Neumann AC, 1996, GEOLOGY, V24, P775; Omura Akio, 1995, Quaternary Research (Tokyo), V34, P195; OTA Y, 1993, QUATERNARY RES, V40, P177, DOI 10.1006/qres.1993.1070; REEH N, 1991, QUATERN INT, V10, P123; Sarnthein M, 1990, PALEOCEANOGRAPHY, V5, P1041, DOI 10.1029/PA005i006p01041; Scherer RP, 1998, SCIENCE, V281, P82, DOI 10.1126/science.281.5373.82; Seidenkrantz MS, 1996, QUATERNARY SCI REV, V15, P63, DOI 10.1016/0277-3791(95)00086-0; STEIN M, 1993, GEOCHIM COSMOCHIM AC, V57, P2541, DOI 10.1016/0016-7037(93)90416-T; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; STIRLING CH, 1995, EARTH PLANET SC LETT, V135, P115, DOI 10.1016/0012-821X(95)00152-3; STONER JS, 1995, GEOLOGY, V23, P241, DOI 10.1130/0091-7613(1995)023<0241:MPODSS>2.3.CO;2; SZABO BJ, 1994, SCIENCE, V266, P93, DOI 10.1126/science.266.5182.93; TAYLOR FW, 1980, J GEOPHYS RES, V85, P5367, DOI 10.1029/JB085iB10p05367; THOMPSON PR, 1980, NATURE, V287, P829, DOI 10.1038/287829a0; VEEH HH, 1970, SCIENCE, V167, P862, DOI 10.1126/science.167.3919.862; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; ZHU ZR, 1993, EARTH PLANET SC LETT, V118, P281, DOI 10.1016/0012-821X(93)90173-7	63	158	165	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					197	201		10.1126/science.283.5399.197	http://dx.doi.org/10.1126/science.283.5399.197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880247				2022-12-28	WOS:000077976700032
J	Chang, CL; Donaghy, M; Poulter, N				Chang, CL; Donaghy, M; Poulter, N		World Hllth Org Collaborative Study Cardiovasc	Migraine and stroke in young women: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOSE ORAL-CONTRACEPTIVES; CEREBRAL-ISCHEMIA; RISK; ADULTS	Objective To investigate the association between migraine and ischaemic or haemorrhagic stroke in young women. Design Hospital based case-control study. Setting Five European centres participating in the World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Subjects 291 women aged 20-44 years with ischaemic, haemorrhagic, or unclassified arterial stroke compared with 736 age and hospital matched controls. Intervention Questionnaire. Main outcome measure Self reported history of headaches. Results Adjusted odds ratios associated with a personal history of migraine were 1.78 (95% confidence intervals, 1.14 to 2.77), 3.54 (1.30 to 9.61), and 1.10 (0.63 to 1.94) for all stroke, ischaemic stroke, and haemorrhagic stroke respectively. Odds ratios for ischaemic stroke were similar for classical migraine (with aura) (3.81, 1.26 to 11.5) and simple migraine (without aura) (2.97, 0.66 to 13.5). A family history of migraine, irrespective of personal history, was also associated with increased odds ratios, not only for ischaemic stroke but also haemorrhagic stroke. In migrainous women, coexistent use of oral contraceptives or a history of high blood pressure or smoking had greater than multiplicative effects on the odds ratios for ischaemic stroke associated with migraine alone. Change in the frequency or type of migraine on using oral contraceptives did not predict subsequent stroke. Between 20% and 40% of strokes in women with migraine seemed to develop directly from a migraine attack. Conclusions Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke. The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Imperial Coll Sch Med, Dept Clin Pharmacol, Cardiovasc Studies Unit, London W2 1PG, England; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England	Imperial College London; Radcliffe Infirmary	Poulter, N (corresponding author), Imperial Coll Sch Med, Dept Clin Pharmacol, Cardiovasc Studies Unit, London W2 1PG, England.	n.poulter@ic.ac.uk						[Anonymous], 1995, J Clin Epidemiol, V48, P1513; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BICKERSTAFF E, 1975, NEUROLOGICAL COMPLIC; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P223, DOI 10.1212/WNL.38.2.223; Buring JE, 1996, NEW ENGL J MED, V335, P53, DOI 10.1056/NEJM199607043350112; BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012; Carolei A, 1996, LANCET, V347, P1503, DOI 10.1016/S0140-6736(96)90669-8; DARNEY PD, 1995, AM J MED, V98, pS104, DOI 10.1016/S0002-9343(99)80067-9; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; Merikangas KR, 1997, ARCH NEUROL-CHICAGO, V54, P362, DOI 10.1001/archneur.1997.00550160012009; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; ROTHROCK JF, 1988, ARCH NEUROL-CHICAGO, V45, P63, DOI 10.1001/archneur.1988.00520250069023; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; WELCH KMA, 1994, NEUROLOGY, V44, P33; WELCH KMA, 1900, ARCH NEUROL-CHICAGO, V47, P458; 1987, DRUG THER B, V25, P95	23	331	340	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1999	318	7175					13	18						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872876				2022-12-28	WOS:000078013100019
J	Jenkins, S				Jenkins, S			My route to a steroid psychosis	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					67	67						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872915	Green Published			2022-12-28	WOS:000078013100081
J	Farrell, RJ; LaMont, JT				Farrell, RJ; LaMont, JT			Rational approach to iron-deficiency anaemia in premenopausal women	LANCET			English	Editorial Material							GASTROINTESTINAL-TRACT; ANEMIA		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Farrell, RJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA.							Bini ET, 1998, AM J MED, V105, P281, DOI 10.1016/S0002-9343(98)00260-5; Galan P, 1998, EUR J CLIN NUTR, V52, P383, DOI 10.1038/sj.ejcn.1600561; KEPCZYK MT, 1995, DIGEST DIS SCI, V40, P1283, DOI 10.1007/BF02065539; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; Milman N, 1998, ANN HEMATOL, V77, P13, DOI 10.1007/s002770050405; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303	7	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1953	1954		10.1016/S0140-6736(05)61326-8	http://dx.doi.org/10.1016/S0140-6736(05)61326-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872241				2022-12-28	WOS:000077663000005
J	Power, L				Power, L			Good times	LANCET			English	Editorial Material											Power, L (corresponding author), 605 Hidden Valley Dr,Suite 206, Ann Arbor, MI 48104 USA.								0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1999	2000		10.1016/S0140-6736(98)11283-7	http://dx.doi.org/10.1016/S0140-6736(98)11283-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872262				2022-12-28	WOS:000077663000043
J	Bhat, KM				Bhat, KM			frizzled and frizzled 2 play a partially redundant role in wingless signaling and have similar requirements to wingless in neurogenesis	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SEGMENT POLARITY GENES; DROSOPHILA-MELANOGASTER; TISSUE POLARITY; SPECIFICATION; CNS; NEUROECTODERM; LINEAGES; PATTERN; FAMILY	The Drosophila Frizzled (Fz) and Frizzled2 (DFz2) proteins function as receptors for Wingless (Wg) in tissue culture cells. While previous results indicate that loss of function for fi has tissue polarity defects, loss-of-function effects of Dfz2 are not known. Here, we have examined the requirements of fz and Dfz2 during neurogenesis. Our results indicate that both Fz and DFz2 function in Wg signaling, and loss of either of the two affects the same subset of neuroblasts as those affected by loss of wg. While these defects are partially penetrant in embryos lacking either fz or Dfz2, the penetrance is significantly enhanced in embryos lacking both. Since the penetrance of the CNS phenotypes is not complete in double mutants, additional components that allow some degree of Wg signaling must exist in vivo.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Bhat, KM (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058237] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM58237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BHAT KM, 1995, MOL CELL BIOL, V15, P4052; Bhat KM, 1997, DEVELOPMENT, V124, P1675; Bhat KM, 1998, INT J DEV BIOL, V42, P127; BHAT KM, 1996, DEVELOPMENT, V122, P2911; BHAT KM, 1999, IN PRESS BIOESSAYS; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; CHULAGRAFF Q, 1995, NEURON, V15, P1041, DOI 10.1016/0896-6273(95)90093-4; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; DOE CQ, 1992, DEVELOPMENT, V116, P855; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GUBB D, 1993, DEVELOPMENT, P269; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; Hays R, 1997, DEVELOPMENT, V124, P3727; Jones KH, 1996, GENETICS, V142, P205; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Matsuzaki M, 1996, DEVELOPMENT, V122, P3567; MERRILL PT, 1988, DEVELOPMENT, V104, P495; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MULLER AHJ, 1999, IN PRESS DEVELOPMENT; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEIFER M, 1994, DEVELOPMENT, V120, P369; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wieschaus E., 1986, P199; Zhang J, 1998, DEVELOPMENT, V125, P3075	40	99	99	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1027	1036		10.1016/S0092-8674(00)81726-2	http://dx.doi.org/10.1016/S0092-8674(00)81726-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875856	Bronze			2022-12-28	WOS:000077759100017
J	Shiau, AK; Barstad, D; Loria, PM; Cheng, L; Kushner, PJ; Agard, DA; Greene, GL				Shiau, AK; Barstad, D; Loria, PM; Cheng, L; Kushner, PJ; Agard, DA; Greene, GL			The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen	CELL			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR COACTIVATORS; STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; ACTIVATION; COMPLEX; PROTEIN; SUPERFAMILY	Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators. Receptor agonists promote coactivator binding, and antagonists block coactivator binding. Here we report the crystal structure of the human estrogen receptor alpha (hER alpha) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hER alpha LED bound to the selective antagonist 4-hydroxytamoxifen (OHT). In the DES-LBD-peptide complex, the peptide binds as a short alpha helix to a hydrophobic groove on the surface of the LED. In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LED. These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Chicago; University of Chicago; University of California System; University of California San Francisco	Greene, GL (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	ggreene@huggins.bsd.uchicago.edu			NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031627] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-14599] Funding Source: Medline; NIDDK NIH HHS [DK51083] Funding Source: Medline; NIGMS NIH HHS [GM31627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1996, XPLOR VERSION 3 843; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115, DOI 10.1073/pnas.77.9.5115; GREENE GL, 1988, MOL ENDOCRINOL, V2, P714, DOI 10.1210/mend-2-8-714; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; JORDAN VC, 1982, MOL CELL ENDOCRINOL, V27, P291, DOI 10.1016/0303-7207(82)90095-8; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MUELLER K, 1988, B SOC CHIM BELG, V97, P655; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; ONATE SA, 1995, SCIENCE, V270, P1354; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROBERTSON DW, 1982, J MED CHEM, V25, P167, DOI 10.1021/jm00344a015; SEIELSTAD DA, 1995, MOL ENDOCRINOL, V9, P647, DOI 10.1210/me.9.6.647; Smigel K, 1998, J NATL CANCER I, V90, P647, DOI 10.1093/jnci/90.9.647; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	59	2114	2199	0	161	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					927	937		10.1016/S0092-8674(00)81717-1	http://dx.doi.org/10.1016/S0092-8674(00)81717-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875847	Bronze			2022-12-28	WOS:000077759100008
J	Pitti, RM; Marsters, SA; Lawrence, DA; Roy, M; Kischkel, FC; Dowd, P; Huang, A; Donahue, CJ; Sherwood, SW; Baldwin, DT; Godowski, PJ; Wood, WI; Gurney, AL; Hillan, KJ; Cohen, RL; Goddard, AD; Botstein, D; Ashkenazi, A				Pitti, RM; Marsters, SA; Lawrence, DA; Roy, M; Kischkel, FC; Dowd, P; Huang, A; Donahue, CJ; Sherwood, SW; Baldwin, DT; Godowski, PJ; Wood, WI; Gurney, AL; Hillan, KJ; Cohen, RL; Goddard, AD; Botstein, D; Ashkenazi, A			Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; TNF RECEPTOR; APO-2 LIGAND; APOPTOSIS; FAMILY; EXPRESSION; MEMBER; DEATH; ACTIVATION	Fas ligand (FasL) is produced by activated T cells and natural killer cells and it induces apoptosis (programmed cell death) in target cells through the death receptor Fas/Apo1/CD95 (ref. 1). One important role of Fast and Fas is to mediate immune-cytotoxic killing of cells that are potentially harmful to the organism, such as virus-infected or tumour cells(1). Here we report the discovery of a soluble decoy receptor, termed decoy receptor 3 (DcR3), that binds to Fast and inhibits Fast-induced apoptosis. The DcR3 gene was amplified in about half of 35 primary lung and colon tumours studied, and DcR3 messenger RNA was expressed in malignant tissue. Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Stanford University	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.		Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; COLLOTTA F, 1993, SCIENCE, V261, P472; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gelmini S, 1997, CLIN CHEM, V43, P752; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Medvedev AE, 1997, CYTOKINE, V9, P394, DOI 10.1006/cyto.1996.0181; Moretta A, 1997, CELL, V90, P13, DOI 10.1016/S0092-8674(00)80309-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190	24	635	730	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					699	703		10.1038/25387	http://dx.doi.org/10.1038/25387			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872321				2022-12-28	WOS:000077694200059
J	Hennessey, KA; Schulte, JM; Cook, L; Collins, M; Onorato, IM; Valway, SE				Hennessey, KA; Schulte, JM; Cook, L; Collins, M; Onorato, IM; Valway, SE			Tuberculin skin test screening practices among US colleges and universities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1997 International Conference of the American-Thoracic-Society / American-Lung-Association	MAY 18-21, 1997	SAN FRANCISCO, CALIFORNIA	Amer Thorac Soc, Amer Lung Assoc			UNITED-STATES; EPIDEMIOLOGY; INFECTION	Context.-Concern about transmission of Mycobacterium tuberculosis on college campuses has prompted some schools to institute tuberculin skin test screening of students, but this screening has never been evaluated. Objective-To describe tuberculin skin test screening practices and results of screening in colleges and universities in the United States. Design and Setting.-Self-administered mail and telephone questionnaire in November and December 1995 to a stratified random sample of US 2-year and 4-year colleges and universities. Main Outcome Measures.-Type of tuberculin screening required; types of schools requiring screening; number and rate of students with positive skin test results and/or diagnosed as having tuberculosis. Results.-Of the 3148 US colleges and universities, 624 (78%) of 796 schools surveyed responded. Overall, 378 schools (61%) required tuberculin screening; it was required for all new students (US residents and international students) in 161 (26%) of 624 schools, all new international students but not new US residents in 53 (8%), and students in specific academic programs in 294 (47%). Required screening was more likely in 4-year vs 2-year schools, schools that belonged to the American College Health Association vs nonmember schools, schools with immunization requirements vs schools without, and schools with a student health clinic vs those without(P<.001 for all). Public and private schools were equally likely to require screening (64% vs 62%; P=.21). In the 378 schools with screening requirements, tine or multiple puncture tests were accepted in 95 (25%);test results were recorded in millimeters of induration in 95 (25%); and 100 (27%) reported collecting results in a centralized registry or database. Of the 168 (27%) of 624 schools accepting only Mantoux skin tests and reporting results for school years 1992-1993 through 1995-1996, 3.1% of the 348 368 students screened had positive skin test results (median percentage positive, 0.8%). International students had a significantly higher case rate for active tuberculosis than US residents (35.2 vs 1.1 per 100 000 students screened). Conclusions.-Widespread tuberculin screening of students yielded a low prevalence of skin test reactors and few tuberculosis cases. To optimize the use of limited public health resources, tuberculin screening should target students at high risk for infection.	Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Univ Penn, Philadelphia, PA 19104 USA	Centers for Disease Control & Prevention - USA; University of Pennsylvania	Hennessey, KA (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd,Mailstop E10, Atlanta, GA 30333 USA.				PHS HHS [H75/CCU312238-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1996, MMWR Recomm Rep, V45, P1; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BAUGHMAN AL, 1994, JAMA-J AM MED ASSOC, V272, P1127, DOI 10.1001/jama.272.14.1127; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P19; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P253; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; DAVIS TM, 1995, OPEN DOORS 1994 95 R; Driver CR, 1996, PEDIATRICS, V98, P97; Henry P M, 1996, Minn Med, V79, P43; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Levy P., 1991, SAMPLING POPULATIONS; LIFSON AR, IN PRESS AM J EPIDEM; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; NELSON ME, 1995, AM J PREV MED, V11, P48, DOI 10.1016/S0749-3797(18)30407-0; PENDLETON EH, 1994, PETERSONS GUIDE 4 YE; Quillan S, 1990, J Am Coll Health, V38, P165; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Snedecor GW, 1980, STAT METHODS, V7th; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STARKE JR, 1993, PEDIATR ANN, V22, P612, DOI 10.3928/0090-4481-19931001-10; STERN JD, 1995, PETERSONS GUIDE 2 YE; SUSMANO S, 1990, J AM COLL HEALTH, V39, P287; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211	25	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2008	2012		10.1001/jama.280.23.2008	http://dx.doi.org/10.1001/jama.280.23.2008			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863852	Bronze			2022-12-28	WOS:000077462300031
J	Ornish, D; Scherwitz, LW; Billings, JH; Gould, KL; Merritt, TA; Sparler, S; Armstrong, WT; Ports, TA; Kirkeeide, RL; Hogeboom, C; Brand, RJ				Ornish, D; Scherwitz, LW; Billings, JH; Gould, KL; Merritt, TA; Sparler, S; Armstrong, WT; Ports, TA; Kirkeeide, RL; Hogeboom, C; Brand, RJ			Intensive lifestyle changes for reversal of coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR MODIFICATION; LOW-FAT DIETS; ARTERY DISEASE; CHOLESTEROL LEVELS; MEN; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; PRAVASTATIN; REGRESSION; THERAPY	Context.-The Lifestyle Heart Trial demonstrated that intensive lifestyle changes may lead to regression of coronary atherosclerosis after 1 year. Objectives.-To determine the feasibility of patients to sustain intensive lifestyle changes for a total of 5 years and the effects of these lifestyle changes (without lipid-lowering drugs) on coronary heart disease. Design.-Randomized controlled trial conducted from 1986 to 1992 using a randomized invitational design. Patients.-Forty-eight patients with moderate to severe coronary heart disease were randomized to an intensive lifestyle change group or to a usual-care control group, and 35 completed the 5-year follow-up quantitative coronary arteriography, Setting.-Two tertiary care university medical centers. Intervention.-Intensive lifestyle changes (10% fat whole foods vegetarian diet, aerobic exercise, stress management training, smoking cessation, group psychosocial support) for 5 years. Main Outcome Measures.-Adherence to intensive lifestyle changes, changes in coronary artery percent diameter stenosis, and cardiac events. Results.-Experimental group patients (20 [71%] of 28 patients completed Ei-year follow-up) made and maintained comprehensive lifestyle changes for 5 years, whereas control group patients (15 [75%] of 20 patients completed 5-year follow-up) made more moderate changes. In the experimental group, the average percent diameter stenosis at baseline decreased 1.75 absolute percentage points after 1 year (a 4.5% relative improvement) and by 3.1 absolute percentage points after 5 years (a 7.9% relative improvement). In contrast, the average percent diameter stenosis in the control group increased by 2.3 percentage points after 1 year (a 5.4% relative worsening) and by 11.8 percentage points after 5 years (a 27.7% relative worsening) (P=.001 between groups. Twenty-five cardiac events occurred in 28 experimental group patients vs 45 events in 20 control group patients during the 5-year follow-up (risk ratio for any event for the control group, 2.47 [95% confidence interval, 1.48-4.20]). Conclusions.-More regression of coronary atherosclerosis occurred after 5 years than after 1 year in the experimental group. In contrast, in the control group, coronary atherosclerosis continued to progress and more than twice as many cardiac events occurred.	Res Inst Prevent Med, Sausalito, CA 94965 USA; Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA; Calif Pacific Med Ctr, Div Cardiol, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Cardiovasc Res Inst, Cardiac Catheterizat Lab, San Francisco, CA USA; Univ Calif San Francisco, Sch Med, Div Biostat, San Francisco, CA USA; Univ Texas, Sch Med, Div Cardiol, Houston, TX USA	California Pacific Medical Center; California Pacific Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System	Ornish, D (corresponding author), Res Inst Prevent Med, 900 Bridgeway,Suite 1, Sausalito, CA 94965 USA.	DeanOrnish@aol.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042554] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL42554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American College of Sports Medicine, 1986, GUID EX TEST PRESCR; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BILLINGS JH, 1996, HEART MIND PRACTICE, P233; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; Connor WE, 1997, NEW ENGL J MED, V337, P562; Connor WE, 1997, NEW ENGL J MED, V337, P566; ESSELSTYN CB, 1995, J FAM PRACTICE, V41, P560; GOULD KL, 1995, JAMA-J AM MED ASSOC, V274, P894, DOI 10.1001/jama.274.11.894; GOULD KL, 1992, AM J CARDIOL, V69, P845, DOI 10.1016/0002-9149(92)90781-S; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Katan MB, 1997, NEW ENGL J MED, V337, P563; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Lichtenstein AH, 1998, CIRCULATION, V98, P935, DOI 10.1161/01.CIR.98.9.935; MORRISON LM, 1960, JAMA-J AM MED ASSOC, V173, P884, DOI 10.1001/jama.1960.03020260024006; Moyers B., 1993, HEALING MIND; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; ORNISH D, 1979, CLIN RES, V27, pA720; Ornish D, 1998, AM J CARDIOL, V82, p72T; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; Ornish D, 1994, J Cardiovasc Risk, V1, P283, DOI 10.1097/00043798-199412000-00001; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Ornish D, 1998, NEW ENGL J MED, V338, P1624; ORNISH D, 1992, REVERSING HEART DIS; PEDERSEN TR, 1994, LANCET, V344, P1383; *SAS I INC, 1992, P229 SAS I INC; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stefanick ML, 1998, NEW ENGL J MED, V339, P12, DOI 10.1056/NEJM199807023390103; STUFF JE, 1983, AM J CLIN NUTR, V37, P300, DOI 10.1093/ajcn/37.2.300; VIA JA, 1990, CIRCULATION, V81, P491	33	899	920	2	75	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2001	2007		10.1001/jama.280.23.2001	http://dx.doi.org/10.1001/jama.280.23.2001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863851				2022-12-28	WOS:000077462300030
J	Furuta, T; Ohashi, K; Kamata, T; Takashima, M; Kosuge, K; Kawasaki, T; Hanai, H; Kubota, T; Ishizaki, T; Kaneko, E				Furuta, T; Ohashi, K; Kamata, T; Takashima, M; Kosuge, K; Kawasaki, T; Hanai, H; Kubota, T; Ishizaki, T; Kaneko, E			Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer	ANNALS OF INTERNAL MEDICINE			English	Article							S-MEPHENYTOIN 4'-HYDROXYLATION; DOUBLE-BLIND TRIAL; AMOXICILLIN; JAPANESE; CLARITHROMYCIN; METRONIDAZOLE; POLYMORPHISM; POPULATION; MANAGEMENT; DISEASE	Background: Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased. Objective: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacter pylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin. Design: Prospective cohort study. Setting: University hospital and health service center in Hamamatsu, Japan. Patients: 62 patients with peptic ulcer and H. pylori infection. Intervention: Omeprazole and amoxicillin, Measurements: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer. Results: Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection. Conclusion: The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.	Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Clin Pharmacol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med 2, Hamamatsu, Shizuoka 4313192, Japan; Honda Motor Co Ltd, Hamamatsu Hlth Serv Ctr, Hamamatsu, Shizuoka 4338501, Japan; SRL Inc, Hachioji Lab, Res Testing Dept, Hachioji, Tokyo 1928535, Japan; Int Med Ctr Japan, Tokyo, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; SRL Inc.; National Center for Global Health & Medicine - Japan	Furuta, T (corresponding author), Hamamatsu Univ Sch Med, Dept Med 1, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	furuta@akiha.hama-med.ac.jp						ALASSI MT, 1995, AM J GASTROENTEROL, V90, P1411; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; CEDERBRANT G, 1992, J ANTIMICROB CHEMOTH, V29, P115, DOI 10.1093/jac/29.2.115; CHANG M, 1995, BRIT J CLIN PHARMACO, V39, P511, DOI 10.1111/j.1365-2125.1995.tb04488.x; DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; Furuta T, 1996, J CLIN MICROBIOL, V34, P2421, DOI 10.1128/JCM.34.10.2421-2425.1996; Goddard AF, 1996, GASTROENTEROLOGY, V111, P358, DOI 10.1053/gast.1996.v111.pm8690200; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; GRAYSON ML, 1989, EUR J CLIN MICROBIOL, V8, P888, DOI 10.1007/BF01963775; Ieiri I, 1996, CLIN PHARMACOL THER, V59, P647, DOI 10.1016/S0009-9236(96)90004-1; Kubota T, 1996, CLIN PHARMACOL THER, V60, P661, DOI 10.1016/S0009-9236(96)90214-3; Midolo PD, 1996, ANTIMICROB AGENTS CH, V40, P1531, DOI 10.1128/AAC.40.6.1531; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; *RES MULT EUR SURV, 1992, EUR J CLIN MICROBIOL, V11, P777; SOHN DR, 1992, J PHARMACOL EXP THER, V262, P1195; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; Unge P, 1996, SCAND J GASTROENTERO, V31, P74, DOI 10.3109/00365529609094541; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508	20	281	297	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1027	1030		10.7326/0003-4819-129-12-199812150-00006	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867757				2022-12-28	WOS:000077471900005
J	Selwyn, PA; Arnold, R				Selwyn, PA; Arnold, R			From fate to tragedy: The changing meanings of life, death, and AIDS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HIV-1 INFECTION; PATIENT; PHYSICIAN; PROTEASE; PAIN; CARE; COMMUNICATION; SATISFACTION; ADHERENCE	The advent of highly active antiretroviral therapy (HAART) and quantitative Viral load assays has revolutionized the care of HIV-infected patients. However, this paradigm shift has also had unexpected, sometimes adverse consequences that are not always obvious. Before antiretroviral therapy, physicians learned how to accompany patients through their illness; to bear witness to sickness and dying; and to help patients and their families with suffering, closure, and legacy. Since we have become better at treating the virus, a new temptation has emerged to dwell on quantitative aspects of HIV management and monitoring. although the skills that we learned earlier in the epidemic are no less necessary for providing good care. Our new-found therapeutic capabilities should not distract us from the sometimes more difficult and necessary task of simply "being there" for patients for whom HAART is no longer effective. The definition and practice of end-of-life care for patients with AIDS will continue to evolve as AIDS comes to resemble other chronic, treatable, but ultimately fatal illnesses, such as end-stage pulmonary disease and metastatic cancer, in which clinicians must continually readdress with their patients the balance of curative and palliative interventions as the disease process unfolds overtime. The coming challenge in HIV care will be to encourage the maintenance of a "primary care" mentality-with attention to the larger psychosocial issues, end-of-life care, bereavement, and a focus on the patient as opposed to the illness-alongside our new antiretroviral paradigm. Otherwise, we run the risk of forgetting what we learned about healing, from a disease that we could not cure.	Yale Univ, Sch Med, AIDS Program, New Haven, CT 06511 USA; Univ Pittsburgh, Sch Med, Ctr Med Eth, Div Gen Internal Med, Pittsburgh, PA 15213 USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Selwyn, PA (corresponding author), Yale Univ, Sch Med, AIDS Program, 135 Coll St, New Haven, CT 06511 USA.	peter.selwyn@yale.edu						American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Aries Philippe, 1974, W ATTITUDES DEATH MI; BARTLETT EE, 1984, J CHRON DIS, V37, P755, DOI 10.1016/0021-9681(84)90044-4; Breitbart W, 1996, PAIN, V68, P315, DOI 10.1016/S0304-3959(96)03215-0; Breitbart William, 1996, P359; Byock I, 1997, DYING WELL PROSPECT; Callahan Daniel, 1993, TROUBLED DREAM LIFE; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; COHEN PT, 1994, AIDS KNOWLEDGE BASE; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIMATTEO MR, 1992, ACHIEVING PATIENT CO; DYE NE, 1995, MEDICAL, V1, P134; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HALL JA, 1981, J HEALTH SOC BEHAV, V22, P18, DOI 10.2307/2136365; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; *I MED COMM END LI, 1997, APPR DEATH IMPR CAR; Larue F, 1997, BRIT MED J, V314, P23, DOI 10.1136/bmj.314.7073.23; Lewis CE, 1997, JAMA-J AM MED ASSOC, V278, P1133, DOI 10.1001/jama.278.14.1133; LEY P, 1982, BRIT J CLIN PSYCHOL, V21, P241, DOI 10.1111/j.2044-8260.1982.tb00562.x; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Rabkin JG, 1997, ARCH GEN PSYCHIAT, V54, P1049; Rosenfeld B, 1996, PAIN, V68, P323, DOI 10.1016/S0304-3959(96)03220-4; SQUIER RW, 1990, SOC SCI MED, V30, P325, DOI 10.1016/0277-9536(90)90188-X; Zuger A, 1997, JAMA-J AM MED ASSOC, V278, P1131, DOI 10.1001/jama.278.14.1131; 1997, MMWR MORB MORTAL WKL, V46, P861	29	40	40	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					899	902		10.7326/0003-4819-129-11_Part_1-199812010-00012	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867733				2022-12-28	WOS:000077239200009
J	Sikora, K				Sikora, K			Cancer services are suffering in Iraq	BRITISH MEDICAL JOURNAL			English	Editorial Material									WHO, Canc Programme, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, London, England	World Health Organization; Imperial College London	Sikora, K (corresponding author), WHO, Canc Programme, London, England.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					203	203		10.1136/bmj.318.7177.203	http://dx.doi.org/10.1136/bmj.318.7177.203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888945	Green Published			2022-12-28	WOS:000078175100084
J	Thor, S; Andersson, SGE; Tomlinson, A; Thomas, JB				Thor, S; Andersson, SGE; Tomlinson, A; Thomas, JB			A LIM-homeodomain combinatorial code for motor-neuron pathway selection	NATURE			English	Article							HOMEOBOX GENE; C-ELEGANS; DROSOPHILA; EXPRESSION; PROTEIN; DIFFERENTIATION; LOCATION; EMBRYOS; DOMAIN	Different classes of vertebrate motor neuron that innervate distinct muscle targets express unique combinations of LIM-homeodomain transcription factors(1,2), suggesting that a combinatorial code of LIM-homeodomain proteins may underlie the control of motor-neuron pathway selection. Studies of LIM-homeodomain genes in mouse, Drosophila melanogaster and Caenorhabditis elegans have revealed functions of these genes in neuronal survival, axon guidance, neurotransmitter expression and neuronal function(3-8), but, to our knowledge, none of these studies have addressed the issue of a functional code. Here we study two members of this gene family in Drosophila, namely lim3, the homologue of the vertebrate Lhx3 and Lhx4 genes, and islet, the homologue of the vertebrate Isl1 and Isl2 genes. We show that Drosophila lim3 is expressed by a specific subset of islet-expressing motor neurons and that mutating or misexpressing lim3 switches motor-neuron projections predictably. Our results provide evidence that lim3 and islet constitute a combinatorial code that generates distinct motor-neuron identities.	Salk Inst, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Ctr Neurobiol & Behav, New York, NY 10032 USA	Salk Institute; Columbia University	Thor, S (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.		Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X				Appel B, 1995, DEVELOPMENT, V121, P4117; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Callahan CA, 1998, CURR OPIN NEUROBIOL, V8, P582, DOI 10.1016/S0959-4388(98)80084-6; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; HIROYAMA Y, 1987, PEDIATR NEUROL, V3, P54, DOI 10.1016/0887-8994(87)90057-9; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Hobert O, 1998, J NEUROSCI, V18, P2084; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; Landgraf M, 1997, J NEUROSCI, V17, P9642; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SHARMA K, IN PRESS CELL; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; Surdej P, 1998, MOL CELL BIOL, V18, P2892, DOI 10.1128/MCB.18.5.2892; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANVACTOR D, 1993, CELL, V73, P1155; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WRIGHT TRF, 1987, RESULTS PROBLEMS CEL, P95	30	247	251	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					76	80		10.1038/16275	http://dx.doi.org/10.1038/16275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892357				2022-12-28	WOS:000077959400051
J	Armstrong, GL; Conn, LA; Pinner, RW				Armstrong, GL; Conn, LA; Pinner, RW			Trends in infectious disease mortality in the United States during the 20th century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH CERTIFICATES; EPIDEMIOLOGIC TRANSITION; ACCURACY; SURVEILLANCE; AUTOPSY	Context Recent increases in infectious disease mortality and concern about emerging infections warrant an examination of longer-term trends. Objective To describe trends in infectious disease mortality in the United States during the 20th century. Design and Setting Descriptive study of infectious disease mortality in the United States. Deaths due to infectious diseases from 1900 to 1996 were tallied by using mortality tables. Trends in age-specific infectious disease mortality were examined by using age-specific death rates for 9 common infectious causes of death. Subjects Persons who died in the United States between 1900 and 1996. Main Outcome Measures Crude and age-adjusted mortality rates. Results Infectious disease mortality declined during the first 8 decades of the 20th century from 797 deaths per 100 000 in 1900 to 36 deaths per 100 000 in 1980. From 1981 to 1995, the mortality rate increased to a peak of 63 deaths per 100 000 in 1995 and declined to 59 deaths per 100 000 in 1996. The decline was interrupted by a sharp spike in mortality caused by the 1918 influenza epidemic. From 1938 to 1952, the decline was particularly rapid, with mortality decreasing 8.2% per year. Pneumonia and influenza were responsible for the largest number of infectious disease deaths throughout the century. Tuberculosis caused almost as many deaths as pneumonia and influenza early in the century, but tuberculosis mortality dropped off sharply after 1945, Infectious disease mortality increased in the 1980s and early 1990s in persons aged 25 years and older and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-year-olds and, to a lesser degree, to increases in pneumonia and influenza deaths among persons aged 65 years and older. There was considerable year-to-year variability in infectious disease mortality, especially for the youngest and oldest age groups. Conclusions Although most of the 20th century has been marked by declining infectious disease mortality, substantial year-to-year variation as well as recent increases emphasize the dynamic nature of infectious diseases and the need for preparedness to address them.	Ctr Dis Control & Prevent, Natl Fdn Infect Dis, Natl Ctr Infect Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Armstrong, GL (corresponding author), Mailstop C-12,1600 Clifton Rd NE, Atlanta, GA 30333 USA.							ARMITAGE P, 1994, STAT METHODS MED RES, P402; Baldry P., 1976, BATTLE BACTERIA FRES; Banatvala N, 1997, EPIDEMIOL INFECT, V118, P221, DOI 10.1017/S0950268897007425; Barendregt JJ, 1996, B WORLD HEALTH ORGAN, V74, P439; BENAVIDES FG, 1989, AM J PUBLIC HEALTH, V79, P1352, DOI 10.2105/AJPH.79.10.1352; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Black FL, 1989, VIRAL INFECT HUMANS, P451; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P165; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P1245; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; *CO DEP HLTH, 1984, ANN REP VIT STAT; Cox NJ, 1998, INFECT DIS CLIN N AM, V12, P27, DOI 10.1016/S0891-5520(05)70406-2; CROSBY AW, 1976, EPIDEMIC PEACE; FALELLA FJ, 1998, NEW ENGL J MED, V338, P853; Institute of Medicine, 1992, EM INF MICR THREATS; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; MACKENBACH JP, 1994, J EPIDEMIOL COMMUN H, V48, P329, DOI 10.1136/jech.48.4.329-a; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; MORROW RH, 1995, AM J PUBLIC HEALTH, V85, P56; MORTIMER EA, 1994, VACCINES, P91; MORTIMER EA, 1994, VACCINES, P41; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; *NAT CTR HLTH STAT, 1996, VIT STAT MORT DAT MU; *NAT CTR HLTH STAT, 1996, VIT STAT US 1992 A, V2, P1; *NAT CTR HLTH STAT, 1900, VIT STAT US 1900 199; *NAT OFF VIT STAT, 1956, VIT STAT REP DEATH R, V43; NIELSEN GP, 1991, VIRCHOWS ARCH A, V419, P143, DOI 10.1007/BF01600228; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Rogers N., 1992, DIRT DIS POLIO FDR; Washko RM, 1996, PUBLIC HEALTH REP, V111, P251	31	448	474	0	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					61	66		10.1001/jama.281.1.61	http://dx.doi.org/10.1001/jama.281.1.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892452	Bronze			2022-12-28	WOS:000077829300036
J	Macleod, MA; Houston, AS; Sanders, L; Anagnostopoulos, C				Macleod, MA; Houston, AS; Sanders, L; Anagnostopoulos, C			Incidence of trauma related stress fractures and shin splints in male and female army recruits: retrospective case study	BRITISH MEDICAL JOURNAL			English	Article									Royal Hosp Haslar, Dept Nucl Med, Gosport PO12 2AA, Hants, England		Macleod, MA (corresponding author), Royal Hosp Haslar, Dept Nucl Med, Gosport PO12 2AA, Hants, England.		Anagnostopoulos, Constantinos/AAM-4381-2020					HOLDER LE, 1985, CURR CONCEPT DIAGN N, V2, P3; MATIN P, 1983, SEMIN NUCL MED, V13, P104, DOI 10.1016/S0001-2998(83)80004-X	2	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					29	29						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872880				2022-12-28	WOS:000078013100025
J	Perazella, MA; MAhnensmith, RL				Perazella, MA; MAhnensmith, RL			Malignant hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Perazella, MA (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1985	1985		10.1056/NEJM199812313392705	http://dx.doi.org/10.1056/NEJM199812313392705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869670				2022-12-28	WOS:000077803800005
J	Wells, PS; Ginsberg, JS; Anderson, DR; Kearon, C; Gent, M; Turpie, AG; Bormanis, J; Weitz, J; Chamberlain, M; Bowie, D; Barnes, D; Hirsh, J				Wells, PS; Ginsberg, JS; Anderson, DR; Kearon, C; Gent, M; Turpie, AG; Bormanis, J; Weitz, J; Chamberlain, M; Bowie, D; Barnes, D; Hirsh, J			Use of a clinical model for safe management of patients with suspected pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						pulmonary embolism; patient care management; models, statistical; probability; ventilation-perfusion ratio	DEEP-VEIN THROMBOSIS; PERFUSION LUNG-SCAN; IMPEDANCE PLETHYSMOGRAPHY; VENOUS THROMBOSIS; D-DIMER; DIAGNOSIS; ULTRASONOGRAPHY; ANGIOGRAPHY; OUTPATIENTS; VENOGRAPHY	Background: The low specificity of ventilation-perfusion lung scanning complicates the management of patients with suspected pulmonary embolism. Objective: To determine the safety of a clinical model for patients with suspected pulmonary embolism. Design: Prospective cohort study. Setting: Five tertiary care hospitals. Patients: 1239 inpatients and outpatients with suspected pulmonary embolism. Interventions: A clinical model categorized pretest probability of pulmonary embolism as low, moderate, or high, and ventilation-perfusion scanning and bilateral deep venous ultrasonography were done. Testing by serial ultrasonography, venography, or angiography depended on pretest probability and lung scans. Measurements: Patients were considered positive for pulmonary embolism if they had an abnormal pulmonary angiogram, abnormal ultrasonogram or venogram, high-probability ventilation-perfusion scan plus moderate or high pretest probability, or venous thromboembolic event during the 3-month follow-up. All other patients were considered negative for pulmonary embolism. Rates of pulmonary embolism during follow-up in patients who had a normal lung scan and those with a non-high-probability scan and normal serial ultrasonogram were compared. Results: Pretest probability was low in 734 patients (3.4% with pulmonary embolism), moderate in 403 (27.8% with pulmonary embolism), and high in 102 (78.4% with pulmonary embolism). Three of the 665 patients (0.5% [95% CI, 0.1 % to 1.3 % ]) with low or moderate pretest probability and a non-high-probability scan who were considered negative for pulmonary embolism had pulmonary embolism or deep venous thrombosis during 90-day follow-up; this rate did not differ from that in patients with a normal scan (0.6% [CI, 0.1% to 1.8%]; P > 0.2). Conclusion: Management of patients with suspected pulmonary embolism on the basis of pretest probability and results of ventilation-perfusion scanning is safe.			Wells, PS (corresponding author), Suite 467,737 Parkdale Ave, Ottawa, ON K1Y 1J8, Canada.		Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BRADLEY MJ, 1995, CLIN RADIOL, V50, P232, DOI 10.1016/S0009-9260(05)83476-2; CELI A, 1989, CHEST, V95, P332, DOI 10.1378/chest.95.2.332; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; GOTTSCHALK A, 1993, J NUCL MED, V34, P1119; HENRY JW, 1995, CHEST, V107, P1375, DOI 10.1378/chest.107.5.1375; HILDNER FJ, 1967, J AMER MED ASSOC, V202, P567, DOI 10.1001/jama.202.7.567; HOELLERICH VL, 1986, ARCH INTERN MED, V146, P1699, DOI 10.1001/archinte.146.9.1699; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SASAHARA AA, 1983, JAMA-J AM MED ASSOC, V249, P2945, DOI 10.1001/jama.249.21.2945; Schluger N, 1994, J Thorac Imaging, V9, P180, DOI 10.1097/00005382-199422000-00013; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1998, LANCET, V351, P1405, DOI 10.1016/S0140-6736(05)79444-7	26	735	763	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					997	+		10.7326/0003-4819-129-12-199812150-00002	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867786				2022-12-28	WOS:000077471900001
J	Beckerle, MC				Beckerle, MC			Spatial control of actin filament assembly: Lessons from Listeria	CELL			English	Review							VASODILATOR-STIMULATED PHOSPHOPROTEIN; MICROFILAMENT PROTEIN VASP; PROLINE-RICH REGION; FOCAL-ADHESION; PROTOONCOGENE PRODUCT; L-MONOCYTOGENES; BARBED ENDS; MOTILITY; DOMAIN; CYTOSKELETON		Univ Utah, Dept Biol, Salt Lake City, UT 84103 USA	Utah System of Higher Education; University of Utah	Beckerle, MC (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84103 USA.							Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; Alberts B, 1994, MOL BIOL CELL, P786; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Chan AY, 1998, J CELL SCI, V111, P199; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; GALILEO DS, 1992, NEURON, V9, P1117, DOI 10.1016/0896-6273(92)90070-T; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Golsteyn RM, 1997, J CELL SCI, V110, P1893; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hobert O, 1996, ONCOGENE, V12, P1577; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Ma L, 1998, J CELL BIOL, V140, P1125; Machesky LM, 1997, BIOCHEM J, V328, P105; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SMITH DS, 1972, MUSCLE, P9; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1983, J CELL BIOL, V96, P822, DOI 10.1083/jcb.96.3.822; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001	48	90	90	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					741	748		10.1016/S0092-8674(00)81697-9	http://dx.doi.org/10.1016/S0092-8674(00)81697-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865692	Bronze			2022-12-28	WOS:000077498800004
